<!DOCTYPE html>

<html>

<head>

<meta charset="utf-8" />
<meta name="generator" content="pandoc" />
<meta http-equiv="X-UA-Compatible" content="IE=EDGE" />

<meta name="viewport" content="width=device-width, initial-scale=1" />



<title>SUMO R package - general use</title>

<script>// Pandoc 2.9 adds attributes on both header and div. We remove the former (to
// be compatible with the behavior of Pandoc < 2.8).
document.addEventListener('DOMContentLoaded', function(e) {
  var hs = document.querySelectorAll("div.section[class*='level'] > :first-child");
  var i, h, a;
  for (i = 0; i < hs.length; i++) {
    h = hs[i];
    if (!/^h[1-6]$/i.test(h.tagName)) continue;  // it should be a header h1-h6
    a = h.attributes;
    while (a.length > 0) h.removeAttribute(a[0].name);
  }
});
</script>
<script>/**
 * core-js 2.6.11
 * https://github.com/zloirock/core-js
 * License: http://rock.mit-license.org
 * © 2019 Denis Pushkarev
 */
!function(e,i,Jt){"use strict";!function(r){var e={};function __webpack_require__(t){if(e[t])return e[t].exports;var n=e[t]={i:t,l:!1,exports:{}};return r[t].call(n.exports,n,n.exports,__webpack_require__),n.l=!0,n.exports}__webpack_require__.m=r,__webpack_require__.c=e,__webpack_require__.d=function(t,n,r){__webpack_require__.o(t,n)||Object.defineProperty(t,n,{configurable:!1,enumerable:!0,get:r})},__webpack_require__.n=function(t){var n=t&&t.__esModule?function getDefault(){return t["default"]}:function getModuleExports(){return t};return __webpack_require__.d(n,"a",n),n},__webpack_require__.o=function(t,n){return Object.prototype.hasOwnProperty.call(t,n)},__webpack_require__.p="",__webpack_require__(__webpack_require__.s=129)}([function(t,n,r){var v=r(2),g=r(26),y=r(11),d=r(12),b=r(18),S="prototype",_=function(t,n,r){var e,i,o,u,c=t&_.F,a=t&_.G,f=t&_.P,s=t&_.B,l=a?v:t&_.S?v[n]||(v[n]={}):(v[n]||{})[S],h=a?g:g[n]||(g[n]={}),p=h[S]||(h[S]={});for(e in a&&(r=n),r)o=((i=!c&&l&&l[e]!==Jt)?l:r)[e],u=s&&i?b(o,v):f&&"function"==typeof o?b(Function.call,o):o,l&&d(l,e,o,t&_.U),h[e]!=o&&y(h,e,u),f&&p[e]!=o&&(p[e]=o)};v.core=g,_.F=1,_.G=2,_.S=4,_.P=8,_.B=16,_.W=32,_.U=64,_.R=128,t.exports=_},function(t,n,r){var e=r(4);t.exports=function(t){if(!e(t))throw TypeError(t+" is not an object!");return t}},function(t,n){var r=t.exports="undefined"!=typeof window&&window.Math==Math?window:"undefined"!=typeof self&&self.Math==Math?self:Function("return this")();"number"==typeof i&&(i=r)},function(t,n){t.exports=function(t){try{return!!t()}catch(n){return!0}}},function(t,n){t.exports=function(t){return"object"==typeof t?null!==t:"function"==typeof t}},function(t,n,r){var e=r(47)("wks"),i=r(33),o=r(2).Symbol,u="function"==typeof o;(t.exports=function(t){return e[t]||(e[t]=u&&o[t]||(u?o:i)("Symbol."+t))}).store=e},function(t,n,r){var e=r(20),i=Math.min;t.exports=function(t){return 0<t?i(e(t),9007199254740991):0}},function(t,n,r){t.exports=!r(3)(function(){return 7!=Object.defineProperty({},"a",{get:function(){return 7}}).a})},function(t,n,r){var i=r(1),o=r(93),u=r(22),c=Object.defineProperty;n.f=r(7)?Object.defineProperty:function defineProperty(t,n,r){if(i(t),n=u(n,!0),i(r),o)try{return c(t,n,r)}catch(e){}if("get"in r||"set"in r)throw TypeError("Accessors not supported!");return"value"in r&&(t[n]=r.value),t}},function(t,n,r){var e=r(23);t.exports=function(t){return Object(e(t))}},function(t,n){t.exports=function(t){if("function"!=typeof t)throw TypeError(t+" is not a function!");return t}},function(t,n,r){var e=r(8),i=r(32);t.exports=r(7)?function(t,n,r){return e.f(t,n,i(1,r))}:function(t,n,r){return t[n]=r,t}},function(t,n,r){var o=r(2),u=r(11),c=r(14),a=r(33)("src"),e=r(131),i="toString",f=(""+e).split(i);r(26).inspectSource=function(t){return e.call(t)},(t.exports=function(t,n,r,e){var i="function"==typeof r;i&&(c(r,"name")||u(r,"name",n)),t[n]!==r&&(i&&(c(r,a)||u(r,a,t[n]?""+t[n]:f.join(String(n)))),t===o?t[n]=r:e?t[n]?t[n]=r:u(t,n,r):(delete t[n],u(t,n,r)))})(Function.prototype,i,function toString(){return"function"==typeof this&&this[a]||e.call(this)})},function(t,n,r){var e=r(0),i=r(3),u=r(23),c=/"/g,o=function(t,n,r,e){var i=String(u(t)),o="<"+n;return""!==r&&(o+=" "+r+'="'+String(e).replace(c,"&quot;")+'"'),o+">"+i+"</"+n+">"};t.exports=function(n,t){var r={};r[n]=t(o),e(e.P+e.F*i(function(){var t=""[n]('"');return t!==t.toLowerCase()||3<t.split('"').length}),"String",r)}},function(t,n){var r={}.hasOwnProperty;t.exports=function(t,n){return r.call(t,n)}},function(t,n,r){var e=r(48),i=r(23);t.exports=function(t){return e(i(t))}},function(t,n,r){var e=r(49),i=r(32),o=r(15),u=r(22),c=r(14),a=r(93),f=Object.getOwnPropertyDescriptor;n.f=r(7)?f:function getOwnPropertyDescriptor(t,n){if(t=o(t),n=u(n,!0),a)try{return f(t,n)}catch(r){}if(c(t,n))return i(!e.f.call(t,n),t[n])}},function(t,n,r){var e=r(14),i=r(9),o=r(68)("IE_PROTO"),u=Object.prototype;t.exports=Object.getPrototypeOf||function(t){return t=i(t),e(t,o)?t[o]:"function"==typeof t.constructor&&t instanceof t.constructor?t.constructor.prototype:t instanceof Object?u:null}},function(t,n,r){var o=r(10);t.exports=function(e,i,t){if(o(e),i===Jt)return e;switch(t){case 1:return function(t){return e.call(i,t)};case 2:return function(t,n){return e.call(i,t,n)};case 3:return function(t,n,r){return e.call(i,t,n,r)}}return function(){return e.apply(i,arguments)}}},function(t,n){var r={}.toString;t.exports=function(t){return r.call(t).slice(8,-1)}},function(t,n){var r=Math.ceil,e=Math.floor;t.exports=function(t){return isNaN(t=+t)?0:(0<t?e:r)(t)}},function(t,n,r){var e=r(3);t.exports=function(t,n){return!!t&&e(function(){n?t.call(null,function(){},1):t.call(null)})}},function(t,n,r){var i=r(4);t.exports=function(t,n){if(!i(t))return t;var r,e;if(n&&"function"==typeof(r=t.toString)&&!i(e=r.call(t)))return e;if("function"==typeof(r=t.valueOf)&&!i(e=r.call(t)))return e;if(!n&&"function"==typeof(r=t.toString)&&!i(e=r.call(t)))return e;throw TypeError("Can't convert object to primitive value")}},function(t,n){t.exports=function(t){if(t==Jt)throw TypeError("Can't call method on  "+t);return t}},function(t,n,r){var i=r(0),o=r(26),u=r(3);t.exports=function(t,n){var r=(o.Object||{})[t]||Object[t],e={};e[t]=n(r),i(i.S+i.F*u(function(){r(1)}),"Object",e)}},function(t,n,r){var S=r(18),_=r(48),x=r(9),m=r(6),e=r(84);t.exports=function(l,t){var h=1==l,p=2==l,v=3==l,g=4==l,y=6==l,d=5==l||y,b=t||e;return function(t,n,r){for(var e,i,o=x(t),u=_(o),c=S(n,r,3),a=m(u.length),f=0,s=h?b(t,a):p?b(t,0):Jt;f<a;f++)if((d||f in u)&&(i=c(e=u[f],f,o),l))if(h)s[f]=i;else if(i)switch(l){case 3:return!0;case 5:return e;case 6:return f;case 2:s.push(e)}else if(g)return!1;return y?-1:v||g?g:s}}},function(t,n){var r=t.exports={version:"2.6.11"};"number"==typeof e&&(e=r)},function(t,n,r){if(r(7)){var y=r(29),d=r(2),b=r(3),S=r(0),_=r(62),e=r(92),h=r(18),x=r(39),i=r(32),m=r(11),o=r(41),u=r(20),w=r(6),E=r(122),c=r(35),a=r(22),f=r(14),O=r(44),M=r(4),p=r(9),v=r(81),I=r(36),P=r(17),F=r(37).f,g=r(83),s=r(33),l=r(5),A=r(25),k=r(52),N=r(51),j=r(86),R=r(46),T=r(57),L=r(38),D=r(85),C=r(110),U=r(8),W=r(16),G=U.f,V=W.f,B=d.RangeError,z=d.TypeError,q=d.Uint8Array,K="ArrayBuffer",J="Shared"+K,Y="BYTES_PER_ELEMENT",$="prototype",X=Array[$],H=e.ArrayBuffer,Z=e.DataView,Q=A(0),tt=A(2),nt=A(3),rt=A(4),et=A(5),it=A(6),ot=k(!0),ut=k(!1),ct=j.values,at=j.keys,ft=j.entries,st=X.lastIndexOf,lt=X.reduce,ht=X.reduceRight,pt=X.join,vt=X.sort,gt=X.slice,yt=X.toString,dt=X.toLocaleString,bt=l("iterator"),St=l("toStringTag"),_t=s("typed_constructor"),xt=s("def_constructor"),mt=_.CONSTR,wt=_.TYPED,Et=_.VIEW,Ot="Wrong length!",Mt=A(1,function(t,n){return kt(N(t,t[xt]),n)}),It=b(function(){return 1===new q(new Uint16Array([1]).buffer)[0]}),Pt=!!q&&!!q[$].set&&b(function(){new q(1).set({})}),Ft=function(t,n){var r=u(t);if(r<0||r%n)throw B("Wrong offset!");return r},At=function(t){if(M(t)&&wt in t)return t;throw z(t+" is not a typed array!")},kt=function(t,n){if(!(M(t)&&_t in t))throw z("It is not a typed array constructor!");return new t(n)},Nt=function(t,n){return jt(N(t,t[xt]),n)},jt=function(t,n){for(var r=0,e=n.length,i=kt(t,e);r<e;)i[r]=n[r++];return i},Rt=function(t,n,r){G(t,n,{get:function(){return this._d[r]}})},Tt=function from(t){var n,r,e,i,o,u,c=p(t),a=arguments.length,f=1<a?arguments[1]:Jt,s=f!==Jt,l=g(c);if(l!=Jt&&!v(l)){for(u=l.call(c),e=[],n=0;!(o=u.next()).done;n++)e.push(o.value);c=e}for(s&&2<a&&(f=h(f,arguments[2],2)),n=0,r=w(c.length),i=kt(this,r);n<r;n++)i[n]=s?f(c[n],n):c[n];return i},Lt=function of(){for(var t=0,n=arguments.length,r=kt(this,n);t<n;)r[t]=arguments[t++];return r},Dt=!!q&&b(function(){dt.call(new q(1))}),Ct=function toLocaleString(){return dt.apply(Dt?gt.call(At(this)):At(this),arguments)},Ut={copyWithin:function copyWithin(t,n){return C.call(At(this),t,n,2<arguments.length?arguments[2]:Jt)},every:function every(t){return rt(At(this),t,1<arguments.length?arguments[1]:Jt)},fill:function fill(t){return D.apply(At(this),arguments)},filter:function filter(t){return Nt(this,tt(At(this),t,1<arguments.length?arguments[1]:Jt))},find:function find(t){return et(At(this),t,1<arguments.length?arguments[1]:Jt)},findIndex:function findIndex(t){return it(At(this),t,1<arguments.length?arguments[1]:Jt)},forEach:function forEach(t){Q(At(this),t,1<arguments.length?arguments[1]:Jt)},indexOf:function indexOf(t){return ut(At(this),t,1<arguments.length?arguments[1]:Jt)},includes:function includes(t){return ot(At(this),t,1<arguments.length?arguments[1]:Jt)},join:function join(t){return pt.apply(At(this),arguments)},lastIndexOf:function lastIndexOf(t){return st.apply(At(this),arguments)},map:function map(t){return Mt(At(this),t,1<arguments.length?arguments[1]:Jt)},reduce:function reduce(t){return lt.apply(At(this),arguments)},reduceRight:function reduceRight(t){return ht.apply(At(this),arguments)},reverse:function reverse(){for(var t,n=this,r=At(n).length,e=Math.floor(r/2),i=0;i<e;)t=n[i],n[i++]=n[--r],n[r]=t;return n},some:function some(t){return nt(At(this),t,1<arguments.length?arguments[1]:Jt)},sort:function sort(t){return vt.call(At(this),t)},subarray:function subarray(t,n){var r=At(this),e=r.length,i=c(t,e);return new(N(r,r[xt]))(r.buffer,r.byteOffset+i*r.BYTES_PER_ELEMENT,w((n===Jt?e:c(n,e))-i))}},Wt=function slice(t,n){return Nt(this,gt.call(At(this),t,n))},Gt=function set(t){At(this);var n=Ft(arguments[1],1),r=this.length,e=p(t),i=w(e.length),o=0;if(r<i+n)throw B(Ot);for(;o<i;)this[n+o]=e[o++]},Vt={entries:function entries(){return ft.call(At(this))},keys:function keys(){return at.call(At(this))},values:function values(){return ct.call(At(this))}},Bt=function(t,n){return M(t)&&t[wt]&&"symbol"!=typeof n&&n in t&&String(+n)==String(n)},zt=function getOwnPropertyDescriptor(t,n){return Bt(t,n=a(n,!0))?i(2,t[n]):V(t,n)},qt=function defineProperty(t,n,r){return!(Bt(t,n=a(n,!0))&&M(r)&&f(r,"value"))||f(r,"get")||f(r,"set")||r.configurable||f(r,"writable")&&!r.writable||f(r,"enumerable")&&!r.enumerable?G(t,n,r):(t[n]=r.value,t)};mt||(W.f=zt,U.f=qt),S(S.S+S.F*!mt,"Object",{getOwnPropertyDescriptor:zt,defineProperty:qt}),b(function(){yt.call({})})&&(yt=dt=function toString(){return pt.call(this)});var Kt=o({},Ut);o(Kt,Vt),m(Kt,bt,Vt.values),o(Kt,{slice:Wt,set:Gt,constructor:function(){},toString:yt,toLocaleString:Ct}),Rt(Kt,"buffer","b"),Rt(Kt,"byteOffset","o"),Rt(Kt,"byteLength","l"),Rt(Kt,"length","e"),G(Kt,St,{get:function(){return this[wt]}}),t.exports=function(t,l,n,o){var h=t+((o=!!o)?"Clamped":"")+"Array",r="get"+t,u="set"+t,p=d[h],c=p||{},e=p&&P(p),i={},a=p&&p[$],v=function(t,i){G(t,i,{get:function(){return(t=this._d).v[r](i*l+t.o,It);var t},set:function(t){return n=i,r=t,e=this._d,o&&(r=(r=Math.round(r))<0?0:255<r?255:255&r),void e.v[u](n*l+e.o,r,It);var n,r,e},enumerable:!0})};!p||!_.ABV?(p=n(function(t,n,r,e){x(t,p,h,"_d");var i,o,u,c,a=0,f=0;if(M(n)){if(!(n instanceof H||(c=O(n))==K||c==J))return wt in n?jt(p,n):Tt.call(p,n);i=n,f=Ft(r,l);var s=n.byteLength;if(e===Jt){if(s%l)throw B(Ot);if((o=s-f)<0)throw B(Ot)}else if(s<(o=w(e)*l)+f)throw B(Ot);u=o/l}else u=E(n),i=new H(o=u*l);for(m(t,"_d",{b:i,o:f,l:o,e:u,v:new Z(i)});a<u;)v(t,a++)}),a=p[$]=I(Kt),m(a,"constructor",p)):b(function(){p(1)})&&b(function(){new p(-1)})&&T(function(t){new p,new p(null),new p(1.5),new p(t)},!0)||(p=n(function(t,n,r,e){var i;return x(t,p,h),M(n)?n instanceof H||(i=O(n))==K||i==J?e!==Jt?new c(n,Ft(r,l),e):r!==Jt?new c(n,Ft(r,l)):new c(n):wt in n?jt(p,n):Tt.call(p,n):new c(E(n))}),Q(e!==Function.prototype?F(c).concat(F(e)):F(c),function(t){t in p||m(p,t,c[t])}),p[$]=a,y||(a.constructor=p));var f=a[bt],s=!!f&&("values"==f.name||f.name==Jt),g=Vt.values;m(p,_t,!0),m(a,wt,h),m(a,Et,!0),m(a,xt,p),(o?new p(1)[St]==h:St in a)||G(a,St,{get:function(){return h}}),S(S.G+S.W+S.F*((i[h]=p)!=c),i),S(S.S,h,{BYTES_PER_ELEMENT:l}),S(S.S+S.F*b(function(){c.of.call(p,1)}),h,{from:Tt,of:Lt}),Y in a||m(a,Y,l),S(S.P,h,Ut),L(h),S(S.P+S.F*Pt,h,{set:Gt}),S(S.P+S.F*!s,h,Vt),y||a.toString==yt||(a.toString=yt),S(S.P+S.F*b(function(){new p(1).slice()}),h,{slice:Wt}),S(S.P+S.F*(b(function(){return[1,2].toLocaleString()!=new p([1,2]).toLocaleString()})||!b(function(){a.toLocaleString.call([1,2])})),h,{toLocaleString:Ct}),R[h]=s?f:g,y||s||m(a,bt,g)}}else t.exports=function(){}},function(t,n,r){var o=r(116),e=r(0),i=r(47)("metadata"),u=i.store||(i.store=new(r(119))),c=function(t,n,r){var e=u.get(t);if(!e){if(!r)return Jt;u.set(t,e=new o)}var i=e.get(n);if(!i){if(!r)return Jt;e.set(n,i=new o)}return i};t.exports={store:u,map:c,has:function(t,n,r){var e=c(n,r,!1);return e!==Jt&&e.has(t)},get:function(t,n,r){var e=c(n,r,!1);return e===Jt?Jt:e.get(t)},set:function(t,n,r,e){c(r,e,!0).set(t,n)},keys:function(t,n){var r=c(t,n,!1),e=[];return r&&r.forEach(function(t,n){e.push(n)}),e},key:function(t){return t===Jt||"symbol"==typeof t?t:String(t)},exp:function(t){e(e.S,"Reflect",t)}}},function(t,n){t.exports=!1},function(t,n,r){var e=r(33)("meta"),i=r(4),o=r(14),u=r(8).f,c=0,a=Object.isExtensible||function(){return!0},f=!r(3)(function(){return a(Object.preventExtensions({}))}),s=function(t){u(t,e,{value:{i:"O"+ ++c,w:{}}})},l=t.exports={KEY:e,NEED:!1,fastKey:function(t,n){if(!i(t))return"symbol"==typeof t?t:("string"==typeof t?"S":"P")+t;if(!o(t,e)){if(!a(t))return"F";if(!n)return"E";s(t)}return t[e].i},getWeak:function(t,n){if(!o(t,e)){if(!a(t))return!0;if(!n)return!1;s(t)}return t[e].w},onFreeze:function(t){return f&&l.NEED&&a(t)&&!o(t,e)&&s(t),t}}},function(t,n,r){var e=r(5)("unscopables"),i=Array.prototype;i[e]==Jt&&r(11)(i,e,{}),t.exports=function(t){i[e][t]=!0}},function(t,n){t.exports=function(t,n){return{enumerable:!(1&t),configurable:!(2&t),writable:!(4&t),value:n}}},function(t,n){var r=0,e=Math.random();t.exports=function(t){return"Symbol(".concat(t===Jt?"":t,")_",(++r+e).toString(36))}},function(t,n,r){var e=r(95),i=r(69);t.exports=Object.keys||function keys(t){return e(t,i)}},function(t,n,r){var e=r(20),i=Math.max,o=Math.min;t.exports=function(t,n){return(t=e(t))<0?i(t+n,0):o(t,n)}},function(t,n,e){var i=e(1),o=e(96),u=e(69),c=e(68)("IE_PROTO"),a=function(){},f="prototype",s=function(){var t,n=e(66)("iframe"),r=u.length;for(n.style.display="none",e(70).appendChild(n),n.src="javascript:",(t=n.contentWindow.document).open(),t.write("<script>document.F=Object<\/script>"),t.close(),s=t.F;r--;)delete s[f][u[r]];return s()};t.exports=Object.create||function create(t,n){var r;return null!==t?(a[f]=i(t),r=new a,a[f]=null,r[c]=t):r=s(),n===Jt?r:o(r,n)}},function(t,n,r){var e=r(95),i=r(69).concat("length","prototype");n.f=Object.getOwnPropertyNames||function getOwnPropertyNames(t){return e(t,i)}},function(t,n,r){var e=r(2),i=r(8),o=r(7),u=r(5)("species");t.exports=function(t){var n=e[t];o&&n&&!n[u]&&i.f(n,u,{configurable:!0,get:function(){return this}})}},function(t,n){t.exports=function(t,n,r,e){if(!(t instanceof n)||e!==Jt&&e in t)throw TypeError(r+": incorrect invocation!");return t}},function(t,n,r){var h=r(18),p=r(108),v=r(81),g=r(1),y=r(6),d=r(83),b={},S={};(n=t.exports=function(t,n,r,e,i){var o,u,c,a,f=i?function(){return t}:d(t),s=h(r,e,n?2:1),l=0;if("function"!=typeof f)throw TypeError(t+" is not iterable!");if(v(f)){for(o=y(t.length);l<o;l++)if((a=n?s(g(u=t[l])[0],u[1]):s(t[l]))===b||a===S)return a}else for(c=f.call(t);!(u=c.next()).done;)if((a=p(c,s,u.value,n))===b||a===S)return a}).BREAK=b,n.RETURN=S},function(t,n,r){var i=r(12);t.exports=function(t,n,r){for(var e in n)i(t,e,n[e],r);return t}},function(t,n,r){var e=r(4);t.exports=function(t,n){if(!e(t)||t._t!==n)throw TypeError("Incompatible receiver, "+n+" required!");return t}},function(t,n,r){var e=r(8).f,i=r(14),o=r(5)("toStringTag");t.exports=function(t,n,r){t&&!i(t=r?t:t.prototype,o)&&e(t,o,{configurable:!0,value:n})}},function(t,n,r){var i=r(19),o=r(5)("toStringTag"),u="Arguments"==i(function(){return arguments}());t.exports=function(t){var n,r,e;return t===Jt?"Undefined":null===t?"Null":"string"==typeof(r=function(t,n){try{return t[n]}catch(r){}}(n=Object(t),o))?r:u?i(n):"Object"==(e=i(n))&&"function"==typeof n.callee?"Arguments":e}},function(t,n,r){var u=r(0),e=r(23),c=r(3),a=r(73),i="["+a+"]",o=RegExp("^"+i+i+"*"),f=RegExp(i+i+"*$"),s=function(t,n,r){var e={},i=c(function(){return!!a[t]()||"​"!="​"[t]()}),o=e[t]=i?n(l):a[t];r&&(e[r]=o),u(u.P+u.F*i,"String",e)},l=s.trim=function(t,n){return t=String(e(t)),1&n&&(t=t.replace(o,"")),2&n&&(t=t.replace(f,"")),t};t.exports=s},function(t,n){t.exports={}},function(t,n,r){var e=r(26),i=r(2),o="__core-js_shared__",u=i[o]||(i[o]={});(t.exports=function(t,n){return u[t]||(u[t]=n!==Jt?n:{})})("versions",[]).push({version:e.version,mode:r(29)?"pure":"global",copyright:"© 2019 Denis Pushkarev (zloirock.ru)"})},function(t,n,r){var e=r(19);t.exports=Object("z").propertyIsEnumerable(0)?Object:function(t){return"String"==e(t)?t.split(""):Object(t)}},function(t,n){n.f={}.propertyIsEnumerable},function(t,n,r){var e=r(1);t.exports=function(){var t=e(this),n="";return t.global&&(n+="g"),t.ignoreCase&&(n+="i"),t.multiline&&(n+="m"),t.unicode&&(n+="u"),t.sticky&&(n+="y"),n}},function(t,n,r){var i=r(1),o=r(10),u=r(5)("species");t.exports=function(t,n){var r,e=i(t).constructor;return e===Jt||(r=i(e)[u])==Jt?n:o(r)}},function(t,n,r){var a=r(15),f=r(6),s=r(35);t.exports=function(c){return function(t,n,r){var e,i=a(t),o=f(i.length),u=s(r,o);if(c&&n!=n){for(;u<o;)if((e=i[u++])!=e)return!0}else for(;u<o;u++)if((c||u in i)&&i[u]===n)return c||u||0;return!c&&-1}}},function(t,n){n.f=Object.getOwnPropertySymbols},function(t,n,r){var e=r(19);t.exports=Array.isArray||function isArray(t){return"Array"==e(t)}},function(t,n,r){var a=r(20),f=r(23);t.exports=function(c){return function(t,n){var r,e,i=String(f(t)),o=a(n),u=i.length;return o<0||u<=o?c?"":Jt:(r=i.charCodeAt(o))<55296||56319<r||o+1===u||(e=i.charCodeAt(o+1))<56320||57343<e?c?i.charAt(o):r:c?i.slice(o,o+2):e-56320+(r-55296<<10)+65536}}},function(t,n,r){var e=r(4),i=r(19),o=r(5)("match");t.exports=function(t){var n;return e(t)&&((n=t[o])!==Jt?!!n:"RegExp"==i(t))}},function(t,n,r){var o=r(5)("iterator"),u=!1;try{var e=[7][o]();e["return"]=function(){u=!0},Array.from(e,function(){throw 2})}catch(c){}t.exports=function(t,n){if(!n&&!u)return!1;var r=!1;try{var e=[7],i=e[o]();i.next=function(){return{done:r=!0}},e[o]=function(){return i},t(e)}catch(c){}return r}},function(t,n,r){var i=r(44),o=RegExp.prototype.exec;t.exports=function(t,n){var r=t.exec;if("function"==typeof r){var e=r.call(t,n);if("object"!=typeof e)throw new TypeError("RegExp exec method returned something other than an Object or null");return e}if("RegExp"!==i(t))throw new TypeError("RegExp#exec called on incompatible receiver");return o.call(t,n)}},function(t,n,r){r(112);var f=r(12),s=r(11),l=r(3),h=r(23),p=r(5),v=r(87),g=p("species"),y=!l(function(){var t=/./;return t.exec=function(){var t=[];return t.groups={a:"7"},t},"7"!=="".replace(t,"$<a>")}),d=function(){var t=/(?:)/,n=t.exec;t.exec=function(){return n.apply(this,arguments)};var r="ab".split(t);return 2===r.length&&"a"===r[0]&&"b"===r[1]}();t.exports=function(r,t,n){var e=p(r),o=!l(function(){var t={};return t[e]=function(){return 7},7!=""[r](t)}),i=o?!l(function(){var t=!1,n=/a/;return n.exec=function(){return t=!0,null},"split"===r&&(n.constructor={},n.constructor[g]=function(){return n}),n[e](""),!t}):Jt;if(!o||!i||"replace"===r&&!y||"split"===r&&!d){var u=/./[e],c=n(h,e,""[r],function maybeCallNative(t,n,r,e,i){return n.exec===v?o&&!i?{done:!0,value:u.call(n,r,e)}:{done:!0,value:t.call(r,n,e)}:{done:!1}}),a=c[1];f(String.prototype,r,c[0]),s(RegExp.prototype,e,2==t?function(t,n){return a.call(t,this,n)}:function(t){return a.call(t,this)})}}},function(t,n,r){var e=r(2).navigator;t.exports=e&&e.userAgent||""},function(t,n,r){var d=r(2),b=r(0),S=r(12),_=r(41),x=r(30),m=r(40),w=r(39),E=r(4),O=r(3),M=r(57),I=r(43),P=r(72);t.exports=function(e,t,n,r,i,o){var u=d[e],c=u,a=i?"set":"add",f=c&&c.prototype,s={},l=function(t){var r=f[t];S(f,t,"delete"==t?function(t){return!(o&&!E(t))&&r.call(this,0===t?0:t)}:"has"==t?function has(t){return!(o&&!E(t))&&r.call(this,0===t?0:t)}:"get"==t?function get(t){return o&&!E(t)?Jt:r.call(this,0===t?0:t)}:"add"==t?function add(t){return r.call(this,0===t?0:t),this}:function set(t,n){return r.call(this,0===t?0:t,n),this})};if("function"==typeof c&&(o||f.forEach&&!O(function(){(new c).entries().next()}))){var h=new c,p=h[a](o?{}:-0,1)!=h,v=O(function(){h.has(1)}),g=M(function(t){new c(t)}),y=!o&&O(function(){for(var t=new c,n=5;n--;)t[a](n,n);return!t.has(-0)});g||(((c=t(function(t,n){w(t,c,e);var r=P(new u,t,c);return n!=Jt&&m(n,i,r[a],r),r})).prototype=f).constructor=c),(v||y)&&(l("delete"),l("has"),i&&l("get")),(y||p)&&l(a),o&&f.clear&&delete f.clear}else c=r.getConstructor(t,e,i,a),_(c.prototype,n),x.NEED=!0;return I(c,e),b(b.G+b.W+b.F*((s[e]=c)!=u),s),o||r.setStrong(c,e,i),c}},function(t,n,r){for(var e,i=r(2),o=r(11),u=r(33),c=u("typed_array"),a=u("view"),f=!(!i.ArrayBuffer||!i.DataView),s=f,l=0,h="Int8Array,Uint8Array,Uint8ClampedArray,Int16Array,Uint16Array,Int32Array,Uint32Array,Float32Array,Float64Array".split(",");l<9;)(e=i[h[l++]])?(o(e.prototype,c,!0),o(e.prototype,a,!0)):s=!1;t.exports={ABV:f,CONSTR:s,TYPED:c,VIEW:a}},function(t,n,r){t.exports=r(29)||!r(3)(function(){var t=Math.random();__defineSetter__.call(null,t,function(){}),delete r(2)[t]})},function(t,n,r){var e=r(0);t.exports=function(t){e(e.S,t,{of:function of(){for(var t=arguments.length,n=new Array(t);t--;)n[t]=arguments[t];return new this(n)}})}},function(t,n,r){var e=r(0),u=r(10),c=r(18),a=r(40);t.exports=function(t){e(e.S,t,{from:function from(t){var n,r,e,i,o=arguments[1];return u(this),(n=o!==Jt)&&u(o),t==Jt?new this:(r=[],n?(e=0,i=c(o,arguments[2],2),a(t,!1,function(t){r.push(i(t,e++))})):a(t,!1,r.push,r),new this(r))}})}},function(t,n,r){var e=r(4),i=r(2).document,o=e(i)&&e(i.createElement);t.exports=function(t){return o?i.createElement(t):{}}},function(t,n,r){var e=r(2),i=r(26),o=r(29),u=r(94),c=r(8).f;t.exports=function(t){var n=i.Symbol||(i.Symbol=o?{}:e.Symbol||{});"_"==t.charAt(0)||t in n||c(n,t,{value:u.f(t)})}},function(t,n,r){var e=r(47)("keys"),i=r(33);t.exports=function(t){return e[t]||(e[t]=i(t))}},function(t,n){t.exports="constructor,hasOwnProperty,isPrototypeOf,propertyIsEnumerable,toLocaleString,toString,valueOf".split(",")},function(t,n,r){var e=r(2).document;t.exports=e&&e.documentElement},function(t,n,i){var r=i(4),e=i(1),o=function(t,n){if(e(t),!r(n)&&null!==n)throw TypeError(n+": can't set as prototype!")};t.exports={set:Object.setPrototypeOf||("__proto__"in{}?function(t,r,e){try{(e=i(18)(Function.call,i(16).f(Object.prototype,"__proto__").set,2))(t,[]),r=!(t instanceof Array)}catch(n){r=!0}return function setPrototypeOf(t,n){return o(t,n),r?t.__proto__=n:e(t,n),t}}({},!1):Jt),check:o}},function(t,n,r){var o=r(4),u=r(71).set;t.exports=function(t,n,r){var e,i=n.constructor;return i!==r&&"function"==typeof i&&(e=i.prototype)!==r.prototype&&o(e)&&u&&u(t,e),t}},function(t,n){t.exports="\t\n\x0B\f\r   ᠎             　\u2028\u2029\ufeff"},function(t,n,r){var i=r(20),o=r(23);t.exports=function repeat(t){var n=String(o(this)),r="",e=i(t);if(e<0||e==Infinity)throw RangeError("Count can't be negative");for(;0<e;(e>>>=1)&&(n+=n))1&e&&(r+=n);return r}},function(t,n){t.exports=Math.sign||function sign(t){return 0==(t=+t)||t!=t?t:t<0?-1:1}},function(t,n){var r=Math.expm1;t.exports=!r||22025.465794806718<r(10)||r(10)<22025.465794806718||-2e-17!=r(-2e-17)?function expm1(t){return 0==(t=+t)?t:-1e-6<t&&t<1e-6?t+t*t/2:Math.exp(t)-1}:r},function(t,n,r){var e=r(56),i=r(23);t.exports=function(t,n,r){if(e(n))throw TypeError("String#"+r+" doesn't accept regex!");return String(i(t))}},function(t,n,r){var i=r(5)("match");t.exports=function(t){var n=/./;try{"/./"[t](n)}catch(r){try{return n[i]=!1,!"/./"[t](n)}catch(e){}}return!0}},function(t,n,r){var S=r(29),_=r(0),x=r(12),m=r(11),w=r(46),E=r(80),O=r(43),M=r(17),I=r(5)("iterator"),P=!([].keys&&"next"in[].keys()),F="values",A=function(){return this};t.exports=function(t,n,r,e,i,o,u){E(r,n,e);var c,a,f,s=function(t){if(!P&&t in v)return v[t];switch(t){case"keys":return function keys(){return new r(this,t)};case F:return function values(){return new r(this,t)}}return function entries(){return new r(this,t)}},l=n+" Iterator",h=i==F,p=!1,v=t.prototype,g=v[I]||v["@@iterator"]||i&&v[i],y=g||s(i),d=i?h?s("entries"):y:Jt,b="Array"==n&&v.entries||g;if(b&&(f=M(b.call(new t)))!==Object.prototype&&f.next&&(O(f,l,!0),S||"function"==typeof f[I]||m(f,I,A)),h&&g&&g.name!==F&&(p=!0,y=function values(){return g.call(this)}),S&&!u||!P&&!p&&v[I]||m(v,I,y),w[n]=y,w[l]=A,i)if(c={values:h?y:s(F),keys:o?y:s("keys"),entries:d},u)for(a in c)a in v||x(v,a,c[a]);else _(_.P+_.F*(P||p),n,c);return c}},function(t,n,r){var e=r(36),i=r(32),o=r(43),u={};r(11)(u,r(5)("iterator"),function(){return this}),t.exports=function(t,n,r){t.prototype=e(u,{next:i(1,r)}),o(t,n+" Iterator")}},function(t,n,r){var e=r(46),i=r(5)("iterator"),o=Array.prototype;t.exports=function(t){return t!==Jt&&(e.Array===t||o[i]===t)}},function(t,n,r){var e=r(8),i=r(32);t.exports=function(t,n,r){n in t?e.f(t,n,i(0,r)):t[n]=r}},function(t,n,r){var e=r(44),i=r(5)("iterator"),o=r(46);t.exports=r(26).getIteratorMethod=function(t){if(t!=Jt)return t[i]||t["@@iterator"]||o[e(t)]}},function(t,n,r){var e=r(213);t.exports=function(t,n){return new(e(t))(n)}},function(t,n,r){var c=r(9),a=r(35),f=r(6);t.exports=function fill(t){for(var n=c(this),r=f(n.length),e=arguments.length,i=a(1<e?arguments[1]:Jt,r),o=2<e?arguments[2]:Jt,u=o===Jt?r:a(o,r);i<u;)n[i++]=t;return n}},function(t,n,r){var e=r(31),i=r(111),o=r(46),u=r(15);t.exports=r(79)(Array,"Array",function(t,n){this._t=u(t),this._i=0,this._k=n},function(){var t=this._t,n=this._k,r=this._i++;return!t||t.length<=r?(this._t=Jt,i(1)):i(0,"keys"==n?r:"values"==n?t[r]:[r,t[r]])},"values"),o.Arguments=o.Array,e("keys"),e("values"),e("entries")},function(t,n,r){var e,i,u=r(50),c=RegExp.prototype.exec,a=String.prototype.replace,o=c,f="lastIndex",s=(i=/b*/g,c.call(e=/a/,"a"),c.call(i,"a"),0!==e[f]||0!==i[f]),l=/()??/.exec("")[1]!==Jt;(s||l)&&(o=function exec(t){var n,r,e,i,o=this;return l&&(r=new RegExp("^"+o.source+"$(?!\\s)",u.call(o))),s&&(n=o[f]),e=c.call(o,t),s&&e&&(o[f]=o.global?e.index+e[0].length:n),l&&e&&1<e.length&&a.call(e[0],r,function(){for(i=1;i<arguments.length-2;i++)arguments[i]===Jt&&(e[i]=Jt)}),e}),t.exports=o},function(t,n,r){var e=r(55)(!0);t.exports=function(t,n,r){return n+(r?e(t,n).length:1)}},function(t,n,r){var e,i,o,u=r(18),c=r(101),a=r(70),f=r(66),s=r(2),l=s.process,h=s.setImmediate,p=s.clearImmediate,v=s.MessageChannel,g=s.Dispatch,y=0,d={},b="onreadystatechange",S=function(){var t=+this;if(d.hasOwnProperty(t)){var n=d[t];delete d[t],n()}},_=function(t){S.call(t.data)};h&&p||(h=function setImmediate(t){for(var n=[],r=1;r<arguments.length;)n.push(arguments[r++]);return d[++y]=function(){c("function"==typeof t?t:Function(t),n)},e(y),y},p=function clearImmediate(t){delete d[t]},"process"==r(19)(l)?e=function(t){l.nextTick(u(S,t,1))}:g&&g.now?e=function(t){g.now(u(S,t,1))}:v?(o=(i=new v).port2,i.port1.onmessage=_,e=u(o.postMessage,o,1)):s.addEventListener&&"function"==typeof postMessage&&!s.importScripts?(e=function(t){s.postMessage(t+"","*")},s.addEventListener("message",_,!1)):e=b in f("script")?function(t){a.appendChild(f("script"))[b]=function(){a.removeChild(this),S.call(t)}}:function(t){setTimeout(u(S,t,1),0)}),t.exports={set:h,clear:p}},function(t,n,r){var c=r(2),a=r(89).set,f=c.MutationObserver||c.WebKitMutationObserver,s=c.process,l=c.Promise,h="process"==r(19)(s);t.exports=function(){var e,i,o,t=function(){var t,n;for(h&&(t=s.domain)&&t.exit();e;){n=e.fn,e=e.next;try{n()}catch(r){throw e?o():i=Jt,r}}i=Jt,t&&t.enter()};if(h)o=function(){s.nextTick(t)};else if(!f||c.navigator&&c.navigator.standalone)if(l&&l.resolve){var n=l.resolve(Jt);o=function(){n.then(t)}}else o=function(){a.call(c,t)};else{var r=!0,u=document.createTextNode("");new f(t).observe(u,{characterData:!0}),o=function(){u.data=r=!r}}return function(t){var n={fn:t,next:Jt};i&&(i.next=n),e||(e=n,o()),i=n}}},function(t,n,r){var i=r(10);function PromiseCapability(t){var r,e;this.promise=new t(function(t,n){if(r!==Jt||e!==Jt)throw TypeError("Bad Promise constructor");r=t,e=n}),this.resolve=i(r),this.reject=i(e)}t.exports.f=function(t){return new PromiseCapability(t)}},function(t,n,r){var e=r(2),i=r(7),o=r(29),u=r(62),c=r(11),a=r(41),f=r(3),s=r(39),l=r(20),h=r(6),p=r(122),v=r(37).f,g=r(8).f,y=r(85),d=r(43),b="ArrayBuffer",S="DataView",_="prototype",x="Wrong index!",m=e[b],w=e[S],E=e.Math,O=e.RangeError,M=e.Infinity,I=m,P=E.abs,F=E.pow,A=E.floor,k=E.log,N=E.LN2,j="byteLength",R="byteOffset",T=i?"_b":"buffer",L=i?"_l":j,D=i?"_o":R;function packIEEE754(t,n,r){var e,i,o,u=new Array(r),c=8*r-n-1,a=(1<<c)-1,f=a>>1,s=23===n?F(2,-24)-F(2,-77):0,l=0,h=t<0||0===t&&1/t<0?1:0;for((t=P(t))!=t||t===M?(i=t!=t?1:0,e=a):(e=A(k(t)/N),t*(o=F(2,-e))<1&&(e--,o*=2),2<=(t+=1<=e+f?s/o:s*F(2,1-f))*o&&(e++,o/=2),a<=e+f?(i=0,e=a):1<=e+f?(i=(t*o-1)*F(2,n),e+=f):(i=t*F(2,f-1)*F(2,n),e=0));8<=n;u[l++]=255&i,i/=256,n-=8);for(e=e<<n|i,c+=n;0<c;u[l++]=255&e,e/=256,c-=8);return u[--l]|=128*h,u}function unpackIEEE754(t,n,r){var e,i=8*r-n-1,o=(1<<i)-1,u=o>>1,c=i-7,a=r-1,f=t[a--],s=127&f;for(f>>=7;0<c;s=256*s+t[a],a--,c-=8);for(e=s&(1<<-c)-1,s>>=-c,c+=n;0<c;e=256*e+t[a],a--,c-=8);if(0===s)s=1-u;else{if(s===o)return e?NaN:f?-M:M;e+=F(2,n),s-=u}return(f?-1:1)*e*F(2,s-n)}function unpackI32(t){return t[3]<<24|t[2]<<16|t[1]<<8|t[0]}function packI8(t){return[255&t]}function packI16(t){return[255&t,t>>8&255]}function packI32(t){return[255&t,t>>8&255,t>>16&255,t>>24&255]}function packF64(t){return packIEEE754(t,52,8)}function packF32(t){return packIEEE754(t,23,4)}function addGetter(t,n,r){g(t[_],n,{get:function(){return this[r]}})}function get(t,n,r,e){var i=p(+r);if(t[L]<i+n)throw O(x);var o=i+t[D],u=t[T]._b.slice(o,o+n);return e?u:u.reverse()}function set(t,n,r,e,i,o){var u=p(+r);if(t[L]<u+n)throw O(x);for(var c=t[T]._b,a=u+t[D],f=e(+i),s=0;s<n;s++)c[a+s]=f[o?s:n-s-1]}if(u.ABV){if(!f(function(){m(1)})||!f(function(){new m(-1)})||f(function(){return new m,new m(1.5),new m(NaN),m.name!=b})){for(var C,U=(m=function ArrayBuffer(t){return s(this,m),new I(p(t))})[_]=I[_],W=v(I),G=0;G<W.length;)(C=W[G++])in m||c(m,C,I[C]);o||(U.constructor=m)}var V=new w(new m(2)),B=w[_].setInt8;V.setInt8(0,2147483648),V.setInt8(1,2147483649),!V.getInt8(0)&&V.getInt8(1)||a(w[_],{setInt8:function setInt8(t,n){B.call(this,t,n<<24>>24)},setUint8:function setUint8(t,n){B.call(this,t,n<<24>>24)}},!0)}else m=function ArrayBuffer(t){s(this,m,b);var n=p(t);this._b=y.call(new Array(n),0),this[L]=n},w=function DataView(t,n,r){s(this,w,S),s(t,m,S);var e=t[L],i=l(n);if(i<0||e<i)throw O("Wrong offset!");if(e<i+(r=r===Jt?e-i:h(r)))throw O("Wrong length!");this[T]=t,this[D]=i,this[L]=r},i&&(addGetter(m,j,"_l"),addGetter(w,"buffer","_b"),addGetter(w,j,"_l"),addGetter(w,R,"_o")),a(w[_],{getInt8:function getInt8(t){return get(this,1,t)[0]<<24>>24},getUint8:function getUint8(t){return get(this,1,t)[0]},getInt16:function getInt16(t){var n=get(this,2,t,arguments[1]);return(n[1]<<8|n[0])<<16>>16},getUint16:function getUint16(t){var n=get(this,2,t,arguments[1]);return n[1]<<8|n[0]},getInt32:function getInt32(t){return unpackI32(get(this,4,t,arguments[1]))},getUint32:function getUint32(t){return unpackI32(get(this,4,t,arguments[1]))>>>0},getFloat32:function getFloat32(t){return unpackIEEE754(get(this,4,t,arguments[1]),23,4)},getFloat64:function getFloat64(t){return unpackIEEE754(get(this,8,t,arguments[1]),52,8)},setInt8:function setInt8(t,n){set(this,1,t,packI8,n)},setUint8:function setUint8(t,n){set(this,1,t,packI8,n)},setInt16:function setInt16(t,n){set(this,2,t,packI16,n,arguments[2])},setUint16:function setUint16(t,n){set(this,2,t,packI16,n,arguments[2])},setInt32:function setInt32(t,n){set(this,4,t,packI32,n,arguments[2])},setUint32:function setUint32(t,n){set(this,4,t,packI32,n,arguments[2])},setFloat32:function setFloat32(t,n){set(this,4,t,packF32,n,arguments[2])},
setFloat64:function setFloat64(t,n){set(this,8,t,packF64,n,arguments[2])}});d(m,b),d(w,S),c(w[_],u.VIEW,!0),n[b]=m,n[S]=w},function(t,n,r){t.exports=!r(7)&&!r(3)(function(){return 7!=Object.defineProperty(r(66)("div"),"a",{get:function(){return 7}}).a})},function(t,n,r){n.f=r(5)},function(t,n,r){var u=r(14),c=r(15),a=r(52)(!1),f=r(68)("IE_PROTO");t.exports=function(t,n){var r,e=c(t),i=0,o=[];for(r in e)r!=f&&u(e,r)&&o.push(r);for(;i<n.length;)u(e,r=n[i++])&&(~a(o,r)||o.push(r));return o}},function(t,n,r){var u=r(8),c=r(1),a=r(34);t.exports=r(7)?Object.defineProperties:function defineProperties(t,n){c(t);for(var r,e=a(n),i=e.length,o=0;o<i;)u.f(t,r=e[o++],n[r]);return t}},function(t,n,r){var e=r(15),i=r(37).f,o={}.toString,u="object"==typeof window&&window&&Object.getOwnPropertyNames?Object.getOwnPropertyNames(window):[];t.exports.f=function getOwnPropertyNames(t){return u&&"[object Window]"==o.call(t)?function(t){try{return i(t)}catch(n){return u.slice()}}(t):i(e(t))}},function(t,n,r){var h=r(7),p=r(34),v=r(53),g=r(49),y=r(9),d=r(48),i=Object.assign;t.exports=!i||r(3)(function(){var t={},n={},r=Symbol(),e="abcdefghijklmnopqrst";return t[r]=7,e.split("").forEach(function(t){n[t]=t}),7!=i({},t)[r]||Object.keys(i({},n)).join("")!=e})?function assign(t,n){for(var r=y(t),e=arguments.length,i=1,o=v.f,u=g.f;i<e;)for(var c,a=d(arguments[i++]),f=o?p(a).concat(o(a)):p(a),s=f.length,l=0;l<s;)c=f[l++],h&&!u.call(a,c)||(r[c]=a[c]);return r}:i},function(t,n){t.exports=Object.is||function is(t,n){return t===n?0!==t||1/t==1/n:t!=t&&n!=n}},function(t,n,r){var o=r(10),u=r(4),c=r(101),a=[].slice,f={};t.exports=Function.bind||function bind(n){var r=o(this),e=a.call(arguments,1),i=function(){var t=e.concat(a.call(arguments));return this instanceof i?function(t,n,r){if(!(n in f)){for(var e=[],i=0;i<n;i++)e[i]="a["+i+"]";f[n]=Function("F,a","return new F("+e.join(",")+")")}return f[n](t,r)}(r,t.length,t):c(r,t,n)};return u(r.prototype)&&(i.prototype=r.prototype),i}},function(t,n){t.exports=function(t,n,r){var e=r===Jt;switch(n.length){case 0:return e?t():t.call(r);case 1:return e?t(n[0]):t.call(r,n[0]);case 2:return e?t(n[0],n[1]):t.call(r,n[0],n[1]);case 3:return e?t(n[0],n[1],n[2]):t.call(r,n[0],n[1],n[2]);case 4:return e?t(n[0],n[1],n[2],n[3]):t.call(r,n[0],n[1],n[2],n[3])}return t.apply(r,n)}},function(t,n,r){var e=r(19);t.exports=function(t,n){if("number"!=typeof t&&"Number"!=e(t))throw TypeError(n);return+t}},function(t,n,r){var e=r(4),i=Math.floor;t.exports=function isInteger(t){return!e(t)&&isFinite(t)&&i(t)===t}},function(t,n,r){var e=r(2).parseFloat,i=r(45).trim;t.exports=1/e(r(73)+"-0")!=-Infinity?function parseFloat(t){var n=i(String(t),3),r=e(n);return 0===r&&"-"==n.charAt(0)?-0:r}:e},function(t,n,r){var e=r(2).parseInt,i=r(45).trim,o=r(73),u=/^[-+]?0[xX]/;t.exports=8!==e(o+"08")||22!==e(o+"0x16")?function parseInt(t,n){var r=i(String(t),3);return e(r,n>>>0||(u.test(r)?16:10))}:e},function(t,n){t.exports=Math.log1p||function log1p(t){return-1e-8<(t=+t)&&t<1e-8?t-t*t/2:Math.log(1+t)}},function(t,n,r){var o=r(75),e=Math.pow,u=e(2,-52),c=e(2,-23),a=e(2,127)*(2-c),f=e(2,-126);t.exports=Math.fround||function fround(t){var n,r,e=Math.abs(t),i=o(t);return e<f?i*(e/f/c+1/u-1/u)*f*c:a<(r=(n=(1+c/u)*e)-(n-e))||r!=r?i*Infinity:i*r}},function(t,n,r){var u=r(1);t.exports=function(t,n,r,e){try{return e?n(u(r)[0],r[1]):n(r)}catch(o){var i=t["return"];throw i!==Jt&&u(i.call(t)),o}}},function(t,n,r){var s=r(10),l=r(9),h=r(48),p=r(6);t.exports=function(t,n,r,e,i){s(n);var o=l(t),u=h(o),c=p(o.length),a=i?c-1:0,f=i?-1:1;if(r<2)for(;;){if(a in u){e=u[a],a+=f;break}if(a+=f,i?a<0:c<=a)throw TypeError("Reduce of empty array with no initial value")}for(;i?0<=a:a<c;a+=f)a in u&&(e=n(e,u[a],a,o));return e}},function(t,n,r){var f=r(9),s=r(35),l=r(6);t.exports=[].copyWithin||function copyWithin(t,n){var r=f(this),e=l(r.length),i=s(t,e),o=s(n,e),u=2<arguments.length?arguments[2]:Jt,c=Math.min((u===Jt?e:s(u,e))-o,e-i),a=1;for(o<i&&i<o+c&&(a=-1,o+=c-1,i+=c-1);0<c--;)o in r?r[i]=r[o]:delete r[i],i+=a,o+=a;return r}},function(t,n){t.exports=function(t,n){return{value:n,done:!!t}}},function(t,n,r){var e=r(87);r(0)({target:"RegExp",proto:!0,forced:e!==/./.exec},{exec:e})},function(t,n,r){r(7)&&"g"!=/./g.flags&&r(8).f(RegExp.prototype,"flags",{configurable:!0,get:r(50)})},function(t,n){t.exports=function(t){try{return{e:!1,v:t()}}catch(n){return{e:!0,v:n}}}},function(t,n,r){var e=r(1),i=r(4),o=r(91);t.exports=function(t,n){if(e(t),i(n)&&n.constructor===t)return n;var r=o.f(t);return(0,r.resolve)(n),r.promise}},function(t,n,r){var e=r(117),i=r(42);t.exports=r(61)("Map",function(t){return function Map(){return t(this,0<arguments.length?arguments[0]:Jt)}},{get:function get(t){var n=e.getEntry(i(this,"Map"),t);return n&&n.v},set:function set(t,n){return e.def(i(this,"Map"),0===t?0:t,n)}},e,!0)},function(t,n,r){var u=r(8).f,c=r(36),a=r(41),f=r(18),s=r(39),l=r(40),e=r(79),i=r(111),o=r(38),h=r(7),p=r(30).fastKey,v=r(42),g=h?"_s":"size",y=function(t,n){var r,e=p(n);if("F"!==e)return t._i[e];for(r=t._f;r;r=r.n)if(r.k==n)return r};t.exports={getConstructor:function(t,o,r,e){var i=t(function(t,n){s(t,i,o,"_i"),t._t=o,t._i=c(null),t._f=Jt,t._l=Jt,t[g]=0,n!=Jt&&l(n,r,t[e],t)});return a(i.prototype,{clear:function clear(){for(var t=v(this,o),n=t._i,r=t._f;r;r=r.n)r.r=!0,r.p&&(r.p=r.p.n=Jt),delete n[r.i];t._f=t._l=Jt,t[g]=0},"delete":function(t){var n=v(this,o),r=y(n,t);if(r){var e=r.n,i=r.p;delete n._i[r.i],r.r=!0,i&&(i.n=e),e&&(e.p=i),n._f==r&&(n._f=e),n._l==r&&(n._l=i),n[g]--}return!!r},forEach:function forEach(t){v(this,o);for(var n,r=f(t,1<arguments.length?arguments[1]:Jt,3);n=n?n.n:this._f;)for(r(n.v,n.k,this);n&&n.r;)n=n.p},has:function has(t){return!!y(v(this,o),t)}}),h&&u(i.prototype,"size",{get:function(){return v(this,o)[g]}}),i},def:function(t,n,r){var e,i,o=y(t,n);return o?o.v=r:(t._l=o={i:i=p(n,!0),k:n,v:r,p:e=t._l,n:Jt,r:!1},t._f||(t._f=o),e&&(e.n=o),t[g]++,"F"!==i&&(t._i[i]=o)),t},getEntry:y,setStrong:function(t,r,n){e(t,r,function(t,n){this._t=v(t,r),this._k=n,this._l=Jt},function(){for(var t=this,n=t._k,r=t._l;r&&r.r;)r=r.p;return t._t&&(t._l=r=r?r.n:t._t._f)?i(0,"keys"==n?r.k:"values"==n?r.v:[r.k,r.v]):(t._t=Jt,i(1))},n?"entries":"values",!n,!0),o(r)}}},function(t,n,r){var e=r(117),i=r(42);t.exports=r(61)("Set",function(t){return function Set(){return t(this,0<arguments.length?arguments[0]:Jt)}},{add:function add(t){return e.def(i(this,"Set"),t=0===t?0:t,t)}},e)},function(t,n,r){var o,e=r(2),i=r(25)(0),u=r(12),c=r(30),a=r(98),f=r(120),s=r(4),l=r(42),h=r(42),p=!e.ActiveXObject&&"ActiveXObject"in e,v="WeakMap",g=c.getWeak,y=Object.isExtensible,d=f.ufstore,b=function(t){return function WeakMap(){return t(this,0<arguments.length?arguments[0]:Jt)}},S={get:function get(t){if(s(t)){var n=g(t);return!0===n?d(l(this,v)).get(t):n?n[this._i]:Jt}},set:function set(t,n){return f.def(l(this,v),t,n)}},_=t.exports=r(61)(v,b,S,f,!0,!0);h&&p&&(a((o=f.getConstructor(b,v)).prototype,S),c.NEED=!0,i(["delete","has","get","set"],function(e){var t=_.prototype,i=t[e];u(t,e,function(t,n){if(s(t)&&!y(t)){this._f||(this._f=new o);var r=this._f[e](t,n);return"set"==e?this:r}return i.call(this,t,n)})}))},function(t,n,r){var u=r(41),c=r(30).getWeak,i=r(1),a=r(4),f=r(39),s=r(40),e=r(25),l=r(14),h=r(42),o=e(5),p=e(6),v=0,g=function(t){return t._l||(t._l=new y)},y=function(){this.a=[]},d=function(t,n){return o(t.a,function(t){return t[0]===n})};y.prototype={get:function(t){var n=d(this,t);if(n)return n[1]},has:function(t){return!!d(this,t)},set:function(t,n){var r=d(this,t);r?r[1]=n:this.a.push([t,n])},"delete":function(n){var t=p(this.a,function(t){return t[0]===n});return~t&&this.a.splice(t,1),!!~t}},t.exports={getConstructor:function(t,r,e,i){var o=t(function(t,n){f(t,o,r,"_i"),t._t=r,t._i=v++,n!=(t._l=Jt)&&s(n,e,t[i],t)});return u(o.prototype,{"delete":function(t){if(!a(t))return!1;var n=c(t);return!0===n?g(h(this,r))["delete"](t):n&&l(n,this._i)&&delete n[this._i]},has:function has(t){if(!a(t))return!1;var n=c(t);return!0===n?g(h(this,r)).has(t):n&&l(n,this._i)}}),o},def:function(t,n,r){var e=c(i(n),!0);return!0===e?g(t).set(n,r):e[t._i]=r,t},ufstore:g}},function(t,n,r){var e=r(37),i=r(53),o=r(1),u=r(2).Reflect;t.exports=u&&u.ownKeys||function ownKeys(t){var n=e.f(o(t)),r=i.f;return r?n.concat(r(t)):n}},function(t,n,r){var e=r(20),i=r(6);t.exports=function(t){if(t===Jt)return 0;var n=e(t),r=i(n);if(n!==r)throw RangeError("Wrong length!");return r}},function(t,n,r){var p=r(54),v=r(4),g=r(6),y=r(18),d=r(5)("isConcatSpreadable");t.exports=function flattenIntoArray(t,n,r,e,i,o,u,c){for(var a,f,s=i,l=0,h=!!u&&y(u,c,3);l<e;){if(l in r){if(a=h?h(r[l],l,n):r[l],f=!1,v(a)&&(f=(f=a[d])!==Jt?!!f:p(a)),f&&0<o)s=flattenIntoArray(t,n,a,g(a.length),s,o-1)-1;else{if(9007199254740991<=s)throw TypeError();t[s]=a}s++}l++}return s}},function(t,n,r){var s=r(6),l=r(74),h=r(23);t.exports=function(t,n,r,e){var i=String(h(t)),o=i.length,u=r===Jt?" ":String(r),c=s(n);if(c<=o||""==u)return i;var a=c-o,f=l.call(u,Math.ceil(a/u.length));return a<f.length&&(f=f.slice(0,a)),e?f+i:i+f}},function(t,n,r){var a=r(7),f=r(34),s=r(15),l=r(49).f;t.exports=function(c){return function(t){for(var n,r=s(t),e=f(r),i=e.length,o=0,u=[];o<i;)n=e[o++],a&&!l.call(r,n)||u.push(c?[n,r[n]]:r[n]);return u}}},function(t,n,r){var e=r(44),i=r(127);t.exports=function(t){return function toJSON(){if(e(this)!=t)throw TypeError(t+"#toJSON isn't generic");return i(this)}}},function(t,n,r){var e=r(40);t.exports=function(t,n){var r=[];return e(t,!1,r.push,r,n),r}},function(t,n){t.exports=Math.scale||function scale(t,n,r,e,i){return 0===arguments.length||t!=t||n!=n||r!=r||e!=e||i!=i?NaN:t===Infinity||t===-Infinity?t:(t-n)*(i-e)/(r-n)+e}},function(t,n,r){r(130),r(133),r(134),r(135),r(136),r(137),r(138),r(139),r(140),r(141),r(142),r(143),r(144),r(145),r(146),r(147),r(148),r(149),r(150),r(151),r(152),r(153),r(154),r(155),r(156),r(157),r(158),r(159),r(160),r(161),r(162),r(163),r(164),r(165),r(166),r(167),r(168),r(169),r(170),r(171),r(172),r(173),r(174),r(175),r(176),r(177),r(178),r(179),r(180),r(181),r(182),r(183),r(184),r(185),r(186),r(187),r(188),r(189),r(190),r(191),r(192),r(193),r(194),r(195),r(196),r(197),r(198),r(199),r(200),r(201),r(202),r(203),r(204),r(205),r(206),r(207),r(208),r(209),r(210),r(211),r(212),r(214),r(215),r(216),r(217),r(218),r(219),r(220),r(221),r(222),r(223),r(224),r(225),r(86),r(226),r(227),r(112),r(228),r(113),r(229),r(230),r(231),r(232),r(233),r(116),r(118),r(119),r(234),r(235),r(236),r(237),r(238),r(239),r(240),r(241),r(242),r(243),r(244),r(245),r(246),r(247),r(248),r(249),r(250),r(251),r(253),r(254),r(256),r(257),r(258),r(259),r(260),r(261),r(262),r(263),r(264),r(265),r(266),r(267),r(268),r(269),r(270),r(271),r(272),r(273),r(274),r(275),r(276),r(277),r(278),r(279),r(280),r(281),r(282),r(283),r(284),r(285),r(286),r(287),r(288),r(289),r(290),r(291),r(292),r(293),r(294),r(295),r(296),r(297),r(298),r(299),r(300),r(301),r(302),r(303),r(304),r(305),r(306),r(307),r(308),r(309),r(310),r(311),r(312),r(313),r(314),r(315),r(316),r(317),r(318),r(319),r(320),r(321),r(322),r(323),r(324),t.exports=r(325)},function(t,n,r){var e=r(2),u=r(14),i=r(7),o=r(0),c=r(12),a=r(30).KEY,f=r(3),s=r(47),l=r(43),h=r(33),p=r(5),v=r(94),g=r(67),y=r(132),d=r(54),b=r(1),S=r(4),_=r(9),x=r(15),m=r(22),w=r(32),E=r(36),O=r(97),M=r(16),I=r(53),P=r(8),F=r(34),A=M.f,k=P.f,N=O.f,j=e.Symbol,R=e.JSON,T=R&&R.stringify,L="prototype",D=p("_hidden"),C=p("toPrimitive"),U={}.propertyIsEnumerable,W=s("symbol-registry"),G=s("symbols"),V=s("op-symbols"),B=Object[L],z="function"==typeof j&&!!I.f,q=e.QObject,K=!q||!q[L]||!q[L].findChild,J=i&&f(function(){return 7!=E(k({},"a",{get:function(){return k(this,"a",{value:7}).a}})).a})?function(t,n,r){var e=A(B,n);e&&delete B[n],k(t,n,r),e&&t!==B&&k(B,n,e)}:k,Y=function(t){var n=G[t]=E(j[L]);return n._k=t,n},$=z&&"symbol"==typeof j.iterator?function(t){return"symbol"==typeof t}:function(t){return t instanceof j},X=function defineProperty(t,n,r){return t===B&&X(V,n,r),b(t),n=m(n,!0),b(r),u(G,n)?(r.enumerable?(u(t,D)&&t[D][n]&&(t[D][n]=!1),r=E(r,{enumerable:w(0,!1)})):(u(t,D)||k(t,D,w(1,{})),t[D][n]=!0),J(t,n,r)):k(t,n,r)},H=function defineProperties(t,n){b(t);for(var r,e=y(n=x(n)),i=0,o=e.length;i<o;)X(t,r=e[i++],n[r]);return t},Z=function propertyIsEnumerable(t){var n=U.call(this,t=m(t,!0));return!(this===B&&u(G,t)&&!u(V,t))&&(!(n||!u(this,t)||!u(G,t)||u(this,D)&&this[D][t])||n)},Q=function getOwnPropertyDescriptor(t,n){if(t=x(t),n=m(n,!0),t!==B||!u(G,n)||u(V,n)){var r=A(t,n);return!r||!u(G,n)||u(t,D)&&t[D][n]||(r.enumerable=!0),r}},tt=function getOwnPropertyNames(t){for(var n,r=N(x(t)),e=[],i=0;i<r.length;)u(G,n=r[i++])||n==D||n==a||e.push(n);return e},nt=function getOwnPropertySymbols(t){for(var n,r=t===B,e=N(r?V:x(t)),i=[],o=0;o<e.length;)!u(G,n=e[o++])||r&&!u(B,n)||i.push(G[n]);return i};z||(c((j=function Symbol(){if(this instanceof j)throw TypeError("Symbol is not a constructor!");var n=h(0<arguments.length?arguments[0]:Jt),r=function(t){this===B&&r.call(V,t),u(this,D)&&u(this[D],n)&&(this[D][n]=!1),J(this,n,w(1,t))};return i&&K&&J(B,n,{configurable:!0,set:r}),Y(n)})[L],"toString",function toString(){return this._k}),M.f=Q,P.f=X,r(37).f=O.f=tt,r(49).f=Z,I.f=nt,i&&!r(29)&&c(B,"propertyIsEnumerable",Z,!0),v.f=function(t){return Y(p(t))}),o(o.G+o.W+o.F*!z,{Symbol:j});for(var rt="hasInstance,isConcatSpreadable,iterator,match,replace,search,species,split,toPrimitive,toStringTag,unscopables".split(","),et=0;et<rt.length;)p(rt[et++]);for(var it=F(p.store),ot=0;ot<it.length;)g(it[ot++]);o(o.S+o.F*!z,"Symbol",{"for":function(t){return u(W,t+="")?W[t]:W[t]=j(t)},keyFor:function keyFor(t){if(!$(t))throw TypeError(t+" is not a symbol!");for(var n in W)if(W[n]===t)return n},useSetter:function(){K=!0},useSimple:function(){K=!1}}),o(o.S+o.F*!z,"Object",{create:function create(t,n){return n===Jt?E(t):H(E(t),n)},defineProperty:X,defineProperties:H,getOwnPropertyDescriptor:Q,getOwnPropertyNames:tt,getOwnPropertySymbols:nt});var ut=f(function(){I.f(1)});o(o.S+o.F*ut,"Object",{getOwnPropertySymbols:function getOwnPropertySymbols(t){return I.f(_(t))}}),R&&o(o.S+o.F*(!z||f(function(){var t=j();return"[null]"!=T([t])||"{}"!=T({a:t})||"{}"!=T(Object(t))})),"JSON",{stringify:function stringify(t){for(var n,r,e=[t],i=1;i<arguments.length;)e.push(arguments[i++]);if(r=n=e[1],(S(n)||t!==Jt)&&!$(t))return d(n)||(n=function(t,n){if("function"==typeof r&&(n=r.call(this,t,n)),!$(n))return n}),e[1]=n,T.apply(R,e)}}),j[L][C]||r(11)(j[L],C,j[L].valueOf),l(j,"Symbol"),l(Math,"Math",!0),l(e.JSON,"JSON",!0)},function(t,n,r){t.exports=r(47)("native-function-to-string",Function.toString)},function(t,n,r){var c=r(34),a=r(53),f=r(49);t.exports=function(t){var n=c(t),r=a.f;if(r)for(var e,i=r(t),o=f.f,u=0;u<i.length;)o.call(t,e=i[u++])&&n.push(e);return n}},function(t,n,r){var e=r(0);e(e.S+e.F*!r(7),"Object",{defineProperty:r(8).f})},function(t,n,r){var e=r(0);e(e.S+e.F*!r(7),"Object",{defineProperties:r(96)})},function(t,n,r){var e=r(15),i=r(16).f;r(24)("getOwnPropertyDescriptor",function(){return function getOwnPropertyDescriptor(t,n){return i(e(t),n)}})},function(t,n,r){var e=r(0);e(e.S,"Object",{create:r(36)})},function(t,n,r){var e=r(9),i=r(17);r(24)("getPrototypeOf",function(){return function getPrototypeOf(t){return i(e(t))}})},function(t,n,r){var e=r(9),i=r(34);r(24)("keys",function(){return function keys(t){return i(e(t))}})},function(t,n,r){r(24)("getOwnPropertyNames",function(){return r(97).f})},function(t,n,r){var e=r(4),i=r(30).onFreeze;r(24)("freeze",function(n){return function freeze(t){return n&&e(t)?n(i(t)):t}})},function(t,n,r){var e=r(4),i=r(30).onFreeze;r(24)("seal",function(n){return function seal(t){return n&&e(t)?n(i(t)):t}})},function(t,n,r){var e=r(4),i=r(30).onFreeze;r(24)("preventExtensions",function(n){return function preventExtensions(t){return n&&e(t)?n(i(t)):t}})},function(t,n,r){var e=r(4);r(24)("isFrozen",function(n){return function isFrozen(t){return!e(t)||!!n&&n(t)}})},function(t,n,r){var e=r(4);r(24)("isSealed",function(n){return function isSealed(t){return!e(t)||!!n&&n(t)}})},function(t,n,r){var e=r(4);r(24)("isExtensible",function(n){return function isExtensible(t){return!!e(t)&&(!n||n(t))}})},function(t,n,r){var e=r(0);e(e.S+e.F,"Object",{assign:r(98)})},function(t,n,r){var e=r(0);e(e.S,"Object",{is:r(99)})},function(t,n,r){var e=r(0);e(e.S,"Object",{setPrototypeOf:r(71).set})},function(t,n,r){var e=r(44),i={};i[r(5)("toStringTag")]="z",i+""!="[object z]"&&r(12)(Object.prototype,"toString",function toString(){return"[object "+e(this)+"]"},!0)},function(t,n,r){var e=r(0);e(e.P,"Function",{bind:r(100)})},function(t,n,r){var e=r(8).f,i=Function.prototype,o=/^\s*function ([^ (]*)/;"name"in i||r(7)&&e(i,"name",{configurable:!0,get:function(){try{return(""+this).match(o)[1]}catch(t){return""}}})},function(t,n,r){var e=r(4),i=r(17),o=r(5)("hasInstance"),u=Function.prototype;o in u||r(8).f(u,o,{value:function(t){if("function"!=typeof this||!e(t))return!1;if(!e(this.prototype))return t instanceof this;for(;t=i(t);)if(this.prototype===t)return!0;return!1}})},function(t,n,r){var e=r(2),i=r(14),o=r(19),u=r(72),s=r(22),c=r(3),a=r(37).f,f=r(16).f,l=r(8).f,h=r(45).trim,p="Number",v=e[p],g=v,y=v.prototype,d=o(r(36)(y))==p,b="trim"in String.prototype,S=function(t){var n=s(t,!1);if("string"==typeof n&&2<n.length){var r,e,i,o=(n=b?n.trim():h(n,3)).charCodeAt(0);if(43===o||45===o){if(88===(r=n.charCodeAt(2))||120===r)return NaN}else if(48===o){switch(n.charCodeAt(1)){case 66:case 98:e=2,i=49;break;case 79:case 111:e=8,i=55;break;default:return+n}for(var u,c=n.slice(2),a=0,f=c.length;a<f;a++)if((u=c.charCodeAt(a))<48||i<u)return NaN;return parseInt(c,e)}}return+n};if(!v(" 0o1")||!v("0b1")||v("+0x1")){v=function Number(t){var n=arguments.length<1?0:t,r=this;return r instanceof v&&(d?c(function(){y.valueOf.call(r)}):o(r)!=p)?u(new g(S(n)),r,v):S(n)};for(var _,x=r(7)?a(g):"MAX_VALUE,MIN_VALUE,NaN,NEGATIVE_INFINITY,POSITIVE_INFINITY,EPSILON,isFinite,isInteger,isNaN,isSafeInteger,MAX_SAFE_INTEGER,MIN_SAFE_INTEGER,parseFloat,parseInt,isInteger".split(","),m=0;m<x.length;m++)i(g,_=x[m])&&!i(v,_)&&l(v,_,f(g,_));(v.prototype=y).constructor=v,r(12)(e,p,v)}},function(t,n,r){var e=r(0),f=r(20),s=r(102),l=r(74),i=1..toFixed,o=Math.floor,u=[0,0,0,0,0,0],h="Number.toFixed: incorrect invocation!",p=function(t,n){for(var r=-1,e=n;++r<6;)u[r]=(e+=t*u[r])%1e7,e=o(e/1e7)},v=function(t){for(var n=6,r=0;0<=--n;)u[n]=o((r+=u[n])/t),r=r%t*1e7},g=function(){for(var t=6,n="";0<=--t;)if(""!==n||0===t||0!==u[t]){var r=String(u[t]);n=""===n?r:n+l.call("0",7-r.length)+r}return n},y=function(t,n,r){return 0===n?r:n%2==1?y(t,n-1,r*t):y(t*t,n/2,r)};e(e.P+e.F*(!!i&&("0.000"!==8e-5.toFixed(3)||"1"!==.9.toFixed(0)||"1.25"!==1.255.toFixed(2)||"1000000000000000128"!==(0xde0b6b3a7640080).toFixed(0))||!r(3)(function(){i.call({})})),"Number",{toFixed:function toFixed(t){var n,r,e,i,o=s(this,h),u=f(t),c="",a="0";if(u<0||20<u)throw RangeError(h);if(o!=o)return"NaN";if(o<=-1e21||1e21<=o)return String(o);if(o<0&&(c="-",o=-o),1e-21<o)if(r=(n=function(t){for(var n=0,r=t;4096<=r;)n+=12,r/=4096;for(;2<=r;)n+=1,r/=2;return n}(o*y(2,69,1))-69)<0?o*y(2,-n,1):o/y(2,n,1),r*=4503599627370496,0<(n=52-n)){for(p(0,r),e=u;7<=e;)p(1e7,0),e-=7;for(p(y(10,e,1),0),e=n-1;23<=e;)v(1<<23),e-=23;v(1<<e),p(1,1),v(2),a=g()}else p(0,r),p(1<<-n,0),a=g()+l.call("0",u);return a=0<u?c+((i=a.length)<=u?"0."+l.call("0",u-i)+a:a.slice(0,i-u)+"."+a.slice(i-u)):c+a}})},function(t,n,r){var e=r(0),i=r(3),o=r(102),u=1..toPrecision;e(e.P+e.F*(i(function(){return"1"!==u.call(1,Jt)})||!i(function(){u.call({})})),"Number",{toPrecision:function toPrecision(t){var n=o(this,"Number#toPrecision: incorrect invocation!");return t===Jt?u.call(n):u.call(n,t)}})},function(t,n,r){var e=r(0);e(e.S,"Number",{EPSILON:Math.pow(2,-52)})},function(t,n,r){var e=r(0),i=r(2).isFinite;e(e.S,"Number",{isFinite:function isFinite(t){return"number"==typeof t&&i(t)}})},function(t,n,r){var e=r(0);e(e.S,"Number",{isInteger:r(103)})},function(t,n,r){var e=r(0);e(e.S,"Number",{isNaN:function isNaN(t){return t!=t}})},function(t,n,r){var e=r(0),i=r(103),o=Math.abs;e(e.S,"Number",{isSafeInteger:function isSafeInteger(t){return i(t)&&o(t)<=9007199254740991}})},function(t,n,r){var e=r(0);e(e.S,"Number",{MAX_SAFE_INTEGER:9007199254740991})},function(t,n,r){var e=r(0);e(e.S,"Number",{MIN_SAFE_INTEGER:-9007199254740991})},function(t,n,r){var e=r(0),i=r(104);e(e.S+e.F*(Number.parseFloat!=i),"Number",{parseFloat:i})},function(t,n,r){var e=r(0),i=r(105);e(e.S+e.F*(Number.parseInt!=i),"Number",{parseInt:i})},function(t,n,r){var e=r(0),i=r(105);e(e.G+e.F*(parseInt!=i),{parseInt:i})},function(t,n,r){var e=r(0),i=r(104);e(e.G+e.F*(parseFloat!=i),{parseFloat:i})},function(t,n,r){var e=r(0),i=r(106),o=Math.sqrt,u=Math.acosh;e(e.S+e.F*!(u&&710==Math.floor(u(Number.MAX_VALUE))&&u(Infinity)==Infinity),"Math",{acosh:function acosh(t){return(t=+t)<1?NaN:94906265.62425156<t?Math.log(t)+Math.LN2:i(t-1+o(t-1)*o(t+1))}})},function(t,n,r){var e=r(0),i=Math.asinh;e(e.S+e.F*!(i&&0<1/i(0)),"Math",{asinh:function asinh(t){return isFinite(t=+t)&&0!=t?t<0?-asinh(-t):Math.log(t+Math.sqrt(t*t+1)):t}})},function(t,n,r){var e=r(0),i=Math.atanh;e(e.S+e.F*!(i&&1/i(-0)<0),"Math",{atanh:function atanh(t){return 0==(t=+t)?t:Math.log((1+t)/(1-t))/2}})},function(t,n,r){var e=r(0),i=r(75);e(e.S,"Math",{cbrt:function cbrt(t){return i(t=+t)*Math.pow(Math.abs(t),1/3)}})},function(t,n,r){var e=r(0);e(e.S,"Math",{clz32:function clz32(t){return(t>>>=0)?31-Math.floor(Math.log(t+.5)*Math.LOG2E):32}})},function(t,n,r){var e=r(0),i=Math.exp;e(e.S,"Math",{cosh:function cosh(t){return(i(t=+t)+i(-t))/2}})},function(t,n,r){var e=r(0),i=r(76);e(e.S+e.F*(i!=Math.expm1),"Math",{expm1:i})},function(t,n,r){var e=r(0);e(e.S,"Math",{fround:r(107)})},function(t,n,r){var e=r(0),a=Math.abs;e(e.S,"Math",{hypot:function hypot(t,n){for(var r,e,i=0,o=0,u=arguments.length,c=0;o<u;)c<(r=a(arguments[o++]))?(i=i*(e=c/r)*e+1,c=r):i+=0<r?(e=r/c)*e:r;return c===Infinity?Infinity:c*Math.sqrt(i)}})},function(t,n,r){var e=r(0),i=Math.imul;e(e.S+e.F*r(3)(function(){return-5!=i(4294967295,5)||2!=i.length}),"Math",{imul:function imul(t,n){var r=65535,e=+t,i=+n,o=r&e,u=r&i;return 0|o*u+((r&e>>>16)*u+o*(r&i>>>16)<<16>>>0)}})},function(t,n,r){var e=r(0);e(e.S,"Math",{log10:function log10(t){return Math.log(t)*Math.LOG10E}})},function(t,n,r){var e=r(0);e(e.S,"Math",{log1p:r(106)})},function(t,n,r){var e=r(0);e(e.S,"Math",{log2:function log2(t){return Math.log(t)/Math.LN2}})},function(t,n,r){var e=r(0);e(e.S,"Math",{sign:r(75)})},function(t,n,r){var e=r(0),i=r(76),o=Math.exp;e(e.S+e.F*r(3)(function(){return-2e-17!=!Math.sinh(-2e-17)}),"Math",{sinh:function sinh(t){return Math.abs(t=+t)<1?(i(t)-i(-t))/2:(o(t-1)-o(-t-1))*(Math.E/2)}})},function(t,n,r){var e=r(0),i=r(76),o=Math.exp;e(e.S,"Math",{tanh:function tanh(t){var n=i(t=+t),r=i(-t);return n==Infinity?1:r==Infinity?-1:(n-r)/(o(t)+o(-t))}})},function(t,n,r){var e=r(0);e(e.S,"Math",{trunc:function trunc(t){return(0<t?Math.floor:Math.ceil)(t)}})},function(t,n,r){var e=r(0),o=r(35),u=String.fromCharCode,i=String.fromCodePoint;e(e.S+e.F*(!!i&&1!=i.length),"String",{fromCodePoint:function fromCodePoint(t){for(var n,r=[],e=arguments.length,i=0;i<e;){if(n=+arguments[i++],o(n,1114111)!==n)throw RangeError(n+" is not a valid code point");r.push(n<65536?u(n):u(55296+((n-=65536)>>10),n%1024+56320))}return r.join("")}})},function(t,n,r){var e=r(0),u=r(15),c=r(6);e(e.S,"String",{raw:function raw(t){for(var n=u(t.raw),r=c(n.length),e=arguments.length,i=[],o=0;o<r;)i.push(String(n[o++])),o<e&&i.push(String(arguments[o]));return i.join("")}})},function(t,n,r){r(45)("trim",function(t){return function trim(){return t(this,3)}})},function(t,n,r){var e=r(0),i=r(55)(!1);e(e.P,"String",{codePointAt:function codePointAt(t){return i(this,t)}})},function(t,n,r){var e=r(0),u=r(6),c=r(77),a="endsWith",f=""[a];e(e.P+e.F*r(78)(a),"String",{endsWith:function endsWith(t){var n=c(this,t,a),r=1<arguments.length?arguments[1]:Jt,e=u(n.length),i=r===Jt?e:Math.min(u(r),e),o=String(t);return f?f.call(n,o,i):n.slice(i-o.length,i)===o}})},function(t,n,r){var e=r(0),i=r(77),o="includes";e(e.P+e.F*r(78)(o),"String",{includes:function includes(t){return!!~i(this,t,o).indexOf(t,1<arguments.length?arguments[1]:Jt)}})},function(t,n,r){var e=r(0);e(e.P,"String",{repeat:r(74)})},function(t,n,r){var e=r(0),i=r(6),o=r(77),u="startsWith",c=""[u];e(e.P+e.F*r(78)(u),"String",{startsWith:function startsWith(t){var n=o(this,t,u),r=i(Math.min(1<arguments.length?arguments[1]:Jt,n.length)),e=String(t);return c?c.call(n,e,r):n.slice(r,r+e.length)===e}})},function(t,n,r){var e=r(55)(!0);r(79)(String,"String",function(t){this._t=String(t),this._i=0},function(){var t,n=this._t,r=this._i;return n.length<=r?{value:Jt,done:!0}:(t=e(n,r),this._i+=t.length,{value:t,done:!1})})},function(t,n,r){r(13)("anchor",function(n){return function anchor(t){return n(this,"a","name",t)}})},function(t,n,r){r(13)("big",function(t){return function big(){return t(this,"big","","")}})},function(t,n,r){r(13)("blink",function(t){return function blink(){return t(this,"blink","","")}})},function(t,n,r){r(13)("bold",function(t){return function bold(){return t(this,"b","","")}})},function(t,n,r){r(13)("fixed",function(t){return function fixed(){return t(this,"tt","","")}})},function(t,n,r){r(13)("fontcolor",function(n){return function fontcolor(t){return n(this,"font","color",t)}})},function(t,n,r){r(13)("fontsize",function(n){return function fontsize(t){return n(this,"font","size",t)}})},function(t,n,r){r(13)("italics",function(t){return function italics(){return t(this,"i","","")}})},function(t,n,r){r(13)("link",function(n){return function link(t){return n(this,"a","href",t)}})},function(t,n,r){r(13)("small",function(t){return function small(){return t(this,"small","","")}})},function(t,n,r){r(13)("strike",function(t){return function strike(){return t(this,"strike","","")}})},function(t,n,r){r(13)("sub",function(t){return function sub(){return t(this,"sub","","")}})},function(t,n,r){r(13)("sup",function(t){return function sup(){return t(this,"sup","","")}})},function(t,n,r){var e=r(0);e(e.S,"Array",{isArray:r(54)})},function(t,n,r){var h=r(18),e=r(0),p=r(9),v=r(108),g=r(81),y=r(6),d=r(82),b=r(83);e(e.S+e.F*!r(57)(function(t){Array.from(t)}),"Array",{from:function from(t){var n,r,e,i,o=p(t),u="function"==typeof this?this:Array,c=arguments.length,a=1<c?arguments[1]:Jt,f=a!==Jt,s=0,l=b(o);if(f&&(a=h(a,2<c?arguments[2]:Jt,2)),l==Jt||u==Array&&g(l))for(r=new u(n=y(o.length));s<n;s++)d(r,s,f?a(o[s],s):o[s]);else for(i=l.call(o),r=new u;!(e=i.next()).done;s++)d(r,s,f?v(i,a,[e.value,s],!0):e.value);return r.length=s,r}})},function(t,n,r){var e=r(0),i=r(82);e(e.S+e.F*r(3)(function(){function F(){}return!(Array.of.call(F)instanceof F)}),"Array",{of:function of(){for(var t=0,n=arguments.length,r=new("function"==typeof this?this:Array)(n);t<n;)i(r,t,arguments[t++]);return r.length=n,r}})},function(t,n,r){var e=r(0),i=r(15),o=[].join;e(e.P+e.F*(r(48)!=Object||!r(21)(o)),"Array",{join:function join(t){return o.call(i(this),t===Jt?",":t)}})},function(t,n,r){var e=r(0),i=r(70),f=r(19),s=r(35),l=r(6),h=[].slice;e(e.P+e.F*r(3)(function(){i&&h.call(i)}),"Array",{slice:function slice(t,n){var r=l(this.length),e=f(this);if(n=n===Jt?r:n,"Array"==e)return h.call(this,t,n);for(var i=s(t,r),o=s(n,r),u=l(o-i),c=new Array(u),a=0;a<u;a++)c[a]="String"==e?this.charAt(i+a):this[i+a];return c}})},function(t,n,r){var e=r(0),i=r(10),o=r(9),u=r(3),c=[].sort,a=[1,2,3];e(e.P+e.F*(u(function(){a.sort(Jt)})||!u(function(){a.sort(null)})||!r(21)(c)),"Array",{sort:function sort(t){return t===Jt?c.call(o(this)):c.call(o(this),i(t))}})},function(t,n,r){var e=r(0),i=r(25)(0),o=r(21)([].forEach,!0);e(e.P+e.F*!o,"Array",{forEach:function forEach(t){return i(this,t,arguments[1])}})},function(t,n,r){var e=r(4),i=r(54),o=r(5)("species");t.exports=function(t){var n;return i(t)&&("function"!=typeof(n=t.constructor)||n!==Array&&!i(n.prototype)||(n=Jt),e(n)&&null===(n=n[o])&&(n=Jt)),n===Jt?Array:n}},function(t,n,r){var e=r(0),i=r(25)(1);e(e.P+e.F*!r(21)([].map,!0),"Array",{map:function map(t){return i(this,t,arguments[1])}})},function(t,n,r){var e=r(0),i=r(25)(2);e(e.P+e.F*!r(21)([].filter,!0),"Array",{filter:function filter(t){return i(this,t,arguments[1])}})},function(t,n,r){var e=r(0),i=r(25)(3);e(e.P+e.F*!r(21)([].some,!0),"Array",{some:function some(t){return i(this,t,arguments[1])}})},function(t,n,r){var e=r(0),i=r(25)(4);e(e.P+e.F*!r(21)([].every,!0),"Array",{every:function every(t){return i(this,t,arguments[1])}})},function(t,n,r){var e=r(0),i=r(109);e(e.P+e.F*!r(21)([].reduce,!0),"Array",{reduce:function reduce(t){return i(this,t,arguments.length,arguments[1],!1)}})},function(t,n,r){var e=r(0),i=r(109);e(e.P+e.F*!r(21)([].reduceRight,!0),"Array",{reduceRight:function reduceRight(t){return i(this,t,arguments.length,arguments[1],!0)}})},function(t,n,r){var e=r(0),i=r(52)(!1),o=[].indexOf,u=!!o&&1/[1].indexOf(1,-0)<0;e(e.P+e.F*(u||!r(21)(o)),"Array",{indexOf:function indexOf(t){return u?o.apply(this,arguments)||0:i(this,t,arguments[1])}})},function(t,n,r){var e=r(0),i=r(15),o=r(20),u=r(6),c=[].lastIndexOf,a=!!c&&1/[1].lastIndexOf(1,-0)<0;e(e.P+e.F*(a||!r(21)(c)),"Array",{lastIndexOf:function lastIndexOf(t){if(a)return c.apply(this,arguments)||0;var n=i(this),r=u(n.length),e=r-1;for(1<arguments.length&&(e=Math.min(e,o(arguments[1]))),e<0&&(e=r+e);0<=e;e--)if(e in n&&n[e]===t)return e||0;return-1}})},function(t,n,r){var e=r(0);e(e.P,"Array",{copyWithin:r(110)}),r(31)("copyWithin")},function(t,n,r){var e=r(0);e(e.P,"Array",{fill:r(85)}),r(31)("fill")},function(t,n,r){var e=r(0),i=r(25)(5),o="find",u=!0;o in[]&&Array(1)[o](function(){u=!1}),e(e.P+e.F*u,"Array",{find:function find(t){return i(this,t,1<arguments.length?arguments[1]:Jt)}}),r(31)(o)},function(t,n,r){var e=r(0),i=r(25)(6),o="findIndex",u=!0;o in[]&&Array(1)[o](function(){u=!1}),e(e.P+e.F*u,"Array",{findIndex:function findIndex(t){return i(this,t,1<arguments.length?arguments[1]:Jt)}}),r(31)(o)},function(t,n,r){r(38)("Array")},function(t,n,r){var e=r(2),o=r(72),i=r(8).f,u=r(37).f,c=r(56),a=r(50),f=e.RegExp,s=f,l=f.prototype,h=/a/g,p=/a/g,v=new f(h)!==h;if(r(7)&&(!v||r(3)(function(){return p[r(5)("match")]=!1,f(h)!=h||f(p)==p||"/a/i"!=f(h,"i")}))){f=function RegExp(t,n){var r=this instanceof f,e=c(t),i=n===Jt;return!r&&e&&t.constructor===f&&i?t:o(v?new s(e&&!i?t.source:t,n):s((e=t instanceof f)?t.source:t,e&&i?a.call(t):n),r?this:l,f)};for(var g=function(n){n in f||i(f,n,{configurable:!0,get:function(){return s[n]},set:function(t){s[n]=t}})},y=u(s),d=0;d<y.length;)g(y[d++]);(l.constructor=f).prototype=l,r(12)(e,"RegExp",f)}r(38)("RegExp")},function(t,n,r){r(113);var e=r(1),i=r(50),o=r(7),u="toString",c=/./[u],a=function(t){r(12)(RegExp.prototype,u,t,!0)};r(3)(function(){return"/a/b"!=c.call({source:"a",flags:"b"})})?a(function toString(){var t=e(this);return"/".concat(t.source,"/","flags"in t?t.flags:!o&&t instanceof RegExp?i.call(t):Jt)}):c.name!=u&&a(function toString(){return c.call(this)})},function(t,n,r){var l=r(1),h=r(6),p=r(88),v=r(58);r(59)("match",1,function(e,i,f,s){return[function match(t){var n=e(this),r=t==Jt?Jt:t[i];return r!==Jt?r.call(t,n):new RegExp(t)[i](String(n))},function(t){var n=s(f,t,this);if(n.done)return n.value;var r=l(t),e=String(this);if(!r.global)return v(r,e);for(var i,o=r.unicode,u=[],c=r.lastIndex=0;null!==(i=v(r,e));){var a=String(i[0]);""===(u[c]=a)&&(r.lastIndex=p(e,h(r.lastIndex),o)),c++}return 0===c?null:u}]})},function(t,n,r){var w=r(1),e=r(9),E=r(6),O=r(20),M=r(88),I=r(58),P=Math.max,F=Math.min,h=Math.floor,p=/\$([$&`']|\d\d?|<[^>]*>)/g,v=/\$([$&`']|\d\d?)/g;r(59)("replace",2,function(i,o,x,m){return[function replace(t,n){var r=i(this),e=t==Jt?Jt:t[o];return e!==Jt?e.call(t,r,n):x.call(String(r),t,n)},function(t,n){var r=m(x,t,this,n);if(r.done)return r.value;var e=w(t),i=String(this),o="function"==typeof n;o||(n=String(n));var u=e.global;if(u){var c=e.unicode;e.lastIndex=0}for(var a=[];;){var f=I(e,i);if(
null===f)break;if(a.push(f),!u)break;""===String(f[0])&&(e.lastIndex=M(i,E(e.lastIndex),c))}for(var s,l="",h=0,p=0;p<a.length;p++){f=a[p];for(var v=String(f[0]),g=P(F(O(f.index),i.length),0),y=[],d=1;d<f.length;d++)y.push((s=f[d])===Jt?s:String(s));var b=f.groups;if(o){var S=[v].concat(y,g,i);b!==Jt&&S.push(b);var _=String(n.apply(Jt,S))}else _=getSubstitution(v,i,g,y,b,n);h<=g&&(l+=i.slice(h,g)+_,h=g+v.length)}return l+i.slice(h)}];function getSubstitution(o,u,c,a,f,t){var s=c+o.length,l=a.length,n=v;return f!==Jt&&(f=e(f),n=p),x.call(t,n,function(t,n){var r;switch(n.charAt(0)){case"$":return"$";case"&":return o;case"`":return u.slice(0,c);case"'":return u.slice(s);case"<":r=f[n.slice(1,-1)];break;default:var e=+n;if(0===e)return t;if(l<e){var i=h(e/10);return 0===i?t:i<=l?a[i-1]===Jt?n.charAt(1):a[i-1]+n.charAt(1):t}r=a[e-1]}return r===Jt?"":r})}})},function(t,n,r){var a=r(1),f=r(99),s=r(58);r(59)("search",1,function(e,i,u,c){return[function search(t){var n=e(this),r=t==Jt?Jt:t[i];return r!==Jt?r.call(t,n):new RegExp(t)[i](String(n))},function(t){var n=c(u,t,this);if(n.done)return n.value;var r=a(t),e=String(this),i=r.lastIndex;f(i,0)||(r.lastIndex=0);var o=s(r,e);return f(r.lastIndex,i)||(r.lastIndex=i),null===o?-1:o.index}]})},function(t,n,r){var s=r(56),b=r(1),S=r(51),_=r(88),x=r(6),m=r(58),l=r(87),e=r(3),w=Math.min,h=[].push,u="split",p="length",v="lastIndex",E=4294967295,O=!e(function(){RegExp(E,"y")});r(59)("split",2,function(i,o,g,y){var d;return d="c"=="abbc"[u](/(b)*/)[1]||4!="test"[u](/(?:)/,-1)[p]||2!="ab"[u](/(?:ab)*/)[p]||4!="."[u](/(.?)(.?)/)[p]||1<"."[u](/()()/)[p]||""[u](/.?/)[p]?function(t,n){var r=String(this);if(t===Jt&&0===n)return[];if(!s(t))return g.call(r,t,n);for(var e,i,o,u=[],c=0,a=n===Jt?E:n>>>0,f=new RegExp(t.source,(t.ignoreCase?"i":"")+(t.multiline?"m":"")+(t.unicode?"u":"")+(t.sticky?"y":"")+"g");(e=l.call(f,r))&&!(c<(i=f[v])&&(u.push(r.slice(c,e.index)),1<e[p]&&e.index<r[p]&&h.apply(u,e.slice(1)),o=e[0][p],c=i,a<=u[p]));)f[v]===e.index&&f[v]++;return c===r[p]?!o&&f.test("")||u.push(""):u.push(r.slice(c)),a<u[p]?u.slice(0,a):u}:"0"[u](Jt,0)[p]?function(t,n){return t===Jt&&0===n?[]:g.call(this,t,n)}:g,[function split(t,n){var r=i(this),e=t==Jt?Jt:t[o];return e!==Jt?e.call(t,r,n):d.call(String(r),t,n)},function(t,n){var r=y(d,t,this,n,d!==g);if(r.done)return r.value;var e=b(t),i=String(this),o=S(e,RegExp),u=e.unicode,c=new o(O?e:"^(?:"+e.source+")",(e.ignoreCase?"i":"")+(e.multiline?"m":"")+(e.unicode?"u":"")+(O?"y":"g")),a=n===Jt?E:n>>>0;if(0===a)return[];if(0===i.length)return null===m(c,i)?[i]:[];for(var f=0,s=0,l=[];s<i.length;){c.lastIndex=O?s:0;var h,p=m(c,O?i:i.slice(s));if(null===p||(h=w(x(c.lastIndex+(O?0:s)),i.length))===f)s=_(i,s,u);else{if(l.push(i.slice(f,s)),l.length===a)return l;for(var v=1;v<=p.length-1;v++)if(l.push(p[v]),l.length===a)return l;s=f=h}}return l.push(i.slice(f)),l}]})},function(t,n,e){var r,i,o,u,c=e(29),a=e(2),f=e(18),s=e(44),l=e(0),h=e(4),p=e(10),v=e(39),g=e(40),y=e(51),d=e(89).set,b=e(90)(),S=e(91),_=e(114),x=e(60),m=e(115),w="Promise",E=a.TypeError,O=a.process,M=O&&O.versions,I=M&&M.v8||"",P=a[w],F="process"==s(O),A=function(){},k=i=S.f,N=!!function(){try{var t=P.resolve(1),n=(t.constructor={})[e(5)("species")]=function(t){t(A,A)};return(F||"function"==typeof PromiseRejectionEvent)&&t.then(A)instanceof n&&0!==I.indexOf("6.6")&&-1===x.indexOf("Chrome/66")}catch(r){}}(),j=function(t){var n;return!(!h(t)||"function"!=typeof(n=t.then))&&n},R=function(l,r){if(!l._n){l._n=!0;var e=l._c;b(function(){for(var f=l._v,s=1==l._s,t=0,n=function(t){var n,r,e,i=s?t.ok:t.fail,o=t.resolve,u=t.reject,c=t.domain;try{i?(s||(2==l._h&&D(l),l._h=1),!0===i?n=f:(c&&c.enter(),n=i(f),c&&(c.exit(),e=!0)),n===t.promise?u(E("Promise-chain cycle")):(r=j(n))?r.call(n,o,u):o(n)):u(f)}catch(a){c&&!e&&c.exit(),u(a)}};t<e.length;)n(e[t++]);l._c=[],l._n=!1,r&&!l._h&&T(l)})}},T=function(o){d.call(a,function(){var t,n,r,e=o._v,i=L(o);if(i&&(t=_(function(){F?O.emit("unhandledRejection",e,o):(n=a.onunhandledrejection)?n({promise:o,reason:e}):(r=a.console)&&r.error&&r.error("Unhandled promise rejection",e)}),o._h=F||L(o)?2:1),o._a=Jt,i&&t.e)throw t.v})},L=function(t){return 1!==t._h&&0===(t._a||t._c).length},D=function(n){d.call(a,function(){var t;F?O.emit("rejectionHandled",n):(t=a.onrejectionhandled)&&t({promise:n,reason:n._v})})},C=function(t){var n=this;n._d||(n._d=!0,(n=n._w||n)._v=t,n._s=2,n._a||(n._a=n._c.slice()),R(n,!0))},U=function(r){var e,i=this;if(!i._d){i._d=!0,i=i._w||i;try{if(i===r)throw E("Promise can't be resolved itself");(e=j(r))?b(function(){var t={_w:i,_d:!1};try{e.call(r,f(U,t,1),f(C,t,1))}catch(n){C.call(t,n)}}):(i._v=r,i._s=1,R(i,!1))}catch(t){C.call({_w:i,_d:!1},t)}}};N||(P=function Promise(t){v(this,P,w,"_h"),p(t),r.call(this);try{t(f(U,this,1),f(C,this,1))}catch(n){C.call(this,n)}},(r=function Promise(t){this._c=[],this._a=Jt,this._s=0,this._d=!1,this._v=Jt,this._h=0,this._n=!1}).prototype=e(41)(P.prototype,{then:function then(t,n){var r=k(y(this,P));return r.ok="function"!=typeof t||t,r.fail="function"==typeof n&&n,r.domain=F?O.domain:Jt,this._c.push(r),this._a&&this._a.push(r),this._s&&R(this,!1),r.promise},"catch":function(t){return this.then(Jt,t)}}),o=function(){var t=new r;this.promise=t,this.resolve=f(U,t,1),this.reject=f(C,t,1)},S.f=k=function(t){return t===P||t===u?new o(t):i(t)}),l(l.G+l.W+l.F*!N,{Promise:P}),e(43)(P,w),e(38)(w),u=e(26)[w],l(l.S+l.F*!N,w,{reject:function reject(t){var n=k(this);return(0,n.reject)(t),n.promise}}),l(l.S+l.F*(c||!N),w,{resolve:function resolve(t){return m(c&&this===u?P:this,t)}}),l(l.S+l.F*!(N&&e(57)(function(t){P.all(t)["catch"](A)})),w,{all:function all(t){var u=this,n=k(u),c=n.resolve,a=n.reject,r=_(function(){var e=[],i=0,o=1;g(t,!1,function(t){var n=i++,r=!1;e.push(Jt),o++,u.resolve(t).then(function(t){r||(r=!0,e[n]=t,--o||c(e))},a)}),--o||c(e)});return r.e&&a(r.v),n.promise},race:function race(t){var n=this,r=k(n),e=r.reject,i=_(function(){g(t,!1,function(t){n.resolve(t).then(r.resolve,e)})});return i.e&&e(i.v),r.promise}})},function(t,n,r){var e=r(120),i=r(42),o="WeakSet";r(61)(o,function(t){return function WeakSet(){return t(this,0<arguments.length?arguments[0]:Jt)}},{add:function add(t){return e.def(i(this,o),t,!0)}},e,!1,!0)},function(t,n,r){var e=r(0),o=r(10),u=r(1),c=(r(2).Reflect||{}).apply,a=Function.apply;e(e.S+e.F*!r(3)(function(){c(function(){})}),"Reflect",{apply:function apply(t,n,r){var e=o(t),i=u(r);return c?c(e,n,i):a.call(e,n,i)}})},function(t,n,r){var e=r(0),c=r(36),a=r(10),f=r(1),s=r(4),i=r(3),l=r(100),h=(r(2).Reflect||{}).construct,p=i(function(){function F(){}return!(h(function(){},[],F)instanceof F)}),v=!i(function(){h(function(){})});e(e.S+e.F*(p||v),"Reflect",{construct:function construct(t,n){a(t),f(n);var r=arguments.length<3?t:a(arguments[2]);if(v&&!p)return h(t,n,r);if(t==r){switch(n.length){case 0:return new t;case 1:return new t(n[0]);case 2:return new t(n[0],n[1]);case 3:return new t(n[0],n[1],n[2]);case 4:return new t(n[0],n[1],n[2],n[3])}var e=[null];return e.push.apply(e,n),new(l.apply(t,e))}var i=r.prototype,o=c(s(i)?i:Object.prototype),u=Function.apply.call(t,o,n);return s(u)?u:o}})},function(t,n,r){var i=r(8),e=r(0),o=r(1),u=r(22);e(e.S+e.F*r(3)(function(){Reflect.defineProperty(i.f({},1,{value:1}),1,{value:2})}),"Reflect",{defineProperty:function defineProperty(t,n,r){o(t),n=u(n,!0),o(r);try{return i.f(t,n,r),!0}catch(e){return!1}}})},function(t,n,r){var e=r(0),i=r(16).f,o=r(1);e(e.S,"Reflect",{deleteProperty:function deleteProperty(t,n){var r=i(o(t),n);return!(r&&!r.configurable)&&delete t[n]}})},function(t,n,r){var e=r(0),i=r(1),o=function(t){this._t=i(t),this._i=0;var n,r=this._k=[];for(n in t)r.push(n)};r(80)(o,"Object",function(){var t,n=this._k;do{if(n.length<=this._i)return{value:Jt,done:!0}}while(!((t=n[this._i++])in this._t));return{value:t,done:!1}}),e(e.S,"Reflect",{enumerate:function enumerate(t){return new o(t)}})},function(t,n,r){var o=r(16),u=r(17),c=r(14),e=r(0),a=r(4),f=r(1);e(e.S,"Reflect",{get:function get(t,n){var r,e,i=arguments.length<3?t:arguments[2];return f(t)===i?t[n]:(r=o.f(t,n))?c(r,"value")?r.value:r.get!==Jt?r.get.call(i):Jt:a(e=u(t))?get(e,n,i):void 0}})},function(t,n,r){var e=r(16),i=r(0),o=r(1);i(i.S,"Reflect",{getOwnPropertyDescriptor:function getOwnPropertyDescriptor(t,n){return e.f(o(t),n)}})},function(t,n,r){var e=r(0),i=r(17),o=r(1);e(e.S,"Reflect",{getPrototypeOf:function getPrototypeOf(t){return i(o(t))}})},function(t,n,r){var e=r(0);e(e.S,"Reflect",{has:function has(t,n){return n in t}})},function(t,n,r){var e=r(0),i=r(1),o=Object.isExtensible;e(e.S,"Reflect",{isExtensible:function isExtensible(t){return i(t),!o||o(t)}})},function(t,n,r){var e=r(0);e(e.S,"Reflect",{ownKeys:r(121)})},function(t,n,r){var e=r(0),i=r(1),o=Object.preventExtensions;e(e.S,"Reflect",{preventExtensions:function preventExtensions(t){i(t);try{return o&&o(t),!0}catch(n){return!1}}})},function(t,n,r){var c=r(8),a=r(16),f=r(17),s=r(14),e=r(0),l=r(32),h=r(1),p=r(4);e(e.S,"Reflect",{set:function set(t,n,r){var e,i,o=arguments.length<4?t:arguments[3],u=a.f(h(t),n);if(!u){if(p(i=f(t)))return set(i,n,r,o);u=l(0)}if(s(u,"value")){if(!1===u.writable||!p(o))return!1;if(e=a.f(o,n)){if(e.get||e.set||!1===e.writable)return!1;e.value=r,c.f(o,n,e)}else c.f(o,n,l(0,r));return!0}return u.set!==Jt&&(u.set.call(o,r),!0)}})},function(t,n,r){var e=r(0),i=r(71);i&&e(e.S,"Reflect",{setPrototypeOf:function setPrototypeOf(t,n){i.check(t,n);try{return i.set(t,n),!0}catch(r){return!1}}})},function(t,n,r){var e=r(0);e(e.S,"Date",{now:function(){return(new Date).getTime()}})},function(t,n,r){var e=r(0),i=r(9),o=r(22);e(e.P+e.F*r(3)(function(){return null!==new Date(NaN).toJSON()||1!==Date.prototype.toJSON.call({toISOString:function(){return 1}})}),"Date",{toJSON:function toJSON(t){var n=i(this),r=o(n);return"number"!=typeof r||isFinite(r)?n.toISOString():null}})},function(t,n,r){var e=r(0),i=r(252);e(e.P+e.F*(Date.prototype.toISOString!==i),"Date",{toISOString:i})},function(t,n,r){var e=r(3),i=Date.prototype.getTime,o=Date.prototype.toISOString,u=function(t){return 9<t?t:"0"+t};t.exports=e(function(){return"0385-07-25T07:06:39.999Z"!=o.call(new Date(-5e13-1))})||!e(function(){o.call(new Date(NaN))})?function toISOString(){if(!isFinite(i.call(this)))throw RangeError("Invalid time value");var t=this,n=t.getUTCFullYear(),r=t.getUTCMilliseconds(),e=n<0?"-":9999<n?"+":"";return e+("00000"+Math.abs(n)).slice(e?-6:-4)+"-"+u(t.getUTCMonth()+1)+"-"+u(t.getUTCDate())+"T"+u(t.getUTCHours())+":"+u(t.getUTCMinutes())+":"+u(t.getUTCSeconds())+"."+(99<r?r:"0"+u(r))+"Z"}:o},function(t,n,r){var e=Date.prototype,i="Invalid Date",o="toString",u=e[o],c=e.getTime;new Date(NaN)+""!=i&&r(12)(e,o,function toString(){var t=c.call(this);return t==t?u.call(this):i})},function(t,n,r){var e=r(5)("toPrimitive"),i=Date.prototype;e in i||r(11)(i,e,r(255))},function(t,n,r){var e=r(1),i=r(22);t.exports=function(t){if("string"!==t&&"number"!==t&&"default"!==t)throw TypeError("Incorrect hint");return i(e(this),"number"!=t)}},function(t,n,r){var e=r(0),i=r(62),o=r(92),f=r(1),s=r(35),l=r(6),u=r(4),c=r(2).ArrayBuffer,h=r(51),p=o.ArrayBuffer,v=o.DataView,a=i.ABV&&c.isView,g=p.prototype.slice,y=i.VIEW,d="ArrayBuffer";e(e.G+e.W+e.F*(c!==p),{ArrayBuffer:p}),e(e.S+e.F*!i.CONSTR,d,{isView:function isView(t){return a&&a(t)||u(t)&&y in t}}),e(e.P+e.U+e.F*r(3)(function(){return!new p(2).slice(1,Jt).byteLength}),d,{slice:function slice(t,n){if(g!==Jt&&n===Jt)return g.call(f(this),t);for(var r=f(this).byteLength,e=s(t,r),i=s(n===Jt?r:n,r),o=new(h(this,p))(l(i-e)),u=new v(this),c=new v(o),a=0;e<i;)c.setUint8(a++,u.getUint8(e++));return o}}),r(38)(d)},function(t,n,r){var e=r(0);e(e.G+e.W+e.F*!r(62).ABV,{DataView:r(92).DataView})},function(t,n,r){r(27)("Int8",1,function(e){return function Int8Array(t,n,r){return e(this,t,n,r)}})},function(t,n,r){r(27)("Uint8",1,function(e){return function Uint8Array(t,n,r){return e(this,t,n,r)}})},function(t,n,r){r(27)("Uint8",1,function(e){return function Uint8ClampedArray(t,n,r){return e(this,t,n,r)}},!0)},function(t,n,r){r(27)("Int16",2,function(e){return function Int16Array(t,n,r){return e(this,t,n,r)}})},function(t,n,r){r(27)("Uint16",2,function(e){return function Uint16Array(t,n,r){return e(this,t,n,r)}})},function(t,n,r){r(27)("Int32",4,function(e){return function Int32Array(t,n,r){return e(this,t,n,r)}})},function(t,n,r){r(27)("Uint32",4,function(e){return function Uint32Array(t,n,r){return e(this,t,n,r)}})},function(t,n,r){r(27)("Float32",4,function(e){return function Float32Array(t,n,r){return e(this,t,n,r)}})},function(t,n,r){r(27)("Float64",8,function(e){return function Float64Array(t,n,r){return e(this,t,n,r)}})},function(t,n,r){var e=r(0),i=r(52)(!0);e(e.P,"Array",{includes:function includes(t){return i(this,t,1<arguments.length?arguments[1]:Jt)}}),r(31)("includes")},function(t,n,r){var e=r(0),i=r(123),o=r(9),u=r(6),c=r(10),a=r(84);e(e.P,"Array",{flatMap:function flatMap(t){var n,r,e=o(this);return c(t),n=u(e.length),r=a(e,0),i(r,e,e,n,0,1,t,arguments[1]),r}}),r(31)("flatMap")},function(t,n,r){var e=r(0),i=r(123),o=r(9),u=r(6),c=r(20),a=r(84);e(e.P,"Array",{flatten:function flatten(){var t=arguments[0],n=o(this),r=u(n.length),e=a(n,0);return i(e,n,n,r,0,t===Jt?1:c(t)),e}}),r(31)("flatten")},function(t,n,r){var e=r(0),i=r(55)(!0);e(e.P,"String",{at:function at(t){return i(this,t)}})},function(t,n,r){var e=r(0),i=r(124),o=r(60),u=/Version\/10\.\d+(\.\d+)?( Mobile\/\w+)? Safari\//.test(o);e(e.P+e.F*u,"String",{padStart:function padStart(t){return i(this,t,1<arguments.length?arguments[1]:Jt,!0)}})},function(t,n,r){var e=r(0),i=r(124),o=r(60),u=/Version\/10\.\d+(\.\d+)?( Mobile\/\w+)? Safari\//.test(o);e(e.P+e.F*u,"String",{padEnd:function padEnd(t){return i(this,t,1<arguments.length?arguments[1]:Jt,!1)}})},function(t,n,r){r(45)("trimLeft",function(t){return function trimLeft(){return t(this,1)}},"trimStart")},function(t,n,r){r(45)("trimRight",function(t){return function trimRight(){return t(this,2)}},"trimEnd")},function(t,n,r){var e=r(0),i=r(23),o=r(6),u=r(56),c=r(50),a=RegExp.prototype,f=function(t,n){this._r=t,this._s=n};r(80)(f,"RegExp String",function next(){var t=this._r.exec(this._s);return{value:t,done:null===t}}),e(e.P,"String",{matchAll:function matchAll(t){if(i(this),!u(t))throw TypeError(t+" is not a regexp!");var n=String(this),r="flags"in a?String(t.flags):c.call(t),e=new RegExp(t.source,~r.indexOf("g")?r:"g"+r);return e.lastIndex=o(t.lastIndex),new f(e,n)}})},function(t,n,r){r(67)("asyncIterator")},function(t,n,r){r(67)("observable")},function(t,n,r){var e=r(0),a=r(121),f=r(15),s=r(16),l=r(82);e(e.S,"Object",{getOwnPropertyDescriptors:function getOwnPropertyDescriptors(t){for(var n,r,e=f(t),i=s.f,o=a(e),u={},c=0;c<o.length;)(r=i(e,n=o[c++]))!==Jt&&l(u,n,r);return u}})},function(t,n,r){var e=r(0),i=r(125)(!1);e(e.S,"Object",{values:function values(t){return i(t)}})},function(t,n,r){var e=r(0),i=r(125)(!0);e(e.S,"Object",{entries:function entries(t){return i(t)}})},function(t,n,r){var e=r(0),i=r(9),o=r(10),u=r(8);r(7)&&e(e.P+r(63),"Object",{__defineGetter__:function __defineGetter__(t,n){u.f(i(this),t,{get:o(n),enumerable:!0,configurable:!0})}})},function(t,n,r){var e=r(0),i=r(9),o=r(10),u=r(8);r(7)&&e(e.P+r(63),"Object",{__defineSetter__:function __defineSetter__(t,n){u.f(i(this),t,{set:o(n),enumerable:!0,configurable:!0})}})},function(t,n,r){var e=r(0),i=r(9),o=r(22),u=r(17),c=r(16).f;r(7)&&e(e.P+r(63),"Object",{__lookupGetter__:function __lookupGetter__(t){var n,r=i(this),e=o(t,!0);do{if(n=c(r,e))return n.get}while(r=u(r))}})},function(t,n,r){var e=r(0),i=r(9),o=r(22),u=r(17),c=r(16).f;r(7)&&e(e.P+r(63),"Object",{__lookupSetter__:function __lookupSetter__(t){var n,r=i(this),e=o(t,!0);do{if(n=c(r,e))return n.set}while(r=u(r))}})},function(t,n,r){var e=r(0);e(e.P+e.R,"Map",{toJSON:r(126)("Map")})},function(t,n,r){var e=r(0);e(e.P+e.R,"Set",{toJSON:r(126)("Set")})},function(t,n,r){r(64)("Map")},function(t,n,r){r(64)("Set")},function(t,n,r){r(64)("WeakMap")},function(t,n,r){r(64)("WeakSet")},function(t,n,r){r(65)("Map")},function(t,n,r){r(65)("Set")},function(t,n,r){r(65)("WeakMap")},function(t,n,r){r(65)("WeakSet")},function(t,n,r){var e=r(0);e(e.G,{global:r(2)})},function(t,n,r){var e=r(0);e(e.S,"System",{global:r(2)})},function(t,n,r){var e=r(0),i=r(19);e(e.S,"Error",{isError:function isError(t){return"Error"===i(t)}})},function(t,n,r){var e=r(0);e(e.S,"Math",{clamp:function clamp(t,n,r){return Math.min(r,Math.max(n,t))}})},function(t,n,r){var e=r(0);e(e.S,"Math",{DEG_PER_RAD:Math.PI/180})},function(t,n,r){var e=r(0),i=180/Math.PI;e(e.S,"Math",{degrees:function degrees(t){return t*i}})},function(t,n,r){var e=r(0),o=r(128),u=r(107);e(e.S,"Math",{fscale:function fscale(t,n,r,e,i){return u(o(t,n,r,e,i))}})},function(t,n,r){var e=r(0);e(e.S,"Math",{iaddh:function iaddh(t,n,r,e){var i=t>>>0,o=r>>>0;return(n>>>0)+(e>>>0)+((i&o|(i|o)&~(i+o>>>0))>>>31)|0}})},function(t,n,r){var e=r(0);e(e.S,"Math",{isubh:function isubh(t,n,r,e){var i=t>>>0,o=r>>>0;return(n>>>0)-(e>>>0)-((~i&o|~(i^o)&i-o>>>0)>>>31)|0}})},function(t,n,r){var e=r(0);e(e.S,"Math",{imulh:function imulh(t,n){var r=+t,e=+n,i=65535&r,o=65535&e,u=r>>16,c=e>>16,a=(u*o>>>0)+(i*o>>>16);return u*c+(a>>16)+((i*c>>>0)+(65535&a)>>16)}})},function(t,n,r){var e=r(0);e(e.S,"Math",{RAD_PER_DEG:180/Math.PI})},function(t,n,r){var e=r(0),i=Math.PI/180;e(e.S,"Math",{radians:function radians(t){return t*i}})},function(t,n,r){var e=r(0);e(e.S,"Math",{scale:r(128)})},function(t,n,r){var e=r(0);e(e.S,"Math",{umulh:function umulh(t,n){var r=+t,e=+n,i=65535&r,o=65535&e,u=r>>>16,c=e>>>16,a=(u*o>>>0)+(i*o>>>16);return u*c+(a>>>16)+((i*c>>>0)+(65535&a)>>>16)}})},function(t,n,r){var e=r(0);e(e.S,"Math",{signbit:function signbit(t){return(t=+t)!=t?t:0==t?1/t==Infinity:0<t}})},function(t,n,r){var e=r(0),i=r(26),o=r(2),u=r(51),c=r(115);e(e.P+e.R,"Promise",{"finally":function(n){var r=u(this,i.Promise||o.Promise),t="function"==typeof n;return this.then(t?function(t){return c(r,n()).then(function(){return t})}:n,t?function(t){return c(r,n()).then(function(){throw t})}:n)}})},function(t,n,r){var e=r(0),i=r(91),o=r(114);e(e.S,"Promise",{"try":function(t){var n=i.f(this),r=o(t);return(r.e?n.reject:n.resolve)(r.v),n.promise}})},function(t,n,r){var e=r(28),i=r(1),o=e.key,u=e.set;e.exp({defineMetadata:function defineMetadata(t,n,r,e){u(t,n,i(r),o(e))}})},function(t,n,r){var e=r(28),o=r(1),u=e.key,c=e.map,a=e.store;e.exp({deleteMetadata:function deleteMetadata(t,n){var r=arguments.length<3?Jt:u(arguments[2]),e=c(o(n),r,!1);if(e===Jt||!e["delete"](t))return!1;if(e.size)return!0;var i=a.get(n);return i["delete"](r),!!i.size||a["delete"](n)}})},function(t,n,r){var e=r(28),i=r(1),o=r(17),u=e.has,c=e.get,a=e.key,f=function(t,n,r){if(u(t,n,r))return c(t,n,r);var e=o(n);return null!==e?f(t,e,r):Jt};e.exp({getMetadata:function getMetadata(t,n){return f(t,i(n),arguments.length<3?Jt:a(arguments[2]))}})},function(t,n,r){var o=r(118),u=r(127),e=r(28),i=r(1),c=r(17),a=e.keys,f=e.key,s=function(t,n){var r=a(t,n),e=c(t);if(null===e)return r;var i=s(e,n);return i.length?r.length?u(new o(r.concat(i))):i:r};e.exp({getMetadataKeys:function getMetadataKeys(t){return s(i(t),arguments.length<2?Jt:f(arguments[1]))}})},function(t,n,r){var e=r(28),i=r(1),o=e.get,u=e.key;e.exp({getOwnMetadata:function getOwnMetadata(t,n){return o(t,i(n),arguments.length<3?Jt:u(arguments[2]))}})},function(t,n,r){var e=r(28),i=r(1),o=e.keys,u=e.key;e.exp({getOwnMetadataKeys:function getOwnMetadataKeys(t){return o(i(t),arguments.length<2?Jt:u(arguments[1]))}})},function(t,n,r){var e=r(28),i=r(1),o=r(17),u=e.has,c=e.key,a=function(t,n,r){if(u(t,n,r))return!0;var e=o(n);return null!==e&&a(t,e,r)};e.exp({hasMetadata:function hasMetadata(t,n){return a(t,i(n),arguments.length<3?Jt:c(arguments[2]))}})},function(t,n,r){var e=r(28),i=r(1),o=e.has,u=e.key;e.exp({hasOwnMetadata:function hasOwnMetadata(t,n){return o(t,i(n),arguments.length<3?Jt:u(arguments[2]))}})},function(t,n,r){var e=r(28),i=r(1),o=r(10),u=e.key,c=e.set;e.exp({metadata:function metadata(r,e){return function decorator(t,n){c(r,e,(n!==Jt?i:o)(t),u(n))}}})},function(t,n,r){var e=r(0),i=r(90)(),o=r(2).process,u="process"==r(19)(o);e(e.G,{asap:function asap(t){var n=u&&o.domain;i(n?n.bind(t):t)}})},function(t,n,r){var e=r(0),o=r(2),u=r(26),i=r(90)(),c=r(5)("observable"),a=r(10),f=r(1),s=r(39),l=r(41),h=r(11),p=r(40),v=p.RETURN,g=function(t){return null==t?Jt:a(t)},y=function(t){var n=t._c;n&&(t._c=Jt,n())},d=function(t){return t._o===Jt},b=function(t){d(t)||(t._o=Jt,y(t))},S=function(t,n){f(t),this._c=Jt,this._o=t,t=new _(this);try{var r=n(t),e=r;null!=r&&("function"==typeof r.unsubscribe?r=function(){e.unsubscribe()}:a(r),this._c=r)}catch(i){return void t.error(i)}d(this)&&y(this)};S.prototype=l({},{unsubscribe:function unsubscribe(){b(this)}});var _=function(t){this._s=t};_.prototype=l({},{next:function next(t){var n=this._s;if(!d(n)){var r=n._o;try{var e=g(r.next);if(e)return e.call(r,t)}catch(i){try{b(n)}finally{throw i}}}},error:function error(t){var n=this._s;if(d(n))throw t;var r=n._o;n._o=Jt;try{var e=g(r.error);if(!e)throw t;t=e.call(r,t)}catch(i){try{y(n)}finally{throw i}}return y(n),t},complete:function complete(t){var n=this._s;if(!d(n)){var r=n._o;n._o=Jt;try{var e=g(r.complete);t=e?e.call(r,t):Jt}catch(i){try{y(n)}finally{throw i}}return y(n),t}}});var x=function Observable(t){s(this,x,"Observable","_f")._f=a(t)};l(x.prototype,{subscribe:function subscribe(t){return new S(t,this._f)},forEach:function forEach(i){var n=this;return new(u.Promise||o.Promise)(function(t,r){a(i);var e=n.subscribe({next:function(t){try{return i(t)}catch(n){r(n),e.unsubscribe()}},error:r,complete:t})})}}),l(x,{from:function from(e){var t="function"==typeof this?this:x,n=g(f(e)[c]);if(n){var r=f(n.call(e));return r.constructor===t?r:new t(function(t){return r.subscribe(t)})}return new t(function(n){var r=!1;return i(function(){if(!r){try{if(p(e,!1,function(t){if(n.next(t),r)return v})===v)return}catch(t){if(r)throw t;return void n.error(t)}n.complete()}}),function(){r=!0}})},of:function of(){for(var t=0,n=arguments.length,e=new Array(n);t<n;)e[t]=arguments[t++];return new("function"==typeof this?this:x)(function(n){var r=!1;return i(function(){if(!r){for(var t=0;t<e.length;++t)if(n.next(e[t]),r)return;n.complete()}}),function(){r=!0}})}}),h(x.prototype,c,function(){return this}),e(e.G,{Observable:x}),r(38)("Observable")},function(t,n,r){var e=r(0),i=r(89);e(e.G+e.B,{setImmediate:i.set,clearImmediate:i.clear})},function(t,n,r){for(var e=r(86),i=r(34),o=r(12),u=r(2),c=r(11),a=r(46),f=r(5),s=f("iterator"),l=f("toStringTag"),h=a.Array,p={CSSRuleList:!0,CSSStyleDeclaration:!1,CSSValueList:!1,ClientRectList:!1,DOMRectList:!1,DOMStringList:!1,DOMTokenList:!0,DataTransferItemList:!1,FileList:!1,HTMLAllCollection:!1,HTMLCollection:!1,HTMLFormElement:!1,HTMLSelectElement:!1,MediaList:!0,MimeTypeArray:!1,NamedNodeMap:!1,NodeList:!0,PaintRequestList:!1,Plugin:!1,PluginArray:!1,SVGLengthList:!1,SVGNumberList:!1,SVGPathSegList:!1,SVGPointList:!1,SVGStringList:!1,SVGTransformList:!1,SourceBufferList:!1,StyleSheetList:!0,TextTrackCueList:!1,TextTrackList:!1,TouchList:!1},v=i(p),g=0;g<v.length;g++){var y,d=v[g],b=p[d],S=u[d],_=S&&S.prototype;if(_&&(_[s]||c(_,s,h),_[l]||c(_,l,d),a[d]=h,b))for(y in e)_[y]||o(_,y,e[y],!0)}},function(t,n,r){var e=r(2),i=r(0),o=r(60),u=[].slice,c=/MSIE .\./.test(o),a=function(i){return function(t,n){var r=2<arguments.length,e=!!r&&u.call(arguments,2);return i(r?function(){("function"==typeof t?t:Function(t)).apply(this,e)}:t,n)}};i(i.G+i.B+i.F*c,{setTimeout:a(e.setTimeout),setInterval:a(e.setInterval)})}]),"undefined"!=typeof module&&module.exports?module.exports=e:"function"==typeof define&&define.amd?define(function(){return e}):i.core=e}(1,1);
//# sourceMappingURL=shim.min.js.map</script>
<script>/** @license React v17.0.0
 * react.production.min.js
 *
 * Copyright (c) Facebook, Inc. and its affiliates.
 *
 * This source code is licensed under the MIT license found in the
 * LICENSE file in the root directory of this source tree.
 */
(function(){'use strict';(function(c,x){"object"===typeof exports&&"undefined"!==typeof module?x(exports):"function"===typeof define&&define.amd?define(["exports"],x):(c=c||self,x(c.React={}))})(this,function(c){function x(a){if(null===a||"object"!==typeof a)return null;a=Y&&a[Y]||a["@@iterator"];return"function"===typeof a?a:null}function y(a){for(var b="https://reactjs.org/docs/error-decoder.html?invariant="+a,e=1;e<arguments.length;e++)b+="&args[]="+encodeURIComponent(arguments[e]);return"Minified React error #"+
a+"; visit "+b+" for the full message or use the non-minified dev environment for full errors and additional helpful warnings."}function v(a,b,e){this.props=a;this.context=b;this.refs=Z;this.updater=e||aa}function ba(){}function K(a,b,e){this.props=a;this.context=b;this.refs=Z;this.updater=e||aa}function ca(a,b,e){var l,f={},c=null,da=null;if(null!=b)for(l in void 0!==b.ref&&(da=b.ref),void 0!==b.key&&(c=""+b.key),b)ea.call(b,l)&&!fa.hasOwnProperty(l)&&(f[l]=b[l]);var k=arguments.length-2;if(1===
k)f.children=e;else if(1<k){for(var h=Array(k),d=0;d<k;d++)h[d]=arguments[d+2];f.children=h}if(a&&a.defaultProps)for(l in k=a.defaultProps,k)void 0===f[l]&&(f[l]=k[l]);return{$$typeof:w,type:a,key:c,ref:da,props:f,_owner:L.current}}function va(a,b){return{$$typeof:w,type:a.type,key:b,ref:a.ref,props:a.props,_owner:a._owner}}function M(a){return"object"===typeof a&&null!==a&&a.$$typeof===w}function wa(a){var b={"=":"=0",":":"=2"};return"$"+a.replace(/[=:]/g,function(a){return b[a]})}function N(a,b){return"object"===
typeof a&&null!==a&&null!=a.key?wa(""+a.key):b.toString(36)}function C(a,b,e,l,f){var c=typeof a;if("undefined"===c||"boolean"===c)a=null;var d=!1;if(null===a)d=!0;else switch(c){case "string":case "number":d=!0;break;case "object":switch(a.$$typeof){case w:case ha:d=!0}}if(d)return d=a,f=f(d),a=""===l?"."+N(d,0):l,Array.isArray(f)?(e="",null!=a&&(e=a.replace(ia,"$&/")+"/"),C(f,b,e,"",function(a){return a})):null!=f&&(M(f)&&(f=va(f,e+(!f.key||d&&d.key===f.key?"":(""+f.key).replace(ia,"$&/")+"/")+
a)),b.push(f)),1;d=0;l=""===l?".":l+":";if(Array.isArray(a))for(var k=0;k<a.length;k++){c=a[k];var h=l+N(c,k);d+=C(c,b,e,h,f)}else if(h=x(a),"function"===typeof h)for(a=h.call(a),k=0;!(c=a.next()).done;)c=c.value,h=l+N(c,k++),d+=C(c,b,e,h,f);else if("object"===c)throw b=""+a,Error(y(31,"[object Object]"===b?"object with keys {"+Object.keys(a).join(", ")+"}":b));return d}function D(a,b,e){if(null==a)return a;var l=[],c=0;C(a,l,"","",function(a){return b.call(e,a,c++)});return l}function xa(a){if(-1===
a._status){var b=a._result;b=b();a._status=0;a._result=b;b.then(function(b){0===a._status&&(b=b.default,a._status=1,a._result=b)},function(b){0===a._status&&(a._status=2,a._result=b)})}if(1===a._status)return a._result;throw a._result;}function n(){var a=ja.current;if(null===a)throw Error(y(321));return a}function O(a,b){var e=a.length;a.push(b);a:for(;;){var c=e-1>>>1,f=a[c];if(void 0!==f&&0<E(f,b))a[c]=b,a[e]=f,e=c;else break a}}function p(a){a=a[0];return void 0===a?null:a}function F(a){var b=
a[0];if(void 0!==b){var e=a.pop();if(e!==b){a[0]=e;a:for(var c=0,f=a.length;c<f;){var d=2*(c+1)-1,g=a[d],k=d+1,h=a[k];if(void 0!==g&&0>E(g,e))void 0!==h&&0>E(h,g)?(a[c]=h,a[k]=e,c=k):(a[c]=g,a[d]=e,c=d);else if(void 0!==h&&0>E(h,e))a[c]=h,a[k]=e,c=k;else break a}}return b}return null}function E(a,b){var e=a.sortIndex-b.sortIndex;return 0!==e?e:a.id-b.id}function P(a){for(var b=p(r);null!==b;){if(null===b.callback)F(r);else if(b.startTime<=a)F(r),b.sortIndex=b.expirationTime,O(q,b);else break;b=p(r)}}
function Q(a){z=!1;P(a);if(!u)if(null!==p(q))u=!0,A(R);else{var b=p(r);null!==b&&G(Q,b.startTime-a)}}function R(a,b){u=!1;z&&(z=!1,S());H=!0;var e=g;try{P(b);for(m=p(q);null!==m&&(!(m.expirationTime>b)||a&&!T());){var c=m.callback;if("function"===typeof c){m.callback=null;g=m.priorityLevel;var f=c(m.expirationTime<=b);b=t();"function"===typeof f?m.callback=f:m===p(q)&&F(q);P(b)}else F(q);m=p(q)}if(null!==m)var d=!0;else{var n=p(r);null!==n&&G(Q,n.startTime-b);d=!1}return d}finally{m=null,g=e,H=!1}}
var w=60103,ha=60106;c.Fragment=60107;c.StrictMode=60108;c.Profiler=60114;var ka=60109,la=60110,ma=60112;c.Suspense=60113;var na=60115,oa=60116;if("function"===typeof Symbol&&Symbol.for){var d=Symbol.for;w=d("react.element");ha=d("react.portal");c.Fragment=d("react.fragment");c.StrictMode=d("react.strict_mode");c.Profiler=d("react.profiler");ka=d("react.provider");la=d("react.context");ma=d("react.forward_ref");c.Suspense=d("react.suspense");na=d("react.memo");oa=d("react.lazy")}var Y="function"===
typeof Symbol&&Symbol.iterator,ya=Object.prototype.hasOwnProperty,U=Object.assign||function(a,b){if(null==a)throw new TypeError("Object.assign target cannot be null or undefined");for(var e=Object(a),c=1;c<arguments.length;c++){var d=arguments[c];if(null!=d){var g=void 0;d=Object(d);for(g in d)ya.call(d,g)&&(e[g]=d[g])}}return e},aa={isMounted:function(a){return!1},enqueueForceUpdate:function(a,b,c){},enqueueReplaceState:function(a,b,c,d){},enqueueSetState:function(a,b,c,d){}},Z={};v.prototype.isReactComponent=
{};v.prototype.setState=function(a,b){if("object"!==typeof a&&"function"!==typeof a&&null!=a)throw Error(y(85));this.updater.enqueueSetState(this,a,b,"setState")};v.prototype.forceUpdate=function(a){this.updater.enqueueForceUpdate(this,a,"forceUpdate")};ba.prototype=v.prototype;d=K.prototype=new ba;d.constructor=K;U(d,v.prototype);d.isPureReactComponent=!0;var L={current:null},ea=Object.prototype.hasOwnProperty,fa={key:!0,ref:!0,__self:!0,__source:!0},ia=/\/+/g,ja={current:null},V;if("object"===typeof performance&&
"function"===typeof performance.now){var za=performance;var t=function(){return za.now()}}else{var pa=Date,Aa=pa.now();t=function(){return pa.now()-Aa}}if("undefined"===typeof window||"function"!==typeof MessageChannel){var B=null,qa=null,ra=function(){if(null!==B)try{var a=t();B(!0,a);B=null}catch(b){throw setTimeout(ra,0),b;}};var A=function(a){null!==B?setTimeout(A,0,a):(B=a,setTimeout(ra,0))};var G=function(a,b){qa=setTimeout(a,b)};var S=function(){clearTimeout(qa)};var T=function(){return!1};
d=V=function(){}}else{var Ba=window.setTimeout,Ca=window.clearTimeout;"undefined"!==typeof console&&(d=window.cancelAnimationFrame,"function"!==typeof window.requestAnimationFrame&&console.error("This browser doesn't support requestAnimationFrame. Make sure that you load a polyfill in older browsers. https://reactjs.org/link/react-polyfills"),"function"!==typeof d&&console.error("This browser doesn't support cancelAnimationFrame. Make sure that you load a polyfill in older browsers. https://reactjs.org/link/react-polyfills"));
var I=!1,J=null,W=-1,sa=5,ta=0;T=function(){return t()>=ta};d=function(){};V=function(a){0>a||125<a?console.error("forceFrameRate takes a positive int between 0 and 125, forcing frame rates higher than 125 fps is not supported"):sa=0<a?Math.floor(1E3/a):5};var ua=new MessageChannel,X=ua.port2;ua.port1.onmessage=function(){if(null!==J){var a=t();ta=a+sa;try{J(!0,a)?X.postMessage(null):(I=!1,J=null)}catch(b){throw X.postMessage(null),b;}}else I=!1};A=function(a){J=a;I||(I=!0,X.postMessage(null))};G=
function(a,b){W=Ba(function(){a(t())},b)};S=function(){Ca(W);W=-1}}var q=[],r=[],Da=1,m=null,g=3,H=!1,u=!1,z=!1,Ea=0;d={ReactCurrentDispatcher:ja,ReactCurrentOwner:L,IsSomeRendererActing:{current:!1},ReactCurrentBatchConfig:{transition:0},assign:U,Scheduler:{__proto__:null,unstable_ImmediatePriority:1,unstable_UserBlockingPriority:2,unstable_NormalPriority:3,unstable_IdlePriority:5,unstable_LowPriority:4,unstable_runWithPriority:function(a,b){switch(a){case 1:case 2:case 3:case 4:case 5:break;default:a=
3}var c=g;g=a;try{return b()}finally{g=c}},unstable_next:function(a){switch(g){case 1:case 2:case 3:var b=3;break;default:b=g}var c=g;g=b;try{return a()}finally{g=c}},unstable_scheduleCallback:function(a,b,c){var d=t();"object"===typeof c&&null!==c?(c=c.delay,c="number"===typeof c&&0<c?d+c:d):c=d;switch(a){case 1:var e=-1;break;case 2:e=250;break;case 5:e=1073741823;break;case 4:e=1E4;break;default:e=5E3}e=c+e;a={id:Da++,callback:b,priorityLevel:a,startTime:c,expirationTime:e,sortIndex:-1};c>d?(a.sortIndex=
c,O(r,a),null===p(q)&&a===p(r)&&(z?S():z=!0,G(Q,c-d))):(a.sortIndex=e,O(q,a),u||H||(u=!0,A(R)));return a},unstable_cancelCallback:function(a){a.callback=null},unstable_wrapCallback:function(a){var b=g;return function(){var c=g;g=b;try{return a.apply(this,arguments)}finally{g=c}}},unstable_getCurrentPriorityLevel:function(){return g},get unstable_shouldYield(){return T},unstable_requestPaint:d,unstable_continueExecution:function(){u||H||(u=!0,A(R))},unstable_pauseExecution:function(){},unstable_getFirstCallbackNode:function(){return p(q)},
get unstable_now(){return t},get unstable_forceFrameRate(){return V},unstable_Profiling:null},SchedulerTracing:{__proto__:null,__interactionsRef:null,__subscriberRef:null,unstable_clear:function(a){return a()},unstable_getCurrent:function(){return null},unstable_getThreadID:function(){return++Ea},unstable_trace:function(a,b,c){return c()},unstable_wrap:function(a){return a},unstable_subscribe:function(a){},unstable_unsubscribe:function(a){}}};c.Children={map:D,forEach:function(a,b,c){D(a,function(){b.apply(this,
arguments)},c)},count:function(a){var b=0;D(a,function(){b++});return b},toArray:function(a){return D(a,function(a){return a})||[]},only:function(a){if(!M(a))throw Error(y(143));return a}};c.Component=v;c.PureComponent=K;c.__SECRET_INTERNALS_DO_NOT_USE_OR_YOU_WILL_BE_FIRED=d;c.cloneElement=function(a,b,c){if(null===a||void 0===a)throw Error(y(267,a));var d=U({},a.props),e=a.key,g=a.ref,n=a._owner;if(null!=b){void 0!==b.ref&&(g=b.ref,n=L.current);void 0!==b.key&&(e=""+b.key);if(a.type&&a.type.defaultProps)var k=
a.type.defaultProps;for(h in b)ea.call(b,h)&&!fa.hasOwnProperty(h)&&(d[h]=void 0===b[h]&&void 0!==k?k[h]:b[h])}var h=arguments.length-2;if(1===h)d.children=c;else if(1<h){k=Array(h);for(var m=0;m<h;m++)k[m]=arguments[m+2];d.children=k}return{$$typeof:w,type:a.type,key:e,ref:g,props:d,_owner:n}};c.createContext=function(a,b){void 0===b&&(b=null);a={$$typeof:la,_calculateChangedBits:b,_currentValue:a,_currentValue2:a,_threadCount:0,Provider:null,Consumer:null};a.Provider={$$typeof:ka,_context:a};return a.Consumer=
a};c.createElement=ca;c.createFactory=function(a){var b=ca.bind(null,a);b.type=a;return b};c.createRef=function(){return{current:null}};c.forwardRef=function(a){return{$$typeof:ma,render:a}};c.isValidElement=M;c.lazy=function(a){return{$$typeof:oa,_payload:{_status:-1,_result:a},_init:xa}};c.memo=function(a,b){return{$$typeof:na,type:a,compare:void 0===b?null:b}};c.useCallback=function(a,b){return n().useCallback(a,b)};c.useContext=function(a,b){return n().useContext(a,b)};c.useDebugValue=function(a,
b){};c.useEffect=function(a,b){return n().useEffect(a,b)};c.useImperativeHandle=function(a,b,c){return n().useImperativeHandle(a,b,c)};c.useLayoutEffect=function(a,b){return n().useLayoutEffect(a,b)};c.useMemo=function(a,b){return n().useMemo(a,b)};c.useReducer=function(a,b,c){return n().useReducer(a,b,c)};c.useRef=function(a){return n().useRef(a)};c.useState=function(a){return n().useState(a)};c.version="17.0.0"});
})();
</script>
<script>/** @license React v17.0.0
 * react-dom.production.min.js
 *
 * Copyright (c) Facebook, Inc. and its affiliates.
 *
 * This source code is licensed under the MIT license found in the
 * LICENSE file in the root directory of this source tree.
 */
(function(){/*
 Modernizr 3.0.0pre (Custom Build) | MIT
*/
'use strict';(function(M,ha){"object"===typeof exports&&"undefined"!==typeof module?ha(exports,require("react")):"function"===typeof define&&define.amd?define(["exports","react"],ha):(M=M||self,ha(M.ReactDOM={},M.React))})(this,function(M,ha){function m(a){for(var b="https://reactjs.org/docs/error-decoder.html?invariant="+a,c=1;c<arguments.length;c++)b+="&args[]="+encodeURIComponent(arguments[c]);return"Minified React error #"+a+"; visit "+b+" for the full message or use the non-minified dev environment for full errors and additional helpful warnings."}
function Ta(a,b){gb(a,b);gb(a+"Capture",b)}function gb(a,b){Ib[a]=b;for(a=0;a<b.length;a++)yf.add(b[a])}function ki(a){if(zf.call(Af,a))return!0;if(zf.call(Bf,a))return!1;if(li.test(a))return Af[a]=!0;Bf[a]=!0;return!1}function mi(a,b,c,d){if(null!==c&&0===c.type)return!1;switch(typeof b){case "function":case "symbol":return!0;case "boolean":if(d)return!1;if(null!==c)return!c.acceptsBooleans;a=a.toLowerCase().slice(0,5);return"data-"!==a&&"aria-"!==a;default:return!1}}function ni(a,b,c,d){if(null===
b||"undefined"===typeof b||mi(a,b,c,d))return!0;if(d)return!1;if(null!==c)switch(c.type){case 3:return!b;case 4:return!1===b;case 5:return isNaN(b);case 6:return isNaN(b)||1>b}return!1}function Q(a,b,c,d,e,f,g){this.acceptsBooleans=2===b||3===b||4===b;this.attributeName=d;this.attributeNamespace=e;this.mustUseProperty=c;this.propertyName=a;this.type=b;this.sanitizeURL=f;this.removeEmptyString=g}function Ed(a,b,c,d){var e=I.hasOwnProperty(b)?I[b]:null;var f=null!==e?0===e.type:d?!1:!(2<b.length)||
"o"!==b[0]&&"O"!==b[0]||"n"!==b[1]&&"N"!==b[1]?!1:!0;f||(ni(b,c,e,d)&&(c=null),d||null===e?ki(b)&&(null===c?a.removeAttribute(b):a.setAttribute(b,""+c)):e.mustUseProperty?a[e.propertyName]=null===c?3===e.type?!1:"":c:(b=e.attributeName,d=e.attributeNamespace,null===c?a.removeAttribute(b):(e=e.type,c=3===e||4===e&&!0===c?"":""+c,d?a.setAttributeNS(d,b,c):a.setAttribute(b,c))))}function Jb(a){if(null===a||"object"!==typeof a)return null;a=Cf&&a[Cf]||a["@@iterator"];return"function"===typeof a?a:null}
function Kb(a,b,c){if(void 0===Fd)try{throw Error();}catch(d){Fd=(b=d.stack.trim().match(/\n( *(at )?)/))&&b[1]||""}return"\n"+Fd+a}function Bc(a,b){if(!a||Gd)return"";Gd=!0;var c=Error.prepareStackTrace;Error.prepareStackTrace=void 0;try{if(b)if(b=function(){throw Error();},Object.defineProperty(b.prototype,"props",{set:function(){throw Error();}}),"object"===typeof Reflect&&Reflect.construct){try{Reflect.construct(b,[])}catch(k){var d=k}Reflect.construct(a,[],b)}else{try{b.call()}catch(k){d=k}a.call(b.prototype)}else{try{throw Error();
}catch(k){d=k}a()}}catch(k){if(k&&d&&"string"===typeof k.stack){for(var e=k.stack.split("\n"),f=d.stack.split("\n"),g=e.length-1,h=f.length-1;1<=g&&0<=h&&e[g]!==f[h];)h--;for(;1<=g&&0<=h;g--,h--)if(e[g]!==f[h]){if(1!==g||1!==h){do if(g--,h--,0>h||e[g]!==f[h])return"\n"+e[g].replace(" at new "," at ");while(1<=g&&0<=h)}break}}}finally{Gd=!1,Error.prepareStackTrace=c}return(a=a?a.displayName||a.name:"")?Kb(a):""}function oi(a){switch(a.tag){case 5:return Kb(a.type);case 16:return Kb("Lazy");case 13:return Kb("Suspense");
case 19:return Kb("SuspenseList");case 0:case 2:case 15:return a=Bc(a.type,!1),a;case 11:return a=Bc(a.type.render,!1),a;case 22:return a=Bc(a.type._render,!1),a;case 1:return a=Bc(a.type,!0),a;default:return""}}function hb(a){if(null==a)return null;if("function"===typeof a)return a.displayName||a.name||null;if("string"===typeof a)return a;switch(a){case wa:return"Fragment";case Ua:return"Portal";case Lb:return"Profiler";case Hd:return"StrictMode";case Mb:return"Suspense";case Cc:return"SuspenseList"}if("object"===
typeof a)switch(a.$$typeof){case Id:return(a.displayName||"Context")+".Consumer";case Jd:return(a._context.displayName||"Context")+".Provider";case Dc:var b=a.render;b=b.displayName||b.name||"";return a.displayName||(""!==b?"ForwardRef("+b+")":"ForwardRef");case Ec:return hb(a.type);case Kd:return hb(a._render);case Ld:b=a._payload;a=a._init;try{return hb(a(b))}catch(c){}}return null}function xa(a){switch(typeof a){case "boolean":case "number":case "object":case "string":case "undefined":return a;
default:return""}}function Df(a){var b=a.type;return(a=a.nodeName)&&"input"===a.toLowerCase()&&("checkbox"===b||"radio"===b)}function pi(a){var b=Df(a)?"checked":"value",c=Object.getOwnPropertyDescriptor(a.constructor.prototype,b),d=""+a[b];if(!a.hasOwnProperty(b)&&"undefined"!==typeof c&&"function"===typeof c.get&&"function"===typeof c.set){var e=c.get,f=c.set;Object.defineProperty(a,b,{configurable:!0,get:function(){return e.call(this)},set:function(a){d=""+a;f.call(this,a)}});Object.defineProperty(a,
b,{enumerable:c.enumerable});return{getValue:function(){return d},setValue:function(a){d=""+a},stopTracking:function(){a._valueTracker=null;delete a[b]}}}}function Fc(a){a._valueTracker||(a._valueTracker=pi(a))}function Ef(a){if(!a)return!1;var b=a._valueTracker;if(!b)return!0;var c=b.getValue();var d="";a&&(d=Df(a)?a.checked?"true":"false":a.value);a=d;return a!==c?(b.setValue(a),!0):!1}function Gc(a){a=a||("undefined"!==typeof document?document:void 0);if("undefined"===typeof a)return null;try{return a.activeElement||
a.body}catch(b){return a.body}}function Md(a,b){var c=b.checked;return B({},b,{defaultChecked:void 0,defaultValue:void 0,value:void 0,checked:null!=c?c:a._wrapperState.initialChecked})}function Ff(a,b){var c=null==b.defaultValue?"":b.defaultValue,d=null!=b.checked?b.checked:b.defaultChecked;c=xa(null!=b.value?b.value:c);a._wrapperState={initialChecked:d,initialValue:c,controlled:"checkbox"===b.type||"radio"===b.type?null!=b.checked:null!=b.value}}function Gf(a,b){b=b.checked;null!=b&&Ed(a,"checked",
b,!1)}function Nd(a,b){Gf(a,b);var c=xa(b.value),d=b.type;if(null!=c)if("number"===d){if(0===c&&""===a.value||a.value!=c)a.value=""+c}else a.value!==""+c&&(a.value=""+c);else if("submit"===d||"reset"===d){a.removeAttribute("value");return}b.hasOwnProperty("value")?Od(a,b.type,c):b.hasOwnProperty("defaultValue")&&Od(a,b.type,xa(b.defaultValue));null==b.checked&&null!=b.defaultChecked&&(a.defaultChecked=!!b.defaultChecked)}function Hf(a,b,c){if(b.hasOwnProperty("value")||b.hasOwnProperty("defaultValue")){var d=
b.type;if(!("submit"!==d&&"reset"!==d||void 0!==b.value&&null!==b.value))return;b=""+a._wrapperState.initialValue;c||b===a.value||(a.value=b);a.defaultValue=b}c=a.name;""!==c&&(a.name="");a.defaultChecked=!!a._wrapperState.initialChecked;""!==c&&(a.name=c)}function Od(a,b,c){if("number"!==b||Gc(a.ownerDocument)!==a)null==c?a.defaultValue=""+a._wrapperState.initialValue:a.defaultValue!==""+c&&(a.defaultValue=""+c)}function qi(a){var b="";ha.Children.forEach(a,function(a){null!=a&&(b+=a)});return b}
function Pd(a,b){a=B({children:void 0},b);if(b=qi(b.children))a.children=b;return a}function ib(a,b,c,d){a=a.options;if(b){b={};for(var e=0;e<c.length;e++)b["$"+c[e]]=!0;for(c=0;c<a.length;c++)e=b.hasOwnProperty("$"+a[c].value),a[c].selected!==e&&(a[c].selected=e),e&&d&&(a[c].defaultSelected=!0)}else{c=""+xa(c);b=null;for(e=0;e<a.length;e++){if(a[e].value===c){a[e].selected=!0;d&&(a[e].defaultSelected=!0);return}null!==b||a[e].disabled||(b=a[e])}null!==b&&(b.selected=!0)}}function Qd(a,b){if(null!=
b.dangerouslySetInnerHTML)throw Error(m(91));return B({},b,{value:void 0,defaultValue:void 0,children:""+a._wrapperState.initialValue})}function If(a,b){var c=b.value;if(null==c){c=b.children;b=b.defaultValue;if(null!=c){if(null!=b)throw Error(m(92));if(Array.isArray(c)){if(!(1>=c.length))throw Error(m(93));c=c[0]}b=c}null==b&&(b="");c=b}a._wrapperState={initialValue:xa(c)}}function Jf(a,b){var c=xa(b.value),d=xa(b.defaultValue);null!=c&&(c=""+c,c!==a.value&&(a.value=c),null==b.defaultValue&&a.defaultValue!==
c&&(a.defaultValue=c));null!=d&&(a.defaultValue=""+d)}function Kf(a,b){b=a.textContent;b===a._wrapperState.initialValue&&""!==b&&null!==b&&(a.value=b)}function Lf(a){switch(a){case "svg":return"http://www.w3.org/2000/svg";case "math":return"http://www.w3.org/1998/Math/MathML";default:return"http://www.w3.org/1999/xhtml"}}function Rd(a,b){return null==a||"http://www.w3.org/1999/xhtml"===a?Lf(b):"http://www.w3.org/2000/svg"===a&&"foreignObject"===b?"http://www.w3.org/1999/xhtml":a}function Mf(a,b,c){return null==
b||"boolean"===typeof b||""===b?"":c||"number"!==typeof b||0===b||Nb.hasOwnProperty(a)&&Nb[a]?(""+b).trim():b+"px"}function Nf(a,b){a=a.style;for(var c in b)if(b.hasOwnProperty(c)){var d=0===c.indexOf("--"),e=Mf(c,b[c],d);"float"===c&&(c="cssFloat");d?a.setProperty(c,e):a[c]=e}}function Sd(a,b){if(b){if(ri[a]&&(null!=b.children||null!=b.dangerouslySetInnerHTML))throw Error(m(137,a));if(null!=b.dangerouslySetInnerHTML){if(null!=b.children)throw Error(m(60));if(!("object"===typeof b.dangerouslySetInnerHTML&&
"__html"in b.dangerouslySetInnerHTML))throw Error(m(61));}if(null!=b.style&&"object"!==typeof b.style)throw Error(m(62));}}function Td(a,b){if(-1===a.indexOf("-"))return"string"===typeof b.is;switch(a){case "annotation-xml":case "color-profile":case "font-face":case "font-face-src":case "font-face-uri":case "font-face-format":case "font-face-name":case "missing-glyph":return!1;default:return!0}}function Ud(a){a=a.target||a.srcElement||window;a.correspondingUseElement&&(a=a.correspondingUseElement);
return 3===a.nodeType?a.parentNode:a}function Of(a){if(a=Ob(a)){if("function"!==typeof Vd)throw Error(m(280));var b=a.stateNode;b&&(b=Hc(b),Vd(a.stateNode,a.type,b))}}function Pf(a){jb?kb?kb.push(a):kb=[a]:jb=a}function Qf(){if(jb){var a=jb,b=kb;kb=jb=null;Of(a);if(b)for(a=0;a<b.length;a++)Of(b[a])}}function Wd(){if(null!==jb||null!==kb)Xd(),Qf()}function si(a,b,c){if(Yd)return a(b,c);Yd=!0;try{return Rf(a,b,c)}finally{Yd=!1,Wd()}}function Pb(a,b){var c=a.stateNode;if(null===c)return null;var d=Hc(c);
if(null===d)return null;c=d[b];a:switch(b){case "onClick":case "onClickCapture":case "onDoubleClick":case "onDoubleClickCapture":case "onMouseDown":case "onMouseDownCapture":case "onMouseMove":case "onMouseMoveCapture":case "onMouseUp":case "onMouseUpCapture":case "onMouseEnter":(d=!d.disabled)||(a=a.type,d=!("button"===a||"input"===a||"select"===a||"textarea"===a));a=!d;break a;default:a=!1}if(a)return null;if(c&&"function"!==typeof c)throw Error(m(231,b,typeof c));return c}function ti(a,b,c,d,e,
f,g,h,k){Qb=!1;Ic=null;ui.apply(vi,arguments)}function wi(a,b,c,d,e,f,g,h,k){ti.apply(this,arguments);if(Qb){if(Qb){var v=Ic;Qb=!1;Ic=null}else throw Error(m(198));Jc||(Jc=!0,Zd=v)}}function Va(a){var b=a,c=a;if(a.alternate)for(;b.return;)b=b.return;else{a=b;do b=a,0!==(b.flags&1026)&&(c=b.return),a=b.return;while(a)}return 3===b.tag?c:null}function Sf(a){if(13===a.tag){var b=a.memoizedState;null===b&&(a=a.alternate,null!==a&&(b=a.memoizedState));if(null!==b)return b.dehydrated}return null}function Tf(a){if(Va(a)!==
a)throw Error(m(188));}function xi(a){var b=a.alternate;if(!b){b=Va(a);if(null===b)throw Error(m(188));return b!==a?null:a}for(var c=a,d=b;;){var e=c.return;if(null===e)break;var f=e.alternate;if(null===f){d=e.return;if(null!==d){c=d;continue}break}if(e.child===f.child){for(f=e.child;f;){if(f===c)return Tf(e),a;if(f===d)return Tf(e),b;f=f.sibling}throw Error(m(188));}if(c.return!==d.return)c=e,d=f;else{for(var g=!1,h=e.child;h;){if(h===c){g=!0;c=e;d=f;break}if(h===d){g=!0;d=e;c=f;break}h=h.sibling}if(!g){for(h=
f.child;h;){if(h===c){g=!0;c=f;d=e;break}if(h===d){g=!0;d=f;c=e;break}h=h.sibling}if(!g)throw Error(m(189));}}if(c.alternate!==d)throw Error(m(190));}if(3!==c.tag)throw Error(m(188));return c.stateNode.current===c?a:b}function Uf(a){a=xi(a);if(!a)return null;for(var b=a;;){if(5===b.tag||6===b.tag)return b;if(b.child)b.child.return=b,b=b.child;else{if(b===a)break;for(;!b.sibling;){if(!b.return||b.return===a)return null;b=b.return}b.sibling.return=b.return;b=b.sibling}}return null}function Vf(a,b){for(var c=
a.alternate;null!==b;){if(b===a||b===c)return!0;b=b.return}return!1}function $d(a,b,c,d,e){return{blockedOn:a,domEventName:b,eventSystemFlags:c|16,nativeEvent:e,targetContainers:[d]}}function Wf(a,b){switch(a){case "focusin":case "focusout":ya=null;break;case "dragenter":case "dragleave":za=null;break;case "mouseover":case "mouseout":Aa=null;break;case "pointerover":case "pointerout":Rb.delete(b.pointerId);break;case "gotpointercapture":case "lostpointercapture":Sb.delete(b.pointerId)}}function Tb(a,
b,c,d,e,f){if(null===a||a.nativeEvent!==f)return a=$d(b,c,d,e,f),null!==b&&(b=Ob(b),null!==b&&Xf(b)),a;a.eventSystemFlags|=d;b=a.targetContainers;null!==e&&-1===b.indexOf(e)&&b.push(e);return a}function yi(a,b,c,d,e){switch(b){case "focusin":return ya=Tb(ya,a,b,c,d,e),!0;case "dragenter":return za=Tb(za,a,b,c,d,e),!0;case "mouseover":return Aa=Tb(Aa,a,b,c,d,e),!0;case "pointerover":var f=e.pointerId;Rb.set(f,Tb(Rb.get(f)||null,a,b,c,d,e));return!0;case "gotpointercapture":return f=e.pointerId,Sb.set(f,
Tb(Sb.get(f)||null,a,b,c,d,e)),!0}return!1}function zi(a){var b=Wa(a.target);if(null!==b){var c=Va(b);if(null!==c)if(b=c.tag,13===b){if(b=Sf(c),null!==b){a.blockedOn=b;Ai(a.lanePriority,function(){ae(a.priority,function(){Bi(c)})});return}}else if(3===b&&c.stateNode.hydrate){a.blockedOn=3===c.tag?c.stateNode.containerInfo:null;return}}a.blockedOn=null}function Kc(a){if(null!==a.blockedOn)return!1;for(var b=a.targetContainers;0<b.length;){var c=be(a.domEventName,a.eventSystemFlags,b[0],a.nativeEvent);
if(null!==c)return b=Ob(c),null!==b&&Xf(b),a.blockedOn=c,!1;b.shift()}return!0}function Yf(a,b,c){Kc(a)&&c.delete(b)}function Ci(){for(ce=!1;0<ia.length;){var a=ia[0];if(null!==a.blockedOn){a=Ob(a.blockedOn);null!==a&&Di(a);break}for(var b=a.targetContainers;0<b.length;){var c=be(a.domEventName,a.eventSystemFlags,b[0],a.nativeEvent);if(null!==c){a.blockedOn=c;break}b.shift()}null===a.blockedOn&&ia.shift()}null!==ya&&Kc(ya)&&(ya=null);null!==za&&Kc(za)&&(za=null);null!==Aa&&Kc(Aa)&&(Aa=null);Rb.forEach(Yf);
Sb.forEach(Yf)}function Ub(a,b){a.blockedOn===b&&(a.blockedOn=null,ce||(ce=!0,Zf($f,Ci)))}function ag(a){if(0<ia.length){Ub(ia[0],a);for(var b=1;b<ia.length;b++){var c=ia[b];c.blockedOn===a&&(c.blockedOn=null)}}null!==ya&&Ub(ya,a);null!==za&&Ub(za,a);null!==Aa&&Ub(Aa,a);b=function(b){return Ub(b,a)};Rb.forEach(b);Sb.forEach(b);for(b=0;b<Vb.length;b++)c=Vb[b],c.blockedOn===a&&(c.blockedOn=null);for(;0<Vb.length&&(b=Vb[0],null===b.blockedOn);)zi(b),null===b.blockedOn&&Vb.shift()}function Lc(a,b){var c=
{};c[a.toLowerCase()]=b.toLowerCase();c["Webkit"+a]="webkit"+b;c["Moz"+a]="moz"+b;return c}function Mc(a){if(de[a])return de[a];if(!lb[a])return a;var b=lb[a],c;for(c in b)if(b.hasOwnProperty(c)&&c in bg)return de[a]=b[c];return a}function ee(a,b){for(var c=0;c<a.length;c+=2){var d=a[c],e=a[c+1];e="on"+(e[0].toUpperCase()+e.slice(1));fe.set(d,b);cg.set(d,e);Ta(e,[d])}}function mb(a){if(0!==(1&a))return w=15,1;if(0!==(2&a))return w=14,2;if(0!==(4&a))return w=13,4;var b=24&a;if(0!==b)return w=12,b;
if(0!==(a&32))return w=11,32;b=192&a;if(0!==b)return w=10,b;if(0!==(a&256))return w=9,256;b=3584&a;if(0!==b)return w=8,b;if(0!==(a&4096))return w=7,4096;b=4186112&a;if(0!==b)return w=6,b;b=62914560&a;if(0!==b)return w=5,b;if(a&67108864)return w=4,67108864;if(0!==(a&134217728))return w=3,134217728;b=805306368&a;if(0!==b)return w=2,b;if(0!==(1073741824&a))return w=1,1073741824;w=8;return a}function Ei(a){switch(a){case 99:return 15;case 98:return 10;case 97:case 96:return 8;case 95:return 2;default:return 0}}
function Fi(a){switch(a){case 15:case 14:return 99;case 13:case 12:case 11:case 10:return 98;case 9:case 8:case 7:case 6:case 4:case 5:return 97;case 3:case 2:case 1:return 95;case 0:return 90;default:throw Error(m(358,a));}}function Wb(a,b){var c=a.pendingLanes;if(0===c)return w=0;var d=0,e=0,f=a.expiredLanes,g=a.suspendedLanes,h=a.pingedLanes;if(0!==f)d=f,e=w=15;else if(f=c&134217727,0!==f){var k=f&~g;0!==k?(d=mb(k),e=w):(h&=f,0!==h&&(d=mb(h),e=w))}else f=c&~g,0!==f?(d=mb(f),e=w):0!==h&&(d=mb(h),
e=w);if(0===d)return 0;d=31-Ba(d);d=c&((0>d?0:1<<d)<<1)-1;if(0!==b&&b!==d&&0===(b&g)){mb(b);if(e<=w)return b;w=e}b=a.entangledLanes;if(0!==b)for(a=a.entanglements,b&=d;0<b;)c=31-Ba(b),e=1<<c,d|=a[c],b&=~e;return d}function dg(a){a=a.pendingLanes&-1073741825;return 0!==a?a:a&1073741824?1073741824:0}function Nc(a,b){switch(a){case 15:return 1;case 14:return 2;case 12:return a=nb(24&~b),0===a?Nc(10,b):a;case 10:return a=nb(192&~b),0===a?Nc(8,b):a;case 8:return a=nb(3584&~b),0===a&&(a=nb(4186112&~b),
0===a&&(a=512)),a;case 2:return b=nb(805306368&~b),0===b&&(b=268435456),b}throw Error(m(358,a));}function nb(a){return a&-a}function Oc(a,b,c){a.pendingLanes|=b;var d=b-1;a.suspendedLanes&=d;a.pingedLanes&=d;a=a.eventTimes;b=31-Ba(b);a[b]=c}function Gi(a){return 0===a?32:31-(Hi(a)/Ii|0)|0}function Ji(a,b,c,d){Xa||Xd();var e=ge,f=Xa;Xa=!0;try{eg(e,a,b,c,d)}finally{(Xa=f)||Wd()}}function Ki(a,b,c,d){Li(Mi,ge.bind(null,a,b,c,d))}function ge(a,b,c,d){if(Pc){var e;if((e=0===(b&4))&&0<ia.length&&-1<fg.indexOf(a))a=
$d(null,a,b,c,d),ia.push(a);else{var f=be(a,b,c,d);if(null===f)e&&Wf(a,d);else{if(e){if(-1<fg.indexOf(a)){a=$d(f,a,b,c,d);ia.push(a);return}if(yi(f,a,b,c,d))return;Wf(a,d)}gg(a,b,d,null,c)}}}}function be(a,b,c,d){var e=Ud(d);e=Wa(e);if(null!==e){var f=Va(e);if(null===f)e=null;else{var g=f.tag;if(13===g){e=Sf(f);if(null!==e)return e;e=null}else if(3===g){if(f.stateNode.hydrate)return 3===f.tag?f.stateNode.containerInfo:null;e=null}else f!==e&&(e=null)}}gg(a,b,d,e,c);return null}function hg(){if(Qc)return Qc;
var a,b=he,c=b.length,d,e="value"in Ca?Ca.value:Ca.textContent,f=e.length;for(a=0;a<c&&b[a]===e[a];a++);var g=c-a;for(d=1;d<=g&&b[c-d]===e[f-d];d++);return Qc=e.slice(a,1<d?1-d:void 0)}function Rc(a){var b=a.keyCode;"charCode"in a?(a=a.charCode,0===a&&13===b&&(a=13)):a=b;10===a&&(a=13);return 32<=a||13===a?a:0}function Sc(){return!0}function ig(){return!1}function V(a){function b(b,d,e,f,g){this._reactName=b;this._targetInst=e;this.type=d;this.nativeEvent=f;this.target=g;this.currentTarget=null;for(var c in a)a.hasOwnProperty(c)&&
(b=a[c],this[c]=b?b(f):f[c]);this.isDefaultPrevented=(null!=f.defaultPrevented?f.defaultPrevented:!1===f.returnValue)?Sc:ig;this.isPropagationStopped=ig;return this}B(b.prototype,{preventDefault:function(){this.defaultPrevented=!0;var a=this.nativeEvent;a&&(a.preventDefault?a.preventDefault():"unknown"!==typeof a.returnValue&&(a.returnValue=!1),this.isDefaultPrevented=Sc)},stopPropagation:function(){var a=this.nativeEvent;a&&(a.stopPropagation?a.stopPropagation():"unknown"!==typeof a.cancelBubble&&
(a.cancelBubble=!0),this.isPropagationStopped=Sc)},persist:function(){},isPersistent:Sc});return b}function Ni(a){var b=this.nativeEvent;return b.getModifierState?b.getModifierState(a):(a=Oi[a])?!!b[a]:!1}function ie(a){return Ni}function jg(a,b){switch(a){case "keyup":return-1!==Pi.indexOf(b.keyCode);case "keydown":return 229!==b.keyCode;case "keypress":case "mousedown":case "focusout":return!0;default:return!1}}function kg(a){a=a.detail;return"object"===typeof a&&"data"in a?a.data:null}function Qi(a,
b){switch(a){case "compositionend":return kg(b);case "keypress":if(32!==b.which)return null;lg=!0;return mg;case "textInput":return a=b.data,a===mg&&lg?null:a;default:return null}}function Ri(a,b){if(ob)return"compositionend"===a||!je&&jg(a,b)?(a=hg(),Qc=he=Ca=null,ob=!1,a):null;switch(a){case "paste":return null;case "keypress":if(!(b.ctrlKey||b.altKey||b.metaKey)||b.ctrlKey&&b.altKey){if(b.char&&1<b.char.length)return b.char;if(b.which)return String.fromCharCode(b.which)}return null;case "compositionend":return ng&&
"ko"!==b.locale?null:b.data;default:return null}}function og(a){var b=a&&a.nodeName&&a.nodeName.toLowerCase();return"input"===b?!!Si[a.type]:"textarea"===b?!0:!1}function Ti(a){if(!oa)return!1;a="on"+a;var b=a in document;b||(b=document.createElement("div"),b.setAttribute(a,"return;"),b="function"===typeof b[a]);return b}function pg(a,b,c,d){Pf(d);b=Tc(b,"onChange");0<b.length&&(c=new ke("onChange","change",null,c,d),a.push({event:c,listeners:b}))}function Ui(a){qg(a,0)}function Uc(a){var b=pb(a);
if(Ef(b))return a}function Vi(a,b){if("change"===a)return b}function rg(){Xb&&(Xb.detachEvent("onpropertychange",sg),Yb=Xb=null)}function sg(a){if("value"===a.propertyName&&Uc(Yb)){var b=[];pg(b,Yb,a,Ud(a));a=Ui;if(Xa)a(b);else{Xa=!0;try{le(a,b)}finally{Xa=!1,Wd()}}}}function Wi(a,b,c){"focusin"===a?(rg(),Xb=b,Yb=c,Xb.attachEvent("onpropertychange",sg)):"focusout"===a&&rg()}function Xi(a,b){if("selectionchange"===a||"keyup"===a||"keydown"===a)return Uc(Yb)}function Yi(a,b){if("click"===a)return Uc(b)}
function Zi(a,b){if("input"===a||"change"===a)return Uc(b)}function $i(a,b){return a===b&&(0!==a||1/a===1/b)||a!==a&&b!==b}function Zb(a,b){if(X(a,b))return!0;if("object"!==typeof a||null===a||"object"!==typeof b||null===b)return!1;var c=Object.keys(a),d=Object.keys(b);if(c.length!==d.length)return!1;for(d=0;d<c.length;d++)if(!aj.call(b,c[d])||!X(a[c[d]],b[c[d]]))return!1;return!0}function tg(a){for(;a&&a.firstChild;)a=a.firstChild;return a}function ug(a,b){var c=tg(a);a=0;for(var d;c;){if(3===c.nodeType){d=
a+c.textContent.length;if(a<=b&&d>=b)return{node:c,offset:b-a};a=d}a:{for(;c;){if(c.nextSibling){c=c.nextSibling;break a}c=c.parentNode}c=void 0}c=tg(c)}}function vg(a,b){return a&&b?a===b?!0:a&&3===a.nodeType?!1:b&&3===b.nodeType?vg(a,b.parentNode):"contains"in a?a.contains(b):a.compareDocumentPosition?!!(a.compareDocumentPosition(b)&16):!1:!1}function wg(){for(var a=window,b=Gc();b instanceof a.HTMLIFrameElement;){try{var c="string"===typeof b.contentWindow.location.href}catch(d){c=!1}if(c)a=b.contentWindow;
else break;b=Gc(a.document)}return b}function me(a){var b=a&&a.nodeName&&a.nodeName.toLowerCase();return b&&("input"===b&&("text"===a.type||"search"===a.type||"tel"===a.type||"url"===a.type||"password"===a.type)||"textarea"===b||"true"===a.contentEditable)}function xg(a,b,c){var d=c.window===c?c.document:9===c.nodeType?c:c.ownerDocument;ne||null==qb||qb!==Gc(d)||(d=qb,"selectionStart"in d&&me(d)?d={start:d.selectionStart,end:d.selectionEnd}:(d=(d.ownerDocument&&d.ownerDocument.defaultView||window).getSelection(),
d={anchorNode:d.anchorNode,anchorOffset:d.anchorOffset,focusNode:d.focusNode,focusOffset:d.focusOffset}),$b&&Zb($b,d)||($b=d,d=Tc(oe,"onSelect"),0<d.length&&(b=new ke("onSelect","select",null,b,c),a.push({event:b,listeners:d}),b.target=qb)))}function yg(a,b,c){var d=a.type||"unknown-event";a.currentTarget=c;wi(d,b,void 0,a);a.currentTarget=null}function qg(a,b){b=0!==(b&4);for(var c=0;c<a.length;c++){var d=a[c],e=d.event;d=d.listeners;a:{var f=void 0;if(b)for(var g=d.length-1;0<=g;g--){var h=d[g],
k=h.instance,v=h.currentTarget;h=h.listener;if(k!==f&&e.isPropagationStopped())break a;yg(e,h,v);f=k}else for(g=0;g<d.length;g++){h=d[g];k=h.instance;v=h.currentTarget;h=h.listener;if(k!==f&&e.isPropagationStopped())break a;yg(e,h,v);f=k}}}if(Jc)throw a=Zd,Jc=!1,Zd=null,a;}function z(a,b){var c=zg(b),d=a+"__bubble";c.has(d)||(Ag(b,a,2,!1),c.add(d))}function Bg(a){a[Cg]||(a[Cg]=!0,yf.forEach(function(b){Dg.has(b)||Eg(b,!1,a,null);Eg(b,!0,a,null)}))}function Eg(a,b,c,d){var e=4<arguments.length&&void 0!==
arguments[4]?arguments[4]:0,f=c;"selectionchange"===a&&9!==c.nodeType&&(f=c.ownerDocument);if(null!==d&&!b&&Dg.has(a)){if("scroll"!==a)return;e|=2;f=d}var g=zg(f),h=a+"__"+(b?"capture":"bubble");g.has(h)||(b&&(e|=4),Ag(f,a,e,b),g.add(h))}function Ag(a,b,c,d,e){e=fe.get(b);switch(void 0===e?2:e){case 0:e=Ji;break;case 1:e=Ki;break;default:e=ge}c=e.bind(null,b,c,a);e=void 0;!pe||"touchstart"!==b&&"touchmove"!==b&&"wheel"!==b||(e=!0);d?void 0!==e?a.addEventListener(b,c,{capture:!0,passive:e}):a.addEventListener(b,
c,!0):void 0!==e?a.addEventListener(b,c,{passive:e}):a.addEventListener(b,c,!1)}function gg(a,b,c,d,e){var f=d;if(0===(b&1)&&0===(b&2)&&null!==d)a:for(;;){if(null===d)return;var g=d.tag;if(3===g||4===g){var h=d.stateNode.containerInfo;if(h===e||8===h.nodeType&&h.parentNode===e)break;if(4===g)for(g=d.return;null!==g;){var k=g.tag;if(3===k||4===k)if(k=g.stateNode.containerInfo,k===e||8===k.nodeType&&k.parentNode===e)return;g=g.return}for(;null!==h;){g=Wa(h);if(null===g)return;k=g.tag;if(5===k||6===
k){d=f=g;continue a}h=h.parentNode}}d=d.return}si(function(){var d=f,e=Ud(c),g=[];a:{var h=cg.get(a);if(void 0!==h){var k=ke,m=a;switch(a){case "keypress":if(0===Rc(c))break a;case "keydown":case "keyup":k=bj;break;case "focusin":m="focus";k=qe;break;case "focusout":m="blur";k=qe;break;case "beforeblur":case "afterblur":k=qe;break;case "click":if(2===c.button)break a;case "auxclick":case "dblclick":case "mousedown":case "mousemove":case "mouseup":case "mouseout":case "mouseover":case "contextmenu":k=
Fg;break;case "drag":case "dragend":case "dragenter":case "dragexit":case "dragleave":case "dragover":case "dragstart":case "drop":k=cj;break;case "touchcancel":case "touchend":case "touchmove":case "touchstart":k=dj;break;case Gg:case Hg:case Ig:k=ej;break;case Jg:k=fj;break;case "scroll":k=gj;break;case "wheel":k=hj;break;case "copy":case "cut":case "paste":k=ij;break;case "gotpointercapture":case "lostpointercapture":case "pointercancel":case "pointerdown":case "pointermove":case "pointerout":case "pointerover":case "pointerup":k=
Kg}var l=0!==(b&4),C=!l&&"scroll"===a,x=l?null!==h?h+"Capture":null:h;l=[];for(var p=d,q;null!==p;){q=p;var u=q.stateNode;5===q.tag&&null!==u&&(q=u,null!==x&&(u=Pb(p,x),null!=u&&l.push(ac(p,u,q))));if(C)break;p=p.return}0<l.length&&(h=new k(h,m,null,c,e),g.push({event:h,listeners:l}))}}if(0===(b&7)){a:{h="mouseover"===a||"pointerover"===a;k="mouseout"===a||"pointerout"===a;if(h&&0===(b&16)&&(m=c.relatedTarget||c.fromElement)&&(Wa(m)||m[rb]))break a;if(k||h){h=e.window===e?e:(h=e.ownerDocument)?h.defaultView||
h.parentWindow:window;if(k){if(m=c.relatedTarget||c.toElement,k=d,m=m?Wa(m):null,null!==m&&(C=Va(m),m!==C||5!==m.tag&&6!==m.tag))m=null}else k=null,m=d;if(k!==m){l=Fg;u="onMouseLeave";x="onMouseEnter";p="mouse";if("pointerout"===a||"pointerover"===a)l=Kg,u="onPointerLeave",x="onPointerEnter",p="pointer";C=null==k?h:pb(k);q=null==m?h:pb(m);h=new l(u,p+"leave",k,c,e);h.target=C;h.relatedTarget=q;u=null;Wa(e)===d&&(l=new l(x,p+"enter",m,c,e),l.target=q,l.relatedTarget=C,u=l);C=u;if(k&&m)b:{l=k;x=m;p=
0;for(q=l;q;q=sb(q))p++;q=0;for(u=x;u;u=sb(u))q++;for(;0<p-q;)l=sb(l),p--;for(;0<q-p;)x=sb(x),q--;for(;p--;){if(l===x||null!==x&&l===x.alternate)break b;l=sb(l);x=sb(x)}l=null}else l=null;null!==k&&Lg(g,h,k,l,!1);null!==m&&null!==C&&Lg(g,C,m,l,!0)}}}a:{h=d?pb(d):window;k=h.nodeName&&h.nodeName.toLowerCase();if("select"===k||"input"===k&&"file"===h.type)var n=Vi;else if(og(h))if(Mg)n=Zi;else{n=Xi;var da=Wi}else(k=h.nodeName)&&"input"===k.toLowerCase()&&("checkbox"===h.type||"radio"===h.type)&&(n=Yi);
if(n&&(n=n(a,d))){pg(g,n,c,e);break a}da&&da(a,h,d);"focusout"===a&&(da=h._wrapperState)&&da.controlled&&"number"===h.type&&Od(h,"number",h.value)}da=d?pb(d):window;switch(a){case "focusin":if(og(da)||"true"===da.contentEditable)qb=da,oe=d,$b=null;break;case "focusout":$b=oe=qb=null;break;case "mousedown":ne=!0;break;case "contextmenu":case "mouseup":case "dragend":ne=!1;xg(g,c,e);break;case "selectionchange":if(jj)break;case "keydown":case "keyup":xg(g,c,e)}var Ea;if(je)b:{switch(a){case "compositionstart":var F=
"onCompositionStart";break b;case "compositionend":F="onCompositionEnd";break b;case "compositionupdate":F="onCompositionUpdate";break b}F=void 0}else ob?jg(a,c)&&(F="onCompositionEnd"):"keydown"===a&&229===c.keyCode&&(F="onCompositionStart");F&&(ng&&"ko"!==c.locale&&(ob||"onCompositionStart"!==F?"onCompositionEnd"===F&&ob&&(Ea=hg()):(Ca=e,he="value"in Ca?Ca.value:Ca.textContent,ob=!0)),da=Tc(d,F),0<da.length&&(F=new Ng(F,a,null,c,e),g.push({event:F,listeners:da}),Ea?F.data=Ea:(Ea=kg(c),null!==Ea&&
(F.data=Ea))));if(Ea=kj?Qi(a,c):Ri(a,c))d=Tc(d,"onBeforeInput"),0<d.length&&(e=new lj("onBeforeInput","beforeinput",null,c,e),g.push({event:e,listeners:d}),e.data=Ea)}qg(g,b)})}function ac(a,b,c){return{instance:a,listener:b,currentTarget:c}}function Tc(a,b){for(var c=b+"Capture",d=[];null!==a;){var e=a,f=e.stateNode;5===e.tag&&null!==f&&(e=f,f=Pb(a,c),null!=f&&d.unshift(ac(a,f,e)),f=Pb(a,b),null!=f&&d.push(ac(a,f,e)));a=a.return}return d}function sb(a){if(null===a)return null;do a=a.return;while(a&&
5!==a.tag);return a?a:null}function Lg(a,b,c,d,e){for(var f=b._reactName,g=[];null!==c&&c!==d;){var h=c,k=h.alternate,v=h.stateNode;if(null!==k&&k===d)break;5===h.tag&&null!==v&&(h=v,e?(k=Pb(c,f),null!=k&&g.unshift(ac(c,k,h))):e||(k=Pb(c,f),null!=k&&g.push(ac(c,k,h))));c=c.return}0!==g.length&&a.push({event:b,listeners:g})}function Vc(){}function Og(a,b){switch(a){case "button":case "input":case "select":case "textarea":return!!b.autoFocus}return!1}function re(a,b){return"textarea"===a||"option"===
a||"noscript"===a||"string"===typeof b.children||"number"===typeof b.children||"object"===typeof b.dangerouslySetInnerHTML&&null!==b.dangerouslySetInnerHTML&&null!=b.dangerouslySetInnerHTML.__html}function se(a){1===a.nodeType?a.textContent="":9===a.nodeType&&(a=a.body,null!=a&&(a.textContent=""))}function tb(a){for(;null!=a;a=a.nextSibling){var b=a.nodeType;if(1===b||3===b)break}return a}function Pg(a){a=a.previousSibling;for(var b=0;a;){if(8===a.nodeType){var c=a.data;if("$"===c||"$!"===c||"$?"===
c){if(0===b)return a;b--}else"/$"===c&&b++}a=a.previousSibling}return null}function mj(a){return{$$typeof:te,toString:a,valueOf:a}}function Wa(a){var b=a[Fa];if(b)return b;for(var c=a.parentNode;c;){if(b=c[rb]||c[Fa]){c=b.alternate;if(null!==b.child||null!==c&&null!==c.child)for(a=Pg(a);null!==a;){if(c=a[Fa])return c;a=Pg(a)}return b}a=c;c=a.parentNode}return null}function Ob(a){a=a[Fa]||a[rb];return!a||5!==a.tag&&6!==a.tag&&13!==a.tag&&3!==a.tag?null:a}function pb(a){if(5===a.tag||6===a.tag)return a.stateNode;
throw Error(m(33));}function Hc(a){return a[Wc]||null}function zg(a){var b=a[Qg];void 0===b&&(b=a[Qg]=new Set);return b}function Ga(a){return{current:a}}function t(a,b){0>ub||(a.current=ue[ub],ue[ub]=null,ub--)}function A(a,b,c){ub++;ue[ub]=a.current;a.current=b}function vb(a,b){var c=a.type.contextTypes;if(!c)return Ha;var d=a.stateNode;if(d&&d.__reactInternalMemoizedUnmaskedChildContext===b)return d.__reactInternalMemoizedMaskedChildContext;var e={},f;for(f in c)e[f]=b[f];d&&(a=a.stateNode,a.__reactInternalMemoizedUnmaskedChildContext=
b,a.__reactInternalMemoizedMaskedChildContext=e);return e}function S(a){a=a.childContextTypes;return null!==a&&void 0!==a}function Rg(a,b,c){if(D.current!==Ha)throw Error(m(168));A(D,b);A(J,c)}function Sg(a,b,c){var d=a.stateNode;a=b.childContextTypes;if("function"!==typeof d.getChildContext)return c;d=d.getChildContext();for(var e in d)if(!(e in a))throw Error(m(108,hb(b)||"Unknown",e));return B({},c,d)}function Xc(a){a=(a=a.stateNode)&&a.__reactInternalMemoizedMergedChildContext||Ha;Ya=D.current;
A(D,a);A(J,J.current);return!0}function Tg(a,b,c){var d=a.stateNode;if(!d)throw Error(m(169));c?(a=Sg(a,b,Ya),d.__reactInternalMemoizedMergedChildContext=a,t(J),t(D),A(D,a)):t(J);A(J,c)}function wb(){switch(nj()){case Yc:return 99;case Ug:return 98;case Vg:return 97;case Wg:return 96;case Xg:return 95;default:throw Error(m(332));}}function Yg(a){switch(a){case 99:return Yc;case 98:return Ug;case 97:return Vg;case 96:return Wg;case 95:return Xg;default:throw Error(m(332));}}function Za(a,b){a=Yg(a);
return oj(a,b)}function bc(a,b,c){a=Yg(a);return ve(a,b,c)}function ja(){if(null!==Zc){var a=Zc;Zc=null;we(a)}Zg()}function Zg(){if(!xe&&null!==pa){xe=!0;var a=0;try{var b=pa;Za(99,function(){for(;a<b.length;a++){var c=b[a];do c=c(!0);while(null!==c)}});pa=null}catch(c){throw null!==pa&&(pa=pa.slice(a+1)),ve(Yc,ja),c;}finally{xe=!1}}}function ea(a,b){if(a&&a.defaultProps){b=B({},b);a=a.defaultProps;for(var c in a)void 0===b[c]&&(b[c]=a[c]);return b}return b}function ye(){$c=xb=ad=null}function ze(a){var b=
bd.current;t(bd);a.type._context._currentValue=b}function $g(a,b){for(;null!==a;){var c=a.alternate;if((a.childLanes&b)===b)if(null===c||(c.childLanes&b)===b)break;else c.childLanes|=b;else a.childLanes|=b,null!==c&&(c.childLanes|=b);a=a.return}}function yb(a,b){ad=a;$c=xb=null;a=a.dependencies;null!==a&&null!==a.firstContext&&(0!==(a.lanes&b)&&(fa=!0),a.firstContext=null)}function Y(a,b){if($c!==a&&!1!==b&&0!==b){if("number"!==typeof b||1073741823===b)$c=a,b=1073741823;b={context:a,observedBits:b,
next:null};if(null===xb){if(null===ad)throw Error(m(308));xb=b;ad.dependencies={lanes:0,firstContext:b,responders:null}}else xb=xb.next=b}return a._currentValue}function Ae(a){a.updateQueue={baseState:a.memoizedState,firstBaseUpdate:null,lastBaseUpdate:null,shared:{pending:null},effects:null}}function ah(a,b){a=a.updateQueue;b.updateQueue===a&&(b.updateQueue={baseState:a.baseState,firstBaseUpdate:a.firstBaseUpdate,lastBaseUpdate:a.lastBaseUpdate,shared:a.shared,effects:a.effects})}function Ia(a,b){return{eventTime:a,
lane:b,tag:0,payload:null,callback:null,next:null}}function Ja(a,b){a=a.updateQueue;if(null!==a){a=a.shared;var c=a.pending;null===c?b.next=b:(b.next=c.next,c.next=b);a.pending=b}}function bh(a,b){var c=a.updateQueue,d=a.alternate;if(null!==d&&(d=d.updateQueue,c===d)){var e=null,f=null;c=c.firstBaseUpdate;if(null!==c){do{var g={eventTime:c.eventTime,lane:c.lane,tag:c.tag,payload:c.payload,callback:c.callback,next:null};null===f?e=f=g:f=f.next=g;c=c.next}while(null!==c);null===f?e=f=b:f=f.next=b}else e=
f=b;c={baseState:d.baseState,firstBaseUpdate:e,lastBaseUpdate:f,shared:d.shared,effects:d.effects};a.updateQueue=c;return}a=c.lastBaseUpdate;null===a?c.firstBaseUpdate=b:a.next=b;c.lastBaseUpdate=b}function cc(a,b,c,d){var e=a.updateQueue;Ka=!1;var f=e.firstBaseUpdate,g=e.lastBaseUpdate,h=e.shared.pending;if(null!==h){e.shared.pending=null;var k=h,v=k.next;k.next=null;null===g?f=v:g.next=v;g=k;var m=a.alternate;if(null!==m){m=m.updateQueue;var l=m.lastBaseUpdate;l!==g&&(null===l?m.firstBaseUpdate=
v:l.next=v,m.lastBaseUpdate=k)}}if(null!==f){l=e.baseState;g=0;m=v=k=null;do{h=f.lane;var r=f.eventTime;if((d&h)===h){null!==m&&(m=m.next={eventTime:r,lane:0,tag:f.tag,payload:f.payload,callback:f.callback,next:null});a:{var n=a,t=f;h=b;r=c;switch(t.tag){case 1:n=t.payload;if("function"===typeof n){l=n.call(r,l,h);break a}l=n;break a;case 3:n.flags=n.flags&-4097|64;case 0:n=t.payload;h="function"===typeof n?n.call(r,l,h):n;if(null===h||void 0===h)break a;l=B({},l,h);break a;case 2:Ka=!0}}null!==f.callback&&
(a.flags|=32,h=e.effects,null===h?e.effects=[f]:h.push(f))}else r={eventTime:r,lane:h,tag:f.tag,payload:f.payload,callback:f.callback,next:null},null===m?(v=m=r,k=l):m=m.next=r,g|=h;f=f.next;if(null===f)if(h=e.shared.pending,null===h)break;else f=h.next,h.next=null,e.lastBaseUpdate=h,e.shared.pending=null}while(1);null===m&&(k=l);e.baseState=k;e.firstBaseUpdate=v;e.lastBaseUpdate=m;La|=g;a.lanes=g;a.memoizedState=l}}function ch(a,b,c){a=b.effects;b.effects=null;if(null!==a)for(b=0;b<a.length;b++){var d=
a[b],e=d.callback;if(null!==e){d.callback=null;d=c;if("function"!==typeof e)throw Error(m(191,e));e.call(d)}}}function cd(a,b,c,d){b=a.memoizedState;c=c(d,b);c=null===c||void 0===c?b:B({},b,c);a.memoizedState=c;0===a.lanes&&(a.updateQueue.baseState=c)}function dh(a,b,c,d,e,f,g){a=a.stateNode;return"function"===typeof a.shouldComponentUpdate?a.shouldComponentUpdate(d,f,g):b.prototype&&b.prototype.isPureReactComponent?!Zb(c,d)||!Zb(e,f):!0}function eh(a,b,c){var d=!1,e=Ha;var f=b.contextType;"object"===
typeof f&&null!==f?f=Y(f):(e=S(b)?Ya:D.current,d=b.contextTypes,f=(d=null!==d&&void 0!==d)?vb(a,e):Ha);b=new b(c,f);a.memoizedState=null!==b.state&&void 0!==b.state?b.state:null;b.updater=dd;a.stateNode=b;b._reactInternals=a;d&&(a=a.stateNode,a.__reactInternalMemoizedUnmaskedChildContext=e,a.__reactInternalMemoizedMaskedChildContext=f);return b}function fh(a,b,c,d){a=b.state;"function"===typeof b.componentWillReceiveProps&&b.componentWillReceiveProps(c,d);"function"===typeof b.UNSAFE_componentWillReceiveProps&&
b.UNSAFE_componentWillReceiveProps(c,d);b.state!==a&&dd.enqueueReplaceState(b,b.state,null)}function Be(a,b,c,d){var e=a.stateNode;e.props=c;e.state=a.memoizedState;e.refs=gh;Ae(a);var f=b.contextType;"object"===typeof f&&null!==f?e.context=Y(f):(f=S(b)?Ya:D.current,e.context=vb(a,f));cc(a,c,e,d);e.state=a.memoizedState;f=b.getDerivedStateFromProps;"function"===typeof f&&(cd(a,b,f,c),e.state=a.memoizedState);"function"===typeof b.getDerivedStateFromProps||"function"===typeof e.getSnapshotBeforeUpdate||
"function"!==typeof e.UNSAFE_componentWillMount&&"function"!==typeof e.componentWillMount||(b=e.state,"function"===typeof e.componentWillMount&&e.componentWillMount(),"function"===typeof e.UNSAFE_componentWillMount&&e.UNSAFE_componentWillMount(),b!==e.state&&dd.enqueueReplaceState(e,e.state,null),cc(a,c,e,d),e.state=a.memoizedState);"function"===typeof e.componentDidMount&&(a.flags|=4)}function dc(a,b,c){a=c.ref;if(null!==a&&"function"!==typeof a&&"object"!==typeof a){if(c._owner){c=c._owner;if(c){if(1!==
c.tag)throw Error(m(309));var d=c.stateNode}if(!d)throw Error(m(147,a));var e=""+a;if(null!==b&&null!==b.ref&&"function"===typeof b.ref&&b.ref._stringRef===e)return b.ref;b=function(a){var b=d.refs;b===gh&&(b=d.refs={});null===a?delete b[e]:b[e]=a};b._stringRef=e;return b}if("string"!==typeof a)throw Error(m(284));if(!c._owner)throw Error(m(290,a));}return a}function ed(a,b){if("textarea"!==a.type)throw Error(m(31,"[object Object]"===Object.prototype.toString.call(b)?"object with keys {"+Object.keys(b).join(", ")+
"}":b));}function hh(a){function b(b,c){if(a){var d=b.lastEffect;null!==d?(d.nextEffect=c,b.lastEffect=c):b.firstEffect=b.lastEffect=c;c.nextEffect=null;c.flags=8}}function c(c,d){if(!a)return null;for(;null!==d;)b(c,d),d=d.sibling;return null}function d(a,b){for(a=new Map;null!==b;)null!==b.key?a.set(b.key,b):a.set(b.index,b),b=b.sibling;return a}function e(a,b){a=Ma(a,b);a.index=0;a.sibling=null;return a}function f(b,c,d){b.index=d;if(!a)return c;d=b.alternate;if(null!==d)return d=d.index,d<c?(b.flags=
2,c):d;b.flags=2;return c}function g(b){a&&null===b.alternate&&(b.flags=2);return b}function h(a,b,c,d){if(null===b||6!==b.tag)return b=Ce(c,a.mode,d),b.return=a,b;b=e(b,c);b.return=a;return b}function k(a,b,c,d){if(null!==b&&b.elementType===c.type)return d=e(b,c.props),d.ref=dc(a,b,c),d.return=a,d;d=fd(c.type,c.key,c.props,null,a.mode,d);d.ref=dc(a,b,c);d.return=a;return d}function v(a,b,c,d){if(null===b||4!==b.tag||b.stateNode.containerInfo!==c.containerInfo||b.stateNode.implementation!==c.implementation)return b=
De(c,a.mode,d),b.return=a,b;b=e(b,c.children||[]);b.return=a;return b}function l(a,b,c,d,f){if(null===b||7!==b.tag)return b=zb(c,a.mode,d,f),b.return=a,b;b=e(b,c);b.return=a;return b}function n(a,b,c){if("string"===typeof b||"number"===typeof b)return b=Ce(""+b,a.mode,c),b.return=a,b;if("object"===typeof b&&null!==b){switch(b.$$typeof){case ec:return c=fd(b.type,b.key,b.props,null,a.mode,c),c.ref=dc(a,null,b),c.return=a,c;case Ua:return b=De(b,a.mode,c),b.return=a,b}if(gd(b)||Jb(b))return b=zb(b,
a.mode,c,null),b.return=a,b;ed(a,b)}return null}function r(a,b,c,d){var e=null!==b?b.key:null;if("string"===typeof c||"number"===typeof c)return null!==e?null:h(a,b,""+c,d);if("object"===typeof c&&null!==c){switch(c.$$typeof){case ec:return c.key===e?c.type===wa?l(a,b,c.props.children,d,e):k(a,b,c,d):null;case Ua:return c.key===e?v(a,b,c,d):null}if(gd(c)||Jb(c))return null!==e?null:l(a,b,c,d,null);ed(a,c)}return null}function t(a,b,c,d,e){if("string"===typeof d||"number"===typeof d)return a=a.get(c)||
null,h(b,a,""+d,e);if("object"===typeof d&&null!==d){switch(d.$$typeof){case ec:return a=a.get(null===d.key?c:d.key)||null,d.type===wa?l(b,a,d.props.children,e,d.key):k(b,a,d,e);case Ua:return a=a.get(null===d.key?c:d.key)||null,v(b,a,d,e)}if(gd(d)||Jb(d))return a=a.get(c)||null,l(b,a,d,e,null);ed(b,d)}return null}function w(e,g,h,k){for(var m=null,v=null,l=g,p=g=0,x=null;null!==l&&p<h.length;p++){l.index>p?(x=l,l=null):x=l.sibling;var C=r(e,l,h[p],k);if(null===C){null===l&&(l=x);break}a&&l&&null===
C.alternate&&b(e,l);g=f(C,g,p);null===v?m=C:v.sibling=C;v=C;l=x}if(p===h.length)return c(e,l),m;if(null===l){for(;p<h.length;p++)l=n(e,h[p],k),null!==l&&(g=f(l,g,p),null===v?m=l:v.sibling=l,v=l);return m}for(l=d(e,l);p<h.length;p++)x=t(l,e,p,h[p],k),null!==x&&(a&&null!==x.alternate&&l.delete(null===x.key?p:x.key),g=f(x,g,p),null===v?m=x:v.sibling=x,v=x);a&&l.forEach(function(a){return b(e,a)});return m}function z(e,g,h,k){var l=Jb(h);if("function"!==typeof l)throw Error(m(150));h=l.call(h);if(null==
h)throw Error(m(151));for(var v=l=null,p=g,x=g=0,C=null,q=h.next();null!==p&&!q.done;x++,q=h.next()){p.index>x?(C=p,p=null):C=p.sibling;var Da=r(e,p,q.value,k);if(null===Da){null===p&&(p=C);break}a&&p&&null===Da.alternate&&b(e,p);g=f(Da,g,x);null===v?l=Da:v.sibling=Da;v=Da;p=C}if(q.done)return c(e,p),l;if(null===p){for(;!q.done;x++,q=h.next())q=n(e,q.value,k),null!==q&&(g=f(q,g,x),null===v?l=q:v.sibling=q,v=q);return l}for(p=d(e,p);!q.done;x++,q=h.next())q=t(p,e,x,q.value,k),null!==q&&(a&&null!==
q.alternate&&p.delete(null===q.key?x:q.key),g=f(q,g,x),null===v?l=q:v.sibling=q,v=q);a&&p.forEach(function(a){return b(e,a)});return l}return function(a,d,f,h){var k="object"===typeof f&&null!==f&&f.type===wa&&null===f.key;k&&(f=f.props.children);var l="object"===typeof f&&null!==f;if(l)switch(f.$$typeof){case ec:a:{l=f.key;for(k=d;null!==k;){if(k.key===l){switch(k.tag){case 7:if(f.type===wa){c(a,k.sibling);d=e(k,f.props.children);d.return=a;a=d;break a}break;default:if(k.elementType===f.type){c(a,
k.sibling);d=e(k,f.props);d.ref=dc(a,k,f);d.return=a;a=d;break a}}c(a,k);break}else b(a,k);k=k.sibling}f.type===wa?(d=zb(f.props.children,a.mode,h,f.key),d.return=a,a=d):(h=fd(f.type,f.key,f.props,null,a.mode,h),h.ref=dc(a,d,f),h.return=a,a=h)}return g(a);case Ua:a:{for(k=f.key;null!==d;){if(d.key===k)if(4===d.tag&&d.stateNode.containerInfo===f.containerInfo&&d.stateNode.implementation===f.implementation){c(a,d.sibling);d=e(d,f.children||[]);d.return=a;a=d;break a}else{c(a,d);break}else b(a,d);d=
d.sibling}d=De(f,a.mode,h);d.return=a;a=d}return g(a)}if("string"===typeof f||"number"===typeof f)return f=""+f,null!==d&&6===d.tag?(c(a,d.sibling),d=e(d,f),d.return=a,a=d):(c(a,d),d=Ce(f,a.mode,h),d.return=a,a=d),g(a);if(gd(f))return w(a,d,f,h);if(Jb(f))return z(a,d,f,h);l&&ed(a,f);if("undefined"===typeof f&&!k)switch(a.tag){case 1:case 22:case 0:case 11:case 15:throw Error(m(152,hb(a.type)||"Component"));}return c(a,d)}}function $a(a){if(a===fc)throw Error(m(174));return a}function Ee(a,b){A(gc,
b);A(hc,a);A(ka,fc);a=b.nodeType;switch(a){case 9:case 11:b=(b=b.documentElement)?b.namespaceURI:Rd(null,"");break;default:a=8===a?b.parentNode:b,b=a.namespaceURI||null,a=a.tagName,b=Rd(b,a)}t(ka);A(ka,b)}function Ab(a){t(ka);t(hc);t(gc)}function ih(a){$a(gc.current);var b=$a(ka.current);var c=Rd(b,a.type);b!==c&&(A(hc,a),A(ka,c))}function Fe(a){hc.current===a&&(t(ka),t(hc))}function hd(a){for(var b=a;null!==b;){if(13===b.tag){var c=b.memoizedState;if(null!==c&&(c=c.dehydrated,null===c||"$?"===c.data||
"$!"===c.data))return b}else if(19===b.tag&&void 0!==b.memoizedProps.revealOrder){if(0!==(b.flags&64))return b}else if(null!==b.child){b.child.return=b;b=b.child;continue}if(b===a)break;for(;null===b.sibling;){if(null===b.return||b.return===a)return null;b=b.return}b.sibling.return=b.return;b=b.sibling}return null}function jh(a,b){var c=Z(5,null,null,0);c.elementType="DELETED";c.type="DELETED";c.stateNode=b;c.return=a;c.flags=8;null!==a.lastEffect?(a.lastEffect.nextEffect=c,a.lastEffect=c):a.firstEffect=
a.lastEffect=c}function kh(a,b){switch(a.tag){case 5:var c=a.type;b=1!==b.nodeType||c.toLowerCase()!==b.nodeName.toLowerCase()?null:b;return null!==b?(a.stateNode=b,!0):!1;case 6:return b=""===a.pendingProps||3!==b.nodeType?null:b,null!==b?(a.stateNode=b,!0):!1;case 13:return!1;default:return!1}}function Ge(a){if(la){var b=Na;if(b){var c=b;if(!kh(a,b)){b=tb(c.nextSibling);if(!b||!kh(a,b)){a.flags=a.flags&-1025|2;la=!1;ra=a;return}jh(ra,c)}ra=a;Na=tb(b.firstChild)}else a.flags=a.flags&-1025|2,la=!1,
ra=a}}function lh(a){for(a=a.return;null!==a&&5!==a.tag&&3!==a.tag&&13!==a.tag;)a=a.return;ra=a}function id(a){if(a!==ra)return!1;if(!la)return lh(a),la=!0,!1;var b=a.type;if(5!==a.tag||"head"!==b&&"body"!==b&&!re(b,a.memoizedProps))for(b=Na;b;)jh(a,b),b=tb(b.nextSibling);lh(a);if(13===a.tag){a=a.memoizedState;a=null!==a?a.dehydrated:null;if(!a)throw Error(m(317));a:{a=a.nextSibling;for(b=0;a;){if(8===a.nodeType){var c=a.data;if("/$"===c){if(0===b){Na=tb(a.nextSibling);break a}b--}else"$"!==c&&"$!"!==
c&&"$?"!==c||b++}a=a.nextSibling}Na=null}}else Na=ra?tb(a.stateNode.nextSibling):null;return!0}function He(){Na=ra=null;la=!1}function Ie(){for(var a=0;a<Bb.length;a++)Bb[a]._workInProgressVersionPrimary=null;Bb.length=0}function T(){throw Error(m(321));}function Je(a,b){if(null===b)return!1;for(var c=0;c<b.length&&c<a.length;c++)if(!X(a[c],b[c]))return!1;return!0}function Ke(a,b,c,d,e,f){ic=f;y=b;b.memoizedState=null;b.updateQueue=null;b.lanes=0;jc.current=null===a||null===a.memoizedState?pj:qj;
a=c(d,e);if(kc){f=0;do{kc=!1;if(!(25>f))throw Error(m(301));f+=1;K=N=null;b.updateQueue=null;jc.current=rj;a=c(d,e)}while(kc)}jc.current=jd;b=null!==N&&null!==N.next;ic=0;K=N=y=null;kd=!1;if(b)throw Error(m(300));return a}function ab(){var a={memoizedState:null,baseState:null,baseQueue:null,queue:null,next:null};null===K?y.memoizedState=K=a:K=K.next=a;return K}function bb(){if(null===N){var a=y.alternate;a=null!==a?a.memoizedState:null}else a=N.next;var b=null===K?y.memoizedState:K.next;if(null!==
b)K=b,N=a;else{if(null===a)throw Error(m(310));N=a;a={memoizedState:N.memoizedState,baseState:N.baseState,baseQueue:N.baseQueue,queue:N.queue,next:null};null===K?y.memoizedState=K=a:K=K.next=a}return K}function ma(a,b){return"function"===typeof b?b(a):b}function lc(a,b,c){b=bb();c=b.queue;if(null===c)throw Error(m(311));c.lastRenderedReducer=a;var d=N,e=d.baseQueue,f=c.pending;if(null!==f){if(null!==e){var g=e.next;e.next=f.next;f.next=g}d.baseQueue=e=f;c.pending=null}if(null!==e){e=e.next;d=d.baseState;
var h=g=f=null,k=e;do{var l=k.lane;if((ic&l)===l)null!==h&&(h=h.next={lane:0,action:k.action,eagerReducer:k.eagerReducer,eagerState:k.eagerState,next:null}),d=k.eagerReducer===a?k.eagerState:a(d,k.action);else{var n={lane:l,action:k.action,eagerReducer:k.eagerReducer,eagerState:k.eagerState,next:null};null===h?(g=h=n,f=d):h=h.next=n;y.lanes|=l;La|=l}k=k.next}while(null!==k&&k!==e);null===h?f=d:h.next=g;X(d,b.memoizedState)||(fa=!0);b.memoizedState=d;b.baseState=f;b.baseQueue=h;c.lastRenderedState=
d}return[b.memoizedState,c.dispatch]}function mc(a,b,c){b=bb();c=b.queue;if(null===c)throw Error(m(311));c.lastRenderedReducer=a;var d=c.dispatch,e=c.pending,f=b.memoizedState;if(null!==e){c.pending=null;var g=e=e.next;do f=a(f,g.action),g=g.next;while(g!==e);X(f,b.memoizedState)||(fa=!0);b.memoizedState=f;null===b.baseQueue&&(b.baseState=f);c.lastRenderedState=f}return[f,d]}function mh(a,b,c){var d=b._getVersion;d=d(b._source);var e=b._workInProgressVersionPrimary;if(null!==e)a=e===d;else if(a=a.mutableReadLanes,
a=(ic&a)===a)b._workInProgressVersionPrimary=d,Bb.push(b);if(a)return c(b._source);Bb.push(b);throw Error(m(350));}function nh(a,b,c,d){var e=R;if(null===e)throw Error(m(349));var f=b._getVersion,g=f(b._source),h=jc.current,k=h.useState(function(){return mh(e,b,c)}),l=k[1],n=k[0];k=K;var t=a.memoizedState,r=t.refs,w=r.getSnapshot,z=t.source;t=t.subscribe;var B=y;a.memoizedState={refs:r,source:b,subscribe:d};h.useEffect(function(){r.getSnapshot=c;r.setSnapshot=l;var a=f(b._source);if(!X(g,a)){a=c(b._source);
X(n,a)||(l(a),a=Oa(B),e.mutableReadLanes|=a&e.pendingLanes);a=e.mutableReadLanes;e.entangledLanes|=a;for(var d=e.entanglements,h=a;0<h;){var k=31-Ba(h),m=1<<k;d[k]|=a;h&=~m}}},[c,b,d]);h.useEffect(function(){return d(b._source,function(){var a=r.getSnapshot,c=r.setSnapshot;try{c(a(b._source));var d=Oa(B);e.mutableReadLanes|=d&e.pendingLanes}catch(q){c(function(){throw q;})}})},[b,d]);X(w,c)&&X(z,b)&&X(t,d)||(a={pending:null,dispatch:null,lastRenderedReducer:ma,lastRenderedState:n},a.dispatch=l=Le.bind(null,
y,a),k.queue=a,k.baseQueue=null,n=mh(e,b,c),k.memoizedState=k.baseState=n);return n}function oh(a,b,c){var d=bb();return nh(d,a,b,c)}function nc(a){var b=ab();"function"===typeof a&&(a=a());b.memoizedState=b.baseState=a;a=b.queue={pending:null,dispatch:null,lastRenderedReducer:ma,lastRenderedState:a};a=a.dispatch=Le.bind(null,y,a);return[b.memoizedState,a]}function ld(a,b,c,d){a={tag:a,create:b,destroy:c,deps:d,next:null};b=y.updateQueue;null===b?(b={lastEffect:null},y.updateQueue=b,b.lastEffect=
a.next=a):(c=b.lastEffect,null===c?b.lastEffect=a.next=a:(d=c.next,c.next=a,a.next=d,b.lastEffect=a));return a}function ph(a){var b=ab();a={current:a};return b.memoizedState=a}function md(a){return bb().memoizedState}function Me(a,b,c,d){var e=ab();y.flags|=a;e.memoizedState=ld(1|b,c,void 0,void 0===d?null:d)}function Ne(a,b,c,d){var e=bb();d=void 0===d?null:d;var f=void 0;if(null!==N){var g=N.memoizedState;f=g.destroy;if(null!==d&&Je(d,g.deps)){ld(b,c,f,d);return}}y.flags|=a;e.memoizedState=ld(1|
b,c,f,d)}function qh(a,b){return Me(516,4,a,b)}function nd(a,b){return Ne(516,4,a,b)}function rh(a,b){return Ne(4,2,a,b)}function sh(a,b){if("function"===typeof b)return a=a(),b(a),function(){b(null)};if(null!==b&&void 0!==b)return a=a(),b.current=a,function(){b.current=null}}function th(a,b,c){c=null!==c&&void 0!==c?c.concat([a]):null;return Ne(4,2,sh.bind(null,b,a),c)}function Oe(a,b){}function uh(a,b){var c=bb();b=void 0===b?null:b;var d=c.memoizedState;if(null!==d&&null!==b&&Je(b,d[1]))return d[0];
c.memoizedState=[a,b];return a}function vh(a,b){var c=bb();b=void 0===b?null:b;var d=c.memoizedState;if(null!==d&&null!==b&&Je(b,d[1]))return d[0];a=a();c.memoizedState=[a,b];return a}function sj(a,b){var c=wb();Za(98>c?98:c,function(){a(!0)});Za(97<c?97:c,function(){var c=aa.transition;aa.transition=1;try{a(!1),b()}finally{aa.transition=c}})}function Le(a,b,c){var d=W(),e=Oa(a),f={lane:e,action:c,eagerReducer:null,eagerState:null,next:null},g=b.pending;null===g?f.next=f:(f.next=g.next,g.next=f);
b.pending=f;g=a.alternate;if(a===y||null!==g&&g===y)kc=kd=!0;else{if(0===a.lanes&&(null===g||0===g.lanes)&&(g=b.lastRenderedReducer,null!==g))try{var h=b.lastRenderedState,k=g(h,c);f.eagerReducer=g;f.eagerState=k;if(X(k,h))return}catch(v){}finally{}Pa(a,e,d)}}function U(a,b,c,d){b.child=null===a?wh(b,null,c,d):od(b,a.child,c,d)}function xh(a,b,c,d,e){c=c.render;var f=b.ref;yb(b,e);d=Ke(a,b,c,d,f,e);if(null!==a&&!fa)return b.updateQueue=a.updateQueue,b.flags&=-517,a.lanes&=~e,sa(a,b,e);b.flags|=1;
U(a,b,d,e);return b.child}function yh(a,b,c,d,e,f){if(null===a){var g=c.type;if("function"===typeof g&&!Pe(g)&&void 0===g.defaultProps&&null===c.compare&&void 0===c.defaultProps)return b.tag=15,b.type=g,zh(a,b,g,d,e,f);a=fd(c.type,null,d,b,b.mode,f);a.ref=b.ref;a.return=b;return b.child=a}g=a.child;if(0===(e&f)&&(e=g.memoizedProps,c=c.compare,c=null!==c?c:Zb,c(e,d)&&a.ref===b.ref))return sa(a,b,f);b.flags|=1;a=Ma(g,d);a.ref=b.ref;a.return=b;return b.child=a}function zh(a,b,c,d,e,f){if(null!==a&&Zb(a.memoizedProps,
d)&&a.ref===b.ref)if(fa=!1,0!==(f&e))0!==(a.flags&16384)&&(fa=!0);else return b.lanes=a.lanes,sa(a,b,f);return Qe(a,b,c,d,f)}function Re(a,b,c){var d=b.pendingProps,e=d.children,f=null!==a?a.memoizedState:null;if("hidden"===d.mode||"unstable-defer-without-hiding"===d.mode)if(0===(b.mode&4))b.memoizedState={baseLanes:0},pd(b,c);else if(0!==(c&1073741824))b.memoizedState={baseLanes:0},pd(b,null!==f?f.baseLanes:c);else return a=null!==f?f.baseLanes|c:c,b.lanes=b.childLanes=1073741824,b.memoizedState=
{baseLanes:a},pd(b,a),null;else null!==f?(d=f.baseLanes|c,b.memoizedState=null):d=c,pd(b,d);U(a,b,e,c);return b.child}function Ah(a,b){var c=b.ref;if(null===a&&null!==c||null!==a&&a.ref!==c)b.flags|=128}function Qe(a,b,c,d,e){var f=S(c)?Ya:D.current;f=vb(b,f);yb(b,e);c=Ke(a,b,c,d,f,e);if(null!==a&&!fa)return b.updateQueue=a.updateQueue,b.flags&=-517,a.lanes&=~e,sa(a,b,e);b.flags|=1;U(a,b,c,e);return b.child}function Bh(a,b,c,d,e){if(S(c)){var f=!0;Xc(b)}else f=!1;yb(b,e);if(null===b.stateNode)null!==
a&&(a.alternate=null,b.alternate=null,b.flags|=2),eh(b,c,d),Be(b,c,d,e),d=!0;else if(null===a){var g=b.stateNode,h=b.memoizedProps;g.props=h;var k=g.context,l=c.contextType;"object"===typeof l&&null!==l?l=Y(l):(l=S(c)?Ya:D.current,l=vb(b,l));var m=c.getDerivedStateFromProps,n="function"===typeof m||"function"===typeof g.getSnapshotBeforeUpdate;n||"function"!==typeof g.UNSAFE_componentWillReceiveProps&&"function"!==typeof g.componentWillReceiveProps||(h!==d||k!==l)&&fh(b,g,d,l);Ka=!1;var r=b.memoizedState;
g.state=r;cc(b,d,g,e);k=b.memoizedState;h!==d||r!==k||J.current||Ka?("function"===typeof m&&(cd(b,c,m,d),k=b.memoizedState),(h=Ka||dh(b,c,h,d,r,k,l))?(n||"function"!==typeof g.UNSAFE_componentWillMount&&"function"!==typeof g.componentWillMount||("function"===typeof g.componentWillMount&&g.componentWillMount(),"function"===typeof g.UNSAFE_componentWillMount&&g.UNSAFE_componentWillMount()),"function"===typeof g.componentDidMount&&(b.flags|=4)):("function"===typeof g.componentDidMount&&(b.flags|=4),
b.memoizedProps=d,b.memoizedState=k),g.props=d,g.state=k,g.context=l,d=h):("function"===typeof g.componentDidMount&&(b.flags|=4),d=!1)}else{g=b.stateNode;ah(a,b);h=b.memoizedProps;l=b.type===b.elementType?h:ea(b.type,h);g.props=l;n=b.pendingProps;r=g.context;k=c.contextType;"object"===typeof k&&null!==k?k=Y(k):(k=S(c)?Ya:D.current,k=vb(b,k));var t=c.getDerivedStateFromProps;(m="function"===typeof t||"function"===typeof g.getSnapshotBeforeUpdate)||"function"!==typeof g.UNSAFE_componentWillReceiveProps&&
"function"!==typeof g.componentWillReceiveProps||(h!==n||r!==k)&&fh(b,g,d,k);Ka=!1;r=b.memoizedState;g.state=r;cc(b,d,g,e);var w=b.memoizedState;h!==n||r!==w||J.current||Ka?("function"===typeof t&&(cd(b,c,t,d),w=b.memoizedState),(l=Ka||dh(b,c,l,d,r,w,k))?(m||"function"!==typeof g.UNSAFE_componentWillUpdate&&"function"!==typeof g.componentWillUpdate||("function"===typeof g.componentWillUpdate&&g.componentWillUpdate(d,w,k),"function"===typeof g.UNSAFE_componentWillUpdate&&g.UNSAFE_componentWillUpdate(d,
w,k)),"function"===typeof g.componentDidUpdate&&(b.flags|=4),"function"===typeof g.getSnapshotBeforeUpdate&&(b.flags|=256)):("function"!==typeof g.componentDidUpdate||h===a.memoizedProps&&r===a.memoizedState||(b.flags|=4),"function"!==typeof g.getSnapshotBeforeUpdate||h===a.memoizedProps&&r===a.memoizedState||(b.flags|=256),b.memoizedProps=d,b.memoizedState=w),g.props=d,g.state=w,g.context=k,d=l):("function"!==typeof g.componentDidUpdate||h===a.memoizedProps&&r===a.memoizedState||(b.flags|=4),"function"!==
typeof g.getSnapshotBeforeUpdate||h===a.memoizedProps&&r===a.memoizedState||(b.flags|=256),d=!1)}return Se(a,b,c,d,f,e)}function Se(a,b,c,d,e,f){Ah(a,b);var g=0!==(b.flags&64);if(!d&&!g)return e&&Tg(b,c,!1),sa(a,b,f);d=b.stateNode;tj.current=b;var h=g&&"function"!==typeof c.getDerivedStateFromError?null:d.render();b.flags|=1;null!==a&&g?(b.child=od(b,a.child,null,f),b.child=od(b,null,h,f)):U(a,b,h,f);b.memoizedState=d.state;e&&Tg(b,c,!0);return b.child}function Ch(a){var b=a.stateNode;b.pendingContext?
Rg(a,b.pendingContext,b.pendingContext!==b.context):b.context&&Rg(a,b.context,!1);Ee(a,b.containerInfo)}function Dh(a,b,c){var d=b.pendingProps,e=E.current,f=!1,g;(g=0!==(b.flags&64))||(g=null!==a&&null===a.memoizedState?!1:0!==(e&2));g?(f=!0,b.flags&=-65):null!==a&&null===a.memoizedState||void 0===d.fallback||!0===d.unstable_avoidThisFallback||(e|=1);A(E,e&1);if(null===a){void 0!==d.fallback&&Ge(b);a=d.children;e=d.fallback;if(f)return a=Eh(b,a,e,c),b.child.memoizedState={baseLanes:c},b.memoizedState=
qd,a;if("number"===typeof d.unstable_expectedLoadTime)return a=Eh(b,a,e,c),b.child.memoizedState={baseLanes:c},b.memoizedState=qd,b.lanes=33554432,a;c=Te({mode:"visible",children:a},b.mode,c,null);c.return=b;return b.child=c}if(null!==a.memoizedState){if(f)return d=Fh(a,b,d.children,d.fallback,c),f=b.child,e=a.child.memoizedState,f.memoizedState=null===e?{baseLanes:c}:{baseLanes:e.baseLanes|c},f.childLanes=a.childLanes&~c,b.memoizedState=qd,d;c=Gh(a,b,d.children,c);b.memoizedState=null;return c}if(f)return d=
Fh(a,b,d.children,d.fallback,c),f=b.child,e=a.child.memoizedState,f.memoizedState=null===e?{baseLanes:c}:{baseLanes:e.baseLanes|c},f.childLanes=a.childLanes&~c,b.memoizedState=qd,d;c=Gh(a,b,d.children,c);b.memoizedState=null;return c}function Eh(a,b,c,d){var e=a.mode,f=a.child;b={mode:"hidden",children:b};0===(e&2)&&null!==f?(f.childLanes=0,f.pendingProps=b):f=Te(b,e,0,null);c=zb(c,e,d,null);f.return=a;c.return=a;f.sibling=c;a.child=f;return c}function Gh(a,b,c,d){var e=a.child;a=e.sibling;c=Ma(e,
{mode:"visible",children:c});0===(b.mode&2)&&(c.lanes=d);c.return=b;c.sibling=null;null!==a&&(a.nextEffect=null,a.flags=8,b.firstEffect=b.lastEffect=a);return b.child=c}function Fh(a,b,c,d,e){var f=b.mode,g=a.child;a=g.sibling;var h={mode:"hidden",children:c};0===(f&2)&&b.child!==g?(c=b.child,c.childLanes=0,c.pendingProps=h,g=c.lastEffect,null!==g?(b.firstEffect=c.firstEffect,b.lastEffect=g,g.nextEffect=null):b.firstEffect=b.lastEffect=null):c=Ma(g,h);null!==a?d=Ma(a,d):(d=zb(d,f,e,null),d.flags|=
2);d.return=b;c.return=b;c.sibling=d;b.child=c;return d}function Hh(a,b){a.lanes|=b;var c=a.alternate;null!==c&&(c.lanes|=b);$g(a.return,b)}function Ue(a,b,c,d,e,f){var g=a.memoizedState;null===g?a.memoizedState={isBackwards:b,rendering:null,renderingStartTime:0,last:d,tail:c,tailMode:e,lastEffect:f}:(g.isBackwards=b,g.rendering=null,g.renderingStartTime=0,g.last=d,g.tail=c,g.tailMode=e,g.lastEffect=f)}function Ih(a,b,c){var d=b.pendingProps,e=d.revealOrder,f=d.tail;U(a,b,d.children,c);d=E.current;
if(0!==(d&2))d=d&1|2,b.flags|=64;else{if(null!==a&&0!==(a.flags&64))a:for(a=b.child;null!==a;){if(13===a.tag)null!==a.memoizedState&&Hh(a,c);else if(19===a.tag)Hh(a,c);else if(null!==a.child){a.child.return=a;a=a.child;continue}if(a===b)break a;for(;null===a.sibling;){if(null===a.return||a.return===b)break a;a=a.return}a.sibling.return=a.return;a=a.sibling}d&=1}A(E,d);if(0===(b.mode&2))b.memoizedState=null;else switch(e){case "forwards":c=b.child;for(e=null;null!==c;)a=c.alternate,null!==a&&null===
hd(a)&&(e=c),c=c.sibling;c=e;null===c?(e=b.child,b.child=null):(e=c.sibling,c.sibling=null);Ue(b,!1,e,c,f,b.lastEffect);break;case "backwards":c=null;e=b.child;for(b.child=null;null!==e;){a=e.alternate;if(null!==a&&null===hd(a)){b.child=e;break}a=e.sibling;e.sibling=c;c=e;e=a}Ue(b,!0,c,null,f,b.lastEffect);break;case "together":Ue(b,!1,null,null,void 0,b.lastEffect);break;default:b.memoizedState=null}return b.child}function sa(a,b,c){null!==a&&(b.dependencies=a.dependencies);La|=b.lanes;if(0!==(c&
b.childLanes)){if(null!==a&&b.child!==a.child)throw Error(m(153));if(null!==b.child){a=b.child;c=Ma(a,a.pendingProps);b.child=c;for(c.return=b;null!==a.sibling;)a=a.sibling,c=c.sibling=Ma(a,a.pendingProps),c.return=b;c.sibling=null}return b.child}return null}function oc(a,b){if(!la)switch(a.tailMode){case "hidden":b=a.tail;for(var c=null;null!==b;)null!==b.alternate&&(c=b),b=b.sibling;null===c?a.tail=null:c.sibling=null;break;case "collapsed":c=a.tail;for(var d=null;null!==c;)null!==c.alternate&&
(d=c),c=c.sibling;null===d?b||null===a.tail?a.tail=null:a.tail.sibling=null:d.sibling=null}}function uj(a,b,c){var d=b.pendingProps;switch(b.tag){case 2:case 16:case 15:case 0:case 11:case 7:case 8:case 12:case 9:case 14:return null;case 1:return S(b.type)&&(t(J),t(D)),null;case 3:Ab();t(J);t(D);Ie();d=b.stateNode;d.pendingContext&&(d.context=d.pendingContext,d.pendingContext=null);if(null===a||null===a.child)id(b)?b.flags|=4:d.hydrate||(b.flags|=256);Jh(b);return null;case 5:Fe(b);var e=$a(gc.current);
c=b.type;if(null!==a&&null!=b.stateNode)vj(a,b,c,d,e),a.ref!==b.ref&&(b.flags|=128);else{if(!d){if(null===b.stateNode)throw Error(m(166));return null}a=$a(ka.current);if(id(b)){d=b.stateNode;c=b.type;var f=b.memoizedProps;d[Fa]=b;d[Wc]=f;switch(c){case "dialog":z("cancel",d);z("close",d);break;case "iframe":case "object":case "embed":z("load",d);break;case "video":case "audio":for(a=0;a<pc.length;a++)z(pc[a],d);break;case "source":z("error",d);break;case "img":case "image":case "link":z("error",d);
z("load",d);break;case "details":z("toggle",d);break;case "input":Ff(d,f);z("invalid",d);break;case "select":d._wrapperState={wasMultiple:!!f.multiple};z("invalid",d);break;case "textarea":If(d,f),z("invalid",d)}Sd(c,f);a=null;for(var g in f)f.hasOwnProperty(g)&&(e=f[g],"children"===g?"string"===typeof e?d.textContent!==e&&(a=["children",e]):"number"===typeof e&&d.textContent!==""+e&&(a=["children",""+e]):Ib.hasOwnProperty(g)&&null!=e&&"onScroll"===g&&z("scroll",d));switch(c){case "input":Fc(d);Hf(d,
f,!0);break;case "textarea":Fc(d);Kf(d);break;case "select":case "option":break;default:"function"===typeof f.onClick&&(d.onclick=Vc)}d=a;b.updateQueue=d;null!==d&&(b.flags|=4)}else{g=9===e.nodeType?e:e.ownerDocument;"http://www.w3.org/1999/xhtml"===a&&(a=Lf(c));"http://www.w3.org/1999/xhtml"===a?"script"===c?(a=g.createElement("div"),a.innerHTML="<script>\x3c/script>",a=a.removeChild(a.firstChild)):"string"===typeof d.is?a=g.createElement(c,{is:d.is}):(a=g.createElement(c),"select"===c&&(g=a,d.multiple?
g.multiple=!0:d.size&&(g.size=d.size))):a=g.createElementNS(a,c);a[Fa]=b;a[Wc]=d;wj(a,b,!1,!1);b.stateNode=a;g=Td(c,d);switch(c){case "dialog":z("cancel",a);z("close",a);e=d;break;case "iframe":case "object":case "embed":z("load",a);e=d;break;case "video":case "audio":for(e=0;e<pc.length;e++)z(pc[e],a);e=d;break;case "source":z("error",a);e=d;break;case "img":case "image":case "link":z("error",a);z("load",a);e=d;break;case "details":z("toggle",a);e=d;break;case "input":Ff(a,d);e=Md(a,d);z("invalid",
a);break;case "option":e=Pd(a,d);break;case "select":a._wrapperState={wasMultiple:!!d.multiple};e=B({},d,{value:void 0});z("invalid",a);break;case "textarea":If(a,d);e=Qd(a,d);z("invalid",a);break;default:e=d}Sd(c,e);var h=e;for(f in h)if(h.hasOwnProperty(f)){var k=h[f];"style"===f?Nf(a,k):"dangerouslySetInnerHTML"===f?(k=k?k.__html:void 0,null!=k&&Kh(a,k)):"children"===f?"string"===typeof k?("textarea"!==c||""!==k)&&qc(a,k):"number"===typeof k&&qc(a,""+k):"suppressContentEditableWarning"!==f&&"suppressHydrationWarning"!==
f&&"autoFocus"!==f&&(Ib.hasOwnProperty(f)?null!=k&&"onScroll"===f&&z("scroll",a):null!=k&&Ed(a,f,k,g))}switch(c){case "input":Fc(a);Hf(a,d,!1);break;case "textarea":Fc(a);Kf(a);break;case "option":null!=d.value&&a.setAttribute("value",""+xa(d.value));break;case "select":a.multiple=!!d.multiple;f=d.value;null!=f?ib(a,!!d.multiple,f,!1):null!=d.defaultValue&&ib(a,!!d.multiple,d.defaultValue,!0);break;default:"function"===typeof e.onClick&&(a.onclick=Vc)}Og(c,d)&&(b.flags|=4)}null!==b.ref&&(b.flags|=
128)}return null;case 6:if(a&&null!=b.stateNode)xj(a,b,a.memoizedProps,d);else{if("string"!==typeof d&&null===b.stateNode)throw Error(m(166));c=$a(gc.current);$a(ka.current);id(b)?(d=b.stateNode,c=b.memoizedProps,d[Fa]=b,d.nodeValue!==c&&(b.flags|=4)):(d=(9===c.nodeType?c:c.ownerDocument).createTextNode(d),d[Fa]=b,b.stateNode=d)}return null;case 13:t(E);d=b.memoizedState;if(0!==(b.flags&64))return b.lanes=c,b;d=null!==d;c=!1;null===a?void 0!==b.memoizedProps.fallback&&id(b):c=null!==a.memoizedState;
if(d&&!c&&0!==(b.mode&2))if(null===a&&!0!==b.memoizedProps.unstable_avoidThisFallback||0!==(E.current&1))0===L&&(L=3);else{if(0===L||3===L)L=4;null===R||0===(La&134217727)&&0===(Cb&134217727)||Db(R,O)}if(d||c)b.flags|=4;return null;case 4:return Ab(),Jh(b),null===a&&Bg(b.stateNode.containerInfo),null;case 10:return ze(b),null;case 17:return S(b.type)&&(t(J),t(D)),null;case 19:t(E);d=b.memoizedState;if(null===d)return null;f=0!==(b.flags&64);g=d.rendering;if(null===g)if(f)oc(d,!1);else{if(0!==L||null!==
a&&0!==(a.flags&64))for(a=b.child;null!==a;){g=hd(a);if(null!==g){b.flags|=64;oc(d,!1);f=g.updateQueue;null!==f&&(b.updateQueue=f,b.flags|=4);null===d.lastEffect&&(b.firstEffect=null);b.lastEffect=d.lastEffect;d=c;for(c=b.child;null!==c;)f=c,a=d,f.flags&=2,f.nextEffect=null,f.firstEffect=null,f.lastEffect=null,g=f.alternate,null===g?(f.childLanes=0,f.lanes=a,f.child=null,f.memoizedProps=null,f.memoizedState=null,f.updateQueue=null,f.dependencies=null,f.stateNode=null):(f.childLanes=g.childLanes,f.lanes=
g.lanes,f.child=g.child,f.memoizedProps=g.memoizedProps,f.memoizedState=g.memoizedState,f.updateQueue=g.updateQueue,f.type=g.type,a=g.dependencies,f.dependencies=null===a?null:{lanes:a.lanes,firstContext:a.firstContext}),c=c.sibling;A(E,E.current&1|2);return b.child}a=a.sibling}null!==d.tail&&P()>Ve&&(b.flags|=64,f=!0,oc(d,!1),b.lanes=33554432)}else{if(!f)if(a=hd(g),null!==a){if(b.flags|=64,f=!0,c=a.updateQueue,null!==c&&(b.updateQueue=c,b.flags|=4),oc(d,!0),null===d.tail&&"hidden"===d.tailMode&&
!g.alternate&&!la)return b=b.lastEffect=d.lastEffect,null!==b&&(b.nextEffect=null),null}else 2*P()-d.renderingStartTime>Ve&&1073741824!==c&&(b.flags|=64,f=!0,oc(d,!1),b.lanes=33554432);d.isBackwards?(g.sibling=b.child,b.child=g):(c=d.last,null!==c?c.sibling=g:b.child=g,d.last=g)}return null!==d.tail?(c=d.tail,d.rendering=c,d.tail=c.sibling,d.lastEffect=b.lastEffect,d.renderingStartTime=P(),c.sibling=null,b=E.current,A(E,f?b&1|2:b&1),c):null;case 23:case 24:return ta=cb.current,t(cb),null!==a&&null!==
a.memoizedState!==(null!==b.memoizedState)&&"unstable-defer-without-hiding"!==d.mode&&(b.flags|=4),null}throw Error(m(156,b.tag));}function yj(a,b){switch(a.tag){case 1:return S(a.type)&&(t(J),t(D)),b=a.flags,b&4096?(a.flags=b&-4097|64,a):null;case 3:Ab();t(J);t(D);Ie();b=a.flags;if(0!==(b&64))throw Error(m(285));a.flags=b&-4097|64;return a;case 5:return Fe(a),null;case 13:return t(E),b=a.flags,b&4096?(a.flags=b&-4097|64,a):null;case 19:return t(E),null;case 4:return Ab(),null;case 10:return ze(a),
null;case 23:case 24:return ta=cb.current,t(cb),null;default:return null}}function We(a,b){try{var c="",d=b;do c+=oi(d),d=d.return;while(d);var e=c}catch(f){e="\nError generating stack: "+f.message+"\n"+f.stack}return{value:a,source:b,stack:e}}function Xe(a,b){try{console.error(b.value)}catch(c){setTimeout(function(){throw c;})}}function Lh(a,b,c){c=Ia(-1,c);c.tag=3;c.payload={element:null};var d=b.value;c.callback=function(){rd||(rd=!0,Ye=d);Xe(a,b)};return c}function Mh(a,b,c){c=Ia(-1,c);c.tag=
3;var d=a.type.getDerivedStateFromError;if("function"===typeof d){var e=b.value;c.payload=function(){Xe(a,b);return d(e)}}var f=a.stateNode;null!==f&&"function"===typeof f.componentDidCatch&&(c.callback=function(){"function"!==typeof d&&(null===na?na=new Set([this]):na.add(this),Xe(a,b));var c=b.stack;this.componentDidCatch(b.value,{componentStack:null!==c?c:""})});return c}function Nh(a){var b=a.ref;if(null!==b)if("function"===typeof b)try{b(null)}catch(c){Qa(a,c)}else b.current=null}function zj(a,
b){switch(b.tag){case 0:case 11:case 15:case 22:return;case 1:if(b.flags&256&&null!==a){var c=a.memoizedProps,d=a.memoizedState;a=b.stateNode;b=a.getSnapshotBeforeUpdate(b.elementType===b.type?c:ea(b.type,c),d);a.__reactInternalSnapshotBeforeUpdate=b}return;case 3:b.flags&256&&se(b.stateNode.containerInfo);return;case 5:case 6:case 4:case 17:return}throw Error(m(163));}function Aj(a,b,c,d){switch(c.tag){case 0:case 11:case 15:case 22:b=c.updateQueue;b=null!==b?b.lastEffect:null;if(null!==b){a=b=b.next;
do 3===(a.tag&3)&&(d=a.create,a.destroy=d()),a=a.next;while(a!==b)}b=c.updateQueue;b=null!==b?b.lastEffect:null;if(null!==b){a=b=b.next;do{var e=a;d=e.next;e=e.tag;0!==(e&4)&&0!==(e&1)&&(Oh(c,a),Bj(c,a));a=d}while(a!==b)}return;case 1:a=c.stateNode;c.flags&4&&(null===b?a.componentDidMount():(d=c.elementType===c.type?b.memoizedProps:ea(c.type,b.memoizedProps),a.componentDidUpdate(d,b.memoizedState,a.__reactInternalSnapshotBeforeUpdate)));b=c.updateQueue;null!==b&&ch(c,b,a);return;case 3:b=c.updateQueue;
if(null!==b){a=null;if(null!==c.child)switch(c.child.tag){case 5:a=c.child.stateNode;break;case 1:a=c.child.stateNode}ch(c,b,a)}return;case 5:a=c.stateNode;null===b&&c.flags&4&&Og(c.type,c.memoizedProps)&&a.focus();return;case 6:return;case 4:return;case 12:return;case 13:null===c.memoizedState&&(c=c.alternate,null!==c&&(c=c.memoizedState,null!==c&&(c=c.dehydrated,null!==c&&ag(c))));return;case 19:case 17:case 20:case 21:case 23:case 24:return}throw Error(m(163));}function Ph(a,b){for(var c=a;;){if(5===
c.tag){var d=c.stateNode;if(b)d=d.style,"function"===typeof d.setProperty?d.setProperty("display","none","important"):d.display="none";else{d=c.stateNode;var e=c.memoizedProps.style;e=void 0!==e&&null!==e&&e.hasOwnProperty("display")?e.display:null;d.style.display=Mf("display",e)}}else if(6===c.tag)c.stateNode.nodeValue=b?"":c.memoizedProps;else if((23!==c.tag&&24!==c.tag||null===c.memoizedState||c===a)&&null!==c.child){c.child.return=c;c=c.child;continue}if(c===a)break;for(;null===c.sibling;){if(null===
c.return||c.return===a)return;c=c.return}c.sibling.return=c.return;c=c.sibling}}function Qh(a,b,c){if(db&&"function"===typeof db.onCommitFiberUnmount)try{db.onCommitFiberUnmount(Ze,b)}catch(f){}switch(b.tag){case 0:case 11:case 14:case 15:case 22:a=b.updateQueue;if(null!==a&&(a=a.lastEffect,null!==a)){c=a=a.next;do{var d=c,e=d.destroy;d=d.tag;if(void 0!==e)if(0!==(d&4))Oh(b,c);else{d=b;try{e()}catch(f){Qa(d,f)}}c=c.next}while(c!==a)}break;case 1:Nh(b);a=b.stateNode;if("function"===typeof a.componentWillUnmount)try{a.props=
b.memoizedProps,a.state=b.memoizedState,a.componentWillUnmount()}catch(f){Qa(b,f)}break;case 5:Nh(b);break;case 4:Rh(a,b)}}function Sh(a){a.alternate=null;a.child=null;a.dependencies=null;a.firstEffect=null;a.lastEffect=null;a.memoizedProps=null;a.memoizedState=null;a.pendingProps=null;a.return=null;a.updateQueue=null}function Th(a){return 5===a.tag||3===a.tag||4===a.tag}function Uh(a){a:{for(var b=a.return;null!==b;){if(Th(b))break a;b=b.return}throw Error(m(160));}var c=b;b=c.stateNode;switch(c.tag){case 5:var d=
!1;break;case 3:b=b.containerInfo;d=!0;break;case 4:b=b.containerInfo;d=!0;break;default:throw Error(m(161));}c.flags&16&&(qc(b,""),c.flags&=-17);a:b:for(c=a;;){for(;null===c.sibling;){if(null===c.return||Th(c.return)){c=null;break a}c=c.return}c.sibling.return=c.return;for(c=c.sibling;5!==c.tag&&6!==c.tag&&18!==c.tag;){if(c.flags&2)continue b;if(null===c.child||4===c.tag)continue b;else c.child.return=c,c=c.child}if(!(c.flags&2)){c=c.stateNode;break a}}d?$e(a,c,b):af(a,c,b)}function $e(a,b,c){var d=
a.tag,e=5===d||6===d;if(e)a=e?a.stateNode:a.stateNode.instance,b?8===c.nodeType?c.parentNode.insertBefore(a,b):c.insertBefore(a,b):(8===c.nodeType?(b=c.parentNode,b.insertBefore(a,c)):(b=c,b.appendChild(a)),c=c._reactRootContainer,null!==c&&void 0!==c||null!==b.onclick||(b.onclick=Vc));else if(4!==d&&(a=a.child,null!==a))for($e(a,b,c),a=a.sibling;null!==a;)$e(a,b,c),a=a.sibling}function af(a,b,c){var d=a.tag,e=5===d||6===d;if(e)a=e?a.stateNode:a.stateNode.instance,b?c.insertBefore(a,b):c.appendChild(a);
else if(4!==d&&(a=a.child,null!==a))for(af(a,b,c),a=a.sibling;null!==a;)af(a,b,c),a=a.sibling}function Rh(a,b,c){c=b;for(var d=!1,e,f;;){if(!d){e=c.return;a:for(;;){if(null===e)throw Error(m(160));f=e.stateNode;switch(e.tag){case 5:e=f;f=!1;break a;case 3:e=f.containerInfo;f=!0;break a;case 4:e=f.containerInfo;f=!0;break a}e=e.return}d=!0}if(5===c.tag||6===c.tag){a:for(var g=a,h=c,k=h;;)if(Qh(g,k),null!==k.child&&4!==k.tag)k.child.return=k,k=k.child;else{if(k===h)break a;for(;null===k.sibling;){if(null===
k.return||k.return===h)break a;k=k.return}k.sibling.return=k.return;k=k.sibling}f?(g=e,h=c.stateNode,8===g.nodeType?g.parentNode.removeChild(h):g.removeChild(h)):e.removeChild(c.stateNode)}else if(4===c.tag){if(null!==c.child){e=c.stateNode.containerInfo;f=!0;c.child.return=c;c=c.child;continue}}else if(Qh(a,c),null!==c.child){c.child.return=c;c=c.child;continue}if(c===b)break;for(;null===c.sibling;){if(null===c.return||c.return===b)return;c=c.return;4===c.tag&&(d=!1)}c.sibling.return=c.return;c=
c.sibling}}function bf(a,b){switch(b.tag){case 0:case 11:case 14:case 15:case 22:var c=b.updateQueue;c=null!==c?c.lastEffect:null;if(null!==c){var d=c=c.next;do 3===(d.tag&3)&&(a=d.destroy,d.destroy=void 0,void 0!==a&&a()),d=d.next;while(d!==c)}return;case 1:return;case 5:c=b.stateNode;if(null!=c){d=b.memoizedProps;var e=null!==a?a.memoizedProps:d;a=b.type;var f=b.updateQueue;b.updateQueue=null;if(null!==f){c[Wc]=d;"input"===a&&"radio"===d.type&&null!=d.name&&Gf(c,d);Td(a,e);b=Td(a,d);for(e=0;e<f.length;e+=
2){var g=f[e],h=f[e+1];"style"===g?Nf(c,h):"dangerouslySetInnerHTML"===g?Kh(c,h):"children"===g?qc(c,h):Ed(c,g,h,b)}switch(a){case "input":Nd(c,d);break;case "textarea":Jf(c,d);break;case "select":a=c._wrapperState.wasMultiple,c._wrapperState.wasMultiple=!!d.multiple,f=d.value,null!=f?ib(c,!!d.multiple,f,!1):a!==!!d.multiple&&(null!=d.defaultValue?ib(c,!!d.multiple,d.defaultValue,!0):ib(c,!!d.multiple,d.multiple?[]:"",!1))}}}return;case 6:if(null===b.stateNode)throw Error(m(162));b.stateNode.nodeValue=
b.memoizedProps;return;case 3:c=b.stateNode;c.hydrate&&(c.hydrate=!1,ag(c.containerInfo));return;case 12:return;case 13:null!==b.memoizedState&&(cf=P(),Ph(b.child,!0));Vh(b);return;case 19:Vh(b);return;case 17:return;case 23:case 24:Ph(b,null!==b.memoizedState);return}throw Error(m(163));}function Vh(a){var b=a.updateQueue;if(null!==b){a.updateQueue=null;var c=a.stateNode;null===c&&(c=a.stateNode=new Cj);b.forEach(function(b){var d=Dj.bind(null,a,b);c.has(b)||(c.add(b),b.then(d,d))})}}function Ej(a,
b){return null!==a&&(a=a.memoizedState,null===a||null!==a.dehydrated)?(b=b.memoizedState,null!==b&&null===b.dehydrated):!1}function Eb(){Ve=P()+500}function W(){return 0!==(n&48)?P():-1!==sd?sd:sd=P()}function Oa(a){a=a.mode;if(0===(a&2))return 1;if(0===(a&4))return 99===wb()?1:2;0===ua&&(ua=Fb);if(0!==Fj.transition){0!==td&&(td=null!==df?df.pendingLanes:0);a=ua;var b=4186112&~td;b&=-b;0===b&&(a=4186112&~a,b=a&-a,0===b&&(b=8192));return b}a=wb();0!==(n&4)&&98===a?a=Nc(12,ua):(a=Ei(a),a=Nc(a,ua));
return a}function Pa(a,b,c){if(50<rc)throw rc=0,ef=null,Error(m(185));a=ud(a,b);if(null===a)return null;Oc(a,b,c);a===R&&(Cb|=b,4===L&&Db(a,O));var d=wb();1===b?0!==(n&8)&&0===(n&48)?ff(a):(ba(a,c),0===n&&(Eb(),ja())):(0===(n&4)||98!==d&&99!==d||(null===va?va=new Set([a]):va.add(a)),ba(a,c));df=a}function ud(a,b){a.lanes|=b;var c=a.alternate;null!==c&&(c.lanes|=b);c=a;for(a=a.return;null!==a;)a.childLanes|=b,c=a.alternate,null!==c&&(c.childLanes|=b),c=a,a=a.return;return 3===c.tag?c.stateNode:null}
function ba(a,b){for(var c=a.callbackNode,d=a.suspendedLanes,e=a.pingedLanes,f=a.expirationTimes,g=a.pendingLanes;0<g;){var h=31-Ba(g),k=1<<h,l=f[h];if(-1===l){if(0===(k&d)||0!==(k&e)){l=b;mb(k);var m=w;f[h]=10<=m?l+250:6<=m?l+5E3:-1}}else l<=b&&(a.expiredLanes|=k);g&=~k}d=Wb(a,a===R?O:0);b=w;if(0===d)null!==c&&(c!==gf&&we(c),a.callbackNode=null,a.callbackPriority=0);else{if(null!==c){if(a.callbackPriority===b)return;c!==gf&&we(c)}15===b?(c=ff.bind(null,a),null===pa?(pa=[c],Zc=ve(Yc,Zg)):pa.push(c),
c=gf):14===b?c=bc(99,ff.bind(null,a)):(c=Fi(b),c=bc(c,Wh.bind(null,a)));a.callbackPriority=b;a.callbackNode=c}}function Wh(a){sd=-1;td=ua=0;if(0!==(n&48))throw Error(m(327));var b=a.callbackNode;if(Ra()&&a.callbackNode!==b)return null;var c=Wb(a,a===R?O:0);if(0===c)return null;var d=c;var e=n;n|=16;var f=Xh();if(R!==a||O!==d)Eb(),Gb(a,d);do try{Gj();break}catch(h){Yh(a,h)}while(1);ye();vd.current=f;n=e;null!==G?d=0:(R=null,O=0,d=L);if(0!==(Fb&Cb))Gb(a,0);else if(0!==d){2===d&&(n|=64,a.hydrate&&(a.hydrate=
!1,se(a.containerInfo)),c=dg(a),0!==c&&(d=sc(a,c)));if(1===d)throw b=wd,Gb(a,0),Db(a,c),ba(a,P()),b;a.finishedWork=a.current.alternate;a.finishedLanes=c;switch(d){case 0:case 1:throw Error(m(345));case 2:eb(a);break;case 3:Db(a,c);if((c&62914560)===c&&(d=cf+500-P(),10<d)){if(0!==Wb(a,0))break;e=a.suspendedLanes;if((e&c)!==c){W();a.pingedLanes|=a.suspendedLanes&e;break}a.timeoutHandle=Zh(eb.bind(null,a),d);break}eb(a);break;case 4:Db(a,c);if((c&4186112)===c)break;d=a.eventTimes;for(e=-1;0<c;){var g=
31-Ba(c);f=1<<g;g=d[g];g>e&&(e=g);c&=~f}c=e;c=P()-c;c=(120>c?120:480>c?480:1080>c?1080:1920>c?1920:3E3>c?3E3:4320>c?4320:1960*Hj(c/1960))-c;if(10<c){a.timeoutHandle=Zh(eb.bind(null,a),c);break}eb(a);break;case 5:eb(a);break;default:throw Error(m(329));}}ba(a,P());return a.callbackNode===b?Wh.bind(null,a):null}function Db(a,b){b&=~hf;b&=~Cb;a.suspendedLanes|=b;a.pingedLanes&=~b;for(a=a.expirationTimes;0<b;){var c=31-Ba(b),d=1<<c;a[c]=-1;b&=~d}}function ff(a){if(0!==(n&48))throw Error(m(327));Ra();
if(a===R&&0!==(a.expiredLanes&O)){var b=O;var c=sc(a,b);0!==(Fb&Cb)&&(b=Wb(a,b),c=sc(a,b))}else b=Wb(a,0),c=sc(a,b);0!==a.tag&&2===c&&(n|=64,a.hydrate&&(a.hydrate=!1,se(a.containerInfo)),b=dg(a),0!==b&&(c=sc(a,b)));if(1===c)throw c=wd,Gb(a,0),Db(a,b),ba(a,P()),c;a.finishedWork=a.current.alternate;a.finishedLanes=b;eb(a);ba(a,P());return null}function Ij(){if(null!==va){var a=va;va=null;a.forEach(function(a){a.expiredLanes|=24&a.pendingLanes;ba(a,P())})}ja()}function $h(a,b){var c=n;n|=1;try{return a(b)}finally{n=
c,0===n&&(Eb(),ja())}}function ai(a,b){var c=n;n&=-2;n|=8;try{return a(b)}finally{n=c,0===n&&(Eb(),ja())}}function pd(a,b){A(cb,ta);ta|=b;Fb|=b}function Gb(a,b){a.finishedWork=null;a.finishedLanes=0;var c=a.timeoutHandle;-1!==c&&(a.timeoutHandle=-1,Jj(c));if(null!==G)for(c=G.return;null!==c;){var d=c;switch(d.tag){case 1:d=d.type.childContextTypes;null!==d&&void 0!==d&&(t(J),t(D));break;case 3:Ab();t(J);t(D);Ie();break;case 5:Fe(d);break;case 4:Ab();break;case 13:t(E);break;case 19:t(E);break;case 10:ze(d);
break;case 23:case 24:ta=cb.current,t(cb)}c=c.return}R=a;G=Ma(a.current,null);O=ta=Fb=b;L=0;wd=null;hf=Cb=La=0}function Yh(a,b){do{var c=G;try{ye();jc.current=jd;if(kd){for(var d=y.memoizedState;null!==d;){var e=d.queue;null!==e&&(e.pending=null);d=d.next}kd=!1}ic=0;K=N=y=null;kc=!1;jf.current=null;if(null===c||null===c.return){L=1;wd=b;G=null;break}a:{var f=a,g=c.return,h=c,k=b;b=O;h.flags|=2048;h.firstEffect=h.lastEffect=null;if(null!==k&&"object"===typeof k&&"function"===typeof k.then){var l=k;
if(0===(h.mode&2)){var m=h.alternate;m?(h.updateQueue=m.updateQueue,h.memoizedState=m.memoizedState,h.lanes=m.lanes):(h.updateQueue=null,h.memoizedState=null)}var n=0!==(E.current&1),r=g;do{var t;if(t=13===r.tag){var w=r.memoizedState;if(null!==w)t=null!==w.dehydrated?!0:!1;else{var z=r.memoizedProps;t=void 0===z.fallback?!1:!0!==z.unstable_avoidThisFallback?!0:n?!1:!0}}if(t){var C=r.updateQueue;if(null===C){var x=new Set;x.add(l);r.updateQueue=x}else C.add(l);if(0===(r.mode&2)){r.flags|=64;h.flags|=
16384;h.flags&=-2981;if(1===h.tag)if(null===h.alternate)h.tag=17;else{var p=Ia(-1,1);p.tag=2;Ja(h,p)}h.lanes|=1;break a}k=void 0;h=b;var q=f.pingCache;null===q?(q=f.pingCache=new Kj,k=new Set,q.set(l,k)):(k=q.get(l),void 0===k&&(k=new Set,q.set(l,k)));if(!k.has(h)){k.add(h);var u=Lj.bind(null,f,l,h);l.then(u,u)}r.flags|=4096;r.lanes=b;break a}r=r.return}while(null!==r);k=Error((hb(h.type)||"A React component")+" suspended while rendering, but no fallback UI was specified.\n\nAdd a <Suspense fallback=...> component higher in the tree to provide a loading indicator or placeholder to display.")}5!==
L&&(L=2);k=We(k,h);r=g;do{switch(r.tag){case 3:f=k;r.flags|=4096;b&=-b;r.lanes|=b;var B=Lh(r,f,b);bh(r,B);break a;case 1:f=k;var A=r.type,D=r.stateNode;if(0===(r.flags&64)&&("function"===typeof A.getDerivedStateFromError||null!==D&&"function"===typeof D.componentDidCatch&&(null===na||!na.has(D)))){r.flags|=4096;b&=-b;r.lanes|=b;var F=Mh(r,f,b);bh(r,F);break a}}r=r.return}while(null!==r)}bi(c)}catch(qa){b=qa;G===c&&null!==c&&(G=c=c.return);continue}break}while(1)}function Xh(){var a=vd.current;vd.current=
jd;return null===a?jd:a}function sc(a,b){var c=n;n|=16;var d=Xh();R===a&&O===b||Gb(a,b);do try{Mj();break}catch(e){Yh(a,e)}while(1);ye();n=c;vd.current=d;if(null!==G)throw Error(m(261));R=null;O=0;return L}function Mj(){for(;null!==G;)ci(G)}function Gj(){for(;null!==G&&!Nj();)ci(G)}function ci(a){var b=Oj(a.alternate,a,ta);a.memoizedProps=a.pendingProps;null===b?bi(a):G=b;jf.current=null}function bi(a){var b=a;do{var c=b.alternate;a=b.return;if(0===(b.flags&2048)){c=uj(c,b,ta);if(null!==c){G=c;return}c=
b;if(24!==c.tag&&23!==c.tag||null===c.memoizedState||0!==(ta&1073741824)||0===(c.mode&4)){for(var d=0,e=c.child;null!==e;)d|=e.lanes|e.childLanes,e=e.sibling;c.childLanes=d}null!==a&&0===(a.flags&2048)&&(null===a.firstEffect&&(a.firstEffect=b.firstEffect),null!==b.lastEffect&&(null!==a.lastEffect&&(a.lastEffect.nextEffect=b.firstEffect),a.lastEffect=b.lastEffect),1<b.flags&&(null!==a.lastEffect?a.lastEffect.nextEffect=b:a.firstEffect=b,a.lastEffect=b))}else{c=yj(b);if(null!==c){c.flags&=2047;G=c;
return}null!==a&&(a.firstEffect=a.lastEffect=null,a.flags|=2048)}b=b.sibling;if(null!==b){G=b;return}G=b=a}while(null!==b);0===L&&(L=5)}function eb(a){var b=wb();Za(99,Pj.bind(null,a,b));return null}function Pj(a,b){do Ra();while(null!==tc);if(0!==(n&48))throw Error(m(327));var c=a.finishedWork;if(null===c)return null;a.finishedWork=null;a.finishedLanes=0;if(c===a.current)throw Error(m(177));a.callbackNode=null;var d=c.lanes|c.childLanes,e=d,f=a.pendingLanes&~e;a.pendingLanes=e;a.suspendedLanes=0;
a.pingedLanes=0;a.expiredLanes&=e;a.mutableReadLanes&=e;a.entangledLanes&=e;e=a.entanglements;for(var g=a.eventTimes,h=a.expirationTimes;0<f;){var k=31-Ba(f),v=1<<k;e[k]=0;g[k]=-1;h[k]=-1;f&=~v}null!==va&&0===(d&24)&&va.has(a)&&va.delete(a);a===R&&(G=R=null,O=0);1<c.flags?null!==c.lastEffect?(c.lastEffect.nextEffect=c,d=c.firstEffect):d=c:d=c.firstEffect;if(null!==d){e=n;n|=32;jf.current=null;kf=Pc;g=wg();if(me(g)){if("selectionStart"in g)h={start:g.selectionStart,end:g.selectionEnd};else a:if(h=
(h=g.ownerDocument)&&h.defaultView||window,(v=h.getSelection&&h.getSelection())&&0!==v.rangeCount){h=v.anchorNode;f=v.anchorOffset;k=v.focusNode;v=v.focusOffset;try{h.nodeType,k.nodeType}catch(qa){h=null;break a}var t=0,w=-1,r=-1,z=0,B=0,y=g,C=null;b:for(;;){for(var x;;){y!==h||0!==f&&3!==y.nodeType||(w=t+f);y!==k||0!==v&&3!==y.nodeType||(r=t+v);3===y.nodeType&&(t+=y.nodeValue.length);if(null===(x=y.firstChild))break;C=y;y=x}for(;;){if(y===g)break b;C===h&&++z===f&&(w=t);C===k&&++B===v&&(r=t);if(null!==
(x=y.nextSibling))break;y=C;C=y.parentNode}y=x}h=-1===w||-1===r?null:{start:w,end:r}}else h=null;h=h||{start:0,end:0}}else h=null;lf={focusedElem:g,selectionRange:h};Pc=!1;uc=null;xd=!1;l=d;do try{Qj()}catch(qa){if(null===l)throw Error(m(330));Qa(l,qa);l=l.nextEffect}while(null!==l);uc=null;l=d;do try{for(g=a;null!==l;){var p=l.flags;p&16&&qc(l.stateNode,"");if(p&128){var q=l.alternate;if(null!==q){var u=q.ref;null!==u&&("function"===typeof u?u(null):u.current=null)}}switch(p&1038){case 2:Uh(l);l.flags&=
-3;break;case 6:Uh(l);l.flags&=-3;bf(l.alternate,l);break;case 1024:l.flags&=-1025;break;case 1028:l.flags&=-1025;bf(l.alternate,l);break;case 4:bf(l.alternate,l);break;case 8:h=l;Rh(g,h);var A=h.alternate;Sh(h);null!==A&&Sh(A)}l=l.nextEffect}}catch(qa){if(null===l)throw Error(m(330));Qa(l,qa);l=l.nextEffect}while(null!==l);u=lf;q=wg();p=u.focusedElem;g=u.selectionRange;if(q!==p&&p&&p.ownerDocument&&vg(p.ownerDocument.documentElement,p)){null!==g&&me(p)&&(q=g.start,u=g.end,void 0===u&&(u=q),"selectionStart"in
p?(p.selectionStart=q,p.selectionEnd=Math.min(u,p.value.length)):(u=(q=p.ownerDocument||document)&&q.defaultView||window,u.getSelection&&(u=u.getSelection(),h=p.textContent.length,A=Math.min(g.start,h),g=void 0===g.end?A:Math.min(g.end,h),!u.extend&&A>g&&(h=g,g=A,A=h),h=ug(p,A),f=ug(p,g),h&&f&&(1!==u.rangeCount||u.anchorNode!==h.node||u.anchorOffset!==h.offset||u.focusNode!==f.node||u.focusOffset!==f.offset)&&(q=q.createRange(),q.setStart(h.node,h.offset),u.removeAllRanges(),A>g?(u.addRange(q),u.extend(f.node,
f.offset)):(q.setEnd(f.node,f.offset),u.addRange(q))))));q=[];for(u=p;u=u.parentNode;)1===u.nodeType&&q.push({element:u,left:u.scrollLeft,top:u.scrollTop});"function"===typeof p.focus&&p.focus();for(p=0;p<q.length;p++)u=q[p],u.element.scrollLeft=u.left,u.element.scrollTop=u.top}Pc=!!kf;lf=kf=null;a.current=c;l=d;do try{for(p=a;null!==l;){var D=l.flags;D&36&&Aj(p,l.alternate,l);if(D&128){q=void 0;var E=l.ref;if(null!==E){var F=l.stateNode;switch(l.tag){case 5:q=F;break;default:q=F}"function"===typeof E?
E(q):E.current=q}}l=l.nextEffect}}catch(qa){if(null===l)throw Error(m(330));Qa(l,qa);l=l.nextEffect}while(null!==l);l=null;Rj();n=e}else a.current=c;if(Sa)Sa=!1,tc=a,vc=b;else for(l=d;null!==l;)b=l.nextEffect,l.nextEffect=null,l.flags&8&&(D=l,D.sibling=null,D.stateNode=null),l=b;d=a.pendingLanes;0===d&&(na=null);1===d?a===ef?rc++:(rc=0,ef=a):rc=0;c=c.stateNode;if(db&&"function"===typeof db.onCommitFiberRoot)try{db.onCommitFiberRoot(Ze,c,void 0,64===(c.current.flags&64))}catch(qa){}ba(a,P());if(rd)throw rd=
!1,a=Ye,Ye=null,a;if(0!==(n&8))return null;ja();return null}function Qj(){for(;null!==l;){var a=l.alternate;xd||null===uc||(0!==(l.flags&8)?Vf(l,uc)&&(xd=!0):13===l.tag&&Ej(a,l)&&Vf(l,uc)&&(xd=!0));var b=l.flags;0!==(b&256)&&zj(a,l);0===(b&512)||Sa||(Sa=!0,bc(97,function(){Ra();return null}));l=l.nextEffect}}function Ra(){if(90!==vc){var a=97<vc?97:vc;vc=90;return Za(a,Sj)}return!1}function Bj(a,b){mf.push(b,a);Sa||(Sa=!0,bc(97,function(){Ra();return null}))}function Oh(a,b){nf.push(b,a);Sa||(Sa=
!0,bc(97,function(){Ra();return null}))}function Sj(){if(null===tc)return!1;var a=tc;tc=null;if(0!==(n&48))throw Error(m(331));var b=n;n|=32;var c=nf;nf=[];for(var d=0;d<c.length;d+=2){var e=c[d],f=c[d+1],g=e.destroy;e.destroy=void 0;if("function"===typeof g)try{g()}catch(k){if(null===f)throw Error(m(330));Qa(f,k)}}c=mf;mf=[];for(d=0;d<c.length;d+=2){e=c[d];f=c[d+1];try{var h=e.create;e.destroy=h()}catch(k){if(null===f)throw Error(m(330));Qa(f,k)}}for(h=a.current.firstEffect;null!==h;)a=h.nextEffect,
h.nextEffect=null,h.flags&8&&(h.sibling=null,h.stateNode=null),h=a;n=b;ja();return!0}function di(a,b,c){b=We(c,b);b=Lh(a,b,1);Ja(a,b);b=W();a=ud(a,1);null!==a&&(Oc(a,1,b),ba(a,b))}function Qa(a,b){if(3===a.tag)di(a,a,b);else for(var c=a.return;null!==c;){if(3===c.tag){di(c,a,b);break}else if(1===c.tag){var d=c.stateNode;if("function"===typeof c.type.getDerivedStateFromError||"function"===typeof d.componentDidCatch&&(null===na||!na.has(d))){a=We(b,a);var e=Mh(c,a,1);Ja(c,e);e=W();c=ud(c,1);if(null!==
c)Oc(c,1,e),ba(c,e);else if("function"===typeof d.componentDidCatch&&(null===na||!na.has(d)))try{d.componentDidCatch(b,a)}catch(f){}break}}c=c.return}}function Lj(a,b,c){var d=a.pingCache;null!==d&&d.delete(b);b=W();a.pingedLanes|=a.suspendedLanes&c;R===a&&(O&c)===c&&(4===L||3===L&&(O&62914560)===O&&500>P()-cf?Gb(a,0):hf|=c);ba(a,b)}function Dj(a,b){var c=a.stateNode;null!==c&&c.delete(b);b=0;0===b&&(b=a.mode,0===(b&2)?b=1:0===(b&4)?b=99===wb()?1:2:(0===ua&&(ua=Fb),b=nb(62914560&~ua),0===b&&(b=4194304)));
c=W();a=ud(a,b);null!==a&&(Oc(a,b,c),ba(a,c))}function Tj(a,b,c,d){this.tag=a;this.key=c;this.sibling=this.child=this.return=this.stateNode=this.type=this.elementType=null;this.index=0;this.ref=null;this.pendingProps=b;this.dependencies=this.memoizedState=this.updateQueue=this.memoizedProps=null;this.mode=d;this.flags=0;this.lastEffect=this.firstEffect=this.nextEffect=null;this.childLanes=this.lanes=0;this.alternate=null}function Pe(a){a=a.prototype;return!(!a||!a.isReactComponent)}function Uj(a){if("function"===
typeof a)return Pe(a)?1:0;if(void 0!==a&&null!==a){a=a.$$typeof;if(a===Dc)return 11;if(a===Ec)return 14}return 2}function Ma(a,b){var c=a.alternate;null===c?(c=Z(a.tag,b,a.key,a.mode),c.elementType=a.elementType,c.type=a.type,c.stateNode=a.stateNode,c.alternate=a,a.alternate=c):(c.pendingProps=b,c.type=a.type,c.flags=0,c.nextEffect=null,c.firstEffect=null,c.lastEffect=null);c.childLanes=a.childLanes;c.lanes=a.lanes;c.child=a.child;c.memoizedProps=a.memoizedProps;c.memoizedState=a.memoizedState;c.updateQueue=
a.updateQueue;b=a.dependencies;c.dependencies=null===b?null:{lanes:b.lanes,firstContext:b.firstContext};c.sibling=a.sibling;c.index=a.index;c.ref=a.ref;return c}function fd(a,b,c,d,e,f){var g=2;d=a;if("function"===typeof a)Pe(a)&&(g=1);else if("string"===typeof a)g=5;else a:switch(a){case wa:return zb(c.children,e,f,b);case ei:g=8;e|=16;break;case Hd:g=8;e|=1;break;case Lb:return a=Z(12,c,b,e|8),a.elementType=Lb,a.type=Lb,a.lanes=f,a;case Mb:return a=Z(13,c,b,e),a.type=Mb,a.elementType=Mb,a.lanes=
f,a;case Cc:return a=Z(19,c,b,e),a.elementType=Cc,a.lanes=f,a;case of:return Te(c,e,f,b);case pf:return a=Z(24,c,b,e),a.elementType=pf,a.lanes=f,a;default:if("object"===typeof a&&null!==a)switch(a.$$typeof){case Jd:g=10;break a;case Id:g=9;break a;case Dc:g=11;break a;case Ec:g=14;break a;case Ld:g=16;d=null;break a;case Kd:g=22;break a}throw Error(m(130,null==a?a:typeof a,""));}b=Z(g,c,b,e);b.elementType=a;b.type=d;b.lanes=f;return b}function zb(a,b,c,d){a=Z(7,a,d,b);a.lanes=c;return a}function Te(a,
b,c,d){a=Z(23,a,d,b);a.elementType=of;a.lanes=c;return a}function Ce(a,b,c){a=Z(6,a,null,b);a.lanes=c;return a}function De(a,b,c){b=Z(4,null!==a.children?a.children:[],a.key,b);b.lanes=c;b.stateNode={containerInfo:a.containerInfo,pendingChildren:null,implementation:a.implementation};return b}function Vj(a,b,c){this.tag=b;this.containerInfo=a;this.finishedWork=this.pingCache=this.current=this.pendingChildren=null;this.timeoutHandle=-1;this.pendingContext=this.context=null;this.hydrate=c;this.callbackNode=
null;this.callbackPriority=0;this.eventTimes=Array(31).fill(0);this.expirationTimes=Array(31).fill(-1);this.entangledLanes=this.finishedLanes=this.mutableReadLanes=this.expiredLanes=this.pingedLanes=this.suspendedLanes=this.pendingLanes=0;this.entanglements=Array(31).fill(0);this.mutableSourceEagerHydrationData=null}function Wj(a,b,c){var d=3<arguments.length&&void 0!==arguments[3]?arguments[3]:null;return{$$typeof:Ua,key:null==d?null:""+d,children:a,containerInfo:b,implementation:c}}function yd(a,
b,c,d){var e=b.current,f=W(),g=Oa(e);a:if(c){c=c._reactInternals;b:{if(Va(c)!==c||1!==c.tag)throw Error(m(170));var h=c;do{switch(h.tag){case 3:h=h.stateNode.context;break b;case 1:if(S(h.type)){h=h.stateNode.__reactInternalMemoizedMergedChildContext;break b}}h=h.return}while(null!==h);throw Error(m(171));}if(1===c.tag){var k=c.type;if(S(k)){c=Sg(c,k,h);break a}}c=h}else c=Ha;null===b.context?b.context=c:b.pendingContext=c;b=Ia(f,g);b.payload={element:a};d=void 0===d?null:d;null!==d&&(b.callback=
d);Ja(e,b);Pa(e,g,f);return g}function qf(a){a=a.current;if(!a.child)return null;switch(a.child.tag){case 5:return a.child.stateNode;default:return a.child.stateNode}}function fi(a,b){a=a.memoizedState;if(null!==a&&null!==a.dehydrated){var c=a.retryLane;a.retryLane=0!==c&&c<b?c:b}}function rf(a,b){fi(a,b);(a=a.alternate)&&fi(a,b)}function Xj(a){a=Uf(a);return null===a?null:a.stateNode}function Yj(a){return null}function sf(a,b,c){var d=null!=c&&null!=c.hydrationOptions&&c.hydrationOptions.mutableSources||
null;c=new Vj(a,b,null!=c&&!0===c.hydrate);b=Z(3,null,null,2===b?7:1===b?3:0);c.current=b;b.stateNode=c;Ae(b);a[rb]=c.current;Bg(8===a.nodeType?a.parentNode:a);if(d)for(a=0;a<d.length;a++){b=d[a];var e=b._getVersion;e=e(b._source);null==c.mutableSourceEagerHydrationData?c.mutableSourceEagerHydrationData=[b,e]:c.mutableSourceEagerHydrationData.push(b,e)}this._internalRoot=c}function wc(a){return!(!a||1!==a.nodeType&&9!==a.nodeType&&11!==a.nodeType&&(8!==a.nodeType||" react-mount-point-unstable "!==
a.nodeValue))}function Zj(a,b){b||(b=a?9===a.nodeType?a.documentElement:a.firstChild:null,b=!(!b||1!==b.nodeType||!b.hasAttribute("data-reactroot")));if(!b)for(var c;c=a.lastChild;)a.removeChild(c);return new sf(a,0,b?{hydrate:!0}:void 0)}function zd(a,b,c,d,e){var f=c._reactRootContainer;if(f){var g=f._internalRoot;if("function"===typeof e){var h=e;e=function(){var a=qf(g);h.call(a)}}yd(b,g,a,e)}else{f=c._reactRootContainer=Zj(c,d);g=f._internalRoot;if("function"===typeof e){var k=e;e=function(){var a=
qf(g);k.call(a)}}ai(function(){yd(b,g,a,e)})}return qf(g)}function gi(a,b){var c=2<arguments.length&&void 0!==arguments[2]?arguments[2]:null;if(!wc(b))throw Error(m(200));return Wj(a,b,null,c)}if(!ha)throw Error(m(227));var yf=new Set,Ib={},oa=!("undefined"===typeof window||"undefined"===typeof window.document||"undefined"===typeof window.document.createElement),li=/^[:A-Z_a-z\u00C0-\u00D6\u00D8-\u00F6\u00F8-\u02FF\u0370-\u037D\u037F-\u1FFF\u200C-\u200D\u2070-\u218F\u2C00-\u2FEF\u3001-\uD7FF\uF900-\uFDCF\uFDF0-\uFFFD][:A-Z_a-z\u00C0-\u00D6\u00D8-\u00F6\u00F8-\u02FF\u0370-\u037D\u037F-\u1FFF\u200C-\u200D\u2070-\u218F\u2C00-\u2FEF\u3001-\uD7FF\uF900-\uFDCF\uFDF0-\uFFFD\-.0-9\u00B7\u0300-\u036F\u203F-\u2040]*$/,
zf=Object.prototype.hasOwnProperty,Bf={},Af={},I={};"children dangerouslySetInnerHTML defaultValue defaultChecked innerHTML suppressContentEditableWarning suppressHydrationWarning style".split(" ").forEach(function(a){I[a]=new Q(a,0,!1,a,null,!1,!1)});[["acceptCharset","accept-charset"],["className","class"],["htmlFor","for"],["httpEquiv","http-equiv"]].forEach(function(a){var b=a[0];I[b]=new Q(b,1,!1,a[1],null,!1,!1)});["contentEditable","draggable","spellCheck","value"].forEach(function(a){I[a]=
new Q(a,2,!1,a.toLowerCase(),null,!1,!1)});["autoReverse","externalResourcesRequired","focusable","preserveAlpha"].forEach(function(a){I[a]=new Q(a,2,!1,a,null,!1,!1)});"allowFullScreen async autoFocus autoPlay controls default defer disabled disablePictureInPicture disableRemotePlayback formNoValidate hidden loop noModule noValidate open playsInline readOnly required reversed scoped seamless itemScope".split(" ").forEach(function(a){I[a]=new Q(a,3,!1,a.toLowerCase(),null,!1,!1)});["checked","multiple",
"muted","selected"].forEach(function(a){I[a]=new Q(a,3,!0,a,null,!1,!1)});["capture","download"].forEach(function(a){I[a]=new Q(a,4,!1,a,null,!1,!1)});["cols","rows","size","span"].forEach(function(a){I[a]=new Q(a,6,!1,a,null,!1,!1)});["rowSpan","start"].forEach(function(a){I[a]=new Q(a,5,!1,a.toLowerCase(),null,!1,!1)});var tf=/[\-:]([a-z])/g,uf=function(a){return a[1].toUpperCase()};"accent-height alignment-baseline arabic-form baseline-shift cap-height clip-path clip-rule color-interpolation color-interpolation-filters color-profile color-rendering dominant-baseline enable-background fill-opacity fill-rule flood-color flood-opacity font-family font-size font-size-adjust font-stretch font-style font-variant font-weight glyph-name glyph-orientation-horizontal glyph-orientation-vertical horiz-adv-x horiz-origin-x image-rendering letter-spacing lighting-color marker-end marker-mid marker-start overline-position overline-thickness paint-order panose-1 pointer-events rendering-intent shape-rendering stop-color stop-opacity strikethrough-position strikethrough-thickness stroke-dasharray stroke-dashoffset stroke-linecap stroke-linejoin stroke-miterlimit stroke-opacity stroke-width text-anchor text-decoration text-rendering underline-position underline-thickness unicode-bidi unicode-range units-per-em v-alphabetic v-hanging v-ideographic v-mathematical vector-effect vert-adv-y vert-origin-x vert-origin-y word-spacing writing-mode xmlns:xlink x-height".split(" ").forEach(function(a){var b=
a.replace(tf,uf);I[b]=new Q(b,1,!1,a,null,!1,!1)});"xlink:actuate xlink:arcrole xlink:role xlink:show xlink:title xlink:type".split(" ").forEach(function(a){var b=a.replace(tf,uf);I[b]=new Q(b,1,!1,a,"http://www.w3.org/1999/xlink",!1,!1)});["xml:base","xml:lang","xml:space"].forEach(function(a){var b=a.replace(tf,uf);I[b]=new Q(b,1,!1,a,"http://www.w3.org/XML/1998/namespace",!1,!1)});["tabIndex","crossOrigin"].forEach(function(a){I[a]=new Q(a,1,!1,a.toLowerCase(),null,!1,!1)});I.xlinkHref=new Q("xlinkHref",
1,!1,"xlink:href","http://www.w3.org/1999/xlink",!0,!1);["src","href","action","formAction"].forEach(function(a){I[a]=new Q(a,1,!1,a.toLowerCase(),null,!0,!0)});var B=ha.__SECRET_INTERNALS_DO_NOT_USE_OR_YOU_WILL_BE_FIRED.assign,fb=ha.__SECRET_INTERNALS_DO_NOT_USE_OR_YOU_WILL_BE_FIRED,ec=60103,Ua=60106,wa=60107,Hd=60108,Lb=60114,Jd=60109,Id=60110,Dc=60112,Mb=60113,Cc=60120,Ec=60115,Ld=60116,Kd=60121,te=60128,ei=60129,of=60130,pf=60131;if("function"===typeof Symbol&&Symbol.for){var H=Symbol.for;ec=
H("react.element");Ua=H("react.portal");wa=H("react.fragment");Hd=H("react.strict_mode");Lb=H("react.profiler");Jd=H("react.provider");Id=H("react.context");Dc=H("react.forward_ref");Mb=H("react.suspense");Cc=H("react.suspense_list");Ec=H("react.memo");Ld=H("react.lazy");Kd=H("react.block");H("react.scope");te=H("react.opaque.id");ei=H("react.debug_trace_mode");of=H("react.offscreen");pf=H("react.legacy_hidden")}var Cf="function"===typeof Symbol&&Symbol.iterator,Fd,Gd=!1,Ad,Kh=function(a){return"undefined"!==
typeof MSApp&&MSApp.execUnsafeLocalFunction?function(b,c,d,e){MSApp.execUnsafeLocalFunction(function(){return a(b,c,d,e)})}:a}(function(a,b){if("http://www.w3.org/2000/svg"!==a.namespaceURI||"innerHTML"in a)a.innerHTML=b;else{Ad=Ad||document.createElement("div");Ad.innerHTML="<svg>"+b.valueOf().toString()+"</svg>";for(b=Ad.firstChild;a.firstChild;)a.removeChild(a.firstChild);for(;b.firstChild;)a.appendChild(b.firstChild)}}),qc=function(a,b){if(b){var c=a.firstChild;if(c&&c===a.lastChild&&3===c.nodeType){c.nodeValue=
b;return}}a.textContent=b},Nb={animationIterationCount:!0,borderImageOutset:!0,borderImageSlice:!0,borderImageWidth:!0,boxFlex:!0,boxFlexGroup:!0,boxOrdinalGroup:!0,columnCount:!0,columns:!0,flex:!0,flexGrow:!0,flexPositive:!0,flexShrink:!0,flexNegative:!0,flexOrder:!0,gridArea:!0,gridRow:!0,gridRowEnd:!0,gridRowSpan:!0,gridRowStart:!0,gridColumn:!0,gridColumnEnd:!0,gridColumnSpan:!0,gridColumnStart:!0,fontWeight:!0,lineClamp:!0,lineHeight:!0,opacity:!0,order:!0,orphans:!0,tabSize:!0,widows:!0,zIndex:!0,
zoom:!0,fillOpacity:!0,floodOpacity:!0,stopOpacity:!0,strokeDasharray:!0,strokeDashoffset:!0,strokeMiterlimit:!0,strokeOpacity:!0,strokeWidth:!0},ak=["Webkit","ms","Moz","O"];Object.keys(Nb).forEach(function(a){ak.forEach(function(b){b=b+a.charAt(0).toUpperCase()+a.substring(1);Nb[b]=Nb[a]})});var ri=B({menuitem:!0},{area:!0,base:!0,br:!0,col:!0,embed:!0,hr:!0,img:!0,input:!0,keygen:!0,link:!0,meta:!0,param:!0,source:!0,track:!0,wbr:!0}),Vd=null,jb=null,kb=null,le=function(a,b){return a(b)},eg=function(a,
b,c,d,e){return a(b,c,d,e)},Xd=function(){},Rf=le,Xa=!1,Yd=!1,pe=!1;if(oa)try{var xc={};Object.defineProperty(xc,"passive",{get:function(){pe=!0}});window.addEventListener("test",xc,xc);window.removeEventListener("test",xc,xc)}catch(a){pe=!1}var ui=function(a,b,c,d,e,f,g,h,k){var l=Array.prototype.slice.call(arguments,3);try{b.apply(c,l)}catch(Da){this.onError(Da)}},Qb=!1,Ic=null,Jc=!1,Zd=null,vi={onError:function(a){Qb=!0;Ic=a}},ca=ha.__SECRET_INTERNALS_DO_NOT_USE_OR_YOU_WILL_BE_FIRED.Scheduler,
bk=ca.unstable_cancelCallback,Bd=ca.unstable_now,Zf=ca.unstable_scheduleCallback,ck=ca.unstable_shouldYield,hi=ca.unstable_requestPaint,ae=ca.unstable_runWithPriority,dk=ca.unstable_getCurrentPriorityLevel,ek=ca.unstable_ImmediatePriority,ii=ca.unstable_UserBlockingPriority,$f=ca.unstable_NormalPriority,fk=ca.unstable_LowPriority,gk=ca.unstable_IdlePriority,ce=!1,ia=[],ya=null,za=null,Aa=null,Rb=new Map,Sb=new Map,Vb=[],fg="mousedown mouseup touchcancel touchend touchstart auxclick dblclick pointercancel pointerdown pointerup dragend dragstart drop compositionend compositionstart keydown keypress keyup input textInput copy cut paste click change contextmenu reset submit".split(" "),
lb={animationend:Lc("Animation","AnimationEnd"),animationiteration:Lc("Animation","AnimationIteration"),animationstart:Lc("Animation","AnimationStart"),transitionend:Lc("Transition","TransitionEnd")},de={},bg={};oa&&(bg=document.createElement("div").style,"AnimationEvent"in window||(delete lb.animationend.animation,delete lb.animationiteration.animation,delete lb.animationstart.animation),"TransitionEvent"in window||delete lb.transitionend.transition);var Gg=Mc("animationend"),Hg=Mc("animationiteration"),
Ig=Mc("animationstart"),Jg=Mc("transitionend"),cg=new Map,fe=new Map,hk=["abort","abort",Gg,"animationEnd",Hg,"animationIteration",Ig,"animationStart","canplay","canPlay","canplaythrough","canPlayThrough","durationchange","durationChange","emptied","emptied","encrypted","encrypted","ended","ended","error","error","gotpointercapture","gotPointerCapture","load","load","loadeddata","loadedData","loadedmetadata","loadedMetadata","loadstart","loadStart","lostpointercapture","lostPointerCapture","playing",
"playing","progress","progress","seeking","seeking","stalled","stalled","suspend","suspend","timeupdate","timeUpdate",Jg,"transitionEnd","waiting","waiting"];Bd();var w=8,Ba=Math.clz32?Math.clz32:Gi,Hi=Math.log,Ii=Math.LN2,Mi=ii,Li=ae,Pc=!0,Ca=null,he=null,Qc=null,Hb={eventPhase:0,bubbles:0,cancelable:0,timeStamp:function(a){return a.timeStamp||Date.now()},defaultPrevented:0,isTrusted:0},ke=V(Hb),yc=B({},Hb,{view:0,detail:0}),gj=V(yc),vf,wf,zc,Cd=B({},yc,{screenX:0,screenY:0,clientX:0,clientY:0,pageX:0,
pageY:0,ctrlKey:0,shiftKey:0,altKey:0,metaKey:0,getModifierState:ie,button:0,buttons:0,relatedTarget:function(a){return void 0===a.relatedTarget?a.fromElement===a.srcElement?a.toElement:a.fromElement:a.relatedTarget},movementX:function(a){if("movementX"in a)return a.movementX;a!==zc&&(zc&&"mousemove"===a.type?(vf=a.screenX-zc.screenX,wf=a.screenY-zc.screenY):wf=vf=0,zc=a);return vf},movementY:function(a){return"movementY"in a?a.movementY:wf}}),Fg=V(Cd),ik=B({},Cd,{dataTransfer:0}),cj=V(ik),jk=B({},
yc,{relatedTarget:0}),qe=V(jk),kk=B({},Hb,{animationName:0,elapsedTime:0,pseudoElement:0}),ej=V(kk),lk=B({},Hb,{clipboardData:function(a){return"clipboardData"in a?a.clipboardData:window.clipboardData}}),ij=V(lk),mk=B({},Hb,{data:0}),Ng=V(mk),lj=Ng,nk={Esc:"Escape",Spacebar:" ",Left:"ArrowLeft",Up:"ArrowUp",Right:"ArrowRight",Down:"ArrowDown",Del:"Delete",Win:"OS",Menu:"ContextMenu",Apps:"ContextMenu",Scroll:"ScrollLock",MozPrintableKey:"Unidentified"},ok={8:"Backspace",9:"Tab",12:"Clear",13:"Enter",
16:"Shift",17:"Control",18:"Alt",19:"Pause",20:"CapsLock",27:"Escape",32:" ",33:"PageUp",34:"PageDown",35:"End",36:"Home",37:"ArrowLeft",38:"ArrowUp",39:"ArrowRight",40:"ArrowDown",45:"Insert",46:"Delete",112:"F1",113:"F2",114:"F3",115:"F4",116:"F5",117:"F6",118:"F7",119:"F8",120:"F9",121:"F10",122:"F11",123:"F12",144:"NumLock",145:"ScrollLock",224:"Meta"},Oi={Alt:"altKey",Control:"ctrlKey",Meta:"metaKey",Shift:"shiftKey"},pk=B({},yc,{key:function(a){if(a.key){var b=nk[a.key]||a.key;if("Unidentified"!==
b)return b}return"keypress"===a.type?(a=Rc(a),13===a?"Enter":String.fromCharCode(a)):"keydown"===a.type||"keyup"===a.type?ok[a.keyCode]||"Unidentified":""},code:0,location:0,ctrlKey:0,shiftKey:0,altKey:0,metaKey:0,repeat:0,locale:0,getModifierState:ie,charCode:function(a){return"keypress"===a.type?Rc(a):0},keyCode:function(a){return"keydown"===a.type||"keyup"===a.type?a.keyCode:0},which:function(a){return"keypress"===a.type?Rc(a):"keydown"===a.type||"keyup"===a.type?a.keyCode:0}}),bj=V(pk),qk=B({},
Cd,{pointerId:0,width:0,height:0,pressure:0,tangentialPressure:0,tiltX:0,tiltY:0,twist:0,pointerType:0,isPrimary:0}),Kg=V(qk),rk=B({},yc,{touches:0,targetTouches:0,changedTouches:0,altKey:0,metaKey:0,ctrlKey:0,shiftKey:0,getModifierState:ie}),dj=V(rk),sk=B({},Hb,{propertyName:0,elapsedTime:0,pseudoElement:0}),fj=V(sk),tk=B({},Cd,{deltaX:function(a){return"deltaX"in a?a.deltaX:"wheelDeltaX"in a?-a.wheelDeltaX:0},deltaY:function(a){return"deltaY"in a?a.deltaY:"wheelDeltaY"in a?-a.wheelDeltaY:"wheelDelta"in
a?-a.wheelDelta:0},deltaZ:0,deltaMode:0}),hj=V(tk),Pi=[9,13,27,32],je=oa&&"CompositionEvent"in window,Ac=null;oa&&"documentMode"in document&&(Ac=document.documentMode);var kj=oa&&"TextEvent"in window&&!Ac,ng=oa&&(!je||Ac&&8<Ac&&11>=Ac),mg=String.fromCharCode(32),lg=!1,ob=!1,Si={color:!0,date:!0,datetime:!0,"datetime-local":!0,email:!0,month:!0,number:!0,password:!0,range:!0,search:!0,tel:!0,text:!0,time:!0,url:!0,week:!0},Xb=null,Yb=null,Mg=!1;oa&&(Mg=Ti("input")&&(!document.documentMode||9<document.documentMode));
var X="function"===typeof Object.is?Object.is:$i,aj=Object.prototype.hasOwnProperty,jj=oa&&"documentMode"in document&&11>=document.documentMode,qb=null,oe=null,$b=null,ne=!1;ee("cancel cancel click click close close contextmenu contextMenu copy copy cut cut auxclick auxClick dblclick doubleClick dragend dragEnd dragstart dragStart drop drop focusin focus focusout blur input input invalid invalid keydown keyDown keypress keyPress keyup keyUp mousedown mouseDown mouseup mouseUp paste paste pause pause play play pointercancel pointerCancel pointerdown pointerDown pointerup pointerUp ratechange rateChange reset reset seeked seeked submit submit touchcancel touchCancel touchend touchEnd touchstart touchStart volumechange volumeChange".split(" "),
0);ee("drag drag dragenter dragEnter dragexit dragExit dragleave dragLeave dragover dragOver mousemove mouseMove mouseout mouseOut mouseover mouseOver pointermove pointerMove pointerout pointerOut pointerover pointerOver scroll scroll toggle toggle touchmove touchMove wheel wheel".split(" "),1);ee(hk,2);(function(a,b){for(var c=0;c<a.length;c++)fe.set(a[c],b)})("change selectionchange textInput compositionstart compositionend compositionupdate".split(" "),0);gb("onMouseEnter",["mouseout","mouseover"]);
gb("onMouseLeave",["mouseout","mouseover"]);gb("onPointerEnter",["pointerout","pointerover"]);gb("onPointerLeave",["pointerout","pointerover"]);Ta("onChange","change click focusin focusout input keydown keyup selectionchange".split(" "));Ta("onSelect","focusout contextmenu dragend focusin keydown keyup mousedown mouseup selectionchange".split(" "));Ta("onBeforeInput",["compositionend","keypress","textInput","paste"]);Ta("onCompositionEnd","compositionend focusout keydown keypress keyup mousedown".split(" "));
Ta("onCompositionStart","compositionstart focusout keydown keypress keyup mousedown".split(" "));Ta("onCompositionUpdate","compositionupdate focusout keydown keypress keyup mousedown".split(" "));var pc="abort canplay canplaythrough durationchange emptied encrypted ended error loadeddata loadedmetadata loadstart pause play playing progress ratechange seeked seeking stalled suspend timeupdate volumechange waiting".split(" "),Dg=new Set("cancel close invalid load scroll toggle".split(" ").concat(pc)),
Cg="_reactListening"+Math.random().toString(36).slice(2),kf=null,lf=null,Zh="function"===typeof setTimeout?setTimeout:void 0,Jj="function"===typeof clearTimeout?clearTimeout:void 0,xf=0,Dd=Math.random().toString(36).slice(2),Fa="__reactFiber$"+Dd,Wc="__reactProps$"+Dd,rb="__reactContainer$"+Dd,Qg="__reactEvents$"+Dd,ue=[],ub=-1,Ha={},D=Ga(Ha),J=Ga(!1),Ya=Ha,Ze=null,db=null,oj=ae,ve=Zf,we=bk,nj=dk,Yc=ek,Ug=ii,Vg=$f,Wg=fk,Xg=gk,gf={},Nj=ck,Rj=void 0!==hi?hi:function(){},pa=null,Zc=null,xe=!1,ji=Bd(),
P=1E4>ji?Bd:function(){return Bd()-ji},Fj=fb.ReactCurrentBatchConfig,bd=Ga(null),ad=null,xb=null,$c=null,Ka=!1,gh=(new ha.Component).refs,dd={isMounted:function(a){return(a=a._reactInternals)?Va(a)===a:!1},enqueueSetState:function(a,b,c){a=a._reactInternals;var d=W(),e=Oa(a),f=Ia(d,e);f.payload=b;void 0!==c&&null!==c&&(f.callback=c);Ja(a,f);Pa(a,e,d)},enqueueReplaceState:function(a,b,c){a=a._reactInternals;var d=W(),e=Oa(a),f=Ia(d,e);f.tag=1;f.payload=b;void 0!==c&&null!==c&&(f.callback=c);Ja(a,f);
Pa(a,e,d)},enqueueForceUpdate:function(a,b){a=a._reactInternals;var c=W(),d=Oa(a),e=Ia(c,d);e.tag=2;void 0!==b&&null!==b&&(e.callback=b);Ja(a,e);Pa(a,d,c)}},gd=Array.isArray,od=hh(!0),wh=hh(!1),fc={},ka=Ga(fc),hc=Ga(fc),gc=Ga(fc),E=Ga(0),ra=null,Na=null,la=!1,Bb=[],jc=fb.ReactCurrentDispatcher,aa=fb.ReactCurrentBatchConfig,ic=0,y=null,N=null,K=null,kd=!1,kc=!1,jd={readContext:Y,useCallback:T,useContext:T,useEffect:T,useImperativeHandle:T,useLayoutEffect:T,useMemo:T,useReducer:T,useRef:T,useState:T,
useDebugValue:T,useDeferredValue:T,useTransition:T,useMutableSource:T,useOpaqueIdentifier:T,unstable_isNewReconciler:!1},pj={readContext:Y,useCallback:function(a,b){ab().memoizedState=[a,void 0===b?null:b];return a},useContext:Y,useEffect:qh,useImperativeHandle:function(a,b,c){c=null!==c&&void 0!==c?c.concat([a]):null;return Me(4,2,sh.bind(null,b,a),c)},useLayoutEffect:function(a,b){return Me(4,2,a,b)},useMemo:function(a,b){var c=ab();b=void 0===b?null:b;a=a();c.memoizedState=[a,b];return a},useReducer:function(a,
b,c){var d=ab();b=void 0!==c?c(b):b;d.memoizedState=d.baseState=b;a=d.queue={pending:null,dispatch:null,lastRenderedReducer:a,lastRenderedState:b};a=a.dispatch=Le.bind(null,y,a);return[d.memoizedState,a]},useRef:ph,useState:nc,useDebugValue:Oe,useDeferredValue:function(a){var b=nc(a),c=b[0],d=b[1];qh(function(){var b=aa.transition;aa.transition=1;try{d(a)}finally{aa.transition=b}},[a]);return c},useTransition:function(){var a=nc(!1),b=a[0];a=sj.bind(null,a[1]);ph(a);return[a,b]},useMutableSource:function(a,
b,c){var d=ab();d.memoizedState={refs:{getSnapshot:b,setSnapshot:null},source:a,subscribe:c};return nh(d,a,b,c)},useOpaqueIdentifier:function(){if(la){var a=!1,b=mj(function(){a||(a=!0,c("r:"+(xf++).toString(36)));throw Error(m(355));}),c=nc(b)[1];0===(y.mode&2)&&(y.flags|=516,ld(5,function(){c("r:"+(xf++).toString(36))},void 0,null));return b}b="r:"+(xf++).toString(36);nc(b);return b},unstable_isNewReconciler:!1},qj={readContext:Y,useCallback:uh,useContext:Y,useEffect:nd,useImperativeHandle:th,useLayoutEffect:rh,
useMemo:vh,useReducer:lc,useRef:md,useState:function(a){return lc(ma)},useDebugValue:Oe,useDeferredValue:function(a){var b=lc(ma),c=b[0],d=b[1];nd(function(){var b=aa.transition;aa.transition=1;try{d(a)}finally{aa.transition=b}},[a]);return c},useTransition:function(){var a=lc(ma)[0];return[md().current,a]},useMutableSource:oh,useOpaqueIdentifier:function(){return lc(ma)[0]},unstable_isNewReconciler:!1},rj={readContext:Y,useCallback:uh,useContext:Y,useEffect:nd,useImperativeHandle:th,useLayoutEffect:rh,
useMemo:vh,useReducer:mc,useRef:md,useState:function(a){return mc(ma)},useDebugValue:Oe,useDeferredValue:function(a){var b=mc(ma),c=b[0],d=b[1];nd(function(){var b=aa.transition;aa.transition=1;try{d(a)}finally{aa.transition=b}},[a]);return c},useTransition:function(){var a=mc(ma)[0];return[md().current,a]},useMutableSource:oh,useOpaqueIdentifier:function(){return mc(ma)[0]},unstable_isNewReconciler:!1},tj=fb.ReactCurrentOwner,fa=!1,qd={dehydrated:null,retryLane:0};var wj=function(a,b,c,d){for(c=
b.child;null!==c;){if(5===c.tag||6===c.tag)a.appendChild(c.stateNode);else if(4!==c.tag&&null!==c.child){c.child.return=c;c=c.child;continue}if(c===b)break;for(;null===c.sibling;){if(null===c.return||c.return===b)return;c=c.return}c.sibling.return=c.return;c=c.sibling}};var Jh=function(a){};var vj=function(a,b,c,d,e){var f=a.memoizedProps;if(f!==d){a=b.stateNode;$a(ka.current);e=null;switch(c){case "input":f=Md(a,f);d=Md(a,d);e=[];break;case "option":f=Pd(a,f);d=Pd(a,d);e=[];break;case "select":f=
B({},f,{value:void 0});d=B({},d,{value:void 0});e=[];break;case "textarea":f=Qd(a,f);d=Qd(a,d);e=[];break;default:"function"!==typeof f.onClick&&"function"===typeof d.onClick&&(a.onclick=Vc)}Sd(c,d);var g;c=null;for(l in f)if(!d.hasOwnProperty(l)&&f.hasOwnProperty(l)&&null!=f[l])if("style"===l){var h=f[l];for(g in h)h.hasOwnProperty(g)&&(c||(c={}),c[g]="")}else"dangerouslySetInnerHTML"!==l&&"children"!==l&&"suppressContentEditableWarning"!==l&&"suppressHydrationWarning"!==l&&"autoFocus"!==l&&(Ib.hasOwnProperty(l)?
e||(e=[]):(e=e||[]).push(l,null));for(l in d){var k=d[l];h=null!=f?f[l]:void 0;if(d.hasOwnProperty(l)&&k!==h&&(null!=k||null!=h))if("style"===l)if(h){for(g in h)!h.hasOwnProperty(g)||k&&k.hasOwnProperty(g)||(c||(c={}),c[g]="");for(g in k)k.hasOwnProperty(g)&&h[g]!==k[g]&&(c||(c={}),c[g]=k[g])}else c||(e||(e=[]),e.push(l,c)),c=k;else"dangerouslySetInnerHTML"===l?(k=k?k.__html:void 0,h=h?h.__html:void 0,null!=k&&h!==k&&(e=e||[]).push(l,k)):"children"===l?"string"!==typeof k&&"number"!==typeof k||(e=
e||[]).push(l,""+k):"suppressContentEditableWarning"!==l&&"suppressHydrationWarning"!==l&&(Ib.hasOwnProperty(l)?(null!=k&&"onScroll"===l&&z("scroll",a),e||h===k||(e=[])):"object"===typeof k&&null!==k&&k.$$typeof===te?k.toString():(e=e||[]).push(l,k))}c&&(e=e||[]).push("style",c);var l=e;if(b.updateQueue=l)b.flags|=4}};var xj=function(a,b,c,d){c!==d&&(b.flags|=4)};var Kj="function"===typeof WeakMap?WeakMap:Map,Cj="function"===typeof WeakSet?WeakSet:Set,Hj=Math.ceil,vd=fb.ReactCurrentDispatcher,jf=
fb.ReactCurrentOwner,n=0,R=null,G=null,O=0,ta=0,cb=Ga(0),L=0,wd=null,Fb=0,La=0,Cb=0,hf=0,df=null,cf=0,Ve=Infinity,l=null,rd=!1,Ye=null,na=null,Sa=!1,tc=null,vc=90,mf=[],nf=[],va=null,rc=0,ef=null,sd=-1,ua=0,td=0,uc=null,xd=!1;var Oj=function(a,b,c){var d=b.lanes;if(null!==a)if(a.memoizedProps!==b.pendingProps||J.current)fa=!0;else if(0!==(c&d))fa=0!==(a.flags&16384)?!0:!1;else{fa=!1;switch(b.tag){case 3:Ch(b);He();break;case 5:ih(b);break;case 1:S(b.type)&&Xc(b);break;case 4:Ee(b,b.stateNode.containerInfo);
break;case 10:d=b.memoizedProps.value;var e=b.type._context;A(bd,e._currentValue);e._currentValue=d;break;case 13:if(null!==b.memoizedState){if(0!==(c&b.child.childLanes))return Dh(a,b,c);A(E,E.current&1);b=sa(a,b,c);return null!==b?b.sibling:null}A(E,E.current&1);break;case 19:d=0!==(c&b.childLanes);if(0!==(a.flags&64)){if(d)return Ih(a,b,c);b.flags|=64}e=b.memoizedState;null!==e&&(e.rendering=null,e.tail=null,e.lastEffect=null);A(E,E.current);if(d)break;else return null;case 23:case 24:return b.lanes=
0,Re(a,b,c)}return sa(a,b,c)}else fa=!1;b.lanes=0;switch(b.tag){case 2:d=b.type;null!==a&&(a.alternate=null,b.alternate=null,b.flags|=2);a=b.pendingProps;e=vb(b,D.current);yb(b,c);e=Ke(null,b,d,a,e,c);b.flags|=1;if("object"===typeof e&&null!==e&&"function"===typeof e.render&&void 0===e.$$typeof){b.tag=1;b.memoizedState=null;b.updateQueue=null;if(S(d)){var f=!0;Xc(b)}else f=!1;b.memoizedState=null!==e.state&&void 0!==e.state?e.state:null;Ae(b);var g=d.getDerivedStateFromProps;"function"===typeof g&&
cd(b,d,g,a);e.updater=dd;b.stateNode=e;e._reactInternals=b;Be(b,d,a,c);b=Se(null,b,d,!0,f,c)}else b.tag=0,U(null,b,e,c),b=b.child;return b;case 16:e=b.elementType;a:{null!==a&&(a.alternate=null,b.alternate=null,b.flags|=2);a=b.pendingProps;f=e._init;e=f(e._payload);b.type=e;f=b.tag=Uj(e);a=ea(e,a);switch(f){case 0:b=Qe(null,b,e,a,c);break a;case 1:b=Bh(null,b,e,a,c);break a;case 11:b=xh(null,b,e,a,c);break a;case 14:b=yh(null,b,e,ea(e.type,a),d,c);break a}throw Error(m(306,e,""));}return b;case 0:return d=
b.type,e=b.pendingProps,e=b.elementType===d?e:ea(d,e),Qe(a,b,d,e,c);case 1:return d=b.type,e=b.pendingProps,e=b.elementType===d?e:ea(d,e),Bh(a,b,d,e,c);case 3:Ch(b);d=b.updateQueue;if(null===a||null===d)throw Error(m(282));d=b.pendingProps;e=b.memoizedState;e=null!==e?e.element:null;ah(a,b);cc(b,d,null,c);d=b.memoizedState.element;if(d===e)He(),b=sa(a,b,c);else{e=b.stateNode;if(f=e.hydrate)Na=tb(b.stateNode.containerInfo.firstChild),ra=b,f=la=!0;if(f){a=e.mutableSourceEagerHydrationData;if(null!=
a)for(e=0;e<a.length;e+=2)f=a[e],f._workInProgressVersionPrimary=a[e+1],Bb.push(f);c=wh(b,null,d,c);for(b.child=c;c;)c.flags=c.flags&-3|1024,c=c.sibling}else U(a,b,d,c),He();b=b.child}return b;case 5:return ih(b),null===a&&Ge(b),d=b.type,e=b.pendingProps,f=null!==a?a.memoizedProps:null,g=e.children,re(d,e)?g=null:null!==f&&re(d,f)&&(b.flags|=16),Ah(a,b),U(a,b,g,c),b.child;case 6:return null===a&&Ge(b),null;case 13:return Dh(a,b,c);case 4:return Ee(b,b.stateNode.containerInfo),d=b.pendingProps,null===
a?b.child=od(b,null,d,c):U(a,b,d,c),b.child;case 11:return d=b.type,e=b.pendingProps,e=b.elementType===d?e:ea(d,e),xh(a,b,d,e,c);case 7:return U(a,b,b.pendingProps,c),b.child;case 8:return U(a,b,b.pendingProps.children,c),b.child;case 12:return U(a,b,b.pendingProps.children,c),b.child;case 10:a:{d=b.type._context;e=b.pendingProps;g=b.memoizedProps;f=e.value;var h=b.type._context;A(bd,h._currentValue);h._currentValue=f;if(null!==g)if(h=g.value,f=X(h,f)?0:("function"===typeof d._calculateChangedBits?
d._calculateChangedBits(h,f):1073741823)|0,0===f){if(g.children===e.children&&!J.current){b=sa(a,b,c);break a}}else for(h=b.child,null!==h&&(h.return=b);null!==h;){var k=h.dependencies;if(null!==k){g=h.child;for(var l=k.firstContext;null!==l;){if(l.context===d&&0!==(l.observedBits&f)){1===h.tag&&(l=Ia(-1,c&-c),l.tag=2,Ja(h,l));h.lanes|=c;l=h.alternate;null!==l&&(l.lanes|=c);$g(h.return,c);k.lanes|=c;break}l=l.next}}else g=10===h.tag?h.type===b.type?null:h.child:h.child;if(null!==g)g.return=h;else for(g=
h;null!==g;){if(g===b){g=null;break}h=g.sibling;if(null!==h){h.return=g.return;g=h;break}g=g.return}h=g}U(a,b,e.children,c);b=b.child}return b;case 9:return e=b.type,f=b.pendingProps,d=f.children,yb(b,c),e=Y(e,f.unstable_observedBits),d=d(e),b.flags|=1,U(a,b,d,c),b.child;case 14:return e=b.type,f=ea(e,b.pendingProps),f=ea(e.type,f),yh(a,b,e,f,d,c);case 15:return zh(a,b,b.type,b.pendingProps,d,c);case 17:return d=b.type,e=b.pendingProps,e=b.elementType===d?e:ea(d,e),null!==a&&(a.alternate=null,b.alternate=
null,b.flags|=2),b.tag=1,S(d)?(a=!0,Xc(b)):a=!1,yb(b,c),eh(b,d,e),Be(b,d,e,c),Se(null,b,d,!0,a,c);case 19:return Ih(a,b,c);case 23:return Re(a,b,c);case 24:return Re(a,b,c)}throw Error(m(156,b.tag));};var Z=function(a,b,c,d){return new Tj(a,b,c,d)};sf.prototype.render=function(a){yd(a,this._internalRoot,null,null)};sf.prototype.unmount=function(){var a=this._internalRoot,b=a.containerInfo;yd(null,a,null,function(){b[rb]=null})};var Di=function(a){if(13===a.tag){var b=W();Pa(a,4,b);rf(a,4)}};var Xf=
function(a){if(13===a.tag){var b=W();Pa(a,67108864,b);rf(a,67108864)}};var Bi=function(a){if(13===a.tag){var b=W(),c=Oa(a);Pa(a,c,b);rf(a,c)}};var Ai=function(a,b){return b()};Vd=function(a,b,c){switch(b){case "input":Nd(a,c);b=c.name;if("radio"===c.type&&null!=b){for(c=a;c.parentNode;)c=c.parentNode;c=c.querySelectorAll("input[name="+JSON.stringify(""+b)+'][type="radio"]');for(b=0;b<c.length;b++){var d=c[b];if(d!==a&&d.form===a.form){var e=Hc(d);if(!e)throw Error(m(90));Ef(d);Nd(d,e)}}}break;case "textarea":Jf(a,
c);break;case "select":b=c.value,null!=b&&ib(a,!!c.multiple,b,!1)}};(function(a,b,c,d){le=a;eg=b;Xd=c;Rf=d})($h,function(a,b,c,d,e){var f=n;n|=4;try{return Za(98,a.bind(null,b,c,d,e))}finally{n=f,0===n&&(Eb(),ja())}},function(){0===(n&49)&&(Ij(),Ra())},function(a,b){var c=n;n|=2;try{return a(b)}finally{n=c,0===n&&(Eb(),ja())}});var uk={Events:[Ob,pb,Hc,Pf,Qf,Ra,{current:!1}]};(function(a){a={bundleType:a.bundleType,version:a.version,rendererPackageName:a.rendererPackageName,rendererConfig:a.rendererConfig,
overrideHookState:null,overrideHookStateDeletePath:null,overrideHookStateRenamePath:null,overrideProps:null,overridePropsDeletePath:null,overridePropsRenamePath:null,setSuspenseHandler:null,scheduleUpdate:null,currentDispatcherRef:fb.ReactCurrentDispatcher,findHostInstanceByFiber:Xj,findFiberByHostInstance:a.findFiberByHostInstance||Yj,findHostInstancesForRefresh:null,scheduleRefresh:null,scheduleRoot:null,setRefreshHandler:null,getCurrentFiber:null};if("undefined"===typeof __REACT_DEVTOOLS_GLOBAL_HOOK__)a=
!1;else{var b=__REACT_DEVTOOLS_GLOBAL_HOOK__;if(!b.isDisabled&&b.supportsFiber)try{Ze=b.inject(a),db=b}catch(c){}a=!0}return a})({findFiberByHostInstance:Wa,bundleType:0,version:"17.0.0",rendererPackageName:"react-dom"});M.__SECRET_INTERNALS_DO_NOT_USE_OR_YOU_WILL_BE_FIRED=uk;M.createPortal=gi;M.findDOMNode=function(a){if(null==a)return null;if(1===a.nodeType)return a;var b=a._reactInternals;if(void 0===b){if("function"===typeof a.render)throw Error(m(188));throw Error(m(268,Object.keys(a)));
}a=Uf(b);a=null===a?null:a.stateNode;return a};M.flushSync=function(a,b){var c=n;if(0!==(c&48))return a(b);n|=1;try{if(a)return Za(99,a.bind(null,b))}finally{n=c,ja()}};M.hydrate=function(a,b,c){if(!wc(b))throw Error(m(200));return zd(null,a,b,!0,c)};M.render=function(a,b,c){if(!wc(b))throw Error(m(200));return zd(null,a,b,!1,c)};M.unmountComponentAtNode=function(a){if(!wc(a))throw Error(m(40));return a._reactRootContainer?(ai(function(){zd(null,null,a,!1,function(){a._reactRootContainer=null;a[rb]=
null})}),!0):!1};M.unstable_batchedUpdates=$h;M.unstable_createPortal=function(a,b){return gi(a,b,2<arguments.length&&void 0!==arguments[2]?arguments[2]:null)};M.unstable_renderSubtreeIntoContainer=function(a,b,c,d){if(!wc(c))throw Error(m(200));if(null==a||void 0===a._reactInternals)throw Error(m(38));return zd(a,b,c,!1,d)};M.version="17.0.0"});
})();
</script>
<script>/******/ (function(modules) { // webpackBootstrap
/******/ 	// The module cache
/******/ 	var installedModules = {};
/******/
/******/ 	// The require function
/******/ 	function __webpack_require__(moduleId) {
/******/
/******/ 		// Check if module is in cache
/******/ 		if(installedModules[moduleId]) {
/******/ 			return installedModules[moduleId].exports;
/******/ 		}
/******/ 		// Create a new module (and put it into the cache)
/******/ 		var module = installedModules[moduleId] = {
/******/ 			i: moduleId,
/******/ 			l: false,
/******/ 			exports: {}
/******/ 		};
/******/
/******/ 		// Execute the module function
/******/ 		modules[moduleId].call(module.exports, module, module.exports, __webpack_require__);
/******/
/******/ 		// Flag the module as loaded
/******/ 		module.l = true;
/******/
/******/ 		// Return the exports of the module
/******/ 		return module.exports;
/******/ 	}
/******/
/******/
/******/ 	// expose the modules object (__webpack_modules__)
/******/ 	__webpack_require__.m = modules;
/******/
/******/ 	// expose the module cache
/******/ 	__webpack_require__.c = installedModules;
/******/
/******/ 	// define getter function for harmony exports
/******/ 	__webpack_require__.d = function(exports, name, getter) {
/******/ 		if(!__webpack_require__.o(exports, name)) {
/******/ 			Object.defineProperty(exports, name, { enumerable: true, get: getter });
/******/ 		}
/******/ 	};
/******/
/******/ 	// define __esModule on exports
/******/ 	__webpack_require__.r = function(exports) {
/******/ 		if(typeof Symbol !== 'undefined' && Symbol.toStringTag) {
/******/ 			Object.defineProperty(exports, Symbol.toStringTag, { value: 'Module' });
/******/ 		}
/******/ 		Object.defineProperty(exports, '__esModule', { value: true });
/******/ 	};
/******/
/******/ 	// create a fake namespace object
/******/ 	// mode & 1: value is a module id, require it
/******/ 	// mode & 2: merge all properties of value into the ns
/******/ 	// mode & 4: return value when already ns object
/******/ 	// mode & 8|1: behave like require
/******/ 	__webpack_require__.t = function(value, mode) {
/******/ 		if(mode & 1) value = __webpack_require__(value);
/******/ 		if(mode & 8) return value;
/******/ 		if((mode & 4) && typeof value === 'object' && value && value.__esModule) return value;
/******/ 		var ns = Object.create(null);
/******/ 		__webpack_require__.r(ns);
/******/ 		Object.defineProperty(ns, 'default', { enumerable: true, value: value });
/******/ 		if(mode & 2 && typeof value != 'string') for(var key in value) __webpack_require__.d(ns, key, function(key) { return value[key]; }.bind(null, key));
/******/ 		return ns;
/******/ 	};
/******/
/******/ 	// getDefaultExport function for compatibility with non-harmony modules
/******/ 	__webpack_require__.n = function(module) {
/******/ 		var getter = module && module.__esModule ?
/******/ 			function getDefault() { return module['default']; } :
/******/ 			function getModuleExports() { return module; };
/******/ 		__webpack_require__.d(getter, 'a', getter);
/******/ 		return getter;
/******/ 	};
/******/
/******/ 	// Object.prototype.hasOwnProperty.call
/******/ 	__webpack_require__.o = function(object, property) { return Object.prototype.hasOwnProperty.call(object, property); };
/******/
/******/ 	// __webpack_public_path__
/******/ 	__webpack_require__.p = "";
/******/
/******/
/******/ 	// Load entry module and return exports
/******/ 	return __webpack_require__(__webpack_require__.s = "./srcjs/react-tools.js");
/******/ })
/************************************************************************/
/******/ ({

/***/ "./srcjs/input.js":
/*!************************!*\
  !*** ./srcjs/input.js ***!
  \************************/
/*! exports provided: reactShinyInput */
/***/ (function(module, __webpack_exports__, __webpack_require__) {

"use strict";
__webpack_require__.r(__webpack_exports__);
/* harmony export (binding) */ __webpack_require__.d(__webpack_exports__, "reactShinyInput", function() { return reactShinyInput; });
/* harmony import */ var react__WEBPACK_IMPORTED_MODULE_0__ = __webpack_require__(/*! react */ "react");
/* harmony import */ var react__WEBPACK_IMPORTED_MODULE_0___default = /*#__PURE__*/__webpack_require__.n(react__WEBPACK_IMPORTED_MODULE_0__);
/* harmony import */ var react_dom__WEBPACK_IMPORTED_MODULE_1__ = __webpack_require__(/*! react-dom */ "react-dom");
/* harmony import */ var react_dom__WEBPACK_IMPORTED_MODULE_1___default = /*#__PURE__*/__webpack_require__.n(react_dom__WEBPACK_IMPORTED_MODULE_1__);
/* harmony import */ var shiny__WEBPACK_IMPORTED_MODULE_2__ = __webpack_require__(/*! shiny */ "shiny");
/* harmony import */ var shiny__WEBPACK_IMPORTED_MODULE_2___default = /*#__PURE__*/__webpack_require__.n(shiny__WEBPACK_IMPORTED_MODULE_2__);
/* harmony import */ var jquery__WEBPACK_IMPORTED_MODULE_3__ = __webpack_require__(/*! jquery */ "jquery");
/* harmony import */ var jquery__WEBPACK_IMPORTED_MODULE_3___default = /*#__PURE__*/__webpack_require__.n(jquery__WEBPACK_IMPORTED_MODULE_3__);
function _typeof(obj) { "@babel/helpers - typeof"; if (typeof Symbol === "function" && typeof Symbol.iterator === "symbol") { _typeof = function _typeof(obj) { return typeof obj; }; } else { _typeof = function _typeof(obj) { return obj && typeof Symbol === "function" && obj.constructor === Symbol && obj !== Symbol.prototype ? "symbol" : typeof obj; }; } return _typeof(obj); }

function _classCallCheck(instance, Constructor) { if (!(instance instanceof Constructor)) { throw new TypeError("Cannot call a class as a function"); } }

function _defineProperties(target, props) { for (var i = 0; i < props.length; i++) { var descriptor = props[i]; descriptor.enumerable = descriptor.enumerable || false; descriptor.configurable = true; if ("value" in descriptor) descriptor.writable = true; Object.defineProperty(target, descriptor.key, descriptor); } }

function _createClass(Constructor, protoProps, staticProps) { if (protoProps) _defineProperties(Constructor.prototype, protoProps); if (staticProps) _defineProperties(Constructor, staticProps); return Constructor; }

function _inherits(subClass, superClass) { if (typeof superClass !== "function" && superClass !== null) { throw new TypeError("Super expression must either be null or a function"); } subClass.prototype = Object.create(superClass && superClass.prototype, { constructor: { value: subClass, writable: true, configurable: true } }); if (superClass) _setPrototypeOf(subClass, superClass); }

function _setPrototypeOf(o, p) { _setPrototypeOf = Object.setPrototypeOf || function _setPrototypeOf(o, p) { o.__proto__ = p; return o; }; return _setPrototypeOf(o, p); }

function _createSuper(Derived) { var hasNativeReflectConstruct = _isNativeReflectConstruct(); return function _createSuperInternal() { var Super = _getPrototypeOf(Derived), result; if (hasNativeReflectConstruct) { var NewTarget = _getPrototypeOf(this).constructor; result = Reflect.construct(Super, arguments, NewTarget); } else { result = Super.apply(this, arguments); } return _possibleConstructorReturn(this, result); }; }

function _possibleConstructorReturn(self, call) { if (call && (_typeof(call) === "object" || typeof call === "function")) { return call; } return _assertThisInitialized(self); }

function _assertThisInitialized(self) { if (self === void 0) { throw new ReferenceError("this hasn't been initialised - super() hasn't been called"); } return self; }

function _isNativeReflectConstruct() { if (typeof Reflect === "undefined" || !Reflect.construct) return false; if (Reflect.construct.sham) return false; if (typeof Proxy === "function") return true; try { Date.prototype.toString.call(Reflect.construct(Date, [], function () {})); return true; } catch (e) { return false; } }

function _getPrototypeOf(o) { _getPrototypeOf = Object.setPrototypeOf ? Object.getPrototypeOf : function _getPrototypeOf(o) { return o.__proto__ || Object.getPrototypeOf(o); }; return _getPrototypeOf(o); }





/*
 * This default receiveMessage implementation expects data to contain whole
 * configuration and value properties. If either is present, it will be set and
 * the component will be re-rendered. Because receiveMessage is typically used
 * by input authors to perform incremental updates, this default implementation
 * can be overriden by the user with the receiveMessage arguments to
 * reactShinyInput.
 */

function defaultReceiveMessage(el, _ref) {
  var configuration = _ref.configuration,
      value = _ref.value;
  var dirty = false;

  if (configuration !== undefined) {
    this.setInputConfiguration(el, configuration);
    dirty = true;
  }

  if (value !== undefined) {
    this.setInputValue(el, value);
    dirty = true;
  }

  if (dirty) {
    this.getCallback(el)();
    this.render(el);
  }
}

var defaultOptions = {
  receiveMessage: defaultReceiveMessage,
  type: false,
  ratePolicy: null
};
/**
 * Installs a new Shiny input binding based on a React component.
 *
 * @param {string} selector - jQuery selector that should identify the set of
 * container elements within the scope argument of Shiny.InputBinding.find.
 * @param {string} name - A name such as 'acme.FooInput' that should uniquely
 * identify the component.
 * @param {Object} component - React Component, either class or function.
 * @param {Object} options - Additional configuration options. Supported
 * options are:
 * - receiveMessage: Implementation of Shiny.InputBinding to use in place of
 *   the default. Typically overridden as an optimization to perform
 *   incremental value updates.
 * - type: `false`, a string, or a function.
 *     - `false` (the default): denotes that the value produced by this input
 *       should not be intercepted by any handlers registered in R on the
 *       server using shiny::registerInputHandler().
 *     - string: denotes the input's *type* and should correspond to the
 *       type parameter of shiny::registerInputHandler().
 *     - function: A function called with `this` bound to the InputBinding
 *       instance and passed a single argument, the input's containing DOM
 *       element. The function should return either `false` or a string
 *       corresponding to the type parameter of shiny::registerInputHandler().
 * - ratePolicy: A rate policy object as defined in the documentation for
 *     getRatePolicy(): https://shiny.rstudio.com/articles/building-inputs.html
 *     A rate policy object has two members:
 *     - `policy`: Valid values are the strings "direct", "debounce", and
 *       "throttle". "direct" means that all events are sent immediately.
 *     - `delay`: Number indicating the number of milliseconds that should be
 *       used when debouncing or throttling. Has no effect if the policy is
 *       direct.
 *     The specified rate policy is only applied when `true` is passed as the
 *     second argument to the `setValue` function passed as a prop to the
 *     input component.
 *
 */

function reactShinyInput(selector, name, component, options) {
  options = Object.assign({}, defaultOptions, options);
  shiny__WEBPACK_IMPORTED_MODULE_2___default.a.inputBindings.register(new ( /*#__PURE__*/function (_Shiny$InputBinding) {
    _inherits(_class, _Shiny$InputBinding);

    var _super = _createSuper(_class);

    function _class() {
      _classCallCheck(this, _class);

      return _super.apply(this, arguments);
    }

    _createClass(_class, [{
      key: "find",

      /*
       * Methods override those in Shiny.InputBinding
       */
      value: function find(scope) {
        return jquery__WEBPACK_IMPORTED_MODULE_3___default()(scope).find(selector);
      }
    }, {
      key: "getValue",
      value: function getValue(el) {
        return this.getInputValue(el);
      }
    }, {
      key: "setValue",
      value: function setValue(el, value) {
        var rateLimited = arguments.length > 2 && arguments[2] !== undefined ? arguments[2] : false;

        /*
         * We have to check whether $(el).data('callback') is undefined here
         * in case shiny::renderUI() is involved. If an input is contained in a
         * shiny::uiOutput(), the following strange thing happens occasionally:
         *
         *   1. setValue() is bound to an el in this.render(), below
         *   2. An event that will call setValue() is enqueued
         *   3. While the event is still enqueued, el is unbound and removed
         *      from the DOM by the JS code associated with shiny::uiOutput()
         *      - That code uses jQuery .html() in output_binding_html.js
         *      - .html() removes el from the DOM and clears ist data and events
         *   4. By the time the setValue() bound to the original el is invoked,
         *      el has been unbound and its data cleared.
         *
         *  Since the original input is gone along with its callback, it
         *  seems to make the most sense to do nothing.
         */
        if (jquery__WEBPACK_IMPORTED_MODULE_3___default()(el).data('callback') !== undefined) {
          this.setInputValue(el, value);
          this.getCallback(el)(rateLimited);
          this.render(el);
        }
      }
    }, {
      key: "initialize",
      value: function initialize(el) {
        jquery__WEBPACK_IMPORTED_MODULE_3___default()(el).data('value', JSON.parse(jquery__WEBPACK_IMPORTED_MODULE_3___default()(el).next().text()));
        jquery__WEBPACK_IMPORTED_MODULE_3___default()(el).data('configuration', JSON.parse(jquery__WEBPACK_IMPORTED_MODULE_3___default()(el).next().next().text()));
      }
    }, {
      key: "subscribe",
      value: function subscribe(el, callback) {
        jquery__WEBPACK_IMPORTED_MODULE_3___default()(el).data('callback', callback);
        this.render(el);
      }
    }, {
      key: "unsubscribe",
      value: function unsubscribe(el) {
        react_dom__WEBPACK_IMPORTED_MODULE_1___default.a.render(null, el);
      }
    }, {
      key: "receiveMessage",
      value: function receiveMessage(el, data) {
        options.receiveMessage.call(this, el, data);
      }
    }, {
      key: "getType",
      value: function getType(el) {
        if (typeof options.type === 'function') {
          return options.type.call(this, el);
        } else if (options.type === false || typeof options.type === 'string') {
          return options.type;
        } else {
          throw new Error('options.type must be false, a string, or a function');
        }
      }
    }, {
      key: "getRatePolicy",
      value: function getRatePolicy() {
        return options.ratePolicy;
      }
      /*
       * Methods not present in Shiny.InputBinding but accessible to users
       * through `this` in receiveMessage
       */

    }, {
      key: "getInputValue",
      value: function getInputValue(el) {
        return jquery__WEBPACK_IMPORTED_MODULE_3___default()(el).data('value');
      }
    }, {
      key: "setInputValue",
      value: function setInputValue(el, value) {
        jquery__WEBPACK_IMPORTED_MODULE_3___default()(el).data('value', value);
      }
    }, {
      key: "getInputConfiguration",
      value: function getInputConfiguration(el) {
        return jquery__WEBPACK_IMPORTED_MODULE_3___default()(el).data('configuration');
      }
    }, {
      key: "setInputConfiguration",
      value: function setInputConfiguration(el, configuration) {
        jquery__WEBPACK_IMPORTED_MODULE_3___default()(el).data('configuration', configuration);
      }
    }, {
      key: "getCallback",
      value: function getCallback(el) {
        return jquery__WEBPACK_IMPORTED_MODULE_3___default()(el).data('callback');
      }
    }, {
      key: "render",
      value: function render(el) {
        var element = /*#__PURE__*/react__WEBPACK_IMPORTED_MODULE_0___default.a.createElement(component, {
          configuration: this.getInputConfiguration(el),
          value: this.getValue(el),
          setValue: this.setValue.bind(this, el),
          el: el
        });
        react_dom__WEBPACK_IMPORTED_MODULE_1___default.a.render(element, el);
      }
    }]);

    return _class;
  }(shiny__WEBPACK_IMPORTED_MODULE_2___default.a.InputBinding))(), name);
}

/***/ }),

/***/ "./srcjs/react-tools.js":
/*!******************************!*\
  !*** ./srcjs/react-tools.js ***!
  \******************************/
/*! no exports provided */
/***/ (function(module, __webpack_exports__, __webpack_require__) {

"use strict";
__webpack_require__.r(__webpack_exports__);
/* harmony import */ var _widget__WEBPACK_IMPORTED_MODULE_0__ = __webpack_require__(/*! ./widget */ "./srcjs/widget.js");
/* harmony import */ var _input__WEBPACK_IMPORTED_MODULE_1__ = __webpack_require__(/*! ./input */ "./srcjs/input.js");


window.reactR = {
  reactShinyInput: _input__WEBPACK_IMPORTED_MODULE_1__["reactShinyInput"],
  reactWidget: _widget__WEBPACK_IMPORTED_MODULE_0__["reactWidget"],
  hydrate: _widget__WEBPACK_IMPORTED_MODULE_0__["hydrate"]
};

/***/ }),

/***/ "./srcjs/widget.js":
/*!*************************!*\
  !*** ./srcjs/widget.js ***!
  \*************************/
/*! exports provided: hydrate, defaultOptions, mergeOptions, formatDimension, isTag, reactWidget */
/***/ (function(module, __webpack_exports__, __webpack_require__) {

"use strict";
__webpack_require__.r(__webpack_exports__);
/* harmony export (binding) */ __webpack_require__.d(__webpack_exports__, "hydrate", function() { return hydrate; });
/* harmony export (binding) */ __webpack_require__.d(__webpack_exports__, "defaultOptions", function() { return defaultOptions; });
/* harmony export (binding) */ __webpack_require__.d(__webpack_exports__, "mergeOptions", function() { return mergeOptions; });
/* harmony export (binding) */ __webpack_require__.d(__webpack_exports__, "formatDimension", function() { return formatDimension; });
/* harmony export (binding) */ __webpack_require__.d(__webpack_exports__, "isTag", function() { return isTag; });
/* harmony export (binding) */ __webpack_require__.d(__webpack_exports__, "reactWidget", function() { return reactWidget; });
function _typeof(obj) { "@babel/helpers - typeof"; if (typeof Symbol === "function" && typeof Symbol.iterator === "symbol") { _typeof = function _typeof(obj) { return typeof obj; }; } else { _typeof = function _typeof(obj) { return obj && typeof Symbol === "function" && obj.constructor === Symbol && obj !== Symbol.prototype ? "symbol" : typeof obj; }; } return _typeof(obj); }

/**
 * Recursively transforms tag, a JSON representation of an instance of a
 * React component and its children, into a React element suitable for
 * passing to ReactDOM.render.
 * @param {Object} components
 * @param {Object} tag
 */
function hydrate(components, tag) {
  if (typeof tag === 'string') return tag;

  if (tag.name[0] === tag.name[0].toUpperCase() && !components.hasOwnProperty(tag.name)) {
    throw new Error("Unknown component: " + tag.name);
  }

  var elem = components.hasOwnProperty(tag.name) ? components[tag.name] : tag.name,
      args = [elem, tag.attribs];

  for (var i = 0; i < tag.children.length; i++) {
    args.push(hydrate(components, tag.children[i]));
  }

  return React.createElement.apply(React, args);
}
var defaultOptions = {
  // The name of the property on the root tag to use for the width, if
  // it's updated.
  widthProperty: "width",
  // The name of the property on the root tag to use for the height, if
  // it's updated.
  heightProperty: "height",
  // Whether or not to append the string 'px' to the width and height
  // properties when they change.
  appendPx: false,
  // Whether or not to dynamically update the width and height properties
  // of the last known tag when the computed width and height change in
  // the browser.
  renderOnResize: false
};
function mergeOptions(options) {
  var merged = {};

  for (var k in defaultOptions) {
    merged[k] = defaultOptions[k];
  }

  for (var k in options) {
    if (!defaultOptions.hasOwnProperty(k)) {
      throw new Error("Unrecognized option: " + k);
    }

    merged[k] = options[k];
  }

  return merged;
}
function formatDimension(dim, options) {
  if (options.appendPx) {
    return dim + 'px';
  } else {
    return dim;
  }
}
function isTag(value) {
  return _typeof(value) === 'object' && value.hasOwnProperty('name') && value.hasOwnProperty('attribs') && value.hasOwnProperty('children');
}
/**
 * Creates an HTMLWidget that is updated by rendering a React component.
 * React component constructors are made available by specifying them by
 * name in the components object.
 * @param {string} name
 * @param {string} type
 * @param {Object} components
 * @param {Object} options
 */

function reactWidget(name, type, components, options) {
  var actualOptions = mergeOptions(options);
  window.HTMLWidgets.widget({
    name: name,
    type: type,
    factory: function factory(el, width, height) {
      var lastValue,
          instance = {},
          renderValue = function renderValue(value) {
        if (actualOptions.renderOnResize) {
          // value.tag might be a primitive string, in which
          // case there is no attribs property.
          if (_typeof(value.tag) === 'object') {
            value.tag.attribs[actualOptions["widthProperty"]] = formatDimension(width);
            value.tag.attribs[actualOptions["heightProperty"]] = formatDimension(height);
          }

          lastValue = value;
        } // with functional stateless components this will be null
        // see https://reactjs.org/docs/react-dom.html#render for more details


        this.instance.component = ReactDOM.render(hydrate(components, value.tag), el);
      };

      return {
        instance: instance,
        renderValue: renderValue,
        resize: function resize(newWidth, newHeight) {
          if (actualOptions.renderOnResize) {
            width = newWidth;
            height = newHeight;
            renderValue(lastValue);
          }
        }
      };
    }
  });
}

/***/ }),

/***/ "jquery":
/*!********************************!*\
  !*** external "window.jQuery" ***!
  \********************************/
/*! no static exports found */
/***/ (function(module, exports) {

module.exports = window.jQuery;

/***/ }),

/***/ "react":
/*!*******************************!*\
  !*** external "window.React" ***!
  \*******************************/
/*! no static exports found */
/***/ (function(module, exports) {

module.exports = window.React;

/***/ }),

/***/ "react-dom":
/*!**********************************!*\
  !*** external "window.ReactDOM" ***!
  \**********************************/
/*! no static exports found */
/***/ (function(module, exports) {

module.exports = window.ReactDOM;

/***/ }),

/***/ "shiny":
/*!*******************************!*\
  !*** external "window.Shiny" ***!
  \*******************************/
/*! no static exports found */
/***/ (function(module, exports) {

module.exports = window.Shiny;

/***/ })

/******/ });
//# sourceMappingURL=react-tools.js.map</script>
<script>(function() {
  // If window.HTMLWidgets is already defined, then use it; otherwise create a
  // new object. This allows preceding code to set options that affect the
  // initialization process (though none currently exist).
  window.HTMLWidgets = window.HTMLWidgets || {};

  // See if we're running in a viewer pane. If not, we're in a web browser.
  var viewerMode = window.HTMLWidgets.viewerMode =
      /\bviewer_pane=1\b/.test(window.location);

  // See if we're running in Shiny mode. If not, it's a static document.
  // Note that static widgets can appear in both Shiny and static modes, but
  // obviously, Shiny widgets can only appear in Shiny apps/documents.
  var shinyMode = window.HTMLWidgets.shinyMode =
      typeof(window.Shiny) !== "undefined" && !!window.Shiny.outputBindings;

  // We can't count on jQuery being available, so we implement our own
  // version if necessary.
  function querySelectorAll(scope, selector) {
    if (typeof(jQuery) !== "undefined" && scope instanceof jQuery) {
      return scope.find(selector);
    }
    if (scope.querySelectorAll) {
      return scope.querySelectorAll(selector);
    }
  }

  function asArray(value) {
    if (value === null)
      return [];
    if ($.isArray(value))
      return value;
    return [value];
  }

  // Implement jQuery's extend
  function extend(target /*, ... */) {
    if (arguments.length == 1) {
      return target;
    }
    for (var i = 1; i < arguments.length; i++) {
      var source = arguments[i];
      for (var prop in source) {
        if (source.hasOwnProperty(prop)) {
          target[prop] = source[prop];
        }
      }
    }
    return target;
  }

  // IE8 doesn't support Array.forEach.
  function forEach(values, callback, thisArg) {
    if (values.forEach) {
      values.forEach(callback, thisArg);
    } else {
      for (var i = 0; i < values.length; i++) {
        callback.call(thisArg, values[i], i, values);
      }
    }
  }

  // Replaces the specified method with the return value of funcSource.
  //
  // Note that funcSource should not BE the new method, it should be a function
  // that RETURNS the new method. funcSource receives a single argument that is
  // the overridden method, it can be called from the new method. The overridden
  // method can be called like a regular function, it has the target permanently
  // bound to it so "this" will work correctly.
  function overrideMethod(target, methodName, funcSource) {
    var superFunc = target[methodName] || function() {};
    var superFuncBound = function() {
      return superFunc.apply(target, arguments);
    };
    target[methodName] = funcSource(superFuncBound);
  }

  // Add a method to delegator that, when invoked, calls
  // delegatee.methodName. If there is no such method on
  // the delegatee, but there was one on delegator before
  // delegateMethod was called, then the original version
  // is invoked instead.
  // For example:
  //
  // var a = {
  //   method1: function() { console.log('a1'); }
  //   method2: function() { console.log('a2'); }
  // };
  // var b = {
  //   method1: function() { console.log('b1'); }
  // };
  // delegateMethod(a, b, "method1");
  // delegateMethod(a, b, "method2");
  // a.method1();
  // a.method2();
  //
  // The output would be "b1", "a2".
  function delegateMethod(delegator, delegatee, methodName) {
    var inherited = delegator[methodName];
    delegator[methodName] = function() {
      var target = delegatee;
      var method = delegatee[methodName];

      // The method doesn't exist on the delegatee. Instead,
      // call the method on the delegator, if it exists.
      if (!method) {
        target = delegator;
        method = inherited;
      }

      if (method) {
        return method.apply(target, arguments);
      }
    };
  }

  // Implement a vague facsimilie of jQuery's data method
  function elementData(el, name, value) {
    if (arguments.length == 2) {
      return el["htmlwidget_data_" + name];
    } else if (arguments.length == 3) {
      el["htmlwidget_data_" + name] = value;
      return el;
    } else {
      throw new Error("Wrong number of arguments for elementData: " +
        arguments.length);
    }
  }

  // http://stackoverflow.com/questions/3446170/escape-string-for-use-in-javascript-regex
  function escapeRegExp(str) {
    return str.replace(/[\-\[\]\/\{\}\(\)\*\+\?\.\\\^\$\|]/g, "\\$&");
  }

  function hasClass(el, className) {
    var re = new RegExp("\\b" + escapeRegExp(className) + "\\b");
    return re.test(el.className);
  }

  // elements - array (or array-like object) of HTML elements
  // className - class name to test for
  // include - if true, only return elements with given className;
  //   if false, only return elements *without* given className
  function filterByClass(elements, className, include) {
    var results = [];
    for (var i = 0; i < elements.length; i++) {
      if (hasClass(elements[i], className) == include)
        results.push(elements[i]);
    }
    return results;
  }

  function on(obj, eventName, func) {
    if (obj.addEventListener) {
      obj.addEventListener(eventName, func, false);
    } else if (obj.attachEvent) {
      obj.attachEvent(eventName, func);
    }
  }

  function off(obj, eventName, func) {
    if (obj.removeEventListener)
      obj.removeEventListener(eventName, func, false);
    else if (obj.detachEvent) {
      obj.detachEvent(eventName, func);
    }
  }

  // Translate array of values to top/right/bottom/left, as usual with
  // the "padding" CSS property
  // https://developer.mozilla.org/en-US/docs/Web/CSS/padding
  function unpackPadding(value) {
    if (typeof(value) === "number")
      value = [value];
    if (value.length === 1) {
      return {top: value[0], right: value[0], bottom: value[0], left: value[0]};
    }
    if (value.length === 2) {
      return {top: value[0], right: value[1], bottom: value[0], left: value[1]};
    }
    if (value.length === 3) {
      return {top: value[0], right: value[1], bottom: value[2], left: value[1]};
    }
    if (value.length === 4) {
      return {top: value[0], right: value[1], bottom: value[2], left: value[3]};
    }
  }

  // Convert an unpacked padding object to a CSS value
  function paddingToCss(paddingObj) {
    return paddingObj.top + "px " + paddingObj.right + "px " + paddingObj.bottom + "px " + paddingObj.left + "px";
  }

  // Makes a number suitable for CSS
  function px(x) {
    if (typeof(x) === "number")
      return x + "px";
    else
      return x;
  }

  // Retrieves runtime widget sizing information for an element.
  // The return value is either null, or an object with fill, padding,
  // defaultWidth, defaultHeight fields.
  function sizingPolicy(el) {
    var sizingEl = document.querySelector("script[data-for='" + el.id + "'][type='application/htmlwidget-sizing']");
    if (!sizingEl)
      return null;
    var sp = JSON.parse(sizingEl.textContent || sizingEl.text || "{}");
    if (viewerMode) {
      return sp.viewer;
    } else {
      return sp.browser;
    }
  }

  // @param tasks Array of strings (or falsy value, in which case no-op).
  //   Each element must be a valid JavaScript expression that yields a
  //   function. Or, can be an array of objects with "code" and "data"
  //   properties; in this case, the "code" property should be a string
  //   of JS that's an expr that yields a function, and "data" should be
  //   an object that will be added as an additional argument when that
  //   function is called.
  // @param target The object that will be "this" for each function
  //   execution.
  // @param args Array of arguments to be passed to the functions. (The
  //   same arguments will be passed to all functions.)
  function evalAndRun(tasks, target, args) {
    if (tasks) {
      forEach(tasks, function(task) {
        var theseArgs = args;
        if (typeof(task) === "object") {
          theseArgs = theseArgs.concat([task.data]);
          task = task.code;
        }
        var taskFunc = tryEval(task);
        if (typeof(taskFunc) !== "function") {
          throw new Error("Task must be a function! Source:\n" + task);
        }
        taskFunc.apply(target, theseArgs);
      });
    }
  }

  // Attempt eval() both with and without enclosing in parentheses.
  // Note that enclosing coerces a function declaration into
  // an expression that eval() can parse
  // (otherwise, a SyntaxError is thrown)
  function tryEval(code) {
    var result = null;
    try {
      result = eval("(" + code + ")");
    } catch(error) {
      if (!(error instanceof SyntaxError)) {
        throw error;
      }
      try {
        result = eval(code);
      } catch(e) {
        if (e instanceof SyntaxError) {
          throw error;
        } else {
          throw e;
        }
      }
    }
    return result;
  }

  function initSizing(el) {
    var sizing = sizingPolicy(el);
    if (!sizing)
      return;

    var cel = document.getElementById("htmlwidget_container");
    if (!cel)
      return;

    if (typeof(sizing.padding) !== "undefined") {
      document.body.style.margin = "0";
      document.body.style.padding = paddingToCss(unpackPadding(sizing.padding));
    }

    if (sizing.fill) {
      document.body.style.overflow = "hidden";
      document.body.style.width = "100%";
      document.body.style.height = "100%";
      document.documentElement.style.width = "100%";
      document.documentElement.style.height = "100%";
      cel.style.position = "absolute";
      var pad = unpackPadding(sizing.padding);
      cel.style.top = pad.top + "px";
      cel.style.right = pad.right + "px";
      cel.style.bottom = pad.bottom + "px";
      cel.style.left = pad.left + "px";
      el.style.width = "100%";
      el.style.height = "100%";

      return {
        getWidth: function() { return cel.getBoundingClientRect().width; },
        getHeight: function() { return cel.getBoundingClientRect().height; }
      };

    } else {
      el.style.width = px(sizing.width);
      el.style.height = px(sizing.height);

      return {
        getWidth: function() { return cel.getBoundingClientRect().width; },
        getHeight: function() { return cel.getBoundingClientRect().height; }
      };
    }
  }

  // Default implementations for methods
  var defaults = {
    find: function(scope) {
      return querySelectorAll(scope, "." + this.name);
    },
    renderError: function(el, err) {
      var $el = $(el);

      this.clearError(el);

      // Add all these error classes, as Shiny does
      var errClass = "shiny-output-error";
      if (err.type !== null) {
        // use the classes of the error condition as CSS class names
        errClass = errClass + " " + $.map(asArray(err.type), function(type) {
          return errClass + "-" + type;
        }).join(" ");
      }
      errClass = errClass + " htmlwidgets-error";

      // Is el inline or block? If inline or inline-block, just display:none it
      // and add an inline error.
      var display = $el.css("display");
      $el.data("restore-display-mode", display);

      if (display === "inline" || display === "inline-block") {
        $el.hide();
        if (err.message !== "") {
          var errorSpan = $("<span>").addClass(errClass);
          errorSpan.text(err.message);
          $el.after(errorSpan);
        }
      } else if (display === "block") {
        // If block, add an error just after the el, set visibility:none on the
        // el, and position the error to be on top of the el.
        // Mark it with a unique ID and CSS class so we can remove it later.
        $el.css("visibility", "hidden");
        if (err.message !== "") {
          var errorDiv = $("<div>").addClass(errClass).css("position", "absolute")
            .css("top", el.offsetTop)
            .css("left", el.offsetLeft)
            // setting width can push out the page size, forcing otherwise
            // unnecessary scrollbars to appear and making it impossible for
            // the element to shrink; so use max-width instead
            .css("maxWidth", el.offsetWidth)
            .css("height", el.offsetHeight);
          errorDiv.text(err.message);
          $el.after(errorDiv);

          // Really dumb way to keep the size/position of the error in sync with
          // the parent element as the window is resized or whatever.
          var intId = setInterval(function() {
            if (!errorDiv[0].parentElement) {
              clearInterval(intId);
              return;
            }
            errorDiv
              .css("top", el.offsetTop)
              .css("left", el.offsetLeft)
              .css("maxWidth", el.offsetWidth)
              .css("height", el.offsetHeight);
          }, 500);
        }
      }
    },
    clearError: function(el) {
      var $el = $(el);
      var display = $el.data("restore-display-mode");
      $el.data("restore-display-mode", null);

      if (display === "inline" || display === "inline-block") {
        if (display)
          $el.css("display", display);
        $(el.nextSibling).filter(".htmlwidgets-error").remove();
      } else if (display === "block"){
        $el.css("visibility", "inherit");
        $(el.nextSibling).filter(".htmlwidgets-error").remove();
      }
    },
    sizing: {}
  };

  // Called by widget bindings to register a new type of widget. The definition
  // object can contain the following properties:
  // - name (required) - A string indicating the binding name, which will be
  //   used by default as the CSS classname to look for.
  // - initialize (optional) - A function(el) that will be called once per
  //   widget element; if a value is returned, it will be passed as the third
  //   value to renderValue.
  // - renderValue (required) - A function(el, data, initValue) that will be
  //   called with data. Static contexts will cause this to be called once per
  //   element; Shiny apps will cause this to be called multiple times per
  //   element, as the data changes.
  window.HTMLWidgets.widget = function(definition) {
    if (!definition.name) {
      throw new Error("Widget must have a name");
    }
    if (!definition.type) {
      throw new Error("Widget must have a type");
    }
    // Currently we only support output widgets
    if (definition.type !== "output") {
      throw new Error("Unrecognized widget type '" + definition.type + "'");
    }
    // TODO: Verify that .name is a valid CSS classname

    // Support new-style instance-bound definitions. Old-style class-bound
    // definitions have one widget "object" per widget per type/class of
    // widget; the renderValue and resize methods on such widget objects
    // take el and instance arguments, because the widget object can't
    // store them. New-style instance-bound definitions have one widget
    // object per widget instance; the definition that's passed in doesn't
    // provide renderValue or resize methods at all, just the single method
    //   factory(el, width, height)
    // which returns an object that has renderValue(x) and resize(w, h).
    // This enables a far more natural programming style for the widget
    // author, who can store per-instance state using either OO-style
    // instance fields or functional-style closure variables (I guess this
    // is in contrast to what can only be called C-style pseudo-OO which is
    // what we required before).
    if (definition.factory) {
      definition = createLegacyDefinitionAdapter(definition);
    }

    if (!definition.renderValue) {
      throw new Error("Widget must have a renderValue function");
    }

    // For static rendering (non-Shiny), use a simple widget registration
    // scheme. We also use this scheme for Shiny apps/documents that also
    // contain static widgets.
    window.HTMLWidgets.widgets = window.HTMLWidgets.widgets || [];
    // Merge defaults into the definition; don't mutate the original definition.
    var staticBinding = extend({}, defaults, definition);
    overrideMethod(staticBinding, "find", function(superfunc) {
      return function(scope) {
        var results = superfunc(scope);
        // Filter out Shiny outputs, we only want the static kind
        return filterByClass(results, "html-widget-output", false);
      };
    });
    window.HTMLWidgets.widgets.push(staticBinding);

    if (shinyMode) {
      // Shiny is running. Register the definition with an output binding.
      // The definition itself will not be the output binding, instead
      // we will make an output binding object that delegates to the
      // definition. This is because we foolishly used the same method
      // name (renderValue) for htmlwidgets definition and Shiny bindings
      // but they actually have quite different semantics (the Shiny
      // bindings receive data that includes lots of metadata that it
      // strips off before calling htmlwidgets renderValue). We can't
      // just ignore the difference because in some widgets it's helpful
      // to call this.renderValue() from inside of resize(), and if
      // we're not delegating, then that call will go to the Shiny
      // version instead of the htmlwidgets version.

      // Merge defaults with definition, without mutating either.
      var bindingDef = extend({}, defaults, definition);

      // This object will be our actual Shiny binding.
      var shinyBinding = new Shiny.OutputBinding();

      // With a few exceptions, we'll want to simply use the bindingDef's
      // version of methods if they are available, otherwise fall back to
      // Shiny's defaults. NOTE: If Shiny's output bindings gain additional
      // methods in the future, and we want them to be overrideable by
      // HTMLWidget binding definitions, then we'll need to add them to this
      // list.
      delegateMethod(shinyBinding, bindingDef, "getId");
      delegateMethod(shinyBinding, bindingDef, "onValueChange");
      delegateMethod(shinyBinding, bindingDef, "onValueError");
      delegateMethod(shinyBinding, bindingDef, "renderError");
      delegateMethod(shinyBinding, bindingDef, "clearError");
      delegateMethod(shinyBinding, bindingDef, "showProgress");

      // The find, renderValue, and resize are handled differently, because we
      // want to actually decorate the behavior of the bindingDef methods.

      shinyBinding.find = function(scope) {
        var results = bindingDef.find(scope);

        // Only return elements that are Shiny outputs, not static ones
        var dynamicResults = results.filter(".html-widget-output");

        // It's possible that whatever caused Shiny to think there might be
        // new dynamic outputs, also caused there to be new static outputs.
        // Since there might be lots of different htmlwidgets bindings, we
        // schedule execution for later--no need to staticRender multiple
        // times.
        if (results.length !== dynamicResults.length)
          scheduleStaticRender();

        return dynamicResults;
      };

      // Wrap renderValue to handle initialization, which unfortunately isn't
      // supported natively by Shiny at the time of this writing.

      shinyBinding.renderValue = function(el, data) {
        Shiny.renderDependencies(data.deps);
        // Resolve strings marked as javascript literals to objects
        if (!(data.evals instanceof Array)) data.evals = [data.evals];
        for (var i = 0; data.evals && i < data.evals.length; i++) {
          window.HTMLWidgets.evaluateStringMember(data.x, data.evals[i]);
        }
        if (!bindingDef.renderOnNullValue) {
          if (data.x === null) {
            el.style.visibility = "hidden";
            return;
          } else {
            el.style.visibility = "inherit";
          }
        }
        if (!elementData(el, "initialized")) {
          initSizing(el);

          elementData(el, "initialized", true);
          if (bindingDef.initialize) {
            var rect = el.getBoundingClientRect();
            var result = bindingDef.initialize(el, rect.width, rect.height);
            elementData(el, "init_result", result);
          }
        }
        bindingDef.renderValue(el, data.x, elementData(el, "init_result"));
        evalAndRun(data.jsHooks.render, elementData(el, "init_result"), [el, data.x]);
      };

      // Only override resize if bindingDef implements it
      if (bindingDef.resize) {
        shinyBinding.resize = function(el, width, height) {
          // Shiny can call resize before initialize/renderValue have been
          // called, which doesn't make sense for widgets.
          if (elementData(el, "initialized")) {
            bindingDef.resize(el, width, height, elementData(el, "init_result"));
          }
        };
      }

      Shiny.outputBindings.register(shinyBinding, bindingDef.name);
    }
  };

  var scheduleStaticRenderTimerId = null;
  function scheduleStaticRender() {
    if (!scheduleStaticRenderTimerId) {
      scheduleStaticRenderTimerId = setTimeout(function() {
        scheduleStaticRenderTimerId = null;
        window.HTMLWidgets.staticRender();
      }, 1);
    }
  }

  // Render static widgets after the document finishes loading
  // Statically render all elements that are of this widget's class
  window.HTMLWidgets.staticRender = function() {
    var bindings = window.HTMLWidgets.widgets || [];
    forEach(bindings, function(binding) {
      var matches = binding.find(document.documentElement);
      forEach(matches, function(el) {
        var sizeObj = initSizing(el, binding);

        var getSize = function(el) {
          if (sizeObj) {
            return {w: sizeObj.getWidth(), h: sizeObj.getHeight()}
          } else {
            var rect = el.getBoundingClientRect();
            return {w: rect.width, h: rect.height}
          }
        };

        if (hasClass(el, "html-widget-static-bound"))
          return;
        el.className = el.className + " html-widget-static-bound";

        var initResult;
        if (binding.initialize) {
          var size = getSize(el);
          initResult = binding.initialize(el, size.w, size.h);
          elementData(el, "init_result", initResult);
        }

        if (binding.resize) {
          var lastSize = getSize(el);
          var resizeHandler = function(e) {
            var size = getSize(el);
            if (size.w === 0 && size.h === 0)
              return;
            if (size.w === lastSize.w && size.h === lastSize.h)
              return;
            lastSize = size;
            binding.resize(el, size.w, size.h, initResult);
          };

          on(window, "resize", resizeHandler);

          // This is needed for cases where we're running in a Shiny
          // app, but the widget itself is not a Shiny output, but
          // rather a simple static widget. One example of this is
          // an rmarkdown document that has runtime:shiny and widget
          // that isn't in a render function. Shiny only knows to
          // call resize handlers for Shiny outputs, not for static
          // widgets, so we do it ourselves.
          if (window.jQuery) {
            window.jQuery(document).on(
              "shown.htmlwidgets shown.bs.tab.htmlwidgets shown.bs.collapse.htmlwidgets",
              resizeHandler
            );
            window.jQuery(document).on(
              "hidden.htmlwidgets hidden.bs.tab.htmlwidgets hidden.bs.collapse.htmlwidgets",
              resizeHandler
            );
          }

          // This is needed for the specific case of ioslides, which
          // flips slides between display:none and display:block.
          // Ideally we would not have to have ioslide-specific code
          // here, but rather have ioslides raise a generic event,
          // but the rmarkdown package just went to CRAN so the
          // window to getting that fixed may be long.
          if (window.addEventListener) {
            // It's OK to limit this to window.addEventListener
            // browsers because ioslides itself only supports
            // such browsers.
            on(document, "slideenter", resizeHandler);
            on(document, "slideleave", resizeHandler);
          }
        }

        var scriptData = document.querySelector("script[data-for='" + el.id + "'][type='application/json']");
        if (scriptData) {
          var data = JSON.parse(scriptData.textContent || scriptData.text);
          // Resolve strings marked as javascript literals to objects
          if (!(data.evals instanceof Array)) data.evals = [data.evals];
          for (var k = 0; data.evals && k < data.evals.length; k++) {
            window.HTMLWidgets.evaluateStringMember(data.x, data.evals[k]);
          }
          binding.renderValue(el, data.x, initResult);
          evalAndRun(data.jsHooks.render, initResult, [el, data.x]);
        }
      });
    });

    invokePostRenderHandlers();
  }


  function has_jQuery3() {
    if (!window.jQuery) {
      return false;
    }
    var $version = window.jQuery.fn.jquery;
    var $major_version = parseInt($version.split(".")[0]);
    return $major_version >= 3;
  }

  /*
  / Shiny 1.4 bumped jQuery from 1.x to 3.x which means jQuery's
  / on-ready handler (i.e., $(fn)) is now asyncronous (i.e., it now
  / really means $(setTimeout(fn)).
  / https://jquery.com/upgrade-guide/3.0/#breaking-change-document-ready-handlers-are-now-asynchronous
  /
  / Since Shiny uses $() to schedule initShiny, shiny>=1.4 calls initShiny
  / one tick later than it did before, which means staticRender() is
  / called renderValue() earlier than (advanced) widget authors might be expecting.
  / https://github.com/rstudio/shiny/issues/2630
  /
  / For a concrete example, leaflet has some methods (e.g., updateBounds)
  / which reference Shiny methods registered in initShiny (e.g., setInputValue).
  / Since leaflet is privy to this life-cycle, it knows to use setTimeout() to
  / delay execution of those methods (until Shiny methods are ready)
  / https://github.com/rstudio/leaflet/blob/18ec981/javascript/src/index.js#L266-L268
  /
  / Ideally widget authors wouldn't need to use this setTimeout() hack that
  / leaflet uses to call Shiny methods on a staticRender(). In the long run,
  / the logic initShiny should be broken up so that method registration happens
  / right away, but binding happens later.
  */
  function maybeStaticRenderLater() {
    if (shinyMode && has_jQuery3()) {
      window.jQuery(window.HTMLWidgets.staticRender);
    } else {
      window.HTMLWidgets.staticRender();
    }
  }

  if (document.addEventListener) {
    document.addEventListener("DOMContentLoaded", function() {
      document.removeEventListener("DOMContentLoaded", arguments.callee, false);
      maybeStaticRenderLater();
    }, false);
  } else if (document.attachEvent) {
    document.attachEvent("onreadystatechange", function() {
      if (document.readyState === "complete") {
        document.detachEvent("onreadystatechange", arguments.callee);
        maybeStaticRenderLater();
      }
    });
  }


  window.HTMLWidgets.getAttachmentUrl = function(depname, key) {
    // If no key, default to the first item
    if (typeof(key) === "undefined")
      key = 1;

    var link = document.getElementById(depname + "-" + key + "-attachment");
    if (!link) {
      throw new Error("Attachment " + depname + "/" + key + " not found in document");
    }
    return link.getAttribute("href");
  };

  window.HTMLWidgets.dataframeToD3 = function(df) {
    var names = [];
    var length;
    for (var name in df) {
        if (df.hasOwnProperty(name))
            names.push(name);
        if (typeof(df[name]) !== "object" || typeof(df[name].length) === "undefined") {
            throw new Error("All fields must be arrays");
        } else if (typeof(length) !== "undefined" && length !== df[name].length) {
            throw new Error("All fields must be arrays of the same length");
        }
        length = df[name].length;
    }
    var results = [];
    var item;
    for (var row = 0; row < length; row++) {
        item = {};
        for (var col = 0; col < names.length; col++) {
            item[names[col]] = df[names[col]][row];
        }
        results.push(item);
    }
    return results;
  };

  window.HTMLWidgets.transposeArray2D = function(array) {
      if (array.length === 0) return array;
      var newArray = array[0].map(function(col, i) {
          return array.map(function(row) {
              return row[i]
          })
      });
      return newArray;
  };
  // Split value at splitChar, but allow splitChar to be escaped
  // using escapeChar. Any other characters escaped by escapeChar
  // will be included as usual (including escapeChar itself).
  function splitWithEscape(value, splitChar, escapeChar) {
    var results = [];
    var escapeMode = false;
    var currentResult = "";
    for (var pos = 0; pos < value.length; pos++) {
      if (!escapeMode) {
        if (value[pos] === splitChar) {
          results.push(currentResult);
          currentResult = "";
        } else if (value[pos] === escapeChar) {
          escapeMode = true;
        } else {
          currentResult += value[pos];
        }
      } else {
        currentResult += value[pos];
        escapeMode = false;
      }
    }
    if (currentResult !== "") {
      results.push(currentResult);
    }
    return results;
  }
  // Function authored by Yihui/JJ Allaire
  window.HTMLWidgets.evaluateStringMember = function(o, member) {
    var parts = splitWithEscape(member, '.', '\\');
    for (var i = 0, l = parts.length; i < l; i++) {
      var part = parts[i];
      // part may be a character or 'numeric' member name
      if (o !== null && typeof o === "object" && part in o) {
        if (i == (l - 1)) { // if we are at the end of the line then evalulate
          if (typeof o[part] === "string")
            o[part] = tryEval(o[part]);
        } else { // otherwise continue to next embedded object
          o = o[part];
        }
      }
    }
  };

  // Retrieve the HTMLWidget instance (i.e. the return value of an
  // HTMLWidget binding's initialize() or factory() function)
  // associated with an element, or null if none.
  window.HTMLWidgets.getInstance = function(el) {
    return elementData(el, "init_result");
  };

  // Finds the first element in the scope that matches the selector,
  // and returns the HTMLWidget instance (i.e. the return value of
  // an HTMLWidget binding's initialize() or factory() function)
  // associated with that element, if any. If no element matches the
  // selector, or the first matching element has no HTMLWidget
  // instance associated with it, then null is returned.
  //
  // The scope argument is optional, and defaults to window.document.
  window.HTMLWidgets.find = function(scope, selector) {
    if (arguments.length == 1) {
      selector = scope;
      scope = document;
    }

    var el = scope.querySelector(selector);
    if (el === null) {
      return null;
    } else {
      return window.HTMLWidgets.getInstance(el);
    }
  };

  // Finds all elements in the scope that match the selector, and
  // returns the HTMLWidget instances (i.e. the return values of
  // an HTMLWidget binding's initialize() or factory() function)
  // associated with the elements, in an array. If elements that
  // match the selector don't have an associated HTMLWidget
  // instance, the returned array will contain nulls.
  //
  // The scope argument is optional, and defaults to window.document.
  window.HTMLWidgets.findAll = function(scope, selector) {
    if (arguments.length == 1) {
      selector = scope;
      scope = document;
    }

    var nodes = scope.querySelectorAll(selector);
    var results = [];
    for (var i = 0; i < nodes.length; i++) {
      results.push(window.HTMLWidgets.getInstance(nodes[i]));
    }
    return results;
  };

  var postRenderHandlers = [];
  function invokePostRenderHandlers() {
    while (postRenderHandlers.length) {
      var handler = postRenderHandlers.shift();
      if (handler) {
        handler();
      }
    }
  }

  // Register the given callback function to be invoked after the
  // next time static widgets are rendered.
  window.HTMLWidgets.addPostRenderHandler = function(callback) {
    postRenderHandlers.push(callback);
  };

  // Takes a new-style instance-bound definition, and returns an
  // old-style class-bound definition. This saves us from having
  // to rewrite all the logic in this file to accomodate both
  // types of definitions.
  function createLegacyDefinitionAdapter(defn) {
    var result = {
      name: defn.name,
      type: defn.type,
      initialize: function(el, width, height) {
        return defn.factory(el, width, height);
      },
      renderValue: function(el, x, instance) {
        return instance.renderValue(x);
      },
      resize: function(el, width, height, instance) {
        return instance.resize(width, height);
      }
    };

    if (defn.find)
      result.find = defn.find;
    if (defn.renderError)
      result.renderError = defn.renderError;
    if (defn.clearError)
      result.clearError = defn.clearError;

    return result;
  }
})();
</script>
<link href="data:text/css,%2EReactable%7B%2Dwebkit%2Dbox%2Dorient%3Avertical%3B%2Dwebkit%2Dbox%2Ddirection%3Anormal%3Bdisplay%3A%2Dwebkit%2Dbox%3Bdisplay%3A%2Dms%2Dflexbox%3Bdisplay%3Aflex%3B%2Dms%2Dflex%2Ddirection%3Acolumn%3Bflex%2Ddirection%3Acolumn%3Bposition%3Arelative%7D%2EReactable%20%2A%7B%2Dwebkit%2Dbox%2Dsizing%3Aborder%2Dbox%3Bbox%2Dsizing%3Aborder%2Dbox%7D%2EReactable%20%2Ert%2Dtable%7B%2Dwebkit%2Dbox%2Dflex%3A1%3B%2Dwebkit%2Dbox%2Dalign%3Astretch%3B%2Dms%2Dflex%2Dalign%3Astretch%3Balign%2Ditems%3Astretch%3Bborder%2Dcollapse%3Acollapse%3B%2Dms%2Dflex%3Aauto%201%3Bflex%3Aauto%201%3Boverflow%3Aauto%3Bwidth%3A100%25%7D%2EReactable%20%2Ert%2Dtable%2C%2EReactable%20%2Ert%2Dthead%7B%2Dwebkit%2Dbox%2Dorient%3Avertical%3B%2Dwebkit%2Dbox%2Ddirection%3Anormal%3Bdisplay%3A%2Dwebkit%2Dbox%3Bdisplay%3A%2Dms%2Dflexbox%3Bdisplay%3Aflex%3B%2Dms%2Dflex%2Ddirection%3Acolumn%3Bflex%2Ddirection%3Acolumn%7D%2EReactable%20%2Ert%2Dthead%20%2Ert%2Dtd%2C%2EReactable%20%2Ert%2Dthead%20%2Ert%2Dth%7Bline%2Dheight%3Anormal%3Bposition%3Arelative%7D%2EReactable%20%2Ert%2Dth%2Ert%2Dth%2Dresizable%7Boverflow%3Avisible%7D%2EReactable%20%2Ert%2Dth%2Ert%2Dth%2Dresizable%3Alast%2Dchild%7Boverflow%3Ahidden%7D%2EReactable%20%2Ert%2Dtbody%7B%2Dwebkit%2Dbox%2Dorient%3Avertical%3B%2Dwebkit%2Dbox%2Ddirection%3Anormal%3Bdisplay%3A%2Dwebkit%2Dbox%3Bdisplay%3A%2Dms%2Dflexbox%3Bdisplay%3Aflex%3B%2Dms%2Dflex%2Ddirection%3Acolumn%3Bflex%2Ddirection%3Acolumn%3Boverflow%3Aauto%7D%2Ert%2Dtd%2Dexpandable%7Bcursor%3Apointer%7D%2EReactable%20%2Ert%2Dtr%2Dgroup%7B%2Dwebkit%2Dbox%2Dorient%3Avertical%3B%2Dwebkit%2Dbox%2Ddirection%3Anormal%3B%2Dwebkit%2Dbox%2Dalign%3Astretch%3B%2Dms%2Dflex%2Dalign%3Astretch%3Balign%2Ditems%3Astretch%3B%2Dms%2Dflex%3A1%200%20auto%3Bflex%3A1%200%20auto%3B%2Dms%2Dflex%2Ddirection%3Acolumn%3Bflex%2Ddirection%3Acolumn%7D%2EReactable%20%2Ert%2Dtr%2C%2EReactable%20%2Ert%2Dtr%2Dgroup%7B%2Dwebkit%2Dbox%2Dflex%3A1%3Bdisplay%3A%2Dwebkit%2Dbox%3Bdisplay%3A%2Dms%2Dflexbox%3Bdisplay%3Aflex%7D%2EReactable%20%2Ert%2Dtr%7B%2Dms%2Dflex%3A1%200%20auto%3Bflex%3A1%200%20auto%7D%2EReactable%20%2Ert%2Dtd%2C%2EReactable%20%2Ert%2Dth%7B%2Dwebkit%2Dbox%2Dflex%3A1%3B%2Dms%2Dflex%3A1%200%200px%3Bflex%3A1%200%200%3Boverflow%3Ahidden%7D%2EReactable%20%2Ert%2Dresizer%7Bbottom%3A0%3Bcursor%3Acol%2Dresize%3Bdisplay%3Ainline%2Dblock%3Bposition%3Aabsolute%3Bright%3A%2D18px%3Btop%3A0%3Bwidth%3A36px%3Bz%2Dindex%3A10%7D%2EReactable%20%2Ert%2Dtfoot%7B%2Dwebkit%2Dbox%2Dorient%3Avertical%3B%2Dwebkit%2Dbox%2Ddirection%3Anormal%3Bdisplay%3A%2Dwebkit%2Dbox%3Bdisplay%3A%2Dms%2Dflexbox%3Bdisplay%3Aflex%3B%2Dms%2Dflex%2Ddirection%3Acolumn%3Bflex%2Ddirection%3Acolumn%7D%2EReactable%20%2Ert%2Dresizing%20%2Ert%2Dtd%2C%2EReactable%20%2Ert%2Dresizing%20%2Ert%2Dth%7Bcursor%3Acol%2Dresize%3B%2Dwebkit%2Dtransition%3Anone%21important%3Btransition%3Anone%21important%3B%2Dwebkit%2Duser%2Dselect%3Anone%3B%2Dmoz%2Duser%2Dselect%3Anone%3B%2Dms%2Duser%2Dselect%3Anone%3Buser%2Dselect%3Anone%7D%0A%2EReactable%7Bbackground%2Dcolor%3A%23fff%3Bheight%3A100%25%7D%2Ert%2Dinline%7Bdisplay%3A%2Dwebkit%2Dinline%2Dbox%3Bdisplay%3A%2Dms%2Dinline%2Dflexbox%3Bdisplay%3Ainline%2Dflex%7D%2Ert%2Dth%7Bfont%2Dweight%3A600%7D%2Ert%2Dtd%2C%2Ert%2Dth%7Bword%2Dwrap%3Abreak%2Dword%3Bdisplay%3A%2Dwebkit%2Dbox%3Bdisplay%3A%2Dms%2Dflexbox%3Bdisplay%3Aflex%3Bmax%2Dwidth%3A100%25%3Boverflow%2Dwrap%3Abreak%2Dword%7D%2Ert%2Dtd%2Dinner%2C%2Ert%2Dth%2Dinner%7Boverflow%3Ahidden%3Bpadding%3A7px%208px%3Bwidth%3A100%25%7D%2Ert%2Dcompact%20%2Ert%2Dtd%2Dinner%2C%2Ert%2Dcompact%20%2Ert%2Dth%2Dinner%7Bpadding%3A4px%206px%7D%2Ert%2Dtext%2Dcontent%7Boverflow%3Ahidden%7D%2Ert%2Dnowrap%20%2Ert%2Dtd%2Dinner%2C%2Ert%2Dnowrap%20%2Ert%2Dtext%2Dcontent%2C%2Ert%2Dnowrap%20%2Ert%2Dth%2Dinner%7Btext%2Doverflow%3Aellipsis%3Bwhite%2Dspace%3Anowrap%7D%2Ert%2Dselect%7B%2Dwebkit%2Dbox%2Dalign%3Acenter%3B%2Dms%2Dflex%2Dalign%3Acenter%3B%2Dwebkit%2Dbox%2Dpack%3Acenter%3B%2Dms%2Dflex%2Dpack%3Acenter%3Balign%2Ditems%3Acenter%3Bdisplay%3A%2Dwebkit%2Dbox%3Bdisplay%3A%2Dms%2Dflexbox%3Bdisplay%3Aflex%3Bjustify%2Dcontent%3Acenter%7Dinput%5Btype%3Dcheckbox%5D%2Ert%2Dselect%2Dinput%2Cinput%5Btype%3Dradio%5D%2Ert%2Dselect%2Dinput%7Bdisplay%3Ablock%3Bmargin%3A0%7D%2Ert%2Dalign%2Dleft%7Btext%2Dalign%3Aleft%7D%2Ert%2Dalign%2Dright%7Btext%2Dalign%3Aright%7D%2Ert%2Dalign%2Dcenter%7Btext%2Dalign%3Acenter%7D%2Ert%2Dvalign%2Dcenter%7B%2Dwebkit%2Dbox%2Dalign%3Acenter%3B%2Dms%2Dflex%2Dalign%3Acenter%3Balign%2Ditems%3Acenter%7D%2Ert%2Dvalign%2Dbottom%7B%2Dwebkit%2Dbox%2Dalign%3Aend%3B%2Dms%2Dflex%2Dalign%3Aend%3Balign%2Ditems%3Aflex%2Dend%7D%2Ert%2Dsticky%2C%2Ert%2Dtbody%2C%2Ert%2Dtr%2C%2Ert%2Dtr%2Dgroup%7Bbackground%2Dcolor%3Ainherit%7D%2Ert%2Dsticky%7Bz%2Dindex%3A1%7D%2Ert%2Dtable%7Bborder%2Dcolor%3A%23e6e6e6%3Bborder%2Dwidth%3A1px%7D%2Ert%2Dbordered%20%2Ert%2Dtable%2C%2Ert%2Doutlined%20%2Ert%2Dtable%7Bborder%2Dstyle%3Asolid%7D%2EReactable%3Anot%28%2Ert%2Dkeyboard%2Dactive%29%20%2Ert%2Dtable%3Afocus%7Boutline%2Dstyle%3Asolid%3Boutline%2Dwidth%3A0%7D%2Ert%2Dth%7Bborder%2Dbottom%3A2px%20solid%20%23e6e6e6%3Bborder%2Dleft%2Dcolor%3Argba%280%2C0%2C0%2C%2E05%29%3Bborder%2Dleft%2Dwidth%3A1px%7D%2Ert%2Dbordered%20%2Ert%2Dth%2C%2Ert%2Doutlined%20%2Ert%2Dth%7Bborder%2Dbottom%2Dwidth%3A1px%7D%2Ert%2Dtd%7Bborder%2Dleft%2Dcolor%3Argba%280%2C0%2C0%2C%2E05%29%3Bborder%2Dleft%2Dwidth%3A1px%3Bborder%2Dtop%3A1px%20solid%20%23f2f2f2%7D%2Ert%2Dborderless%20%2Ert%2Dtd%2C%2Ert%2Dtr%2Dgroup%3Afirst%2Dchild%3E%2Ert%2Dtr%3Afirst%2Dchild%20%2Ert%2Dtd%7Bborder%2Dtop%3Anone%7D%2Ert%2Dbordered%20%2Ert%2Dtd%2C%2Ert%2Dbordered%20%2Ert%2Dth%7Bborder%2Dleft%2Dstyle%3Asolid%7D%2Ert%2Dbordered%20%2Ert%2Dtd%3Afirst%2Dchild%2C%2Ert%2Dbordered%20%2Ert%2Dth%3Afirst%2Dchild%7Bborder%2Dleft%3Anone%7D%2Ert%2Dth%2Dgroup%2C%2Ert%2Dth%2Dgroup%2Dnone%7Bborder%2Dbottom%2Dstyle%3Anone%7D%2Ert%2Dth%2Dgroup%3Aafter%7Bbackground%2Dcolor%3A%23e6e6e6%3Bbottom%3A0%3Bcontent%3A%22%22%3Bheight%3A1px%3Bleft%3A8px%3Bmargin%3Aauto%3Bposition%3Aabsolute%3Bright%3A8px%3Bwidth%3A100%25%7D%2Ert%2Dbordered%20%2Ert%2Dth%2Dgroup%3Aafter%2C%2Ert%2Doutlined%20%2Ert%2Dth%2Dgroup%3Aafter%7Bleft%3A0%3Bright%3A0%7D%2Ert%2Dbordered%20%2Ert%2Dth%2Dgroup%2Dnone%7Bborder%2Dbottom%2Dstyle%3Asolid%7D%2Ert%2Dtr%2Dstriped%7Bbackground%2Dcolor%3Argba%280%2C0%2C0%2C%2E03%29%7D%2Ert%2Dtr%2Dstriped%2Dsticky%7Bbackground%2Dcolor%3A%23f7f7f7%7D%2Ert%2Dtr%2Dhighlight%3Ahover%7Bbackground%2Dcolor%3Argba%280%2C0%2C0%2C%2E05%29%7D%2Ert%2Dtr%2Dhighlight%2Dsticky%3Ahover%7Bbackground%2Dcolor%3A%23f2f2f2%7D%2Ert%2Dtr%2Dpad%7B%2Dwebkit%2Duser%2Dselect%3Anone%3B%2Dmoz%2Duser%2Dselect%3Anone%3B%2Dms%2Duser%2Dselect%3Anone%3Buser%2Dselect%3Anone%7D%2EReactable%20%2Ert%2Dtbody%2C%2EReactable%20%2Ert%2Dtfoot%2C%2EReactable%20%2Ert%2Dthead%7B%2Dms%2Dflex%2Dnegative%3A0%3Bflex%2Dshrink%3A0%7D%40supports%20%28position%3Asticky%29%7B%2EReactable%20%2Ert%2Dtable%7Bbackground%3Ainherit%7D%2EReactable%20%2Ert%2Dtbody%7Boverflow%3Avisible%7D%2EReactable%20%2Ert%2Dthead%7Btop%3A0%7D%2EReactable%20%2Ert%2Dtfoot%2C%2EReactable%20%2Ert%2Dthead%7Bbackground%3Ainherit%3Bposition%3Asticky%3Bz%2Dindex%3A2%7D%2EReactable%20%2Ert%2Dtfoot%7Bbottom%3A0%7D%7D%40media%20screen%20and%20%28%2Dms%2Dhigh%2Dcontrast%3Aactive%29%2Cscreen%20and%20%28%2Dms%2Dhigh%2Dcontrast%3Anone%29%7B%2EReactable%20%2Ert%2Dtbody%7B%2Dms%2Doverflow%2Dstyle%3A%2Dms%2Dautohiding%2Dscrollbar%3Boverflow%3Aauto%7D%7D%2Ert%2Dtd%2Dfilter%7Bborder%2Dbottom%3A1px%20solid%20%23f2f2f2%3Bborder%2Dtop%3A0%7D%2Ert%2Dborderless%20%2Ert%2Dtd%2Dfilter%7Bborder%2Dbottom%3A0%7D%2Ert%2Dfilter%7Bbackground%2Dcolor%3A%23fff%3Bborder%3A1px%20solid%20rgba%280%2C0%2C0%2C%2E1%29%3Bborder%2Dradius%3A3px%3Bcolor%3Ainherit%3Bfont%2Dfamily%3Ainherit%3Bfont%2Dsize%3Ainherit%3Bfont%2Dweight%3A400%3Bmargin%3A0%3Boutline%2Dstyle%3Asolid%3Boutline%2Dwidth%3A0%3Bpadding%3A5px%207px%3Bwidth%3A100%25%7D%2Ert%2Dfilter%3Afocus%7Bborder%3A1px%20solid%20rgba%280%2C0%2C0%2C%2E25%29%7D%2Ert%2Dsort%2Dheader%7Bdisplay%3A%2Dwebkit%2Dbox%3Bdisplay%3A%2Dms%2Dflexbox%3Bdisplay%3Aflex%7D%2Ert%2Dalign%2Dcenter%20%2Ert%2Dsort%2Dheader%7B%2Dwebkit%2Dbox%2Dpack%3Acenter%3B%2Dms%2Dflex%2Dpack%3Acenter%3Bjustify%2Dcontent%3Acenter%7D%2Ert%2Dalign%2Dright%20%2Ert%2Dsort%2Dheader%7B%2Dwebkit%2Dbox%2Dpack%3Aend%3B%2Dms%2Dflex%2Dpack%3Aend%3Bjustify%2Dcontent%3Aflex%2Dend%7D%2Ert%2Dth%7Boutline%2Dstyle%3Asolid%3Boutline%2Dwidth%3A0%7D%2Ert%2Dth%5Baria%2Dsort%5D%7Bcursor%3Apointer%7D%2Ert%2Dth%5Baria%2Dsort%5D%20%2Ert%2Dsort%2Dleft%3Aafter%7Bline%2Dheight%3A0%3Bpadding%2Dright%3A5px%7D%2Ert%2Dth%5Baria%2Dsort%5D%20%2Ert%2Dsort%2Dright%3Aafter%7Bline%2Dheight%3A0%3Bpadding%2Dleft%3A5px%7D%2Ert%2Dth%5Baria%2Dsort%3Dascending%5D%20%2Ert%2Dsort%2Dleft%3Aafter%2C%2Ert%2Dth%5Baria%2Dsort%3Dascending%5D%20%2Ert%2Dsort%2Dright%3Aafter%7Bcontent%3A%22%5C2191%22%7D%2Ert%2Dth%5Baria%2Dsort%3Ddescending%5D%20%2Ert%2Dsort%2Dleft%3Aafter%2C%2Ert%2Dth%5Baria%2Dsort%3Ddescending%5D%20%2Ert%2Dsort%2Dright%3Aafter%7Bcontent%3A%22%5C2193%22%7D%2Ert%2Dth%5Baria%2Dsort%3Dnone%5D%20%2Ert%2Dsort%3Aafter%7Bcontent%3A%22%5C2195%22%3Bopacity%3A%2E4%7D%2Ert%2Dkeyboard%2Dactive%20%2Ert%2Dth%5Bdata%2Dsort%2Dhint%3Dascending%5D%3Afocus%20%2Ert%2Dsort%2Dleft%3Aafter%2C%2Ert%2Dkeyboard%2Dactive%20%2Ert%2Dth%5Bdata%2Dsort%2Dhint%3Dascending%5D%3Afocus%20%2Ert%2Dsort%2Dright%3Aafter%7Bcontent%3A%22%5C2191%22%3Bopacity%3A%2E4%7D%2Ert%2Dkeyboard%2Dactive%20%2Ert%2Dth%5Bdata%2Dsort%2Dhint%3Ddescending%5D%3Afocus%20%2Ert%2Dsort%2Dleft%3Aafter%2C%2Ert%2Dkeyboard%2Dactive%20%2Ert%2Dth%5Bdata%2Dsort%2Dhint%3Ddescending%5D%3Afocus%20%2Ert%2Dsort%2Dright%3Aafter%7Bcontent%3A%22%5C2193%22%3Bopacity%3A%2E4%7D%2Ert%2Dexpander%2Dbutton%7Bbackground%3Anone%3Bborder%3Anone%3Bcursor%3Apointer%3Bmargin%3A0%202px%3Bpadding%3A0%7D%2Ert%2Dexpander%7Bcolor%3Atransparent%3Bdisplay%3Ainline%2Dblock%3Boutline%2Dstyle%3Asolid%3Boutline%2Dwidth%3A0%3Bpadding%3A0%208px%3Bposition%3Arelative%7D%2Ert%2Dexpander%3Aafter%7Bborder%2Dleft%3A5%2E04px%20solid%20transparent%3Bborder%2Dright%3A5%2E04px%20solid%20transparent%3Bborder%2Dtop%3A7px%20solid%20rgba%280%2C0%2C0%2C%2E8%29%3Bcontent%3A%22%22%3Bcursor%3Apointer%3Bheight%3A0%3Bleft%3A50%25%3Bposition%3Aabsolute%3Btop%3A50%25%3B%2Dwebkit%2Dtransform%3Atranslate%28%2D50%25%2C%2D50%25%29%20rotate%28%2D90deg%29%3Btransform%3Atranslate%28%2D50%25%2C%2D50%25%29%20rotate%28%2D90deg%29%3B%2Dwebkit%2Dtransition%3Aall%20%2E3s%20cubic%2Dbezier%28%2E175%2C%2E885%2C%2E32%2C1%2E275%29%3Btransition%3Aall%20%2E3s%20cubic%2Dbezier%28%2E175%2C%2E885%2C%2E32%2C1%2E275%29%3Bwidth%3A0%7D%2Ert%2Dexpander%2Ert%2Dexpander%2Dopen%3Aafter%7B%2Dwebkit%2Dtransform%3Atranslate%28%2D50%25%2C%2D50%25%29%20rotate%280%29%3Btransform%3Atranslate%28%2D50%25%2C%2D50%25%29%20rotate%280%29%7D%2Ert%2Dpagination%7B%2Dwebkit%2Dbox%2Dpack%3Ajustify%3B%2Dms%2Dflex%2Dpack%3Ajustify%3B%2Dwebkit%2Dbox%2Dalign%3Abaseline%3B%2Dms%2Dflex%2Dalign%3Abaseline%3Balign%2Ditems%3Abaseline%3Bborder%2Dtop%3A1px%20solid%20%23f2f2f2%3Bdisplay%3A%2Dwebkit%2Dbox%3Bdisplay%3A%2Dms%2Dflexbox%3Bdisplay%3Aflex%3B%2Dms%2Dflex%2Dwrap%3Awrap%3Bflex%2Dwrap%3Awrap%3Bjustify%2Dcontent%3Aspace%2Dbetween%3Bpadding%3A6px%204px%7D%2Ert%2Dbordered%20%2Ert%2Dpagination%2C%2Ert%2Doutlined%20%2Ert%2Dpagination%7Bborder%2Dtop%3Anone%7D%2Ert%2Dpagination%2Dinfo%20%3Anot%28%3Alast%2Dchild%29%7Bmargin%2Dright%3A16px%7D%2Ert%2Dpage%2Dinfo%7Bdisplay%3Ainline%2Dblock%3Bmargin%3A6px%208px%3Bopacity%3A%2E9%7D%2Ert%2Dpage%2Dsize%7Bdisplay%3Ainline%2Dblock%3Bmargin%3A0%208px%7D%2Ert%2Dpage%2Dsize%2Dselect%7Bmargin%3A0%202px%7D%2Ert%2Dpage%2Dbutton%2C%2Ert%2Dpage%2Djump%2C%2Ert%2Dpage%2Dsize%2Dselect%7Bcolor%3Ainherit%3Bfont%2Dfamily%3Ainherit%3Bfont%2Dsize%3Ainherit%3Bline%2Dheight%3Ainherit%7D%2Ert%2Dpage%2Djump%2C%2Ert%2Dpage%2Dsize%2Dselect%7Bbackground%2Dcolor%3A%23fff%3Bborder%3A1px%20solid%20rgba%280%2C0%2C0%2C%2E05%29%3Bborder%2Dradius%3A3px%3Bpadding%3A3px%7D%40supports%20%28%2Dmoz%2Dappearance%3Anone%29%7B%2Ert%2Dpage%2Dsize%2Dselect%7B%2Dmoz%2Dappearance%3Anone%3Bbackground%2Dimage%3Aurl%28%27data%3Aimage%2Fsvg%2Bxml%3Bcharset%3DUS%2DASCII%2C%3Csvg%20width%3D%2224%22%20height%3D%2224%22%20xmlns%3D%22http%3A%2F%2Fwww%2Ew3%2Eorg%2F2000%2Fsvg%22%3E%3Cpath%20fill%3D%22%2523333%22%20d%3D%22M24%201%2E5l%2D12%2021%2D12%2D21h24z%22%2F%3E%3C%2Fsvg%3E%27%29%3Bbackground%2Dposition%3Aright%206px%20center%3Bbackground%2Drepeat%3Ano%2Drepeat%3Bbackground%2Dsize%3A6px%3Bpadding%2Dright%3A12px%7D%7D%2Ert%2Dpage%2Dbutton%7Bbackground%2Dcolor%3Atransparent%3Bborder%3Anone%3Bborder%2Dradius%3A3px%3Bcursor%3Apointer%3Boutline%2Dstyle%3Asolid%3Boutline%2Dwidth%3A0%3Bpadding%3A6px%2012px%7D%2Ert%2Dpage%2Dbutton%3A%3A%2Dmoz%2Dfocus%2Dinner%7Bborder%2Dstyle%3Anone%3Bpadding%3A0%7D%2Ert%2Dpage%2Dbutton%3Adisabled%7Bcursor%3Adefault%3Bopacity%3A%2E6%7D%2Ert%2Dpage%2Dbutton%3Ahover%7Bbackground%2Dcolor%3Argba%280%2C0%2C0%2C%2E04%29%7D%2Ert%2Dpage%2Dbutton%3Aactive%7Bbackground%2Dcolor%3Argba%280%2C0%2C0%2C%2E08%29%7D%2Ert%2Dkeyboard%2Dactive%20%2Ert%2Dpage%2Dbutton%3Afocus%7Bbackground%2Dcolor%3Argba%280%2C0%2C0%2C%2E04%29%7D%2Ert%2Dpage%2Dbutton%3Adisabled%3Afocus%2C%2Ert%2Dpage%2Dbutton%3Adisabled%3Ahover%7Bbackground%2Dcolor%3Atransparent%7D%2Ert%2Dpage%2Dbutton%2Dcurrent%7Bfont%2Dweight%3A700%7D%2Ert%2Dpage%2Dellipsis%7Bmargin%3A0%204px%3Bpointer%2Devents%3Anone%7D%2Ert%2Dpage%2Dnumbers%7Bdisplay%3Ainline%2Dblock%3Bmargin%3A0%208px%3Bwhite%2Dspace%3Anowrap%7D%2Ert%2Dpage%2Djump%7Btext%2Dalign%3Acenter%3Bwidth%3A70px%7D%2Ert%2Dtbody%2Dno%2Ddata%7Bposition%3Arelative%7D%2Ert%2Dtbody%2Dno%2Ddata%20%2Ert%2Dtd%7Bborder%2Dcolor%3Atransparent%7D%2Ert%2Dno%2Ddata%7Bdisplay%3Ablock%3Bleft%3A50%25%3Bline%2Dheight%3A0%3Bposition%3Aabsolute%3Btop%3A50%25%3B%2Dwebkit%2Dtransform%3Atranslate%28%2D50%25%2C%2D50%25%29%3Btransform%3Atranslate%28%2D50%25%2C%2D50%25%29%3Bz%2Dindex%3A1%7D%2Ert%2Dsearch%7B%2Dms%2Dflex%2Ditem%2Dalign%3Aend%3Balign%2Dself%3Aflex%2Dend%3Bbackground%2Dcolor%3A%23fff%3Bborder%3A1px%20solid%20rgba%280%2C0%2C0%2C%2E1%29%3Bborder%2Dradius%3A3px%3Bcolor%3Ainherit%3Bdisplay%3Ablock%3Bfont%2Dfamily%3Ainherit%3Bfont%2Dsize%3Ainherit%3Bmargin%3A0%200%208px%3Boutline%2Dstyle%3Asolid%3Boutline%2Dwidth%3A0%3Bpadding%3A5px%207px%7D%2Ert%2Dsearch%3Aactive%2C%2Ert%2Dsearch%3Afocus%7Bborder%3A1px%20solid%20rgba%280%2C0%2C0%2C%2E25%29%7D%0A" rel="stylesheet" />
<script>!function(){var e={n:function(t){var r=t&&t.__esModule?function(){return t.default}:function(){return t};return e.d(r,{a:r}),r},d:function(t,r){for(var n in r)e.o(r,n)&&!e.o(t,n)&&Object.defineProperty(t,n,{enumerable:!0,get:r[n]})},o:function(e,t){return Object.prototype.hasOwnProperty.call(e,t)},r:function(e){"undefined"!=typeof Symbol&&Symbol.toStringTag&&Object.defineProperty(e,Symbol.toStringTag,{value:"Module"}),Object.defineProperty(e,"__esModule",{value:!0})}},t={};!function(){"use strict";e.r(t),e.d(t,{downloadDataCSV:function(){return qi},getDataCSV:function(){return Zi},getInstance:function(){return _i},getState:function(){return Li},onStateChange:function(){return rl},setAllFilters:function(){return $i},setData:function(){return tl},setFilter:function(){return Vi},setGroupBy:function(){return Xi},setHiddenColumns:function(){return el},setMeta:function(){return Yi},setSearch:function(){return Ui},toggleAllRowsExpanded:function(){return Ji},toggleGroupBy:function(){return Ki},toggleHideColumn:function(){return Qi}});var r={};e.r(r),e.d(r,{between:function(){return it},equals:function(){return at},exact:function(){return ot},exactText:function(){return Ye},exactTextCase:function(){return Qe},includes:function(){return et},includesAll:function(){return tt},includesSome:function(){return rt},includesValue:function(){return nt},text:function(){return Ze}});var n={};e.r(n),e.d(n,{average:function(){return At},count:function(){return Nt},max:function(){return Et},median:function(){return xt},min:function(){return Pt},minMax:function(){return Ct},sum:function(){return jt},unique:function(){return kt},uniqueCount:function(){return It}});var o={};e.r(o),e.d(o,{alphanumeric:function(){return Gt},basic:function(){return Mt},datetime:function(){return zt},number:function(){return Wt},string:function(){return Tt}});var a=window.React,i=e.n(a),l=window.ReactDOM,u=e.n(l);function c(e,t){(null==t||t>e.length)&&(t=e.length);for(var r=0,n=new Array(t);r<t;r++)n[r]=e[r];return n}function s(e,t){if("string"==typeof t)return t;if(t.name[0]===t.name[0].toUpperCase()&&!e[t.name])throw new Error("Unknown component: "+t.name);var r,n=[e[t.name]||t.name,t.attribs],o=function(e,t){var r="undefined"!=typeof Symbol&&e[Symbol.iterator]||e["@@iterator"];if(!r){if(Array.isArray(e)||(r=function(e,t){if(e){if("string"==typeof e)return c(e,t);var r=Object.prototype.toString.call(e).slice(8,-1);return"Object"===r&&e.constructor&&(r=e.constructor.name),"Map"===r||"Set"===r?Array.from(e):"Arguments"===r||/^(?:Ui|I)nt(?:8|16|32)(?:Clamped)?Array$/.test(r)?c(e,t):void 0}}(e))||t&&e&&"number"==typeof e.length){r&&(e=r);var n=0,o=function(){};return{s:o,n:function(){return n>=e.length?{done:!0}:{done:!1,value:e[n++]}},e:function(e){throw e},f:o}}throw new TypeError("Invalid attempt to iterate non-iterable instance.\nIn order to be iterable, non-array objects must have a [Symbol.iterator]() method.")}var a,i=!0,l=!1;return{s:function(){r=r.call(e)},n:function(){var e=r.next();return i=e.done,e},e:function(e){l=!0,a=e},f:function(){try{i||null==r.return||r.return()}finally{if(l)throw a}}}}(t.children);try{for(o.s();!(r=o.n()).done;){var a=r.value;n.push(s(e,a))}}catch(e){o.e(e)}finally{o.f()}return i().createElement.apply(i(),n)}var f=["style","className"];function d(e){return d="function"==typeof Symbol&&"symbol"==typeof Symbol.iterator?function(e){return typeof e}:function(e){return e&&"function"==typeof Symbol&&e.constructor===Symbol&&e!==Symbol.prototype?"symbol":typeof e},d(e)}function p(e){return function(e){if(Array.isArray(e))return g(e)}(e)||function(e){if("undefined"!=typeof Symbol&&null!=e[Symbol.iterator]||null!=e["@@iterator"])return Array.from(e)}(e)||function(e,t){if(e){if("string"==typeof e)return g(e,t);var r=Object.prototype.toString.call(e).slice(8,-1);return"Object"===r&&e.constructor&&(r=e.constructor.name),"Map"===r||"Set"===r?Array.from(e):"Arguments"===r||/^(?:Ui|I)nt(?:8|16|32)(?:Clamped)?Array$/.test(r)?g(e,t):void 0}}(e)||function(){throw new TypeError("Invalid attempt to spread non-iterable instance.\nIn order to be iterable, non-array objects must have a [Symbol.iterator]() method.")}()}function g(e,t){(null==t||t>e.length)&&(t=e.length);for(var r=0,n=new Array(t);r<t;r++)n[r]=e[r];return n}function y(e,t){var r=Object.keys(e);if(Object.getOwnPropertySymbols){var n=Object.getOwnPropertySymbols(e);t&&(n=n.filter((function(t){return Object.getOwnPropertyDescriptor(e,t).enumerable}))),r.push.apply(r,n)}return r}function m(e){for(var t=1;t<arguments.length;t++){var r=null!=arguments[t]?arguments[t]:{};t%2?y(Object(r),!0).forEach((function(t){h(e,t,r[t])})):Object.getOwnPropertyDescriptors?Object.defineProperties(e,Object.getOwnPropertyDescriptors(r)):y(Object(r)).forEach((function(t){Object.defineProperty(e,t,Object.getOwnPropertyDescriptor(r,t))}))}return e}function h(e,t,r){return t in e?Object.defineProperty(e,t,{value:r,enumerable:!0,configurable:!0,writable:!0}):e[t]=r,e}function b(e,t){if(null==e)return{};var r,n,o=function(e,t){if(null==e)return{};var r,n,o={},a=Object.keys(e);for(n=0;n<a.length;n++)r=a[n],t.indexOf(r)>=0||(o[r]=e[r]);return o}(e,t);if(Object.getOwnPropertySymbols){var a=Object.getOwnPropertySymbols(e);for(n=0;n<a.length;n++)r=a[n],t.indexOf(r)>=0||Object.prototype.propertyIsEnumerable.call(e,r)&&(o[r]=e[r])}return o}var v="Renderer Error ☝️",w={init:"init"},S=function(){return i().createElement(i().Fragment,null," ")},O={Cell:function(e){var t=e.value;return void 0===t?"":t},width:150,minWidth:0,maxWidth:Number.MAX_SAFE_INTEGER};function R(){for(var e=arguments.length,t=new Array(e),r=0;r<e;r++)t[r]=arguments[r];return t.reduce((function(e,t){var r=t.style,n=t.className,o=b(t,f);return e=m(m({},e),o),r&&(e.style=e.style?m(m({},e.style||{}),r||{}):r),n&&(e.className=e.className?e.className+" "+n:n),""===e.className&&delete e.className,e}),{})}function j(e,t,r){return"function"==typeof t?j({},t(e,r)):Array.isArray(t)?R.apply(void 0,[e].concat(p(t))):R(e,t)}var P=function(e){var t=arguments.length>1&&void 0!==arguments[1]?arguments[1]:{};return function(){var r=arguments.length>0&&void 0!==arguments[0]?arguments[0]:{};return[].concat(p(e),[r]).reduce((function(e,n){return j(e,n,m(m({},t),{},{userProps:r}))}),{})}},E=function(e,t){var r=arguments.length>2&&void 0!==arguments[2]?arguments[2]:{};return e.reduce((function(e,t){return t(e,r)}),t)},C=function(e,t){var r=arguments.length>2&&void 0!==arguments[2]?arguments[2]:{};return e.forEach((function(e){e(t,r)}))};function A(e,t,r,n){e.findIndex((function(e){return e.pluginName===r})),t.forEach((function(t){e.findIndex((function(e){return e.pluginName===t}))}))}function x(e,t){return"function"==typeof e?e(t):e}function k(e){var t=i().useRef();return t.current=e,i().useCallback((function(){return t.current}),[])}var I="undefined"!=typeof document?i().useLayoutEffect:i().useEffect;function N(e,t){var r=i().useRef(!1);I((function(){r.current&&e(),r.current=!0}),t)}function B(e,t){var r=arguments.length>2&&void 0!==arguments[2]?arguments[2]:{};return function(n){var o=arguments.length>1&&void 0!==arguments[1]?arguments[1]:{},a="string"==typeof n?t[n]:n;if(void 0===a)throw console.info(t),new Error(v);return F(a,m(m(m({},e),{},{column:t},r),o))}}function F(e,t){return function(e){return"function"==typeof e&&(t=Object.getPrototypeOf(e)).prototype&&t.prototype.isReactComponent;var t}(r=e)||"function"==typeof r||function(e){return"object"===d(e)&&"symbol"===d(e.$$typeof)&&["react.memo","react.forward_ref"].includes(e.$$typeof.description)}(r)?i().createElement(e,t):e;var r}function D(e,t){var r=Object.keys(e);if(Object.getOwnPropertySymbols){var n=Object.getOwnPropertySymbols(e);t&&(n=n.filter((function(t){return Object.getOwnPropertyDescriptor(e,t).enumerable}))),r.push.apply(r,n)}return r}function G(e){for(var t=1;t<arguments.length;t++){var r=null!=arguments[t]?arguments[t]:{};t%2?D(Object(r),!0).forEach((function(t){z(e,t,r[t])})):Object.getOwnPropertyDescriptors?Object.defineProperties(e,Object.getOwnPropertyDescriptors(r)):D(Object(r)).forEach((function(t){Object.defineProperty(e,t,Object.getOwnPropertyDescriptor(r,t))}))}return e}function z(e,t,r){return t in e?Object.defineProperty(e,t,{value:r,enumerable:!0,configurable:!0,writable:!0}):e[t]=r,e}function M(e,t){var r=arguments.length>2&&void 0!==arguments[2]?arguments[2]:0;return e.map((function(e){return W(e=G(G({},e),{},{parent:t,depth:r})),e.columns&&(e.columns=M(e.columns,e,r+1)),e}))}function T(e){return t="columns",r=[],function e(n){n.forEach((function(n){n[t]?e(n[t]):r.push(n)}))}(e),r;var t,r}function W(e){var t=e.id,r=e.accessor,n=e.Header;if("string"==typeof r){t=t||r;var o=r.split(".");r=function(e){return function(e,t,r){if(!t)return e;var n,o="function"==typeof t?t:JSON.stringify(t),a=L.get(o)||function(){var e=function(e){return Y(e).map((function(e){return String(e).replace(".","_")})).join(".").replace(q,".").replace(Z,"").split(".")}(t);return L.set(o,e),e}();try{n=a.reduce((function(e,t){return e[t]}),e)}catch(e){}return void 0!==n?n:void 0}(e,o)}}if(!t&&"string"==typeof n&&n&&(t=n),!t&&e.columns)throw console.error(e),new Error('A column ID (or unique "Header" value) is required!');if(!t)throw console.error(e),new Error("A column ID (or string accessor) is required!");return Object.assign(e,{id:t,accessor:r}),e}function H(e,t){if(!t)throw new Error;return Object.assign(e,G(G(G({Header:S,Footer:S},O),t),e)),Object.assign(e,{originalWidth:e.width}),e}function _(e,t){for(var r=arguments.length>2&&void 0!==arguments[2]?arguments[2]:function(){return{}},n=[],o=e,a=0,i=function(){return a++},l=function(){var e={headers:[]},a=[],l=o.some((function(e){return e.parent}));o.forEach((function(n){var o,u=[].concat(a).reverse()[0];l&&(o=n.parent?G(G({},n.parent),{},{originalId:n.parent.id,id:"".concat(n.parent.id,"_").concat(i()),headers:[n]},r(n)):H(G({originalId:"".concat(n.id,"_placeholder"),id:"".concat(n.id,"_placeholder_").concat(i()),placeholderOf:n,headers:[n]},r(n)),t),u&&u.originalId===o.originalId?u.headers.push(n):a.push(o)),e.headers.push(n)})),n.push(e),o=a};o.length;)l();return n.reverse()}var L=new Map;function V(){for(var e=arguments.length,t=new Array(e),r=0;r<e;r++)t[r]=arguments[r];for(var n=0;n<t.length;n+=1)if(void 0!==t[n])return t[n]}function $(e){if("function"==typeof e)return e}function U(e,t){var r=t.manualExpandedKey,n=t.expanded,o=t.expandSubRows,a=void 0===o||o,i=[],l=function e(t){var o=!(arguments.length>1&&void 0!==arguments[1])||arguments[1];t.isExpanded=t.original&&t.original[r]||n[t.id],t.canExpand=t.subRows&&!!t.subRows.length,o&&i.push(t),t.subRows&&t.subRows.length&&t.isExpanded&&t.subRows.forEach((function(t){return e(t,a)}))};return e.forEach((function(e){return l(e)})),i}function K(e,t,r){return $(e)||t[e]||r[e]||r.text}function X(e,t,r){return e?e(t,r):void 0===t}function J(){throw new Error("React-Table: You have not called prepareRow(row) one or more rows you are attempting to render.")}var q=/\[/g,Z=/\]/g;function Y(e){var t=arguments.length>1&&void 0!==arguments[1]?arguments[1]:[];if(Array.isArray(e))for(var r=0;r<e.length;r+=1)Y(e[r],t);else t.push(e);return t}function Q(e,t){var r=Object.keys(e);if(Object.getOwnPropertySymbols){var n=Object.getOwnPropertySymbols(e);t&&(n=n.filter((function(t){return Object.getOwnPropertyDescriptor(e,t).enumerable}))),r.push.apply(r,n)}return r}function ee(e){for(var t=1;t<arguments.length;t++){var r=null!=arguments[t]?arguments[t]:{};t%2?Q(Object(r),!0).forEach((function(t){te(e,t,r[t])})):Object.getOwnPropertyDescriptors?Object.defineProperties(e,Object.getOwnPropertyDescriptors(r)):Q(Object(r)).forEach((function(t){Object.defineProperty(e,t,Object.getOwnPropertyDescriptor(r,t))}))}return e}function te(e,t,r){return t in e?Object.defineProperty(e,t,{value:r,enumerable:!0,configurable:!0,writable:!0}):e[t]=r,e}var re=function(e){return ee({role:"table"},e)},ne=function(e){return ee({role:"rowgroup"},e)},oe=function(e,t){var r=t.column;return ee({key:"header_".concat(r.id),colSpan:r.totalVisibleHeaderCount,role:"columnheader"},e)},ae=function(e,t){var r=t.column;return ee({key:"footer_".concat(r.id),colSpan:r.totalVisibleHeaderCount},e)},ie=function(e,t){var r=t.index;return ee({key:"headerGroup_".concat(r),role:"row"},e)},le=function(e,t){var r=t.index;return ee({key:"footerGroup_".concat(r)},e)},ue=function(e,t){var r=t.row;return ee({key:"row_".concat(r.id),role:"row"},e)},ce=function(e,t){var r=t.cell;return ee({key:"cell_".concat(r.row.id,"_").concat(r.column.id),role:"cell"},e)};function se(){return{useOptions:[],stateReducers:[],useControlledState:[],columns:[],columnsDeps:[],allColumns:[],allColumnsDeps:[],accessValue:[],materializedColumns:[],materializedColumnsDeps:[],useInstanceAfterData:[],visibleColumns:[],visibleColumnsDeps:[],headerGroups:[],headerGroupsDeps:[],useInstanceBeforeDimensions:[],useInstance:[],prepareRow:[],getTableProps:[re],getTableBodyProps:[ne],getHeaderGroupProps:[ie],getFooterGroupProps:[le],getHeaderProps:[oe],getFooterProps:[ae],getRowProps:[ue],getCellProps:[ce],useFinalInstance:[]}}function fe(e,t){var r=Object.keys(e);if(Object.getOwnPropertySymbols){var n=Object.getOwnPropertySymbols(e);t&&(n=n.filter((function(t){return Object.getOwnPropertyDescriptor(e,t).enumerable}))),r.push.apply(r,n)}return r}function de(e){for(var t=1;t<arguments.length;t++){var r=null!=arguments[t]?arguments[t]:{};t%2?fe(Object(r),!0).forEach((function(t){pe(e,t,r[t])})):Object.getOwnPropertyDescriptors?Object.defineProperties(e,Object.getOwnPropertyDescriptors(r)):fe(Object(r)).forEach((function(t){Object.defineProperty(e,t,Object.getOwnPropertyDescriptor(r,t))}))}return e}function pe(e,t,r){return t in e?Object.defineProperty(e,t,{value:r,enumerable:!0,configurable:!0,writable:!0}):e[t]=r,e}function ge(e){return function(e){if(Array.isArray(e))return ye(e)}(e)||function(e){if("undefined"!=typeof Symbol&&null!=e[Symbol.iterator]||null!=e["@@iterator"])return Array.from(e)}(e)||function(e,t){if(e){if("string"==typeof e)return ye(e,t);var r=Object.prototype.toString.call(e).slice(8,-1);return"Object"===r&&e.constructor&&(r=e.constructor.name),"Map"===r||"Set"===r?Array.from(e):"Arguments"===r||/^(?:Ui|I)nt(?:8|16|32)(?:Clamped)?Array$/.test(r)?ye(e,t):void 0}}(e)||function(){throw new TypeError("Invalid attempt to spread non-iterable instance.\nIn order to be iterable, non-array objects must have a [Symbol.iterator]() method.")}()}function ye(e,t){(null==t||t>e.length)&&(t=e.length);for(var r=0,n=new Array(t);r<t;r++)n[r]=e[r];return n}w.resetHiddenColumns="resetHiddenColumns",w.toggleHideColumn="toggleHideColumn",w.setHiddenColumns="setHiddenColumns",w.toggleHideAllColumns="toggleHideAllColumns";var me=function(e){e.getToggleHiddenProps=[he],e.getToggleHideAllColumnsProps=[be],e.stateReducers.push(ve),e.useInstanceBeforeDimensions.push(we),e.headerGroupsDeps.push((function(e,t){var r=t.instance;return[].concat(ge(e),[r.state.hiddenColumns])})),e.useInstance.push(Se)};me.pluginName="useColumnVisibility";var he=function(e,t){var r=t.column;return[e,{onChange:function(e){r.toggleHidden(!e.target.checked)},style:{cursor:"pointer"},checked:r.isVisible,title:"Toggle Column Visible"}]},be=function(e,t){var r=t.instance;return[e,{onChange:function(e){r.toggleHideAllColumns(!e.target.checked)},style:{cursor:"pointer"},checked:!r.allColumnsHidden&&!r.state.hiddenColumns.length,title:"Toggle All Columns Hidden",indeterminate:!r.allColumnsHidden&&r.state.hiddenColumns.length}]};function ve(e,t,r,n){if(t.type===w.init)return de({hiddenColumns:[]},e);if(t.type===w.resetHiddenColumns)return de(de({},e),{},{hiddenColumns:n.initialState.hiddenColumns||[]});if(t.type===w.toggleHideColumn){var o=(void 0!==t.value?t.value:!e.hiddenColumns.includes(t.columnId))?[].concat(ge(e.hiddenColumns),[t.columnId]):e.hiddenColumns.filter((function(e){return e!==t.columnId}));return de(de({},e),{},{hiddenColumns:o})}if(t.type===w.setHiddenColumns)return de(de({},e),{},{hiddenColumns:x(t.value,e.hiddenColumns)});if(t.type===w.toggleHideAllColumns){var a=void 0!==t.value?t.value:!e.hiddenColumns.length;return de(de({},e),{},{hiddenColumns:a?n.allColumns.map((function(e){return e.id})):[]})}}function we(e){var t=e.headers,r=e.state.hiddenColumns;i().useRef(!1).current;var n=function e(t,n){t.isVisible=n&&!r.includes(t.id);var o=0;return t.headers&&t.headers.length?t.headers.forEach((function(r){return o+=e(r,t.isVisible)})):o=t.isVisible?1:0,t.totalVisibleHeaderCount=o,o},o=0;t.forEach((function(e){return o+=n(e,!0)}))}function Se(e){var t=e.columns,r=e.flatHeaders,n=e.dispatch,o=e.allColumns,a=e.getHooks,l=e.state.hiddenColumns,u=e.autoResetHiddenColumns,c=void 0===u||u,s=k(e),f=o.length===l.length,d=i().useCallback((function(e,t){return n({type:w.toggleHideColumn,columnId:e,value:t})}),[n]),p=i().useCallback((function(e){return n({type:w.setHiddenColumns,value:e})}),[n]),g=i().useCallback((function(e){return n({type:w.toggleHideAllColumns,value:e})}),[n]),y=P(a().getToggleHideAllColumnsProps,{instance:s()});r.forEach((function(e){e.toggleHidden=function(t){n({type:w.toggleHideColumn,columnId:e.id,value:t})},e.getToggleHiddenProps=P(a().getToggleHiddenProps,{instance:s(),column:e})}));var m=k(c);N((function(){m()&&n({type:w.resetHiddenColumns})}),[n,t]),Object.assign(e,{allColumnsHidden:f,toggleHideColumn:d,setHiddenColumns:p,toggleHideAllColumns:g,getToggleHideAllColumnsProps:y})}var Oe=["initialState","defaultColumn","getSubRows","getRowId","stateReducer","useControlledState"];function Re(e,t){return function(e){if(Array.isArray(e))return e}(e)||function(e,t){var r=null==e?null:"undefined"!=typeof Symbol&&e[Symbol.iterator]||e["@@iterator"];if(null!=r){var n,o,a=[],i=!0,l=!1;try{for(r=r.call(e);!(i=(n=r.next()).done)&&(a.push(n.value),!t||a.length!==t);i=!0);}catch(e){l=!0,o=e}finally{try{i||null==r.return||r.return()}finally{if(l)throw o}}return a}}(e,t)||Pe(e,t)||function(){throw new TypeError("Invalid attempt to destructure non-iterable instance.\nIn order to be iterable, non-array objects must have a [Symbol.iterator]() method.")}()}function je(e){return function(e){if(Array.isArray(e))return Ee(e)}(e)||function(e){if("undefined"!=typeof Symbol&&null!=e[Symbol.iterator]||null!=e["@@iterator"])return Array.from(e)}(e)||Pe(e)||function(){throw new TypeError("Invalid attempt to spread non-iterable instance.\nIn order to be iterable, non-array objects must have a [Symbol.iterator]() method.")}()}function Pe(e,t){if(e){if("string"==typeof e)return Ee(e,t);var r=Object.prototype.toString.call(e).slice(8,-1);return"Object"===r&&e.constructor&&(r=e.constructor.name),"Map"===r||"Set"===r?Array.from(e):"Arguments"===r||/^(?:Ui|I)nt(?:8|16|32)(?:Clamped)?Array$/.test(r)?Ee(e,t):void 0}}function Ee(e,t){(null==t||t>e.length)&&(t=e.length);for(var r=0,n=new Array(t);r<t;r++)n[r]=e[r];return n}function Ce(e,t){var r=Object.keys(e);if(Object.getOwnPropertySymbols){var n=Object.getOwnPropertySymbols(e);t&&(n=n.filter((function(t){return Object.getOwnPropertyDescriptor(e,t).enumerable}))),r.push.apply(r,n)}return r}function Ae(e){for(var t=1;t<arguments.length;t++){var r=null!=arguments[t]?arguments[t]:{};t%2?Ce(Object(r),!0).forEach((function(t){xe(e,t,r[t])})):Object.getOwnPropertyDescriptors?Object.defineProperties(e,Object.getOwnPropertyDescriptors(r)):Ce(Object(r)).forEach((function(t){Object.defineProperty(e,t,Object.getOwnPropertyDescriptor(r,t))}))}return e}function xe(e,t,r){return t in e?Object.defineProperty(e,t,{value:r,enumerable:!0,configurable:!0,writable:!0}):e[t]=r,e}var ke={},Ie={},Ne=function(e,t,r){return e},Be=function(e,t){return e.subRows||[]},Fe=function(e,t,r){return"".concat(r?[r.id,t].join("."):t)},De=function(e){return e};function Ge(e){var t=e.initialState,r=void 0===t?ke:t,n=e.defaultColumn,o=void 0===n?Ie:n,a=e.getSubRows,i=void 0===a?Be:a,l=e.getRowId,u=void 0===l?Fe:l,c=e.stateReducer,s=void 0===c?Ne:c,f=e.useControlledState,d=void 0===f?De:f;return Ae(Ae({},function(e,t){if(null==e)return{};var r,n,o=function(e,t){if(null==e)return{};var r,n,o={},a=Object.keys(e);for(n=0;n<a.length;n++)r=a[n],t.indexOf(r)>=0||(o[r]=e[r]);return o}(e,t);if(Object.getOwnPropertySymbols){var a=Object.getOwnPropertySymbols(e);for(n=0;n<a.length;n++)r=a[n],t.indexOf(r)>=0||Object.prototype.propertyIsEnumerable.call(e,r)&&(o[r]=e[r])}return o}(e,Oe)),{},{initialState:r,defaultColumn:o,getSubRows:i,getRowId:u,stateReducer:s,useControlledState:d})}function ze(e){var t=arguments.length>1&&void 0!==arguments[1]?arguments[1]:0,r=0,n=0,o=0,a=0;return e.forEach((function(e){var i=e.headers;if(e.totalLeft=t,i&&i.length){var l=Re(ze(i,t),4),u=l[0],c=l[1],s=l[2],f=l[3];e.totalMinWidth=u,e.totalWidth=c,e.totalMaxWidth=s,e.totalFlexWidth=f}else e.totalMinWidth=e.minWidth,e.totalWidth=Math.min(Math.max(e.minWidth,e.width),e.maxWidth),e.totalMaxWidth=e.maxWidth,e.totalFlexWidth=e.canResize?e.totalWidth:0;e.isVisible&&(t+=e.totalWidth,r+=e.totalMinWidth,n+=e.totalWidth,o+=e.totalMaxWidth,a+=e.totalFlexWidth)})),[r,n,o,a]}function Me(e){var t=e.data,r=e.rows,n=e.flatRows,o=e.rowsById,a=e.column,i=e.getRowId,l=e.getSubRows,u=e.accessValueHooks,c=e.getInstance,s=function e(r,s){var f=arguments.length>2&&void 0!==arguments[2]?arguments[2]:0,d=arguments.length>3?arguments[3]:void 0,p=arguments.length>4?arguments[4]:void 0,g=r,y=i(r,s,d),m=o[y];if(m)m.subRows&&m.originalSubRows.forEach((function(t,r){return e(t,r,f+1,m)}));else if((m={id:y,original:g,index:s,depth:f,cells:[{}]}).cells.map=J,m.cells.filter=J,m.cells.forEach=J,m.cells[0].getCellProps=J,m.values={},p.push(m),n.push(m),o[y]=m,m.originalSubRows=l(r,s),m.originalSubRows){var h=[];m.originalSubRows.forEach((function(t,r){return e(t,r,f+1,m,h)})),m.subRows=h}a.accessor&&(m.values[a.id]=a.accessor(r,s,m,p,t)),m.values[a.id]=E(u,m.values[a.id],{row:m,column:a,instance:c()},!0)};t.forEach((function(e,t){return s(e,t,0,void 0,r)}))}function Te(e){return Te="function"==typeof Symbol&&"symbol"==typeof Symbol.iterator?function(e){return typeof e}:function(e){return e&&"function"==typeof Symbol&&e.constructor===Symbol&&e!==Symbol.prototype?"symbol":typeof e},Te(e)}function We(e){var t=function(e,t){if("object"!==Te(e)||null===e)return e;var r=e[Symbol.toPrimitive];if(void 0!==r){var n=r.call(e,t);if("object"!==Te(n))return n;throw new TypeError("@@toPrimitive must return a primitive value.")}return String(e)}(e,"string");return"symbol"===Te(t)?t:String(t)}function He(e,t){var r=Object.keys(e);if(Object.getOwnPropertySymbols){var n=Object.getOwnPropertySymbols(e);t&&(n=n.filter((function(t){return Object.getOwnPropertyDescriptor(e,t).enumerable}))),r.push.apply(r,n)}return r}function _e(e){for(var t=1;t<arguments.length;t++){var r=null!=arguments[t]?arguments[t]:{};t%2?He(Object(r),!0).forEach((function(t){Le(e,t,r[t])})):Object.getOwnPropertyDescriptors?Object.defineProperties(e,Object.getOwnPropertyDescriptors(r)):He(Object(r)).forEach((function(t){Object.defineProperty(e,t,Object.getOwnPropertyDescriptor(r,t))}))}return e}function Le(e,t,r){return t in e?Object.defineProperty(e,t,{value:r,enumerable:!0,configurable:!0,writable:!0}):e[t]=r,e}w.resetExpanded="resetExpanded",w.toggleRowExpanded="toggleRowExpanded",w.toggleAllRowsExpanded="toggleAllRowsExpanded";var Ve=function(e){e.getToggleAllRowsExpandedProps=[$e],e.getToggleRowExpandedProps=[Ue],e.stateReducers.push(Ke),e.useInstance.push(Xe),e.prepareRow.push(Je)};Ve.pluginName="useExpanded";var $e=function(e,t){var r=t.instance;return[e,{onClick:function(e){r.toggleAllRowsExpanded()},style:{cursor:"pointer"},title:"Toggle All Rows Expanded"}]},Ue=function(e,t){var r=t.row;return[e,{onClick:function(){r.toggleRowExpanded()},style:{cursor:"pointer"},title:"Toggle Row Expanded"}]};function Ke(e,t,r,n){if(t.type===w.init)return _e({expanded:{}},e);if(t.type===w.resetExpanded)return _e(_e({},e),{},{expanded:n.initialState.expanded||{}});if(t.type===w.toggleAllRowsExpanded){var o=t.value,a=n.rowsById,i=Object.keys(a).length===Object.keys(e.expanded).length;if(void 0!==o?o:!i){var l={};return Object.keys(a).forEach((function(e){l[e]=!0})),_e(_e({},e),{},{expanded:l})}return _e(_e({},e),{},{expanded:{}})}if(t.type===w.toggleRowExpanded){var u=t.id,c=t.value,s=e.expanded[u],f=void 0!==c?c:!s;if(!s&&f)return _e(_e({},e),{},{expanded:_e(_e({},e.expanded),{},Le({},u,!0))});if(s&&!f){var d=e.expanded,p=(d[u],function(e,t){if(null==e)return{};var r,n,o=function(e,t){if(null==e)return{};var r,n,o={},a=Object.keys(e);for(n=0;n<a.length;n++)r=a[n],t.indexOf(r)>=0||(o[r]=e[r]);return o}(e,t);if(Object.getOwnPropertySymbols){var a=Object.getOwnPropertySymbols(e);for(n=0;n<a.length;n++)r=a[n],t.indexOf(r)>=0||Object.prototype.propertyIsEnumerable.call(e,r)&&(o[r]=e[r])}return o}(d,[u].map(We)));return _e(_e({},e),{},{expanded:p})}return e}}function Xe(e){var t=e.data,r=e.rows,n=e.rowsById,o=e.manualExpandedKey,a=void 0===o?"expanded":o,l=e.paginateExpandedRows,u=void 0===l||l,c=e.expandSubRows,s=void 0===c||c,f=e.autoResetExpanded,d=void 0===f||f,p=e.getHooks,g=e.plugins,y=e.state.expanded,m=e.dispatch;A(g,["useSortBy","useGroupBy","usePivotColumns","useGlobalFilter"],"useExpanded");var h=k(d),b=Boolean(Object.keys(n).length&&Object.keys(y).length);b&&Object.keys(n).some((function(e){return!y[e]}))&&(b=!1),N((function(){h()&&m({type:w.resetExpanded})}),[m,t]);var v=i().useCallback((function(e,t){m({type:w.toggleRowExpanded,id:e,value:t})}),[m]),S=i().useCallback((function(e){return m({type:w.toggleAllRowsExpanded,value:e})}),[m]),O=i().useMemo((function(){return u?U(r,{manualExpandedKey:a,expanded:y,expandSubRows:s}):r}),[u,r,a,y,s]),R=i().useMemo((function(){return function(e){var t=0;return Object.keys(e).forEach((function(e){var r=e.split(".");t=Math.max(t,r.length)})),t}(y)}),[y]),j=k(e),E=P(p().getToggleAllRowsExpandedProps,{instance:j()});Object.assign(e,{preExpandedRows:r,expandedRows:O,rows:O,expandedDepth:R,isAllRowsExpanded:b,toggleRowExpanded:v,toggleAllRowsExpanded:S,getToggleAllRowsExpandedProps:E})}function Je(e,t){var r=t.instance.getHooks,n=t.instance;e.toggleRowExpanded=function(t){return n.toggleRowExpanded(e.id,t)},e.getToggleRowExpandedProps=P(r().getToggleRowExpandedProps,{instance:n,row:e})}function qe(e,t){(null==t||t>e.length)&&(t=e.length);for(var r=0,n=new Array(t);r<t;r++)n[r]=e[r];return n}var Ze=function(e,t,r){return e.filter((function(e){return t.some((function(t){var n=e.values[t];return String(n).toLowerCase().includes(String(r).toLowerCase())}))}))};Ze.autoRemove=function(e){return!e};var Ye=function(e,t,r){return e.filter((function(e){return t.some((function(t){var n=e.values[t];return void 0===n||String(n).toLowerCase()===String(r).toLowerCase()}))}))};Ye.autoRemove=function(e){return!e};var Qe=function(e,t,r){return e.filter((function(e){return t.some((function(t){var n=e.values[t];return void 0===n||String(n)===String(r)}))}))};Qe.autoRemove=function(e){return!e};var et=function(e,t,r){return e.filter((function(e){return t.some((function(t){return e.values[t].includes(r)}))}))};et.autoRemove=function(e){return!e||!e.length};var tt=function(e,t,r){return e.filter((function(e){return t.some((function(t){var n=e.values[t];return n&&n.length&&r.every((function(e){return n.includes(e)}))}))}))};tt.autoRemove=function(e){return!e||!e.length};var rt=function(e,t,r){return e.filter((function(e){return t.some((function(t){var n=e.values[t];return n&&n.length&&r.some((function(e){return n.includes(e)}))}))}))};rt.autoRemove=function(e){return!e||!e.length};var nt=function(e,t,r){return e.filter((function(e){return t.some((function(t){var n=e.values[t];return r.includes(n)}))}))};nt.autoRemove=function(e){return!e||!e.length};var ot=function(e,t,r){return e.filter((function(e){return t.some((function(t){return e.values[t]===r}))}))};ot.autoRemove=function(e){return void 0===e};var at=function(e,t,r){return e.filter((function(e){return t.some((function(t){return e.values[t]==r}))}))};at.autoRemove=function(e){return null==e};var it=function(e,t,r){var n=function(e,t){return function(e){if(Array.isArray(e))return e}(e)||function(e,t){var r=null==e?null:"undefined"!=typeof Symbol&&e[Symbol.iterator]||e["@@iterator"];if(null!=r){var n,o,a=[],i=!0,l=!1;try{for(r=r.call(e);!(i=(n=r.next()).done)&&(a.push(n.value),!t||a.length!==t);i=!0);}catch(e){l=!0,o=e}finally{try{i||null==r.return||r.return()}finally{if(l)throw o}}return a}}(e,t)||function(e,t){if(e){if("string"==typeof e)return qe(e,t);var r=Object.prototype.toString.call(e).slice(8,-1);return"Object"===r&&e.constructor&&(r=e.constructor.name),"Map"===r||"Set"===r?Array.from(e):"Arguments"===r||/^(?:Ui|I)nt(?:8|16|32)(?:Clamped)?Array$/.test(r)?qe(e,t):void 0}}(e,t)||function(){throw new TypeError("Invalid attempt to destructure non-iterable instance.\nIn order to be iterable, non-array objects must have a [Symbol.iterator]() method.")}()}(r||[],2),o=n[0],a=n[1];if((o="number"==typeof o?o:-1/0)>(a="number"==typeof a?a:1/0)){var i=o;o=a,a=i}return e.filter((function(e){return t.some((function(t){var r=e.values[t];return r>=o&&r<=a}))}))};function lt(e,t){if(e){if("string"==typeof e)return ut(e,t);var r=Object.prototype.toString.call(e).slice(8,-1);return"Object"===r&&e.constructor&&(r=e.constructor.name),"Map"===r||"Set"===r?Array.from(e):"Arguments"===r||/^(?:Ui|I)nt(?:8|16|32)(?:Clamped)?Array$/.test(r)?ut(e,t):void 0}}function ut(e,t){(null==t||t>e.length)&&(t=e.length);for(var r=0,n=new Array(t);r<t;r++)n[r]=e[r];return n}function ct(e,t){var r=Object.keys(e);if(Object.getOwnPropertySymbols){var n=Object.getOwnPropertySymbols(e);t&&(n=n.filter((function(t){return Object.getOwnPropertyDescriptor(e,t).enumerable}))),r.push.apply(r,n)}return r}function st(e){for(var t=1;t<arguments.length;t++){var r=null!=arguments[t]?arguments[t]:{};t%2?ct(Object(r),!0).forEach((function(t){ft(e,t,r[t])})):Object.getOwnPropertyDescriptors?Object.defineProperties(e,Object.getOwnPropertyDescriptors(r)):ct(Object(r)).forEach((function(t){Object.defineProperty(e,t,Object.getOwnPropertyDescriptor(r,t))}))}return e}function ft(e,t,r){return t in e?Object.defineProperty(e,t,{value:r,enumerable:!0,configurable:!0,writable:!0}):e[t]=r,e}it.autoRemove=function(e){return!e||"number"!=typeof e[0]&&"number"!=typeof e[1]},w.resetFilters="resetFilters",w.setFilter="setFilter",w.setAllFilters="setAllFilters";var dt=function(e){e.stateReducers.push(pt),e.useInstance.push(gt)};function pt(e,t,n,o){if(t.type===w.init)return st({filters:[]},e);if(t.type===w.resetFilters)return st(st({},e),{},{filters:o.initialState.filters||[]});if(t.type===w.setFilter){var a=t.columnId,i=t.filterValue,l=o.allColumns,u=o.filterTypes,c=l.find((function(e){return e.id===a}));if(!c)throw new Error("React-Table: Could not find a column with id: ".concat(a));var s=K(c.filter,u||{},r),f=e.filters.find((function(e){return e.id===a})),d=x(i,f&&f.value);return X(s.autoRemove,d,c)?st(st({},e),{},{filters:e.filters.filter((function(e){return e.id!==a}))}):st(st({},e),{},f?{filters:e.filters.map((function(e){return e.id===a?{id:a,value:d}:e}))}:{filters:[].concat((p=e.filters,function(e){if(Array.isArray(e))return ut(e)}(p)||function(e){if("undefined"!=typeof Symbol&&null!=e[Symbol.iterator]||null!=e["@@iterator"])return Array.from(e)}(p)||lt(p)||function(){throw new TypeError("Invalid attempt to spread non-iterable instance.\nIn order to be iterable, non-array objects must have a [Symbol.iterator]() method.")}()),[{id:a,value:d}])})}var p;if(t.type===w.setAllFilters){var g=t.filters,y=o.allColumns,m=o.filterTypes;return st(st({},e),{},{filters:x(g,e.filters).filter((function(e){var t=y.find((function(t){return t.id===e.id}));return!X(K(t.filter,m||{},r).autoRemove,e.value,t)}))})}}function gt(e){var t=e.data,n=e.rows,o=e.flatRows,a=e.rowsById,l=e.allColumns,u=e.filterTypes,c=e.manualFilters,s=e.defaultCanFilter,f=void 0!==s&&s,d=e.disableFilters,p=e.state.filters,g=e.dispatch,y=e.autoResetFilters,m=void 0===y||y,h=i().useCallback((function(e,t){g({type:w.setFilter,columnId:e,filterValue:t})}),[g]),b=i().useCallback((function(e){g({type:w.setAllFilters,filters:e})}),[g]);l.forEach((function(e){var t=e.id,r=e.accessor,n=e.defaultCanFilter,o=e.disableFilters;e.canFilter=r?V(!0!==o&&void 0,!0!==d&&void 0,!0):V(n,f,!1),e.setFilter=function(t){return h(e.id,t)};var a=p.find((function(e){return e.id===t}));e.filterValue=a&&a.value}));var v=i().useMemo((function(){if(c||!p.length)return[n,o,a];var e=[],t={};return[function n(o){var a=arguments.length>1&&void 0!==arguments[1]?arguments[1]:0,i=o;return i=p.reduce((function(e,t){var n=t.id,o=t.value,i=l.find((function(e){return e.id===n}));if(!i)return e;0===a&&(i.preFilteredRows=e);var c=K(i.filter,u||{},r);return c?(i.filteredRows=c(e,[n],o),i.filteredRows):(console.warn("Could not find a valid 'column.filter' for column with the ID: ".concat(i.id,".")),e)}),o),i.forEach((function(r){e.push(r),t[r.id]=r,r.subRows&&(r.subRows=r.subRows&&r.subRows.length>0?n(r.subRows,a+1):r.subRows)})),i}(n),e,t]}),[c,p,n,o,a,l,u]),S=function(e,t){return function(e){if(Array.isArray(e))return e}(e)||function(e,t){var r=null==e?null:"undefined"!=typeof Symbol&&e[Symbol.iterator]||e["@@iterator"];if(null!=r){var n,o,a=[],i=!0,l=!1;try{for(r=r.call(e);!(i=(n=r.next()).done)&&(a.push(n.value),!t||a.length!==t);i=!0);}catch(e){l=!0,o=e}finally{try{i||null==r.return||r.return()}finally{if(l)throw o}}return a}}(e,t)||lt(e,t)||function(){throw new TypeError("Invalid attempt to destructure non-iterable instance.\nIn order to be iterable, non-array objects must have a [Symbol.iterator]() method.")}()}(v,3),O=S[0],R=S[1],j=S[2];i().useMemo((function(){var e=l.filter((function(e){return!p.find((function(t){return t.id===e.id}))}));e.forEach((function(e){e.preFilteredRows=O,e.filteredRows=O}))}),[O,p,l]);var P=k(m);N((function(){P()&&g({type:w.resetFilters})}),[g,c?null:t]),Object.assign(e,{preFilteredRows:n,preFilteredFlatRows:o,preFilteredRowsById:a,filteredRows:O,filteredFlatRows:R,filteredRowsById:j,rows:O,flatRows:R,rowsById:j,setFilter:h,setAllFilters:b})}dt.pluginName="useFilters";var yt=["globalFilter"];function mt(e,t){(null==t||t>e.length)&&(t=e.length);for(var r=0,n=new Array(t);r<t;r++)n[r]=e[r];return n}function ht(e,t){var r=Object.keys(e);if(Object.getOwnPropertySymbols){var n=Object.getOwnPropertySymbols(e);t&&(n=n.filter((function(t){return Object.getOwnPropertyDescriptor(e,t).enumerable}))),r.push.apply(r,n)}return r}function bt(e){for(var t=1;t<arguments.length;t++){var r=null!=arguments[t]?arguments[t]:{};t%2?ht(Object(r),!0).forEach((function(t){vt(e,t,r[t])})):Object.getOwnPropertyDescriptors?Object.defineProperties(e,Object.getOwnPropertyDescriptors(r)):ht(Object(r)).forEach((function(t){Object.defineProperty(e,t,Object.getOwnPropertyDescriptor(r,t))}))}return e}function vt(e,t,r){return t in e?Object.defineProperty(e,t,{value:r,enumerable:!0,configurable:!0,writable:!0}):e[t]=r,e}w.resetGlobalFilter="resetGlobalFilter",w.setGlobalFilter="setGlobalFilter";var wt=function(e){e.stateReducers.push(St),e.useInstance.push(Ot)};function St(e,t,n,o){if(t.type===w.resetGlobalFilter)return bt(bt({},e),{},{globalFilter:o.initialState.globalFilter||void 0});if(t.type===w.setGlobalFilter){var a=t.filterValue,i=o.userFilterTypes,l=K(o.globalFilter,i||{},r),u=x(a,e.globalFilter);return X(l.autoRemove,u)?(e.globalFilter,function(e,t){if(null==e)return{};var r,n,o=function(e,t){if(null==e)return{};var r,n,o={},a=Object.keys(e);for(n=0;n<a.length;n++)r=a[n],t.indexOf(r)>=0||(o[r]=e[r]);return o}(e,t);if(Object.getOwnPropertySymbols){var a=Object.getOwnPropertySymbols(e);for(n=0;n<a.length;n++)r=a[n],t.indexOf(r)>=0||Object.prototype.propertyIsEnumerable.call(e,r)&&(o[r]=e[r])}return o}(e,yt)):bt(bt({},e),{},{globalFilter:u})}}function Ot(e){var t=e.data,n=e.rows,o=e.flatRows,a=e.rowsById,l=e.allColumns,u=e.filterTypes,c=e.globalFilter,s=e.manualGlobalFilter,f=e.state.globalFilter,d=e.dispatch,p=e.autoResetGlobalFilter,g=void 0===p||p,y=e.disableGlobalFilter,m=i().useCallback((function(e){d({type:w.setGlobalFilter,filterValue:e})}),[d]),h=i().useMemo((function(){if(s||void 0===f)return[n,o,a];var e=[],t={},i=K(c,u||{},r);if(!i)return console.warn("Could not find a valid 'globalFilter' option."),n;l.forEach((function(e){var t=e.disableGlobalFilter;e.canFilter=V(!0!==t&&void 0,!0!==y&&void 0,!0)}));var d=l.filter((function(e){return!0===e.canFilter}));return[function r(n){return(n=i(n,d.map((function(e){return e.id})),f)).forEach((function(n){e.push(n),t[n.id]=n,n.subRows=n.subRows&&n.subRows.length?r(n.subRows):n.subRows})),n}(n),e,t]}),[s,f,c,u,l,n,o,a,y]),b=function(e,t){return function(e){if(Array.isArray(e))return e}(e)||function(e,t){var r=null==e?null:"undefined"!=typeof Symbol&&e[Symbol.iterator]||e["@@iterator"];if(null!=r){var n,o,a=[],i=!0,l=!1;try{for(r=r.call(e);!(i=(n=r.next()).done)&&(a.push(n.value),!t||a.length!==t);i=!0);}catch(e){l=!0,o=e}finally{try{i||null==r.return||r.return()}finally{if(l)throw o}}return a}}(e,t)||function(e,t){if(e){if("string"==typeof e)return mt(e,t);var r=Object.prototype.toString.call(e).slice(8,-1);return"Object"===r&&e.constructor&&(r=e.constructor.name),"Map"===r||"Set"===r?Array.from(e):"Arguments"===r||/^(?:Ui|I)nt(?:8|16|32)(?:Clamped)?Array$/.test(r)?mt(e,t):void 0}}(e,t)||function(){throw new TypeError("Invalid attempt to destructure non-iterable instance.\nIn order to be iterable, non-array objects must have a [Symbol.iterator]() method.")}()}(h,3),v=b[0],S=b[1],O=b[2],R=k(g);N((function(){R()&&d({type:w.resetGlobalFilter})}),[d,s?null:t]),Object.assign(e,{preGlobalFilteredRows:n,preGlobalFilteredFlatRows:o,preGlobalFilteredRowsById:a,globalFilteredRows:v,globalFilteredFlatRows:S,globalFilteredRowsById:O,rows:v,flatRows:S,rowsById:O,setGlobalFilter:m,disableGlobalFilter:y})}function Rt(e,t){(null==t||t>e.length)&&(t=e.length);for(var r=0,n=new Array(t);r<t;r++)n[r]=e[r];return n}function jt(e,t){return t.reduce((function(e,t){return e+("number"==typeof t?t:0)}),0)}function Pt(e){var t=e[0]||0;return e.forEach((function(e){"number"==typeof e&&(t=Math.min(t,e))})),t}function Et(e){var t=e[0]||0;return e.forEach((function(e){"number"==typeof e&&(t=Math.max(t,e))})),t}function Ct(e){var t=e[0]||0,r=e[0]||0;return e.forEach((function(e){"number"==typeof e&&(t=Math.min(t,e),r=Math.max(r,e))})),"".concat(t,"..").concat(r)}function At(e){return jt(0,e)/e.length}function xt(e){if(!e.length)return null;var t,r=Math.floor(e.length/2),n=(t=e,function(e){if(Array.isArray(e))return Rt(e)}(t)||function(e){if("undefined"!=typeof Symbol&&null!=e[Symbol.iterator]||null!=e["@@iterator"])return Array.from(e)}(t)||function(e,t){if(e){if("string"==typeof e)return Rt(e,t);var r=Object.prototype.toString.call(e).slice(8,-1);return"Object"===r&&e.constructor&&(r=e.constructor.name),"Map"===r||"Set"===r?Array.from(e):"Arguments"===r||/^(?:Ui|I)nt(?:8|16|32)(?:Clamped)?Array$/.test(r)?Rt(e,t):void 0}}(t)||function(){throw new TypeError("Invalid attempt to spread non-iterable instance.\nIn order to be iterable, non-array objects must have a [Symbol.iterator]() method.")}()).sort((function(e,t){return e-t}));return e.length%2!=0?n[r]:(n[r-1]+n[r])/2}function kt(e){return Array.from(new Set(e).values())}function It(e){return new Set(e).size}function Nt(e){return e.length}function Bt(e,t){return function(e){if(Array.isArray(e))return e}(e)||function(e,t){var r=null==e?null:"undefined"!=typeof Symbol&&e[Symbol.iterator]||e["@@iterator"];if(null!=r){var n,o,a=[],i=!0,l=!1;try{for(r=r.call(e);!(i=(n=r.next()).done)&&(a.push(n.value),!t||a.length!==t);i=!0);}catch(e){l=!0,o=e}finally{try{i||null==r.return||r.return()}finally{if(l)throw o}}return a}}(e,t)||function(e,t){if(e){if("string"==typeof e)return Ft(e,t);var r=Object.prototype.toString.call(e).slice(8,-1);return"Object"===r&&e.constructor&&(r=e.constructor.name),"Map"===r||"Set"===r?Array.from(e):"Arguments"===r||/^(?:Ui|I)nt(?:8|16|32)(?:Clamped)?Array$/.test(r)?Ft(e,t):void 0}}(e,t)||function(){throw new TypeError("Invalid attempt to destructure non-iterable instance.\nIn order to be iterable, non-array objects must have a [Symbol.iterator]() method.")}()}function Ft(e,t){(null==t||t>e.length)&&(t=e.length);for(var r=0,n=new Array(t);r<t;r++)n[r]=e[r];return n}wt.pluginName="useGlobalFilter",w.resetGroupBy="resetGroupBy",w.setGroupBy="setGroupBy",w.toggleGroupBy="toggleGroupBy";var Dt=/([0-9]+)/gm,Gt=function(e,t,r){var n=Bt(_t(e,t,r),2),o=n[0],a=n[1];for(o=Lt(o),a=Lt(a),o=o.split(Dt).filter(Boolean),a=a.split(Dt).filter(Boolean);o.length&&a.length;){var i=o.shift(),l=a.shift(),u=parseInt(i,10),c=parseInt(l,10),s=[u,c].sort();if(isNaN(s[0])){if(i>l)return 1;if(l>i)return-1}else{if(isNaN(s[1]))return isNaN(u)?-1:1;if(u>c)return 1;if(c>u)return-1}}return o.length-a.length};function zt(e,t,r){var n=Bt(_t(e,t,r),2),o=n[0],a=n[1];return Ht(o=o.getTime(),a=a.getTime())}function Mt(e,t,r){var n=Bt(_t(e,t,r),2);return Ht(n[0],n[1])}function Tt(e,t,r){var n=Bt(_t(e,t,r),2),o=n[0],a=n[1];for(o=o.split("").filter(Boolean),a=a.split("").filter(Boolean);o.length&&a.length;){var i=o.shift(),l=a.shift(),u=i.toLowerCase(),c=l.toLowerCase();if(u>c)return 1;if(c>u)return-1;if(i>l)return 1;if(l>i)return-1}return o.length-a.length}function Wt(e,t,r){var n=Bt(_t(e,t,r),2),o=n[0],a=n[1],i=/[^0-9.]/gi;return Ht(o=Number(String(o).replace(i,"")),a=Number(String(a).replace(i,"")))}function Ht(e,t){return e===t?0:e>t?1:-1}function _t(e,t,r){return[e.values[r],t.values[r]]}function Lt(e){return"number"==typeof e?isNaN(e)||e===1/0||e===-1/0?"":String(e):"string"==typeof e?e:""}function Vt(e){return function(e){if(Array.isArray(e))return Ut(e)}(e)||function(e){if("undefined"!=typeof Symbol&&null!=e[Symbol.iterator]||null!=e["@@iterator"])return Array.from(e)}(e)||$t(e)||function(){throw new TypeError("Invalid attempt to spread non-iterable instance.\nIn order to be iterable, non-array objects must have a [Symbol.iterator]() method.")}()}function $t(e,t){if(e){if("string"==typeof e)return Ut(e,t);var r=Object.prototype.toString.call(e).slice(8,-1);return"Object"===r&&e.constructor&&(r=e.constructor.name),"Map"===r||"Set"===r?Array.from(e):"Arguments"===r||/^(?:Ui|I)nt(?:8|16|32)(?:Clamped)?Array$/.test(r)?Ut(e,t):void 0}}function Ut(e,t){(null==t||t>e.length)&&(t=e.length);for(var r=0,n=new Array(t);r<t;r++)n[r]=e[r];return n}function Kt(e,t){var r=Object.keys(e);if(Object.getOwnPropertySymbols){var n=Object.getOwnPropertySymbols(e);t&&(n=n.filter((function(t){return Object.getOwnPropertyDescriptor(e,t).enumerable}))),r.push.apply(r,n)}return r}function Xt(e){for(var t=1;t<arguments.length;t++){var r=null!=arguments[t]?arguments[t]:{};t%2?Kt(Object(r),!0).forEach((function(t){Jt(e,t,r[t])})):Object.getOwnPropertyDescriptors?Object.defineProperties(e,Object.getOwnPropertyDescriptors(r)):Kt(Object(r)).forEach((function(t){Object.defineProperty(e,t,Object.getOwnPropertyDescriptor(r,t))}))}return e}function Jt(e,t,r){return t in e?Object.defineProperty(e,t,{value:r,enumerable:!0,configurable:!0,writable:!0}):e[t]=r,e}w.resetSortBy="resetSortBy",w.setSortBy="setSortBy",w.toggleSortBy="toggleSortBy",w.clearSortBy="clearSortBy",O.sortType="alphanumeric",O.sortDescFirst=!1;var qt=function(e){e.getSortByToggleProps=[Zt],e.stateReducers.push(Yt),e.useInstance.push(Qt)};qt.pluginName="useSortBy";var Zt=function(e,t){var r=t.instance,n=t.column,o=r.isMultiSortEvent,a=void 0===o?function(e){return e.shiftKey}:o;return[e,{onClick:n.canSort?function(e){e.persist(),n.toggleSortBy(void 0,!r.disableMultiSort&&a(e))}:void 0,style:{cursor:n.canSort?"pointer":void 0},title:n.canSort?"Toggle SortBy":void 0}]};function Yt(e,t,r,n){if(t.type===w.init)return Xt({sortBy:[]},e);if(t.type===w.resetSortBy)return Xt(Xt({},e),{},{sortBy:n.initialState.sortBy||[]});if(t.type===w.clearSortBy){var o=e.sortBy.filter((function(e){return e.id!==t.columnId}));return Xt(Xt({},e),{},{sortBy:o})}if(t.type===w.setSortBy){var a=t.sortBy;return Xt(Xt({},e),{},{sortBy:a})}if(t.type===w.toggleSortBy){var i,l=t.columnId,u=t.desc,c=t.multi,s=n.allColumns,f=n.disableMultiSort,d=n.disableSortRemove,p=n.disableMultiRemove,g=n.maxMultiSortColCount,y=void 0===g?Number.MAX_SAFE_INTEGER:g,m=e.sortBy,h=s.find((function(e){return e.id===l})).sortDescFirst,b=m.find((function(e){return e.id===l})),v=m.findIndex((function(e){return e.id===l})),S=null!=u,O=[];return"toggle"!=(i=!f&&c?b?"toggle":"add":v!==m.length-1||1!==m.length?"replace":b?"toggle":"replace")||d||S||c&&p||!(b&&b.desc&&!h||!b.desc&&h)||(i="remove"),"replace"===i?O=[{id:l,desc:S?u:h}]:"add"===i?(O=[].concat(Vt(m),[{id:l,desc:S?u:h}])).splice(0,O.length-y):"toggle"===i?O=m.map((function(e){return e.id===l?Xt(Xt({},e),{},{desc:S?u:!b.desc}):e})):"remove"===i&&(O=m.filter((function(e){return e.id!==l}))),Xt(Xt({},e),{},{sortBy:O})}}function Qt(e){var t=e.data,r=e.rows,n=e.flatRows,a=e.allColumns,l=e.orderByFn,u=void 0===l?er:l,c=e.sortTypes,s=e.manualSortBy,f=e.defaultCanSort,d=e.disableSortBy,p=e.flatHeaders,g=e.state.sortBy,y=e.dispatch,m=e.plugins,h=e.getHooks,b=e.autoResetSortBy,v=void 0===b||b;A(m,["useFilters","useGlobalFilter","useGroupBy","usePivotColumns"],"useSortBy");var S=i().useCallback((function(e){y({type:w.setSortBy,sortBy:e})}),[y]),O=i().useCallback((function(e,t,r){y({type:w.toggleSortBy,columnId:e,desc:t,multi:r})}),[y]),R=k(e);p.forEach((function(e){var t=e.accessor,r=e.canSort,n=e.disableSortBy,o=e.id,a=t?V(!0!==n&&void 0,!0!==d&&void 0,!0):V(f,r,!1);e.canSort=a,e.canSort&&(e.toggleSortBy=function(t,r){return O(e.id,t,r)},e.clearSortBy=function(){y({type:w.clearSortBy,columnId:e.id})}),e.getSortByToggleProps=P(h().getSortByToggleProps,{instance:R(),column:e});var i=g.find((function(e){return e.id===o}));e.isSorted=!!i,e.sortedIndex=g.findIndex((function(e){return e.id===o})),e.isSortedDesc=e.isSorted?i.desc:void 0}));var j=i().useMemo((function(){if(s||!g.length)return[r,n];var e=[],t=g.filter((function(e){return a.find((function(t){return t.id===e.id}))}));return[function r(n){var i=u(n,t.map((function(e){var t=a.find((function(t){return t.id===e.id}));if(!t)throw new Error("React-Table: Could not find a column with id: ".concat(e.id," while sorting"));var r=t.sortType,n=$(r)||(c||{})[r]||o[r];if(!n)throw new Error("React-Table: Could not find a valid sortType of '".concat(r,"' for column '").concat(e.id,"'."));return function(t,r){return n(t,r,e.id,e.desc)}})),t.map((function(e){var t=a.find((function(t){return t.id===e.id}));return t&&t.sortInverted?e.desc:!e.desc})));return i.forEach((function(t){e.push(t),t.subRows&&0!==t.subRows.length&&(t.subRows=r(t.subRows))})),i}(r),e]}),[s,g,r,n,a,u,c]),E=function(e,t){return function(e){if(Array.isArray(e))return e}(e)||function(e,t){var r=null==e?null:"undefined"!=typeof Symbol&&e[Symbol.iterator]||e["@@iterator"];if(null!=r){var n,o,a=[],i=!0,l=!1;try{for(r=r.call(e);!(i=(n=r.next()).done)&&(a.push(n.value),!t||a.length!==t);i=!0);}catch(e){l=!0,o=e}finally{try{i||null==r.return||r.return()}finally{if(l)throw o}}return a}}(e,t)||$t(e,t)||function(){throw new TypeError("Invalid attempt to destructure non-iterable instance.\nIn order to be iterable, non-array objects must have a [Symbol.iterator]() method.")}()}(j,2),C=E[0],x=E[1],I=k(v);N((function(){I()&&y({type:w.resetSortBy})}),[s?null:t]),Object.assign(e,{preSortedRows:r,preSortedFlatRows:n,sortedRows:C,sortedFlatRows:x,rows:C,flatRows:x,setSortBy:S,toggleSortBy:O})}function er(e,t,r){return Vt(e).sort((function(e,n){for(var o=0;o<t.length;o+=1){var a=t[o],i=!1===r[o]||"desc"===r[o],l=a(e,n);if(0!==l)return i?-l:l}return r[0]?e.index-n.index:n.index-e.index}))}w.resetPage="resetPage",w.gotoPage="gotoPage",w.setPageSize="setPageSize",w.resetPivot="resetPivot",w.togglePivot="togglePivot",w.resetSelectedRows="resetSelectedRows",w.toggleAllRowsSelected="toggleAllRowsSelected",w.toggleRowSelected="toggleRowSelected",w.toggleAllPageRowsSelected="toggleAllPageRowsSelected",w.setRowState="setRowState",w.setCellState="setCellState",w.resetRowState="resetRowState",w.resetColumnOrder="resetColumnOrder",w.setColumnOrder="setColumnOrder",O.canResize=!0,w.columnStartResizing="columnStartResizing",w.columnResizing="columnResizing",w.columnDoneResizing="columnDoneResizing",w.resetResize="resetResize",w.columnStartResizing="columnStartResizing",w.columnResizing="columnResizing",w.columnDoneResizing="columnDoneResizing",w.resetResize="resetResize";var tr=window.reactR,rr=function(){function e(e){var t=this;this._insertTag=function(e){var r;r=0===t.tags.length?t.insertionPoint?t.insertionPoint.nextSibling:t.prepend?t.container.firstChild:t.before:t.tags[t.tags.length-1].nextSibling,t.container.insertBefore(e,r),t.tags.push(e)},this.isSpeedy=void 0===e.speedy||e.speedy,this.tags=[],this.ctr=0,this.nonce=e.nonce,this.key=e.key,this.container=e.container,this.prepend=e.prepend,this.insertionPoint=e.insertionPoint,this.before=null}var t=e.prototype;return t.hydrate=function(e){e.forEach(this._insertTag)},t.insert=function(e){this.ctr%(this.isSpeedy?65e3:1)==0&&this._insertTag(function(e){var t=document.createElement("style");return t.setAttribute("data-emotion",e.key),void 0!==e.nonce&&t.setAttribute("nonce",e.nonce),t.appendChild(document.createTextNode("")),t.setAttribute("data-s",""),t}(this));var t=this.tags[this.tags.length-1];if(this.isSpeedy){var r=function(e){if(e.sheet)return e.sheet;for(var t=0;t<document.styleSheets.length;t++)if(document.styleSheets[t].ownerNode===e)return document.styleSheets[t]}(t);try{r.insertRule(e,r.cssRules.length)}catch(e){}}else t.appendChild(document.createTextNode(e));this.ctr++},t.flush=function(){this.tags.forEach((function(e){return e.parentNode&&e.parentNode.removeChild(e)})),this.tags=[],this.ctr=0},e}(),nr=Math.abs,or=String.fromCharCode,ar=Object.assign;function ir(e){return e.trim()}function lr(e,t,r){return e.replace(t,r)}function ur(e,t){return e.indexOf(t)}function cr(e,t){return 0|e.charCodeAt(t)}function sr(e,t,r){return e.slice(t,r)}function fr(e){return e.length}function dr(e){return e.length}function pr(e,t){return t.push(e),e}var gr=1,yr=1,mr=0,hr=0,br=0,vr="";function wr(e,t,r,n,o,a,i){return{value:e,root:t,parent:r,type:n,props:o,children:a,line:gr,column:yr,length:i,return:""}}function Sr(e,t){return ar(wr("",null,null,"",null,null,0),e,{length:-e.length},t)}function Or(){return br=hr>0?cr(vr,--hr):0,yr--,10===br&&(yr=1,gr--),br}function Rr(){return br=hr<mr?cr(vr,hr++):0,yr++,10===br&&(yr=1,gr++),br}function jr(){return cr(vr,hr)}function Pr(){return hr}function Er(e,t){return sr(vr,e,t)}function Cr(e){switch(e){case 0:case 9:case 10:case 13:case 32:return 5;case 33:case 43:case 44:case 47:case 62:case 64:case 126:case 59:case 123:case 125:return 4;case 58:return 3;case 34:case 39:case 40:case 91:return 2;case 41:case 93:return 1}return 0}function Ar(e){return gr=yr=1,mr=fr(vr=e),hr=0,[]}function xr(e){return vr="",e}function kr(e){return ir(Er(hr-1,Br(91===e?e+2:40===e?e+1:e)))}function Ir(e){for(;(br=jr())&&br<33;)Rr();return Cr(e)>2||Cr(br)>3?"":" "}function Nr(e,t){for(;--t&&Rr()&&!(br<48||br>102||br>57&&br<65||br>70&&br<97););return Er(e,Pr()+(t<6&&32==jr()&&32==Rr()))}function Br(e){for(;Rr();)switch(br){case e:return hr;case 34:case 39:34!==e&&39!==e&&Br(br);break;case 40:41===e&&Br(e);break;case 92:Rr()}return hr}function Fr(e,t){for(;Rr()&&e+br!==57&&(e+br!==84||47!==jr()););return"/*"+Er(t,hr-1)+"*"+or(47===e?e:Rr())}function Dr(e){for(;!Cr(jr());)Rr();return Er(e,hr)}var Gr="-ms-",zr="-moz-",Mr="-webkit-",Tr="comm",Wr="rule",Hr="decl",_r="@keyframes";function Lr(e,t){for(var r="",n=dr(e),o=0;o<n;o++)r+=t(e[o],o,e,t)||"";return r}function Vr(e,t,r,n){switch(e.type){case"@import":case Hr:return e.return=e.return||e.value;case Tr:return"";case _r:return e.return=e.value+"{"+Lr(e.children,n)+"}";case Wr:e.value=e.props.join(",")}return fr(r=Lr(e.children,n))?e.return=e.value+"{"+r+"}":""}function $r(e,t){switch(function(e,t){return(((t<<2^cr(e,0))<<2^cr(e,1))<<2^cr(e,2))<<2^cr(e,3)}(e,t)){case 5103:return Mr+"print-"+e+e;case 5737:case 4201:case 3177:case 3433:case 1641:case 4457:case 2921:case 5572:case 6356:case 5844:case 3191:case 6645:case 3005:case 6391:case 5879:case 5623:case 6135:case 4599:case 4855:case 4215:case 6389:case 5109:case 5365:case 5621:case 3829:return Mr+e+e;case 5349:case 4246:case 4810:case 6968:case 2756:return Mr+e+zr+e+Gr+e+e;case 6828:case 4268:return Mr+e+Gr+e+e;case 6165:return Mr+e+Gr+"flex-"+e+e;case 5187:return Mr+e+lr(e,/(\w+).+(:[^]+)/,"-webkit-box-$1$2-ms-flex-$1$2")+e;case 5443:return Mr+e+Gr+"flex-item-"+lr(e,/flex-|-self/,"")+e;case 4675:return Mr+e+Gr+"flex-line-pack"+lr(e,/align-content|flex-|-self/,"")+e;case 5548:return Mr+e+Gr+lr(e,"shrink","negative")+e;case 5292:return Mr+e+Gr+lr(e,"basis","preferred-size")+e;case 6060:return Mr+"box-"+lr(e,"-grow","")+Mr+e+Gr+lr(e,"grow","positive")+e;case 4554:return Mr+lr(e,/([^-])(transform)/g,"$1-webkit-$2")+e;case 6187:return lr(lr(lr(e,/(zoom-|grab)/,Mr+"$1"),/(image-set)/,Mr+"$1"),e,"")+e;case 5495:case 3959:return lr(e,/(image-set\([^]*)/,Mr+"$1$`$1");case 4968:return lr(lr(e,/(.+:)(flex-)?(.*)/,"-webkit-box-pack:$3-ms-flex-pack:$3"),/s.+-b[^;]+/,"justify")+Mr+e+e;case 4095:case 3583:case 4068:case 2532:return lr(e,/(.+)-inline(.+)/,Mr+"$1$2")+e;case 8116:case 7059:case 5753:case 5535:case 5445:case 5701:case 4933:case 4677:case 5533:case 5789:case 5021:case 4765:if(fr(e)-1-t>6)switch(cr(e,t+1)){case 109:if(45!==cr(e,t+4))break;case 102:return lr(e,/(.+:)(.+)-([^]+)/,"$1-webkit-$2-$3$1"+zr+(108==cr(e,t+3)?"$3":"$2-$3"))+e;case 115:return~ur(e,"stretch")?$r(lr(e,"stretch","fill-available"),t)+e:e}break;case 4949:if(115!==cr(e,t+1))break;case 6444:switch(cr(e,fr(e)-3-(~ur(e,"!important")&&10))){case 107:return lr(e,":",":"+Mr)+e;case 101:return lr(e,/(.+:)([^;!]+)(;|!.+)?/,"$1"+Mr+(45===cr(e,14)?"inline-":"")+"box$3$1"+Mr+"$2$3$1"+Gr+"$2box$3")+e}break;case 5936:switch(cr(e,t+11)){case 114:return Mr+e+Gr+lr(e,/[svh]\w+-[tblr]{2}/,"tb")+e;case 108:return Mr+e+Gr+lr(e,/[svh]\w+-[tblr]{2}/,"tb-rl")+e;case 45:return Mr+e+Gr+lr(e,/[svh]\w+-[tblr]{2}/,"lr")+e}return Mr+e+Gr+e+e}return e}function Ur(e){return xr(Kr("",null,null,null,[""],e=Ar(e),0,[0],e))}function Kr(e,t,r,n,o,a,i,l,u){for(var c=0,s=0,f=i,d=0,p=0,g=0,y=1,m=1,h=1,b=0,v="",w=o,S=a,O=n,R=v;m;)switch(g=b,b=Rr()){case 40:if(108!=g&&58==R.charCodeAt(f-1)){-1!=ur(R+=lr(kr(b),"&","&\f"),"&\f")&&(h=-1);break}case 34:case 39:case 91:R+=kr(b);break;case 9:case 10:case 13:case 32:R+=Ir(g);break;case 92:R+=Nr(Pr()-1,7);continue;case 47:switch(jr()){case 42:case 47:pr(Jr(Fr(Rr(),Pr()),t,r),u);break;default:R+="/"}break;case 123*y:l[c++]=fr(R)*h;case 125*y:case 59:case 0:switch(b){case 0:case 125:m=0;case 59+s:p>0&&fr(R)-f&&pr(p>32?qr(R+";",n,r,f-1):qr(lr(R," ","")+";",n,r,f-2),u);break;case 59:R+=";";default:if(pr(O=Xr(R,t,r,c,s,o,l,v,w=[],S=[],f),a),123===b)if(0===s)Kr(R,t,O,O,w,a,f,l,S);else switch(d){case 100:case 109:case 115:Kr(e,O,O,n&&pr(Xr(e,O,O,0,0,o,l,v,o,w=[],f),S),o,S,f,l,n?w:S);break;default:Kr(R,O,O,O,[""],S,0,l,S)}}c=s=p=0,y=h=1,v=R="",f=i;break;case 58:f=1+fr(R),p=g;default:if(y<1)if(123==b)--y;else if(125==b&&0==y++&&125==Or())continue;switch(R+=or(b),b*y){case 38:h=s>0?1:(R+="\f",-1);break;case 44:l[c++]=(fr(R)-1)*h,h=1;break;case 64:45===jr()&&(R+=kr(Rr())),d=jr(),s=f=fr(v=R+=Dr(Pr())),b++;break;case 45:45===g&&2==fr(R)&&(y=0)}}return a}function Xr(e,t,r,n,o,a,i,l,u,c,s){for(var f=o-1,d=0===o?a:[""],p=dr(d),g=0,y=0,m=0;g<n;++g)for(var h=0,b=sr(e,f+1,f=nr(y=i[g])),v=e;h<p;++h)(v=ir(y>0?d[h]+" "+b:lr(b,/&\f/g,d[h])))&&(u[m++]=v);return wr(e,t,r,0===o?Wr:l,u,c,s)}function Jr(e,t,r){return wr(e,t,r,Tr,or(br),sr(e,2,-2),0)}function qr(e,t,r,n){return wr(e,t,r,Hr,sr(e,0,n),sr(e,n+1,-1),n)}var Zr=function(e,t,r){for(var n=0,o=0;n=o,o=jr(),38===n&&12===o&&(t[r]=1),!Cr(o);)Rr();return Er(e,hr)},Yr=new WeakMap,Qr=function(e){if("rule"===e.type&&e.parent&&!(e.length<1)){for(var t=e.value,r=e.parent,n=e.column===r.column&&e.line===r.line;"rule"!==r.type;)if(!(r=r.parent))return;if((1!==e.props.length||58===t.charCodeAt(0)||Yr.get(r))&&!n){Yr.set(e,!0);for(var o=[],a=function(e,t){return xr(function(e,t){var r=-1,n=44;do{switch(Cr(n)){case 0:38===n&&12===jr()&&(t[r]=1),e[r]+=Zr(hr-1,t,r);break;case 2:e[r]+=kr(n);break;case 4:if(44===n){e[++r]=58===jr()?"&\f":"",t[r]=e[r].length;break}default:e[r]+=or(n)}}while(n=Rr());return e}(Ar(e),t))}(t,o),i=r.props,l=0,u=0;l<a.length;l++)for(var c=0;c<i.length;c++,u++)e.props[u]=o[l]?a[l].replace(/&\f/g,i[c]):i[c]+" "+a[l]}}},en=function(e){if("decl"===e.type){var t=e.value;108===t.charCodeAt(0)&&98===t.charCodeAt(2)&&(e.return="",e.value="")}},tn=[function(e,t,r,n){if(e.length>-1&&!e.return)switch(e.type){case Hr:e.return=$r(e.value,e.length);break;case _r:return Lr([Sr(e,{value:lr(e.value,"@","@"+Mr)})],n);case Wr:if(e.length)return function(e,t){return e.map(t).join("")}(e.props,(function(t){switch(function(e,t){return(e=/(::plac\w+|:read-\w+)/.exec(e))?e[0]:e}(t)){case":read-only":case":read-write":return Lr([Sr(e,{props:[lr(t,/:(read-\w+)/,":-moz-$1")]})],n);case"::placeholder":return Lr([Sr(e,{props:[lr(t,/:(plac\w+)/,":-webkit-input-$1")]}),Sr(e,{props:[lr(t,/:(plac\w+)/,":-moz-$1")]}),Sr(e,{props:[lr(t,/:(plac\w+)/,Gr+"input-$1")]})],n)}return""}))}}],rn=function(e){for(var t,r=0,n=0,o=e.length;o>=4;++n,o-=4)t=1540483477*(65535&(t=255&e.charCodeAt(n)|(255&e.charCodeAt(++n))<<8|(255&e.charCodeAt(++n))<<16|(255&e.charCodeAt(++n))<<24))+(59797*(t>>>16)<<16),r=1540483477*(65535&(t^=t>>>24))+(59797*(t>>>16)<<16)^1540483477*(65535&r)+(59797*(r>>>16)<<16);switch(o){case 3:r^=(255&e.charCodeAt(n+2))<<16;case 2:r^=(255&e.charCodeAt(n+1))<<8;case 1:r=1540483477*(65535&(r^=255&e.charCodeAt(n)))+(59797*(r>>>16)<<16)}return(((r=1540483477*(65535&(r^=r>>>13))+(59797*(r>>>16)<<16))^r>>>15)>>>0).toString(36)},nn={animationIterationCount:1,borderImageOutset:1,borderImageSlice:1,borderImageWidth:1,boxFlex:1,boxFlexGroup:1,boxOrdinalGroup:1,columnCount:1,columns:1,flex:1,flexGrow:1,flexPositive:1,flexShrink:1,flexNegative:1,flexOrder:1,gridRow:1,gridRowEnd:1,gridRowSpan:1,gridRowStart:1,gridColumn:1,gridColumnEnd:1,gridColumnSpan:1,gridColumnStart:1,msGridRow:1,msGridRowSpan:1,msGridColumn:1,msGridColumnSpan:1,fontWeight:1,lineHeight:1,opacity:1,order:1,orphans:1,tabSize:1,widows:1,zIndex:1,zoom:1,WebkitLineClamp:1,fillOpacity:1,floodOpacity:1,stopOpacity:1,strokeDasharray:1,strokeDashoffset:1,strokeMiterlimit:1,strokeOpacity:1,strokeWidth:1},on=/[A-Z]|^ms/g,an=/_EMO_([^_]+?)_([^]*?)_EMO_/g,ln=function(e){return 45===e.charCodeAt(1)},un=function(e){return null!=e&&"boolean"!=typeof e},cn=function(e){var t=Object.create(null);return function(e){return void 0===t[e]&&(t[e]=ln(r=e)?r:r.replace(on,"-$&").toLowerCase()),t[e];var r}}(),sn=function(e,t){switch(e){case"animation":case"animationName":if("string"==typeof t)return t.replace(an,(function(e,t,r){return dn={name:t,styles:r,next:dn},t}))}return 1===nn[e]||ln(e)||"number"!=typeof t||0===t?t:t+"px"};function fn(e,t,r){if(null==r)return"";if(void 0!==r.__emotion_styles)return r;switch(typeof r){case"boolean":return"";case"object":if(1===r.anim)return dn={name:r.name,styles:r.styles,next:dn},r.name;if(void 0!==r.styles){var n=r.next;if(void 0!==n)for(;void 0!==n;)dn={name:n.name,styles:n.styles,next:dn},n=n.next;return r.styles+";"}return function(e,t,r){var n="";if(Array.isArray(r))for(var o=0;o<r.length;o++)n+=fn(e,t,r[o])+";";else for(var a in r){var i=r[a];if("object"!=typeof i)null!=t&&void 0!==t[i]?n+=a+"{"+t[i]+"}":un(i)&&(n+=cn(a)+":"+sn(a,i)+";");else if(!Array.isArray(i)||"string"!=typeof i[0]||null!=t&&void 0!==t[i[0]]){var l=fn(e,t,i);switch(a){case"animation":case"animationName":n+=cn(a)+":"+l+";";break;default:n+=a+"{"+l+"}"}}else for(var u=0;u<i.length;u++)un(i[u])&&(n+=cn(a)+":"+sn(a,i[u])+";")}return n}(e,t,r);case"function":if(void 0!==e){var o=dn,a=r(e);return dn=o,fn(e,t,a)}}if(null==t)return r;var i=t[r];return void 0!==i?i:r}var dn,pn=/label:\s*([^\s;\n{]+)\s*(;|$)/g,gn=function(e,t,r){if(1===e.length&&"object"==typeof e[0]&&null!==e[0]&&void 0!==e[0].styles)return e[0];var n=!0,o="";dn=void 0;var a=e[0];null==a||void 0===a.raw?(n=!1,o+=fn(r,t,a)):o+=a[0];for(var i=1;i<e.length;i++)o+=fn(r,t,e[i]),n&&(o+=a[i]);pn.lastIndex=0;for(var l,u="";null!==(l=pn.exec(o));)u+="-"+l[1];return{name:rn(o)+u,styles:o,next:dn}};function yn(e,t,r){var n="";return r.split(" ").forEach((function(r){void 0!==e[r]?t.push(e[r]+";"):n+=r+" "})),n}var mn=function(e,t,r){!function(e,t,r){var n=e.key+"-"+t.name;!1===r&&void 0===e.registered[n]&&(e.registered[n]=t.styles)}(e,t,r);var n=e.key+"-"+t.name;if(void 0===e.inserted[t.name]){var o=t;do{e.insert(t===o?"."+n:"",o,e.sheet,!0),o=o.next}while(void 0!==o)}};function hn(e,t){if(void 0===e.inserted[t.name])return e.insert("",t,e.sheet,!0)}function bn(e,t,r){var n=[],o=yn(e,n,r);return n.length<2?r:o+t(n)}var vn,wn=function e(t){for(var r="",n=0;n<t.length;n++){var o=t[n];if(null!=o){var a=void 0;switch(typeof o){case"boolean":break;case"object":if(Array.isArray(o))a=e(o);else for(var i in a="",o)o[i]&&i&&(a&&(a+=" "),a+=i);break;default:a=o}a&&(r&&(r+=" "),r+=a)}}return r},Sn=function(e){var t=function(e){var t=e.key;if("css"===t){var r=document.querySelectorAll("style[data-emotion]:not([data-s])");Array.prototype.forEach.call(r,(function(e){-1!==e.getAttribute("data-emotion").indexOf(" ")&&(document.head.appendChild(e),e.setAttribute("data-s",""))}))}var n,o,a=e.stylisPlugins||tn,i={},l=[];n=e.container||document.head,Array.prototype.forEach.call(document.querySelectorAll('style[data-emotion^="'+t+' "]'),(function(e){for(var t=e.getAttribute("data-emotion").split(" "),r=1;r<t.length;r++)i[t[r]]=!0;l.push(e)}));var u,c,s,f,d=[Vr,(f=function(e){u.insert(e)},function(e){e.root||(e=e.return)&&f(e)})],p=(c=[Qr,en].concat(a,d),s=dr(c),function(e,t,r,n){for(var o="",a=0;a<s;a++)o+=c[a](e,t,r,n)||"";return o});o=function(e,t,r,n){u=r,Lr(Ur(e?e+"{"+t.styles+"}":t.styles),p),n&&(g.inserted[t.name]=!0)};var g={key:t,sheet:new rr({key:t,container:n,nonce:e.nonce,speedy:e.speedy,prepend:e.prepend,insertionPoint:e.insertionPoint}),nonce:e.nonce,inserted:i,registered:{},insert:o};return g.sheet.hydrate(l),g}(e);t.sheet.speedy=function(e){this.isSpeedy=e},t.compat=!0;var r=function(){for(var e=arguments.length,r=new Array(e),n=0;n<e;n++)r[n]=arguments[n];var o=gn(r,t.registered,void 0);return mn(t,o,!1),t.key+"-"+o.name};return{css:r,cx:function(){for(var e=arguments.length,n=new Array(e),o=0;o<e;o++)n[o]=arguments[o];return bn(t.registered,r,wn(n))},injectGlobal:function(){for(var e=arguments.length,r=new Array(e),n=0;n<e;n++)r[n]=arguments[n];var o=gn(r,t.registered);hn(t,o)},keyframes:function(){for(var e=arguments.length,r=new Array(e),n=0;n<e;n++)r[n]=arguments[n];var o=gn(r,t.registered),a="animation-"+o.name;return hn(t,{name:o.name,styles:"@keyframes "+a+"{"+o.styles+"}"}),a},hydrate:function(e){e.forEach((function(e){t.inserted[e]=!0}))},flush:function(){t.registered={},t.inserted={},t.sheet.flush()},sheet:t.sheet,cache:t,getRegisteredStyles:yn.bind(null,t.registered),merge:bn.bind(null,t.registered,r)}};function On(e,t){var r="undefined"!=typeof Symbol&&e[Symbol.iterator]||e["@@iterator"];if(!r){if(Array.isArray(e)||(r=function(e,t){if(e){if("string"==typeof e)return Rn(e,t);var r=Object.prototype.toString.call(e).slice(8,-1);return"Object"===r&&e.constructor&&(r=e.constructor.name),"Map"===r||"Set"===r?Array.from(e):"Arguments"===r||/^(?:Ui|I)nt(?:8|16|32)(?:Clamped)?Array$/.test(r)?Rn(e,t):void 0}}(e))||t&&e&&"number"==typeof e.length){r&&(e=r);var n=0,o=function(){};return{s:o,n:function(){return n>=e.length?{done:!0}:{done:!1,value:e[n++]}},e:function(e){throw e},f:o}}throw new TypeError("Invalid attempt to iterate non-iterable instance.\nIn order to be iterable, non-array objects must have a [Symbol.iterator]() method.")}var a,i=!0,l=!1;return{s:function(){r=r.call(e)},n:function(){var e=r.next();return i=e.done,e},e:function(e){l=!0,a=e},f:function(){try{i||null==r.return||r.return()}finally{if(l)throw a}}}}function Rn(e,t){(null==t||t>e.length)&&(t=e.length);for(var r=0,n=new Array(t);r<t;r++)n[r]=e[r];return n}function jn(e,t){var r=Object.keys(e);if(Object.getOwnPropertySymbols){var n=Object.getOwnPropertySymbols(e);t&&(n=n.filter((function(t){return Object.getOwnPropertyDescriptor(e,t).enumerable}))),r.push.apply(r,n)}return r}function Pn(e,t,r){return t in e?Object.defineProperty(e,t,{value:r,enumerable:!0,configurable:!0,writable:!0}):e[t]=r,e}function En(){for(var e=arguments.length,t=new Array(e),r=0;r<e;r++)t[r]=arguments[r];return t.filter((function(e){return e})).join(" ")}function Cn(){for(var e=arguments.length,t=new Array(e),r=0;r<e;r++)t[r]=arguments[r];return t.find((function(e){return null!=e}))}function An(e){return e.replace(/[.*+?^${}()|[\]\\]/g,"\\$&")}function xn(e){var t=[];return function e(r){r.columns?r.columns.forEach(e):t.push(r)}(e),t}function kn(e){return e.map((function(e){return e.subRows&&e.subRows.length>0?function(e){for(var t=1;t<arguments.length;t++){var r=null!=arguments[t]?arguments[t]:{};t%2?jn(Object(r),!0).forEach((function(t){Pn(e,t,r[t])})):Object.getOwnPropertyDescriptors?Object.defineProperties(e,Object.getOwnPropertyDescriptors(r)):jn(Object(r)).forEach((function(t){Object.defineProperty(e,t,Object.getOwnPropertyDescriptor(r,t))}))}return e}({_subRows:kn(e.subRows)},e.values):e.values}))}function In(e){var t=arguments.length>1&&void 0!==arguments[1]?arguments[1]:{},r=t.columnIds,n=t.headers,o=void 0===n||n,a=t.sep,i=void 0===a?",":a,l=t.dec,u=void 0===l?".":l,c=function(e){return e.map((function(e){return null==e&&(e=""),e instanceof Date?e=e.toISOString():"string"!=typeof e&&"number"!=typeof e?e=JSON.stringify(e):"."!==u&&"number"==typeof e&&(e=e.toString().replace(".",u)),"string"==typeof e&&(e.includes('"')||e.includes(i))&&(e='"'.concat(e.replace(/"/g,'""'),'"')),e})).join(i)},s=[];r||(r=e.length>0?Object.keys(e[0]):[]),o&&s.push(c(r));var f,d=On(e);try{var p=function(){var e=f.value,t=r.map((function(t){return e[t]}));s.push(c(t))};for(d.s();!(f=d.n()).done;)p()}catch(e){d.e(e)}finally{d.f()}return s.join("\n")+"\n"}function Nn(e,t){var r=new Blob([e],{type:"text/csv;charset=utf-8"});if(window.navigator.msSaveBlob)window.navigator.msSaveBlob(r,t);else{var n=document.createElement("a"),o=window.URL.createObjectURL(r);n.href=o,n.download=t,n.click(),window.URL.revokeObjectURL(o)}}function Bn(){return"undefined"!=typeof document}function Fn(e){return Fn="function"==typeof Symbol&&"symbol"==typeof Symbol.iterator?function(e){return typeof e}:function(e){return e&&"function"==typeof Symbol&&e.constructor===Symbol&&e!==Symbol.prototype?"symbol":typeof e},Fn(e)}function Dn(e,t){return function(e){if(Array.isArray(e))return e}(e)||function(e,t){var r=null==e?null:"undefined"!=typeof Symbol&&e[Symbol.iterator]||e["@@iterator"];if(null!=r){var n,o,a=[],i=!0,l=!1;try{for(r=r.call(e);!(i=(n=r.next()).done)&&(a.push(n.value),!t||a.length!==t);i=!0);}catch(e){l=!0,o=e}finally{try{i||null==r.return||r.return()}finally{if(l)throw o}}return a}}(e,t)||Gn(e,t)||function(){throw new TypeError("Invalid attempt to destructure non-iterable instance.\nIn order to be iterable, non-array objects must have a [Symbol.iterator]() method.")}()}function Gn(e,t){if(e){if("string"==typeof e)return zn(e,t);var r=Object.prototype.toString.call(e).slice(8,-1);return"Object"===r&&e.constructor&&(r=e.constructor.name),"Map"===r||"Set"===r?Array.from(e):"Arguments"===r||/^(?:Ui|I)nt(?:8|16|32)(?:Clamped)?Array$/.test(r)?zn(e,t):void 0}}function zn(e,t){(null==t||t>e.length)&&(t=e.length);for(var r=0,n=new Array(t);r<t;r++)n[r]=e[r];return n}function Mn(e,t){var r=Object.keys(e);if(Object.getOwnPropertySymbols){var n=Object.getOwnPropertySymbols(e);t&&(n=n.filter((function(t){return Object.getOwnPropertyDescriptor(e,t).enumerable}))),r.push.apply(r,n)}return r}function Tn(e){for(var t=1;t<arguments.length;t++){var r=null!=arguments[t]?arguments[t]:{};t%2?Mn(Object(r),!0).forEach((function(t){Wn(e,t,r[t])})):Object.getOwnPropertyDescriptors?Object.defineProperties(e,Object.getOwnPropertyDescriptors(r)):Mn(Object(r)).forEach((function(t){Object.defineProperty(e,t,Object.getOwnPropertyDescriptor(r,t))}))}return e}function Wn(e,t,r){return t in e?Object.defineProperty(e,t,{value:r,enumerable:!0,configurable:!0,writable:!0}):e[t]=r,e}function Hn(e){if(!e)return null;var t=e.color,r=e.backgroundColor,n=e.borderColor,o=e.borderWidth,a=e.stripedColor,i=e.highlightColor,l=e.cellPadding,u=e.style,c=e.tableBorderColor,s=void 0===c?n:c,f=e.tableBorderWidth,d=void 0===f?o:f,p=e.tableStyle,g=e.headerBorderColor,y=void 0===g?n:g,m=e.headerBorderWidth,h=void 0===m?o:m,b=e.headerStyle,v=e.groupHeaderBorderColor,w=void 0===v?n:v,S=e.groupHeaderBorderWidth,O=void 0===S?o:S,R=e.groupHeaderStyle,j=e.tableBodyStyle,P=e.rowGroupStyle,E=e.rowStyle,C=e.rowStripedStyle,A=e.rowHighlightStyle,x=e.rowSelectedStyle,k=e.cellBorderColor,I=void 0===k?n:k,N=e.cellBorderWidth,B=void 0===N?o:N,F=e.cellStyle,D=e.footerBorderColor,G=void 0===D?n:D,z=e.footerBorderWidth,M=void 0===z?o:z,T=e.footerStyle,W=e.inputStyle,H=e.filterInputStyle,_=e.searchInputStyle,L=e.selectStyle,V=e.paginationStyle,$=e.pageButtonStyle,U=e.pageButtonHoverStyle,K=e.pageButtonActiveStyle,X=e.pageButtonCurrentStyle,J=_n([F,E,j,p,u],"color",t),q=_n([L,u],"color",t);h=_n([b],"borderWidth",h);var Z,Y={style:Tn({color:t,backgroundColor:r},u),tableStyle:Tn({borderColor:s,borderWidth:d},p),headerStyle:Tn(Tn({borderColor:y,borderWidth:h,padding:l},b),{},{".rt-bordered &, .rt-outlined &":{borderWidth:h}}),groupHeaderStyle:Tn(Tn({borderColor:w,borderWidth:O,padding:l},R),{},{"&::after":{backgroundColor:w,height:O},".rt-bordered &":{borderWidth:O}}),tableBodyStyle:j,rowGroupStyle:P,rowStyle:Tn(Tn({},E),{},{"&.rt-tr-striped":Tn({backgroundColor:a},C),"&.rt-tr-highlight:hover":Tn({backgroundColor:i},A),"&.rt-tr-selected":Tn({},x)}),cellStyle:Tn({borderColor:I,borderWidth:B,padding:l},F),footerStyle:Tn({borderColor:G,borderWidth:M,padding:l},T),filterCellStyle:Tn({borderColor:I,borderWidth:B,padding:l},F),expanderStyle:{"&::after":{borderTopColor:J}},filterInputStyle:Tn(Tn({},W),H),searchInputStyle:Tn(Tn({},W),_),paginationStyle:Tn(Tn({borderTopColor:I,borderTopWidth:B},V),{},{".rt-page-jump":Tn({},W),".rt-page-size-select":Tn(Tn({},L),{},{"@supports (-moz-appearance: none)":{backgroundImage:q&&'url(\'data:image/svg+xml;charset=US-ASCII,<svg width="24" height="24" xmlns="http://www.w3.org/2000/svg">'+'<path fill="'.concat((Z=q,encodeURIComponent(Z).replace("(","%28").replace(")","%29")),'" d="M24 1.5l-12 21-12-21h24z"/></svg>\')')}}),".rt-page-button":Tn({},$),".rt-page-button:not(:disabled):hover":Tn({},U),".rt-page-button:not(:disabled):active":Tn({},K),".rt-keyboard-active & .rt-page-button:not(:disabled):focus":Tn({},U),".rt-page-button-current":Tn({},X)})};return Ln(Y),Y}function _n(e,t,r){var n=e.find((function(e){return e&&null!=e[t]}));return n?n[t]:r}function Ln(e){for(var t=0,r=Object.entries(e);t<r.length;t++){var n=Dn(r[t],2),o=n[0],a=n[1];"object"===Fn(a)?(Ln(a),0===Object.keys(a).length&&delete e[o]):null==a&&delete e[o]}}function Vn(){if(vn)return vn;var e,t;if(Bn()){var r,n=function(e,t){var r="undefined"!=typeof Symbol&&e[Symbol.iterator]||e["@@iterator"];if(!r){if(Array.isArray(e)||(r=Gn(e))){r&&(e=r);var n=0,o=function(){};return{s:o,n:function(){return n>=e.length?{done:!0}:{done:!1,value:e[n++]}},e:function(e){throw e},f:o}}throw new TypeError("Invalid attempt to iterate non-iterable instance.\nIn order to be iterable, non-array objects must have a [Symbol.iterator]() method.")}var a,i=!0,l=!1;return{s:function(){r=r.call(e)},n:function(){var e=r.next();return i=e.done,e},e:function(e){l=!0,a=e},f:function(){try{i||null==r.return||r.return()}finally{if(l)throw a}}}}(document.querySelectorAll("link"));try{for(n.s();!(r=n.n()).done;){var o=r.value,a=o.href.substring(o.href.lastIndexOf("/")+1);if("stylesheet"===o.rel&&"reactable.css"===a){e=o.parentElement,t=o;break}}}catch(e){n.e(e)}finally{n.f()}}return vn=Sn({key:"reactable",container:e,insertionPoint:t})}function $n(){for(var e=arguments.length,t=new Array(e),r=0;r<e;r++)t[r]=arguments[r];var n=Vn();return(t=t.filter((function(e){return null!=e}))).length?n.css(t):null}function Un(e){return Un="function"==typeof Symbol&&"symbol"==typeof Symbol.iterator?function(e){return typeof e}:function(e){return e&&"function"==typeof Symbol&&e.constructor===Symbol&&e!==Symbol.prototype?"symbol":typeof e},Un(e)}var Kn={sortLabel:"Sort {name}",filterPlaceholder:"",filterLabel:"Filter {name}",searchPlaceholder:"Search",searchLabel:"Search",noData:"No rows found",pageNext:"Next",pagePrevious:"Previous",pageNumbers:"{page} of {pages}",pageInfo:"{rowStart}".concat(String.fromCharCode(8211),"{rowEnd} of {rows} rows"),pageSizeOptions:"Show {rows}",pageNextLabel:"Next page",pagePreviousLabel:"Previous page",pageNumberLabel:"Page {page}",pageJumpLabel:"Go to page",pageSizeOptionsLabel:"Rows per page",groupExpandLabel:"Toggle group",detailsExpandLabel:"Toggle details",selectAllRowsLabel:"Select all rows",selectAllSubRowsLabel:"Select all rows in group",selectRowLabel:"Select row",defaultGroupHeader:"Grouped",detailsCollapseLabel:"Toggle details",deselectAllRowsLabel:"Deselect all rows",deselectAllSubRowsLabel:"Deselect all rows in group",deselectRowLabel:"Deselect row"};function Xn(e){var t=arguments.length>1&&void 0!==arguments[1]?arguments[1]:{};if(!e||!t)return e;var r=Object.keys(t),n="("+r.map((function(e){return"{".concat(e,"}")})).join("|")+")",o=e.split(new RegExp(n)),a=r.reduce((function(e,r){return e["{".concat(r,"}")]=t[r],e}),{}),i=o.map((function(e){return null!=a[e]?a[e]:e}));return i.some((function(e){return"object"===Un(e)}))?i:i.join("")}function Jn(e){return Jn="function"==typeof Symbol&&"symbol"==typeof Symbol.iterator?function(e){return typeof e}:function(e){return e&&"function"==typeof Symbol&&e.constructor===Symbol&&e!==Symbol.prototype?"symbol":typeof e},Jn(e)}var qn=["isCurrent","className"];function Zn(e,t){for(var r=0;r<t.length;r++){var n=t[r];n.enumerable=n.enumerable||!1,n.configurable=!0,"value"in n&&(n.writable=!0),Object.defineProperty(e,n.key,n)}}function Yn(e,t){return Yn=Object.setPrototypeOf?Object.setPrototypeOf.bind():function(e,t){return e.__proto__=t,e},Yn(e,t)}function Qn(e,t){if(t&&("object"===Jn(t)||"function"==typeof t))return t;if(void 0!==t)throw new TypeError("Derived constructors may only return object or undefined");return eo(e)}function eo(e){if(void 0===e)throw new ReferenceError("this hasn't been initialised - super() hasn't been called");return e}function to(e){return to=Object.setPrototypeOf?Object.getPrototypeOf.bind():function(e){return e.__proto__||Object.getPrototypeOf(e)},to(e)}function ro(e,t){(null==t||t>e.length)&&(t=e.length);for(var r=0,n=new Array(t);r<t;r++)n[r]=e[r];return n}function no(){return no=Object.assign?Object.assign.bind():function(e){for(var t=1;t<arguments.length;t++){var r=arguments[t];for(var n in r)Object.prototype.hasOwnProperty.call(r,n)&&(e[n]=r[n])}return e},no.apply(this,arguments)}var oo=function(e){var t=e.isCurrent,r=e.className,n=function(e,t){if(null==e)return{};var r,n,o=function(e,t){if(null==e)return{};var r,n,o={},a=Object.keys(e);for(n=0;n<a.length;n++)r=a[n],t.indexOf(r)>=0||(o[r]=e[r]);return o}(e,t);if(Object.getOwnPropertySymbols){var a=Object.getOwnPropertySymbols(e);for(n=0;n<a.length;n++)r=a[n],t.indexOf(r)>=0||Object.prototype.propertyIsEnumerable.call(e,r)&&(o[r]=e[r])}return o}(e,qn);return r=En(r,"rt-page-button",t?" rt-page-button-current":null),i().createElement("button",no({type:"button",className:r},n),n.children)},ao=function(e){!function(e,t){if("function"!=typeof t&&null!==t)throw new TypeError("Super expression must either be null or a function");e.prototype=Object.create(t&&t.prototype,{constructor:{value:e,writable:!0,configurable:!0}}),Object.defineProperty(e,"prototype",{writable:!1}),t&&Yn(e,t)}(u,e);var t,r,n,o,a,l=(o=u,a=function(){if("undefined"==typeof Reflect||!Reflect.construct)return!1;if(Reflect.construct.sham)return!1;if("function"==typeof Proxy)return!0;try{return Boolean.prototype.valueOf.call(Reflect.construct(Boolean,[],(function(){}))),!0}catch(e){return!1}}(),function(){var e,t=to(o);if(a){var r=to(this).constructor;e=Reflect.construct(t,arguments,r)}else e=t.apply(this,arguments);return Qn(this,e)});function u(e){var t;return function(e,t){if(!(e instanceof t))throw new TypeError("Cannot call a class as a function")}(this,u),(t=l.call(this,e)).changePage=t.changePage.bind(eo(t)),t.applyPage=t.applyPage.bind(eo(t)),t.state={pageJumpValue:e.page+1,prevPage:e.page},t}return t=u,r=[{key:"changePage",value:function(e){e!==this.props.page+1&&this.props.onPageChange(e-1)}},{key:"applyPage",value:function(e){e&&e.preventDefault();var t=this.state.pageJumpValue;if(""!==t)this.changePage(t);else{var r=this.props.page+1;this.setState({pageJumpValue:r})}}},{key:"renderPageInfo",value:function(e){var t=e.page,r=e.pageSize,n=e.pageRowCount,o=e.rowCount,a=e.language,l=Math.min(t*r+1,o),u=Math.max(Math.min(t*r+r,o),n),c=Xn(a.pageInfo,{rowStart:l,rowEnd:u,rows:o});return i().createElement("div",{className:"rt-page-info","aria-live":"polite"},c)}},{key:"renderPageSizeOptions",value:function(e){var t=e.pageSize,r=e.pageSizeOptions,n=e.onPageSizeChange,o=e.language,a=i().createElement("select",{key:"page-size-select",className:"rt-page-size-select","aria-label":o.pageSizeOptionsLabel,onChange:function(e){return n(Number(e.target.value))},value:t},r.map((function(e,t){return i().createElement("option",{key:t,value:e},e)}))),l=Xn(o.pageSizeOptions,{rows:a});return i().createElement("div",{className:"rt-page-size"},l)}},{key:"renderPageJump",value:function(e){var t=e.onChange,r=e.value,n=e.onBlur,o=e.onKeyPress,a=e.inputType,l=e.language;return i().createElement("input",{key:"page-jump",className:"rt-page-jump","aria-label":l.pageJumpLabel,type:a,onChange:t,value:r,onBlur:n,onKeyPress:o})}},{key:"getPageJumpProperties",value:function(){var e=this;return{onKeyPress:function(t){13!==t.which&&13!==t.keyCode||e.applyPage()},onBlur:this.applyPage,value:this.state.pageJumpValue,onChange:function(t){var r=t.target.value;if(""!==r){var n=Number(r);if(!Number.isNaN(n)){var o=Math.min(Math.max(n,1),Math.max(e.props.pages,1));e.setState({pageJumpValue:o})}}else e.setState({pageJumpValue:r})},inputType:"number",language:this.props.language}}},{key:"render",value:function(){var e,t=this,r=this.props,n=r.paginationType,o=r.showPageSizeOptions,a=r.showPageInfo,l=r.page,u=r.pages,c=r.canPrevious,s=r.canNext,f=r.theme,d=r.language,p=a?this.renderPageInfo(this.props):null,g=o?this.renderPageSizeOptions(this.props):null,y=l+1,m=function(e,t){return t<=6?(r=Array(t),function(e){if(Array.isArray(e))return ro(e)}(r)||function(e){if("undefined"!=typeof Symbol&&null!=e[Symbol.iterator]||null!=e["@@iterator"])return Array.from(e)}(r)||function(e,t){if(e){if("string"==typeof e)return ro(e,t);var r=Object.prototype.toString.call(e).slice(8,-1);return"Object"===r&&e.constructor&&(r=e.constructor.name),"Map"===r||"Set"===r?Array.from(e):"Arguments"===r||/^(?:Ui|I)nt(?:8|16|32)(?:Clamped)?Array$/.test(r)?ro(e,t):void 0}}(r)||function(){throw new TypeError("Invalid attempt to spread non-iterable instance.\nIn order to be iterable, non-array objects must have a [Symbol.iterator]() method.")}()).map((function(e,t){return t+1})):e<=4?[1,2,3,4,5,t]:t-e<3?[1,t-3,t-2,t-1,t]:[1,e-1,e,e+1,t];var r}(y,u);if("numbers"===n){var h=[];m.forEach((function(e,r){var n=y===e,o=i().createElement(oo,{key:e,isCurrent:n,onClick:t.changePage.bind(null,e),"aria-label":Xn(d.pageNumberLabel,{page:e})+(n?" ":""),"aria-current":n?"page":null},e);e-m[r-1]>1&&h.push(i().createElement("span",{className:"rt-page-ellipsis",key:"ellipsis-".concat(e),role:"separator"},"...")),h.push(o)})),e=h}else{var b="jump"===n?this.renderPageJump(this.getPageJumpProperties()):y,v=Math.max(u,1);e=i().createElement("div",{className:"rt-page-numbers"},Xn(d.pageNumbers,{page:b,pages:v}))}var w=i().createElement(oo,{className:"rt-prev-button",onClick:function(){c&&t.changePage(y-1)},disabled:!c,"aria-disabled":c?null:"true","aria-label":d.pagePreviousLabel},d.pagePrevious),S=i().createElement(oo,{className:"rt-next-button",onClick:function(){s&&t.changePage(y+1)},disabled:!s,"aria-disabled":s?null:"true","aria-label":d.pageNextLabel},d.pageNext);return i().createElement("div",{className:En("rt-pagination",$n(f.paginationStyle))},i().createElement("div",{className:"rt-pagination-info"},p,g),i().createElement("div",{className:"rt-pagination-nav"},w,e,S))}}],n=[{key:"getDerivedStateFromProps",value:function(e,t){return e.page!==t.prevPage?{pageJumpValue:e.page+1,prevPage:e.page}:null}}],r&&Zn(t.prototype,r),n&&Zn(t,n),Object.defineProperty(t,"prototype",{writable:!1}),u}(i().Component);function io(e){return io="function"==typeof Symbol&&"symbol"==typeof Symbol.iterator?function(e){return typeof e}:function(e){return e&&"function"==typeof Symbol&&e.constructor===Symbol&&e!==Symbol.prototype?"symbol":typeof e},io(e)}function lo(e,t){if(!(e instanceof t))throw new TypeError("Cannot call a class as a function")}function uo(e,t){for(var r=0;r<t.length;r++){var n=t[r];n.enumerable=n.enumerable||!1,n.configurable=!0,"value"in n&&(n.writable=!0),Object.defineProperty(e,n.key,n)}}function co(e,t){return co=Object.setPrototypeOf?Object.setPrototypeOf.bind():function(e,t){return e.__proto__=t,e},co(e,t)}function so(e,t){if(t&&("object"===io(t)||"function"==typeof t))return t;if(void 0!==t)throw new TypeError("Derived constructors may only return object or undefined");return function(e){if(void 0===e)throw new ReferenceError("this hasn't been initialised - super() hasn't been called");return e}(e)}function fo(e){return fo=Object.setPrototypeOf?Object.getPrototypeOf.bind():function(e){return e.__proto__||Object.getPrototypeOf(e)},fo(e)}ao.defaultProps={paginationType:"numbers",pageSizeOptions:[10,25,50,100],showPageInfo:!0,language:Kn};var po=function(e){!function(e,t){if("function"!=typeof t&&null!==t)throw new TypeError("Super expression must either be null or a function");e.prototype=Object.create(t&&t.prototype,{constructor:{value:e,writable:!0,configurable:!0}}),Object.defineProperty(e,"prototype",{writable:!1}),t&&co(e,t)}(i,e);var t,r,n,o,a=(n=i,o=function(){if("undefined"==typeof Reflect||!Reflect.construct)return!1;if(Reflect.construct.sham)return!1;if("function"==typeof Proxy)return!0;try{return Boolean.prototype.valueOf.call(Reflect.construct(Boolean,[],(function(){}))),!0}catch(e){return!1}}(),function(){var e,t=fo(n);if(o){var r=fo(this).constructor;e=Reflect.construct(t,arguments,r)}else e=t.apply(this,arguments);return so(this,e)});function i(){return lo(this,i),a.apply(this,arguments)}return t=i,(r=[{key:"componentDidMount",value:function(){this.staticRender()}},{key:"staticRender",value:function(){window.HTMLWidgets&&(i.throttled?i.lastCall=!0:(window.HTMLWidgets.staticRender(),i.throttled=!0,setTimeout((function(){i.lastCall&&window.HTMLWidgets.staticRender(),i.throttled=!1,i.lastCall=!1}))))}},{key:"render",value:function(){return Bn()?this.props.children:null}}])&&uo(t.prototype,r),Object.defineProperty(t,"prototype",{writable:!1}),i}(i().Component);function go(e){e.getTheadProps=[yo],e.getTfootProps=[yo],e.getTableBodyProps.push(yo),e.getRowProps.push(mo),e.getHeaderGroupProps.push(mo),e.getFooterGroupProps.push(mo),e.getHeaderProps.push(ho),e.getCellProps.push(bo),e.getFooterProps.push(vo),e.useInstance.push(wo)}go.pluginName="useFlexLayout";var yo=function(e,t){return[e,{style:{minWidth:So(t.instance.totalColumnsWidth)}}]},mo=function(e,t){return[e,{style:{flex:"1 0 auto",minWidth:So(t.instance.totalColumnsWidth)}}]},ho=function(e,t){var r=t.column,n=r.totalMaxWidth<Number.MAX_SAFE_INTEGER?r.totalMaxWidth:null;return[e,{style:{flex:"".concat(r.flexWidth," 0 auto"),minWidth:So(r.totalMinWidth),width:So(r.totalWidth),maxWidth:So(n)}}]},bo=function(e,t){var r=t.cell,n=r.column.totalMaxWidth<Number.MAX_SAFE_INTEGER?r.column.totalMaxWidth:null;return[e,{style:{flex:"".concat(r.column.flexWidth," 0 auto"),minWidth:So(r.column.totalMinWidth),width:So(r.column.totalWidth),maxWidth:So(n)}}]},vo=function(e,t){var r=t.column,n=r.totalMaxWidth<Number.MAX_SAFE_INTEGER?r.totalMaxWidth:null;return[e,{style:{flex:"".concat(r.flexWidth," 0 auto"),minWidth:So(r.totalMinWidth),width:So(r.totalWidth),maxWidth:So(n)}}]};function wo(e){var t=e.headers,r=e.state,n=e.getHooks,o=r.columnResizing.columnWidths;!function e(t){var r=0;return t.forEach((function(t){if(t.headers)t.flexWidth=e(t.headers);else if(null!=o[t.id])t.flexWidth=0;else{var n=t.totalMinWidth===t.totalMaxWidth;t.flexWidth=n?0:t.totalMinWidth}t.isVisible&&(r+=t.flexWidth)})),r}(t);var a=k(e),i=P(n().getTheadProps,{instance:a()}),l=P(n().getTfootProps,{instance:a()});Object.assign(e,{getTheadProps:i,getTfootProps:l})}function So(e){return"number"==typeof e?"".concat(e,"px"):void 0}function Oo(e,t){var r="undefined"!=typeof Symbol&&e[Symbol.iterator]||e["@@iterator"];if(!r){if(Array.isArray(e)||(r=Ro(e))||t&&e&&"number"==typeof e.length){r&&(e=r);var n=0,o=function(){};return{s:o,n:function(){return n>=e.length?{done:!0}:{done:!1,value:e[n++]}},e:function(e){throw e},f:o}}throw new TypeError("Invalid attempt to iterate non-iterable instance.\nIn order to be iterable, non-array objects must have a [Symbol.iterator]() method.")}var a,i=!0,l=!1;return{s:function(){r=r.call(e)},n:function(){var e=r.next();return i=e.done,e},e:function(e){l=!0,a=e},f:function(){try{i||null==r.return||r.return()}finally{if(l)throw a}}}}function Ro(e,t){if(e){if("string"==typeof e)return jo(e,t);var r=Object.prototype.toString.call(e).slice(8,-1);return"Object"===r&&e.constructor&&(r=e.constructor.name),"Map"===r||"Set"===r?Array.from(e):"Arguments"===r||/^(?:Ui|I)nt(?:8|16|32)(?:Clamped)?Array$/.test(r)?jo(e,t):void 0}}function jo(e,t){(null==t||t>e.length)&&(t=e.length);for(var r=0,n=new Array(t);r<t;r++)n[r]=e[r];return n}function Po(e){e.getHeaderProps.push(Eo),e.getCellProps.push(Co),e.getFooterProps.push(Ao),e.useInstance.push(xo)}Po.pluginName="useStickyColumns";var Eo=function(e,t){var r=t.column;return r.stickyProps?[e,r.stickyProps]:e},Co=function(e,t){var r=t.cell;return r.column.stickyProps?[e,r.column.stickyProps]:e},Ao=function(e,t){var r=t.column;return r.stickyProps?[e,r.stickyProps]:e};function xo(e){var t=e.plugins,r=e.headerGroups;A(t,["useResizeColumns"],"useStickyColumns"),r.forEach((function(e){var t=e.headers;t.forEach((function(e){var t,r=[e];e.columns&&r.push.apply(r,function(e){if(Array.isArray(e))return jo(e)}(t=xn(e))||function(e){if("undefined"!=typeof Symbol&&null!=e[Symbol.iterator]||null!=e["@@iterator"])return Array.from(e)}(t)||Ro(t)||function(){throw new TypeError("Invalid attempt to spread non-iterable instance.\nIn order to be iterable, non-array objects must have a [Symbol.iterator]() method.")}());var n=r.find((function(e){return e.sticky}));n&&r.forEach((function(e){e.sticky=n.sticky}))})),t.forEach((function(e){e.sticky&&(e.stickyProps=function(e,t){var r={className:"rt-sticky",style:{position:"sticky"}};if("left"===e.sticky){var n=t.filter((function(e){return"left"===e.sticky}));r.style.left=0;var o,a=Oo(n);try{for(a.s();!(o=a.n()).done;){var i=o.value;if(i.id===e.id)break;r.style.left+=i.totalWidth}}catch(e){a.e(e)}finally{a.f()}}else if("right"===e.sticky){var l=t.filter((function(e){return"right"===e.sticky}));r.style.right=0;var u,c=Oo(l.reverse());try{for(c.s();!(u=c.n()).done;){var s=u.value;if(s.id===e.id)break;r.style.right+=s.totalWidth}}catch(e){c.e(e)}finally{c.f()}}return r}(e,t))}))}))}function ko(e,t){return function(e){if(Array.isArray(e))return e}(e)||function(e,t){var r=null==e?null:"undefined"!=typeof Symbol&&e[Symbol.iterator]||e["@@iterator"];if(null!=r){var n,o,a=[],i=!0,l=!1;try{for(r=r.call(e);!(i=(n=r.next()).done)&&(a.push(n.value),!t||a.length!==t);i=!0);}catch(e){l=!0,o=e}finally{try{i||null==r.return||r.return()}finally{if(l)throw o}}return a}}(e,t)||Do(e,t)||function(){throw new TypeError("Invalid attempt to destructure non-iterable instance.\nIn order to be iterable, non-array objects must have a [Symbol.iterator]() method.")}()}function Io(e,t){var r=Object.keys(e);if(Object.getOwnPropertySymbols){var n=Object.getOwnPropertySymbols(e);t&&(n=n.filter((function(t){return Object.getOwnPropertyDescriptor(e,t).enumerable}))),r.push.apply(r,n)}return r}function No(e){for(var t=1;t<arguments.length;t++){var r=null!=arguments[t]?arguments[t]:{};t%2?Io(Object(r),!0).forEach((function(t){Bo(e,t,r[t])})):Object.getOwnPropertyDescriptors?Object.defineProperties(e,Object.getOwnPropertyDescriptors(r)):Io(Object(r)).forEach((function(t){Object.defineProperty(e,t,Object.getOwnPropertyDescriptor(r,t))}))}return e}function Bo(e,t,r){return t in e?Object.defineProperty(e,t,{value:r,enumerable:!0,configurable:!0,writable:!0}):e[t]=r,e}function Fo(e){return function(e){if(Array.isArray(e))return Go(e)}(e)||function(e){if("undefined"!=typeof Symbol&&null!=e[Symbol.iterator]||null!=e["@@iterator"])return Array.from(e)}(e)||Do(e)||function(){throw new TypeError("Invalid attempt to spread non-iterable instance.\nIn order to be iterable, non-array objects must have a [Symbol.iterator]() method.")}()}function Do(e,t){if(e){if("string"==typeof e)return Go(e,t);var r=Object.prototype.toString.call(e).slice(8,-1);return"Object"===r&&e.constructor&&(r=e.constructor.name),"Map"===r||"Set"===r?Array.from(e):"Arguments"===r||/^(?:Ui|I)nt(?:8|16|32)(?:Clamped)?Array$/.test(r)?Go(e,t):void 0}}function Go(e,t){(null==t||t>e.length)&&(t=e.length);for(var r=0,n=new Array(t);r<t;r++)n[r]=e[r];return n}var zo={},Mo=[],To={};function Wo(e){e.getGroupByToggleProps=[Ho],e.stateReducers.push(_o),e.visibleColumnsDeps.push((function(e,t){var r=t.instance;return[].concat(Fo(e),[r.state.groupBy])})),e.visibleColumns.push(Lo),e.useInstance.push($o),e.prepareRow.push(Uo)}w.resetGroupBy="resetGroupBy",w.setGroupBy="setGroupBy",w.toggleGroupBy="toggleGroupBy",Wo.pluginName="useGroupBy";var Ho=function(e,t){var r=t.header;return[e,{onClick:r.canGroupBy?function(e){e.persist(),r.toggleGroupBy()}:void 0,style:{cursor:r.canGroupBy?"pointer":void 0},title:"Toggle GroupBy"}]};function _o(e,t,r,n){if(t.type===w.init)return No({groupBy:[]},e);if(t.type===w.resetGroupBy)return No(No({},e),{},{groupBy:n.initialState.groupBy||[]});if(t.type===w.setGroupBy){var o=t.value;return No(No({},e),{},{groupBy:o})}if(t.type===w.toggleGroupBy){var a=t.columnId,i=t.value,l=void 0!==i?i:!e.groupBy.includes(a);return No(No({},e),{},l?{groupBy:[].concat(Fo(e.groupBy),[a])}:{groupBy:e.groupBy.filter((function(e){return e!==a}))})}}function Lo(e,t){var r=t.instance.state.groupBy,n=r.map((function(t){return e.find((function(e){return e.id===t}))})).filter(Boolean),o=e.filter((function(e){return!r.includes(e.id)}));return(e=[].concat(Fo(n),Fo(o))).forEach((function(e){e.isGrouped=r.includes(e.id),e.groupedIndex=r.indexOf(e.id)})),e}var Vo={};function $o(e){var t=e.data,r=e.rows,n=e.flatRows,o=e.rowsById,a=e.allColumns,l=e.flatHeaders,u=e.groupByFn,c=void 0===u?Ko:u,s=e.manualGroupBy,f=e.aggregations,d=void 0===f?Vo:f,p=e.plugins,g=e.state.groupBy,y=e.dispatch,m=e.autoResetGroupBy,h=void 0===m||m,b=e.disableGroupBy,v=e.defaultCanGroupBy,S=e.getHooks;A(p,["useColumnOrder","useFilters"],"useGroupBy");var O=k(e);a.forEach((function(t){var r=t.accessor,n=t.defaultGroupBy,o=t.disableGroupBy;t.canGroupBy=r?Cn(t.canGroupBy,!0!==o&&void 0,!0!==b&&void 0,!0):Cn(t.canGroupBy,n,v,!1),t.canGroupBy&&(t.toggleGroupBy=function(){return e.toggleGroupBy(t.id)}),t.Aggregated=t.Aggregated||t.Cell}));var R=i().useCallback((function(e,t){y({type:w.toggleGroupBy,columnId:e,value:t})}),[y]),j=i().useCallback((function(e){y({type:w.setGroupBy,value:e})}),[y]);l.forEach((function(e){e.getGroupByToggleProps=P(S().getGroupByToggleProps,{instance:O(),header:e})}));var E=i().useMemo((function(){if(s||!g.length)return[r,n,o,Mo,To,n,o];var e=g.filter((function(e){return a.find((function(t){return t.id===e}))})),t=function(e,t,r,n){var o={};return a.forEach((function(a){if(n.includes(a.id)){var i="function"==typeof a.aggregate?a.aggregate:d[a.aggregate]||zo[a.aggregate];if(i){var l=e.map((function(e){var t=e.values[a.id];if(!r&&a.aggregateValue){var n="function"==typeof a.aggregateValue?a.aggregateValue:d[a.aggregateValue]||zo[a.aggregateValue];if(!n)throw console.info({column:a}),new Error("React Table: Invalid column.aggregateValue option for column listed above");t=n(t,e,a)}return t}));o[a.id]=i(l,e.map((function(e){return e.values})),t.map((function(e){return e.values})))}else{if(a.aggregate)throw console.info({column:a}),new Error("React Table: Invalid column.aggregate option for column listed above");o[a.id]=null}}else o[a.id]=t[0]?t[0].values[a.id]:null})),o},i=[],l={},u=[],f={},p=[],y={},m=function r(n){var o=arguments.length>1&&void 0!==arguments[1]?arguments[1]:0,s=arguments.length>2?arguments[2]:void 0;if(o===e.length)return n.forEach((function(e){e.depth=o})),n;var d=e[o],g=c(n,d),m=Object.entries(g).map((function(n,c){var g=ko(n,2),m=g[0],h=g[1],b="".concat(d,":").concat(m);b=s?"".concat(s,">").concat(b):b;var v=r(h,o+1,b),w=o?Xo(h,"leafRows"):h,S=e.slice(0,o+1),O=a.filter((function(e){return!S.includes(e.id)})).map((function(e){return e.id})),R=t(w,v,o,O),j={id:b,isGrouped:!0,groupByID:d,groupByVal:m,values:R,subRows:v,leafRows:w,depth:o,index:void 0,groupIndex:c,aggregatedColumns:O};return v.forEach((function(e){i.push(e),l[e.id]=e,e.isGrouped?(u.push(e),f[e.id]=e):(p.push(e),y[e.id]=e)})),j}));return m}(r);return m.forEach((function(e){i.push(e),l[e.id]=e,e.isGrouped?(u.push(e),f[e.id]=e):(p.push(e),y[e.id]=e)})),[m,i,l,u,f,p,y]}),[s,g,r,n,o,a,d,c]),C=ko(E,7),x=C[0],I=C[1],B=C[2],F=C[3],D=C[4],G=C[5],z=C[6],M=k(h);N((function(){M()&&y({type:w.resetGroupBy})}),[y,s?null:t]),Object.assign(e,{preGroupedRows:r,preGroupedFlatRow:n,preGroupedRowsById:o,groupedRows:x,groupedFlatRows:I,groupedRowsById:B,onlyGroupedFlatRows:F,onlyGroupedRowsById:D,nonGroupedFlatRows:G,nonGroupedRowsById:z,rows:x,flatRows:I,rowsById:B,toggleGroupBy:R,setGroupBy:j})}function Uo(e){e.allCells.forEach((function(t){var r,n;t.isGrouped=t.column.isGrouped&&t.column.id===e.groupByID,t.isAggregated=!t.isGrouped&&(null===(r=e.aggregatedColumns)||void 0===r?void 0:r.includes(t.column.id))&&(null===(n=e.subRows)||void 0===n?void 0:n.length),t.isPlaceholder=!t.isGrouped&&t.column.isGrouped&&!t.isAggregated}))}function Ko(e,t){return e.reduce((function(e,r){var n="".concat(r.values[t]);return e[n]=Array.isArray(e[n])?e[n]:[],e[n].push(r),e}),{})}function Xo(e,t){var r=[];return function e(n){n.forEach((function(n){n[t]?e(n[t]):r.push(n)}))}(e),r}function Jo(e,t){var r=Object.keys(e);if(Object.getOwnPropertySymbols){var n=Object.getOwnPropertySymbols(e);t&&(n=n.filter((function(t){return Object.getOwnPropertyDescriptor(e,t).enumerable}))),r.push.apply(r,n)}return r}function qo(e){for(var t=1;t<arguments.length;t++){var r=null!=arguments[t]?arguments[t]:{};t%2?Jo(Object(r),!0).forEach((function(t){Zo(e,t,r[t])})):Object.getOwnPropertyDescriptors?Object.defineProperties(e,Object.getOwnPropertyDescriptors(r)):Jo(Object(r)).forEach((function(t){Object.defineProperty(e,t,Object.getOwnPropertyDescriptor(r,t))}))}return e}function Zo(e,t,r){return t in e?Object.defineProperty(e,t,{value:r,enumerable:!0,configurable:!0,writable:!0}):e[t]=r,e}function Yo(e,t){return function(e){if(Array.isArray(e))return e}(e)||function(e,t){var r=null==e?null:"undefined"!=typeof Symbol&&e[Symbol.iterator]||e["@@iterator"];if(null!=r){var n,o,a=[],i=!0,l=!1;try{for(r=r.call(e);!(i=(n=r.next()).done)&&(a.push(n.value),!t||a.length!==t);i=!0);}catch(e){l=!0,o=e}finally{try{i||null==r.return||r.return()}finally{if(l)throw o}}return a}}(e,t)||function(e,t){if(e){if("string"==typeof e)return Qo(e,t);var r=Object.prototype.toString.call(e).slice(8,-1);return"Object"===r&&e.constructor&&(r=e.constructor.name),"Map"===r||"Set"===r?Array.from(e):"Arguments"===r||/^(?:Ui|I)nt(?:8|16|32)(?:Clamped)?Array$/.test(r)?Qo(e,t):void 0}}(e,t)||function(){throw new TypeError("Invalid attempt to destructure non-iterable instance.\nIn order to be iterable, non-array objects must have a [Symbol.iterator]() method.")}()}function Qo(e,t){(null==t||t>e.length)&&(t=e.length);for(var r=0,n=new Array(t);r<t;r++)n[r]=e[r];return n}var ea=null;function ta(e){e.getResizerProps=[ra],e.getHeaderProps.push({style:{position:"relative"}}),e.stateReducers.push(na),e.useInstance.push(aa),e.useInstanceBeforeDimensions.push(oa)}O.canResize=!0,w.columnStartResizing="columnStartResizing",w.columnResizing="columnResizing",w.columnDoneResizing="columnDoneResizing",w.resetResize="resetResize";var ra=function(e,t){var r=t.instance,n=t.header,o=r.dispatch,a=function(e,t){var r=!1;if("touchstart"===e.type){if(e.touches&&e.touches.length>1)return;r=!0}var n,a,i=function(e){var t=[];return function e(r){r.columns&&r.columns.length&&r.columns.forEach(e),t.push(r)}(e),t}(t),l=i.map((function(e){return[e.id,e.getDOMWidth()]})),u=l.find((function(e){return Yo(e,1)[0]===t.id}))[1],c=r?Math.round(e.touches[0].clientX):e.clientX,s=function(){window.cancelAnimationFrame(n),n=null,o({type:w.columnResizing,clientX:a})},f=function(){window.cancelAnimationFrame(n),n=null,o({type:w.columnDoneResizing})},d=function(e){a=e,n||(n=window.requestAnimationFrame(s))},p={mouse:{moveEvent:"mousemove",moveHandler:function(e){return d(e.clientX)},upEvent:"mouseup",upHandler:function(){document.removeEventListener("mousemove",p.mouse.moveHandler),document.removeEventListener("mouseup",p.mouse.upHandler),f()}},touch:{moveEvent:"touchmove",moveHandler:function(e){return e.cancelable&&(e.preventDefault(),e.stopPropagation()),d(e.touches[0].clientX),!1},upEvent:"touchend",upHandler:function(){document.removeEventListener(p.touch.moveEvent,p.touch.moveHandler),document.removeEventListener(p.touch.upEvent,p.touch.upHandler),f()}}},g=r?p.touch:p.mouse,y=!!function(){if("boolean"==typeof ea)return ea;var e=!1;try{var t={get passive(){return e=!0,!1}};window.addEventListener("test",null,t),window.removeEventListener("test",null,t)}catch(t){e=!1}return ea=e}()&&{passive:!1};document.addEventListener(g.moveEvent,g.moveHandler,y),document.addEventListener(g.upEvent,g.upHandler,y),o({type:w.columnStartResizing,columnId:t.id,columnWidth:u,headerIdWidths:l,clientX:c})};return[e,{onMouseDown:function(e){return e.persist()||a(e,n)},onTouchStart:function(e){return e.persist()||a(e,n)},style:{cursor:"col-resize"},draggable:!1,role:"separator"}]};function na(e,t){if(t.type===w.init)return qo({columnResizing:{columnWidths:{}}},e);if(t.type===w.resetResize)return qo(qo({},e),{},{columnResizing:{columnWidths:{}}});if(t.type===w.columnStartResizing){var r=t.clientX,n=t.columnId,o=t.columnWidth,a=t.headerIdWidths;return qo(qo({},e),{},{columnResizing:qo(qo({},e.columnResizing),{},{startX:r,headerIdWidths:a,columnWidth:o,isResizingColumn:n})})}if(t.type===w.columnResizing){var i=t.clientX,l=e.columnResizing,u=l.startX,c=l.columnWidth,s=l.headerIdWidths,f=(i-u)/c,d={};return(void 0===s?[]:s).forEach((function(e){var t=Yo(e,2),r=t[0],n=t[1];d[r]=Math.max(n+n*f,0)})),qo(qo({},e),{},{columnResizing:qo(qo({},e.columnResizing),{},{columnWidths:qo(qo({},e.columnResizing.columnWidths),d)})})}return t.type===w.columnDoneResizing?qo(qo({},e),{},{columnResizing:qo(qo({},e.columnResizing),{},{startX:null,isResizingColumn:null})}):void 0}ta.pluginName="useResizeColumns";var oa=function(e){var t=e.flatHeaders,r=e.disableResizing,n=e.getHooks,o=e.state.columnResizing,a=k(e);t.forEach((function(e){var t=Cn(!0!==e.disableResizing&&void 0,!0!==r&&void 0,!0);e.canResize=t,e.width=Cn(o.columnWidths[e.id],e.originalWidth,e.width),e.isResizing=o.isResizingColumn===e.id,t&&(e.getResizerProps=P(n().getResizerProps,{instance:a(),header:e}))}))};function aa(e){var t=e.plugins,r=e.dispatch,n=e.autoResetResize,o=void 0===n||n,a=e.columns;A(t,["useAbsoluteLayout"],"useResizeColumns");var l=k(o);N((function(){l()&&r({type:w.resetResize})}),[a]);var u=i().useCallback((function(){return r({type:w.resetResize})}),[r]);Object.assign(e,{resetResizing:u})}function ia(e,t){var r=Object.keys(e);if(Object.getOwnPropertySymbols){var n=Object.getOwnPropertySymbols(e);t&&(n=n.filter((function(t){return Object.getOwnPropertyDescriptor(e,t).enumerable}))),r.push.apply(r,n)}return r}function la(e){for(var t=1;t<arguments.length;t++){var r=null!=arguments[t]?arguments[t]:{};t%2?ia(Object(r),!0).forEach((function(t){ua(e,t,r[t])})):Object.getOwnPropertyDescriptors?Object.defineProperties(e,Object.getOwnPropertyDescriptors(r)):ia(Object(r)).forEach((function(t){Object.defineProperty(e,t,Object.getOwnPropertyDescriptor(r,t))}))}return e}function ua(e,t,r){return t in e?Object.defineProperty(e,t,{value:r,enumerable:!0,configurable:!0,writable:!0}):e[t]=r,e}function ca(e){e.getToggleRowSelectedProps=[sa],e.getToggleAllRowsSelectedProps=[fa],e.getToggleAllPageRowsSelectedProps=[da],e.stateReducers.push(pa),e.useInstance.push(ga),e.prepareRow.push(ya)}w.resetSelectedRows="resetSelectedRows",w.toggleAllRowsSelected="toggleAllRowsSelected",w.toggleRowSelected="toggleRowSelected",w.toggleAllPageRowsSelected="toggleAllPageRowsSelected",w.setRowsSelected="setRowsSelected",ca.pluginName="useRowSelect";var sa=function(e,t){var r=t.instance,n=t.row,o=r.manualRowSelectedKey,a=void 0===o?"isSelected":o;return[e,{onChange:function(e){n.toggleRowSelected(e.target.checked)},style:{cursor:"pointer"},checked:!(!n.original||!n.original[a])||n.isSelected,title:"Toggle Row Selected",indeterminate:n.isSomeSelected}]},fa=function(e,t){var r=t.instance;return[e,{onChange:function(e){r.toggleAllRowsSelected(e.target.checked)},style:{cursor:"pointer"},checked:r.isAllRowsSelected,title:"Toggle All Rows Selected",indeterminate:Boolean(!r.isAllRowsSelected&&Object.keys(r.state.selectedRowIds).length)}]},da=function(e,t){var r=t.instance;return[e,{onChange:function(e){r.toggleAllPageRowsSelected(e.target.checked)},style:{cursor:"pointer"},checked:r.isAllPageRowsSelected,title:"Toggle All Current Page Rows Selected",indeterminate:Boolean(!r.isAllPageRowsSelected&&r.page.some((function(e){var t=e.id;return r.state.selectedRowIds[t]})))}]};function pa(e,t,r,n){if(t.type===w.init)return la({selectedRowIds:{}},e);if(t.type===w.resetSelectedRows)return la(la({},e),{},{selectedRowIds:n.initialState.selectedRowIds||{}});if(t.type===w.toggleAllRowsSelected){var o=t.value,a=n.isAllRowsSelected,i=n.rowsById,l=n.nonGroupedRowsById,u=void 0===l?i:l,c=void 0!==o?o:!a,s=Object.assign({},e.selectedRowIds);return c?Object.keys(u).forEach((function(e){s[e]=!0})):Object.keys(u).forEach((function(e){delete s[e]})),la(la({},e),{},{selectedRowIds:s})}if(t.type===w.toggleRowSelected){var f=t.id,d=t.value,p=n.rowsById,g=n.selectSubRows,y=void 0===g||g,m=e.selectedRowIds[f],h=void 0!==d?d:!m;if(m===h)return e;var b=la({},e.selectedRowIds);return function e(t){var r=p[t];if(r.isGrouped||(h?b[t]=!0:delete b[t]),y&&r.subRows)return r.subRows.forEach((function(t){return e(t.id)}))}(f),la(la({},e),{},{selectedRowIds:b})}if(t.type===w.toggleAllPageRowsSelected){var v=t.value,S=n.page,O=n.rowsById,R=n.selectSubRows,j=void 0===R||R,P=n.isAllPageRowsSelected,E=void 0!==v?v:!P,C=la({},e.selectedRowIds),A=function e(t){var r=O[t];if(r.isGrouped||(E?C[t]=!0:delete C[t]),j&&r.subRows)return r.subRows.forEach((function(t){return e(t.id)}))};return S.forEach((function(e){return A(e.id)})),la(la({},e),{},{selectedRowIds:C})}if(t.type===w.setRowsSelected){var x=t.ids,k=n.rowsById,I=n.selectSubRows,N=void 0===I||I,B={},F=function e(t){var r=k[t];if(r)return r.isGrouped||(B[t]=!0),N&&r.subRows?r.subRows.forEach((function(t){return e(t.id)})):void 0;B[t]=!0};return x.forEach((function(e){return F(e)})),la(la({},e),{},{selectedRowIds:B})}return e}function ga(e){var t=e.data,r=e.rows,n=e.getHooks,o=e.plugins,a=e.rowsById,l=e.nonGroupedRowsById,u=void 0===l?a:l,c=e.autoResetSelectedRows,s=void 0===c||c,f=e.state.selectedRowIds,d=e.selectSubRows,p=void 0===d||d,g=e.dispatch,y=e.page;A(o,["useFilters","useGroupBy","useSortBy","useExpanded","usePagination"],"useRowSelect");var m=i().useMemo((function(){var e=[],t=function t(r){var n=p?ma(r,f):!!f[r.id];r.isSelected=!!n,r.isSomeSelected=null===n,n&&e.push(r),r.subRows&&r.subRows.length&&r.subRows.forEach((function(e){return t(e)}))};return r.forEach((function(e){return t(e)})),e}),[r,p,f]),h=Boolean(Object.keys(u).length&&Object.keys(f).length),b=h;h&&Object.keys(u).some((function(e){return!f[e]}))&&(h=!1),h||y&&y.length&&y.some((function(e){var t=e.id;return!f[t]}))&&(b=!1);var v=k(s);N((function(){v()&&g({type:w.resetSelectedRows})}),[g,t]);var S=i().useCallback((function(e){return g({type:w.toggleAllRowsSelected,value:e})}),[g]),O=i().useCallback((function(e){return g({type:w.toggleAllPageRowsSelected,value:e})}),[g]),R=i().useCallback((function(e,t){return g({type:w.toggleRowSelected,id:e,value:t})}),[g]),j=i().useCallback((function(e){return g({type:w.setRowsSelected,ids:e})}),[g]),E=k(e),C=P(n().getToggleAllRowsSelectedProps,{instance:E()}),x=P(n().getToggleAllPageRowsSelectedProps,{instance:E()});Object.assign(e,{selectedFlatRows:m,isAllRowsSelected:h,isAllPageRowsSelected:b,toggleRowSelected:R,toggleAllRowsSelected:S,setRowsSelected:j,getToggleAllRowsSelectedProps:C,getToggleAllPageRowsSelectedProps:x,toggleAllPageRowsSelected:O})}function ya(e,t){var r=t.instance;e.toggleRowSelected=function(t){return r.toggleRowSelected(e.id,t)},e.getToggleRowSelectedProps=P(r.getHooks().getToggleRowSelectedProps,{instance:r,row:e})}function ma(e,t){if(t[e.id])return!0;var r=e.subRows;if(r&&r.length){var n=!0,o=!1;return r.forEach((function(e){o&&!n||(ma(e,t)?o=!0:n=!1)})),!!n||!!o&&null}return!1}function ha(e,t){if(e){if("string"==typeof e)return ba(e,t);var r=Object.prototype.toString.call(e).slice(8,-1);return"Object"===r&&e.constructor&&(r=e.constructor.name),"Map"===r||"Set"===r?Array.from(e):"Arguments"===r||/^(?:Ui|I)nt(?:8|16|32)(?:Clamped)?Array$/.test(r)?ba(e,t):void 0}}function ba(e,t){(null==t||t>e.length)&&(t=e.length);for(var r=0,n=new Array(t);r<t;r++)n[r]=e[r];return n}function va(e,t){var r=Object.keys(e);if(Object.getOwnPropertySymbols){var n=Object.getOwnPropertySymbols(e);t&&(n=n.filter((function(t){return Object.getOwnPropertyDescriptor(e,t).enumerable}))),r.push.apply(r,n)}return r}function wa(e){for(var t=1;t<arguments.length;t++){var r=null!=arguments[t]?arguments[t]:{};t%2?va(Object(r),!0).forEach((function(t){Sa(e,t,r[t])})):Object.getOwnPropertyDescriptors?Object.defineProperties(e,Object.getOwnPropertyDescriptors(r)):va(Object(r)).forEach((function(t){Object.defineProperty(e,t,Object.getOwnPropertyDescriptor(r,t))}))}return e}function Sa(e,t,r){return t in e?Object.defineProperty(e,t,{value:r,enumerable:!0,configurable:!0,writable:!0}):e[t]=r,e}function Oa(e){e.stateReducers.push(Ra),e.useInstance.push(ja)}function Ra(e,t,r,n){if(t.type===w.init)return wa({pageSize:10,pageIndex:0},e);if(t.type===w.resetPage)return wa(wa({},e),{},{pageIndex:n.initialState.pageIndex||0});if(t.type===w.gotoPage){var o=n.pageCount,a=n.page,i=x(t.pageIndex,e.pageIndex),l=!1;return i>e.pageIndex?l=-1===o?a.length>=e.pageSize:i<o:i<e.pageIndex&&(l=i>-1),l?wa(wa({},e),{},{pageIndex:i}):e}if(t.type===w.setPageSize){var u=t.pageSize,c=e.pageSize*e.pageIndex,s=Math.floor(c/u);return wa(wa({},e),{},{pageIndex:s,pageSize:u})}}function ja(e){var t=e.rows,r=e.autoResetPage,n=void 0===r||r,o=e.manualExpandedKey,a=void 0===o?"expanded":o,l=e.plugins,u=e.pageCount,c=e.paginateExpandedRows,s=void 0===c||c,f=e.expandSubRows,d=void 0===f||f,p=e.disablePagination,g=e.state,y=g.pageIndex,m=g.expanded,h=g.globalFilter,b=g.filters,v=g.groupBy,S=g.sortBy,O=e.dispatch,R=e.data,j=e.manualPagination;A(l,["useGlobalFilter","useFilters","useGroupBy","useSortBy","useExpanded"],"usePagination");var P=k(n);N((function(){P()&&O({type:w.resetPage})}),[O,j?null:R,h,b,v,S]);var E=p?t.length:e.state.pageSize,C=j?u:Math.ceil(t.length/E),x=i().useMemo((function(){return C>0?(e=new Array(C),function(e){if(Array.isArray(e))return ba(e)}(e)||function(e){if("undefined"!=typeof Symbol&&null!=e[Symbol.iterator]||null!=e["@@iterator"])return Array.from(e)}(e)||ha(e)||function(){throw new TypeError("Invalid attempt to spread non-iterable instance.\nIn order to be iterable, non-array objects must have a [Symbol.iterator]() method.")}()).fill(null).map((function(e,t){return t})):[];var e}),[C]),I=i().useMemo((function(){var e;if(j)e=t;else{var r=E*y,n=r+E;e=t.slice(r,n)}var o=e.length;return s?[e,o]:[Pa(e,{manualExpandedKey:a,expanded:m,expandSubRows:d}),o]}),[d,m,a,j,y,E,s,t]),B=function(e,t){return function(e){if(Array.isArray(e))return e}(e)||function(e,t){var r=null==e?null:"undefined"!=typeof Symbol&&e[Symbol.iterator]||e["@@iterator"];if(null!=r){var n,o,a=[],i=!0,l=!1;try{for(r=r.call(e);!(i=(n=r.next()).done)&&(a.push(n.value),!t||a.length!==t);i=!0);}catch(e){l=!0,o=e}finally{try{i||null==r.return||r.return()}finally{if(l)throw o}}return a}}(e,t)||ha(e,t)||function(){throw new TypeError("Invalid attempt to destructure non-iterable instance.\nIn order to be iterable, non-array objects must have a [Symbol.iterator]() method.")}()}(I,2),F=B[0],D=B[1],G=y>0,z=-1===C?F.length>=E:y<C-1,M=i().useCallback((function(e){O({type:w.gotoPage,pageIndex:e})}),[O]),T=i().useCallback((function(){return M((function(e){return e-1}))}),[M]),W=i().useCallback((function(){return M((function(e){return e+1}))}),[M]),H=i().useCallback((function(e){O({type:w.setPageSize,pageSize:e})}),[O]);Object.assign(e,{pageOptions:x,pageCount:C,page:F,pageRowCount:D,canPreviousPage:G,canNextPage:z,gotoPage:M,previousPage:T,nextPage:W,setPageSize:H})}function Pa(e,t){var r=t.manualExpandedKey,n=t.expanded,o=t.expandSubRows,a=void 0===o||o,i=[],l=function e(t){var o=!(arguments.length>1&&void 0!==arguments[1])||arguments[1];t.isExpanded=t.original&&t.original[r]||n[t.id],t.canExpand=t.subRows&&!!t.subRows.length,o&&i.push(t),t.subRows&&t.subRows.length&&t.isExpanded&&t.subRows.forEach((function(t){return e(t,a)}))};return e.forEach((function(e){return l(e)})),i}function Ea(e,t){var r=Object.keys(e);if(Object.getOwnPropertySymbols){var n=Object.getOwnPropertySymbols(e);t&&(n=n.filter((function(t){return Object.getOwnPropertyDescriptor(e,t).enumerable}))),r.push.apply(r,n)}return r}function Ca(e){for(var t=1;t<arguments.length;t++){var r=null!=arguments[t]?arguments[t]:{};t%2?Ea(Object(r),!0).forEach((function(t){Aa(e,t,r[t])})):Object.getOwnPropertyDescriptors?Object.defineProperties(e,Object.getOwnPropertyDescriptors(r)):Ea(Object(r)).forEach((function(t){Object.defineProperty(e,t,Object.getOwnPropertyDescriptor(r,t))}))}return e}function Aa(e,t,r){return t in e?Object.defineProperty(e,t,{value:r,enumerable:!0,configurable:!0,writable:!0}):e[t]=r,e}function xa(e){return xa="function"==typeof Symbol&&"symbol"==typeof Symbol.iterator?function(e){return typeof e}:function(e){return e&&"function"==typeof Symbol&&e.constructor===Symbol&&e!==Symbol.prototype?"symbol":typeof e},xa(e)}function ka(e,t){return function(e){if(Array.isArray(e))return e}(e)||function(e,t){var r=null==e?null:"undefined"!=typeof Symbol&&e[Symbol.iterator]||e["@@iterator"];if(null!=r){var n,o,a=[],i=!0,l=!1;try{for(r=r.call(e);!(i=(n=r.next()).done)&&(a.push(n.value),!t||a.length!==t);i=!0);}catch(e){l=!0,o=e}finally{try{i||null==r.return||r.return()}finally{if(l)throw o}}return a}}(e,t)||function(e,t){if(e){if("string"==typeof e)return Ia(e,t);var r=Object.prototype.toString.call(e).slice(8,-1);return"Object"===r&&e.constructor&&(r=e.constructor.name),"Map"===r||"Set"===r?Array.from(e):"Arguments"===r||/^(?:Ui|I)nt(?:8|16|32)(?:Clamped)?Array$/.test(r)?Ia(e,t):void 0}}(e,t)||function(){throw new TypeError("Invalid attempt to destructure non-iterable instance.\nIn order to be iterable, non-array objects must have a [Symbol.iterator]() method.")}()}function Ia(e,t){(null==t||t>e.length)&&(t=e.length);for(var r=0,n=new Array(t);r<t;r++)n[r]=e[r];return n}function Na(e,t){(null==t||t>e.length)&&(t=e.length);for(var r=0,n=new Array(t);r<t;r++)n[r]=e[r];return n}function Ba(e){var t=Ta(e);return 0===t.length?0:Ma(t.reduce((function(e,t){return e+t}),0),12)}function Fa(e){var t=Ta(e);return 0===t.length?NaN:Ma(Ba(t)/t.length,12)}w.resetPage="resetPage",w.gotoPage="gotoPage",w.setPageSize="setPageSize",Oa.pluginName="usePagination";var Da={mean:Fa,sum:Ba,max:function(e){var t=Ta(e);return 0===t.length?NaN:Math.max.apply(null,t)},min:function(e){var t=Ta(e);return 0===t.length?NaN:Math.min.apply(null,t)},median:function(e){var t=Ta(e);return 0===t.length?NaN:(t.sort((function(e,t){return e-t})),t.length%2==1?t[(t.length-1)/2]:Fa(t.slice(t.length/2-1,t.length/2+1)))}},Ga={max:function(e){var t;return e.forEach((function(e){(null==t||e>t)&&(t=e)})),t},min:function(e){var t;return e.forEach((function(e){(null==t||e<t)&&(t=e)})),t},count:function(e){return e.length},unique:function(e){return(t=new Set(e),function(e){if(Array.isArray(e))return Na(e)}(t)||function(e){if("undefined"!=typeof Symbol&&null!=e[Symbol.iterator]||null!=e["@@iterator"])return Array.from(e)}(t)||function(e,t){if(e){if("string"==typeof e)return Na(e,t);var r=Object.prototype.toString.call(e).slice(8,-1);return"Object"===r&&e.constructor&&(r=e.constructor.name),"Map"===r||"Set"===r?Array.from(e):"Arguments"===r||/^(?:Ui|I)nt(?:8|16|32)(?:Clamped)?Array$/.test(r)?Na(e,t):void 0}}(t)||function(){throw new TypeError("Invalid attempt to spread non-iterable instance.\nIn order to be iterable, non-array objects must have a [Symbol.iterator]() method.")}()).join(", ");var t},frequency:function(e){var t={};return e.forEach((function(e){t[e]=t[e]||0,t[e]+=1})),Object.keys(t).map((function(e){return e+(t[e]>1?" (".concat(t[e],")"):"")})).join(", ")}};function za(e,t){return"numeric"===t&&Da[e]?Da[e]:Ga[e]}function Ma(e){var t=arguments.length>1&&void 0!==arguments[1]?arguments[1]:3;if(!Number.isFinite(e))return e;t=t>0?t:0;var r=Math.pow(10,t);return Math.sign(e)*Math.round(Math.abs(e)*r)/r}function Ta(e){return e.filter((function(e){return null!=e&&!Number.isNaN(e)}))}var Wa=["html","className"];function Ha(e,t){var r=Object.keys(e);if(Object.getOwnPropertySymbols){var n=Object.getOwnPropertySymbols(e);t&&(n=n.filter((function(t){return Object.getOwnPropertyDescriptor(e,t).enumerable}))),r.push.apply(r,n)}return r}function _a(e){for(var t=1;t<arguments.length;t++){var r=null!=arguments[t]?arguments[t]:{};t%2?Ha(Object(r),!0).forEach((function(t){La(e,t,r[t])})):Object.getOwnPropertyDescriptors?Object.defineProperties(e,Object.getOwnPropertyDescriptors(r)):Ha(Object(r)).forEach((function(t){Object.defineProperty(e,t,Object.getOwnPropertyDescriptor(r,t))}))}return e}function La(e,t,r){return t in e?Object.defineProperty(e,t,{value:r,enumerable:!0,configurable:!0,writable:!0}):e[t]=r,e}function Va(){return Va=Object.assign?Object.assign.bind():function(e){for(var t=1;t<arguments.length;t++){var r=arguments[t];for(var n in r)Object.prototype.hasOwnProperty.call(r,n)&&(e[n]=r[n])}return e},Va.apply(this,arguments)}function $a(e,t){var r="undefined"!=typeof Symbol&&e[Symbol.iterator]||e["@@iterator"];if(!r){if(Array.isArray(e)||(r=function(e,t){if(e){if("string"==typeof e)return Ua(e,t);var r=Object.prototype.toString.call(e).slice(8,-1);return"Object"===r&&e.constructor&&(r=e.constructor.name),"Map"===r||"Set"===r?Array.from(e):"Arguments"===r||/^(?:Ui|I)nt(?:8|16|32)(?:Clamped)?Array$/.test(r)?Ua(e,t):void 0}}(e))||t&&e&&"number"==typeof e.length){r&&(e=r);var n=0,o=function(){};return{s:o,n:function(){return n>=e.length?{done:!0}:{done:!1,value:e[n++]}},e:function(e){throw e},f:o}}throw new TypeError("Invalid attempt to iterate non-iterable instance.\nIn order to be iterable, non-array objects must have a [Symbol.iterator]() method.")}var a,i=!0,l=!1;return{s:function(){r=r.call(e)},n:function(){var e=r.next();return i=e.done,e},e:function(e){l=!0,a=e},f:function(){try{i||null==r.return||r.return()}finally{if(l)throw a}}}}function Ua(e,t){(null==t||t>e.length)&&(t=e.length);for(var r=0,n=new Array(t);r<t;r++)n[r]=e[r];return n}var Ka="​",Xa=".subRows";function Ja(e){return e[Xa]||[]}function qa(e,t){var r,n=$a(t);try{for(n.s();!(r=n.n()).done;){var o=r.value;"numeric"===o.type&&e[o.id]&&Za(e[o.id])}}catch(e){n.e(e)}finally{n.f()}return Ya(e)}function Za(e){for(var t=0;t<e.length;t++){var r=e[t];"number"!=typeof r&&null!=r&&(r="NA"===r?null:"NaN"===r?NaN:"Inf"===r?1/0:"-Inf"===r?-1/0:Number(r),e[t]=r)}}function Ya(e){var t=Object.keys(e);if(0===t.length)return[];for(var r=new Array(e[t[0]].length),n=0;n<r.length;n++){r[n]={};var o,a=$a(t);try{for(a.s();!(o=a.n()).done;){var i=o.value,l=e[i][n];i===Xa?l instanceof Object&&(r[n][i]=Ya(l)):r[n][i]=l}}catch(e){a.e(e)}finally{a.f()}}return r}function Qa(e){var t=e.html,r=e.className,n=function(e,t){if(null==e)return{};var r,n,o=function(e,t){if(null==e)return{};var r,n,o={},a=Object.keys(e);for(n=0;n<a.length;n++)r=a[n],t.indexOf(r)>=0||(o[r]=e[r]);return o}(e,t);if(Object.getOwnPropertySymbols){var a=Object.getOwnPropertySymbols(e);for(n=0;n<a.length;n++)r=a[n],t.indexOf(r)>=0||Object.prototype.propertyIsEnumerable.call(e,r)&&(o[r]=e[r])}return o}(e,Wa);return i().createElement("div",Va({className:En("rt-text-content",r),dangerouslySetInnerHTML:{__html:t}},n))}function ei(e,t){t.forEach((function(t){var r=(t=_a({},t)).columns;t.columns=[],e=e.reduce((function(e,n){return n.id===r[0]?(e.push(t),t.columns.push(n)):r.includes(n.id)?t.columns.push(n):e.push(n),e}),[])}));var r,n=[];return e.forEach((function(e){e.columns?(n.push(e),r=null):(r||(r={columns:[],isUngrouped:!0},n.push(r)),r.columns.push(e))})),e=n}function ti(){var e=arguments.length>0&&void 0!==arguments[0]?arguments[0]:{},t=e.type,r=e.naLast;return function(e,n,o){return"numeric"===t?(e=Number.isNaN(e)?null:e,n=Number.isNaN(n)?null:n):(e="string"==typeof e?e.toLowerCase():e,n="string"==typeof n?n.toLowerCase():n),e===n?0:null==e?r?o?-1:1:-1:null==n?r?o?1:-1:1:e>n?1:e<n?-1:0}}function ri(e,t){var r=t.prefix,n=t.suffix,o=t.digits,a=t.separators,i=t.percent,l=t.currency,u=t.datetime,c=t.date,s=t.time,f=t.hour12,d=t.locales;if("number"==typeof e&&(a||i||l||null!=o||d)){var p=18,g={useGrouping:!!a};i&&(g.style="percent",p=12),l?(g.style="currency",g.currency=l):null!=o?(g.minimumFractionDigits=Math.min(o,p),g.maximumFractionDigits=Math.min(o,p)):g.maximumFractionDigits=p,e=e.toLocaleString(d||void 0,g)}if(u||c||s){d=d||void 0;var y={};null!=f&&(y.hour12=f),u?e=new Date(e).toLocaleString(d,y):c?(!e.includes("-")||e.includes("T")||e.includes("Z")||(e=e.replace(/-/g,"/")),e=new Date(e).toLocaleDateString(d,y)):s&&(e=new Date(e).toLocaleTimeString(d,y))}return null!=r&&(e=null!=e?e:"",e=String(r)+e),null!=n&&(e=null!=e?e:"",e+=String(n)),e}function ni(e){var t=new RegExp("^"+An(e),"i");return function(e){return void 0!==e&&t.test(e)}}function oi(e){var t=new RegExp(An(e),"i");return function(e){return void 0!==e&&t.test(e)}}function ai(e){return"rt-align-".concat(e)}function ii(e){return"top"===e?"":"rt-valign-".concat(e)}var li=["data","columns","columnGroups","sortable","defaultSortDesc","showSortIcon","showSortable","filterable","resizable","theme","language","dataKey"],ui=["className"],ci=["className"],si=["className"],fi=["className"],di=["className"],pi=["className"],gi=["className"],yi=["canSort","sortDescFirst","isSorted","isSortedDesc","toggleSortBy","canResize","isResizing","className","innerClassName","children"],mi=["className","innerClassName","children"],hi=["padding"],bi=["onMouseDown","onTouchStart","className"],vi=["className"],wi=["state"],Si=["key"],Oi=["key"],Ri=["key"],ji=["key"];function Pi(e){return Pi="function"==typeof Symbol&&"symbol"==typeof Symbol.iterator?function(e){return typeof e}:function(e){return e&&"function"==typeof Symbol&&e.constructor===Symbol&&e!==Symbol.prototype?"symbol":typeof e},Pi(e)}function Ei(e){return function(e){if(Array.isArray(e))return Di(e)}(e)||function(e){if("undefined"!=typeof Symbol&&null!=e[Symbol.iterator]||null!=e["@@iterator"])return Array.from(e)}(e)||Fi(e)||function(){throw new TypeError("Invalid attempt to spread non-iterable instance.\nIn order to be iterable, non-array objects must have a [Symbol.iterator]() method.")}()}function Ci(e,t){var r="undefined"!=typeof Symbol&&e[Symbol.iterator]||e["@@iterator"];if(!r){if(Array.isArray(e)||(r=Fi(e))||t&&e&&"number"==typeof e.length){r&&(e=r);var n=0,o=function(){};return{s:o,n:function(){return n>=e.length?{done:!0}:{done:!1,value:e[n++]}},e:function(e){throw e},f:o}}throw new TypeError("Invalid attempt to iterate non-iterable instance.\nIn order to be iterable, non-array objects must have a [Symbol.iterator]() method.")}var a,i=!0,l=!1;return{s:function(){r=r.call(e)},n:function(){var e=r.next();return i=e.done,e},e:function(e){l=!0,a=e},f:function(){try{i||null==r.return||r.return()}finally{if(l)throw a}}}}function Ai(e,t){if(!(e instanceof t))throw new TypeError("Cannot call a class as a function")}function xi(e,t){for(var r=0;r<t.length;r++){var n=t[r];n.enumerable=n.enumerable||!1,n.configurable=!0,"value"in n&&(n.writable=!0),Object.defineProperty(e,n.key,n)}}function ki(e,t){return ki=Object.setPrototypeOf?Object.setPrototypeOf.bind():function(e,t){return e.__proto__=t,e},ki(e,t)}function Ii(e,t){if(t&&("object"===Pi(t)||"function"==typeof t))return t;if(void 0!==t)throw new TypeError("Derived constructors may only return object or undefined");return function(e){if(void 0===e)throw new ReferenceError("this hasn't been initialised - super() hasn't been called");return e}(e)}function Ni(e){return Ni=Object.setPrototypeOf?Object.getPrototypeOf.bind():function(e){return e.__proto__||Object.getPrototypeOf(e)},Ni(e)}function Bi(e,t){return function(e){if(Array.isArray(e))return e}(e)||function(e,t){var r=null==e?null:"undefined"!=typeof Symbol&&e[Symbol.iterator]||e["@@iterator"];if(null!=r){var n,o,a=[],i=!0,l=!1;try{for(r=r.call(e);!(i=(n=r.next()).done)&&(a.push(n.value),!t||a.length!==t);i=!0);}catch(e){l=!0,o=e}finally{try{i||null==r.return||r.return()}finally{if(l)throw o}}return a}}(e,t)||Fi(e,t)||function(){throw new TypeError("Invalid attempt to destructure non-iterable instance.\nIn order to be iterable, non-array objects must have a [Symbol.iterator]() method.")}()}function Fi(e,t){if(e){if("string"==typeof e)return Di(e,t);var r=Object.prototype.toString.call(e).slice(8,-1);return"Object"===r&&e.constructor&&(r=e.constructor.name),"Map"===r||"Set"===r?Array.from(e):"Arguments"===r||/^(?:Ui|I)nt(?:8|16|32)(?:Clamped)?Array$/.test(r)?Di(e,t):void 0}}function Di(e,t){(null==t||t>e.length)&&(t=e.length);for(var r=0,n=new Array(t);r<t;r++)n[r]=e[r];return n}function Gi(){return Gi=Object.assign?Object.assign.bind():function(e){for(var t=1;t<arguments.length;t++){var r=arguments[t];for(var n in r)Object.prototype.hasOwnProperty.call(r,n)&&(e[n]=r[n])}return e},Gi.apply(this,arguments)}function zi(e,t){var r=Object.keys(e);if(Object.getOwnPropertySymbols){var n=Object.getOwnPropertySymbols(e);t&&(n=n.filter((function(t){return Object.getOwnPropertyDescriptor(e,t).enumerable}))),r.push.apply(r,n)}return r}function Mi(e){for(var t=1;t<arguments.length;t++){var r=null!=arguments[t]?arguments[t]:{};t%2?zi(Object(r),!0).forEach((function(t){Ti(e,t,r[t])})):Object.getOwnPropertyDescriptors?Object.defineProperties(e,Object.getOwnPropertyDescriptors(r)):zi(Object(r)).forEach((function(t){Object.defineProperty(e,t,Object.getOwnPropertyDescriptor(r,t))}))}return e}function Ti(e,t,r){return t in e?Object.defineProperty(e,t,{value:r,enumerable:!0,configurable:!0,writable:!0}):e[t]=r,e}function Wi(e,t){if(null==e)return{};var r,n,o=function(e,t){if(null==e)return{};var r,n,o={},a=Object.keys(e);for(n=0;n<a.length;n++)r=a[n],t.indexOf(r)>=0||(o[r]=e[r]);return o}(e,t);if(Object.getOwnPropertySymbols){var a=Object.getOwnPropertySymbols(e);for(n=0;n<a.length;n++)r=a[n],t.indexOf(r)>=0||Object.prototype.propertyIsEnumerable.call(e,r)&&(o[r]=e[r])}return o}var Hi={};function _i(e){if(!e)throw new Error("A reactable table ID must be provided");var t=Hi[e];if(!t)throw new Error("reactable instance '".concat(e,"' not found"));return t()}function Li(e){return _i(e).state}function Vi(e,t,r){_i(e).setFilter(t,r)}function $i(e,t){_i(e).setAllFilters(t)}function Ui(e,t){_i(e).setGlobalFilter(t)}function Ki(e,t,r){_i(e).toggleGroupBy(t,r)}function Xi(e,t){_i(e).setGroupBy(t)}function Ji(e,t){_i(e).toggleAllRowsExpanded(t)}function qi(e){var t=arguments.length>1&&void 0!==arguments[1]?arguments[1]:"data.csv",r=arguments.length>2&&void 0!==arguments[2]?arguments[2]:{};_i(e).downloadDataCSV(t,r)}function Zi(e){var t=arguments.length>1&&void 0!==arguments[1]?arguments[1]:{};return _i(e).getDataCSV(t)}function Yi(e,t){_i(e).setMeta(t)}function Qi(e,t,r){_i(e).toggleHideColumn(t,r)}function el(e,t){_i(e).setHiddenColumns(t)}function tl(e,t,r){_i(e).setData(t,r)}function rl(e,t){return _i(e).onStateChange(t)}function nl(e){var t=e.data,r=e.columns,n=e.columnGroups,o=e.sortable,l=e.defaultSortDesc,u=e.showSortIcon,c=e.showSortable,s=e.filterable,f=e.resizable,d=e.theme,p=e.language,g=e.dataKey,y=Wi(e,li);for(var m in t=qa(t,r),r=function(e,t){var r=arguments.length>2&&void 0!==arguments[2]?arguments[2]:{},n=r.sortable,o=r.defaultSortDesc,l=r.showSortIcon,u=r.showSortable,c=r.filterable,s=r.resizable;return e=e.map((function(e){var t=_a({},e);t.accessor=function(e){return e[t.id]},"string"==typeof t.aggregate&&(t.aggregate=za(t.aggregate,t.type));var r=ti({type:t.type,naLast:t.sortNALast});t.sortType=function(e,t,n,o){return r(e.values[n],t.values[n],o)},t.sortable=Cn(t.sortable,n),t.disableSortBy=!t.sortable,t.defaultSortDesc=Cn(t.defaultSortDesc,o),t.sortDescFirst=t.defaultSortDesc,t.filterable=Cn(t.filterable,c),t.disableFilters=!t.filterable,!1===t.searchable&&(t.disableGlobalFilter=!0),!1===t.show&&!0!==t.searchable&&(t.disableGlobalFilter=!0),"numeric"===t.type?t.createMatcher=ni:t.createMatcher=oi,t.filter=function(e,r,n){var o=r[0];if("function"==typeof t.filterMethod)return t.filterMethod(e,o,n);var a=t.createMatcher(n);return e.filter((function(e){var t=e.values[o];return a(t)}))},"numeric"===t.type?t.align=t.align||"right":t.align=t.align||"left",t.vAlign=t.vAlign||"top",t.headerVAlign=t.headerVAlign||"top";var f=t.width,d=t.minWidth,p=t.maxWidth;t.minWidth=Cn(f,d,100),t.maxWidth=Cn(f,p,Number.MAX_SAFE_INTEGER),t.minWidth=Math.min(t.minWidth,t.maxWidth),t.width=t.minWidth,t.resizable=Cn(t.resizable,s),t.minWidth===t.maxWidth&&(t.resizable=!1),t.disableResizing=!t.resizable,t.Cell=function(e,r){var n=e.value,o=null==n||Number.isNaN(n);return o&&(n=t.na),!o&&t.format&&t.format.cell&&(n=ri(n,t.format.cell)),t.cell&&("function"==typeof t.cell&&(n=t.cell(_a(_a({},e),{},{value:n}),r)),Array.isArray(t.cell)&&!e.aggregated&&(n=t.cell[e.index])&&(n=(0,tr.hydrate)({Fragment:a.Fragment,WidgetContainer:po},n))),null!=n&&""!==n||(n=Ka),i().isValidElement(n)?n:t.html?i().createElement(Qa,{style:{display:"inline"},html:n}):String(n)},t.grouped?t.Grouped=function(e,r){var n=e.value,o=null==n||Number.isNaN(n);return o&&(n=t.na),!o&&t.format&&t.format.cell&&(n=ri(n,t.format.cell)),null!=(n=t.grouped(_a(_a({},e),{},{value:n}),r))&&""!==n||(n=Ka),i().isValidElement(n)?n:t.html?i().createElement(Qa,{style:{display:"inline"},html:n}):String(n)}:t.Grouped=function(e,r){var n=t.Cell(e,r);return i().createElement(i().Fragment,null,n,e.subRows&&" (".concat(e.subRows.length,")"))},t.Aggregated=function(e,r){var n,o=e.value;if(null!=o&&t.format&&t.format.aggregated&&(o=ri(o,t.format.aggregated)),t.aggregated&&(o=t.aggregated(_a(_a({},e),{},{value:o}),r)),null==o&&(o=""),i().isValidElement(o))n=o;else{if(t.html)return i().createElement(Qa,{html:o});n=String(o)}return n},t.Header=function(e,r){var n,o=t.name;if(null!=t.header&&(o="function"==typeof t.header?t.header(e,r):(0,tr.hydrate)({Fragment:a.Fragment,WidgetContainer:po},t.header)),n=i().isValidElement(o)?o:t.html?i().createElement(Qa,{html:o}):null!=o?String(o):"",t.sortable&&l){var c=u?"rt-sort":"";return n=t.html?n:i().createElement("div",{className:"rt-text-content"},n),"right"===t.align?i().createElement("div",{className:"rt-sort-header"},i().createElement("span",{className:En(c,"rt-sort-left"),"aria-hidden":"true"}),n):i().createElement("div",{className:"rt-sort-header"},n,i().createElement("span",{className:En(c,"rt-sort-right"),"aria-hidden":"true"}))}return n},null!=t.footer?t.Footer=function(e,r){var n;return n="function"==typeof t.footer?t.footer(e,r):(0,tr.hydrate)({Fragment:a.Fragment,WidgetContainer:po},t.footer),i().isValidElement(n)?n:t.html?i().createElement(Qa,{html:n}):null!=n?String(n):""}:t.Footer=Ka;var g=ai(t.align),y=ii(t.vAlign),m=ii(t.headerVAlign);return t.headerClassName=En(g,m,t.headerClassName),t.footerClassName=En(g,y,t.footerClassName),t.getProps=function(e,r,n){var o,a,i={className:En(g,y)};return t.className&&(o="function"==typeof t.className?t.className(e,r,n):Array.isArray(t.className)?t.className[e.index]:t.className,i.className=En(i.className,o)),t.style&&(a="function"==typeof t.style?t.style(e,r,n):Array.isArray(t.style)?t.style[e.index]:t.style,i.style=a),i},t})),t&&(e=ei(e,t)).forEach((function(e,t){e.id="group_".concat(t),null!=e.name||null!=e.header?e.Header=function(t,r){var n=e.name;return e.header&&(n="function"==typeof e.header?e.header(t,r):(0,tr.hydrate)({Fragment:a.Fragment,WidgetContainer:po},e.header)),i().isValidElement(n)?n:e.html?i().createElement(Qa,{html:n}):null!=n?String(n):""}:e.Header=Ka,xn(e).every((function(e){return e.disableResizing}))&&(e.disableResizing=!0),e.align=e.align||"center",e.headerVAlign=e.headerVAlign||"top";var r=ai(e.align),n=ii(e.headerVAlign);e.headerClassName=En(r,n,e.headerClassName)})),e}(r,n,{sortable:o,defaultSortDesc:l,showSortIcon:u,showSortable:c,filterable:s,resizable:f}),d=Hn(d)||{},p=Mi(Mi({},Kn),p))p[m]=p[m]||null;return i().createElement(Ol,Gi({data:t,columns:r,theme:d,language:p,key:g},y))}var ol=i().forwardRef((function(e,t){var r=e.className,n=Wi(e,ui);return i().createElement("div",Gi({ref:t,className:En("Reactable","ReactTable",r)},n))})),al=i().forwardRef((function(e,t){var r=e.className,n=Wi(e,ci);return i().createElement("div",Gi({ref:t,className:En("rt-table",r),role:"table"},n))}));function il(e){var t=e.className,r=Wi(e,si);return i().createElement("div",Gi({className:En("rt-thead",t),role:"rowgroup"},r))}function ll(e){var t=e.className,r=Wi(e,fi);return i().createElement("div",Gi({className:En("rt-tbody",t),role:"rowgroup"},r))}function ul(e){var t=e.className,r=Wi(e,di);return i().createElement("div",Gi({className:En("rt-tfoot",t),role:"rowgroup"},r))}function cl(e){var t=e.className,r=Wi(e,pi);return i().createElement("div",Gi({className:En("rt-tr-group",t)},r))}function sl(e){var t=e.className,r=Wi(e,gi);return i().createElement("div",Gi({className:En("rt-tr",t),role:"row"},r))}var fl=i().forwardRef((function(e,t){var r=e.canSort,n=e.sortDescFirst,o=e.isSorted,a=e.isSortedDesc,l=e.toggleSortBy,u=e.canResize,c=e.isResizing,s=e.className,f=e.innerClassName,d=e.children,p=Wi(e,yi),g=Bi(i().useState(!1),2),y=g[0],m=g[1];if(r){var h=o?a?"descending":"ascending":"none",b=n?"descending":"ascending",v=function(e){var t=o?!a:n;e&&(t=null),l&&l(t,e)};p=Mi(Mi({},p),{},{"aria-sort":h,tabIndex:"0",onClick:function(e){y||v(e.shiftKey)},onKeyPress:function(e){var t=e.which||e.keyCode;13!==t&&32!==t||v(e.shiftKey)},onMouseUp:function(){m(!!c)},onMouseDown:function(e){(e.detail>1||e.shiftKey)&&e.preventDefault()},"data-sort-hint":o?null:b})}return i().createElement("div",Gi({className:En("rt-th",u&&"rt-th-resizable",s),role:"columnheader",ref:t},p),i().createElement("div",{className:En("rt-th-inner",f)},d))}));function dl(e){var t=e.className,r=e.innerClassName,n=e.children,o=Wi(e,mi);return i().createElement("div",Gi({className:En("rt-td",t),role:"cell"},o),i().createElement("div",{className:En("rt-td-inner",r)},n))}function pl(e){if(!e)return{};if(null!=e.padding){var t=e.padding;return{className:$n(Wi(e,hi)),innerClassName:$n({padding:t})}}return{className:$n(e)}}function gl(e){var t=e.onMouseDown,r=e.onTouchStart,n=e.className,o=Wi(e,bi);return i().createElement("div",Gi({className:En("rt-resizer",n),onMouseDown:t,onTouchStart:r,"aria-hidden":!0},o))}var yl,ml=function(e){!function(e,t){if("function"!=typeof t&&null!==t)throw new TypeError("Super expression must either be null or a function");e.prototype=Object.create(t&&t.prototype,{constructor:{value:e,writable:!0,configurable:!0}}),Object.defineProperty(e,"prototype",{writable:!1}),t&&ki(e,t)}(l,e);var t,r,n,o,a=(n=l,o=function(){if("undefined"==typeof Reflect||!Reflect.construct)return!1;if(Reflect.construct.sham)return!1;if("function"==typeof Proxy)return!0;try{return Boolean.prototype.valueOf.call(Reflect.construct(Boolean,[],(function(){}))),!0}catch(e){return!1}}(),function(){var e,t=Ni(n);if(o){var r=Ni(this).constructor;e=Reflect.construct(t,arguments,r)}else e=t.apply(this,arguments);return Ii(this,e)});function l(){return Ai(this,l),a.apply(this,arguments)}return t=l,(r=[{key:"componentDidMount",value:function(){window.Shiny&&window.Shiny.bindAll&&window.Shiny.bindAll(this.el)}},{key:"componentWillUnmount",value:function(){window.Shiny&&window.Shiny.unbindAll&&window.Shiny.unbindAll(this.el)}},{key:"render",value:function(){var e=this,t=this.props,r=t.children,n=t.html,o={ref:function(t){return e.el=t}};return o=Mi(Mi({},o),{},n?{dangerouslySetInnerHTML:{__html:n}}:{children:r}),i().createElement("div",Gi({className:"rt-tr-details"},o))}}])&&xi(t.prototype,r),Object.defineProperty(t,"prototype",{writable:!1}),l}(i().Component);function hl(e){var t=e.isExpanded,r=e.className,n=e["aria-label"];return i().createElement("button",{className:"rt-expander-button","aria-label":n,"aria-expanded":t?"true":"false"},i().createElement("span",{className:En("rt-expander",t&&"rt-expander-open",r),tabIndex:"-1","aria-hidden":"true"},"​"))}function bl(e){var t=e.filterValue,r=e.setFilter,n=e.className,o=e.placeholder,a=e["aria-label"];return i().createElement("input",{type:"text",className:En("rt-filter",n),value:t||"",onChange:function(e){return r(e.target.value||void 0)},placeholder:o,"aria-label":a})}function vl(e){var t=e.searchValue,r=e.setSearch,n=e.className,o=e.placeholder,a=e["aria-label"];return i().createElement("input",{type:"text",value:t||"",onChange:function(e){return r(e.target.value||void 0)},className:En("rt-search",n),placeholder:o,"aria-label":a})}function wl(e){var t=e.className,r=Wi(e,vi);return i().createElement("div",Gi({className:En("rt-no-data",t),"aria-live":"assertive"},r))}function Sl(e){var t=e.type,r=e.checked,n=e.onChange,o=e["aria-label"];return i().createElement("div",{className:"rt-select"},i().createElement("input",{type:t,checked:r,onChange:n,className:"rt-select-input","aria-label":o}),"​")}function Ol(e){var t=e.data,r=e.columns,n=e.groupBy,o=e.searchable,l=e.searchMethod,u=e.defaultSorted,c=e.pagination,s=e.paginationType,f=e.showPagination,d=e.showPageSizeOptions,p=e.showPageInfo,g=e.defaultPageSize,y=e.pageSizeOptions,m=e.minRows,h=e.paginateSubRows,b=e.defaultExpanded,v=e.selection,S=e.defaultSelected,O=e.selectionId,R=e.onClick,j=e.outlined,A=e.bordered,x=e.borderless,F=e.compact,D=e.nowrap,G=e.striped,z=e.highlight,L=e.className,V=e.style,$=e.rowClassName,U=e.rowStyle,K=e.inline,X=e.width,J=e.height,q=e.theme,Z=e.language,Y=e.meta,Q=e.crosstalkKey,ee=e.crosstalkGroup,te=e.crosstalkId,re=e.elementId,ne=e.nested,oe=Bi(i().useState(null),2),ae=oe[0],ie=oe[1],le=i().useMemo((function(){return ae||t}),[ae,t]),ue=i().useMemo((function(){return r.reduce((function(e,t){return e.concat(xn(t))}),[])}),[r]),ce=i().useMemo((function(){return l||function(e,t,r){var n=ue.reduce((function(e,t){return e[t.id]=t.createMatcher(r),e}),{});return e.filter((function(e){var r,o=Ci(t);try{for(o.s();!(r=o.n()).done;){var a=r.value,i=e.values[a];if(n[a](i))return!0}}catch(e){o.e(e)}finally{o.f()}}))}}),[ue,l]),fe=function(){var e=arguments.length>0&&void 0!==arguments[0]?arguments[0]:{},t=ka(i().useState(e),2),r=t[0],n=t[1],o=function(e){if(null!=e){if("object"!==xa(e)&&"function"!=typeof e)throw new Error("meta must be an object or function");n((function(t){"function"==typeof e&&(e=e(t));for(var r=Ca(Ca({},t),e),n=0,o=Object.entries(r);n<o.length;n++){var a=ka(o[n],2),i=a[0];void 0===a[1]&&delete e[i]}return r}))}else n({})};return[r,o]}(Y),de=Bi(fe,2),pe=de[0],ge=de[1],ye=function(e){for(var t=arguments.length,r=new Array(t>1?t-1:0),n=1;n<t;n++)r[n-1]=arguments[n];e=Ge(e),r=[me].concat(je(r));var o=k(i().useRef({}).current);Object.assign(o(),Ae(Ae({},e),{},{plugins:r,hooks:se()})),r.filter(Boolean).forEach((function(e){e(o().hooks)}));var a=k(o().hooks);o().getHooks=a,delete o().hooks,Object.assign(o(),E(a().useOptions,Ge(e)));var l=o(),u=l.data,c=l.columns,s=l.initialState,f=l.defaultColumn,d=l.getSubRows,p=l.getRowId,g=l.stateReducer,y=l.useControlledState,m=k(g),h=i().useCallback((function(e,t){if(!t.type)throw console.info({action:t}),new Error("Unknown Action 👆");return[].concat(je(a().stateReducers),je(Array.isArray(m())?m():[m()])).reduce((function(r,n){return n(r,t,e,o())||r}),e)}),[a,m,o]),b=Re(i().useReducer(h,void 0,(function(){return h(s,{type:w.init})})),2),v=b[0],S=b[1],O=E([].concat(je(a().useControlledState),[y]),v,{instance:o()});Object.assign(o(),{state:O,dispatch:S});var R=i().useMemo((function(){return M(E(a().columns,c,{instance:o()}))}),[a,o,c].concat(je(E(a().columnsDeps,[],{instance:o()}))));o().columns=R;var j=i().useMemo((function(){return E(a().allColumns,T(R),{instance:o()}).map(W)}),[R,a,o].concat(je(E(a().allColumnsDeps,[],{instance:o()}))));o().allColumns=j;var A=i().useMemo((function(){for(var e=[],t=[],r={},n=je(j);n.length;){var i=n.shift();Me({data:u,rows:e,flatRows:t,rowsById:r,column:i,getRowId:p,getSubRows:d,accessValueHooks:a().accessValue,getInstance:o})}return[e,t,r]}),[j,u,p,d,a,o]),x=Re(A,3),I=x[0],N=x[1],F=x[2];Object.assign(o(),{rows:I,initialRows:je(I),flatRows:N,rowsById:F}),C(a().useInstanceAfterData,o());var D=i().useMemo((function(){return E(a().visibleColumns,j,{instance:o()}).map((function(e){return H(e,f)}))}),[a,j,o,f].concat(je(E(a().visibleColumnsDeps,[],{instance:o()}))));j=i().useMemo((function(){var e=je(D);return j.forEach((function(t){e.find((function(e){return e.id===t.id}))||e.push(t)})),e}),[j,D]),o().allColumns=j;var G=i().useMemo((function(){return E(a().headerGroups,_(D,f),o())}),[a,D,f,o].concat(je(E(a().headerGroupsDeps,[],{instance:o()}))));o().headerGroups=G;var z=i().useMemo((function(){return G.length?G[0].headers:[]}),[G]);o().headers=z,o().flatHeaders=G.reduce((function(e,t){return[].concat(je(e),je(t.headers))}),[]),C(a().useInstanceBeforeDimensions,o());var L=D.filter((function(e){return e.isVisible})).map((function(e){return e.id})).sort().join("_");D=i().useMemo((function(){return D.filter((function(e){return e.isVisible}))}),[D,L]),o().visibleColumns=D;var V=Re(ze(z),3),$=V[0],U=V[1],K=V[2];return o().totalColumnsMinWidth=$,o().totalColumnsWidth=U,o().totalColumnsMaxWidth=K,C(a().useInstance,o()),[].concat(je(o().flatHeaders),je(o().allColumns)).forEach((function(e){e.render=B(o(),e),e.getHeaderProps=P(a().getHeaderProps,{instance:o(),column:e}),e.getFooterProps=P(a().getFooterProps,{instance:o(),column:e})})),o().headerGroups=i().useMemo((function(){return G.filter((function(e,t){return e.headers=e.headers.filter((function(e){return e.headers?function e(t){return t.filter((function(t){return t.headers?e(t.headers):t.isVisible})).length}(e.headers):e.isVisible})),!!e.headers.length&&(e.getHeaderGroupProps=P(a().getHeaderGroupProps,{instance:o(),headerGroup:e,index:t}),e.getFooterGroupProps=P(a().getFooterGroupProps,{instance:o(),headerGroup:e,index:t}),!0)}))}),[G,o,a]),o().footerGroups=je(o().headerGroups).reverse(),o().prepareRow=i().useCallback((function(e){e.getRowProps=P(a().getRowProps,{instance:o(),row:e}),e.allCells=j.map((function(t){var r=e.values[t.id],n={column:t,row:e,value:r};return n.getCellProps=P(a().getCellProps,{instance:o(),cell:n}),n.render=B(o(),t,{row:e,cell:n,value:r}),n})),e.cells=D.map((function(t){return e.allCells.find((function(e){return e.column.id===t.id}))})),C(a().prepareRow,e,{instance:o()})}),[a,o,j,D]),o().getTableProps=P(a().getTableProps,{instance:o()}),o().getTableBodyProps=P(a().getTableBodyProps,{instance:o()}),C(a().useFinalInstance,o()),o()}({columns:r,data:le,initialState:{hiddenColumns:ue.filter((function(e){return!1===e.show})).map((function(e){return e.id})),groupBy:n||[],sortBy:u||[],pageSize:g,selectedRowIds:S?S.reduce((function(e,t){return Mi(Mi({},e),{},Ti({},t,!0))}),{}):{}},globalFilter:ce,paginateExpandedRows:!!h,disablePagination:!c,getSubRows:Ja,manualExpandedKey:null,autoResetGroupBy:!1,autoResetSortBy:!1,autoResetExpanded:!1,autoResetFilters:!1,autoResetGlobalFilter:!1,autoResetSelectedRows:!1,autoResetResize:!1,autoResetPage:!0},ta,go,Po,dt,wt,Wo,qt,Ve,Oa,ca,(function(e){v&&e.visibleColumns.push((function(e){return[Mi(Mi({},e.find((function(e){return e.selectable}))),{},{selectable:!0,disableSortBy:!0,filterable:!1,disableFilters:!0,disableGlobalFilter:!0})].concat(Ei(e.filter((function(e){return!e.selectable}))))}))}),(function(e){ee&&(e.visibleColumns.push((function(e){var t={id:te,filter:function(e,t,r){return r?e.filter((function(e){if(r.includes(e.index))return!0})):e},disableGlobalFilter:!0};return e.concat(t)})),e.stateReducers.push((function(e){return e.hiddenColumns.includes(te)?e:Mi(Mi({},e),{},{hiddenColumns:e.hiddenColumns.concat(te)})})))})),he=ye.state,be=Wi(ye,wi);N((function(){(0,be.setSortBy)(u||[])}),[be.setSortBy,u]),N((function(){(0,be.setGroupBy)(n||[])}),[be.setGroupBy,n]),N((function(){(0,be.setPageSize)(g)}),[be.setPageSize,g]),N((function(){(0,be.setRowsSelected)((S||[]).map((function(e){return String(e)})))}),[be.setRowsSelected,S]);var ve=be.preFilteredRowsById||be.rowsById,we=i().useMemo((function(){return Object.keys(he.selectedRowIds).reduce((function(e,t){var r=ve[t];return r&&e.push(r.index),e}),[])}),[he.selectedRowIds,ve]);i().useEffect((function(){if(v){var e=we.map((function(e){return e+1}));O&&window.Shiny&&window.Shiny.onInputChange(O,e)}}),[we,v,O]);var Se=i().useRef(o);I((function(){Se.current&&!o&&(0,be.setGlobalFilter)(void 0),Se.current=o}),[o,be.setGlobalFilter]);var Oe=kn(be.rows),Pe=i().useMemo((function(){return Mi(Mi({},he),{},{searchValue:he.globalFilter,meta:pe,hiddenColumns:he.hiddenColumns.filter((function(e){return e!==te})),sorted:he.sortBy,pageRows:kn(be.page),sortedData:Oe,data:le,page:he.pageIndex,pageSize:he.pageSize,pages:be.pageCount,selected:we})}),[he,pe,te,be.page,Oe,le,be.pageCount,we]),Ee=i().useRef({});be.headers.forEach((function e(t){t.getDOMWidth=function(){return Ee.current[t.id].getBoundingClientRect().width},t.headers&&t.headers.length&&t.headers.forEach((function(t){return e(t)}))}));var Ce=be.visibleColumns.some((function(e){return e.filterable})),xe=i().useRef(Ce);I((function(){xe.current&&!Ce&&(0,be.setAllFilters)(be.visibleColumns.map((function(e){return{id:e.id,value:void 0}}))),xe.current=Ce}),[Ce,be.visibleColumns,be.setAllFilters]);I((function(){(0,be.toggleAllRowsExpanded)(!!b)}),[be.toggleAllRowsExpanded,b]);var ke=Bi(i().useState({}),2),Ie=ke[0],Ne=ke[1],Be=i().useRef(h?be.flatRows.length:be.rows.length);i().useEffect((function(){Be.current=0}),[le]),i().useEffect((function(){var e=h?be.flatRows.length:be.rows.length;e>Be.current&&(Be.current=e)}),[h,be.flatRows,be.rows]);var Fe=i().useRef(null),De={onMouseDown:function(){Fe.current.classList.remove("rt-keyboard-active")},onKeyDown:function(){Fe.current.classList.add("rt-keyboard-active")},onKeyUp:function(e){9===(e.which||e.keyCode)&&Fe.current.classList.add("rt-keyboard-active")}},Te=i().useRef(null),We=Bi(i().useState(!1),2),He=We[0],_e=We[1];I((function(){var e=function(){var e=Te.current,t=e.scrollHeight,r=e.clientHeight,n=e.scrollWidth,o=e.clientWidth;_e(t>r||n>o)};if(window.ResizeObserver){var t=new ResizeObserver((function(){e()}));return t.observe(Te.current),function(){t.disconnect()}}e()}),[]),i().useEffect((function(){if(window.Shiny&&window.Shiny.onInputChange&&!ne){var e=Fe.current.parentElement.getAttribute("data-reactable-output");if(e){var t,r=Pe.selected.map((function(e){return e+1})),n=Pe.page+1,o=Pe.sorted.length>0?{}:null,a=Ci(Pe.sorted);try{for(a.s();!(t=a.n()).done;){var i=t.value;o[i.id]=i.desc?"desc":"asc"}}catch(e){a.e(e)}finally{a.f()}var l={page:n,pageSize:Pe.pageSize,pages:Pe.pages,sorted:o,selected:r};Object.keys(l).forEach((function(t){window.Shiny.onInputChange("".concat(e,"__reactable__").concat(t),l[t])}))}}}),[ne,Pe.page,Pe.pageSize,Pe.pages,Pe.sorted,Pe.selected]);var Le=k(be.pageCount);i().useEffect((function(){if(window.Shiny&&!ne){var e=Fe.current.parentElement.getAttribute("data-reactable-output");if(e){var t=be.setRowsSelected,r=be.gotoPage,n=be.toggleAllRowsExpanded;window.Shiny.addCustomMessageHandler("__reactable__".concat(e),(function(e){if(e.jsEvals){var o,a=Ci(e.jsEvals);try{for(a.s();!(o=a.n()).done;){var i=o.value;window.HTMLWidgets.evaluateStringMember(e,i)}}catch(e){a.e(e)}finally{a.f()}}if(null!=e.data){var l=qa(e.data,ue);ie(l)}if(null!=e.selected){var u=e.selected.map((function(e){return String(e)}));t(u)}if(null!=e.page){var c=Math.min(Math.max(e.page,0),Math.max(Le()-1,0));r(c)}null!=e.expanded&&(e.expanded?n(!0):n(!1)),void 0!==e.meta&&ge(e.meta)}))}}}),[ne,be.setRowsSelected,be.gotoPage,be.toggleAllRowsExpanded,ue,Le,ge]);var $e=i().useRef(null);I((function(){if(ee&&window.crosstalk){var e={};e.selection=new window.crosstalk.SelectionHandle(ee),e.filter=new window.crosstalk.FilterHandle(ee),e.selected=e.selection.value,e.filtered=e.filter.filteredKeys,$e.current=e;var t=(Q||[]).reduce((function(e,t,r){return e[t]=r,e}),{}),r=be.setFilter,n=be.setRowsSelected,o=function(){var n,o=e.selected&&e.selected.length>0?e.selected:null,a=e.filtered,i=(n=o||a?o?a?o.filter((function(e){return a.includes(e)})):o:a:null)?n.map((function(e){return t[e]})):null;r(te,i)},a=function(t){e.selected!==t&&(e.selected=t,o())};return e.selection.on("change",(function(t){t.sender!==e.selection?(a(t.value),e.skipNextSelection=!0,n([])):a(null)})),e.filter.on("change",(function(t){var r;t.sender!==e.filter&&(r=t.value,e.filtered!==r&&(e.filtered=r,o()))})),(e.selected||e.filtered)&&o(),function(){try{e.selection.close()}catch(e){console.error("Error closing Crosstalk selection handle:",e)}try{e.filter.close()}catch(e){console.error("Error closing Crosstalk filter handle:",e)}}}}),[Q,ee,te,be.setFilter,be.setRowsSelected]),I((function(){$e.current&&(S||($e.current.skipNextSelection=!0))}),[S]),I((function(){if($e.current&&v){var e=$e.current;if(e.skipNextSelection)e.skipNextSelection=!1;else{var t=Object.keys(he.selectedRowIds).map((function(e){return Q[ve[e].index]}));try{e.selection.set(t)}catch(e){console.error("Error selecting Crosstalk keys:",e)}}}}),[he.selectedRowIds,ve,v,Q]),be.state=Pe,be.downloadDataCSV=function(e){var t=arguments.length>1&&void 0!==arguments[1]?arguments[1]:{};e=e||"data.csv";var r=be.getDataCSV(t);Nn(r,e)},be.getDataCSV=function(){var e=arguments.length>0&&void 0!==arguments[0]?arguments[0]:{};e.columnIds||(e.columnIds=ue.map((function(e){return e.id})));var t=le.length>0?Object.keys(le[0]):[];e.columnIds=e.columnIds.filter((function(e){return t.includes(e)}));var r=be.preGroupedRows.map((function(e){return e.values})),n=In(r,e);return n},be.setMeta=ge;var Ue=be.toggleHideColumn;be.toggleHideColumn=function(e,t){t&&Pe.hiddenColumns.includes(e)||Ue(e,t)},be.setData=function(e){var t=arguments.length>1&&void 0!==arguments[1]?arguments[1]:{};if(t=Object.assign({resetSelected:!0,resetExpanded:!1},t),"object"!==Pi(e)||null==e)throw new Error("data must be an array of row objects or an object containing column arrays");Array.isArray(e)||(e=qa(e,ue)),ie(e),t.resetSelected&&be.setRowsSelected([]),t.resetExpanded&&be.toggleAllRowsExpanded(!1)};var Ke=i().useRef([]);be.onStateChange=function(e){if("function"!=typeof e)throw new Error("listenerFn must be a function");return Ke.current.push(e),function(){Ke.current=Ke.current.filter((function(t){return t!==e}))}};var Xe=function(e){var t=arguments.length>1&&void 0!==arguments[1]?arguments[1]:0,r=i().useRef({}),n=k(e),o=k(t);return i().useCallback((function(){for(var e=arguments.length,t=new Array(e),a=0;a<e;a++)t[a]=arguments[a];return r.current.promise||(r.current.promise=new Promise((function(e,t){r.current.resolve=e,r.current.reject=t}))),r.current.timeout&&clearTimeout(r.current.timeout),r.current.timeout=setTimeout((function(){delete r.current.timeout;try{r.current.resolve(n().apply(void 0,t))}catch(e){r.current.reject(e)}finally{delete r.current.promise}}),o()),r.current.promise}),[n,o])}((function(e){Ke.current.forEach((function(t){t(e)}))}),0);i().useEffect((function(){Xe(Pe)}),[Pe,Xe]);var Je=k(be);i().useEffect((function(){var e=re;if(e||(e=Fe.current.parentElement.getAttribute("data-reactable-output")),e)return Hi[e]=Je,function(){delete Hi[e]}}),[re,Je]),L=En(L,$n(q.style),j&&"rt-outlined",A&&"rt-bordered",x&&"rt-borderless",F&&"rt-compact",D&&"rt-nowrap",K&&" rt-inline"),V=Mi({width:X,height:J},V);var qe,Ze=null!=he.columnResizing.isResizingColumn,Ye=En($n(q.tableStyle),Ze&&"rt-resizing");return i().createElement(ol,Gi({ref:Fe},De,{className:L,style:V}),o?i().createElement(vl,{searchValue:he.globalFilter,setSearch:be.setGlobalFilter,className:$n(q.searchInputStyle),placeholder:Z.searchPlaceholder,"aria-label":Z.searchLabel}):null,i().createElement(al,{ref:Te,tabIndex:He?0:null,className:Ye},(qe=be.getTheadProps(),i().createElement(il,qe,be.headerGroups.map((function(e,t){var r=t<be.headerGroups.length-1,n=e.getHeaderGroupProps({className:r?"rt-tr-group-header":"rt-tr-header"}),o=n.key,a=Wi(n,Si);return i().createElement(sl,Gi({key:o},a),e.headers.map((function(e){var t,n="function"==typeof(e=Mi(Mi({},e),{},{column:e,data:Oe})).Header?e.Header(e,Pe):e.render("Header"),o={colSpan:null,ref:function(t){return Ee.current[e.id]=t}};if(r){var a=pl(q.groupHeaderStyle),l=a.className,u=a.innerClassName;o=Mi(Mi({},o),{},{"aria-colspan":e.totalVisibleHeaderCount,className:En(e.isUngrouped?"rt-th-group-none":"rt-th-group",e.headerClassName,l),innerClassName:u,style:e.headerStyle,canResize:e.canResize})}else{var c=pl(q.headerStyle),s=c.className,f=c.innerClassName;o=Mi(Mi({},o),{},{role:e.selectable?"cell":"columnheader",className:En(e.headerClassName,s),innerClassName:f,style:e.headerStyle,canResize:e.canResize,isResizing:e.isResizing}),e.canSort&&(o=Mi(Mi({},o),{},{"aria-label":Xn(Z.sortLabel,{name:e.name}),canSort:e.canSort,sortDescFirst:e.sortDescFirst,isSorted:e.isSorted,isSortedDesc:e.isSortedDesc,toggleSortBy:e.toggleSortBy}))}if(e.canResize){var d=e.getResizerProps(),p=d.onMouseDown,g=d.onTouchStart;t=i().createElement(gl,{onMouseDown:function(e){p(e),e.preventDefault()},onTouchStart:g,onClick:function(e){e.stopPropagation()}})}if(e.selectable&&"multiple"===v&&be.rows.length>0){var y=function(){return be.toggleAllRowsSelected()};o=Mi(Mi({},o),{},{onClick:y,className:En(o.className,"rt-td-select")}),n=i().createElement(Sl,{type:"checkbox",checked:be.isAllRowsSelected,onChange:y,"aria-label":Z.selectAllRowsLabel})}var m=e.getHeaderProps(o),h=m.key,b=Wi(m,Oi);return i().createElement(fl,Gi({key:h},b),n,t)})))})),Ce?i().createElement(sl,{className:En("rt-tr-filters",$n(q.rowStyle))},be.visibleColumns.map((function(e){var t,r;e.filterable&&(null!=e.filterInput?(r="function"==typeof e.filterInput?e.filterInput(e,Pe):(0,tr.hydrate)({Fragment:a.Fragment,WidgetContainer:po},e.filterInput),i().isValidElement(r)?t=r:e.html&&(t=i().createElement(Qa,{html:r}))):t=i().createElement(bl,{filterValue:e.filterValue,setFilter:e.setFilter,className:$n(q.filterInputStyle),placeholder:Z.filterPlaceholder,"aria-label":Xn(Z.filterLabel,{name:e.name})}));var n=pl(q.filterCellStyle),o=n.className,l=n.innerClassName,u={role:"cell",colSpan:null,className:En("rt-td-filter",e.headerClassName,o),innerClassName:l,style:e.headerStyle},c=e.getHeaderProps(u),s=c.key,f=Wi(c,Ri);return i().createElement(dl,Gi({key:s},f),t)}))):null)),function(){var e,t=be.visibleColumns.some((function(e){return e.sticky})),r=t?"rt-tr-highlight-sticky":"rt-tr-highlight",n=t?"rt-tr-striped-sticky":"rt-tr-striped",o=be.page.map((function(e,t){be.prepareRow(e);var o,l=function(t){null==t&&(t=!e.isSelected),"single"===v&&be.setRowsSelected([]),e.toggleRowSelected(t)},u=Mi(Mi({},e),{},{toggleRowSelected:l,viewIndex:t,row:e.values,subRows:kn(e.subRows),aggregated:e.isGrouped,expanded:e.isExpanded,level:e.depth,selected:e.isSelected,page:he.pageIndex}),c={className:En(G&&(t%2?null:n),z&&r,e.isSelected&&"rt-tr-selected",$n(q.rowStyle))};$&&(o="function"==typeof $?$(u,Pe):Array.isArray($)?$[u.index]:$,c.className=En(c.className,o)),U&&("function"==typeof U?c.style=U(u,Pe):Array.isArray(U)?c.style=U[u.index]:c.style=U);var s,f=function(e,t){if(!e.isExpanded||e.isGrouped)return null;var r,n=Ie[e.id];if(!(r=null!=n?be.visibleColumns.find((function(e){return e.id===n})):be.visibleColumns.find((function(e){return e.details}))))return null;var o=r,l=o.details,u=o.html,c={};if("function"==typeof l){var s=l(e,t);u&&(c.html=s),c.children=s}else if(Array.isArray(l)){var f=l[e.index];if(null==f)return null;u&&(c.html=f),c.children=(0,tr.hydrate)({Reactable:nl,Fragment:a.Fragment,WidgetContainer:po},f)}return i().createElement(ml,Gi({key:"".concat(r.id,"_").concat(e.index)},c))}(u,Pe);if(e.isExpanded)if(null!=Ie[e.id])s=Ie[e.id];else{var d=be.visibleColumns.find((function(e){return e.details}));s=d?d.id:null}var p=e.getRowProps(c);return i().createElement(cl,{key:"".concat(e.depth,"_").concat(t),className:$n(q.rowGroupStyle)},i().createElement(sl,Gi({},p,{key:void 0}),e.cells.map((function(t,r){var n=t.column,o=n.getProps?n.getProps(u,n,Pe):{},a=pl(q.cellStyle),c=a.className,f=a.innerClassName;o=Mi(Mi({},o),{},{className:En(o.className,c),innerClassName:f,role:n.rowHeader?"rowheader":"cell"});var d,p,g,y=Mi(Mi({},t),{},{column:n,filterValue:n.filterValue},u);if(d=t.isGrouped?n.Grouped?n.Grouped(y,Pe):y.value:t.isAggregated?n.Aggregated?n.Aggregated(y,Pe):t.render("Aggregated"):t.isPlaceholder?"":n.Cell?n.Cell(y,Pe):t.render("Cell"),n.details&&!e.isGrouped&&(Array.isArray(n.details)&&null==n.details[e.index]||(p=!0)),p){var m=e.isExpanded&&s===n.id;o=Mi(Mi({},o),{},{onClick:function(){if(m){e.toggleRowExpanded(!1);var t=Mi({},Ie);delete t[e.id],Ne(t)}else{e.toggleRowExpanded(!0);var r=Mi(Mi({},Ie),{},Ti({},e.id,n.id));Ne(r)}},className:En(o.className,"rt-td-expandable")}),d===Ka&&(o.style=Mi({textOverflow:"clip",userSelect:"none"},o.style));var h={isExpanded:m,className:$n(q.expanderStyle),"aria-label":Z.detailsExpandLabel};g=i().createElement(hl,h)}else if(t.isGrouped){var b=e.isExpanded;o=Mi(Mi({},o),{},{onClick:function(){return e.toggleRowExpanded()},className:En(o.className,"rt-td-expandable")});var w={isExpanded:b,className:$n(q.expanderStyle),"aria-label":Z.groupExpandLabel};g=i().createElement(hl,w)}else t.column.isGrouped&&e.canExpand&&(o=Mi(Mi({},o),{},{onClick:function(){return e.toggleRowExpanded()},className:En(o.className,"rt-td-expandable")}));var S,O="multiple"===v||"single"===v&&!t.isAggregated;n.selectable&&O&&(o=Mi(Mi({},o),{},{onClick:function(){return l()},className:En(o.className,"rt-td-select")}),S=t.isAggregated?Z.selectAllSubRowsLabel:Z.selectRowLabel,d=i().createElement(Sl,{type:"multiple"===v?"checkbox":"radio",checked:e.isSelected,onChange:function(){return l()},"aria-label":S})),R&&!o.onClick&&("expand"===R?o.onClick=function(){return e.toggleRowExpanded()}:"select"===R&&O?o.onClick=function(){return l()}:"function"==typeof R&&(o.onClick=function(){return R(u,n,Pe)}));var j=t.getCellProps(o);return i().createElement(dl,Gi({},j,{key:"".concat(r,"_").concat(n.id)}),g,d)}))),f)}));m=m?Math.max(m,1):1;var l=Math.max(m-be.page.length,0);l>0&&(e=Ei(Array(l)).map((function(e,t){var r,n={className:En("rt-tr-pad",$n(q.rowStyle))};return $&&("function"==typeof $?r=$(void 0,Pe):Array.isArray($)||(r=$),n.className=En(n.className,r)),U&&("function"==typeof U?n.style=U(void 0,Pe):Array.isArray(U)||(n.style=U)),i().createElement(cl,{key:t,className:$n(q.rowGroupStyle),"aria-hidden":!0},i().createElement(sl,n,be.visibleColumns.map((function(e){var r=pl(q.cellStyle),n=r.className,o=r.innerClassName,a={className:n},l=e.getFooterProps(a),u=l.className,c=l.style;return i().createElement(dl,{key:"".concat(t,"_").concat(e.id),className:u,innerClassName:o,style:c}," ")}))))})));var u,c=$n(q.tableBodyStyle);0===be.rows.length?(u=i().createElement(wl,null,Z.noData),c=En("rt-tbody-no-data",c)):u=i().createElement(wl,null);var s=be.getTableBodyProps({className:c});return i().createElement(ll,s,o,e,u)}(),function(){var e=be.visibleColumns.some((function(e){return null!=e.footer}));if(!e)return null;var t=be.getTfootProps();return i().createElement(ul,t,i().createElement(sl,null,be.visibleColumns.map((function(e){var t="function"==typeof(e=Mi(Mi({},e),{},{column:e,data:Oe})).Footer?e.Footer(e,Pe):e.render("Footer"),r=pl(q.footerStyle),n=r.className,o=r.innerClassName,a={className:En("rt-td-footer",e.footerClassName,n),innerClassName:o,style:e.footerStyle,role:e.rowHeader?"rowheader":"cell",colSpan:null},l=e.getFooterProps(a),u=l.key,c=Wi(l,ji);return i().createElement(dl,Gi({key:u},c),t)}))))}()),function(){if(!1===f)return null;if(!c&&null==f)return null;if(c&&null==f){var e=d?Math.min.apply(Math,[he.pageSize].concat(Ei(y||[]))):he.pageSize;if(Be.current<=e)return null}return i().createElement(ao,{paginationType:s,pageSizeOptions:y,showPageInfo:p,showPageSizeOptions:d,page:he.pageIndex,pages:be.pageCount,pageSize:he.pageSize,pageRowCount:be.pageRowCount,canNext:be.canNextPage,canPrevious:be.canPreviousPage,onPageChange:be.gotoPage,onPageSizeChange:be.setPageSize,rowCount:be.rows.length,theme:q,language:Z})}())}nl.defaultProps={sortable:!0,pagination:!0,defaultPageSize:10,paginationType:"numbers",pageSizeOptions:[10,25,50,100],showPageInfo:!0,minRows:1,showSortIcon:!0,crosstalkId:"__crosstalk__"},yl={Reactable:nl},window.HTMLWidgets.widget({name:"reactable",type:"output",factory:function(e){return{renderValue:function(t){e.hasAttribute("data-react-ssr")?u().hydrate(s(yl,t.tag),e):u().render(s(yl,t.tag),e)},resize:function(){}}}})}();var r=Reactable="undefined"==typeof Reactable?{}:Reactable;for(var n in t)r[n]=t[n];t.__esModule&&Object.defineProperty(r,"__esModule",{value:!0})}();
//# sourceMappingURL=reactable.js.map</script>

<style type="text/css">
code{white-space: pre-wrap;}
span.smallcaps{font-variant: small-caps;}
span.underline{text-decoration: underline;}
div.column{display: inline-block; vertical-align: top; width: 50%;}
div.hanging-indent{margin-left: 1.5em; text-indent: -1.5em;}
ul.task-list{list-style: none;}
</style>



<style type="text/css">
code {
white-space: pre;
}
.sourceCode {
overflow: visible;
}
</style>
<style type="text/css" data-origin="pandoc">
pre > code.sourceCode { white-space: pre; position: relative; }
pre > code.sourceCode > span { display: inline-block; line-height: 1.25; }
pre > code.sourceCode > span:empty { height: 1.2em; }
.sourceCode { overflow: visible; }
code.sourceCode > span { color: inherit; text-decoration: inherit; }
div.sourceCode { margin: 1em 0; }
pre.sourceCode { margin: 0; }
@media screen {
div.sourceCode { overflow: auto; }
}
@media print {
pre > code.sourceCode { white-space: pre-wrap; }
pre > code.sourceCode > span { text-indent: -5em; padding-left: 5em; }
}
pre.numberSource code
{ counter-reset: source-line 0; }
pre.numberSource code > span
{ position: relative; left: -4em; counter-increment: source-line; }
pre.numberSource code > span > a:first-child::before
{ content: counter(source-line);
position: relative; left: -1em; text-align: right; vertical-align: baseline;
border: none; display: inline-block;
-webkit-touch-callout: none; -webkit-user-select: none;
-khtml-user-select: none; -moz-user-select: none;
-ms-user-select: none; user-select: none;
padding: 0 4px; width: 4em;
color: #aaaaaa;
}
pre.numberSource { margin-left: 3em; border-left: 1px solid #aaaaaa; padding-left: 4px; }
div.sourceCode
{ }
@media screen {
pre > code.sourceCode > span > a:first-child::before { text-decoration: underline; }
}
code span.al { color: #ff0000; font-weight: bold; } 
code span.an { color: #60a0b0; font-weight: bold; font-style: italic; } 
code span.at { color: #7d9029; } 
code span.bn { color: #40a070; } 
code span.bu { color: #008000; } 
code span.cf { color: #007020; font-weight: bold; } 
code span.ch { color: #4070a0; } 
code span.cn { color: #880000; } 
code span.co { color: #60a0b0; font-style: italic; } 
code span.cv { color: #60a0b0; font-weight: bold; font-style: italic; } 
code span.do { color: #ba2121; font-style: italic; } 
code span.dt { color: #902000; } 
code span.dv { color: #40a070; } 
code span.er { color: #ff0000; font-weight: bold; } 
code span.ex { } 
code span.fl { color: #40a070; } 
code span.fu { color: #06287e; } 
code span.im { color: #008000; font-weight: bold; } 
code span.in { color: #60a0b0; font-weight: bold; font-style: italic; } 
code span.kw { color: #007020; font-weight: bold; } 
code span.op { color: #666666; } 
code span.ot { color: #007020; } 
code span.pp { color: #bc7a00; } 
code span.sc { color: #4070a0; } 
code span.ss { color: #bb6688; } 
code span.st { color: #4070a0; } 
code span.va { color: #19177c; } 
code span.vs { color: #4070a0; } 
code span.wa { color: #60a0b0; font-weight: bold; font-style: italic; } 
</style>
<script>
// apply pandoc div.sourceCode style to pre.sourceCode instead
(function() {
  var sheets = document.styleSheets;
  for (var i = 0; i < sheets.length; i++) {
    if (sheets[i].ownerNode.dataset["origin"] !== "pandoc") continue;
    try { var rules = sheets[i].cssRules; } catch (e) { continue; }
    var j = 0;
    while (j < rules.length) {
      var rule = rules[j];
      // check if there is a div.sourceCode rule
      if (rule.type !== rule.STYLE_RULE || rule.selectorText !== "div.sourceCode") {
        j++;
        continue;
      }
      var style = rule.style.cssText;
      // check if color or background-color is set
      if (rule.style.color === '' && rule.style.backgroundColor === '') {
        j++;
        continue;
      }
      // replace div.sourceCode by a pre.sourceCode rule
      sheets[i].deleteRule(j);
      sheets[i].insertRule('pre.sourceCode{' + style + '}', j);
    }
  }
})();
</script>




<style type="text/css">body {
background-color: #fff;
margin: 1em auto;
max-width: 700px;
overflow: visible;
padding-left: 2em;
padding-right: 2em;
font-family: "Open Sans", "Helvetica Neue", Helvetica, Arial, sans-serif;
font-size: 14px;
line-height: 1.35;
}
#TOC {
clear: both;
margin: 0 0 10px 10px;
padding: 4px;
width: 400px;
border: 1px solid #CCCCCC;
border-radius: 5px;
background-color: #f6f6f6;
font-size: 13px;
line-height: 1.3;
}
#TOC .toctitle {
font-weight: bold;
font-size: 15px;
margin-left: 5px;
}
#TOC ul {
padding-left: 40px;
margin-left: -1.5em;
margin-top: 5px;
margin-bottom: 5px;
}
#TOC ul ul {
margin-left: -2em;
}
#TOC li {
line-height: 16px;
}
table {
margin: 1em auto;
border-width: 1px;
border-color: #DDDDDD;
border-style: outset;
border-collapse: collapse;
}
table th {
border-width: 2px;
padding: 5px;
border-style: inset;
}
table td {
border-width: 1px;
border-style: inset;
line-height: 18px;
padding: 5px 5px;
}
table, table th, table td {
border-left-style: none;
border-right-style: none;
}
table thead, table tr.even {
background-color: #f7f7f7;
}
p {
margin: 0.5em 0;
}
blockquote {
background-color: #f6f6f6;
padding: 0.25em 0.75em;
}
hr {
border-style: solid;
border: none;
border-top: 1px solid #777;
margin: 28px 0;
}
dl {
margin-left: 0;
}
dl dd {
margin-bottom: 13px;
margin-left: 13px;
}
dl dt {
font-weight: bold;
}
ul {
margin-top: 0;
}
ul li {
list-style: circle outside;
}
ul ul {
margin-bottom: 0;
}
pre, code {
background-color: #f7f7f7;
border-radius: 3px;
color: #333;
white-space: pre-wrap; 
}
pre {
border-radius: 3px;
margin: 5px 0px 10px 0px;
padding: 10px;
}
pre:not([class]) {
background-color: #f7f7f7;
}
code {
font-family: Consolas, Monaco, 'Courier New', monospace;
font-size: 85%;
}
p > code, li > code {
padding: 2px 0px;
}
div.figure {
text-align: center;
}
img {
background-color: #FFFFFF;
padding: 2px;
border: 1px solid #DDDDDD;
border-radius: 3px;
border: 1px solid #CCCCCC;
margin: 0 5px;
}
h1 {
margin-top: 0;
font-size: 35px;
line-height: 40px;
}
h2 {
border-bottom: 4px solid #f7f7f7;
padding-top: 10px;
padding-bottom: 2px;
font-size: 145%;
}
h3 {
border-bottom: 2px solid #f7f7f7;
padding-top: 10px;
font-size: 120%;
}
h4 {
border-bottom: 1px solid #f7f7f7;
margin-left: 8px;
font-size: 105%;
}
h5, h6 {
border-bottom: 1px solid #ccc;
font-size: 105%;
}
a {
color: #0033dd;
text-decoration: none;
}
a:hover {
color: #6666ff; }
a:visited {
color: #800080; }
a:visited:hover {
color: #BB00BB; }
a[href^="http:"] {
text-decoration: underline; }
a[href^="https:"] {
text-decoration: underline; }

code > span.kw { color: #555; font-weight: bold; } 
code > span.dt { color: #902000; } 
code > span.dv { color: #40a070; } 
code > span.bn { color: #d14; } 
code > span.fl { color: #d14; } 
code > span.ch { color: #d14; } 
code > span.st { color: #d14; } 
code > span.co { color: #888888; font-style: italic; } 
code > span.ot { color: #007020; } 
code > span.al { color: #ff0000; font-weight: bold; } 
code > span.fu { color: #900; font-weight: bold; } 
code > span.er { color: #a61717; background-color: #e3d2d2; } 
</style>




</head>

<body>




<h1 class="title toc-ignore">SUMO R package - general use</h1>



<div id="set-up" class="section level1">
<h1>Set up</h1>
<p>First, let’s set up the packages that will allow us to access the
PubMed API and the OMOP CDM. If you haven’t already, you can use
install.packages(““) for the following packages to install these into
your R package directory.</p>
<div class="sourceCode" id="cb1"><pre class="sourceCode r"><code class="sourceCode r"><span id="cb1-1"><a href="#cb1-1" aria-hidden="true" tabindex="-1"></a><span class="fu">library</span>(sumo)</span>
<span id="cb1-2"><a href="#cb1-2" aria-hidden="true" tabindex="-1"></a><span class="fu">library</span>(rentrez)</span>
<span id="cb1-3"><a href="#cb1-3" aria-hidden="true" tabindex="-1"></a><span class="fu">library</span>(CDMConnector)</span>
<span id="cb1-4"><a href="#cb1-4" aria-hidden="true" tabindex="-1"></a><span class="co">#&gt; Warning: package &#39;CDMConnector&#39; was built under R version 4.2.3</span></span>
<span id="cb1-5"><a href="#cb1-5" aria-hidden="true" tabindex="-1"></a><span class="fu">library</span>(DBI)</span>
<span id="cb1-6"><a href="#cb1-6" aria-hidden="true" tabindex="-1"></a><span class="fu">library</span>(reactable)</span></code></pre></div>
<div id="setting-up-our-cdm-connection" class="section level3">
<h3>Setting up our CDM connection</h3>
<p>Before we get started with running SUMO, we’ll need to connect to a
CDM utilizing the package CDMConnector. In this vignette we’ll be using
a SynPuf 110k datasource, but any valid database with an attached OMOP
vocabulary will do.</p>
<p>We will use the keyring package to retrieve our personal access data,
but you will need to supply your own valid credentials for your CDM.</p>
<div class="sourceCode" id="cb2"><pre class="sourceCode r"><code class="sourceCode r"><span id="cb2-1"><a href="#cb2-1" aria-hidden="true" tabindex="-1"></a>con <span class="ot">&lt;-</span> DBI<span class="sc">::</span><span class="fu">dbConnect</span>(</span>
<span id="cb2-2"><a href="#cb2-2" aria-hidden="true" tabindex="-1"></a>  RPostgres<span class="sc">::</span><span class="fu">Postgres</span>(),</span>
<span id="cb2-3"><a href="#cb2-3" aria-hidden="true" tabindex="-1"></a>  <span class="at">host     =</span> keyring<span class="sc">::</span><span class="fu">key_get</span>(<span class="st">&quot;host&quot;</span>),</span>
<span id="cb2-4"><a href="#cb2-4" aria-hidden="true" tabindex="-1"></a>  <span class="at">dbname   =</span> <span class="st">&quot;synpuf_110k&quot;</span>,</span>
<span id="cb2-5"><a href="#cb2-5" aria-hidden="true" tabindex="-1"></a>  <span class="at">user     =</span> keyring<span class="sc">::</span><span class="fu">key_get</span>(<span class="st">&quot;user&quot;</span>),</span>
<span id="cb2-6"><a href="#cb2-6" aria-hidden="true" tabindex="-1"></a>  <span class="at">password =</span> keyring<span class="sc">::</span><span class="fu">key_get</span>(<span class="st">&quot;password&quot;</span>),</span>
<span id="cb2-7"><a href="#cb2-7" aria-hidden="true" tabindex="-1"></a>  <span class="at">port     =</span> keyring<span class="sc">::</span><span class="fu">key_get</span>(<span class="st">&quot;port&quot;</span>)</span>
<span id="cb2-8"><a href="#cb2-8" aria-hidden="true" tabindex="-1"></a>)</span>
<span id="cb2-9"><a href="#cb2-9" aria-hidden="true" tabindex="-1"></a></span>
<span id="cb2-10"><a href="#cb2-10" aria-hidden="true" tabindex="-1"></a>cdmSchema <span class="ot">=</span> keyring<span class="sc">::</span><span class="fu">key_get</span>(<span class="st">&quot;cdmSchema&quot;</span>)</span>
<span id="cb2-11"><a href="#cb2-11" aria-hidden="true" tabindex="-1"></a></span>
<span id="cb2-12"><a href="#cb2-12" aria-hidden="true" tabindex="-1"></a>cdm <span class="ot">&lt;-</span> <span class="fu">cdm_from_con</span>(con, <span class="at">cdm_schema =</span> cdmSchema)</span></code></pre></div>
<p>This CDMConnecter object is how we’ll connect to the OMOP vocabulary
for our MeSH mapping going forward, as tt provides us with a direct
connection to the concept vocabularies.</p>
</div>
<div id="optional-inputting-pubmed-api-key" class="section level3">
<h3>Optional: Inputting PubMed API Key</h3>
<p>The PubMed API that rentrez relies on has an inbuilt query limit of 3
requests per second. This is quite generous, but if you wish, by logging
onto PubMed, you can utilise your own API key to increase this more than
threefold to 10 queries per second. We can do this as follows:</p>
<div class="sourceCode" id="cb3"><pre class="sourceCode r"><code class="sourceCode r"><span id="cb3-1"><a href="#cb3-1" aria-hidden="true" tabindex="-1"></a><span class="fu">set_entrez_key</span>(keyring<span class="sc">::</span><span class="fu">key_get</span>(<span class="st">&quot;PubMed_API&quot;</span>))</span></code></pre></div>
</div>
<div id="creating-a-search-strategy" class="section level2">
<h2>Creating a search strategy</h2>
<p>The first step in utilizing the SUMO package is to create a search
strategy that will be sent to the PubMed servers. SUMO comes pre-built
with a few helpful functions that will assist you in creating a set of
useful terms and combining these together.</p>
<p>We can see these individual steps as follows:</p>
<p>Firstly, we may wish to limit our query to a set of high impact
journals. This string can be generated as follows, or manually input by
the user as a string.</p>
<div class="sourceCode" id="cb4"><pre class="sourceCode r"><code class="sourceCode r"><span id="cb4-1"><a href="#cb4-1" aria-hidden="true" tabindex="-1"></a>journals <span class="ot">&lt;-</span> <span class="fu">journalSearch</span>(<span class="fu">highImpactJournals</span>())</span>
<span id="cb4-2"><a href="#cb4-2" aria-hidden="true" tabindex="-1"></a>journals</span>
<span id="cb4-3"><a href="#cb4-3" aria-hidden="true" tabindex="-1"></a><span class="co">#&gt; [1] &quot;(&#39;Science&#39;[ta] OR &#39;Nature&#39;[ta] OR &#39;Nature Medicine&#39;[ta] OR &#39;Nature Communications&#39;[ta] OR &#39;Nature Digital Health&#39;[ta] OR &#39;The New England journal of medicine&#39;[ta] OR &#39;JAMA&#39;[ta] OR &#39;JAMA internal medicine&#39;[ta] OR &#39;JAMA Surgery&#39;[ta] OR &#39;JAMA Psychiatry&#39;[ta] OR &#39;JAMA Cardiology&#39;[ta] OR &#39;JAMA Pediatrics&#39;[ta] OR &#39;JAMA Neurology&#39;[ta] OR &#39;JAMA Ophthalmology&#39;[ta] OR &#39;JAMA Oncology&#39;[ta] OR &#39;BMJ&#39;[ta] OR &#39;Pharmacoepidemiology and drug safety&#39;[ta] OR &#39;Drug safety&#39;[ta] OR &#39;Annals of internal medicine&#39;[ta] OR &#39;Lancet&#39;[ta] OR &#39;The Lancet. Digital health&#39;[ta] OR &#39;The Lancet. Infectious diseases&#39;[ta] OR &#39;The Lancet. Diabetes endocrinology&#39;[ta] OR &#39;The Lancet. Neurology&#39;[ta] OR &#39;The Lancet. Oncology&#39;[ta] OR &#39;The Lancet. Respiratory medicine&#39;[ta] OR &#39;The Lancet. Psychiatry&#39;[ta] OR &#39;The Lancet. Global health&#39;[ta] OR &#39;The Lancet Digital Health&#39;[ta] OR &#39;The Lancet Haematology&#39;[ta] OR &#39;The Lancet Gastroenterology &amp; Hepatology&#39;[ta] OR &#39;Circulation&#39;[ta] OR &#39;Diabetes Care&#39;[ta] OR &#39;Hypertension&#39;[ta] OR &#39;Journal of the American College of Cardiology&#39;[ta] OR &#39;Vaccine&#39;[ta] OR &#39;Journal of Clinical Oncology&#39;[ta] OR &#39;Journal of the National Cancer Institute&#39;[ta] OR &#39;International Journal of Epidemiology&#39;[ta] OR &#39;American Journal of Epidemiology&#39;[ta] OR &#39;PLOS Digital Health&#39;[ta] OR &#39;PLOS Medicine&#39;[ta] OR &#39;PLOS One&#39;[ta])&quot;</span></span></code></pre></div>
<p>Secondly, we may want to limit our query to a particular
timeframe:</p>
<div class="sourceCode" id="cb5"><pre class="sourceCode r"><code class="sourceCode r"><span id="cb5-1"><a href="#cb5-1" aria-hidden="true" tabindex="-1"></a>timeFrame <span class="ot">&lt;-</span> <span class="fu">dateRange</span>(<span class="st">&quot;2013/01/01&quot;</span>, <span class="st">&quot;2023/01/01&quot;</span>)</span>
<span id="cb5-2"><a href="#cb5-2" aria-hidden="true" tabindex="-1"></a>timeFrame</span>
<span id="cb5-3"><a href="#cb5-3" aria-hidden="true" tabindex="-1"></a><span class="co">#&gt; [1] &quot;(&#39;2013/01/01&#39;:&#39;2023/01/01&#39;[dp])&quot;</span></span></code></pre></div>
<p>Next, we may wish to add terms that will limit our results to
observational studies that utilize the methods we are interested in to
specifically generate real world evidence:</p>
<div class="sourceCode" id="cb6"><pre class="sourceCode r"><code class="sourceCode r"><span id="cb6-1"><a href="#cb6-1" aria-hidden="true" tabindex="-1"></a>terms <span class="ot">&lt;-</span> <span class="fu">textSearch</span>(<span class="at">text =</span> <span class="fu">observationalStudy</span>())</span>
<span id="cb6-2"><a href="#cb6-2" aria-hidden="true" tabindex="-1"></a>terms</span>
<span id="cb6-3"><a href="#cb6-3" aria-hidden="true" tabindex="-1"></a><span class="co">#&gt; [1] &quot;(&#39;cohort&#39;[tw] OR &#39;case-control&#39;[tw] OR &#39;self-controlled&#39;[tw] OR &#39;retrospective analysis&#39;[tw] OR &#39;active comparator&#39;[tw] OR &#39;comparative effectiveness&#39;[tw])&quot;</span></span></code></pre></div>
<p>Finally, we wish to input our concept code as a mapping term to
complete out search. It is also possible to skip any of these steps and
submit a blank query, but do note that this is likely to exceed the
maximum number of possible results (~10,000).</p>
<p>In this case, we wish to use the concept code “439777”, which refers
to anemia.</p>
<div class="sourceCode" id="cb7"><pre class="sourceCode r"><code class="sourceCode r"><span id="cb7-1"><a href="#cb7-1" aria-hidden="true" tabindex="-1"></a>conceptIds <span class="ot">&lt;-</span> <span class="fu">c</span>(<span class="st">&quot;439777&quot;</span>)</span>
<span id="cb7-2"><a href="#cb7-2" aria-hidden="true" tabindex="-1"></a>keyword <span class="ot">&lt;-</span> <span class="fu">searchOmop</span>(<span class="at">conceptIds =</span> conceptIds, <span class="at">cdm =</span> cdm, <span class="at">explosion =</span> <span class="cn">TRUE</span>)</span>
<span id="cb7-3"><a href="#cb7-3" aria-hidden="true" tabindex="-1"></a></span>
<span id="cb7-4"><a href="#cb7-4" aria-hidden="true" tabindex="-1"></a>keyword</span>
<span id="cb7-5"><a href="#cb7-5" aria-hidden="true" tabindex="-1"></a><span class="co">#&gt; [1] &quot;(&#39;Anemia&#39;[MeSH])&quot;</span></span></code></pre></div>
<p>Here we have supplied two additional arguments. We must first specify
the CDM which we have constructed earlier. Secondly, we specify that we
wish to perform MeSH explosion on our anemia term, which will allow
PubMed to return terms it deems similar to anemia. More information on
MeSH explosion may be found here:</p>
<p><a href="https://www.nlm.nih.gov/pubs/techbull/mj98/mj98_truncation.html" class="uri">https://www.nlm.nih.gov/pubs/techbull/mj98/mj98_truncation.html</a></p>
<p>Finally, we can view our lengthy search query which will be submitted
to PubMed:</p>
<div class="sourceCode" id="cb8"><pre class="sourceCode r"><code class="sourceCode r"><span id="cb8-1"><a href="#cb8-1" aria-hidden="true" tabindex="-1"></a>searchStrategy <span class="ot">&lt;-</span> <span class="fu">combineSearchStrategy</span>(terms, timeFrame, journals, keyword)</span>
<span id="cb8-2"><a href="#cb8-2" aria-hidden="true" tabindex="-1"></a>searchStrategy</span>
<span id="cb8-3"><a href="#cb8-3" aria-hidden="true" tabindex="-1"></a><span class="co">#&gt; [1] &quot;(&#39;cohort&#39;[tw] OR &#39;case-control&#39;[tw] OR &#39;self-controlled&#39;[tw] OR &#39;retrospective analysis&#39;[tw] OR &#39;active comparator&#39;[tw] OR &#39;comparative effectiveness&#39;[tw]) AND (&#39;2013/01/01&#39;:&#39;2023/01/01&#39;[dp]) AND (&#39;Science&#39;[ta] OR &#39;Nature&#39;[ta] OR &#39;Nature Medicine&#39;[ta] OR &#39;Nature Communications&#39;[ta] OR &#39;Nature Digital Health&#39;[ta] OR &#39;The New England journal of medicine&#39;[ta] OR &#39;JAMA&#39;[ta] OR &#39;JAMA internal medicine&#39;[ta] OR &#39;JAMA Surgery&#39;[ta] OR &#39;JAMA Psychiatry&#39;[ta] OR &#39;JAMA Cardiology&#39;[ta] OR &#39;JAMA Pediatrics&#39;[ta] OR &#39;JAMA Neurology&#39;[ta] OR &#39;JAMA Ophthalmology&#39;[ta] OR &#39;JAMA Oncology&#39;[ta] OR &#39;BMJ&#39;[ta] OR &#39;Pharmacoepidemiology and drug safety&#39;[ta] OR &#39;Drug safety&#39;[ta] OR &#39;Annals of internal medicine&#39;[ta] OR &#39;Lancet&#39;[ta] OR &#39;The Lancet. Digital health&#39;[ta] OR &#39;The Lancet. Infectious diseases&#39;[ta] OR &#39;The Lancet. Diabetes endocrinology&#39;[ta] OR &#39;The Lancet. Neurology&#39;[ta] OR &#39;The Lancet. Oncology&#39;[ta] OR &#39;The Lancet. Respiratory medicine&#39;[ta] OR &#39;The Lancet. Psychiatry&#39;[ta] OR &#39;The Lancet. Global health&#39;[ta] OR &#39;The Lancet Digital Health&#39;[ta] OR &#39;The Lancet Haematology&#39;[ta] OR &#39;The Lancet Gastroenterology &amp; Hepatology&#39;[ta] OR &#39;Circulation&#39;[ta] OR &#39;Diabetes Care&#39;[ta] OR &#39;Hypertension&#39;[ta] OR &#39;Journal of the American College of Cardiology&#39;[ta] OR &#39;Vaccine&#39;[ta] OR &#39;Journal of Clinical Oncology&#39;[ta] OR &#39;Journal of the National Cancer Institute&#39;[ta] OR &#39;International Journal of Epidemiology&#39;[ta] OR &#39;American Journal of Epidemiology&#39;[ta] OR &#39;PLOS Digital Health&#39;[ta] OR &#39;PLOS Medicine&#39;[ta] OR &#39;PLOS One&#39;[ta]) AND (&#39;Anemia&#39;[MeSH])&quot;</span></span></code></pre></div>
</div>
<div id="running-a-search" class="section level2">
<h2>Running a search</h2>
<p>Now that we have constructed our query, running a search is achieved
by calling the following functions:</p>
<div class="sourceCode" id="cb9"><pre class="sourceCode r"><code class="sourceCode r"><span id="cb9-1"><a href="#cb9-1" aria-hidden="true" tabindex="-1"></a>hits <span class="ot">&lt;-</span> <span class="fu">searchPubmed</span>(searchStrategy)</span>
<span id="cb9-2"><a href="#cb9-2" aria-hidden="true" tabindex="-1"></a></span>
<span id="cb9-3"><a href="#cb9-3" aria-hidden="true" tabindex="-1"></a>res <span class="ot">&lt;-</span> <span class="fu">fetchPubmed</span>(hits, searchStrategy)</span>
<span id="cb9-4"><a href="#cb9-4" aria-hidden="true" tabindex="-1"></a></span>
<span id="cb9-5"><a href="#cb9-5" aria-hidden="true" tabindex="-1"></a>res</span>
<span id="cb9-6"><a href="#cb9-6" aria-hidden="true" tabindex="-1"></a><span class="co">#&gt; # A tibble: 237 × 10</span></span>
<span id="cb9-7"><a href="#cb9-7" aria-hidden="true" tabindex="-1"></a><span class="co">#&gt;    pmid     title        journal year  doi   abstract key_words count totalCount</span></span>
<span id="cb9-8"><a href="#cb9-8" aria-hidden="true" tabindex="-1"></a><span class="co">#&gt;    &lt;chr&gt;    &lt;chr&gt;        &lt;chr&gt;   &lt;chr&gt; &lt;chr&gt; &lt;chr&gt;    &lt;chr&gt;     &lt;int&gt;      &lt;int&gt;</span></span>
<span id="cb9-9"><a href="#cb9-9" aria-hidden="true" tabindex="-1"></a><span class="co">#&gt;  1 23364878 Optimal rec… Americ… 2013  10.1… &quot;Many c… Adult; A…   237      32855</span></span>
<span id="cb9-10"><a href="#cb9-10" aria-hidden="true" tabindex="-1"></a><span class="co">#&gt;  2 23390525 Outbreak of… PloS o… 2013  10.1… &quot;Shiga … Adolesce…   237      32855</span></span>
<span id="cb9-11"><a href="#cb9-11" aria-hidden="true" tabindex="-1"></a><span class="co">#&gt;  3 23405194 Real time b… PloS o… 2013  10.1… &quot;We dem… Algorith…   237      32855</span></span>
<span id="cb9-12"><a href="#cb9-12" aria-hidden="true" tabindex="-1"></a><span class="co">#&gt;  4 23460784 Symptoms an… PloS o… 2013  10.1… &quot;Shiga-… Adult; B…   237      32855</span></span>
<span id="cb9-13"><a href="#cb9-13" aria-hidden="true" tabindex="-1"></a><span class="co">#&gt;  5 23469126 Low vitamin… PloS o… 2013  10.1… &quot;Vitami… Adolesce…   237      32855</span></span>
<span id="cb9-14"><a href="#cb9-14" aria-hidden="true" tabindex="-1"></a><span class="co">#&gt;  6 23533606 Risk factor… PloS o… 2013  10.1… &quot;The ou… Adult; E…   237      32855</span></span>
<span id="cb9-15"><a href="#cb9-15" aria-hidden="true" tabindex="-1"></a><span class="co">#&gt;  7 23554855 Outcomes of… PloS o… 2013  10.1… &quot;Previo… Adolesce…   237      32855</span></span>
<span id="cb9-16"><a href="#cb9-16" aria-hidden="true" tabindex="-1"></a><span class="co">#&gt;  8 23555926 Risk factor… PloS o… 2013  10.1… &quot;Anemia… Adult; A…   237      32855</span></span>
<span id="cb9-17"><a href="#cb9-17" aria-hidden="true" tabindex="-1"></a><span class="co">#&gt;  9 23593217 MicroRNA-48… PloS o… 2013  10.1… &quot;MicroR… Alternat…   237      32855</span></span>
<span id="cb9-18"><a href="#cb9-18" aria-hidden="true" tabindex="-1"></a><span class="co">#&gt; 10 23593351 Expression … PloS o… 2013  10.1… &quot;Increa… Adult; A…   237      32855</span></span>
<span id="cb9-19"><a href="#cb9-19" aria-hidden="true" tabindex="-1"></a><span class="co">#&gt; # ℹ 227 more rows</span></span>
<span id="cb9-20"><a href="#cb9-20" aria-hidden="true" tabindex="-1"></a><span class="co">#&gt; # ℹ 1 more variable: epubdate &lt;date&gt;</span></span></code></pre></div>
<p>We see that our res object does not yet have any back mapping to the
OMOP CDM, which can be achieved by creating a dictionary of OMOP concept
codes found within the results object:</p>
<div class="sourceCode" id="cb10"><pre class="sourceCode r"><code class="sourceCode r"><span id="cb10-1"><a href="#cb10-1" aria-hidden="true" tabindex="-1"></a>resDict <span class="ot">&lt;-</span> <span class="fu">makeDict</span>(res, cdm, <span class="at">rollup =</span> <span class="cn">TRUE</span>)</span>
<span id="cb10-2"><a href="#cb10-2" aria-hidden="true" tabindex="-1"></a></span>
<span id="cb10-3"><a href="#cb10-3" aria-hidden="true" tabindex="-1"></a>res <span class="ot">&lt;-</span> <span class="fu">addDictToRes</span>(res, resDict)</span>
<span id="cb10-4"><a href="#cb10-4" aria-hidden="true" tabindex="-1"></a></span>
<span id="cb10-5"><a href="#cb10-5" aria-hidden="true" tabindex="-1"></a>res</span>
<span id="cb10-6"><a href="#cb10-6" aria-hidden="true" tabindex="-1"></a><span class="co">#&gt; # A tibble: 237 × 13</span></span>
<span id="cb10-7"><a href="#cb10-7" aria-hidden="true" tabindex="-1"></a><span class="co">#&gt; # Rowwise: </span></span>
<span id="cb10-8"><a href="#cb10-8" aria-hidden="true" tabindex="-1"></a><span class="co">#&gt;    pmid     title journal year  doi   abstract key_words conceptIds conceptNames</span></span>
<span id="cb10-9"><a href="#cb10-9" aria-hidden="true" tabindex="-1"></a><span class="co">#&gt;    &lt;chr&gt;    &lt;chr&gt; &lt;chr&gt;   &lt;chr&gt; &lt;chr&gt; &lt;chr&gt;    &lt;chr&gt;     &lt;chr&gt;      &lt;chr&gt;       </span></span>
<span id="cb10-10"><a href="#cb10-10" aria-hidden="true" tabindex="-1"></a><span class="co">#&gt;  1 23364878 Opti… Americ… 2013  10.1… &quot;Many c… Adult; A… 4158493; … C/O - cough…</span></span>
<span id="cb10-11"><a href="#cb10-11" aria-hidden="true" tabindex="-1"></a><span class="co">#&gt;  2 23390525 Outb… PloS o… 2013  10.1… &quot;Shiga … Adolesce… 197253     Hemolytic u…</span></span>
<span id="cb10-12"><a href="#cb10-12" aria-hidden="true" tabindex="-1"></a><span class="co">#&gt;  3 23405194 Real… PloS o… 2013  10.1… &quot;We dem… Algorith… 4308125; … Macrocytic …</span></span>
<span id="cb10-13"><a href="#cb10-13" aria-hidden="true" tabindex="-1"></a><span class="co">#&gt;  4 23460784 Symp… PloS o… 2013  10.1… &quot;Shiga-… Adult; B… 4037672; … Ultrasonogr…</span></span>
<span id="cb10-14"><a href="#cb10-14" aria-hidden="true" tabindex="-1"></a><span class="co">#&gt;  5 23469126 Low … PloS o… 2013  10.1… &quot;Vitami… Adolesce… 4030871; … Red blood c…</span></span>
<span id="cb10-15"><a href="#cb10-15" aria-hidden="true" tabindex="-1"></a><span class="co">#&gt;  6 23533606 Risk… PloS o… 2013  10.1… &quot;The ou… Adult; E… 440320; 1… Infection d…</span></span>
<span id="cb10-16"><a href="#cb10-16" aria-hidden="true" tabindex="-1"></a><span class="co">#&gt;  7 23554855 Outc… PloS o… 2013  10.1… &quot;Previo… Adolesce… 4119473; … Hematopoiet…</span></span>
<span id="cb10-17"><a href="#cb10-17" aria-hidden="true" tabindex="-1"></a><span class="co">#&gt;  8 23555926 Risk… PloS o… 2013  10.1… &quot;Anemia… Adult; A… 439727; 1… Human immun…</span></span>
<span id="cb10-18"><a href="#cb10-18" aria-hidden="true" tabindex="-1"></a><span class="co">#&gt;  9 23593217 Micr… PloS o… 2013  10.1… &quot;MicroR… Alternat… 4339104; … Hemoglobin …</span></span>
<span id="cb10-19"><a href="#cb10-19" aria-hidden="true" tabindex="-1"></a><span class="co">#&gt; 10 23593351 Expr… PloS o… 2013  10.1… &quot;Increa… Adult; A… 4006971; … Tricuspid v…</span></span>
<span id="cb10-20"><a href="#cb10-20" aria-hidden="true" tabindex="-1"></a><span class="co">#&gt; # ℹ 227 more rows</span></span>
<span id="cb10-21"><a href="#cb10-21" aria-hidden="true" tabindex="-1"></a><span class="co">#&gt; # ℹ 4 more variables: count &lt;int&gt;, totalCount &lt;int&gt;, epubdate &lt;date&gt;,</span></span>
<span id="cb10-22"><a href="#cb10-22" aria-hidden="true" tabindex="-1"></a><span class="co">#&gt; #   concepts &lt;chr&gt;</span></span></code></pre></div>
<p>Now that we have added our back mapping of OMOP concepts to our
results, we have a complete dataframe of relevant publications and the
terms they contain.</p>
</div>
<div id="search-summary-and-visualization" class="section level2">
<h2>Search Summary and visualization</h2>
<p>We may now view the summarized abstracts returned by our search query
in a reactable table format:</p>
<div class="sourceCode" id="cb11"><pre class="sourceCode r"><code class="sourceCode r"><span id="cb11-1"><a href="#cb11-1" aria-hidden="true" tabindex="-1"></a>tab <span class="ot">&lt;-</span> <span class="fu">printAbstract</span>(res, <span class="at">view =</span> T)</span>
<span id="cb11-2"><a href="#cb11-2" aria-hidden="true" tabindex="-1"></a></span>
<span id="cb11-3"><a href="#cb11-3" aria-hidden="true" tabindex="-1"></a>tab</span></code></pre></div>
<div class="reactable html-widget html-fill-item-overflow-hidden html-fill-item" id="htmlwidget-7eeef2b25873b5583cce" style="width:auto;height:auto;"></div>
<script type="application/json" data-for="htmlwidget-7eeef2b25873b5583cce">{"x":{"tag":{"name":"Reactable","attribs":{"data":{"pmid":["PMID: 23364878","PMID: 23390525","PMID: 23405194","PMID: 23460784","PMID: 23469126","PMID: 23533606","PMID: 23554855","PMID: 23555926","PMID: 23593217","PMID: 23593351","PMID: 23755165","PMID: 23861932","PMID: 23861946","PMID: 23922670","PMID: 23925429","PMID: 23935124","PMID: 24058526","PMID: 24081970","PMID: 24086319","PMID: 24194926","PMID: 24223742","PMID: 24224021","PMID: 24244292","PMID: 24244638","PMID: 24295807","PMID: 24349404","PMID: 24402422","PMID: 24466209","PMID: 24498320","PMID: 24505406","PMID: 24515990","PMID: 24533156","PMID: 24585758","PMID: 24609013","PMID: 24642836","PMID: 24667352","PMID: 24676783","PMID: 24740290","PMID: 24740295","PMID: 24743879","PMID: 24878740","PMID: 24988120","PMID: 25145526","PMID: 25145527","PMID: 25207808","PMID: 25222119","PMID: 25275451","PMID: 25299063","PMID: 25360671","PMID: 25470614","PMID: 25478953","PMID: 25489846","PMID: 25490722","PMID: 25502228","PMID: 25506921","PMID: 25679510","PMID: 25700159","PMID: 25761112","PMID: 25775246","PMID: 25875012","PMID: 25885271","PMID: 25923706","PMID: 26000799","PMID: 26024473","PMID: 26144903","PMID: 26237222","PMID: 26237421","PMID: 26253625","PMID: 26313356","PMID: 26327623","PMID: 26335226","PMID: 26366562","PMID: 26391409","PMID: 26394142","PMID: 26406317","PMID: 26406992","PMID: 26430892","PMID: 26445270","PMID: 26474481","PMID: 26588085","PMID: 26599216","PMID: 26599634","PMID: 26670100","PMID: 26683994","PMID: 26785407","PMID: 26807799","PMID: 26867226","PMID: 26939055","PMID: 27018988","PMID: 27076671","PMID: 27079334","PMID: 27092778","PMID: 27116614","PMID: 27187171","PMID: 27276035","PMID: 27281287","PMID: 27351925","PMID: 27388623","PMID: 27404556","PMID: 27414024","PMID: 27467818","PMID: 27528724","PMID: 27582110","PMID: 27598789","PMID: 27611583","PMID: 27636371","PMID: 27711207","PMID: 27736922","PMID: 27764159","PMID: 27764168","PMID: 27776167","PMID: 27824927","PMID: 27907058","PMID: 28005920","PMID: 28152086","PMID: 28158216","PMID: 28235023","PMID: 28288159","PMID: 28291790","PMID: 28350519","PMID: 28380009","PMID: 28419299","PMID: 28475591","PMID: 28542469","PMID: 28542627","PMID: 28598970","PMID: 28777814","PMID: 28863145","PMID: 28877261","PMID: 29020197","PMID: 29023457","PMID: 29099850","PMID: 29136640","PMID: 29244881","PMID: 29342203","PMID: 29494636","PMID: 29677205","PMID: 29795576","PMID: 29941517","PMID: 30086179","PMID: 30096167","PMID: 30161219","PMID: 30161261","PMID: 30222732","PMID: 30256836","PMID: 30300403","PMID: 30327363","PMID: 30379899","PMID: 30521614","PMID: 30551126","PMID: 30562086","PMID: 30601843","PMID: 30794672","PMID: 30794713","PMID: 30884493","PMID: 30913234","PMID: 30969847","PMID: 31022266","PMID: 31059543","PMID: 31107926","PMID: 31170159","PMID: 31220109","PMID: 31251783","PMID: 31295273","PMID: 31344117","PMID: 31408501","PMID: 31600331","PMID: 31661492","PMID: 31671128","PMID: 31800574","PMID: 31830127","PMID: 31846473","PMID: 31869367","PMID: 31923240","PMID: 31940411","PMID: 32027674","PMID: 32032395","PMID: 32045443","PMID: 32084207","PMID: 32240223","PMID: 32271826","PMID: 32379790","PMID: 32520956","PMID: 32663844","PMID: 32687544","PMID: 32750060","PMID: 32776978","PMID: 32887708","PMID: 32898174","PMID: 32924542","PMID: 33147287","PMID: 33170905","PMID: 33270733","PMID: 33370352","PMID: 33382828","PMID: 33439871","PMID: 33481933","PMID: 33529189","PMID: 33529195","PMID: 33539452","PMID: 33891581","PMID: 33905433","PMID: 33970934","PMID: 34283868","PMID: 34432825","PMID: 34506574","PMID: 34597127","PMID: 34618852","PMID: 34653184","PMID: 34735494","PMID: 34748552","PMID: 34780475","PMID: 34972180","PMID: 35020736","PMID: 35025925","PMID: 35061819","PMID: 35120154","PMID: 35139138","PMID: 35167662","PMID: 35213569","PMID: 35333889","PMID: 35613111","PMID: 35857790","PMID: 35895618","PMID: 35984839","PMID: 36054881","PMID: 36170343","PMID: 36201463","PMID: 36201515","PMID: 36399777","PMID: 36409722","PMID: 36445914","PMID: 36520848","PMID: 36520858","PMID: 36525434","PMID: 36989322","PMID: 37058522"],"title":["Optimal recall period for caregiver-reported illness in risk factor and intervention studies: a multicountry study.","Outbreak of Shiga toxin-producing Escherichia coli (STEC) O157:H7 associated with romaine lettuce consumption, 2011.","Real time blood testing using quantitative phase imaging.","Symptoms and clinical course of EHEC O104 infection in hospitalized patients: a prospective single center study.","Low vitamin B12 levels among newly-arrived refugees from Bhutan, Iran and Afghanistan: a multicentre Australian study.","Risk factors for development of hemolytic uremic syndrome in a cohort of adult patients with STEC 0104:H4 infection.","Outcomes of optimized over standard protocol of rabbit antithymocyte globulin for severe aplastic anemia: a single-center experience.","Risk factors of treatment-limiting anemia after substitution of zidovudine for stavudine in HIV-infected adult patients on antiretroviral treatment.","MicroRNA-486-3p regulates γ-globin expression in human erythroid cells by directly modulating BCL11A.","Expression of regulatory platelet microRNAs in patients with sickle cell disease.","Dilemma in differentiating between acute osteomyelitis and bone infarction in children with sickle cell disease: the role of ultrasound.","Iron, hepcidin and inflammatory status of young healthy overweight and obese women in Australia.","Iron status and Helicobacter pylori infection in symptomatic children: an international multi-centered study.","Blood viscosity and the expression of inflammatory and adhesion markers in homozygous sickle cell disease subjects with chronic leg ulcers.","The causal effect of malaria on stunting: a Mendelian randomization and matching approach.","Associations of age and sex with the clinical outcome and incubation period of Shiga toxin-producing Escherichia coli O104:H4 infections, 2011.","Genome-wide meta-analysis of systolic blood pressure in children with sickle cell disease.","Prevalence and risk factors for pulmonary arterial hypertension in a large group of β-thalassemia patients using right heart catheterization: a Webthal study.","Cotrimoxazole prophylaxis and risk of severe anemia or severe neutropenia in HAART-exposed, HIV-uninfected infants.","Prevalence, types, risk factors and clinical correlates of anaemia in older people in a rural Ugandan population.","Serum copeptin and cortisol do not accurately predict sickle cell anaemia vaso-occlusive crisis as C-reactive protein.","Severe painful vaso-occlusive crises and mortality in a contemporary adult sickle cell anemia cohort study.","Shiga toxin-producing Escherichia coli O157 is more likely to lead to hospitalization and death than non-O157 serogroups--except O104.","Maternal and antenatal risk factors for stillbirths and neonatal mortality in rural Bangladesh: a case-control study.","Antibody response to human papillomavirus vaccine in subjects with inherited bone marrow failure syndromes.","Association between ischemic stroke and iron-deficiency anemia: a population-based study.","Identification and validation of an anthracycline/cyclophosphamide-based chemotherapy response assay in breast cancer.","Early colonoscopy confers survival benefits on colon cancer patients with pre-existing iron deficiency anemia: a nationwide population-based study.","Disease history and medication use as risk factors for the clinical manifestation of type 1 diabetes in children and young adults: an explorative case control study.","Granulocyte transfusion combined with granulocyte colony stimulating factor in severe infection patients with severe aplastic anemia: a single center experience from China.","Hypoxic response contributes to altered gene expression and precapillary pulmonary hypertension in patients with sickle cell disease.","Inadequate riboflavin intake and anemia risk in a Chinese population: five-year follow up of the Jiangsu Nutrition Study.","Prediction of fetal hemoglobin in sickle cell anemia using an ensemble of genetic risk prediction models.","Anion exchange HPLC isolation of high-density lipoprotein (HDL) and on-line estimation of proinflammatory HDL.","Mycoplasma salivarium as a dominant coloniser of Fanconi anaemia associated oral carcinoma.","Association of variants at BCL11A and HBS1L-MYB with hemoglobin F and hospitalization rates among sickle cell patients in Cameroon.","Mechanistic insights and characterization of sickle cell disease-associated cardiomyopathy.","Outcomes of acute chest syndrome in adult patients with sickle cell disease: predictors of mortality.","Acute moderate exercise does not further alter the autonomic nervous system activity in patients with sickle cell anemia.","Ethnic variations in severe maternal morbidity in the UK- a case control study.","Increase of hemoglobin levels by anti-IL-6 receptor antibody (tocilizumab) in rheumatoid arthritis.","Risk factors for death in 632 patients with sickle cell disease in the United States and United Kingdom.","Blood transfusion during acute myocardial infarction: association with mortality and variability across hospitals.","Blood transfusion in myocardial infarction: opening old wounds for comparative-effectiveness research.","Pre-treatment anemia is a poor prognostic factor in soft tissue sarcoma patients.","Anaemia in pregnancy is associated with advanced HIV disease.","Reduction of the six-minute walk distance in children with sickle cell disease is correlated with silent infarct: results from a cross-sectional evaluation in a single center in Belgium.","Impairment of bone health in pediatric patients with hemolytic anemia.","Whole exome sequencing identifies novel genes for fetal hemoglobin response to hydroxyurea in children with sickle cell anemia.","Micronutrient levels and supplement intake in pregnancy after bariatric surgery: a prospective cohort study.","Elevated pulse pressure is associated with hemolysis, proteinuria and chronic kidney disease in sickle cell disease.","Additive effect of anemia and renal impairment on long-term outcome after percutaneous coronary intervention.","Evaluation of a density-based rapid diagnostic test for sickle cell disease in a clinical setting in Zambia.","Blood thixotropy in patients with sickle cell anaemia: role of haematocrit and red blood cell rheological properties.","Maximal standard dose of parenteral iron for hemodialysis patients: an MRI-based decision tree learning analysis.","Discrimination index of microcytic anemia in young soldiers: a single institutional analysis.","Ferrous sulfate supplementation causes significant gastrointestinal side-effects in adults: a systematic review and meta-analysis.","Detection of a novel, integrative aging process suggests complex physiological integration.","Large cohort screening of G6PD deficiency and the mutational spectrum in the Dongguan District in Southern China.","Risk factors and birth outcomes of anaemia in early pregnancy in a nulliparous cohort.","Independent association of circulating vitamin D metabolites with anemia risk in patients scheduled for cardiac surgery.","Clinical features of children with pulmonary microscopic polyangiitis: report of 9 cases.","Re-examination of 30-day survival and relapse rates in patients with thrombotic thrombocytopenic purpura-hemolytic uremic syndrome.","Does smoke from biomass fuel contribute to anemia in pregnant women in Nagpur, India? A cross-sectional study.","Long-lasting hyporesponsivenss induced by the 23-valent pneumococcal polysaccharide vaccine (PPV23) in asplenic patients with β-thalassemia major.","Potentially Modifiable Factors Associated with Death of Infants and Children with Severe Pneumonia Routinely Managed in District Hospitals in Malawi.","Pentoxifylline for Anemia in Chronic Kidney Disease: A Systematic Review and Meta-Analysis.","Multiparametric Cardiac Magnetic Resonance Survey in Children With Thalassemia Major: A Multicenter Study.","Social Costs of Iron Deficiency Anemia in 6-59-Month-Old Children in India.","Glucose-6-Phosphate Dehydrogenase Deficiency and Haemoglobin Drop after Sulphadoxine-Pyrimethamine Use for Intermittent Preventive Treatment of Malaria during Pregnancy in Ghana - A Cohort Study.","Risk Factors of Pulmonary Hypertension in Brazilian Patients with Sickle Cell Anemia.","Absolute Reticulocyte Count Acts as a Surrogate for Fetal Hemoglobin in Infants and Children with Sickle Cell Anemia.","Pregnancy complications and cardiovascular disease death: 50-year follow-up of the Child Health and Development Studies pregnancy cohort.","Multicenter Experience with Boceprevir or Telaprevir to Treat Hepatitis C Recurrence after Liver Transplantation: When Present Becomes Past, What Lessons for Future?","The Effectiveness of Interventions for Non-Communicable Diseases in Humanitarian Crises: A Systematic Review.","Tissue Iron Distribution Assessed by MRI in Patients with Iron Loading Anemias.","Albuminuria as a Risk Factor for Anemia in Chronic Kidney Disease: Result from the KoreaN Cohort Study for Outcomes in Patients With Chronic Kidney Disease (KNOW-CKD).","Determinants of Iron Deficiency Anemia in a Cohort of Children Aged 6-71 Months Living in the Northeast of Minas Gerais, Brazil.","Predictors of Persistent Anaemia in the First Year of Antiretroviral Therapy: A Retrospective Cohort Study from Goma, the Democratic Republic of Congo.","Association of Erythropoietin-Stimulating Agent Responsiveness with Mortality in Hemodialysis and Peritoneal Dialysis Patients.","The Different Association between Serum Ferritin and Mortality in Hemodialysis and Peritoneal Dialysis Patients Using Japanese Nationwide Dialysis Registry.","Risks of Hemolysis in Glucose-6-Phosphate Dehydrogenase Deficient Infants Exposed to Chlorproguanil-Dapsone, Mefloquine and Sulfadoxine-Pyrimethamine as Part of Intermittent Presumptive Treatment of Malaria in Infants.","Impact of IL28B, APOH and ITPA Polymorphisms on Efficacy and Safety of TVR- or BOC-Based Triple Therapy in Treatment-Experienced HCV-1 Patients with Compensated Cirrhosis from the ANRS CO20-CUPIC Study.","Hemoglobin Constant Spring among Southeast Asian Populations: Haplotypic Heterogeneities and Phylogenetic Analysis.","Neonatal Screening and the Clinical Outcome in Children with Sickle Cell Disease in Central India.","Delineating the Association between Heavy Postpartum Haemorrhage and Postpartum Depression.","Epidemiology and Burden of Bloodstream Infections Caused by Extended-Spectrum Beta-Lactamase Producing Enterobacteriaceae in a Pediatric Hospital in Senegal.","Performance of a Predictive Model for Long-Term Hemoglobin Response to Darbepoetin and Iron Administration in a Large Cohort of Hemodialysis Patients.","Impact of Safety-Related Dose Reductions or Discontinuations on Sustained Virologic Response in HCV-Infected Patients: Results from the GUARD-C Cohort.","Association of Hemoglobin Concentration With Total and Cause-Specific Mortality in a Cohort of Postmenopausal Women.","Coronary Thrombosis and Major Bleeding After PCI With Drug-Eluting Stents: Risk Scores From PARIS.","Mitochondrial Changes in β0-Thalassemia/Hb E Disease.","Examination of Reticulocytosis among Chronically Transfused Children with Sickle Cell Anemia.","Impact of Genetic Polymorphism of methylenetetrahydrofolate reductase C677T on Development of Hyperhomocysteinemia and Related Oxidative Changes in Egyptian β-Thalassemia Major Patients.","Hepcidin Response to Iron Therapy in Patients with Non-Dialysis Dependent CKD: An Analysis of the FIND-CKD Trial.","Cognition and the Default Mode Network in Children with Sickle Cell Disease: A Resting State Functional MRI Study.","Development of a High-Resolution Melting Approach for Scanning Beta Globin Gene Point Mutations in the Greek and Other Mediterranean Populations.","Influence of Ribavirin Serum Levels on Outcome of Antiviral Treatment and Anemia in Hepatitis C Virus Infection.","The Cost-Effectiveness of Anemia Treatment for Persons with Chronic Kidney Disease.","Association between Sickle Cell Trait and the Prevalence and Severity of Diabetic Retinopathy.","G6PD Deficiency Does Not Enhance Susceptibility for Acquiring Helicobacter pylori Infection in Sardinian Patients.","Safety, Antitumor Activity, and Immune Activation of Pegylated Recombinant Human Interleukin-10 (AM0010) in Patients With Advanced Solid Tumors.","Blood Transfusion and the Risk of Acute Kidney Injury Among Patients With Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention.","Limited Generalizability of Registration Trials in Hepatitis C: A Nationwide Cohort Study.","Association of Human Leukocyte Antigen DRB1*15 and DRB1*15:01 Polymorphisms with Response to Immunosuppressive Therapy in Patients with Aplastic Anemia: A Meta-Analysis.","Genome-Wide Analysis Identifies IL-18 and FUCA2 as Novel Genes Associated with Diastolic Function in African Americans with Sickle Cell Disease.","Genetic Modifiers of White Blood Cell Count, Albuminuria and Glomerular Filtration Rate in Children with Sickle Cell Anemia.","Associations of Prolonged QTc in Sickle Cell Disease.","Longitudinal Analysis of Patient Specific Predictors for Mortality in Sickle Cell Disease.","Effects of Secondary Hyperparathyroidism Treatment on Improvement in Anemia: Results from the MBD-5D Study.","Birth Weights in Sickle Cell Disease Pregnancies: A Cohort Study.","Glucose-6-Phosphate Dehydrogenase Deficiency and Physical and Mental Health until Adolescence.","Choice of High-Dose Intravenous Iron Preparation Determines Hypophosphatemia Risk.","Fortified Snack Reduced Anemia in Rural School-Aged Children of Haiti: A Cluster-Randomized, Controlled Trial.","NNKTT120, an anti-iNKT cell monoclonal antibody, produces rapid and sustained iNKT cell depletion in adults with sickle cell disease.","Non-steroidal anti-inflammatory drugs induce severe hematologic toxicities in lung cancer patients receiving pemetrexed plus carboplatin: A retrospective cohort study.","Markers of oxidative stress in umbilical cord blood from G6PD deficient African newborns.","Determinants of anemia among pregnant mothers attending antenatal care in Dessie town health facilities, northern central Ethiopia, unmatched case -control study.","Anaemia among children in a drought affected community in south-central Ethiopia.","Outcome of Lower-Risk Patients With Myelodysplastic Syndromes Without 5q Deletion After Failure of Erythropoiesis-Stimulating Agents.","Impact of fortified biscuits on micronutrient deficiencies among primary school children in Bangladesh.","Pregnancy and Labor Complications in Female Survivors of Childhood Cancer: The British Childhood Cancer Survivor Study.","Ketoanalogues supplementation decreases dialysis and mortality risk in patients with anemic advanced chronic kidney disease.","Biophysical markers of the peripheral vasoconstriction response to pain in sickle cell disease.","Predictive features of chronic kidney disease in atypical haemolytic uremic syndrome.","Seroprevalence and clinical characteristics of viral hepatitis in transfusion-dependent thalassemia and hemophilia patients.","Prevalence of preoperative anemia, abnormal mean corpuscular volume and red cell distribution width among surgical patients in Singapore, and their influence on one year mortality.","Associations between endothelial dysfunction and clinical and laboratory parameters in children and adolescents with sickle cell anemia.","Myelodysplastic syndrome patients present more severe respiratory muscle impairment and reduced forced vital capacity: Is disordered inflammatory signaling the culprit?","Sickle Cell Trait and Heat Injury Among US Army Soldiers.","The DMT1 IVS4+44C>A polymorphism and the risk of iron deficiency anemia in children with celiac disease.","Determinants of severe anemia among laboring mothers in Mekelle city public hospitals, Tigray region, Ethiopia.","Long-term outcomes of the Atypical Hemolytic Uremic Syndrome after kidney transplantation treated with eculizumab as first choice.","Treating iron deficiency in patients with gastrointestinal disease: Risk of re-attendance in secondary care.","Biological pathways underlying the association of red cell distribution width and adverse clinical outcome: Results of a prospective cohort study.","Causes of death and early life determinants of survival in homozygous sickle cell disease: The Jamaican cohort study from birth.","Anemia in tuberculosis cases and household controls from Tanzania: Contribution of disease, coinfections, and the role of hepcidin.","A method for age-matched OCT angiography deviation mapping in the assessment of disease- related changes to the radial peripapillary capillaries.","Evaluation of Hemolysis as a Severe Feature of Preeclampsia.","Renal function and anemia in relation to short- and long-term prognosis of patients with acute heart failure in the period 1985-2008: A clinical cohort study.","Enuresis in children and adolescents with sickle cell anaemia is more frequent and substantially different from the general population.","New cases of Glucose-6-Phosphate Dehydrogenase deficiency in Pulmonary Arterial Hypertension.","The crucial impact of iron deficiency definition for the course of precapillary pulmonary hypertension.","Associations between erythrocyte polymorphisms and risks of uncomplicated and severe malaria in Ugandan children: A case control study.","Predialysis anemia management and outcomes following dialysis initiation: A retrospective cohort analysis.","High rates of death and loss to follow-up by 12 months of rifampicin resistant TB treatment in South Africa.","Increased Prevalence of Type 2 Diabetes-Related Complications in Combined Type 2 Diabetes and Sickle Cell Trait.","Cause-specific mortality patterns among hospital deaths in Tanzania, 2006-2015.","The relationship between iron deficiency anemia and sexual function and satisfaction among reproductive-aged Iranian women.","Predicting peripartum blood transfusion in women undergoing cesarean delivery: A risk prediction model.","Association of Anemia With Outcomes Among ST-Segment-Elevation Myocardial Infarction Patients Receiving Primary Percutaneous Coronary Intervention.","Impact of glucose-6-phosphate dehydrogenase deficiency on dengue infection in Myanmar children.","Effects of high-volume online mixed-hemodiafiltration on anemia management in dialysis patients.","Ovarian reserve in women with sickle cell disease.","Maternal anemia and birth weight: A prospective cohort study.","Nutrition-specific and nutrition-sensitive factors associated with mid-upper arm circumference as a measure of nutritional status in pregnant Ethiopian women: Implications for programming in the first 1000 days.","Management of Cancer-Associated Anemia With Erythropoiesis-Stimulating Agents: ASCO/ASH Clinical Practice Guideline Update.","Low-normal hemoglobin levels and anemia are associated with increased risk of end-stage renal disease in general populations: A prospective cohort study.","Risk factors for incident anemia of chronic diseases: A cohort study.","Chronic pain in adults with sickle cell disease is associated with alterations in functional connectivity of the brain.","Iron deficiency, elevated erythropoietin, fibroblast growth factor 23, and mortality in the general population of the Netherlands: A cohort study.","Very severe anemia and one year mortality outcome after hospitalization in Tanzanian children: A prospective cohort study.","Innate-like T cells in children with sickle cell disease.","Red blood cell transfusion associated with increased morbidity and mortality in patients undergoing elective open abdominal aortic aneurysm repair.","Prevalence of anemia in pregnant women in Styria, Austria-A retrospective analysis of mother-child examinations 2006-2014.","The effect of donation activity dwarfs the effect of lifestyle, diet and targeted iron supplementation on blood donor iron stores.","Alteration of humoral, cellular and cytokine immune response to inactivated influenza vaccine in patients with Sickle Cell Disease.","Impact of the detection of ζ-globin chains and hemoglobin Bart's using immunochromatographic strip tests for α0-thalassemia (--SEA) differential diagnosis.","Determinants of anemia among pregnant women attending antenatal care in Horo Guduru Wollega Zone, West Ethiopia: Unmatched case-control study.","Utilisation of health services fails to meet the needs of pregnancy-related illnesses in rural southern Ethiopia: A prospective cohort study.","Use of an automated pyrosequencing technique for confirmation of sickle cell disease.","Anemia in patients with diabetic foot ulcer and its impact on disease outcome among Nigerians: Results from the MEDFUN study.","Neutrophils remain detrimentally active in hydroxyurea-treated patients with sickle cell disease.","Effect of a community-based approach of iron and folic acid supplementation on compliance by pregnant women in Kiambu County, Kenya: A quasi-experimental study.","Mitochondrial DNA variations and mitochondrial dysfunction in Fanconi anemia.","Inter-pregnancy interval and associated adverse maternal outcomes among women who delivered at Kilimanjaro Christian Medical Centre in Tanzania, 2000-2015.","Bevacizumab for treating Hereditary Hemorrhagic Telangiectasia patients with severe hepatic involvement or refractory anemia.","Psychological morbidity among children with transfusion dependent β-thalassaemia and their parents in Sri Lanka.","Postoperative anaemia might be a risk factor for postoperative delirium and prolonged hospital stay: A secondary analysis of a prospective cohort study.","Prevalence of anemia in predialysis chronic kidney disease: Is the study center a significant factor?","Evans syndrome in children below 13 years of age - A nationwide population-based cohort study.","S100B single nucleotide polymorphisms exhibit sex-specific associations with chronic pain in sickle cell disease in a largely African-American cohort.","Interocular asymmetry of foveal avascular zone morphology and parafoveal capillary density in sickle cell retinopathy.","Marijuana use and health behaviors in a US clinic sample of patients with sickle cell disease.","Prevalence of anemia in patients with chronic kidney disease in Japan: A nationwide, cross-sectional cohort study using data from the Japan Chronic Kidney Disease Database (J-CKD-DB).","Outcomes and adverse events of pre- and extensively drug-resistant tuberculosis patients in Kinshasa, Democratique Republic of the Congo: A retrospective cohort study.","Serum albumin is independently associated with higher mortality in adult sickle cell patients: Results of three independent cohorts.","The Close Link of Pancreatic Iron With Glucose Metabolism and With Cardiac Complications in Thalassemia Major: A Large, Multicenter Observational Study.","Anemia is associated with the risk of Crohn's disease, not ulcerative colitis: A nationwide population-based cohort study.","Genetic Analysis of Patients With Sickle Cell Anemia and Stroke Before 4 Years of Age Suggest an Important Role for Apoliprotein E.","Neurodevelopmental performance among pre-schoolers treated for severe anaemia at Lira Regional Referral Hospital, Uganda.","Hematologic alterations and early mortality in a cohort of HIV positive African patients.","Feasibility and acceptability of early infant screening for sickle cell disease in Lagos, Nigeria-A pilot study.","The prevalence and correlates of the double burden of malnutrition among women in Ghana.","Influence of hemoglobinopathies and glucose-6-phosphate dehydrogenase deficiency on diagnosis of diabetes by HbA1c among Tanzanian adults with and without HIV: A cross-sectional study.","Patient harm associated with serial phlebotomy and blood waste in the intensive care unit: A retrospective cohort study.","Malaria and intestinal parasite co-infection and its association with anaemia among people living with HIV in Buea, Southwest Cameroon: A community-based retrospective cohort study.","A cohort analysis of survival and outcomes in severely anaemic children with moderate to severe acute malnutrition in Malawi.","Anemia in tuberculosis cases: A biomarker of severity?","Priapism in sickle cell disease: Associations between NOS3 and EDN1 genetic polymorphisms and laboratory biomarkers.","Glucose-6-phosphate dehydrogenase activity in individuals with and without malaria: Analysis of clinical trial, cross-sectional and case-control data from Bangladesh.","Factors associated with iron deficiency anaemia among pregnant teenagers in Ashanti Region, Ghana: A hospital-based prospective cohort study.","Effects of intestinal parasite infection on hematological profiles of pregnant women attending antenatal care at Debre Markos Referral Hospital, Northwest Ethiopia: Institution based prospective cohort study.","The association of severe anemia, red blood cell transfusion and necrotizing enterocolitis in neonates.","The gut microbiome in sickle cell disease: Characterization and potential implications.","Effects of blood urea nitrogen independent of the estimated glomerular filtration rate on the development of anemia in non-dialysis chronic kidney disease: The results of the KNOW-CKD study.","Cancer in Children With Fanconi Anemia and Ataxia-Telangiectasia-A Nationwide Register-Based Cohort Study in Germany.","High levels of pathological jaundice in the first 24 hours and neonatal hyperbilirubinaemia in an epidemiological cohort study on the Thailand-Myanmar border.","External validation of the priapism impact profile in a Jamaican cohort of patients with sickle cell disease.","Pediatric thalassemic patients have higher incidence of asthma: A nationwide population-based retrospective cohort study.","Thrombotic microangiopathy after kidney transplantation: Analysis of the Brazilian Atypical Hemolytic Uremic Syndrome cohort.","Association of SNPs within TMPRSS6 and BMP2 genes with iron deficiency status in Saudi Arabia.","Mild anemia and 11- to 15-year mortality risk in young-old and old-old: Results from two population-based cohort studies.","Incidence and predictors of anemia among adults on HIV care at South Gondar Zone Public General Hospital Northwest Ethiopia, 2020; retrospective cohort study.","An evidence-based definition of anemia for singleton, uncomplicated pregnancies.","Assessing fetal growth in Africa: Application of the international WHO and INTERGROWTH-21st standards in a Beninese pregnancy cohort.","Interventions for Shiga toxin-producing Escherichia coli gastroenteritis and risk of hemolytic uremic syndrome: A population-based matched case control study.","Prevalence and determinants of anemia among Iranian population aged ≥35 years: A PERSIAN cohort-based cross-sectional study.","Iron supplementation and paediatric HIV disease progression: a cohort study among children receiving routine HIV care in Dar es Salaam, Tanzania.","Incidence and predictors of severe acute malnutrition mortality in children aged 6-59 months admitted at Pawe general hospital, Northwest Ethiopia.","Prevalence and predictors of anemia among adults on highly active antiretroviral therapy in Northeast Ethiopia: A retrospective cohort study.","Combined nerve and vascular ultrasound in thoracic outlet syndrome: A sensitive method in identifying the site of neurovascular compression.","Hierarchical improvement of regional tissue oxygenation after packed red blood cell transfusion.","Impact of preoperative anemia, iron-deficiency and inflammation on survival after colorectal surgery-A retrospective cohort study.","Is biomass fuel smoke exposure associated with anemia in non-pregnant reproductive-aged women?","Clinical and Molecular Determinants of Clonal Evolution in Aplastic Anemia and Paroxysmal Nocturnal Hemoglobinuria.","Hypoxia-inducible factor prolyl hydroxylase inhibitors for anemia in heart failure patients: A protocol for systematic review and meta-analysis.","Factors associated with early pregnancy anemia in rural Sri Lanka: Does being 'under care' iron out socioeconomic disparities?","Sickle cell disease and pregnancy profile of complicated malaria in 982 pregnancies in Kinshasa.","The Impact of Carbamylation and Anemia on HbA1c's Association With Renal Outcomes in Patients With Diabetes and Chronic Kidney Disease.","Biomarkers of sickle cell nephropathy in Senegal.","Prevalence of comorbidities associated with sickle cell disease among non-elderly individuals with commercial insurance-A retrospective cohort study.","Medically-attended anxiety and depression is increased among newly diagnosed patients with cold agglutinin disease: Analysis of an integrated claim-clinical cohort in the United States.","Iron deficiency, anemia and association with refugee camp exposure among recently resettled refugees: A Canadian retrospective cohort study.","Clinical and laboratory characterization of adult sickle cell anemia patients in Kinshasa.","Serum anti-erythropoietin antibodies among pregnant women with Plasmodium falciparum malaria and anaemia: A case-control study in northern Ghana.","Frequency of unnecessary prenatal diagnosis of hemoglobinopathies: A large retrospective analysis and implication to improvement of the control program."],"journal":["American journal of epidemiology","PloS one","PloS one","PloS one","PloS one","PloS one","PloS one","PloS one","PloS one","PloS one","PloS one","PloS one","PloS one","PloS one","International journal of epidemiology","American journal of epidemiology","PloS one","Circulation","PloS one","PloS one","PloS one","PloS one","PloS one","PloS one","Vaccine","PloS one","Journal of the National Cancer Institute","PloS one","PloS one","PloS one","Circulation","PloS one","Circulation. Cardiovascular genetics","PloS one","PloS one","PloS one","Circulation. Cardiovascular imaging","PloS one","PloS one","PloS one","PloS one","PloS one","Journal of the American College of Cardiology","Journal of the American College of Cardiology","PloS one","PloS one","PloS one","PloS one","PloS one","PloS one","PloS one","PloS one","PloS one","PloS one","PloS one","PloS one","PloS one","PloS one","PloS one","PloS one","PloS one","PloS one","PloS one","PloS one","Vaccine","PloS one","PloS one","Circulation. Cardiovascular imaging","PloS one","PloS one","PloS one","PloS one","Circulation","PloS one","PloS one","PloS one","PloS one","PloS one","PloS one","PloS one","PloS one","PloS one","PloS one","PloS one","PloS one","PloS one","PloS one","PloS one","PloS one","American journal of epidemiology","Journal of the American College of Cardiology","PloS one","PloS one","PloS one","PloS one","PloS one","PloS one","PloS one","PloS one","PloS one","PloS one","Journal of clinical oncology : official journal of the American Society of Clinical Oncology","Circulation. Cardiovascular interventions","PloS one","PloS one","PloS one","PloS one","PloS one","PloS one","PloS one","PloS one","PloS one","PloS one","PloS one","PloS one","PloS one","PloS one","PloS one","PloS one","Journal of clinical oncology : official journal of the American Society of Clinical Oncology","PloS one","Journal of the National Cancer Institute","PloS one","PloS one","PloS one","PloS one","PloS one","PloS one","PloS one","American journal of epidemiology","PloS one","PloS one","PloS one","PloS one","PloS one","PloS one","PloS one","PloS one","Hypertension (Dallas, Tex. : 1979)","PloS one","PloS one","PloS one","PloS one","PloS one","PloS one","PloS one","Diabetes care","PloS one","PloS one","PloS one","Circulation. Cardiovascular interventions","PloS one","PloS one","PloS one","PloS one","PloS one","Journal of clinical oncology : official journal of the American Society of Clinical Oncology","PloS one","PloS one","PloS one","PLoS medicine","PloS one","PloS one","PloS one","PloS one","PloS one","PloS one","PloS one","PloS one","PloS one","PloS one","PloS one","PloS one","PloS one","PloS one","PloS one","PloS one","PloS one","PloS one","PloS one","PloS one","PloS one","PloS one","PloS one","PloS one","PloS one","PloS one","Diabetes care","PloS one","Circulation. Genomic and precision medicine","PloS one","PloS one","PloS one","PloS one","PloS one","PloS one","PloS one","PloS one","PloS one","PloS one","PLoS medicine","PloS one","PloS one","PloS one","PloS one","PloS one","Journal of clinical oncology : official journal of the American Society of Clinical Oncology","PloS one","PloS one","PloS one","PloS one","PloS one","PloS one","PloS one","PloS one","PloS one","PloS one","PloS one","International journal of epidemiology","PloS one","PloS one","PloS one","PloS one","PloS one","PloS one","Journal of clinical oncology : official journal of the American Society of Clinical Oncology","PloS one","PloS one","PloS one","Diabetes care","PloS one","PloS one","PloS one","PloS one","PloS one","PloS one","PloS one"]},"columns":[{"id":".details","name":"","type":null,"sortable":false,"resizable":false,"filterable":false,"searchable":false,"width":45,"align":"center","details":[{"name":"div","attribs":{"style":{"padding":"1rem"}},"children":[{"name":"Reactable","attribs":{"data":{"details":["<b>DOI:<\/b> 10.1093/aje/kws281 <br><br> Many community-based studies of acute child illness rely on cases reported by caregivers. In prior investigations, researchers noted a reporting bias when longer illness recall periods were used. The use of recall periods longer than 2-3 days has been discouraged to minimize this reporting bias. In the present study, we sought to determine the optimal recall period for illness measurement when accounting for both bias and variance. Using data from 12,191 children less than 24 months of age collected in 2008-2009 from Himachal Pradesh in India, Madhya Pradesh in India, Indonesia, Peru, and Senegal, we calculated bias, variance, and mean squared error for estimates of the prevalence ratio between groups defined by anemia, stunting, and underweight status to identify optimal recall periods for caregiver-reported diarrhea, cough, and fever. There was little bias in the prevalence ratio when a 7-day recall period was used (<10% in 35 of 45 scenarios), and the mean squared error was usually minimized with recall periods of 6 or more days. Shortening the recall period from 7 days to 2 days required sample-size increases of 52%-92% for diarrhea, 47%-61% for cough, and 102%-206% for fever. In contrast to the current practice of using 2-day recall periods, this work suggests that studies should measure caregiver-reported illness with a 7-day recall period.\n <br><br> <b>MeSH terms:<\/b> <b>MeSH terms:<\/b> Adult; Algorithms; Anemia; Bias; Caregivers; Child, Preschool; Cluster Analysis; Cohort Studies; Cough; Diarrhea; Fever; Health Surveys; Humans; India; Indonesia; Infant; Infant, Newborn; Male; Mathematical Computing; Mental Recall; Odds Ratio; Peru; Pilot Projects; Prevalence; Respiratory Tract Infections; Risk Assessment; Risk Factors; Sampling Studies; Senegal; Surveys and Questionnaires; Thinness <br><br> <b>OMOP Concepts (IDs):<\/b>  C/O - cough (4158493); Fever (437663); Respiratory tract infection (4170143); Risk assessment (4024612); Thin build (4265473); Anemia (439777); Diarrhea (196523); "]},"columns":[{"id":"details","name":"","type":"character","html":true}],"dataKey":"bd142f432d5ab3920fe5c7201bc890ed","static":false,"nested":true},"children":[]}]},{"name":"div","attribs":{"style":{"padding":"1rem"}},"children":[{"name":"Reactable","attribs":{"data":{"details":["<b>DOI:<\/b> 10.1371/journal.pone.0055300 <br><br> Shiga toxin-producing Escherichia coli (STEC) O157:H7 is the causal agent for more than 96,000 cases of diarrheal illness and 3,200 infection-attributable hospitalizations annually in the United States.<br><br>&emsp;We defined a confirmed case as a compatible illness in a person with the outbreak strain during 10/07/2011-11/30/2011. Investigation included hypothesis generation, a case-control study utilizing geographically-matched controls, and a case series investigation. Environmental inspections and tracebacks were conducted.<br><br>&emsp;We identified 58 cases in 10 states; 67% were hospitalized and 6.4% developed hemolytic uremic syndrome. Any romaine consumption was significantly associated with illness (matched Odds Ratio (mOR) = 10.0, 95% Confidence Interval (CI) = 2.1-97.0). Grocery Store Chain A salad bar was significantly associated with illness (mOR = 18.9, 95% CI = 4.5-176.8). Two separate traceback investigations for romaine lettuce converged on Farm A. Case series results indicate that cases (64.9%) were more likely than the FoodNet population (47%) to eat romaine lettuce (p-value = 0.013); 61.3% of cases reported consuming romaine lettuce from the Grocery Store Chain A salad bar.<br><br>&emsp;This multistate outbreak of STEC O157:H7 infections was associated with consumption of romaine lettuce. Traceback analysis determined that a single common lot of romaine lettuce harvested from Farm A was used to supply Grocery Store Chain A and a university campus linked to a case with the outbreak strain. An investigation at Farm A did not identify the source of contamination. Improved ability to trace produce from the growing fields to the point of consumption will allow more timely prevention and control measures to be implemented.\n <br><br> <b>MeSH terms:<\/b> <b>MeSH terms:<\/b> Adolescent; Adult; Aged; Aged, 80 and over; Bacterial Typing Techniques; Case-Control Studies; Child; Child, Preschool; Disease Outbreaks; Escherichia coli O157; Female; Food Microbiology; Hemolytic-Uremic Syndrome; Humans; Infant; Lettuce; Male; Middle Aged; Odds Ratio; Research Report; Shiga Toxin; United States <br><br> <b>OMOP Concepts (IDs):<\/b>  Hemolytic uremic syndrome (197253); "]},"columns":[{"id":"details","name":"","type":"character","html":true}],"dataKey":"323bc4a6bcb0b6da7005603d3664950b","static":false,"nested":true},"children":[]}]},{"name":"div","attribs":{"style":{"padding":"1rem"}},"children":[{"name":"Reactable","attribs":{"data":{"details":["<b>DOI:<\/b> 10.1371/journal.pone.0055676 <br><br> We demonstrate a real-time blood testing system that can provide remote diagnosis with minimal human intervention in economically challenged areas. Our instrument combines novel advances in label-free optical imaging with parallel computing. Specifically, we use quantitative phase imaging for extracting red blood cell morphology with nanoscale sensitivity and NVIDIA's CUDA programming language to perform real time cellular-level analysis. While the blood smear is translated through focus, our system is able to segment and analyze all the cells in the one megapixel field of view, at a rate of 40 frames/s. The variety of diagnostic parameters measured from each cell (e.g., surface area, sphericity, and minimum cylindrical diameter) are currently not available with current state of the art clinical instruments. In addition, we show that our instrument correctly recovers the red blood cell volume distribution, as evidenced by the excellent agreement with the cell counter results obtained on normal patients and those with microcytic and macrocytic anemia. The final data outputted by our instrument represent arrays of numbers associated with these morphological parameters and not images. Thus, the memory necessary to store these data is of the order of kilobytes, which allows for their remote transmission via, for example, the cellular network. We envision that such a system will dramatically increase access for blood testing and furthermore, may pave the way to digital hematology.\n <br><br> <b>MeSH terms:<\/b> <b>MeSH terms:<\/b> Algorithms; Anemia, Iron-Deficiency; Anemia, Macrocytic; Case-Control Studies; Erythrocytes; Hemoglobins; Humans; Image Processing, Computer-Assisted; Microscopy, Electron, Transmission; Microscopy, Phase-Contrast; Refractometry <br><br> <b>OMOP Concepts (IDs):<\/b>  Macrocytic anemia (4308125); Iron deficiency anemia (436659); "]},"columns":[{"id":"details","name":"","type":"character","html":true}],"dataKey":"8d55778fdd4d087acd1709fc77382cb3","static":false,"nested":true},"children":[]}]},{"name":"div","attribs":{"style":{"padding":"1rem"}},"children":[{"name":"Reactable","attribs":{"data":{"details":["<b>DOI:<\/b> 10.1371/journal.pone.0055278 <br><br> Shiga-toxin producing O157:H7 Entero Haemorrhagic E. coli (STEC/EHEC) is one of the most common causes of Haemolytic Uraemic Syndrome (HUS) related to infectious haemorrhagic colitis. Nearly all recommendations on clinical management of EHEC infections refer to this strain. The 2011 outbreak in Northern Europe was the first to be caused by the serotype O104:H4. This EHEC strain was found to carry genetic features of Entero Aggregative E. coli (EAEC) and extended spectrum β lactamase (ESBL). We report symptoms and complications in patients at one of the most affected centres of the 2011 EHEC O104 outbreak in Northern Germany.<br><br>&emsp;The courses of patients admitted to our hospital due to bloody diarrhoea with suspected EHEC O104 infection were recorded prospectively. These data include the patients' histories, clinical findings, and complications.<br><br>&emsp;EHEC O104 infection was confirmed in 61 patients (female = 37; mean age: 44±2 years). The frequency of HUS was 59% (36/61) in our cohort. An enteric colonisation with co-pathogens was found in 57%. Thirty-one (51%) patients were treated with plasma-separation/plasmapheresis, 16 (26%) with haemodialysis, and 7 (11%) with Eculizumab. Patients receiving antibiotic treatment (n = 37; 61%) experienced no apparent change in their clinical course. Twenty-six (43%) patients suffered from neurological symptoms. One 83-year-old patient died due to comorbidities after HUS was successfully treated.<br><br>&emsp;EHEC O104:H4 infections differ markedly from earlier reports on O157:H7 induced enterocolitis in regard to epidemiology, symptomatology, and frequency of complications. We recommend a standard of practice for clinical monitoring and support the renaming of EHEC O104:H4 syndrome as \"EAHEC disease\".\n <br><br> <b>MeSH terms:<\/b> <b>MeSH terms:<\/b> Adult; Blood Platelets; Coinfection; Creatinine; Disease Progression; Endoscopy; Enterohemorrhagic Escherichia coli; Feces; Female; Gastrointestinal Tract; Germany; Hemolytic-Uremic Syndrome; Hospitalization; Humans; L-Lactate Dehydrogenase; Male; Prospective Studies; Time Factors; Ultrasonography <br><br> <b>OMOP Concepts (IDs):<\/b>  Ultrasonography (4037672); Creatinine (19071968); Endoscopy (4313889); Specimen description (4019497); Mixed infectious disease (4163969); Hemolytic uremic syndrome (197253); Inpatient care (4214577); "]},"columns":[{"id":"details","name":"","type":"character","html":true}],"dataKey":"db71c031547ff677dede6b348e1e1ae4","static":false,"nested":true},"children":[]}]},{"name":"div","attribs":{"style":{"padding":"1rem"}},"children":[{"name":"Reactable","attribs":{"data":{"details":["<b>DOI:<\/b> 10.1371/journal.pone.0057998 <br><br> Vitamin B12 deficiency is prevalent in many countries of origin of refugees. Using a threshold of 5% above which a prevalence of low Vitamin B12 is indicative of a population health problem, we hypothesised that Vitamin B12 deficiency exceeds this threshold among newly-arrived refugees resettling in Australia, and is higher among women due to their increased risk of food insecurity. This paper reports Vitamin B12 levels in a large cohort of newly arrived refugees in five Australian states and territories.<br><br>&emsp;In a cross-sectional descriptive study, we collected Vitamin B12, folate and haematological indices on all refugees (n = 916; response rate 94% of eligible population) who had been in Australia for less than one year, and attended one of the collaborating health services between July 2010 and July 2011.<br><br>&emsp;16.5% of participants had Vitamin B12 deficiency (<150 pmol/L). One-third of participants from Iran and Bhutan, and one-quarter of participants from Afghanistan had Vitamin B12 deficiency. Contrary to our hypothesis, low Vitamin B12 levels were more prevalent in males than females. A higher prevalence of low Vitamin B12 was also reported in older age groups in some countries. The sensitivity of macrocytosis in detecting Vitamin B12 deficiency was only 4.6%.<br><br>&emsp;Vitamin B12 deficiency is an important population health issue in newly-arrived refugees from many countries. All newly-arrived refugees should be tested for Vitamin B12 deficiency. Ongoing research should investigate causes, treatment, and ways to mitigate food insecurity, and the contribution of such measures to enhancing the health of the refugee communities.\n <br><br> <b>MeSH terms:<\/b> <b>MeSH terms:<\/b> Adolescent; Adult; Afghanistan; Anemia; Australia; Bhutan; Child; Child, Preschool; Erythrocyte Count; Female; Humans; Infant; Infant, Newborn; Iran; Male; Middle Aged; Refugees; Vitamin B 12; Vitamin B 12 Deficiency; Young Adult <br><br> <b>OMOP Concepts (IDs):<\/b>  Red blood cell count (4030871); Vitamin B 12 (1308738); Refugee (40488824); Anemia (439777); Cobalamin deficiency (4100822); "]},"columns":[{"id":"details","name":"","type":"character","html":true}],"dataKey":"a4c0617cb0436fc2e35a16f940d58c66","static":false,"nested":true},"children":[]}]},{"name":"div","attribs":{"style":{"padding":"1rem"}},"children":[{"name":"Reactable","attribs":{"data":{"details":["<b>DOI:<\/b> 10.1371/journal.pone.0059209 <br><br> The outbreak of Shiga toxin producing E.coli O104:H4 in northern Germany in 2011 was one of the largest worldwide and involved mainly adults. Post-diarrheal hemolytic uremic syndrome (HUS) occurred in 22% of STEC positive patients. This study's aim was to assess risk factors for HUS in STEC-infected patients and to develop a score from routine hospital parameters to estimate patient risks for developing HUS. In a cohort analysis, adult patients with STEC infection were included in five participating hospitals in northern Germany between May and July 2011. Clinical data were obtained from questionnaires and medical records, laboratory data were extracted from hospitals' electronic data systems. HUS was defined as thrombocytopenia, hemolytic anemia and acute renal dysfunction. Random forests and multivariate logistic regression were used to identify risk factors for HUS and develop a score using the estimated coefficients as weights. Among 259 adults with STEC infection, vomiting (OR 3.48,95%CI 1.88-6.53), visible blood in stools (OR 3.91,95%CI1.20-16.01), age above 75 years (OR 3.27, 95%CI 1.12-9.70) and elevated leukocyte counts (OR 1.20, 95%CI 1.10-1.31, per 1000 cells/mm(3)) were identified as independent risk factors for HUS. A score using these variables has an area under the ROC curve of 0.74 (95%CI 0.68-0.80). Vomiting, visible blood in stools, higher leukocyte counts, and higher age indicate increased risk for developing HUS. A score using these variables might help to identify high risk patients who potentially benefit from aggressive pre-emptive treatment to prevent or mitigate the devastating consequences of HUS.\n <br><br> <b>MeSH terms:<\/b> <b>MeSH terms:<\/b> Adult; Escherichia coli Infections; Female; Hemolytic-Uremic Syndrome; Humans; Male; Middle Aged; Risk Factors <br><br> <b>OMOP Concepts (IDs):<\/b>  Infection due to Escherichia coli (440320); Hemolytic uremic syndrome (197253); "]},"columns":[{"id":"details","name":"","type":"character","html":true}],"dataKey":"58e15b9b3695f902e81f6ef345ececc5","static":false,"nested":true},"children":[]}]},{"name":"div","attribs":{"style":{"padding":"1rem"}},"children":[{"name":"Reactable","attribs":{"data":{"details":["<b>DOI:<\/b> 10.1371/journal.pone.0056648 <br><br> Previous reports showed that outcome of rabbit antithymocyte globulin (rATG) was not satisfactory as the first-line therapy for severe aplastic anemia (SAA). We explored a modifying schedule of administration of rATG.<br><br>&emsp;Outcomes of a cohort of 175 SAA patients, including 51 patients administered with standard protocol (3.55 mg/kg/d for 5 days) and 124 cases with optimized protocol (1.97 mg/kg/d for 9 days) of rATG plus cyclosporine (CSA), were analyzed retrospectively.<br><br>&emsp;Of all 175 patients, response rates at 3 and 6 months were 36.6% and 56.0%, respectively. 51 cases received standard protocol had poor responses at 3 (25.5%) and 6 months (41.2%). However, 124 patients received optimized protocol had better responses at 3 (41.1%, P = 0.14) and 6 (62.1%, P = 0.01). Higher incidences of infection (57.1% versus 37.9%, P = 0.02) and early mortality (17.9% versus 0.8%, P<0.001) occurred in patients received standard protocol compared with optimized protocol. The 5-year overall survival in favor of the optimized over standard rATG protocol (76.0% versus. 50.3%, P<0.001) was observed. By multivariate analysis, optimized protocol (RR = 2.21, P = 0.04), response at 3 months (RR = 10.31, P = 0.03) and shorter interval (<23 days) between diagnosis and initial dose of rATG (RR = 5.35, P = 0.002) were independent favorable predictors of overall survival.<br><br>&emsp;Optimized instead of standard rATG protocol in combination with CSA remained efficacious as a first-line immunosuppressive regimen for SAA.\n <br><br> <b>MeSH terms:<\/b> <b>MeSH terms:<\/b> Adolescent; Adult; Anemia, Aplastic; Animals; Antilymphocyte Serum; Child; Child, Preschool; Cyclosporine; Disease-Free Survival; Female; Follow-Up Studies; Humans; Immunosuppressive Agents; Male; Middle Aged; Rabbits; Retrospective Studies; Survival Rate <br><br> <b>OMOP Concepts (IDs):<\/b>  Hematopoietic aplasia (4119473); Cyclosporine (19010482); "]},"columns":[{"id":"details","name":"","type":"character","html":true}],"dataKey":"f31663c0a61055eaf2b336395c9fafb3","static":false,"nested":true},"children":[]}]},{"name":"div","attribs":{"style":{"padding":"1rem"}},"children":[{"name":"Reactable","attribs":{"data":{"details":["<b>DOI:<\/b> 10.1371/journal.pone.0060206 <br><br> Anemia is the main concern among patients using a zidovudine (AZT)-based antiretroviral treatment (ART). Some studies suggested weight-adjusted AZT dosing as a way to reduce toxicity. We analyzed the risk factors associated with AZT-induced anemia in a cohort using AZT as substitution for stavudine (D4T).<br><br>&emsp;We retrospectively studied HIV-infected patients in a referral hospital in Phnom Penh, Cambodia between 2003 and 2011. Factors associated with AZT-related anemia requiring AZT-discontinuation within the first year after AZT initiation were analyzed using Cox regression.<br><br>&emsp;Overall, 1180 patients, 60.5% female, were included. At AZT initiation, the median hemoglobin was 12.7 g/dL (IQR 11.7-13.9), the median weight: 51 kg (IQR 45-58) and the median time on ART prior to AZT substitution: 1.4 years (IQR 1.0-2.0). Within one year follow-up, 139 patients (11.8%) developed anemia requiring AZT discontinuation. Overall, there was no independent association of body weight with AZT discontinuation. AZT discontinuation was associated with lower hemoglobin level when starting AZT; older age and taking D4T-based ART less than one year prior to AZT. In exploratory analysis, a linear increase in risk of grade 2-4 anemia with lower body weight was seen if starting AZT substitution within less than one year of D4T-based ART.<br><br>&emsp;Our findings argue against the need of weight-based dosing of AZT to reduce anemia among patients using AZT as substitution for D4T. Whether this also applies to ART-naïve individuals remains to be assessed. Future studies with AZT dose reduction should assess efficacy and overall tolerance of AZT.\n <br><br> <b>MeSH terms:<\/b> <b>MeSH terms:<\/b> Adult; Anemia; Anti-HIV Agents; Female; HIV Infections; Humans; Male; Retrospective Studies; Risk Factors; Stavudine; Zidovudine <br><br> <b>OMOP Concepts (IDs):<\/b>  Human immunodeficiency virus infection (439727); Stavudine (1781406); Anemia (439777); Zidovudine (1710612); "]},"columns":[{"id":"details","name":"","type":"character","html":true}],"dataKey":"997bb6f58a2436abe9a6cfdfd15d7091","static":false,"nested":true},"children":[]}]},{"name":"div","attribs":{"style":{"padding":"1rem"}},"children":[{"name":"Reactable","attribs":{"data":{"details":["<b>DOI:<\/b> 10.1371/journal.pone.0060436 <br><br> MicroRNAs (miRNAs) play key roles in modulating a variety of cellular processes through repression of mRNAs target. The functional relevance of microRNAs has been proven in normal and malignant hematopoiesis. While analyzing miRNAs expression profile in unilineage serum-free liquid suspension unilineage cultures of peripheral blood CD34(+) hematopoietic progenitor cells (HPCs) through the erythroid, megakaryocytic, granulocytic and monocytic pathways, we identified miR-486-3p as mainly expressed within the erythroid lineage. We showed that miR-486-3p regulates BCL11A expression by binding to the extra-long isoform of BCL11A 3'UTR. Overexpression of miR-486-3p in erythroid cells resulted in reduced BCL11A protein levels, associated to increased expression of γ-globin gene, whereas inhibition of physiological miR-486-3p levels increased BCL11A and, consequently, reduced γ-globin expression. Thus, miR-486-3p regulating BCL11A expression might contributes to fetal hemoglobin (HbF) modulation and arise the question as to what extent this miRNA might contribute to different HbF levels observed among β-thalassemia patients. Erythroid cells, differentiated from PB CD34(+) cells of a small cohort of patients affected by major or intermedia β-thalassemia, showed miR-486-3p levels significantly higher than those observed in normal counterpart. Importantly, in these patients, miR-486-3p expression correlates with increased HbF synthesis. Thus, our data indicate that miR-486-3p might contribute to different HbF levels observed among thalassemic patients and, possibly, to the clinical severity of the disease.\n <br><br> <b>MeSH terms:<\/b> <b>MeSH terms:<\/b> Alternative Splicing; Antigens, CD34; Base Pairing; Base Sequence; Carrier Proteins; Cell Line; Cell Lineage; Cells, Cultured; Erythroid Cells; Fetal Hemoglobin; Gene Expression Regulation; Gene Knockout Techniques; Genotype; Hematopoietic Stem Cells; Humans; MicroRNAs; Models, Biological; Nuclear Proteins; RNA Isoforms; Repressor Proteins; beta-Thalassemia; gamma-Globins <br><br> <b>OMOP Concepts (IDs):<\/b>  Hemoglobin F (4339104); Beta thalassemia (4278669); Base sequence (4219499); Genetic finding (4025367); "]},"columns":[{"id":"details","name":"","type":"character","html":true}],"dataKey":"3ef3739ba457a971f6580dffdb348acc","static":false,"nested":true},"children":[]}]},{"name":"div","attribs":{"style":{"padding":"1rem"}},"children":[{"name":"Reactable","attribs":{"data":{"details":["<b>DOI:<\/b> 10.1371/journal.pone.0060932 <br><br> Increased platelet activation in sickle cell disease (SCD) contributes to a state of hypercoagulability and confers a risk of thromboembolic complications. The role for post-transcriptional regulation of the platelet transcriptome by microRNAs (miRNAs) in SCD has not been previously explored. This is the first study to determine whether platelets from SCD exhibit an altered miRNA expression profile.<br><br>&emsp;We analyzed the expression of miRNAs isolated from platelets from a primary cohort (SCD = 19, controls = 10) and a validation cohort (SCD = 7, controls = 7) by hybridizing to the Agilent miRNA microarrays. A dramatic difference in miRNA expression profiles between patients and controls was noted in both cohorts separately. A total of 40 differentially expressed platelet miRNAs were identified as common in both cohorts (p-value 0.05, fold change>2) with 24 miRNAs downregulated. Interestingly, 14 of the 24 downregulated miRNAs were members of three families - miR-329, miR-376 and miR-154 - which localized to the epigenetically regulated, maternally imprinted chromosome 14q32 region. We validated the downregulated miRNAs, miR-376a and miR-409-3p, and an upregulated miR-1225-3p using qRT-PCR. Over-expression of the miR-1225-3p in the Meg01 cells was followed by mRNA expression profiling to identify mRNA targets. This resulted in significant transcriptional repression of 1605 transcripts. A combinatorial approach using Meg01 mRNA expression profiles following miR-1225-3p overexpression, a computational prediction analysis of miRNA target sequences and a previously published set of differentially expressed platelet transcripts from SCD patients, identified three novel platelet mRNA targets: PBXIP1, PLAGL2 and PHF20L1.<br><br>&emsp;We have identified significant differences in functionally active platelet miRNAs in patients with SCD as compared to controls. These data provide an important inventory of differentially expressed miRNAs in SCD patients and an experimental framework for future studies of miRNAs as regulators of biological pathways in platelets.\n <br><br> <b>MeSH terms:<\/b> <b>MeSH terms:<\/b> Adult; Aged; Anemia, Sickle Cell; Blood Platelets; Cell Line; Chromosomes, Human, Pair 14; Computational Biology; Down-Regulation; Female; Gene Expression Profiling; Gene Expression Regulation; Genomic Imprinting; Humans; Hydroxyurea; Male; Megakaryocytes; MicroRNAs; Middle Aged; Molecular Sequence Annotation; Oligonucleotide Array Sequence Analysis; Reproducibility of Results; Tricuspid Valve Insufficiency; Up-Regulation; Young Adult <br><br> <b>OMOP Concepts (IDs):<\/b>  Tricuspid valve regurgitation (4006971); Sickle cell-hemoglobin SS disease (22281); hydroxyurea (1377141); "]},"columns":[{"id":"details","name":"","type":"character","html":true}],"dataKey":"cfef79eab0573ea3e406e7c0330e79aa","static":false,"nested":true},"children":[]}]},{"name":"div","attribs":{"style":{"padding":"1rem"}},"children":[{"name":"Reactable","attribs":{"data":{"details":["<b>DOI:<\/b> 10.1371/journal.pone.0065001 <br><br> Distinguishing between acute presentations of osteomyelitis (OM) and vaso-occlusive crisis (VOC) bone infarction in children with sickle cell disease (SCD) remains challenging for clinicians, particularly in culture-negative cases. We examined the combined role of ultrasound scan (USS), C - reactive protein and White blood counts (WCC) in aiding early diagnosis in children with SCD presenting acutely with non-specific symptoms such as bone pain, fever or swelling which are common in acute osteomyelitis or VOC.<br><br>&emsp;We reviewed the records of all children with SCD who were discharged from our department from October 2003 to December 2010 with a diagnosis of osteomyelitis based on clinical features and the results of radiological and laboratory investigations. A case control group with VOC who were investigated for OM were identified over the same period.<br><br>&emsp;In the osteomyelitis group, USS finding of periosteal elevation and/or fluid collection was reported in 76% cases with the first scan (day 0-6). Overall 84% were diagnosed with USS (initial +repeat). 16% had negative USS. With VOC group, USS showed no evidence of fluid collection in 53/58 admissions (91%), none of the repeated USS showed any fluid collection. Mean C-reactive protein (CRP), and white cell count (WCC) were significantly higher in the OM.<br><br>&emsp;The use of Ultrasound in combination with CRP and WCC is a reliable, cost-effective diagnostic tool for differentiating osteomyelitis from VOC bone infarction in SCD. A repeat ultrasound and/or magnetic resonance imaging (MRI) scan may be is necessary to confirm the diagnosis.\n <br><br> <b>MeSH terms:<\/b> <b>MeSH terms:<\/b> Acute Disease; Anemia, Sickle Cell; Bone and Bones; Child; Child, Preschool; Female; Humans; Infarction; Male; Osteomyelitis; Ultrasonography <br><br> <b>OMOP Concepts (IDs):<\/b>  Osteomyelitis (141663); Ultrasonography (4037672); Acute disease (443883); Sickle cell-hemoglobin SS disease (22281); "]},"columns":[{"id":"details","name":"","type":"character","html":true}],"dataKey":"bba610f133bb2a8039c1268ee7d73320","static":false,"nested":true},"children":[]}]},{"name":"div","attribs":{"style":{"padding":"1rem"}},"children":[{"name":"Reactable","attribs":{"data":{"details":["<b>DOI:<\/b> 10.1371/journal.pone.0068675 <br><br> Evidence suggests obesity-related inflammation alters iron metabolism potentially increasing the risk of iron deficiency. This cross-sectional study aimed to investigate iron, hepcidin and inflammatory status in young, healthy overweight and obese women.<br><br>&emsp;114 young (18-25 years), healthy comorbidity-free women with a body mass index (BMI) ≥27.5 kg/m(2) were recruited. Biochemical data were analysed using mean ± standard deviation or median (interquartile range) and multivariate modelling. Biochemical markers were also stratified according to varying degrees of overweight and obesity.<br><br>&emsp;Anaemia (haemoglobin <120 g/l) and iron deficiency (serum ferritin <15.0 µg/l) were prevalent in 10% and 17% of participants respectively. Mean/median soluble transferrin receptor was 1.61±0.44 mg/l; hepcidin 6.40 (7.85) ng/ml and C-reactive protein (CRP) 3.58 (5.81) mg/l. Multivariate modelling showed that BMI was a significant predictor of serum iron (coefficient = -0.379; standard error = 0.139; p = 0.008), transferrin saturation (coefficient = -0.588; standard error = 0.222; p = 0.009) and CRP (coefficient = 0.127; standard error = 0.024; p<0.001). Stratification of participants according to BMI showed those with ≥35.0 kg/m(2) had significantly higher CRP (p<0.001) than those in lower BMI categories.<br><br>&emsp;Increasing obesity was associated with minor disturbances in iron metabolism. However, overall outcomes indicated simple iron deficiency (hypoferritinaemia) was the primary iron-related abnormality with no apparent contribution of inflammation or hepcidin, even in those with BMI >35.0 kg/m(2). This indicates that obesity alone may not be sufficient to induce clinically significant disturbances to iron metabolism as previously described. This may be attributed to the lack of comorbidity in this cohort.\n <br><br> <b>MeSH terms:<\/b> <b>MeSH terms:<\/b> Adolescent; Adult; Analysis of Variance; Anemia, Iron-Deficiency; Australia; Body Mass Index; C-Reactive Protein; Cross-Sectional Studies; Female; Ferritins; Hemoglobins; Hepcidins; Humans; Inflammation; Iron; Obesity; Overweight; Transferrin <br><br> <b>OMOP Concepts (IDs):<\/b>  Overweight (437525); Iron deficiency anemia (436659); Obesity (433736); Iron (1360067); "]},"columns":[{"id":"details","name":"","type":"character","html":true}],"dataKey":"23195ec65104aa66ae6c6254f6536afa","static":false,"nested":true},"children":[]}]},{"name":"div","attribs":{"style":{"padding":"1rem"}},"children":[{"name":"Reactable","attribs":{"data":{"details":["<b>DOI:<\/b> 10.1371/journal.pone.0068833 <br><br> Iron deficiency (ID) and iron deficiency anaemia (IDA) are global major public health problems, particularly in developing countries. Whilst an association between H. pylori infection and ID/IDA has been proposed in the literature, currently there is no consensus. We studied the effects of H. pylori infection on ID/IDA in a cohort of children undergoing upper gastrointestinal endoscopy for upper abdominal pain in two developing and one developed country.<br><br>&emsp;In total 311 children (mean age 10.7±3.2 years) from Latin America--Belo Horizonte/Brazil (n = 125), Santiago/Chile (n = 105)--and London/UK (n = 81), were studied. Gastric and duodenal biopsies were obtained for evaluation of histology and H. pylori status and blood samples for parameters of ID/IDA.<br><br>&emsp;The prevalence of H. pylori infection was 27.7% being significantly higher (p<0.001) in Latin America (35%) than in UK (7%). Multiple linear regression models revealed H. pylori infection as a significant predictor of low ferritin and haemoglobin concentrations in children from Latin-America. A negative correlation was observed between MCV (r = -0.26; p = 0.01) and MCH (r = -0.27; p = 0.01) values and the degree of antral chronic inflammation, and between MCH and the degree of corpus chronic (r = -0.29, p = 0.008) and active (r = -0.27, p = 0.002) inflammation.<br><br>&emsp;This study demonstrates that H. pylori infection in children influences the serum ferritin and haemoglobin concentrations, markers of early depletion of iron stores and anaemia respectively.\n <br><br> <b>MeSH terms:<\/b> <b>MeSH terms:<\/b> Abdominal Pain; Adolescent; Anemia, Iron-Deficiency; Biopsy; Brazil; Child; Chile; Duodenoscopy; Duodenum; Female; Ferritins; Gastric Mucosa; Gastroscopy; Helicobacter Infections; Helicobacter pylori; Hemoglobins; Humans; Iron; London; Male; Prevalence; Stomach <br><br> <b>OMOP Concepts (IDs):<\/b>  Abdominal pain (200219); Endoscopy of stomach (4297516); Biopsy (4311405); Iron deficiency anemia (436659); Duodenoscopy (4214034); Helicobacter pylori (42903959); Iron (1360067); "]},"columns":[{"id":"details","name":"","type":"character","html":true}],"dataKey":"4544961d200437abe4ed23a22939a74d","static":false,"nested":true},"children":[]}]},{"name":"div","attribs":{"style":{"padding":"1rem"}},"children":[{"name":"Reactable","attribs":{"data":{"details":["<b>DOI:<\/b> 10.1371/journal.pone.0068929 <br><br> To determine differences in TNF-α, IL-1β, IL-10, sICAM-1 concentrations, leg hypoxia and whole blood viscosity (WBV) at shear rates of 46 sec(-1) and 230 sec(-1) in persons with homozygous S sickle cell disease (SCD) with and without chronic leg ulceration and in AA genotype controls.<br><br>&emsp;&<br><br>&emsp;fifty-five age-matched participants were recruited into the study: 31 SS subjects without leg ulcers (SSn), 24 SS subjects with leg ulcers (SSu) and 18 AA controls. Haematological indices were measured using an AC.Tron Coulter Counter. Quantification of inflammatory, anti-inflammatory and adhesion molecules was performed by ELISA. Measurement of whole blood viscosity was done using a Wells Brookfield cone-plate viscometer. Quantification of microvascular tissue oxygenation was done by Visible Lightguide spectrophotometry.<br><br>&emsp;TNF-α and whole blood viscosity at 46 sec(-1) and 230 sec(-1) (1.75, 2.02 vs. 0.83, 1.26, p<0.05) were significantly greater in sickle cell disease subjects than in controls. There were no differences in plasma concentration of sICAM-1, IL-1β and IL-10 between SCD subjects and controls. IL-1β (median, IQR: 0.96, 1.7 vs. 0, 0.87; p<0.01) and sICAM-1 (226.5, 156.48 vs. 107.63, 121.5, p<0.005) were significantly greater in SSu group compared with SSn. However there were no differences in TNF-α (2, 3.98 vs. 0, 2.66) and IL-10 (13.34, 5.95 vs. 11.92, 2.99) concentrations between SSu and SSn. WBV in the SSu group at 46 sec(-1) and at 230 Sec 1 were 1.9 (95%CI; 1.2, 3.1) and 2.3 (1.2, 4.4) times greater than in the SSn group. There were no differences in the degree of tissue hypoxia as determined by lightguide spectrophotometry.<br><br>&emsp;Inflammatory, adhesion markers and WBV may be associated with leg ulceration in sickle cell disease by way of inflammation-mediated vasoocclusion/vasoconstriction. Impaired skin oxygenation does not appear to be associated with chronic ulcers in these subjects with sickle cell disease.\n <br><br> <b>MeSH terms:<\/b> <b>MeSH terms:<\/b> Adult; Anemia, Sickle Cell; Biomarkers; Blood Viscosity; Case-Control Studies; Cell Adhesion; Chronic Disease; Cytokines; Erythrocytes; Female; Hemoglobins; Homozygote; Humans; Inflammation Mediators; L-Lactate Dehydrogenase; Leg Ulcer; Male; Oxygen; Shear Strength <br><br> <b>OMOP Concepts (IDs):<\/b>  Oxygen (19025274); Chronic disease (443783); Homozygote (4329704); Sickle cell-hemoglobin SS disease (22281); Ulcer of lower extremity (197304); "]},"columns":[{"id":"details","name":"","type":"character","html":true}],"dataKey":"06488abc95cfc42b4632680772b870e1","static":false,"nested":true},"children":[]}]},{"name":"div","attribs":{"style":{"padding":"1rem"}},"children":[{"name":"Reactable","attribs":{"data":{"details":["<b>DOI:<\/b> 10.1093/ije/dyt116 <br><br> Previous studies on the association of malaria and stunted growth delivered inconsistent results. These conflicting results may be due to different levels of confounding and to considerable difficulties in elucidating a causal relationship. Randomized experiments are impractical and previous observational studies have not fully controlled for potential confounding including nutritional deficiencies, breastfeeding habits, other infectious diseases and socioeconomic status.<br><br>&emsp;This study aims to estimate the causal effect between malaria episodes and stunted growth by applying a combination of Mendelian randomization, using the sickle cell trait, and matching. We demonstrate the method on a cohort of children in the Ashanti Region, Ghana.<br><br>&emsp;We found that the risk of stunting increases by 0.32 (P-value: 0.004, 95% CI: 0.09, 1.0) for every malaria episode. The risk estimate based on Mendelian randomization substantially differs from the multiple regression estimate of 0.02 (P-value: 0.02, 95% CI: 0.003, 0.03). In addition, based on the sensitivity analysis, our results were reasonably insensitive to unmeasured confounders.<br><br>&emsp;The method applied in this study indicates a causal relationship between malaria and stunting in young children in an area of high endemicity and demonstrates the usefulness of the sickle cell trait as an instrument for the analysis of conditions that might be causally related to malaria.\n <br><br> <b>MeSH terms:<\/b> <b>MeSH terms:<\/b> Antimalarials; Case-Control Studies; Causality; Child Development; Child, Preschool; Cohort Studies; Drug Combinations; Female; Genetic Predisposition to Disease; Ghana; Growth Disorders; Hemoglobin A; Hemoglobin, Sickle; Heterozygote; Humans; Infant; Malaria; Male; Mendelian Randomization Analysis; Multivariate Analysis; Poisson Distribution; Pyrimethamine; Regression Analysis; Sickle Cell Trait; Sulfadoxine <br><br> <b>OMOP Concepts (IDs):<\/b>  Pyrimethamine (1760039); Hemoglobin A (4150368); Sulfadoxine (1836410); Malarial fever (4093997); Sickle cell trait (25518); Genetic predisposition (4166231); "]},"columns":[{"id":"details","name":"","type":"character","html":true}],"dataKey":"de6e73a5cb7edc34ad4dae22d0e26b35","static":false,"nested":true},"children":[]}]},{"name":"div","attribs":{"style":{"padding":"1rem"}},"children":[{"name":"Reactable","attribs":{"data":{"details":["<b>DOI:<\/b> 10.1093/aje/kwt069 <br><br> We pooled data on adults who reported diarrhea or developed life-threatening hemolytic uremic syndrome (HUS) in any of 6 closed cohorts from 4 countries (1 cohort each in Denmark, France, and Sweden and 3 in Germany) that were investigated during a large outbreak of Shiga toxin-producing Escherichia coli (STEC) O104:H4 infection in 2011. Logistic regression and Weibull regression for interval censored data were used to assess the relation of age and sex with clinical outcome and with incubation period. Information on the latter was used in a nonparametric back-projection context to estimate when adult cases reported in Germany were exposed to STEC O104:H4. Overall, data from 119 persons (median age, 49 years; 80 women) were analyzed. Bloody diarrhea and HUS were recorded as the most severe outcome for 44 and 26 individuals, respectively. Older age was significantly associated with bloody diarrhea but not with HUS. Woman had nonsignificantly higher odds for bloody diarrhea (odds ratio = 1.81) and developing HUS (odds ratio = 1.83) than did men. Older participants had a statistically significantly reduced incubation period. The shortest interval that included 75% of exposures in adults spanned only 12 days and preceded outbreak detection. In conclusion, the frequency of bloody diarrhea but not of HUS and the length of the incubation period depended on the age of individuals infected with STEC O104:H4. A large number of people were exposed to STEC O104:H4 for a short period of time.\n <br><br> <b>MeSH terms:<\/b> <b>MeSH terms:<\/b> Adolescent; Adult; Age Distribution; Aged; Cohort Studies; Denmark; Diarrhea; Disease Outbreaks; Escherichia coli Infections; Female; France; Germany; Hemolytic-Uremic Syndrome; Humans; Male; Middle Aged; Sex Distribution; Shiga-Toxigenic Escherichia coli; Sweden; Young Adult <br><br> <b>OMOP Concepts (IDs):<\/b>  Infection due to Escherichia coli (440320); Hemolytic uremic syndrome (197253); Diarrhea (196523); "]},"columns":[{"id":"details","name":"","type":"character","html":true}],"dataKey":"08991b086b6b954314ab13cd18b001c4","static":false,"nested":true},"children":[]}]},{"name":"div","attribs":{"style":{"padding":"1rem"}},"children":[{"name":"Reactable","attribs":{"data":{"details":["<b>DOI:<\/b> 10.1371/journal.pone.0074193 <br><br> In pediatric sickle cell disease (SCD) patients, it has been reported that higher systolic blood pressure (SBP) is associated with increased risk of a silent cerebral infarction (SCI). SCI is a major cause of neurologic morbidity in children with SCD, and blood pressure is a potential modulator of clinical manifestations of SCD; however, the risk factors underlying these complications are not well characterized. The aim of this study was to identify genetic variants that influence SBP in an African American population in the setting of SCD, and explore the use of SBP as an endo-phenotype for SCI. We conducted a genome-wide meta-analysis for SBP using two SCD cohorts, as well as a candidate screen based on published SBP loci. A total of 1,617 patients were analyzed, and while no SNP reached genome-wide significance (P-value<5.0 x 10(-8)), a number of suggestive candidate loci were identified. The most significant SNP, rs7952106 (P-value=8.57 x 10(-7)), was in the DRD2 locus on chromosome 11. In a gene-based association analysis, MIR4301 (micro-RNA4301), which resides in an intron of DRD2, was the most significant gene (P-value=5.2 x 10(-5)). Examining 27 of the previously reported SBP associated SNPs, 4 SNPs were nominally significant. A genetic risk score was constructed to assess the aggregated genetic effect of the published SBP variants, demonstrating a significant association (P=0.05). In addition, we also assessed whether these variants are associated with SCI, validating the use of SBP as an endo-phenotype for SCI. Three SNPs were nominally associated, and only rs2357790 (5' CACNB2) was significant for both SBP and SCI. None of these SNPs retained significance after Bonferroni correction. Taken together, our results suggest the importance of DRD2 genetic variation in the modulation of SBP, and extend the aggregated importance of previously reported SNPs in the modulation of SBP in an African American cohort, more specifically in children with SCD.\n <br><br> <b>MeSH terms:<\/b> <b>MeSH terms:<\/b> Adolescent; Black or African American; Anemia, Sickle Cell; Blood Pressure; Cerebral Infarction; Child; Female; Genetic Loci; Genetic Predisposition to Disease; Genome-Wide Association Study; Humans; Hypertension; Male; Phenotype; Polymorphism, Single Nucleotide; Risk Factors <br><br> <b>OMOP Concepts (IDs):<\/b>  Blood pressure (4326744); Hypertensive disorder (316866); Sickle cell-hemoglobin SS disease (22281); Phenotype (4215157); Cerebral infarction (443454); Genetic predisposition (4166231); "]},"columns":[{"id":"details","name":"","type":"character","html":true}],"dataKey":"977c71484acad22f1c1ae92227c63fb5","static":false,"nested":true},"children":[]}]},{"name":"div","attribs":{"style":{"padding":"1rem"}},"children":[{"name":"Reactable","attribs":{"data":{"details":["<b>DOI:<\/b> 10.1161/CIRCULATIONAHA.113.002124 <br><br> Pulmonary arterial hypertension (PAH) remains a concern in patients with β-thalassemia major (TM) and intermedia (TI); however, studies evaluating its prevalence and risk factors using systematic confirmation on right heart catheterization are lacking.<br><br>&emsp;This was a multicenter cross-sectional study of 1309 Italian β-thalassemia patients (mean age 36.4±9.3 years; 46% men; 74.6% TM, 25.4% TI). Patients with a tricuspid-valve regurgitant jet velocity ≥3.2 m/s (3.6%) on transthoracic echocardiography further underwent right heart catheterization to confirm the diagnosis of PAH (mean pulmonary arterial pressure ≥25 mm Hg and pulmonary capillary wedge pressure ≤15mm Hg). The confirmed PAH prevalence on right heart catheterization was 2.1% (95% confidence interval [CI], 1.4-3.0) and was higher in TI (4.8%; 95% CI, 3.0-7.7) than TM (1.1%; 95% CI, 0.6-2.0). The positive predictive value for the tricuspid-valve regurgitant jet velocity ≥3.2 m/s threshold for the diagnosis of pulmonary hypertension was 93.9%. Considerable functional limitation and decrease in the 6-minute walk distance were noted in patients with confirmed PAH. On multivariate logistic regression analysis, independent risk factors for confirmed PAH were age (odds ratio, 1.102 per 1-year increase; 95% CI, 1.06-1.15) and splenectomy (odds ratio, 9.31; 95% CI, 2.57-33.7).<br><br>&emsp;The prevalence of PAH in β-thalassemia patients as confirmed on right heart catheterization was 2.1%, with an ≈5-fold higher prevalence in TI than TM. Advanced age and splenectomy are risk factors for PAH in this patient population.<br><br>&emsp;http://www.ClinicalTrials.gov. Unique identifier: NCT01496963.\n <br><br> <b>MeSH terms:<\/b> <b>MeSH terms:<\/b> Adult; Cardiac Catheterization; Case-Control Studies; Cross-Sectional Studies; Echocardiography; Familial Primary Pulmonary Hypertension; Female; Humans; Hypertension, Pulmonary; Logistic Models; Male; Middle Aged; Multivariate Analysis; Predictive Value of Tests; Prevalence; Pulmonary Wedge Pressure; Risk Factors; beta-Thalassemia <br><br> <b>OMOP Concepts (IDs):<\/b>  Pulmonary artery wedge pressure (4040920); Echocardiography (4230911); Beta thalassemia (4278669); Cardiac catheterization (4223020); Pulmonary hypertension (4322024); Familial primary pulmonary hypertension (4119611); "]},"columns":[{"id":"details","name":"","type":"character","html":true}],"dataKey":"fdb68694a18e9a3aae8ef21fb5a19d3b","static":false,"nested":true},"children":[]}]},{"name":"div","attribs":{"style":{"padding":"1rem"}},"children":[{"name":"Reactable","attribs":{"data":{"details":["<b>DOI:<\/b> 10.1371/journal.pone.0074171 <br><br> Prophylactic cotrimoxazole is recommended for infants born to HIV-infected mothers. However, cotrimoxazole may increase the risk of severe anemia or neutropenia.<br><br>&emsp;We compared the proportion of HIV-exposed uninfected (HIV-EU) infants experiencing incident severe anemia (and separately, severe neutropenia) between a prospective cohort receiving prophylactic cotrimoxazole from 1 to 6 months vs. infants from two prior trials who did not receive cotrimoxazole. Infants were from rural and urban communities in southern Botswana.<br><br>&emsp;A total of 1705 HIV-EU infants were included. Among these 645 (37.8%) were fed with iron-supplemented formula from birth. Severe anemia developed in 87 (5.1%) infants, and severe neutropenia in 164 (9.6%) infants. In an analysis stratified by infant feeding method, there were no significant differences in the risk of severe anemia by prophylactic cotrimoxazole exposure-risk difference, -0.69% (95% confidence interval [CI] -2.1 to 0.76%). Findings were similar in multivariable analysis, adjusted odds ratio (aOR) 0.35 (95% CI 0.07 to 1.65). There were also no significant differences observed for severe neutropenia by cotrimoxazole exposure, risk difference 2.0% (95% CI -1.3 to 5.2%) and aOR 0.80 (95% CI 0.33 to 1.93).<br><br>&emsp;Severe anemia and severe neutropenia were infrequent among HIV-exposed uninfected infants receiving cotrimoxazole from 1-6 months of age. Concerns regarding hematologic toxicity should not limit the use of prophylactic cotrimoxazole in HIV-exposed uninfected infants. CLINICALTRIAL.SGOV REGISTRATION NUMBERS: NCT01086878 (http://clinicaltrials.gov/show/NCT01086878), NCT00197587 (http://clinicaltrials.gov/show/NCT00197587), and NCT00270296 (http://clinicaltrials.gov/show/NCT00270296).\n <br><br> <b>MeSH terms:<\/b> <b>MeSH terms:<\/b> Anemia; Anti-Infective Agents; Antiretroviral Therapy, Highly Active; HIV Infections; Humans; Infant; Neutropenia; Prospective Studies; Trimethoprim, Sulfamethoxazole Drug Combination <br><br> <b>OMOP Concepts (IDs):<\/b>  Human immunodeficiency virus infection (439727); Highly active anti-retroviral therapy (4166414); Anemia (439777); Neutropenic disorder (4119158); "]},"columns":[{"id":"details","name":"","type":"character","html":true}],"dataKey":"bb518bfd1e83b5794c6e70a2c78f0a70","static":false,"nested":true},"children":[]}]},{"name":"div","attribs":{"style":{"padding":"1rem"}},"children":[{"name":"Reactable","attribs":{"data":{"details":["<b>DOI:<\/b> 10.1371/journal.pone.0078394 <br><br> Studies conducted in high income countries have shown that anaemia is a common medical condition among older people, but such data are scarce in Africa. The objectives of this study were to estimate the prevalence, types, risk factors and clinical correlates of anaemia in older people.<br><br>&emsp;Participants were aged (≥ 50) years recruited from a general population cohort from January 2012 to January 2013. Blood samples were collected for assessing hemoglobin, serum ferritin, serum vitamin B12, serum folate, C-reactive protein, malaria infection and stool samples for assessment of hookworm infection. HIV status was assessed using an algorithm for HIV rapid testing. Questionnaires were used to collect data on sociodemographic characteristics and other risk factors for anaemia.<br><br>&emsp;In total, 1449 people participated (response rate 72.3%). The overall prevalence of anaemia was 20.3 % (95% CI 18.2-22.3%), and this was higher for males (24.1%, 95% CI=20.7-27.7%) than females (17.5%, 95% CI=15.0-20.1%). In males, the prevalence of anaemia increased rapidly with age almost doubling between 50 and 65 years (p-trend<0.001). Unexplained anaemia was responsible for more than half of all cases (59.7%). Anaemia was independently associated with infections including malaria (OR 3.49, 95% CI 1.78-6.82), HIV (OR 2.17, 1.32-3.57) heavy hookworm infection (OR 3.45, 1.73-6.91), low fruit consumption (OR 1.55, 1.05-2.29) and being unmarried (OR 1.37 , 95% CI 1.01-1.89). However, the odds of anaemia were lower among older people with elevated blood pressure (OR 0.47, 95% CI 0.29-0.77).<br><br>&emsp;Anaemia control programmes in Uganda should target older people and should include interventions to treat and control hookworms and educational programs on diets that enhance iron absorption. Clinicians should consider screening older people with HIV or malaria for anaemia. Further studies should be done on unexplained anaemia and serum ferritin levels that predict iron deficiency anaemia in older people.\n <br><br> <b>MeSH terms:<\/b> <b>MeSH terms:<\/b> Age Factors; Aged; Anemia; Blood Pressure; C-Reactive Protein; Cross-Sectional Studies; Female; Ferritins; Folic Acid; HIV Seropositivity; Hemoglobins; Hookworm Infections; Humans; Malaria; Male; Middle Aged; Odds Ratio; Prevalence; Risk Factors; Rural Population; Sex Factors; Uganda; Vitamin B 12 <br><br> <b>OMOP Concepts (IDs):<\/b>  Blood pressure (4326744); Vitamin B 12 (1308738); Folic Acid (19111620); Disease due to superfamily Ancylostomatoidea (440948); Malarial fever (4093997); HIV positive (4013106); Anemia (439777); "]},"columns":[{"id":"details","name":"","type":"character","html":true}],"dataKey":"532607b4bc1edee158ef8d02e2a25468","static":false,"nested":true},"children":[]}]},{"name":"div","attribs":{"style":{"padding":"1rem"}},"children":[{"name":"Reactable","attribs":{"data":{"details":["<b>DOI:<\/b> 10.1371/journal.pone.0077913 <br><br> This study assessed the diagnostic performance and prognostic properties of C-reactive protein (CRP), copeptin and cortisol in individuals with sickle cell anaemia (SCA).<br><br>&emsp;Prospective case-control study.<br><br>&emsp;Sixty consecutive SCA subjects (18-40 years) comprising 30 subjects in the steady state and 30 subjects in vaso-occlusive crisis (VOC) were recruited into this study. Thirty (30) apparently healthy individuals with HbAA genotype served as controls. ELISA was used for the determination of serum levels of copeptin, CRP and cortisol. Data obtained were statistically analyzed using the Student's t-test and Mann Whitney U as appropriate and P<0.05 was considered significant.<br><br>&emsp;SCA subjects in VOC had significantly lower copeptin level and significantly higher CRP level compared with controls. However, serum levels of copeptin, cortisol and CRP were significantly higher in SCA subjects in VOC compared with SCA subjects in steady state. Furthermore, CRP had the widest Area under the ROC curve (AUROC) than copeptin and cortisol. No significant difference was observed in the levels of copeptin, CRP and cortisol when SCA subjects in VOC who were hospitalized for less ≤ 5 days were compared with subjects who had longer stays.<br><br>&emsp;It could be concluded that C-reactive protein has a superior diagnostic performance for vaso-occlusive crisis in individuals with sickle cell anaemia and that C-reactive protein, cortisol and copeptin are not good prognostic markers in SCA subjects in vaso-occlusive crisis.\n <br><br> <b>MeSH terms:<\/b> <b>MeSH terms:<\/b> Adolescent; Adult; Anemia, Sickle Cell; Area Under Curve; Biomarkers; C-Reactive Protein; Case-Control Studies; Glycopeptides; Humans; Hydrocortisone; Prognosis; Prospective Studies; ROC Curve; Young Adult <br><br> <b>OMOP Concepts (IDs):<\/b>  Hydrocortisone (975125); Determination of prognosis (4069425); Sickle cell-hemoglobin SS disease (22281); "]},"columns":[{"id":"details","name":"","type":"character","html":true}],"dataKey":"c02bbce867baae08183af10d17f9cf9d","static":false,"nested":true},"children":[]}]},{"name":"div","attribs":{"style":{"padding":"1rem"}},"children":[{"name":"Reactable","attribs":{"data":{"details":["<b>DOI:<\/b> 10.1371/journal.pone.0079923 <br><br> Frequent painful vaso-occlusive crises (VOCs) were associated with mortality in the Cooperative Study of Sickle Cell Disease (CSSCD) over twenty years ago. Modern therapies for sickle cell anemia (SCA) like hydroxyurea are believed to have improved overall patient survival. The current study sought to determine the relevance of the association between more frequent VOCs and death and its relative impact upon overall mortality compared to other known risk factors in a contemporary adult SCA cohort.<br><br>&emsp;Two hundred sixty four SCA adults were assigned into two groups based on patient reported outcomes for emergency department (ED) visits or hospitalizations for painful VOC treatment during the 12 months prior to evaluation.<br><br>&emsp;Higher baseline hematocrit (p = 0.0008), ferritin (p = 0.005), and HDL cholesterol (p = 0.01) were independently associated with 1 or more painful VOCs requiring an ED visit or hospitalization for acute pain. During a median follow-up of 5 years, mortality was higher in the ED visit/hospitalization group (relative risk [RR] 2.68, 95% CI 1.1-6.5, p = 0.03). Higher tricuspid regurgitatant jet velocity (TRV) (RR 2.41, 95% CI 1.5-3.9, p < 0.0001), elevated ferritin (RR 4.00, 95% CI 1.8-9.0, p = 0.001) and lower glomerular filtration rate (RR=2.73, 95% CI 1.6-4.6, p < 0.0001) were also independent risk factors for mortality.<br><br>&emsp;Severe painful VOCs remain a marker for SCA disease severity and premature mortality in a modern cohort along with other known risk factors for death including high TRV, high ferritin and lower renal function. The number of patient reported pain crises requiring healthcare utilization is an easily obtained outcome that could help to identify high risk patients for disease modifying therapies.<br><br>&emsp;ClinicalTrials.gov NCT00011648 http://clinicaltrials.gov/\n <br><br> <b>MeSH terms:<\/b> <b>MeSH terms:<\/b> Adult; Anemia, Sickle Cell; Cholesterol, HDL; Female; Ferritins; Hematocrit; Humans; Kaplan-Meier Estimate; Logistic Models; Male; Middle Aged; Proportional Hazards Models; Risk Factors <br><br> <b>OMOP Concepts (IDs):<\/b>  Sickle cell-hemoglobin SS disease (22281); Hematocrit determination (4151358); "]},"columns":[{"id":"details","name":"","type":"character","html":true}],"dataKey":"df97f14489e4f9c556a43e50bb481f01","static":false,"nested":true},"children":[]}]},{"name":"div","attribs":{"style":{"padding":"1rem"}},"children":[{"name":"Reactable","attribs":{"data":{"details":["<b>DOI:<\/b> 10.1371/journal.pone.0078180 <br><br> The clinical spectrum following infection with Shiga toxin-producing Escherichia coli (STEC) is wide ranging and includes hemorrhagic colitis and life-threatening hemolytic uremic syndrome (HUS). Severity of STEC illness depends on patients' age and strongly on the infecting strains' virulence. Serogroup O157 is often assumed to be more virulent than others. Age-adjusted population-based data supporting this view are lacking thus far. We conducted a large retrospective cohort study among patients of community-acquired gastroenteritis or HUS diagnosed with STEC infection, reported in Germany January 2004 through December 2011. Age-adjusted risks for reported hospitalization and death, as proxies for disease severity, were estimated for STEC serogroups separately, and compared with STEC O157 (reference group) using Poisson regression models with robust error estimation. A total of 8,400 case-patients were included in the analysis; for 2,454 (29%) and 30 (0.4%) hospitalization and death was reported, respectively. Highest risks for hospitalization, adjusted for age and region of residence, were estimated for STEC O104 (68%; risk ratio [RR], 1.33; 95% confidence interval [CI], 1.19-1.45), followed by STEC O157 (46%). Hospitalization risks for the most prevalent non-O157 serogroups (O26, O103, O91, O145, O128, O111) were consistently and markedly lower than for O157, with the highest RR for O145 (0.54; 95% CI, 0.41-0.70) and the lowest for O103 (0.27; 95% CI, 0.20-0.35). Mortality risk of O104 was similar to O157 (1.2% each), but the group of all other non-O157 STEC had only 1/10 the risk (RR, 0.09; 95% CI, 0.02-0.32) compared to O157. The study provides population-based and age-adjusted evidence for the exceptional high virulence of STEC O157 in relation to non-O157 STEC other than O104. Timely diagnosis and surveillance of STEC infections should prioritize HUS-associated E. coli, of which STEC O157 is the most important serogroup.\n <br><br> <b>MeSH terms:<\/b> <b>MeSH terms:<\/b> Adolescent; Adult; Aged; Child; Child, Preschool; Escherichia coli O157; Female; Germany; Hemolytic-Uremic Syndrome; Hospitalization; Humans; Infant; Male; Middle Aged; Prevalence; Retrospective Studies; Risk Factors; Species Specificity <br><br> <b>OMOP Concepts (IDs):<\/b>  Hemolytic uremic syndrome (197253); Inpatient care (4214577); "]},"columns":[{"id":"details","name":"","type":"character","html":true}],"dataKey":"092f390d20459fc130e9e4eb4ec55c25","static":false,"nested":true},"children":[]}]},{"name":"div","attribs":{"style":{"padding":"1rem"}},"children":[{"name":"Reactable","attribs":{"data":{"details":["<b>DOI:<\/b> 10.1371/journal.pone.0080164 <br><br> To identify maternal and antenatal factors associated with stillbirths and neonatal deaths in rural Bangladesh.<br><br>&emsp;A prospective cohort study is being conducted to evaluate a maternal and child nutrition program in rural Bangladesh. Cases were all stillbirths and neonatal deaths that occurred in the cohort between March 7, 2011 and December 30, 2011. Verbal autopsies were used to determine cause of death. For each case, four controls were randomly selected from cohort members alive at age 3-months. Multivariable logistic regression was used to identify factors associated with these deaths.<br><br>&emsp;Overall, 112 adverse pregnancy outcomes (44 stillbirths, 19/1,000 births; 68 neonatal deaths, 29/1,000 live births) were reported. Of the stillbirths 25 (56.8%) were fresh. The main causes of neonatal death were birth asphyxia (35%), sepsis (28%) and preterm birth (19%). History of bleeding during pregnancy was the strongest risk factor for stillbirths (adjusted odds ratio 22.4 [95% confidence interval 2.5, 197.5]) and neonatal deaths (adjusted odds ratio 19.6 [95% confidence interval 2.1, 178.8]). Adequate maternal nutrition was associated with decreased risk of neonatal death (adjusted odds ratio 0.4 [95% confidence interval 0.2, 0.8]).<br><br>&emsp;Identifying high-risk pregnancies during gestation and ensuring adequate antenatal and obstetric care needs to be a priority for any community-based maternal and child health program in similar settings.\n <br><br> <b>MeSH terms:<\/b> <b>MeSH terms:<\/b> Adolescent; Adult; Asphyxia Neonatorum; Bangladesh; Case-Control Studies; Cause of Death; Child; Female; Fetomaternal Transfusion; Humans; Infant Mortality; Infant, Newborn; Live Birth; Logistic Models; Nutritional Status; Pregnancy; Pregnancy, High-Risk; Premature Birth; Prospective Studies; Rural Population; Sepsis; Stillbirth <br><br> <b>OMOP Concepts (IDs):<\/b>  Pregnant (4299535); Stillbirth (443213); Sepsis (132797); Fetal-maternal hemorrhage (201366); Asphyxia, in liveborn infant (439136); Premature pregnancy delivered (4175637); Cause of death (4083743); High risk pregnancy (4188598); "]},"columns":[{"id":"details","name":"","type":"character","html":true}],"dataKey":"59847f23483b75723eff79f2f0bde37d","static":false,"nested":true},"children":[]}]},{"name":"div","attribs":{"style":{"padding":"1rem"}},"children":[{"name":"Reactable","attribs":{"data":{"details":["<b>DOI:<\/b> 10.1016/j.vaccine.2013.11.048 <br><br> Patients with Fanconi anemia (FA) and other inherited bone marrow failure syndromes (IBMFS) have extremely high risks of squamous cell head and neck, and gynecologic carcinomas. In the general population, these sites are often associated with infection with human papillomaviruses (HPV), particularly HPV16 and HPV18. Our objectives were to measure the levels of HPV antibodies in unvaccinated patients, and to determine whether these patients developed and maintained similar levels of antibodies as those observed in healthy women, following vaccination with the currently licensed HPV L1 virus-like particles (VLP) vaccines. We measured anti-HPV IgG antibody levels in sera from patients using an HPV16 or HPV18 L1 VLP enzyme-linked immunoabsorbent assay. Most unvaccinated patients did not have detectable antibody levels, except for a few women above age 25. Both FA and other IBMFS patients developed antibody levels following vaccination that were similar to those previously described in healthy women, and those levels appeared to be sustained out to 5 years after immunization. Thus, antibody responses to the HPV L1 VLP vaccine in patients with FA and other IBMFS appeared to be similar to the responses reported in the general population, implying potential efficacy against future infections with the HPV types contained in the vaccine.\n <br><br> <b>MeSH terms:<\/b> <b>MeSH terms:<\/b> Adolescent; Adult; Anemia, Aplastic; Antibodies, Viral; Antibody Formation; Bone Marrow Diseases; Bone Marrow Failure Disorders; Child; Child, Preschool; Cohort Studies; Fanconi Anemia; Female; Hemoglobinuria, Paroxysmal; Humans; Immunoglobulin G; Male; Middle Aged; Papillomavirus Infections; Papillomavirus Vaccines; Young Adult <br><br> <b>OMOP Concepts (IDs):<\/b>  Hemoglobinuria due to hemolysis from external causes (434616); Hematopoietic aplasia (4119473); Immunoglobulin G (19117912); Immunoglobulin G (4104804); Fanconi's anemia (4148471); Human papilloma virus infection (441788); Bone marrow disorder (4131124); "]},"columns":[{"id":"details","name":"","type":"character","html":true}],"dataKey":"5b93ac8c597648ccd61dda6a2c5151d4","static":false,"nested":true},"children":[]}]},{"name":"div","attribs":{"style":{"padding":"1rem"}},"children":[{"name":"Reactable","attribs":{"data":{"details":["<b>DOI:<\/b> 10.1371/journal.pone.0082952 <br><br> Very little is known about the relationship between non-sickle cell anemia and stroke. The purpose of this study is to evaluate the association of iron-deficiency anemia (IDA) with stroke based on a nationwide coverage database in Taiwan.<br><br>&emsp;The case-control study subjects were obtained from the Taiwanese Longitudinal Health Insurance Database 2000. We included 51,093 subjects with stroke as cases and randomly selected 153,279 controls (3 controls per case) in this study.Separate conditional logistic regression analyses were used to calculate the odds ratio (OR) for having been previously diagnosed with IDA between cases and controls.We further analyzed the association between stroke and IDA by stroke subtype.<br><br>&emsp;Results showed that 3,685 study subjects (1.81%) had been diagnosed with IDA prior to the index date; of those subjects, 1,268 (2.48%) were cases and 2,417 (1.58%) were controls (p<0.001). Conditional logistic regression shows that the OR of having previously received an IDA diagnosis among cases was 1.49 (95% CI: 1.39~1.60; p < 0.01) that of controls after adjusting for monthly income, geographic region, hypertension, diabetes, coronary heart disease, atrial fibrillation, heart failure, hyperlipidemia, tobacco use disorder, and alcohol abuse/alcohol dependency syndrome. Furthermore, the adjusted OR of prior IDA for cases with ischemic stroke was found to be 1.45 (95% CI: 1.34~1.58) compared to controls. However, we did not find any significant relationship between IDA and subarachnoid/intracerebral hemorrhage even adjusting for other confounding factors (OR=1.17, 95% CI=0.97~1.40).<br><br>&emsp;There is a significant association between prior IDA and ischemic stroke.\n <br><br> <b>MeSH terms:<\/b> <b>MeSH terms:<\/b> Adolescent; Adult; Aged; Anemia, Iron-Deficiency; Brain Ischemia; Databases, Factual; Female; Humans; Male; Middle Aged; Risk Factors; Socioeconomic Factors; Stroke; Subarachnoid Hemorrhage; Taiwan <br><br> <b>OMOP Concepts (IDs):<\/b>  Ischemic encephalopathy (4305274); Cerebrovascular accident (381316); Subarachnoid hemorrhage (432923); Iron deficiency anemia (436659); "]},"columns":[{"id":"details","name":"","type":"character","html":true}],"dataKey":"915c8c12d79fc10b352e228ade7cd488","static":false,"nested":true},"children":[]}]},{"name":"div","attribs":{"style":{"padding":"1rem"}},"children":[{"name":"Reactable","attribs":{"data":{"details":["<b>DOI:<\/b> 10.1093/jnci/djt335 <br><br> There is no method routinely used to predict response to anthracycline and cyclophosphamide-based chemotherapy in the clinic; therefore patients often receive treatment for breast cancer with no benefit. Loss of the Fanconi anemia/BRCA (FA/BRCA) DNA damage response (DDR) pathway occurs in approximately 25% of breast cancer patients through several mechanisms and results in sensitization to DNA-damaging agents. The aim of this study was to develop an assay to detect DDR-deficient tumors associated with loss of the FA/BRCA pathway, for the purpose of treatment selection.<br><br>&emsp;DNA microarray data from 21 FA patients and 11 control subjects were analyzed to identify genetic processes associated with a deficiency in DDR. Unsupervised hierarchical clustering was then performed using 60 BRCA1/2 mutant and 47 sporadic tumor samples, and a molecular subgroup was identified that was defined by the molecular processes represented within FA patients. A 44-gene microarray-based assay (the DDR deficiency assay) was developed to prospectively identify this subgroup from formalin-fixed, paraffin-embedded samples. All statistical tests were two-sided.<br><br>&emsp;In a publicly available independent cohort of 203 patients, the assay predicted complete pathologic response vs residual disease after neoadjuvant DNA-damaging chemotherapy (5-fluorouracil, anthracycline, and cyclophosphamide) with an odds ratio of 3.96 (95% confidence interval [Cl] =1.67 to 9.41; P = .002). In a new independent cohort of 191 breast cancer patients treated with adjuvant 5-fluorouracil, epirubicin, and cyclophosphamide, a positive assay result predicted 5-year relapse-free survival with a hazard ratio of 0.37 (95% Cl = 0.15 to 0.88; P = .03) compared with the assay negative population.<br><br>&emsp;A formalin-fixed, paraffin-embedded tissue-based assay has been developed and independently validated as a predictor of response and prognosis after anthracycline/cyclophosphamide-based chemotherapy in the neoadjuvant and adjuvant settings. These findings warrant further validation in a prospective clinical study.\n <br><br> <b>MeSH terms:<\/b> <b>MeSH terms:<\/b> Adult; Aged; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; DNA Damage; DNA, Neoplasm; Disease-Free Survival; Epirubicin; Fanconi Anemia; Female; Fluorouracil; Humans; Middle Aged; Neoadjuvant Therapy; Odds Ratio; Oligonucleotide Array Sequence Analysis; Prospective Studies <br><br> <b>OMOP Concepts (IDs):<\/b>  Neoplasm of breast (81251); DNA damage (4285282); Fluorouracil (955632); Fanconi's anemia (4148471); Cyclophosphamide (1310317); Epirubicin (1344354); "]},"columns":[{"id":"details","name":"","type":"character","html":true}],"dataKey":"03118f5b8e3c72ec2cc431dc2ea5876b","static":false,"nested":true},"children":[]}]},{"name":"div","attribs":{"style":{"padding":"1rem"}},"children":[{"name":"Reactable","attribs":{"data":{"details":["<b>DOI:<\/b> 10.1371/journal.pone.0086714 <br><br> This study aimed to examine the prognostic significance of pre-existing iron deficiency anemia (IDA) and the benefits of early colonoscopy in patients with colon cancer, since these have not been clearly established to date. Using the Taiwanese National Health Insurance Research Database, we retrieved and retrospectively reviewed the records of patients aged ≥ 55 years who were diagnosed with colon cancer between 2000 and 2005. The patient cohort was divided into two groups: patients with (n = 1,260) or without (n = 15,912) an IDA diagnosis during ≤ 18 months preceding the date of colon cancer diagnosis. We found that diabetes (27.9% vs. 20.3%, p<0.0001), cardiovascular disease (61.6% vs. 54.7%, p<0.001), and chronic kidney disease (4.6% vs. 2.2%, p<0.0001) were more common among patients with IDA than among those without IDA. The median overall survival times for patients with IDA and those without IDA were 4.6 and 5.7 years, respectively (p = 0.002). Patients who underwent colonoscopy ≤ 30 days, 31-90, and ≥ 91 days after IDA diagnosis showed median overall survival times of 5.79, 4.43, and 4.04 years, respectively (p = 0.003). Delayed colonoscopy was an independent factor associated with poor overall survival (adjusted hazard ratio, 1.28; 95% confidence interval, 1.07-1.53; p = 0.01). In conclusion, colon cancer patients with IDA were more likely to experience comorbidities than were those without IDA. Pre-existing IDA was a poor prognostic factor in adult men and postmenopausal women who had colon cancer. Early colonoscopy could improve overall survival possibly by facilitating early diagnosis and treatment.\n <br><br> <b>MeSH terms:<\/b> <b>MeSH terms:<\/b> Aged; Aged, 80 and over; Anemia, Iron-Deficiency; Colonic Neoplasms; Colonoscopy; Comorbidity; Databases, Factual; Early Detection of Cancer; Female; Humans; Male; Middle Aged; Neoplasm Staging; Patient Outcome Assessment; Population Surveillance; Prognosis <br><br> <b>OMOP Concepts (IDs):<\/b>  Cancer staging (4123018); Determination of prognosis (4069425); Iron deficiency anemia (436659); Neoplasm of colon (4130995); Colonoscopy (4249893); "]},"columns":[{"id":"details","name":"","type":"character","html":true}],"dataKey":"78d0dad1271ef07a93be8e7bd934fd63","static":false,"nested":true},"children":[]}]},{"name":"div","attribs":{"style":{"padding":"1rem"}},"children":[{"name":"Reactable","attribs":{"data":{"details":["<b>DOI:<\/b> 10.1371/journal.pone.0087408 <br><br> There is a highly variable asymptomatic period of beta cell destruction prior to the clinical presentation of type1 diabetes. It is not well known what triggers type 1 diabetes to become a clinically overt disease. This explorative study aimed to identify the association between disease history/medication use and the clinical manifestation of type 1 diabetes.<br><br>&emsp;An explorative case control study was conducted in the Dutch PHARMO Record Linkage System. Cases (n = 1,107) were younger than 25 years and had at least 2 insulin prescriptions between 1999 and 2009. For each case, up to 4 controls (without any prescription for the glucose lowering medications (n = 4,424)) were matched by age and sex. Conditional logistic regression analysis was used to evaluate the association between disease history/medication use in the year prior to the diagnosis of type 1 diabetes and clinical manifestation of this disease. Type1 diabetes was significantly associated with a history of mental disorder (odds ratio (OR) 8.0, 95% confidence interval (CI) 1.5-43.7), anemia (OR 5.1, 95% CI 1.1-22.9), and disease of digestive system (OR 2.6, 95% CI 1.2-5.5). The following drug exposures were significantly associated with the clinical manifestation of type 1 diabetes: \"systemic hormonal preparations\" (OR 1.7, 95% CI 1.1-2.6), medications for \"blood and blood forming organs\" (OR 1.6, 95% CI 1.1-2.6), \"alimentary tract and metabolism\" (OR 1.3, 95% CI 1.1-1.6), and \"anti-infectives for systemic use\" (OR 1.2, 95% CI 1.01-1.4).<br><br>&emsp;Our explorative study demonstrated that in the year prior to the presentation of type 1 diabetes in children and young adults, hospitalization for a diverse group of diseases and drug exposures were significantly more prevalent compared with age- and sex-matched diabetes-free controls.\n <br><br> <b>MeSH terms:<\/b> <b>MeSH terms:<\/b> Adolescent; Anemia; Case-Control Studies; Child; Child, Preschool; Diabetes Mellitus, Type 1; Digestive System Diseases; Disease; Humans; Infant; Infant, Newborn; Logistic Models; Male; Mental Disorders; Netherlands; Odds Ratio; Pharmaceutical Preparations; Risk Factors; Young Adult <br><br> <b>OMOP Concepts (IDs):<\/b>  Disease (4274025); Disorder of digestive system (4201745); Mental disorder (432586); Anemia (439777); Type 1 diabetes mellitus (201254); "]},"columns":[{"id":"details","name":"","type":"character","html":true}],"dataKey":"130291b490d7d8f992e6d4c64eff6e15","static":false,"nested":true},"children":[]}]},{"name":"div","attribs":{"style":{"padding":"1rem"}},"children":[{"name":"Reactable","attribs":{"data":{"details":["<b>DOI:<\/b> 10.1371/journal.pone.0088148 <br><br> To investigate the efficacy and safety of granulocyte transfusion combined with granulocyte colony stimulating factor (G-CSF) in severe infection patients with severe aplastic anemia (SAA).<br><br>&emsp;Fifty-six patients in severe infections with SAA who had received granulocyte transfusions combined with G-CSF from 2006 to 2012 in our department were analyzed. A retrospective analysis was undertaken to investigate the survival rates (at 30 days, 90 days and 180 days), the responses to treatment (at 7 days and 30 days, including microbiological, radiographic and clinical responses), the neutrophil count and adverse events after transfusion.<br><br>&emsp;All SAA patients with severe infections were treated with granulocyte transfusions combined with G-CSF. Forty-seven patients had received antithymocyte globulin/antilymphocyte globulin and cyclosporine A as immunosuppressive therapy. The median number of granulocyte components transfused was 18 (range, 3-75). The survival at 30 days, 90 days and 180 days were 50(89%), 39(70%) and 37(66%) respectively. Among 31 patients who had invasive fungal infections, the survival at 30 days, 90 days and 180 days were 27(87%), 18(58%) and 16(52%) respectively. Among the 25 patients who had refractory severe bacterial infections, the survival at 30 days, 90 days and 180 days were 23(92%), 21(84%) and 21(84%) respectively. Survival rate was correlated with hematopoietic recovery. Responses of patients at 7 and 30 days were correlated with survival rate. Common adverse effects of granulocyte transfusion included mild to moderate fever, chills, allergy and dyspnea.<br><br>&emsp;Granulocyte transfusions combined with G-CSF could be an adjunctive therapy for treating severe infections of patients with SAA.\n <br><br> <b>MeSH terms:<\/b> <b>MeSH terms:<\/b> Adolescent; Adult; Aged; Anemia, Aplastic; Antilymphocyte Serum; Bacterial Infections; Child; Cyclosporine; Female; Granulocyte Colony-Stimulating Factor; Granulocytes; Humans; Immunosuppressive Agents; Leukocyte Transfusion; Male; Middle Aged; Mycoses; Retrospective Studies; Survival Rate; Young Adult <br><br> <b>OMOP Concepts (IDs):<\/b>  Hematopoietic aplasia (4119473); Transfusion of leukocytes (4148554); Cyclosporine (19010482); Mycosis (433701); Bacterial infectious disease (432545); "]},"columns":[{"id":"details","name":"","type":"character","html":true}],"dataKey":"a86dd498f08775349a33f48b881fa2ca","static":false,"nested":true},"children":[]}]},{"name":"div","attribs":{"style":{"padding":"1rem"}},"children":[{"name":"Reactable","attribs":{"data":{"details":["<b>DOI:<\/b> 10.1161/CIRCULATIONAHA.113.005296 <br><br> We postulated that the hypoxic response in sickle cell disease (SCD) contributes to altered gene expression and pulmonary hypertension, a complication associated with early mortality.<br><br>&emsp;To identify genes regulated by the hypoxic response and not other effects of chronic anemia, we compared expression variation in peripheral blood mononuclear cells from 13 subjects with SCD with hemoglobin SS genotype and 15 subjects with Chuvash polycythemia (VHL(R200W) homozygotes with constitutive upregulation of hypoxia-inducible factors in the absence of anemia or hypoxia). At a 5% false discovery rate, 1040 genes exhibited >1.15-fold change in both conditions; 297 were upregulated and 743 downregulated including MAPK8 encoding a mitogen-activated protein kinase important for apoptosis, T-cell differentiation, and inflammatory responses. Association mapping with a focus on local regulatory polymorphisms in 61 patients with SCD identified expression quantitative trait loci for 103 of these hypoxia response genes. In a University of Illinois SCD cohort, the A allele of a MAPK8 expression quantitative trait locus, rs10857560, was associated with precapillary pulmonary hypertension defined as mean pulmonary artery pressure ≥25 mm Hg and pulmonary capillary wedge pressure ≤15 mm Hg at right heart catheterization (allele frequency, 0.66; odds ratio, 13.8; n=238). This association was confirmed in an independent Walk-Treatment of Pulmonary Hypertension and Sickle Cell Disease With Sildenafil Therapy cohort (allele frequency, 0.65; odds ratio, 11.3; n=519). The homozygous AA genotype of rs10857560 was associated with decreased MAPK8 expression and present in all 14 of the identified precapillary pulmonary hypertension cases among the combined 757 patients.<br><br>&emsp;Our study demonstrates a prominent hypoxic transcription component in SCD and a MAPK8 expression quantitative trait locus associated with precapillary pulmonary hypertension.\n <br><br> <b>MeSH terms:<\/b> <b>MeSH terms:<\/b> Adult; Anemia, Sickle Cell; Apoptosis; Cell Hypoxia; Cohort Studies; Female; Gene Expression Regulation, Enzymologic; Humans; Hypertension, Pulmonary; Inflammation; Leukocytes, Mononuclear; Male; Mitogen-Activated Protein Kinase 8; Prospective Studies; Quantitative Trait Loci; T-Lymphocytes <br><br> <b>OMOP Concepts (IDs):<\/b>  Sickle cell-hemoglobin SS disease (22281); Pulmonary hypertension (4322024); "]},"columns":[{"id":"details","name":"","type":"character","html":true}],"dataKey":"dbee3a39b6111ace3b6146a5a6135a0c","static":false,"nested":true},"children":[]}]},{"name":"div","attribs":{"style":{"padding":"1rem"}},"children":[{"name":"Reactable","attribs":{"data":{"details":["<b>DOI:<\/b> 10.1371/journal.pone.0088862 <br><br> Riboflavin (vitamin B2) has been shown in animal studies to affect the absorption and metabolism of iron. Cross-sectional population studies show a relationship between riboflavin intake and anemia but prospective population studies are limited. The aim of the study was to determine the relationship between riboflavin intake and the risk of anemia in a Chinese cohort.<br><br>&emsp;The study used data from 1253 Chinese men and women who participated in two waves of the Jiangsu Nutrition Study (JIN), five years apart, in 2002 and 2007. Riboflavin intake and hemoglobin (Hb) were quantitatively assessed together with dietary patterns, lifestyle, socio-demographic and health-related factors.<br><br>&emsp;At baseline, 97.2% of participants had inadequate riboflavin intake (below the estimate average requirement). Riboflavin intake was positively associated with anemia at baseline, but low riboflavin intake was associated with an increased risk of anemia at follow-up among those anemic at baseline. In the multivariate model, adjusting for demographic and lifestyle factors and dietary patterns, the relative risk and 95% confidence interval for anemia at follow-up, across quartiles of riboflavin intake were: 1, 0.82(0.54-1.23), 0.56(0.34-0.93), 0.52(0.28-0.98) (p for trend 0.021). There was a significant interaction between riboflavin and iron intake; when riboflavin intake was low, a high iron intake was associated with a lower probability of anemia at follow-up. This association disappeared when riboflavin intake was high.<br><br>&emsp;Inadequate riboflavin intake is common and increases the risk of anemia in Chinese adults. Given the interaction with iron intake correcting inadequate riboflavin intake may be a priority in the prevention of anemia, and population based measurement and intervention trials are required.\n <br><br> <b>MeSH terms:<\/b> <b>MeSH terms:<\/b> Adult; Anemia; China; Eating; Female; Follow-Up Studies; Food Analysis; Humans; Iron; Longitudinal Studies; Male; Middle Aged; Nutrition Surveys; Riboflavin; Risk; Young Adult <br><br> <b>OMOP Concepts (IDs):<\/b>  Riboflavin (19062817); Food analysis (4142642); Anemia (439777); Iron (1360067); "]},"columns":[{"id":"details","name":"","type":"character","html":true}],"dataKey":"2057e312fe9b6abc7c34b4279ce77289","static":false,"nested":true},"children":[]}]},{"name":"div","attribs":{"style":{"padding":"1rem"}},"children":[{"name":"Reactable","attribs":{"data":{"details":["<b>DOI:<\/b> 10.1161/CIRCGENETICS.113.000387 <br><br> Fetal hemoglobin (HbF) is the major modifier of the clinical course of sickle cell anemia. Its levels are highly heritable, and its interpersonal variability is modulated in part by 3 quantitative trait loci that affect HbF gene expression. Genome-wide association studies have identified single-nucleotide polymorphisms (SNPs) in these quantitative trait loci that are highly associated with HbF but explain only 10% to 12% of the variance of HbF. Combining SNPs into a genetic risk score can help to explain a larger amount of the variability of HbF level, but the challenge of this approach is to select the optimal number of SNPs to be included in the genetic risk score.<br><br>&emsp;We developed a collection of 14 models with genetic risk score composed of different numbers of SNPs and used the ensemble of these models to predict HbF in patients with sickle cell anemia. The models were trained in 841 patients with sickle cell anemia and were tested in 3 independent cohorts. The ensemble of 14 models explained 23.4% of the variability in HbF in the discovery cohort, whereas the correlation between predicted and observed HbF in the 3 independent cohorts ranged between 0.28 and 0.44. The models included SNPs in BCL11A, the HBS1L-MYB intergenic region, and the site of the HBB gene cluster, quantitative trait loci previously associated with HbF.<br><br>&emsp;An ensemble of 14 genetic risk models can predict HbF levels with accuracy between 0.28 and 0.44, and the approach may also prove useful in other applications.\n <br><br> <b>MeSH terms:<\/b> <b>MeSH terms:<\/b> Adolescent; Anemia, Sickle Cell; Child; Child, Preschool; Cohort Studies; Female; Fetal Hemoglobin; Genetic Variation; Humans; Male; Middle Aged; Models, Genetic; Polymorphism, Single Nucleotide <br><br> <b>OMOP Concepts (IDs):<\/b>  Hemoglobin F (4339104); Sickle cell-hemoglobin SS disease (22281); Genetic variation (4271711); "]},"columns":[{"id":"details","name":"","type":"character","html":true}],"dataKey":"5fbbf710df5bdfeb4abfae3c2ec0572b","static":false,"nested":true},"children":[]}]},{"name":"div","attribs":{"style":{"padding":"1rem"}},"children":[{"name":"Reactable","attribs":{"data":{"details":["<b>DOI:<\/b> 10.1371/journal.pone.0091089 <br><br> Proinflammatory high-density lipoprotein (p-HDL) is a biomarker of cardiovascular disease. Sickle cell disease (SCD) is characterized by chronic states of oxidative stress that many consider to play a role in forming p-HDL. To measure p-HDL, apolipoprotein (apo) B containing lipoproteins are precipitated. Supernatant HDL is incubated with an oxidant/LDL or an oxidant alone and rates of HDL oxidation monitored with dichlorofluorescein (DCFH). Although apoB precipitation is convenient for isolating HDL, the resulting supernatant matrix likely influences HDL oxidation. To determine effects of supernatants on p-HDL measurements we purified HDL from plasma from SCD subjects by anion exchange (AE) chromatography, determined its rate of oxidation relative to supernatant HDL. SCD decreased total cholesterol but not triglycerides or HDL and increased cell-free (cf) hemoglobin (Hb) and xanthine oxidase (XO). HDL isolated by AE-HPLC had lower p-HDL levels than HDL in supernatants after apoB precipitation. XO+xanthine (X) and cf Hb accelerated purified HDL oxidation. Although the plate and AE-HPLC assays both showed p-HDL directly correlated with cf-Hb in SCD plasma, the plate assay yielded p-HDL data that was influenced more by cf-Hb than AE-HPLC generated p-HDL data. The AE-HPLC p-HDL assay reduces the influence of the supernatants and shows that SCD increases p-HDL.\n <br><br> <b>MeSH terms:<\/b> <b>MeSH terms:<\/b> Anemia, Sickle Cell; Animals; Anion Exchange Resins; Case-Control Studies; Cell-Free System; Cholesterol; Chromatography, High Pressure Liquid; Chromatography, Ion Exchange; Hemoglobins; Humans; Inflammation Mediators; Lipoproteins, HDL; Mice, Inbred C57BL; Online Systems; Oxidation-Reduction; Reference Standards; Triglycerides; Xanthine; Xanthine Oxidase <br><br> <b>OMOP Concepts (IDs):<\/b>  Cholesterol (19059097); High pressure liquid chromatography (4260441); Sickle cell-hemoglobin SS disease (22281); xanthine (42900552); "]},"columns":[{"id":"details","name":"","type":"character","html":true}],"dataKey":"fa206761a53f9ac2c7e8ca3d7b736fc7","static":false,"nested":true},"children":[]}]},{"name":"div","attribs":{"style":{"padding":"1rem"}},"children":[{"name":"Reactable","attribs":{"data":{"details":["<b>DOI:<\/b> 10.1371/journal.pone.0092297 <br><br> Mycoplasma salivarium belongs to the class of the smallest self-replicating Tenericutes and is predominantly found in the oral cavity of humans. In general it is considered as a non-pathogenic commensal. However, some reports point to an association with human diseases. M. salivarium was found e.g. as causative agent of a submasseteric abscess, in necrotic dental pulp, in brain abscess and clogged biliary stent. Here we describe the detection of M. salivarium on the surface of a squamous cell carcinoma of the tongue of a patient with Fanconi anaemia (FA). FA is an inherited bone marrow failure syndrome based on defective DNA-repair that increases the risk of carcinomas especially oral squamous cell carcinoma. Employing high coverage, massive parallel Roche/454-next-generation-sequencing of 16S rRNA gene amplicons we analysed the oral microbiome of this FA patient in comparison to that of an FA patient with a benign leukoplakia and five healthy individuals. The microbiota of the FA patient with leukoplakia correlated well with that of the healthy controls. A dominance of Streptococcus, Veillonella and Neisseria species was typically observed. In contrast, the microbiome of the cancer bearing FA patient was dominated by Pseudomonas aeruginosa at the healthy sites, which changed to a predominance of 98% M. salivarium on the tumour surface. Quantification of the mycoplasma load in five healthy, two tumour- and two leukoplakia-FA patients by TaqMan-PCR confirmed the prevalence of M. salivarium at the tumour sites. These new findings suggest that this mycoplasma species with its reduced coding capacity found ideal breeding grounds at the tumour sites. Interestingly, the oral cavity of all FA patients and especially samples at the tumour sites were in addition positive for Candida albicans. It remains to be elucidated in further studies whether M. salivarium can be used as a predictive biomarker for tumour development in these patients.\n <br><br> <b>MeSH terms:<\/b> <b>MeSH terms:<\/b> Adult; Carcinoma, Squamous Cell; Case-Control Studies; Fanconi Anemia; Genes, Bacterial; Humans; Male; Microbiota; Molecular Typing; Mouth; Mycoplasma Infections; Mycoplasma salivarium; RNA, Ribosomal, 16S; Retrospective Studies; Tongue Neoplasms <br><br> <b>OMOP Concepts (IDs):<\/b>  Neoplasm of tongue (4130375); Squamous cell carcinoma (4300118); Mycoplasma infection (436900); Fanconi's anemia (4148471); "]},"columns":[{"id":"details","name":"","type":"character","html":true}],"dataKey":"439533ce837b11a8dff9251f56c6b575","static":false,"nested":true},"children":[]}]},{"name":"div","attribs":{"style":{"padding":"1rem"}},"children":[{"name":"Reactable","attribs":{"data":{"details":["<b>DOI:<\/b> 10.1371/journal.pone.0092506 <br><br> Genetic variation at loci influencing adult levels of HbF have been shown to modify the clinical course of sickle cell disease (SCD). Data on this important aspect of SCD have not yet been reported from West Africa. We investigated the relationship between HbF levels and the relevant genetic loci in 610 patients with SCD (98% HbSS homozygotes) from Cameroon, and compared the results to a well-characterized African-American cohort.<br><br>&emsp;Socio-demographic and clinical features were collected and medical records reviewed. Only patients >5 years old, who had not received a blood transfusion or treatment with hydroxyurea were included. Hemoglobin electrophoresis and a full blood count were conducted upon arrival at the hospital. RFLP-PCR was used to describe the HBB gene haplotypes. SNaPshot PCR, Capillary electrophoresis and cycle sequencing were used for the genotyping of 10 selected SNPs. Genetic analysis was performed with PLINK software and statistical models in the statistical package R. Allele frequencies of relevant variants at BCL11A were similar to those detected in African Americans; although the relationships with Hb F were significant (p <.001), they explained substantially less of the variance in HbF than was observed among African Americans (∼ 2% vs 10%). SNPs in HBS1L-MYB region (HMIP) likewise had a significant impact on HbF, however, we did not find an association between HbF and the variations in HBB cluster and OR51B5/6 locus on chromosome 11p, due in part to the virtual absence of the Senegal and Indian Arab haplotypes. We also found evidence that selected SNPs in HBS1L-MYB region (HMIP) and BCL11A affect both other hematological indices and rates of hospitalization.<br><br>&emsp;This study has confirmed the associations of SNPs in BCL11A and HBS1L-MYB and fetal haemoglobin in Cameroonian SCA patients; hematological indices and hospitalization rates were also associated with specific allelic variants.\n <br><br> <b>MeSH terms:<\/b> <b>MeSH terms:<\/b> Adolescent; Adult; Black or African American; Anemia, Sickle Cell; Cameroon; Carrier Proteins; Child; Child, Preschool; Erythrocytes, Abnormal; Female; Fetal Hemoglobin; Follow-Up Studies; GTP-Binding Proteins; HSP70 Heat-Shock Proteins; Haplotypes; Hospitalization; Humans; Male; Middle Aged; Nuclear Proteins; Peptide Elongation Factors; Phenotype; Polymerase Chain Reaction; Polymorphism, Restriction Fragment Length; Polymorphism, Single Nucleotide; Prognosis; Proto-Oncogene Proteins c-myb; Repressor Proteins; Young Adult <br><br> <b>OMOP Concepts (IDs):<\/b>  Determination of prognosis (4069425); Hemoglobin F (4339104); Sickle cell-hemoglobin SS disease (22281); Phenotype (4215157); Inpatient care (4214577); "]},"columns":[{"id":"details","name":"","type":"character","html":true}],"dataKey":"39ee02012052a4c2b74ef6fbfbb0abb0","static":false,"nested":true},"children":[]}]},{"name":"div","attribs":{"style":{"padding":"1rem"}},"children":[{"name":"Reactable","attribs":{"data":{"details":["<b>DOI:<\/b> 10.1161/CIRCIMAGING.113.001420 <br><br> Cardiovascular disease is an important cause of morbidity and mortality in sickle cell disease (SCD). We sought to characterize sickle cell cardiomyopathy using multimodality noninvasive cardiovascular testing and identify potential causative mechanisms.<br><br>&emsp;Stable adults with SCD (n=38) and healthy controls (n=13) prospectively underwent same day multiparametric cardiovascular magnetic resonance (cine, T2* iron, vasodilator first pass myocardial perfusion, and late gadolinium enhancement imaging), transthoracic echocardiography, and applanation tonometry. Compared with controls, patients with SCD had severe dilation of the left ventricle (124±27 vs 79±12 mL/m(2)), right ventricle (127±28 vs 83±14 mL/m(2)), left atrium (65±16 vs 41±9 mL/m(2)), and right atrium (78±17 vs 56±17 mL/m(2); P<0.01 for all). Patients with SCD also had a 21% lower myocardial perfusion reserve index than control subjects (1.47±0.34 vs 1.87±0.37; P=0.034). A significant subset of patients with SCD (25%) had evidence of late gadolinium enhancement, whereas only 1 patient had evidence of myocardial iron overload. Diastolic dysfunction was present in 26% of patients with SCD compared with 8% in controls. Estimated filling pressures (E/e', 9.3±2.7 vs 7.3±2.0; P=0.0288) were higher in patients with SCD. Left ventricular dilation and the presence of late gadolinium enhancement were inversely correlated to hepatic T2* times (ie, hepatic iron overload because of frequent blood transfusions; P<0.05 for both), whereas diastolic dysfunction and increased filling pressures were correlated to aortic stiffness (augmentation pressure and index, P<0.05 for all).<br><br>&emsp;Sickle cell cardiomyopathy is characterized by 4-chamber dilation and in some patients myocardial fibrosis, abnormal perfusion reserve, diastolic dysfunction, and only rarely myocardial iron overload. Left ventricular dilation and myocardial fibrosis are associated with increased blood transfusion requirements, whereas left ventricular diastolic dysfunction is predominantly correlated with increased aortic stiffness.<br><br>&emsp;http://www.clinicaltrials.gov. Unique identifier: NCT01044901.\n <br><br> <b>MeSH terms:<\/b> <b>MeSH terms:<\/b> Adult; Anemia, Sickle Cell; Cardiomyopathies; Cohort Studies; Contrast Media; Echocardiography; Female; Gadolinium DTPA; Humans; Image Enhancement; Image Processing, Computer-Assisted; Male <br><br> <b>OMOP Concepts (IDs):<\/b>  Echocardiography (4230911); Cardiomyopathy (321319); Sickle cell-hemoglobin SS disease (22281); "]},"columns":[{"id":"details","name":"","type":"character","html":true}],"dataKey":"201c0897dea6ae10d689373a84b7d93a","static":false,"nested":true},"children":[]}]},{"name":"div","attribs":{"style":{"padding":"1rem"}},"children":[{"name":"Reactable","attribs":{"data":{"details":["<b>DOI:<\/b> 10.1371/journal.pone.0094387 <br><br> Adults with sickle cell disease(SCD) are a growing population. Recent national estimates of outcomes in acute chest syndrome(ACS) among adults with SCD are lacking. We describe the incidence, outcomes and predictors of mortality in ACS in adults. We hypothesize that any need for mechanical ventilation is an independent predictor of mortality.<br><br>&emsp;We performed a retrospective analysis of the Nationwide Inpatient Sample(2004-2010),the largest all payer inpatient database in United States, to estimate the incidence and outcomes of ACS needing mechanical ventilation(MV) and exchange transfusion(ET) in patients >21 years. The effects of MV and ET on outcomes including length of stay(LOS) and in-hospital mortality(IHM) were examined using multivariable linear and logistic regression models respectively. The effects of age, sex, race, type of sickle cell crisis, race, co-morbid burden, insurance status, type of admission, and hospital characteristics were adjusted in the regression models.<br><br>&emsp;Of the 24,699 hospitalizations, 4.6% needed MV(2.7% for <96 hours, 1.9% for ≥96 hours), 6% had ET, with a mean length of stay(LOS) of 7.8 days and an in-hospital mortality rate(IHM) of 1.6%. There was a gradual yearly increase in ACS hospitalizations that needed MV(2.6% in 2004 to 5.8% in 2010). Hb-SS disease was the phenotype in 84.3% of all hospitalizations. After adjusting for a multitude of patient and hospital related factors, patients who had MV for <96 hours(OR = 67.53,p<0.01) or those who had MV for ≥96 hours(OR = 8.73,p<0.01) were associated with a significantly higher odds for IHM when compared to their counterparts. Patients who had MV for ≥96 hours and those who had ET had a significantly longer LOS in-hospitals(p<0.001).<br><br>&emsp;In this large cohort of hospitalized adults with SCD patients with ACS, the need for mechanical ventilation predicted higher mortality rates and increased hospital resource utilization. Identification of risk factors may enable optimization of outcomes.\n <br><br> <b>MeSH terms:<\/b> <b>MeSH terms:<\/b> Acute Chest Syndrome; Adult; Anemia, Sickle Cell; Female; Humans; Incidence; Male; Multivariate Analysis; Regression Analysis; Respiration, Artificial; Retrospective Studies <br><br> <b>OMOP Concepts (IDs):<\/b>  Acute chest syndrome (254062); Sickle cell-hemoglobin SS disease (22281); Artificial respiration (4230167); "]},"columns":[{"id":"details","name":"","type":"character","html":true}],"dataKey":"56ceed322363162509ff6b7fd4128ada","static":false,"nested":true},"children":[]}]},{"name":"div","attribs":{"style":{"padding":"1rem"}},"children":[{"name":"Reactable","attribs":{"data":{"details":["<b>DOI:<\/b> 10.1371/journal.pone.0095563 <br><br> A decreased global autonomic nervous system (ANS) activity and increased sympathetic activation in patients with sickle cell anemia (SCA) seem to worsen the clinical severity and could play a role in the pathophysiology of the disease, notably by triggering vaso-occlusive crises. Because exercise challenges the ANS activity in the general population, we sought to determine whether a short (<15 min) and progressive moderate exercise session conducted until the first ventilatory threshold had an effect on the ANS activity of a group of SCA patients and a group of healthy individuals (CONT group). Temporal and spectral analyses of the nocturnal heart rate variability were performed before and on the 3 nights following the exercise session. Standard deviation of all normal RR intervals (SDNN), total power, low frequencies (LF) and high frequencies powers (HF) were lower but LF/HF was higher in SCA patients than in the CONT group. Moderate exercise did not modify ANS activity in both groups. In addition, no adverse clinical events occurred during the entire protocol. These results imply that this kind of short and moderate exercise is not detrimental for SCA patients.\n <br><br> <b>MeSH terms:<\/b> <b>MeSH terms:<\/b> Adult; Anemia, Sickle Cell; Autonomic Nervous System; Case-Control Studies; Exercise; Female; Heart Rate; Humans; Male; Middle Aged; Severity of Illness Index <br><br> <b>OMOP Concepts (IDs):<\/b>  Heart rate (4239408); Physical exercises (4084182); Sickle cell-hemoglobin SS disease (22281); "]},"columns":[{"id":"details","name":"","type":"character","html":true}],"dataKey":"bbab515acf2a8fdc1a4964d724ef6e76","static":false,"nested":true},"children":[]}]},{"name":"div","attribs":{"style":{"padding":"1rem"}},"children":[{"name":"Reactable","attribs":{"data":{"details":["<b>DOI:<\/b> 10.1371/journal.pone.0095086 <br><br> Previous studies showed a higher risk of maternal morbidity amongst black and other minority ethnic (BME) groups, but were unable to investigate whether this excess risk was concentrated within specific BME groups in the UK. Our aim was to analyse the specific risks and to investigate reasons for any disparity.<br><br>&emsp;Unmatched case-control analysis using data from the United Kingdom Obstetric Surveillance System (UKOSS), February 2005-January 2013. Cases were 1,753 women who experienced severe morbidity during the peripartum period. Controls were 3,310 women who delivered immediately before the cases in the same hospital. Multivariable logistic regression modelling was used to adjust for known confounders and to understand their effects.<br><br>&emsp;Compared with white European women, the odds of severe maternal morbidity were 83% higher among black African women (adjusted odds ratio (aOR) = 1.83; 95% Confidence Interval (CI) = 1.39-2.40), 80% higher among black Caribbean (aOR = 1.80; 95% CI = 1.14-2.82), 74% higher in Bangladeshi (aOR = 1.74; 95% CI = 1.05-2.88), 56% higher in other non-whites (non-Asian) (aOR = 1.56; 95% CI = 1.05-2.33) and 43% higher among Pakistani women (aOR = 1.43; 95% CI = 1.07-1.92). There was no evidence of substantial confounding. Anaemia in current pregnancy, previous pregnancy problems, inadequate utilisation of antenatal care, pre-existing medical conditions, parity>3, and being younger and older were independent risk factors but, the odds of severe maternal morbidity did not differ by socioeconomic status, between smokers and non-smokers or by BMI.<br><br>&emsp;This national study demonstrates an increased risk of severe maternal morbidity among women of ethnic minority backgrounds which could not be explained by known risk factors for severe maternal morbidity.\n <br><br> <b>MeSH terms:<\/b> <b>MeSH terms:<\/b> Adult; Age Factors; Anemia; Black People; Case-Control Studies; Female; Humans; Pregnancy; Pregnancy Complications, Hematologic; Risk Factors; Socioeconomic Factors; United Kingdom <br><br> <b>OMOP Concepts (IDs):<\/b>  Pregnant (4299535); Anemia (439777); "]},"columns":[{"id":"details","name":"","type":"character","html":true}],"dataKey":"fc7845d4dbf4c89802e6773807454382","static":false,"nested":true},"children":[]}]},{"name":"div","attribs":{"style":{"padding":"1rem"}},"children":[{"name":"Reactable","attribs":{"data":{"details":["<b>DOI:<\/b> 10.1371/journal.pone.0098202 <br><br> To compare the effect of tocilizumab (TCZ) with other biologic therapies in improving anemia of rheumatoid arthritis (RA) patients.<br><br>&emsp;We compared the change of hemoglobin (Hb) levels in a cohort of 147 consecutive RA patients who were treated with biologics for more than 12 weeks. Twenty eight patients were treated with TCZ, and 119 patients were treated with biologics other than TCZ (87 with TNF inhibitors and 32 with abatacept). The change of Hb levels from baseline to week 12 was compared between the TCZ and the non-TCZ groups. We performed univariate and multivariate analyses with adjustment of potential confounders such as baseline characteristics, concomitant treatment, and the clinical response to treatment.<br><br>&emsp;Hb levels generally increased after biologic therapies both in the TCZ and the non-TCZ groups. The increase of Hb levels was greater in the TCZ group than in the non-TCZ groups (1.1 g/dL in the TCZ group vs 0.3 g/dL in the non-TCZ group, p = 0.009). Univariate analysis revealed that increase of Hb levels was also significantly associated with lower Hb, higher Low Hemoglobin Density, and higher CRP levels at baseline and greater reduction in the clinical disease activity index. TCZ therapy was significantly associated with the increase of Hb levels even after adjustment for these factors by multivariate analysis (p<0.001, effect size 0.08-0.12).<br><br>&emsp;TCZ therapy is an independent factor associated with the increase of Hb level after biologic therapies in RA patients. It will help in selecting appropriate biologics for RA patients with anemia.\n <br><br> <b>MeSH terms:<\/b> <b>MeSH terms:<\/b> Adult; Aged; Aged, 80 and over; Anemia; Antibodies, Monoclonal, Humanized; Arthritis, Rheumatoid; Cohort Studies; Female; Hemoglobins; Humans; Immunotherapy; Male; Middle Aged; Receptors, Interleukin-6; Young Adult <br><br> <b>OMOP Concepts (IDs):<\/b>  Rheumatoid arthritis (80809); Immunological therapy (4295112); Anemia (439777); "]},"columns":[{"id":"details","name":"","type":"character","html":true}],"dataKey":"004aa9bf1d2b05555e4c321621fd1350","static":false,"nested":true},"children":[]}]},{"name":"div","attribs":{"style":{"padding":"1rem"}},"children":[{"name":"Reactable","attribs":{"data":{"details":["<b>DOI:<\/b> 10.1371/journal.pone.0099489 <br><br> The role of pulmonary hypertension as a cause of mortality in sickle cell disease (SCD) is controversial.<br><br>&emsp;We evaluated the relationship between an elevated estimated pulmonary artery systolic pressure and mortality in patients with SCD. We followed patients from the walk-PHaSST screening cohort for a median of 29 months. A tricuspid regurgitation velocity (TRV)≥ 3.0 m/s cuttof, which has a 67-75% positive predictive value for mean pulmonary artery pressure ≥ 25 mm Hg was used. Among 572 subjects, 11.2% had TRV ≥ 3.0 m/sec. Among 582 with a measured NT-proBNP, 24.1% had values ≥ 160 pg/mL. Of 22 deaths during follow-up, 50% had a TRV ≥ 3.0 m/sec. At 24 months the cumulative survival was 83% with TRV ≥ 3.0 m/sec and 98% with TRV < 3.0 m/sec (p < 0.0001). The hazard ratios for death were 11.1 (95% CI 4.1-30.1; p < 0.0001) for TRV ≥ 3.0 m/sec, 4.6 (1.8-11.3; p = 0.001) for NT-proBNP ≥ 160 pg/mL, and 14.9 (5.5-39.9; p < 0.0001) for both TRV ≥ 3.0 m/sec and NT-proBNP ≥ 160 pg/mL. Age > 47 years, male gender, chronic transfusions, WHO class III-IV, increased hemolytic markers, ferritin and creatinine were also associated with increased risk of death.<br><br>&emsp;A TRV ≥ 3.0 m/sec occurs in approximately 10% of individuals and has the highest risk for death of any measured variable. The study is registered in ClinicalTrials.gov with identifier: NCT00492531.\n <br><br> <b>MeSH terms:<\/b> <b>MeSH terms:<\/b> Adult; Anemia, Sickle Cell; Blood Flow Velocity; Blood Pressure; Cohort Studies; Creatinine; Female; Ferritins; Follow-Up Studies; Hemolysis; Humans; Hypertension, Pulmonary; Kaplan-Meier Estimate; Male; Middle Aged; Natriuretic Peptide, Brain; Peptide Fragments; Proportional Hazards Models; Risk Factors; Severity of Illness Index; United Kingdom; United States; Walking <br><br> <b>OMOP Concepts (IDs):<\/b>  Blood pressure (4326744); Creatinine (19071968); Sickle cell-hemoglobin SS disease (22281); Pulmonary hypertension (4322024); Nesiritide (1338985); "]},"columns":[{"id":"details","name":"","type":"character","html":true}],"dataKey":"a9dfbf96c28ff571863a8e843e9db7f1","static":false,"nested":true},"children":[]}]},{"name":"div","attribs":{"style":{"padding":"1rem"}},"children":[{"name":"Reactable","attribs":{"data":{"details":["<b>DOI:<\/b> 10.1016/j.jacc.2014.05.040 <br><br> Blood transfusion is controversial for anemic patients with acute myocardial infarction (AMI), with some previous studies reporting increased risk of transfusion-associated mortality.<br><br>&emsp;The goal of this study was to examine variability in blood transfusions across hospitals and the relationship between blood transfusion and in-hospital mortality in a large, contemporary cohort of consecutive AMI patients.<br><br>&emsp;Among 34,937 AMI hospitalizations from 57 centers, patients receiving at least 1 packed red blood cell transfusion were compared with those who were not transfused. Using 45 disease severity, comorbidity, laboratory, and in-hospital treatment variables, we propensity matched patients who did and did not receive a packed red blood cell transfusion. A conditional logistic regression model was used to identify the association between transfusion and in-hospital mortality.<br><br>&emsp;A total of 1,778 patients (5.1%) had at least 1 transfusion. In unadjusted analyses, transfusion was associated with higher in-hospital mortality (odds ratio: 2.05 [95% confidence interval: 1.76 to 2.40]). The vast majority of patients (91.1%) with and without transfusion had nonoverlapping propensity scores, reflecting incomparable clinical profiles. Thus, they were excluded from the propensity-matched analyses. After propensity matching those with overlapping scores, blood transfusion was associated with a reduced risk of in-hospital death (odds ratio: 0.73 [95% confidence interval: 0.58 to 0.92]).<br><br>&emsp;The majority of patients undergoing blood transfusion in clinical practice cannot be matched with nontransfused patients due to their markedly different clinical profiles. Among comparable patients, blood transfusion was associated with a lower risk of in-hospital mortality. These findings suggest that previous observational reports of increased mortality with transfusion may have been influenced by selection bias, and they highlight the need for randomized trials to establish the role of transfusion during AMI.\n <br><br> <b>MeSH terms:<\/b> <b>MeSH terms:<\/b> Aged; Aged, 80 and over; Anemia; Blood Transfusion; Female; Humans; Male; Middle Aged; Myocardial Infarction; Patient Admission; United States <br><br> <b>OMOP Concepts (IDs):<\/b>  Transfusion of blood product (4024656); Myocardial infarction (4329847); Anemia (439777); "]},"columns":[{"id":"details","name":"","type":"character","html":true}],"dataKey":"cc1ea067516115b3be8d9711f0ea2350","static":false,"nested":true},"children":[]}]},{"name":"div","attribs":{"style":{"padding":"1rem"}},"children":[{"name":"Reactable","attribs":{"data":{"details":["<b>DOI:<\/b> 10.1016/j.jacc.2014.05.041 <br><br> \n <br><br> <b>MeSH terms:<\/b> <b>MeSH terms:<\/b> Anemia; Blood Transfusion; Female; Humans; Male; Myocardial Infarction <br><br> <b>OMOP Concepts (IDs):<\/b>  Transfusion of blood product (4024656); Myocardial infarction (4329847); Anemia (439777); "]},"columns":[{"id":"details","name":"","type":"character","html":true}],"dataKey":"21e8c7a986d43e46e907c885fd95e3c2","static":false,"nested":true},"children":[]}]},{"name":"div","attribs":{"style":{"padding":"1rem"}},"children":[{"name":"Reactable","attribs":{"data":{"details":["<b>DOI:<\/b> 10.1371/journal.pone.0107297 <br><br> Anemia refers to low hemoglobin (Hb) levels, represents a common symptom and complication in cancer patients and was reported to negatively influence survival in patients with various malignancies. In the present study, we aimed to explore the prognostic impact of pre-operative Hb levels on clinical outcome in a large cohort of soft tissue sarcoma (STS) patients after curative surgery.<br><br>&emsp;Retrospective data from 367 STS patients, which were operated between 1998 and 2013, were included in the study. Cut-off levels for anemia were defined as Hb<13 g/dl in males and Hb<12 g/dl in females according to the current WHO guidelines. The impact of pre-operative Hb levels on cancer-specific survival (CSS) and overall survival (OS) was assessed using Kaplan-Meier curves. Additionally, Hb levels were compared for the prognostic influence on CSS and OS applying univariate and multivariate Cox proportional models.<br><br>&emsp;Hb level was associated with established prognostic factors, including age, tumor grade, size and depth (p<0.05). Kaplan-Meier curves showed that low Hb levels were significantly associated with decreased CSS and OS in STS patients (p<0.001 for both endpoints, log-rank test). In multivariate analysis, we found an independent association between low Hb levels and poor CSS and OS (HR = 0.46, Cl 95% = 0.25-0.85, p = 0.012; HR = 0.34, Cl 95% = 0.23-0.51, p<0.001).<br><br>&emsp;The present data underline a negative prognostic impact of low pre-operative Hb levels on clinical outcome in STS patients. Thus, Hb levels may provide an additional and cost-effective tool to discriminate between STS patients that are at high risk of mortality.\n <br><br> <b>MeSH terms:<\/b> <b>MeSH terms:<\/b> Age Factors; Aged; Anemia; Biomarkers; Female; Hemoglobins; Humans; Male; Middle Aged; Neoplasm Grading; Prognosis; Proportional Hazards Models; Retrospective Studies; Sarcoma; Survival Analysis <br><br> <b>OMOP Concepts (IDs):<\/b>  Determination of prognosis (4069425); Anemia (439777); Sarcoma (4311439); "]},"columns":[{"id":"details","name":"","type":"character","html":true}],"dataKey":"d39510c7040f06c6af21c477449fefe0","static":false,"nested":true},"children":[]}]},{"name":"div","attribs":{"style":{"padding":"1rem"}},"children":[{"name":"Reactable","attribs":{"data":{"details":["<b>DOI:<\/b> 10.1371/journal.pone.0106103 <br><br> Anaemia is a common clinical finding in HIV infected women and has been associated with advanced disease. The use of antiretroviral drugs such as Zidovudine (ZDV) either for prevention of mother to child transmission (MTCT) of HIV or used in combination with other antiretrovirals have been implicated in the development or increased severity of anaemia. We report the prevalence, type, severity and incidence of anaemia in a cohort of HIV infected women who initiated antiretroviral prophylaxis or treatment during pregnancy.<br><br>&emsp;This is a retrospective cohort data analysis of 408 HIV infected pregnant women who participated in a breastfeeding intervention study (HPTN 046 Study, ClinicalTrials.gov NCT 00074412) in South Africa. Women initiated zidovudine prophylaxis for PMTCT or triple antiretroviral treatment in pregnancy according to the standard of care. Laboratory and clinical data in pregnancy, <72 hours and 2 weeks postdelivery were extracted from the main database and analysed.<br><br>&emsp;The mean Hb concentration was 10.6 g/dL at baseline and 262/408 (64.2%) women were diagnosed with anaemia (Hb<11 g/dL) in pregnancy, 48/146 (32.9%) subsequently developed anaemia intrapartum or postpartum and 89/310 (28.7%) of all cases of anaemia remained unresolved by 2 weeks postdelivery. In a univariate analysis, CD4 count and gravidity were significant risk factors for anaemia in pregnancy, RR 1.41; 1.23-1.61 (p<0.001) and 1.10; 1.01-1.18 (p = 0.02) respectively. After adjusting for antiretroviral regimen, age and gravidity in a multivariable analysis, only the CD4 count remains a significant risk factor for anaemia in pregnancy and postdelivery.<br><br>&emsp;In conclusion, anaemia was most common among women in the advanced stage of HIV infection (CD4<200 cells/mm3). There was no evidence of an association between ZDV or triple ARVs and anaemia.\n <br><br> <b>MeSH terms:<\/b> <b>MeSH terms:<\/b> Anemia; Anti-HIV Agents; CD4 Lymphocyte Count; Disease Progression; Female; HIV Infections; Humans; Incidence; Multivariate Analysis; Pregnancy; Pregnancy Complications, Hematologic; Prevalence; Retrospective Studies; Risk Factors; South Africa; Urinary Tract Infections; Zidovudine <br><br> <b>OMOP Concepts (IDs):<\/b>  Pregnant (4299535); Human immunodeficiency virus infection (439727); Urinary tract infectious disease (81902); Anemia (439777); Zidovudine (1710612); "]},"columns":[{"id":"details","name":"","type":"character","html":true}],"dataKey":"4d01a28c256540b478406d3b72482b2d","static":false,"nested":true},"children":[]}]},{"name":"div","attribs":{"style":{"padding":"1rem"}},"children":[{"name":"Reactable","attribs":{"data":{"details":["<b>DOI:<\/b> 10.1371/journal.pone.0108922 <br><br> The 6-minute walk test (6 MWT) is used in adults and children affected by a wide range of chronic diseases to evaluate their sub-maximal exercise capacity. It reflects the global response of various physiological systems in a situation simulating a daily life activity.<br><br>&emsp;We analyzed factors affecting the 6 MWT in 46 Sickle Cell Disease children. Forty-two were treated with hydroxyurea (HU). Patients with normal test (>80% of the age-standardized predicted value) were compared to patients with abnormal test (≤ 80%). Baseline hematological values, clinical events, cerebrovascular disease, cardio-pulmonary parameters and disease-modifying treatment were compared according to the performance of the test.<br><br>&emsp;Among the 46 patients, 14 had an abnormal 6 MWT. In univariate analysis, both groups were similar for biological and clinical data. Six of the 14 patients with an abnormal 6 MWT had silent infarct (SI) compared to 6/32 with a normal test (P = 0.09). When excluding chronically transfused patients, 4 of the 11 patients with an abnormal 6 MWT had SI compared to 1/26 (P = 0.02). Baseline pulse oximetry was normal in both groups but slightly lower in patients with abnormal 6 MWT (P = 0.02). No patient presented exercise-induced desaturation. In multivariate analysis, the only factor associated with abnormal 6 MWT was the presence of SI (P = 0.045).<br><br>&emsp;In our cohort of 46 patients characterized by high exposure rate to HU and by the absence of severe cardiopulmonary disease, the sole factor independently associated with 6 MWT was the presence of SI. The lower exercise capacity of children with SI may reflect some subclinical neurological impairment as they do not differ by hemoglobin level or cardiopulmonary parameters.\n <br><br> <b>MeSH terms:<\/b> <b>MeSH terms:<\/b> Anemia, Sickle Cell; Belgium; Child; Cross-Sectional Studies; Female; Humans; Male; Myocardial Infarction; Time Factors; Walking <br><br> <b>OMOP Concepts (IDs):<\/b>  Sickle cell-hemoglobin SS disease (22281); Myocardial infarction (4329847); "]},"columns":[{"id":"details","name":"","type":"character","html":true}],"dataKey":"4f1a3dc64aed7d33b6d556dc399257c6","static":false,"nested":true},"children":[]}]},{"name":"div","attribs":{"style":{"padding":"1rem"}},"children":[{"name":"Reactable","attribs":{"data":{"details":["<b>DOI:<\/b> 10.1371/journal.pone.0108400 <br><br> Sickle cell anemia and thalassemia result in impaired bone health in both adults and youths. Children with other types of chronic hemolytic anemia may also display impaired bone health.<br><br>&emsp;To assess bone health in pediatric patients with chronic hemolytic anemia, a cross-sectional study was conducted involving 45 patients with different forms of hemolytic anemia (i.e., 17 homozygous sickle cell disease and 14 hereditary spherocytosis patients). Biochemical, radiographic and anamnestic parameters of bone health were assessed.<br><br>&emsp;Vitamin D deficiency with 25 OH-vitamin D serum levels below 20 ng/ml was a common finding (80.5%) in this cohort. Bone pain was present in 31% of patients. Analysis of RANKL, osteoprotegerin (OPG) and osteocalcin levels indicated an alteration in bone modeling with significantly elevated RANKL/OPG ratios (control: 0.08+0.07; patients: 0.26+0.2, P = 0.0007). Osteocalcin levels were found to be lower in patients compared with healthy controls (68.5+39.0 ng/ml vs. 118.0+36.6 ng/ml, P = 0.0001). Multiple stepwise regression analysis revealed a significant (P<0.025) influence of LDH (partial r2 = 0.29), diagnosis of hemolytic anemia (partial r2 = 0.05) and age (partial r2 = 0.03) on osteocalcin levels. Patients with homozygous sickle cell anemia were more frequently and more severely affected by impaired bone health than patients with hereditary spherocytosis.<br><br>&emsp;Bone health is impaired in pediatric patients with hemolytic anemia. In addition to endocrine alterations, an imbalance in the RANKL/OPG system and low levels of osteocalcin may contribute to this impairment.\n <br><br> <b>MeSH terms:<\/b> <b>MeSH terms:<\/b> Adolescent; Anemia, Hemolytic; Bone Density; Bone and Bones; Case-Control Studies; Child; Child, Preschool; Cross-Sectional Studies; Female; Humans; Infant; Infant, Newborn; Male; Osteocalcin; Osteoprotegerin; RANK Ligand <br><br> <b>OMOP Concepts (IDs):<\/b>  Hemolytic anemia (435503); "]},"columns":[{"id":"details","name":"","type":"character","html":true}],"dataKey":"df61b39355d68394ad856403e26a1f91","static":false,"nested":true},"children":[]}]},{"name":"div","attribs":{"style":{"padding":"1rem"}},"children":[{"name":"Reactable","attribs":{"data":{"details":["<b>DOI:<\/b> 10.1371/journal.pone.0110740 <br><br> Hydroxyurea has proven efficacy in children and adults with sickle cell anemia (SCA), but with considerable inter-individual variability in the amount of fetal hemoglobin (HbF) produced. Sibling and twin studies indicate that some of that drug response variation is heritable. To test the hypothesis that genetic modifiers influence pharmacological induction of HbF, we investigated phenotype-genotype associations using whole exome sequencing of children with SCA treated prospectively with hydroxyurea to maximum tolerated dose (MTD). We analyzed 171 unrelated patients enrolled in two prospective clinical trials, all treated with dose escalation to MTD. We examined two MTD drug response phenotypes: HbF (final %HbF minus baseline %HbF), and final %HbF. Analyzing individual genetic variants, we identified multiple low frequency and common variants associated with HbF induction by hydroxyurea. A validation cohort of 130 pediatric sickle cell patients treated to MTD with hydroxyurea was genotyped for 13 non-synonymous variants with the strongest association with HbF response to hydroxyurea in the discovery cohort. A coding variant in Spalt-like transcription factor, or SALL2, was associated with higher final HbF in this second independent replication sample and SALL2 represents an outstanding novel candidate gene for further investigation. These findings may help focus future functional studies and provide new insights into the pharmacological HbF upregulation by hydroxyurea in patients with SCA.\n <br><br> <b>MeSH terms:<\/b> <b>MeSH terms:<\/b> Anemia, Sickle Cell; Child; Cohort Studies; DNA-Binding Proteins; Dose-Response Relationship, Drug; Exome; Fetal Hemoglobin; Genomics; Humans; Hydroxyurea; Maximum Tolerated Dose; Open Reading Frames; Phenotype; Prospective Studies; Sequence Analysis, DNA; Transcription Factors; Treatment Outcome <br><br> <b>OMOP Concepts (IDs):<\/b>  Hemoglobin F (4339104); Sickle cell-hemoglobin SS disease (22281); hydroxyurea (1377141); Phenotype (4215157); "]},"columns":[{"id":"details","name":"","type":"character","html":true}],"dataKey":"eecfb73f15b087b9ca4e6cb4b776b662","static":false,"nested":true},"children":[]}]},{"name":"div","attribs":{"style":{"padding":"1rem"}},"children":[{"name":"Reactable","attribs":{"data":{"details":["<b>DOI:<\/b> 10.1371/journal.pone.0114192 <br><br> Studies report frequent micronutrient deficiencies after bariatric surgery, but less is known about micronutrient levels of pregnant women after bariatric surgery.<br><br>&emsp;To prospectively evaluate micronutrient levels and supplement intake in pregnancy following bariatric surgery.<br><br>&emsp;A multicenter prospective cohort study including women with restrictive or malabsorptive types of bariatric surgery. Nutritional deficiencies, together with supplement intake, were screened during pregnancy.<br><br>&emsp;The total population included 18 women in the restrictive and 31 in the malabsorptive group. Most micronutrients were depleted and declined significantly during pregnancy. The proportion of women with low vitamin A and B-1 levels increased to respectively 58 and 17% at delivery (P = 0.005 and 0.002). The proportion of women with vitamin D deficiency decreased from 14% at trimester 1 to 6% at delivery (P = 0.030). Mild anemia was found in respectively 22 and 40% of the women at trimester 1 and delivery. In the first trimester, most women took a multivitamin (57.1%). In the second and third trimester, the majority took additional supplements (69.4 and 73.5%). No associations were found between supplement intake and micronutrient deficiencies.<br><br>&emsp;Pregnant women with bariatric surgery show frequent low micronutrient levels. Supplementation partially normalizes low levels of micronutrients.\n <br><br> <b>MeSH terms:<\/b> <b>MeSH terms:<\/b> Adolescent; Adult; Anemia; Bariatric Surgery; Cholecalciferol; Cohort Studies; Dietary Supplements; Female; Folic Acid; Humans; Micronutrients; Obesity; Pregnancy; Pregnancy Complications; Pregnancy Trimester, Third; Prospective Studies; Vitamin A; Vitamin B 12; Vitamin D Deficiency; Vitamins; Young Adult <br><br> <b>OMOP Concepts (IDs):<\/b>  Vitamin B 12 (1308738); Pregnant (4299535); Folic Acid (19111620); Vitamin D deficiency (436070); Complication occurring during pregnancy (43530950); Vitamin A (19008339); Cholecalciferol (19095164); Third trimester pregnancy (4218813); Anemia (439777); Obesity (433736); "]},"columns":[{"id":"details","name":"","type":"character","html":true}],"dataKey":"cc48e473709acfe93d0c22c25d36acc4","static":false,"nested":true},"children":[]}]},{"name":"div","attribs":{"style":{"padding":"1rem"}},"children":[{"name":"Reactable","attribs":{"data":{"details":["<b>DOI:<\/b> 10.1371/journal.pone.0114309 <br><br> A seeming paradox of sickle cell disease is that patients do not suffer from a high prevalence of systemic hypertension in spite of endothelial dysfunction, chronic inflammation and vasculopathy. However, some patients do develop systolic hypertension and increased pulse pressure, an increasingly recognized major cardiovascular risk factor in other populations. Hence, we hypothesized that pulse pressure, unlike other blood pressure parameters, is independently associated with markers of hemolytic anemia and cardiovascular risk in sickle cell disease. We analyzed the correlates of pulse pressure in patients (n  =  661) enrolled in a multicenter international sickle cell trial. Markers of hemolysis were analyzed as independent variables and as a previously validated hemolytic index that includes multiple variables. We found that pulse pressure, not systolic, diastolic or mean arterial pressure, independently correlated with high reticulocyte count (beta  =  2.37, p  =  0.02) and high hemolytic index (beta  =  1.53, p = 0.002) in patients with homozygous sickle cell disease in two multiple linear regression models which include the markers of hemolysis as independent variables or the hemolytic index, respectively. Pulse pressure was also independently associated with elevated serum creatinine (beta  =  3.21, p  =  0.02), and with proteinuria (beta  =  2.52, p  =  0.04). These results from the largest sickle cell disease cohort to date since the Cooperative Study of Sickle Cell Disease show that pulse pressure is independently associated with hemolysis, proteinuria and chronic kidney disease. We propose that high pulse pressure may be a risk factor for clinical complications of vascular dysfunction in sickle cell disease. Longitudinal and mechanistic studies should be conducted to confirm these hypotheses.\n <br><br> <b>MeSH terms:<\/b> <b>MeSH terms:<\/b> Adolescent; Adult; Anemia, Sickle Cell; Biomarkers; Blood Pressure; Child; Female; Hemolysis; Humans; Male; Middle Aged; Proteinuria; Renal Insufficiency, Chronic <br><br> <b>OMOP Concepts (IDs):<\/b>  Blood pressure (4326744); Proteinuria (75650); Chronic renal insufficiency (36716947); Sickle cell-hemoglobin SS disease (22281); "]},"columns":[{"id":"details","name":"","type":"character","html":true}],"dataKey":"2d063a9acb5d7ca1c12d2f45eea38e5d","static":false,"nested":true},"children":[]}]},{"name":"div","attribs":{"style":{"padding":"1rem"}},"children":[{"name":"Reactable","attribs":{"data":{"details":["<b>DOI:<\/b> 10.1371/journal.pone.0114846 <br><br> Anemia and renal impairment are important co-morbidities among patients with coronary artery disease undergoing Percutaneous Coronary Intervention (PCI). Disease progression to eventual death can be understood as the combined effect of baseline characteristics and intermediate outcomes.<br><br>&emsp;Using data from a prospective cohort study, we investigated clinical pathways reflecting the transitions from PCI through intermediate ischemic or hemorrhagic events to all-cause mortality in a multi-state analysis as a function of anemia (hemoglobin concentration <120 g/l and <130 g/l, for women and men, respectively) and renal impairment (creatinine clearance <60 ml/min) at baseline.<br><br>&emsp;Among 6029 patients undergoing PCI, anemia and renal impairment were observed isolated or in combination in 990 (16.4%), 384 (6.4%), and 309 (5.1%) patients, respectively. The most frequent transition was from PCI to death (6.7%, 95% CI 6.1-7.3), followed by ischemic events (4.8%, 95 CI 4.3-5.4) and bleeding (3.4%, 95% CI 3.0-3.9). Among patients with both anemia and renal impairment, the risk of death was increased 4-fold as compared to the reference group (HR 3.9, 95% CI 2.9-5.4) and roughly doubled as compared to patients with either anemia (HR 1.7, 95% CI 1.3-2.2) or renal impairment (HR 2.1, 95% CI 1.5-2.9) alone. Hazard ratios indicated an increased risk of bleeding in all three groups compared to patients with neither anemia nor renal impairment.<br><br>&emsp;Applying a multi-state model we found evidence for a gradient of risk for the composite of bleeding, ischemic events, or death as a function of hemoglobin value and estimated glomerular filtration rate at baseline.\n <br><br> <b>MeSH terms:<\/b> <b>MeSH terms:<\/b> Aged; Anemia; Coronary Artery Disease; Female; Follow-Up Studies; Glomerular Filtration Rate; Hemoglobins; Humans; Male; Middle Aged; Percutaneous Coronary Intervention; Prognosis; Prospective Studies; Renal Insufficiency; Risk Assessment; Risk Factors; Survival Rate <br><br> <b>OMOP Concepts (IDs):<\/b>  Disorder of coronary artery (4187067); Determination of prognosis (4069425); Renal impairment (4030518); Risk assessment (4024612); Percutaneous coronary intervention (4216130); Anemia (439777); "]},"columns":[{"id":"details","name":"","type":"character","html":true}],"dataKey":"0b5acee9d019ff94d45b10acfb9419cc","static":false,"nested":true},"children":[]}]},{"name":"div","attribs":{"style":{"padding":"1rem"}},"children":[{"name":"Reactable","attribs":{"data":{"details":["<b>DOI:<\/b> 10.1371/journal.pone.0114540 <br><br> Although simple and low-cost interventions for sickle cell disease (SCD) exist in many developing countries, child mortality associated with SCD remains high, in part, because of the lack of access to diagnostic tests for SCD. A density-based test using aqueous multiphase systems (SCD-AMPS) is a candidate for a low-cost, point-of-care diagnostic for SCD. In this paper, the field evaluation of SCD-AMPS in a large (n = 505) case-control study in Zambia is described. Of the two variations of the SCD-AMPS used, the best system (SCD-AMPS-2) demonstrated a sensitivity of 86% (82-90%) and a specificity of 60% (53-67%). Subsequent analysis identified potential sources of false positives that include clotting, variation between batches of SCD-AMPS, and shipping conditions. Importantly, SCD-AMPS-2 was 84% (62-94%) sensitive in detecting SCD in children between 6 months and 1 year old. In addition to an evaluation of performance, an assessment of end-user operability was done with health workers in rural clinics in Zambia. These health workers rated the SCD-AMPS tests to be as simple to use as lateral flow tests for malaria and HIV.\n <br><br> <b>MeSH terms:<\/b> <b>MeSH terms:<\/b> Adolescent; Anemia, Sickle Cell; Cell Count; Child; Child, Preschool; Data Collection; Diagnostic Tests, Routine; Erythrocytes; Female; Health Personnel; Humans; Infant; Male; Rural Health Services; Specimen Handling; Time Factors; Volatilization; Zambia <br><br> <b>OMOP Concepts (IDs):<\/b>  Cell count (4038498); Sickle cell-hemoglobin SS disease (22281); Specimen processing (4243140); "]},"columns":[{"id":"details","name":"","type":"character","html":true}],"dataKey":"e1bb285fe25be319562529bfdf744c3f","static":false,"nested":true},"children":[]}]},{"name":"div","attribs":{"style":{"padding":"1rem"}},"children":[{"name":"Reactable","attribs":{"data":{"details":["<b>DOI:<\/b> 10.1371/journal.pone.0114412 <br><br> We compared the blood thixotropic/shear-thinning properties and the red blood cells' (RBC) rheological properties between a group of patients with sickle cell anaemia (SS) and healthy individuals (AA). Blood thixotropy was determined by measuring blood viscosity with a capillary viscometer using a \"loop\" protocol: the shear rate started at 1 s-1 and increased progressively to 922 s-1 and then re-decreased to the initial shear rate. Measurements were performed at native haematocrit for the two groups and at 25% and 40% haematocrit for the AA and SS individuals, respectively. RBC deformability was determined by ektacytometry and RBC aggregation properties by laser backscatter versus time. AA at native haematocrit had higher blood thixotropic index than SS at native haematocrit and AA at 25% haematocrit. At 40% haematocrit, SS had higher blood thixotropic index than AA. While RBC deformability and aggregation were lower in SS than in AA, the strength of RBC aggregates was higher in the former population. Our results showed that 1) anaemia is the main modulator of blood thixtropy and 2) the low RBC deformability and high RBC aggregates strength cause higher blood thixotropy in SS patients than in AA individuals at 40% haematocrit, which could impact blood flow in certain vascular compartments.\n <br><br> <b>MeSH terms:<\/b> <b>MeSH terms:<\/b> Anemia, Sickle Cell; Case-Control Studies; Erythrocyte Aggregation; Erythrocyte Deformability; Erythrocytes; Hematocrit; Hemorheology; Humans <br><br> <b>OMOP Concepts (IDs):<\/b>  Sickle cell-hemoglobin SS disease (22281); Hematocrit determination (4151358); "]},"columns":[{"id":"details","name":"","type":"character","html":true}],"dataKey":"f00d3357692f1ab4c08668a27f3264ea","static":false,"nested":true},"children":[]}]},{"name":"div","attribs":{"style":{"padding":"1rem"}},"children":[{"name":"Reactable","attribs":{"data":{"details":["<b>DOI:<\/b> 10.1371/journal.pone.0115096 <br><br> Iron overload used to be considered rare among hemodialysis patients after the advent of erythropoesis-stimulating agents, but recent MRI studies have challenged this view. The aim of this study, based on decision-tree learning and on MRI determination of hepatic iron content, was to identify a noxious pattern of parenteral iron administration in hemodialysis patients.<br><br>&emsp;We performed a prospective cross-sectional study from 31 January 2005 to 31 August 2013 in the dialysis centre of a French community-based private hospital. A cohort of 199 fit hemodialysis patients free of overt inflammation and malnutrition were treated for anemia with parenteral iron-sucrose and an erythropoesis-stimulating agent (darbepoetin), in keeping with current clinical guidelines. Patients had blinded measurements of hepatic iron stores by means of T1 and T2* contrast MRI, without gadolinium, together with CHi-squared Automatic Interaction Detection (CHAID) analysis.<br><br>&emsp;The CHAID algorithm first split the patients according to their monthly infused iron dose, with a single cutoff of 250 mg/month. In the node comprising the 88 hemodialysis patients who received more than 250 mg/month of IV iron, 78 patients had iron overload on MRI (88.6%, 95% CI: 80% to 93%). The odds ratio for hepatic iron overload on MRI was 3.9 (95% CI: 1.81 to 8.4) with >250 mg/month of IV iron as compared to <250 mg/month. Age, gender (female sex) and the hepcidin level also influenced liver iron content on MRI.<br><br>&emsp;The standard maximal amount of iron infused per month should be lowered to 250 mg in order to lessen the risk of dialysis iron overload and to allow safer use of parenteral iron products.\n <br><br> <b>MeSH terms:<\/b> <b>MeSH terms:<\/b> Adult; Aged; Aged, 80 and over; Anemia; Cross-Sectional Studies; Darbepoetin alfa; Decision Support Techniques; Decision Trees; Female; Hematinics; Humans; Infusions, Parenteral; Iron; Iron Overload; Liver; Magnetic Resonance Imaging; Male; Middle Aged; Prospective Studies; Renal Dialysis; Young Adult <br><br> <b>OMOP Concepts (IDs):<\/b>  darbepoetin alfa (1304643); Renal dialysis (4146536); Magnetic resonance imaging (4013636); Iron overload (4246084); Anemia (439777); Iron (1360067); "]},"columns":[{"id":"details","name":"","type":"character","html":true}],"dataKey":"00656532896786fe82f8938fa1c608e7","static":false,"nested":true},"children":[]}]},{"name":"div","attribs":{"style":{"padding":"1rem"}},"children":[{"name":"Reactable","attribs":{"data":{"details":["<b>DOI:<\/b> 10.1371/journal.pone.0114061 <br><br> The common differential diagnosis of microcytic anemia in young Asian men includes iron deficiency anemia (IDA), α-thalassemia (αT) and β-thalassemia (βT). In this study, we aimed to distinguish between these diseases in a distinct population of young men using a specific index.<br><br>&emsp;We retrospectively reviewed the laboratory data of young men with microcytic anemia. The clinical, characteristic and laboratory data, including complete blood cell counts, serum ferritin and hemoglobin electrophoresis results, were collected; genomic DNA mutations were also evaluated. Based on these data, ten discrimination indices were used to differentiate thalassemia from IDA. The sensitivity, specificity, positive and negative predictive values, Youden's index and receiver operating characteristic (ROC) curves were also calculated.<br><br>&emsp;A total of 877 patients (92 patients with IDA, 332 with αT and 453 with βT) were enrolled; the Shine and Lal (S&L) formula was the best method with which to discriminate IDA from thalassemia (100% sensitivity, 91% specificity). The new cut-off values were evaluated, and the approaches used in our study cohort, particularly the Green & King (G&K) formula, significantly increased the accuracies of red cell distribution width-containing indices (cut-off value: 58.66; 89.62% sensitivity and 96.2% specificity; AUC: 0.9716). In addition, when applied properly, these indices could differentiate IDA patients from αT patients, especially Huber-Herklotz index (HH).<br><br>&emsp;The sensitivity and specificity differed among ethnic and age groups. We concluded that when using the original cut-off value, the S&L formula was the best discriminating index for differentiating between IDA and thalassemia in young Asian men. However, when using the G&K formula, the newly obtained cut-off value must be applied to increase accuracy based on the results from our cohort.\n <br><br> <b>MeSH terms:<\/b> <b>MeSH terms:<\/b> Adolescent; Adult; Anemia; Cohort Studies; Diagnosis, Differential; Female; Humans; Male; Military Personnel; Retrospective Studies; Young Adult <br><br> <b>OMOP Concepts (IDs):<\/b>  Anemia (439777); "]},"columns":[{"id":"details","name":"","type":"character","html":true}],"dataKey":"41e40bb28e0cd3a91ebec0b00169a507","static":false,"nested":true},"children":[]}]},{"name":"div","attribs":{"style":{"padding":"1rem"}},"children":[{"name":"Reactable","attribs":{"data":{"details":["<b>DOI:<\/b> 10.1371/journal.pone.0117383 <br><br> The tolerability of oral iron supplementation for the treatment of iron deficiency anemia is disputed.<br><br>&emsp;Our aim was to quantify the odds of GI side-effects in adults related to current gold standard oral iron therapy, namely ferrous sulfate.<br><br>&emsp;Systematic review and meta-analysis of randomized controlled trials (RCTs) evaluating GI side-effects that included ferrous sulfate and a comparator that was either placebo or intravenous (i.v.) iron. Random effects meta-analysis modelling was undertaken and study heterogeneity was summarised using I2 statistics.<br><br>&emsp;Forty three trials comprising 6831 adult participants were included. Twenty trials (n = 3168) had a placebo arm and twenty three trials (n = 3663) had an active comparator arm of i.v. iron. Ferrous sulfate supplementation significantly increased risk of GI side-effects versus placebo with an odds ratio (OR) of 2.32 [95% CI 1.74-3.08, p<0.0001, I2 = 53.6%] and versus i.v. iron with an OR of 3.05 [95% CI 2.07-4.48, p<0.0001, I2 = 41.6%]. Subgroup analysis in IBD patients showed a similar effect versus i.v. iron (OR = 3.14, 95% CI 1.34-7.36, p = 0.008, I2 = 0%). Likewise, subgroup analysis of pooled data from 7 RCTs in pregnant women (n = 1028) showed a statistically significant increased risk of GI side-effects for ferrous sulfate although there was marked heterogeneity in the data (OR = 3.33, 95% CI 1.19-9.28, p = 0.02, I2 = 66.1%). Meta-regression did not provide significant evidence of an association between the study OR and the iron dose.<br><br>&emsp;Our meta-analysis confirms that ferrous sulfate is associated with a significant increase in gastrointestinal-specific side-effects but does not find a relationship with dose.\n <br><br> <b>MeSH terms:<\/b> <b>MeSH terms:<\/b> Anemia, Iron-Deficiency; Clinical Trials as Topic; Databases, Factual; Dietary Supplements; Ferrous Compounds; Gastrointestinal Diseases; Humans; Odds Ratio; Placebo Effect <br><br> <b>OMOP Concepts (IDs):<\/b>  Clinical trial (4002165); Disorder of gastrointestinal tract (4000610); Iron deficiency anemia (436659); "]},"columns":[{"id":"details","name":"","type":"character","html":true}],"dataKey":"e3d41690e8e206fbf00d767e061f2172","static":false,"nested":true},"children":[]}]},{"name":"div","attribs":{"style":{"padding":"1rem"}},"children":[{"name":"Reactable","attribs":{"data":{"details":["<b>DOI:<\/b> 10.1371/journal.pone.0116489 <br><br> Many studies of aging examine biomarkers one at a time, but complex systems theory and network theory suggest that interpretations of individual markers may be context-dependent. Here, we attempted to detect underlying processes governing the levels of many biomarkers simultaneously by applying principal components analysis to 43 common clinical biomarkers measured longitudinally in 3694 humans from three longitudinal cohort studies on two continents (Women's Health and Aging I & II, InCHIANTI, and the Baltimore Longitudinal Study on Aging). The first axis was associated with anemia, inflammation, and low levels of calcium and albumin. The axis structure was precisely reproduced in all three populations and in all demographic sub-populations (by sex, race, etc.); we call the process represented by the axis \"integrated albunemia.\" Integrated albunemia increases and accelerates with age in all populations, and predicts mortality and frailty--but not chronic disease--even after controlling for age. This suggests a role in the aging process, though causality is not yet clear. Integrated albunemia behaves more stably across populations than its component biomarkers, and thus appears to represent a higher-order physiological process emerging from the structure of underlying regulatory networks. If this is correct, detection of this process has substantial implications for physiological organization more generally.\n <br><br> <b>MeSH terms:<\/b> <b>MeSH terms:<\/b> Adult; Aged; Aged, 80 and over; Aging; Albumins; Anemia; Biomarkers; Calcium; Female; Humans; Inflammation; Longitudinal Studies; Male; Middle Aged; Principal Component Analysis; Young Adult <br><br> <b>OMOP Concepts (IDs):<\/b>  Aging (4093849); Anemia (439777); Calcium (19018544); "]},"columns":[{"id":"details","name":"","type":"character","html":true}],"dataKey":"677d0ce9fad384445be3027f53432f0a","static":false,"nested":true},"children":[]}]},{"name":"div","attribs":{"style":{"padding":"1rem"}},"children":[{"name":"Reactable","attribs":{"data":{"details":["<b>DOI:<\/b> 10.1371/journal.pone.0120683 <br><br> Glucose-6-phosphate dehydrogenase (G6PD) deficiency is a common enzymatic disorder of the erythrocytes that affects 400 million people worldwide. We developed a PCR-reverse dot blot (RDB) assay to screen twenty genotypes of seventeen Chinese G6PD mutations and investigate the spectrum of G6PD deficiency mutations in Dongguan District, Guangdong Province, in southern China.<br><br>&emsp;The PCR-RDB assay consists of multiplex PCR amplification of seven fragments in the G6PD target sequence of wild-type and mutant genomic DNA samples followed by hybridization to a test strip containing allele-specific oligonucleotide probes. A total of 16,464 individuals were analyzed by a combination of phenotypic screening and genotypic detection using the PCR-RDB assay and DNA sequence analysis.<br><br>&emsp;The PCR-RDB assay had a detection rate of 98.1%, which was validated by direct sequencing in a blind study with 100% concordance. The G6PD deficiency incidence rate in Dongguan District is 4.08%. Thirty-two genotypes from 469 individuals were found. The two most common variants were c.1376G>T and c.1388G>A, followed by c.95A>G, c.871G>A, c.392G>T, and c.1024 C>T. In addition, two rare mutations (c.703C>A and c.406C>T) were detected by DNA sequencing analysis. In our study, 65 cases harbored the C1311T/IVS polymorphism and 67 cases were homozygote.<br><br>&emsp;The PCR-RDB assay we established is a reliable and effective method for screening G6PD mutations in the Chinese population. Data on the spectrum of mutations in the Dongguan District is beneficial to the clinical diagnosis and prevention of G6PD deficiency.\n <br><br> <b>MeSH terms:<\/b> <b>MeSH terms:<\/b> Adolescent; Adult; Child; Child, Preschool; China; Female; Gene Frequency; Genotype; Glucosephosphate Dehydrogenase; Glucosephosphate Dehydrogenase Deficiency; Humans; Incidence; Infant; Infant, Newborn; Male; Middle Aged; Polymorphism, Single Nucleotide <br><br> <b>OMOP Concepts (IDs):<\/b>  Gene frequency (4238822); Genetic finding (4025367); Deficiency of glucose-6-phosphate dehydrogenase (4050620); "]},"columns":[{"id":"details","name":"","type":"character","html":true}],"dataKey":"9b3c8ed7689ea468bed994e0f10cdf45","static":false,"nested":true},"children":[]}]},{"name":"div","attribs":{"style":{"padding":"1rem"}},"children":[{"name":"Reactable","attribs":{"data":{"details":["<b>DOI:<\/b> 10.1371/journal.pone.0122729 <br><br> Anaemia in pregnancy is a major public health and economic problem worldwide, that contributes to both maternal and fetal morbidity and mortality.<br><br>&emsp;The aim of the study was to calculate the prevalence of anaemia in early pregnancy in a cohort of 'low risk' women participating in a large international multicentre prospective study (n = 5 609), to identify the modifiable risk factors for anaemia in pregnancy in this cohort, and to compare the birth outcomes between pregnancies with and without anaemia in early gestation.<br><br>&emsp;The study is an analysis of data that were collected prospectively during the Screening for Pregnancy Endpoints study. Anaemia was defined according to the World Health Organization's definition of anaemia in pregnancy (haemoglobin < 11g/dL). Binary logistic regression with adjustment for potential confounders (country, maternal age, having a marital partner, ethnic origin, years of schooling, and having paid work) was the main method of analysis.<br><br>&emsp;The hallmark findings were the low prevalence of anaemia (2.2%), that having no marital partner was an independent risk factor for having anaemia (OR 1.34, 95% CI 1.01-1.78), and that there was no statistically significant effect of anaemia on adverse pregnancy outcomes (small for gestational age, pre-tem birth, mode of delivery, low birth weight, APGAR score < 7 at one and five minutes). Adverse pregnancy outcomes were however more common in those with anaemia than in those without.<br><br>&emsp;In this low risk healthy pregnant population we found a low anaemia rate. The absence of a marital partner was a non-modifiable factor, albeit one which may reflect a variety of confounding factors, that should be considered for addition to anaemia's conceptual framework of determinants. Although not statistically significant, clinically, a trend towards a higher risk of adverse pregnancy outcomes was observed in women that were anaemic in early pregnancy.\n <br><br> <b>MeSH terms:<\/b> <b>MeSH terms:<\/b> Adult; Anemia; Cohort Studies; Female; Gestational Age; Humans; Infant, Low Birth Weight; Infant, Newborn; Parity; Pregnancy; Pregnancy Complications, Hematologic; Pregnancy Outcome; Premature Birth; Prospective Studies; Risk Assessment; Risk Factors; Young Adult <br><br> <b>OMOP Concepts (IDs):<\/b>  Pregnant (4299535); Parity finding (4041279); Risk assessment (4024612); Premature pregnancy delivered (4175637); Low birth weight infant (4171115); Anemia (439777); "]},"columns":[{"id":"details","name":"","type":"character","html":true}],"dataKey":"e86eb9588a15e4188690aa1bb2bc1a2d","static":false,"nested":true},"children":[]}]},{"name":"div","attribs":{"style":{"padding":"1rem"}},"children":[{"name":"Reactable","attribs":{"data":{"details":["<b>DOI:<\/b> 10.1371/journal.pone.0124751 <br><br> Preoperative anemia is considered an independent risk factor of poor clinical outcome in cardiac surgical patients. Low vitamin D status may increase anemia risk.<br><br>&emsp;We investigated 3,615 consecutive patients scheduled for cardiac surgery to determine the association between preoperative anemia (hemoglobin [Hb] <12.5 g/dL) and circulating levels of the vitamin D metabolites 25-hydroxyvitamin D (25OHD) and 1,25-dihydroxyvitamin D (1,25[OH]2D).<br><br>&emsp;Of the study cohort, 27.8 % met the criteria for anemia. In patients with deficient 25OHD levels (<30 nmol/l) mean Hb concentrations were 0.5 g/dL lower than in patients with adequate 25OHD levels (50.0-125 nmol/l; P<0.001). Regarding 1,25(OH)2D, mean Hb concentrations were 1.2 g/dL lower in the lowest 1,25(OH)2D category (<40 pmol/l) than in the highest 1,25(OH)2D category (>70 pmol/l; P<0.001). In multivariable-adjusted logistic regression analyses, the odds ratios for anemia of the lowest categories of 25OHD and 1,25(OH)2D were 1.48 (95%CI:1.19-1.83) and 2.35 (95%CI:1.86-2.97), compared with patients who had adequate 25OHD levels and 1,25(OH)2D values in the highest category, respectively. Anemia risk was greatest in patients with dual deficiency of 25OHD and 1,25(OH)2D (multivariable-adjusted OR = 3.60 (95%CI:2.40-5.40). Prevalence of deficient 25OHD levels was highest in anemia of nutrient deficiency, whereas low 1,25(OH)2D levels were most frequent in anemia of chronic kidney disease.<br><br>&emsp;This cross-sectional study demonstrates an independent inverse association between vitamin D status and anemia risk. If confirmed in clinical trials, preoperative administration of vitamin D or activated vitamin D (in case of chronic kidney disease) would be a promising strategy to prevent anemia in patients scheduled for cardiac surgery.\n <br><br> <b>MeSH terms:<\/b> <b>MeSH terms:<\/b> Aged; Aged, 80 and over; Anemia; Cross-Sectional Studies; Female; Humans; Male; Middle Aged; Thoracic Surgical Procedures; Vitamin D <br><br> <b>OMOP Concepts (IDs):<\/b>  Surgical procedure on thorax (4300244); Vitamin D (19009405); Anemia (439777); "]},"columns":[{"id":"details","name":"","type":"character","html":true}],"dataKey":"2a4b20b9874f89f844212da0911cb0be","static":false,"nested":true},"children":[]}]},{"name":"div","attribs":{"style":{"padding":"1rem"}},"children":[{"name":"Reactable","attribs":{"data":{"details":["<b>DOI:<\/b> 10.1371/journal.pone.0124352 <br><br> Kidneys and lungs are the most common organs involved in microscopic polyangiitis (MPA). A retrospective analysis of pediatric MPA patients with pulmonary lesions over the past 10 years was performed to investigate clinical features of MPA in children with pulmonary lesions. There were 9 patients enrolled in our study, including 2 boys and 7 girls, with a median age of 6.6 years at the time of disease onset and a median disease course of 2 months. All of the patients exhibited tachypnea, and 7 exhibited cough and hemoptysis. The most common presentation on pulmonary imaging was ground glass or patchy shadows, which were observed in 6 cases. Seven patients manifested with hematuria and proteinuria, with renal histopathology of fibrinoid necrosis/exudation of the glomerular capillaries. All of the patients presented with normocytic normochromic anemia. Of the 9 patients, 7 were positive for perinuclear antineutrophil cytoplasmic antibody (p-ANCA) and/or myeloperoxidase (MPO), and 2 were positive for p-ANCA/MPO and cytoplasmic ANCA/proteinase 3. Eight patients had normal complement 3 (C3) levels, and one had an elevated C3 level. Five of the 9 patients were positive for antinuclear antibody ANA, and 4 were positive for double strand DNA (ds-DNA) antibody (3 were positive for both). The 7 patients who exhibited renal involvement received steroid plus cyclophosphamide (CTX) treatment. Of these patients, 4 achieved various degrees of remission, 2 were at the beginning of induction therapy, and one was lost to follow-up. Two patients with isolated pulmonary involvement received steroid plus leflunomide treatment and achieved complete remission. Diffuse alveolar hemorrhage was the most frequent presentation of lung involvement in children with MPA, and tachypnea, cough, hemoptysis and anemia were the common clinical symptoms. The majority of these patients exhibited hematuria, proteinuria and renal insufficiency. The efficacy of steroid plus CTX or leflunomide was evident in these patients.\n <br><br> <b>MeSH terms:<\/b> <b>MeSH terms:<\/b> Adolescent; Anemia; Anti-Inflammatory Agents; Antibodies, Antineutrophil Cytoplasmic; Child; Child, Preschool; Complement C3; Cough; Cyclophosphamide; Female; Hematuria; Hemoptysis; Humans; Immunosuppressive Agents; Infant; Isoxazoles; Kidney; Leflunomide; Lung; Male; Microscopic Polyangiitis; Peroxidase; Proteinuria; Steroids; Tachypnea; Treatment Outcome <br><br> <b>OMOP Concepts (IDs):<\/b>  leflunomide (1101898); Proteinuria (75650); C/O - cough (4158493); Hemoptysis (261687); Tachypnea (317376); Complement component C3 (4017767); Hematuria syndrome (79864); Cyclophosphamide (1310317); Anemia (439777); Microscopic polyarteritis nodosa (4344489); Peroxidase (45892043); "]},"columns":[{"id":"details","name":"","type":"character","html":true}],"dataKey":"f30bb227b6b063771a6635195941b250","static":false,"nested":true},"children":[]}]},{"name":"div","attribs":{"style":{"padding":"1rem"}},"children":[{"name":"Reactable","attribs":{"data":{"details":["<b>DOI:<\/b> 10.1371/journal.pone.0127744 <br><br> Thrombotic thrombocytopenic purpura (TTP) and hemolytic uremic syndrome (HUS) are characterized by microangiopathic hemolytic anemia and thrombocytopenia. Interestingly, markedly different survival rates have been reported despite increases in survivability. We studied TTP-HUS 30-day mortality and relapse rates of patients who received TPE at our institution and compared them to published data.<br><br>&emsp;Retrospective study analyzed 30-day mortality and relapse rates attributed to TTP-HUS from 01/01/2008 to 12/31/2012 and compared them to comparable literature reporting mortality and survival. Studies describing other etiologies for TPE and different mortality time interval were excluded.<br><br>&emsp;Fifty-nine patients were analyzed and all were initially treated with TPE and corticosteroids. Eleven patients were classified as not having TTP-HUS due to testing or clinical reassessment which ruled in other etiologies, and 18/59 patients had ADAMTS13 activity <10%. Of remaining patients, 36/48 (75%) were diagnosed as idiopathic and 12/48 (25%) as secondary TTP-HUS. Patients received a mean of 12 TPEs (range 1-42); 42/48 (87.5%) patients had ADAMTS13 activity measured; complete response obtained in 39/48 (81.2%) patients (platelet count >100 x 10(9)/L); partial response in 4/48 (8%); and 5/48 (10.4%) did not have increases in platelet counts (2/5 of these patients died within the study period). Forty percent of patients obtained platelet counts >150 x 10(9)/L. Overall 30-day mortality for our patient cohort was 6.7% (4/59). Comparison of our mortality rate to combined data of five published studies of 16% (92/571) showed a significant difference, p = 0.04. Our relapse rate was 18.6% (11/59) similar to previous reports.<br><br>&emsp;Wide differences in mortality may be due to grouping of two distinct pathologic entities under TTP-HUS; and presence of confounding factors in the patient populations under study such as co-morbidities, promptness of TPE initiation, delay in diagnosis and therapeutic practice.\n <br><br> <b>MeSH terms:<\/b> <b>MeSH terms:<\/b> Adrenal Cortex Hormones; Adult; Aged; Female; Hemolytic-Uremic Syndrome; Humans; Male; Middle Aged; Plasma Exchange; Platelet Count; Purpura, Thrombotic Thrombocytopenic; Recurrence; Remission Induction; Retrospective Studies; Survival Rate <br><br> <b>OMOP Concepts (IDs):<\/b>  Therapeutic plasma exchange (4076662); Platelet count (4267147); Hemolytic uremic syndrome (197253); Thrombotic thrombocytopenic purpura (4301602); "]},"columns":[{"id":"details","name":"","type":"character","html":true}],"dataKey":"6bce7ca73175e3f90f85580f9c39a5cc","static":false,"nested":true},"children":[]}]},{"name":"div","attribs":{"style":{"padding":"1rem"}},"children":[{"name":"Reactable","attribs":{"data":{"details":["<b>DOI:<\/b> 10.1371/journal.pone.0127890 <br><br> Anemia affects upwards of 50% of pregnant women in developing countries and is associated with adverse outcomes for mother and child. We hypothesized that exposure to smoke from biomass fuel--which is widely used for household energy needs in resource-limited settings--could exacerbate anemia in pregnancy, possibly as a result of systemic inflammation.<br><br>&emsp;To evaluate whether exposure to smoke from biomass fuel (wood, straw, crop residues, or dung) as opposed to clean fuel (electricity, liquefied petroleum gas, natural gas, or biogas) is an independent risk factor for anemia in pregnancy, classified by severity.<br><br>&emsp;A secondary analysis was performed using data collected from a rural pregnancy cohort (N = 12,782) in Nagpur, India in 2011-2013 as part of the NIH-funded Maternal and Newborn Health Registry Study. Multinomial logistic regression was used to estimate the effect of biomass fuel vs. clean fuel use on anemia in pregnancy, controlling for maternal age, body mass index, education level, exposure to household tobacco smoke, parity, trimester when hemoglobin was measured, and receipt of prenatal iron and folate supplements.<br><br>&emsp;The prevalence of any anemia (hemoglobin < 11 g/dl) was 93% in biomass fuel users and 88% in clean fuel users. Moderate-to-severe anemia (hemoglobin < 10 g/dl) occurred in 53% and 40% of the women, respectively. Multinomial logistic regression showed higher relative risks of mild anemia in pregnancy (hemoglobin 10-11 g/dl; RRR = 1.38, 95% CI = 1.19-1.61) and of moderate-to-severe anemia in pregnancy (RRR = 1.79, 95% CI = 1.53-2.09) in biomass fuel vs. clean fuel users, after adjusting for covariates.<br><br>&emsp;In our study population, exposure to biomass smoke was associated with higher risks of mild and moderate-to-severe anemia in pregnancy, independent of covariates.<br><br>&emsp;ClinicalTrials.gov NCT 01073475.\n <br><br> <b>MeSH terms:<\/b> <b>MeSH terms:<\/b> Adult; Anemia; Biomass; Cooking; Cross-Sectional Studies; Female; Hemoglobins; Humans; India; Multivariate Analysis; Pregnancy; Pregnancy Complications, Hematologic; Risk Factors; Rural Population; Smoke; Wood; Young Adult <br><br> <b>OMOP Concepts (IDs):<\/b>  Pregnant (4299535); Anemia (439777); "]},"columns":[{"id":"details","name":"","type":"character","html":true}],"dataKey":"d4dc4c43109bdbebcedcfcf50082074c","static":false,"nested":true},"children":[]}]},{"name":"div","attribs":{"style":{"padding":"1rem"}},"children":[{"name":"Reactable","attribs":{"data":{"details":["<b>DOI:<\/b> 10.1016/j.vaccine.2015.06.100 <br><br> We have previously shown that multiple vaccinations with 23-valent pneumococcal polysaccharide vaccine (PPV23s) resulted in attenuated antibody responses to subsequent 7-valent conjugate vaccine (PCV7) in asplenic adults with β-thalassemia major (Orthopoulos et al. Vaccine 2009; 27:350). However, there is evidence that PPV23-induced immune hyporesponsiveness could be overcome with time (Papadatou et al. Clin Infect Dis 2014; 59:862). In the current study we investigate the duration of hyporesponsiveness in the same cohort seven years after the original study vaccinations. Patients received one dose of 13-valent conjugate vaccine (PCV13) and antibody levels were measured before and one month after vaccination. Antibodies increased significantly after vaccination with PCV13, but were lower than post-PCV7 seven years earlier. Lower pre-vaccination antibody levels were associated with more robust response to PCV13. Our findings suggest that PPV23 should be used cautiously in asplenic adults vaccinated with multiple PPV23s in the past. Measurement of anti-pneumococcal antibodies before and after vaccination could be used to optimise timing of vaccinations and certify vaccine immunogenicity in such individuals.\n <br><br> <b>MeSH terms:<\/b> <b>MeSH terms:<\/b> Adult; Antibodies, Bacterial; Female; Humans; Immune Tolerance; Male; Pneumococcal Vaccines; Splenectomy; beta-Thalassemia <br><br> <b>OMOP Concepts (IDs):<\/b>  Beta thalassemia (4278669); Splenectomy (4125482); "]},"columns":[{"id":"details","name":"","type":"character","html":true}],"dataKey":"9eff5c54afd4420228cb70bac18aab24","static":false,"nested":true},"children":[]}]},{"name":"div","attribs":{"style":{"padding":"1rem"}},"children":[{"name":"Reactable","attribs":{"data":{"details":["<b>DOI:<\/b> 10.1371/journal.pone.0133365 <br><br> To investigate recognised co-morbidities and clinical management associated with inpatient pneumonia mortality in Malawian district hospitals.<br><br>&emsp;Prospective cohort study, of patient records, carried out in Malawi between 1st October 2000 and 30th June 2003. The study included all children aged 0-59 months admitted to the paediatric wards in sixteen district hospitals throughout Malawi with severe and very severe pneumonia. We compared individual factors between those that survived (n = 14 076) and those that died (n = 1 633).<br><br>&emsp;From logistic regression analysis, predictors of death in hospital, adjusted for age, sex and severity grade included comorbid conditions of meningitis (OR =2.49, 95% CI 1.50-4.15), malnutrition (OR =2.37, 95% CI 1.94-2.88) and severe anaemia (OR =1.41, 95% CI 1.03-1.92). Requiring supplementary oxygen (OR =2.16, 95% CI 1.85-2.51) and intravenous fluids (OR =3.02, 95% CI 2.13-4.28) were associated with death while blood transfusion was no longer significant (OR =1.10, 95% CI 0.77-1.57) when the model included severe anaemia.<br><br>&emsp;This study identified a number of challenges to improve outcome for Malawian infants and children hospitalised with pneumonia. These included improved assessment of co-morbidities and more rigorous application of standard case management.\n <br><br> <b>MeSH terms:<\/b> <b>MeSH terms:<\/b> Anemia; Case Management; Child, Preschool; Female; Hospitalization; Hospitals; Hospitals, District; Humans; Infant; Infant, Newborn; Malawi; Male; Malnutrition; Meningitis; Pneumonia; Prospective Studies; Severity of Illness Index <br><br> <b>OMOP Concepts (IDs):<\/b>  Meningitis (435785); Pneumonia (255848); Case management (4298179); Undernutrition (4276360); Inpatient care (4214577); Anemia (439777); "]},"columns":[{"id":"details","name":"","type":"character","html":true}],"dataKey":"83f40cf85e9c93f362704d914ce4efc2","static":false,"nested":true},"children":[]}]},{"name":"div","attribs":{"style":{"padding":"1rem"}},"children":[{"name":"Reactable","attribs":{"data":{"details":["<b>DOI:<\/b> 10.1371/journal.pone.0134104 <br><br> Pentoxifylline (PTX) is a promising therapeutic approach for reducing inflammation and improving anemia associated to various systemic disorders. However, whether this agent may be helpful for anemia management also in CKD patients is still object of debate.<br><br>&emsp;Systematic review and meta-analysis.<br><br>&emsp;Adults with CKD (any KDOQI stage, including ESKD patients on regular dialysis) and anemia (Hb<13 g/dL in men or < 12 g/dL in women).<br><br>&emsp;Cochrane CENTRAL, EMBASE, Ovid-MEDLINE and PubMed were searched for studies providing data on the effects of PTX on anemia parameters in CKD patients without design or follow-up restriction.<br><br>&emsp;PTX derivatives at any dose regimen.<br><br>&emsp;Hemoglobin, hematocrit, ESAs dosage and resistance (ERI), iron indexes (ferritin, serum iron, TIBC, transferrin and serum hepcidin) and adverse events.<br><br>&emsp;We retrieved 11 studies (377 patients) including seven randomized controlled trials (all comparing PTX to placebo or standard therapy) one retrospective case-control study and three prospective uncontrolled studies. Overall, PTX increased hemoglobin in three uncontrolled studies but such improvement was not confirmed in a meta-analysis of seven studies (299 patients) (MD 0.12 g/dL, 95% CI -0.22 to 0.47). Similarly, there were no conclusive effects of PTX on hematocrit, ESAs dose, ferritin and TSAT in pooled analyses. Data on serum iron, ERI, TIBC and hepcidin were based on single studies. No evidence of increased rate of adverse events was also noticed.<br><br>&emsp;Small sample size and limited number of studies. High heterogeneity among studies with respect to CKD and anemia severity, duration of intervention and responsiveness/current therapy with iron or ESAs.<br><br>&emsp;There is currently no conclusive evidence supporting the utility of pentoxifylline for improving anemia control in CKD patients. Future trials designed on hard, patient-centered outcomes with larger sample size and longer follow-up are advocated.\n <br><br> <b>MeSH terms:<\/b> <b>MeSH terms:<\/b> Adult; Anemia; Anti-Inflammatory Agents; Female; Humans; Male; Pentoxifylline; Phosphodiesterase Inhibitors; Renal Insufficiency, Chronic; Treatment Outcome <br><br> <b>OMOP Concepts (IDs):<\/b>  Pentoxifylline (1331247); Chronic renal insufficiency (36716947); Anemia (439777); "]},"columns":[{"id":"details","name":"","type":"character","html":true}],"dataKey":"3fed5fd2cbb94d9e16e672c827c68b29","static":false,"nested":true},"children":[]}]},{"name":"div","attribs":{"style":{"padding":"1rem"}},"children":[{"name":"Reactable","attribs":{"data":{"details":["<b>DOI:<\/b> 10.1161/CIRCIMAGING.115.003230 <br><br> Cardiovascular magnetic resonance (CMR) plays a key role in the management of thalassemia major patients, but few data are available in pediatric population. This study aims at a retrospective multiparametric CMR assessment of myocardial iron overload, function, and fibrosis in a cohort of pediatric thalassemia major patients.<br><br>&emsp;We studied 107 pediatric thalassemia major patients (61 boys, median age 14.4 years). Myocardial and liver iron overload were measured by T2* multiecho technique. Atrial dimensions and biventricular function were quantified by cine images. Late gadolinium enhancement images were acquired to detect myocardial fibrosis. All scans were performed without sedation. The 21.4% of the patients showed a significant myocardial iron overload correlated with lower compliance to chelation therapy (P<0.013). Serum ferritin ≥2000 ng/mL and liver iron concentration ≥14 mg/g/dw were detected as the best threshold for predicting cardiac iron overload (P=0.001 and P<0.0001, respectively). A homogeneous pattern of myocardial iron overload was associated with a negative cardiac remodeling and significant higher liver iron concentration (P<0.0001). Myocardial fibrosis by late gadolinium enhancement was detected in 15.8% of the patients (youngest children 13 years old). It was correlated with significant lower heart T2* values (P=0.022) and negative cardiac remodeling indexes. A pathological magnetic resonance imaging liver iron concentration was found in the 77.6% of the patients.<br><br>&emsp;Cardiac damage detectable by a multiparametric CMR approach can occur early in thalassemia major patients. So, the first T2* CMR assessment should be performed as early as feasible without sedation to tailor the chelation treatment. Conversely, late gadolinium enhancement CMR should be postponed in the teenager age.\n <br><br> <b>MeSH terms:<\/b> <b>MeSH terms:<\/b> Adolescent; Age Factors; Cardiomyopathies; Child; Contrast Media; Female; Fibrosis; Gadolinium DTPA; Hemosiderosis; Humans; Iron; Iron Chelating Agents; Italy; Liver; Magnetic Resonance Imaging, Cine; Male; Medication Adherence; Myocardium; Predictive Value of Tests; Retrospective Studies; Ventricular Function, Left; Ventricular Function, Right; Ventricular Remodeling; beta-Thalassemia <br><br> <b>OMOP Concepts (IDs):<\/b>  Hemosiderosis (4305596); Beta thalassemia (4278669); Cardiomyopathy (321319); Drug compliance good (4056965); Iron (1360067); "]},"columns":[{"id":"details","name":"","type":"character","html":true}],"dataKey":"718797902926b8c17b5b65861862c4d1","static":false,"nested":true},"children":[]}]},{"name":"div","attribs":{"style":{"padding":"1rem"}},"children":[{"name":"Reactable","attribs":{"data":{"details":["<b>DOI:<\/b> 10.1371/journal.pone.0136581 <br><br> Inadequate nutrition has a severe impact on health in India. According to the WHO, iron deficiency is the single most important nutritional risk factor in India, accounting for more than 3% of all disability-adjusted life years (DALYs) lost. We estimate the social costs of iron deficiency anemia (IDA) in 6-59-month-old children in India in terms of intangible costs and production losses.<br><br>&emsp;We build a health economic model estimating the life-time costs of a birth cohort suffering from IDA between the ages of 6 and 59 months. The model is stratified by 2 age groups (6-23 and 24-59-months), 2 geographical areas (urban and rural), 10 socio-economic strata and 3 degrees of severity of IDA (mild, moderate and severe). Prevalence of anemia is calculated with the last available National Family Health Survey. Information on the health consequences of IDA is extracted from the literature.<br><br>&emsp;IDA prevalence is 49.5% in 6-23-month-old and 39.9% in 24-58-month-old children. Children living in poor households in rural areas are particularly affected but prevalence is high even in wealthy urban households. The estimated yearly costs of IDA in 6-59-month-old children amount to intangible costs of 8.3 m DALYs and production losses of 24,001 m USD, equal to 1.3% of gross domestic product. Previous calculations have considerably underestimated the intangible costs of IDA as the improved WHO methodology leads to a threefold increase of DALYs due to IDA.<br><br>&emsp;Despite years of iron supplementation programs and substantial economic growth, IDA remains a crucial public health issue in India and an obstacle to the economic advancement of the poor. Young children are especially vulnerable due to the irreversible effects of IDA on cognitive development. Our research may contribute to the design of new effective interventions aiming to reduce IDA in early childhood.\n <br><br> <b>MeSH terms:<\/b> <b>MeSH terms:<\/b> Anemia, Iron-Deficiency; Child, Preschool; Cost of Illness; Female; Humans; India; Infant; Iron Deficiencies; Male; Prevalence; Public Health; Quality-Adjusted Life Years; Risk Factors; Rural Population; Urban Population <br><br> <b>OMOP Concepts (IDs):<\/b>  Quality adjusted life years (4158643); Iron deficiency anemia (436659); "]},"columns":[{"id":"details","name":"","type":"character","html":true}],"dataKey":"f3db7e9411b94d118799132d247b05c5","static":false,"nested":true},"children":[]}]},{"name":"div","attribs":{"style":{"padding":"1rem"}},"children":[{"name":"Reactable","attribs":{"data":{"details":["<b>DOI:<\/b> 10.1371/journal.pone.0136828 <br><br> Sulphadoxine-Pyrimethamine (SP) is still the only recommended antimalarial for use in intermittent preventive treatment of malaria during pregnancy (IPTp) in some malaria endemic countries including Ghana. SP has the potential to cause acute haemolysis in G6PD deficient people resulting in significant haemoglobin (Hb) drop but there is limited data on post SP-IPTp Hb drop. This study determined the difference, if any in proportions of women with significant acute haemoglobin drop between G6PD normal, partial deficient and full deficient women after SP-IPTp.<br><br>&emsp;Prospectively, 1518 pregnant women who received SP for IPTp as part of their normal antenatal care were enrolled. Their G6PD status were determined at enrollment followed by assessments on days 3, 7,14 and 28 to document any adverse effects and changes in post-IPTp haemoglobin (Hb) levels. The three groups were comparable at baseline except for their mean Hb (10.3 g/dL for G6PD normal, 10.8 g/dL for G6PD partial deficient and 10.8 g/dL for G6PD full defect women).The prevalence of G6PD full defect was 2.3% and 17.0% for G6PD partial defect. There was no difference in the proportions with fractional Hb drop ≥ 20% as compared to their baseline value post SP-IPTp among the 3 groups on days 3, 7, 14. The G6PD full defect group had the highest median fractional drop at day 7. There was a weak negative correlation between G6PD activity and fractional Hb drop. There was no statistical difference between the three groups in the proportions of those who started the study with Hb ≥ 8g/dl whose Hb level subsequently fell below 8g/dl post-SP IPTp. No study participant required transfusion or hospitalization for severe anaemia.<br><br>&emsp;There was no significant difference between G6PD normal and deficient women in proportions with significant acute haemoglobin drop post SP-IPTp and lower G6PD enzyme activity was not strongly associated with significant acute drug-induced haemoglobin drop post SP-IPTp but a larger study is required to confirm consistency of findings.\n <br><br> <b>MeSH terms:<\/b> <b>MeSH terms:<\/b> Adult; Antimalarials; Cohort Studies; Drug Combinations; Female; Ghana; Glucosephosphate Dehydrogenase; Glucosephosphate Dehydrogenase Deficiency; Hematologic Diseases; Hemoglobins; Humans; Malaria; Pregnancy; Pyrimethamine; Sulfadoxine <br><br> <b>OMOP Concepts (IDs):<\/b>  Pyrimethamine (1760039); Pregnant (4299535); Sulfadoxine (1836410); Malarial fever (4093997); Deficiency of glucose-6-phosphate dehydrogenase (4050620); "]},"columns":[{"id":"details","name":"","type":"character","html":true}],"dataKey":"cb5c350ec495e3cf9c7584e63e59ff93","static":false,"nested":true},"children":[]}]},{"name":"div","attribs":{"style":{"padding":"1rem"}},"children":[{"name":"Reactable","attribs":{"data":{"details":["<b>DOI:<\/b> 10.1371/journal.pone.0137539 <br><br> This study was a prospective cross-sectional cohort study of 125 patients with sickle cell anemia (SS) between the ages of 16 to 60 years. Enrolled patients were followed-up prospectively for 15 months. Demographic, clinical, hematological and routine biochemical data were obtained on all patients. Six-minute walk test and Doppler Echocardiography were performed on all patients. A tricuspid regurgitant jet velocity (TRJV) < 2.5 m/sec was considered normal, 2.5 ≤ TRJV ≤ 3.0 was considered mild-moderate and > 3.0 m/sec, severe. Patients with abnormal TRJV were significantly older and more anemic, had significantly higher lactate dehydrogenase (LDH) levels, reticulocyte count and incidence of death. The logistic multimodal model implemented for the 125 patients indicated that age was the covariate that influenced the outcome of normal or abnormal TRJV with a cutoff age of thirty-two years. The survival rate for the group of patients with creatinine (Cr) > 1.0 mg/dL was lower than the group with Cr ≤ 1 and normal TRJV. A coefficient matrix showed that the LDH values were weakly correlated with the reticulocyte count but strongly correlated with hemoglobin suggesting that the TRJV values were not correlated with the hemolytic rate but with anemia. Ten patients died during the follow-up of whom 7 had TRJV > 2.5 m/sec. Acute chest syndrome was the most common cause of death followed by sepsis. In conclusion, this study shows that patients with SS older than thirty-two years with high LDH, elevated TRJV, severe anemia and Cr > 1 have poor prognosis and may be at risk of having pulmonary hypertension and should undergo RHC.\n <br><br> <b>MeSH terms:<\/b> <b>MeSH terms:<\/b> Adolescent; Adult; Anemia, Sickle Cell; Brazil; Cross-Sectional Studies; Exercise Test; Female; Humans; Hypertension, Pulmonary; Male; Middle Aged; Prognosis; Prospective Studies; Risk Factors; Young Adult <br><br> <b>OMOP Concepts (IDs):<\/b>  Determination of prognosis (4069425); Exercise tolerance test (4065416); Sickle cell-hemoglobin SS disease (22281); Pulmonary hypertension (4322024); "]},"columns":[{"id":"details","name":"","type":"character","html":true}],"dataKey":"7243192c376d49b6c9b5916b058fa5b8","static":false,"nested":true},"children":[]}]},{"name":"div","attribs":{"style":{"padding":"1rem"}},"children":[{"name":"Reactable","attribs":{"data":{"details":["<b>DOI:<\/b> 10.1371/journal.pone.0136672 <br><br> Hemoglobin switching is largely complete in humans by six months of age. Among infants with sickle cell anemia (HbSS, SCA), reticulocytosis begins early in life as fetal hemoglobin (HbF) is replaced by sickle hemoglobin (HbS). The objective of this study was to determine if absolute reticulocyte count (ARC) is related to HbF levels in a cohort of pediatric SCA patients. A convenience sample of 106 children with SCA between the ages of 1 month and 20 years who were not receiving hydroxyurea or monthly blood transfusions were enrolled in this observational study. Hematologic data, including ARC and HbF levels, were measured at steady state. F-cells were enumerated by flow cytometry. Initial studies compared infants with ARC greater than or equal to 200 K/μL (ARC ≥ 200) based upon the previously reported utility of this threshold as a predictive marker for SCA severity. Mean HbF and F-cell levels were significantly lower in the ARC ≥ 200 group when compared to the ARC < 200 group. Both HbF and F-cell percentages were negatively correlated to ARC in infants and in children between the ages of 1 and 9 years. However, the inverse relationship was lost after the age of 10 years. Overall, decreased expression and distribution of HbF during childhood SCA is well-correlated with increased reticulocyte production and release into the peripheral blood. As such, these data further support the clinical use of reticulocyte enumeration as a disease severity biomarker for childhood sickle cell anemia.\n <br><br> <b>MeSH terms:<\/b> <b>MeSH terms:<\/b> Adolescent; Anemia, Sickle Cell; Child; Child, Preschool; Female; Fetal Hemoglobin; Humans; Infant; Male; Reticulocyte Count; Reticulocytes; Young Adult <br><br> <b>OMOP Concepts (IDs):<\/b>  Hemoglobin F (4339104); Reticulocyte count (4263581); Sickle cell-hemoglobin SS disease (22281); "]},"columns":[{"id":"details","name":"","type":"character","html":true}],"dataKey":"1ca9bf6bf4ab7795365b08bd0799a198","static":false,"nested":true},"children":[]}]},{"name":"div","attribs":{"style":{"padding":"1rem"}},"children":[{"name":"Reactable","attribs":{"data":{"details":["<b>DOI:<\/b> 10.1161/CIRCULATIONAHA.113.003901 <br><br> Few studies have investigated the combination of pregnancy complications that predict risk for cardiovascular disease (CVD) death and how risk changes with age. This report presents a comprehensive investigation of the relation of the occurrence of multiple pregnancy complications to CVD death over 5 decades in a large pregnancy cohort.<br><br>&emsp;We examined pregnancy events (1959-1967) and CVD death through 2011 in 14 062 women from the Child Health and Development Studies. CVD death was determined by linkage to California Vital Statistics and National Death Index. Women were a median age of 26 years at enrollment and 66 years in 2011. Preexisting hypertension (hazard ratio, 3.5; 95% confidence interval, 2.4-5.1); glycosuria (hazard ratio, 4.2; confidence interval, 1.3-13.1); late-onset preeclampsia (after week 34, hazard ratio, 2.0; confidence interval, 1.2-3.5); and hemoglobin decline over the second and third trimesters (hazard ratio, 1.7; confidence interval, 1.2-2.7) predicted CVD death. Delivery of a small-for-gestation or preterm infant and early-onset preeclampsia (by week 34) significantly predicted premature CVD death (P<0.05 for age dependence). Preterm birth combined with hemorrhage, gestational hypertension, or preexisting hypertension identified women with a 4- to 7-fold increased risk of CVD death. Preeclampsia in combination with preexisting hypertension conferred a significant nearly 6-fold risk in comparison with a 4-fold risk for preexisting hypertension alone.<br><br>&emsp;We observed combinations of pregnancy complications that predict high risk of death and 2 new risk markers, glycosuria and hemoglobin decline. Obstetricians serve as primary care physicians for many young women and can readily use these complications to identify high-risk women to implement early prevention.\n <br><br> <b>MeSH terms:<\/b> <b>MeSH terms:<\/b> Adult; Anemia; California; Cardiovascular Diseases; Cause of Death; Female; Follow-Up Studies; Forecasting; Glycosuria; Hemoglobins; Humans; Hypertension; Hypertension, Pregnancy-Induced; Infant, Newborn; Infant, Premature; Infant, Small for Gestational Age; Obstetric Labor, Premature; Pre-Eclampsia; Pregnancy; Pregnancy Complications; Prognosis; Proportional Hazards Models; Risk Factors; Young Adult <br><br> <b>OMOP Concepts (IDs):<\/b>  Pregnant (4299535); Disorder of cardiovascular system (134057); Determination of prognosis (4069425); Pregnancy-induced hypertension (4167493); Hypertensive disorder (316866); Premature infant (4217564); Premature labor (4273560); Complication occurring during pregnancy (43530950); Small-for-dates baby (4064286); Cause of death (4083743); Glycosuria (434164); Pre-eclampsia (439393); Anemia (439777); "]},"columns":[{"id":"details","name":"","type":"character","html":true}],"dataKey":"57eeab843a63cd8c7afdc4d694c465f1","static":false,"nested":true},"children":[]}]},{"name":"div","attribs":{"style":{"padding":"1rem"}},"children":[{"name":"Reactable","attribs":{"data":{"details":["<b>DOI:<\/b> 10.1371/journal.pone.0138091 <br><br> First generation protease inhibitors (PI) with peg-interferon (PEG-IFN) and ribavirin (RBV) have been the only therapy available for hepatitis C virus (HCV) genotype 1 infection in most countries for 3 years. We have investigated the efficacy and tolerance of this triple therapy in transplanted patients experiencing a recurrence of HCV infection on the liver graft.<br><br>&emsp;This cohort study enrolled 81 liver transplant patients (Male: 76%, mean age: 55.8±9.7 years) with severe HCV recurrence (F3 or F4: n = 34 (42%), treatment experienced: n = 44 (54%)), treated with boceprevir (n = 36; 44%) or telaprevir (n = 45; 56%). We assessed the percentages of patients with sustained virological responses 24 weeks after therapy (SVR24), and safety.<br><br>&emsp;The SVR24 rate was 47% (telaprevir: 42%; boceprevir: 53%, P = ns). At baseline, a normal bilirubin level (p = 0.0145) and albumin level >35g/L (p = 0.0372) and an initial RBV dosage of ≥800 mg/day (p = 0.0033) predicted SVR24. During treatment, achieving an early virological response after 12 weeks was the strongest independent factor to predict SVR24 (p<0.0001). A premature discontinuation of anti-HCV therapy due to a serious adverse event (SAE) was observed in 22 patients (27%). Hematological toxicity, infections and deaths were observed in 95%, 28% and 7% of patients, respectively. A history of post-LT antiviral therapy and thrombocytopenia (<50G/L) during treatment were both independent predictors of the occurrence of infections or SAE (p = 0.0169 and p = 0.011).<br><br>&emsp;The use of first generation PI after liver transplantation enabled an SVR24 rate of 47% in genotype 1 patients, but induced a high rate of SAE. The identification of predictive factors for a response to treatment, and the occurrence of SAE, have enabled us to establish limits for the use of this anti-HCV therapy in the transplant setting.\n <br><br> <b>MeSH terms:<\/b> <b>MeSH terms:<\/b> Adult; Aged; Anemia; Antiviral Agents; Combined Modality Therapy; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C; Host-Pathogen Interactions; Humans; Interferon-alpha; Liver Transplantation; Male; Middle Aged; Multivariate Analysis; Oligopeptides; Polyethylene Glycols; Postoperative Period; Proline; Prospective Studies; Protease Inhibitors; Recombinant Proteins; Recurrence; Thrombocytopenia; Treatment Outcome <br><br> <b>OMOP Concepts (IDs):<\/b>  Combination therapy (4039581); Proline (19052736); Viral hepatitis C (197494); Thrombocytopenic disorder (432870); Polyethylene Glycols (948515); Transplantation of liver (4076862); Genetic finding (4025367); Anemia (439777); "]},"columns":[{"id":"details","name":"","type":"character","html":true}],"dataKey":"2d660d71b4f3df36c441ff8186f30252","static":false,"nested":true},"children":[]}]},{"name":"div","attribs":{"style":{"padding":"1rem"}},"children":[{"name":"Reactable","attribs":{"data":{"details":["<b>DOI:<\/b> 10.1371/journal.pone.0138303 <br><br> Non-communicable diseases (NCDs) are of increasing concern in low- and middle-income countries (LMICs) affected humanitarian crises. Humanitarian agencies and governments are increasingly challenged with how to effectively tackle NCDs. Reviewing the evidence of interventions for NCDs in humanitarian crises can help guide future policies and research by identifying effective interventions and evidence gaps. The aim of this paper is to systematically review evidence on the effectiveness of interventions targeting NCDs during humanitarian crises in LMICs.<br><br>&emsp;A systematic review methodology was followed using PRISMA standards. Studies were selected on NCD interventions with civilian populations affected by humanitarian crises in low- and middle-income countries. Five bibliographic databases and a range of grey literature sources were searched. Descriptive analysis was applied and a quality assessment conducted using the Newcastle-Ottawa Quality Assessment Scale for observational studies and the Cochrane Risk of Bias Tool for experimental studies.<br><br>&emsp;The search yielded 4919 references of which 8 studies met inclusion criteria. Seven of the 8 studies were observational, and one study was a non-blinded randomised-controlled trial. Diseases examined included hypertension, heart failure, diabetes mellitus, chronic kidney disease, thalassaemia, and arthritis. Study settings included locations in the Middle East, Eastern Europe, and South Asia. Interventions featuring disease-management protocols and/or cohort monitoring demonstrated the strongest evidence of effectiveness. No studies examined intervention costs. The quality of studies was limited, with a reliance on observational study designs, limited use of control groups, biases associated with missing data and inadequate patient-follow-up, and confounding was poorly addressed.<br><br>&emsp;The review highlights the extremely limited quantity and quality of evidence on this topic. Interventions that incorporate standardisation and facilitate patient follow-up appear beneficial. However, substantially more research is needed, including data on costs.\n <br><br> <b>MeSH terms:<\/b> <b>MeSH terms:<\/b> Arthritis; Diabetes Mellitus; Heart Failure; Humans; Hypertension; Randomized Controlled Trials as Topic; Renal Insufficiency, Chronic; Thalassemia; Warfare <br><br> <b>OMOP Concepts (IDs):<\/b>  Chronic renal insufficiency (36716947); Thalassemia (30978); Diabetes mellitus (201820); Heart failure (316139); Hypertensive disorder (316866); Arthritis (4291025); "]},"columns":[{"id":"details","name":"","type":"character","html":true}],"dataKey":"6d5dcd1c6e7b7ed89629cfb6b03bf4aa","static":false,"nested":true},"children":[]}]},{"name":"div","attribs":{"style":{"padding":"1rem"}},"children":[{"name":"Reactable","attribs":{"data":{"details":["<b>DOI:<\/b> 10.1371/journal.pone.0139220 <br><br> Bone marrow, spleen, liver and kidney proton transverse relaxation rates (R2), together with cardiac R2* from patients with sickle cell disease (SCD), paroxysmal nocturnal hemoglobinuria (PNH) and non-transfusion dependent thalassemia (NTDT) have been compared with a control group. Increased liver and bone marrow R2 values for the three groups of patients in comparison with the controls have been found. SCD and PNH patients also present an increased spleen R2 in comparison with the controls. The simultaneous measurement of R2 values for several tissue types by magnetic resonance imaging (MRI) has allowed the identification of iron distribution patterns in diseases associated with iron imbalance. Preferential liver iron loading is found in the highly transfused SCD patients, while the low transfused ones present a preferential iron loading of the spleen. Similar to the highly transfused SCD group, PNH patients preferentially accumulate iron in the liver. A reduced spleen iron accumulation in comparison with the liver and bone marrow loading has been found in NTDT patients, presumably related to the differential increased intestinal iron absorption. The correlation between serum ferritin and tissue R2 is moderate to good for the liver, spleen and bone marrow in SCD and PNH patients. However, serum ferritin does not correlate with NTDT liver R2, spleen R2 or heart R2*. As opposed to serum ferritin measurements, tissue R2 values are a more direct measurement of each tissue's iron loading. This kind of determination will allow a better understanding of the different patterns of tissue iron biodistribution in diseases predisposed to tissue iron accumulation.\n <br><br> <b>MeSH terms:<\/b> <b>MeSH terms:<\/b> Adult; Anemia, Sickle Cell; Bone Marrow; Case-Control Studies; Female; Hemoglobinuria, Paroxysmal; Humans; Iron Compounds; Kidney; Liver; Magnetic Resonance Imaging; Male; Middle Aged; Myocardium; Spleen; Tissue Distribution; beta-Thalassemia <br><br> <b>OMOP Concepts (IDs):<\/b>  Hemoglobinuria due to hemolysis from external causes (434616); Beta thalassemia (4278669); Sickle cell-hemoglobin SS disease (22281); Magnetic resonance imaging (4013636); "]},"columns":[{"id":"details","name":"","type":"character","html":true}],"dataKey":"b3cf1e9b12f93adb54724164e9ae5188","static":false,"nested":true},"children":[]}]},{"name":"div","attribs":{"style":{"padding":"1rem"}},"children":[{"name":"Reactable","attribs":{"data":{"details":["<b>DOI:<\/b> 10.1371/journal.pone.0139747 <br><br> Anemia is a common complication among patients with chronic kidney disease (CKD), and it is associated with unfavorable clinical outcomes in patients with CKD independent of the estimated glomerular filtration rate (eGFR). We assessed the association of the urinary albumin-to-creatinine ratio (ACR) and eGFR with anemia in CKD patients.<br><br>&emsp;We conducted a cross-sectional study using baseline data from the KoreaN Cohort Study for Outcome in Patients With Chronic Kidney Disease (KNOW-CKD). Multiple regression analysis was performed to identify the independent association of albuminuria with anemia. Furthermore, odds ratios for anemia were calculated by cross-categorization of ACR and eGFR.<br><br>&emsp;Among 1,456 patients, the mean age was 53.5 ± 12.4 years, and the mean eGFR and ACR were 51.9 ± 30.5 mL/min per 1.73 m2 and 853.2 ± 1,330.3 mg/g, respectively. Anemia was present in 644 patients (40.5%). Multivariate analysis showed that the odds ratio of anemia increased according to ACR levels, after adjusting for age, sex, eGFR, body mass index, pulse pressure, cause of CKD, use of erythropoiesis stimulating agents, serum calcium and ferritin (ACR < 30 mg/g as a reference group; 30-299 mg/g, adjusted odds ratio (OR) = 1.43, 95% confidence interval (CI) = 0.88-2.33; ≥300 mg/g, adjusted OR = 1.86, 95% CI = 1.12-3.10). In addition, graded associations were observed in cross-categorized groups of a higher ACR and eGFR compared to the reference group with an ACR <30 mg/g and eGFR ≥60 mL/min per 1.73 m2.<br><br>&emsp;The present study demonstrated that albuminuria was a significant risk factor for anemia in CKD patients independent of the eGFR.\n <br><br> <b>MeSH terms:<\/b> <b>MeSH terms:<\/b> Adult; Aged; Albuminuria; Anemia; Cohort Studies; Humans; Kidney Failure, Chronic; Middle Aged; Republic of Korea; Risk Factors; Treatment Outcome <br><br> <b>OMOP Concepts (IDs):<\/b>  End-stage renal disease (193782); Albuminuria (4168705); Anemia (439777); "]},"columns":[{"id":"details","name":"","type":"character","html":true}],"dataKey":"2d23beaefa9729bf064d8925ba7976be","static":false,"nested":true},"children":[]}]},{"name":"div","attribs":{"style":{"padding":"1rem"}},"children":[{"name":"Reactable","attribs":{"data":{"details":["<b>DOI:<\/b> 10.1371/journal.pone.0139555 <br><br> Iron deficiency anemia is one of the most common nutritional disorders worldwide. The aim was to identify the prevalence and incidence of anemia in children and to identify predictors of this condition, including intestinal parasites, social, nutritional and environmental factors, and comorbidities. A population-based cohort study was conducted in a sample of 414 children aged 6-71 months living in Novo Cruzeiro in the Minas Gerais State. Data were collected in 2008 and 2009 by interview and included socio-economic and demographic information about the children and their families. Blood samples were collected for testing of hemoglobin, ferritin and C-reactive protein. Anthropometric measurements and parasitological analyses of fecal samples were performed. To identify risk factors associated with anemia multivariate analyses were performed using the generalized estimating equations (GEE). In 2008 and 2009, respectively, the prevalence rates of anemia were 35.9% (95%CI 31.2-40.8) and 9.8% (95%CI 7.2-12.9), the prevalence rates of iron deficiency were 18.4% (95%CI 14.7-22.6) and 21.8% (95%CI 17.8-26.2), and the incidence rates of anemia and iron deficiency were 3.2% and 21.8%. The following risk factors associated with anemia were: iron deficiency (OR = 3.2; 95%CI 2.0-.5.3), parasitic infections (OR = 1.9; 95%CI 1.2-2.8), being of risk of or being a low length/height-for-age (OR = 2.1; 95%CI 1.4-3.2), and lower retinol intake (OR = 1.7; 95%CI 1.1-2.7), adjusted over time. Nutritional factors, parasitic infections and chronic malnutrition were identified as risk factors for anemia. These factors can be verified in a chronic process and have been classically described as risk factors for these conditions.\n <br><br> <b>MeSH terms:<\/b> <b>MeSH terms:<\/b> Anemia, Iron-Deficiency; Brazil; C-Reactive Protein; Child, Preschool; Cohort Studies; Female; Ferritins; Hemoglobins; Humans; Infant; Intestinal Diseases, Parasitic; Iron Deficiencies; Male; Prevalence; Risk Factors; Socioeconomic Factors <br><br> <b>OMOP Concepts (IDs):<\/b>  Intestinal parasitism (196347); Iron deficiency anemia (436659); "]},"columns":[{"id":"details","name":"","type":"character","html":true}],"dataKey":"e1722ab86d9323cf8d4bedcfdd756c5e","static":false,"nested":true},"children":[]}]},{"name":"div","attribs":{"style":{"padding":"1rem"}},"children":[{"name":"Reactable","attribs":{"data":{"details":["<b>DOI:<\/b> 10.1371/journal.pone.0140240 <br><br> Anaemia is associated with adverse outcomes including early death in the first year of antiretroviral therapy (ART). This study reports on the factors associated with persistent anaemia among HIV-infected patients initiating ART in the Democratic Republic of Congo (DR Congo).<br><br>&emsp;We conducted a retrospective cohort study and analyzed data from patients receiving HIV care between January 2004 and December 2012 at two major hospitals in Goma, DR Congo. Haemoglobin concentrations of all patients on ART regimen were obtained prior to and within one year of ART initiation. A logistic regression model was used to identify the predictors of persistent anaemia after 12 months of ART.<br><br>&emsp;Of 756 patients, 69% of patients were anaemic (IC95%: 65.7-72.3) at baseline. After 12 months of follow up, there was a 1.2 g/dl average increase of haemoglobin concentration (P < 0.001) with differences depending on the therapeutic regimen. Patients who received zidovudine (AZT) gained less than those who did not receive AZT (0.99 g/dl vs 1.33 g/dl; p< 0.001). Among 445 patient who had anaemia at the beginning, 33% (147/445) had the condition resolved. Among patients with anaemia at ART initiation, those who did not receive cotrimoxazole prophylaxis before starting ART(AOR 3.89; 95% CI 2.09-7.25; P < 0.001) and a AZT initial regimen (AOR 2.19; 95% CI 1.36-3.52; P < 0.001) were significantly at risk of persistent anaemia.<br><br>&emsp;More than two thirds of patients had anaemia at baseline. The AZT-containing regimen and absence of cotrimoxazole prophylaxis before starting ART were associated with persistent anaemia 12 months, after initiation of treatment. Considering the large proportion of patients with persistence of anaemia at 12 months, we suggest that it is necessary to conduct a large study to assess anaemia among HIV-infected patients in Goma.\n <br><br> <b>MeSH terms:<\/b> <b>MeSH terms:<\/b> Adult; Anemia; Antiretroviral Therapy, Highly Active; Democratic Republic of the Congo; Female; Follow-Up Studies; HIV; HIV Infections; Humans; Male; Prognosis; Retrospective Studies <br><br> <b>OMOP Concepts (IDs):<\/b>  Determination of prognosis (4069425); Human immunodeficiency virus infection (439727); Highly active anti-retroviral therapy (4166414); Anemia (439777); "]},"columns":[{"id":"details","name":"","type":"character","html":true}],"dataKey":"e8caeca13e3c474e34912686bd736e93","static":false,"nested":true},"children":[]}]},{"name":"div","attribs":{"style":{"padding":"1rem"}},"children":[{"name":"Reactable","attribs":{"data":{"details":["<b>DOI:<\/b> 10.1371/journal.pone.0143348 <br><br> Erythropoiesis-stimulating agent (ESA) responsiveness has been reported to be associated with increased mortality in hemodialysis (HD) patients. ESA requirement to obtain the same hemoglobin (Hb) level is different between HD and peritoneal dialysis (PD) patients. In this study, we investigated the impact of ESA responsiveness on mortality between both HD and PD patients. Prevalent HD and PD patients were selected from the Clinical Research Center registry for end-stage renal disease, a prospective cohort study in Korea. ESA responsiveness was estimated using an erythropoietin resistant index (ERI) (U/kg/week/g/dL). Patients were divided into three groups by tertiles of ERI. ESA responsiveness was also assessed based on a combination of ESA dosage and hemoglobin (Hb) levels. The primary outcome was all-cause mortality. A total of 1,594 HD and 876 PD patients were included. The median ESA dose and ERI were lower in PD patients compared with HD patients (ESA dose: 4000 U/week vs 6000 U/week, respectively. P<0.001, ERI: 7.0 vs 10.4 U/kg/week/g/dl, respectively. P<0.001). The median follow-up period was 40 months. In HD patients, the highest ERI tertile was significantly associated with higher risk for all-cause mortality (HR 1.96, 95% CI, 1.07 to 3.59, P = 0.029). HD patients with high-dose ESA and low Hb levels (ESA hypo-responsiveness) had a significantly higher risk of all-cause mortality (HR 2.24, 95% CI, 1.16 to 4.31, P = 0.016). In PD patients, there was no significant difference in all-cause mortality among the ERI groups (P = 0.247, log-rank test). ESA hypo-responsiveness was not associated with all-cause mortality (HR = 1.75, 95% CI, 0.58 to 5.28, P = 0.319). Our data showed that ESA hypo-responsiveness was associated with an increased risk of all-cause mortality in HD patients. However, in PD patients, ESA hypo-responsiveness was not related to all-cause mortality. These finding suggest the different prognostic value of ESA responsiveness between HD and PD patients.\n <br><br> <b>MeSH terms:<\/b> <b>MeSH terms:<\/b> Aged; Anemia; Erythropoietin; Female; Hematinics; Hemoglobins; Humans; Kaplan-Meier Estimate; Kidney Failure, Chronic; Male; Middle Aged; Peritoneal Dialysis; Prognosis; Proportional Hazards Models; Prospective Studies; Registries; Renal Dialysis; Republic of Korea; Risk; Treatment Outcome <br><br> <b>OMOP Concepts (IDs):<\/b>  End-stage renal disease (193782); Peritoneal dialysis (4324124); Determination of prognosis (4069425); Renal dialysis (4146536); Anemia (439777); "]},"columns":[{"id":"details","name":"","type":"character","html":true}],"dataKey":"085ad0bd72f78cb062f3cd11075d7d18","static":false,"nested":true},"children":[]}]},{"name":"div","attribs":{"style":{"padding":"1rem"}},"children":[{"name":"Reactable","attribs":{"data":{"details":["<b>DOI:<\/b> 10.1371/journal.pone.0143430 <br><br> Monitoring of serum ferritin levels is widely recommended in the management of anemia among patients on dialysis. However, associations between serum ferritin and mortality are unclear and there have been no investigations among patients undergoing peritoneal dialysis (PD).<br><br>&emsp;Baseline data of 191,902 patients on dialysis (age, 65 ± 13 years; male, 61.1%; median dialysis duration, 62 months) were extracted from a nationwide dialysis registry in Japan at the end of 2007. Outcomes, such as one-year mortality, were then evaluated using the registry at the end of 2008.<br><br>&emsp;Within one year, a total of 15,284 (8.0%) patients had died, including 6,210 (3.2%) cardiovascular and 2,707 (1.4%) infection-related causes. Higher baseline serum ferritin levels were associated with higher mortality rates among patients undergoing hemodialysis (HD). In contrast, there were no clear associations between serum ferritin levels and mortality among PD patients. Multivariate Cox regression analysis of HD patients showed that those in the highest serum ferritin decile group had higher rates of all-cause and cardiovascular mortality than those in the lowest decile group (hazard ratio [HR], 1.54; 95% confidence interval [CI], 1.31-1.81 and HR, 1.44; 95% CI, 1.13-1.84, respectively), whereas associations with infection-related mortality became non-significant (HR, 1.14; 95% CI, 0.79-1.65).<br><br>&emsp;Using Japanese nationwide dialysis registry, higher serum ferritin values were associated with mortality not in PD patients but in HD patients.\n <br><br> <b>MeSH terms:<\/b> <b>MeSH terms:<\/b> Aged; Anemia; Cohort Studies; Diabetic Nephropathies; Female; Ferritins; Glomerulonephritis; Humans; Japan; Kidney Failure, Chronic; Male; Middle Aged; Nephrosclerosis; Peritoneal Dialysis; Polycystic Kidney Diseases; Proportional Hazards Models; Registries; Renal Dialysis; Transferrin; Treatment Outcome <br><br> <b>OMOP Concepts (IDs):<\/b>  End-stage renal disease (193782); Multiple congenital cysts of kidney (4220238); Peritoneal dialysis (4324124); Glomerulonephritis (4263367); Renal dialysis (4146536); Disorder of kidney due to diabetes mellitus (192279); Anemia (439777); Nephrosclerosis (4140207); "]},"columns":[{"id":"details","name":"","type":"character","html":true}],"dataKey":"aa6e424059037b22e92b5099c073ec02","static":false,"nested":true},"children":[]}]},{"name":"div","attribs":{"style":{"padding":"1rem"}},"children":[{"name":"Reactable","attribs":{"data":{"details":["<b>DOI:<\/b> 10.1371/journal.pone.0142414 <br><br> Chlorproguanil-dapsone (CD) has been linked to hemolysis in symptomatic glucose-6-phosphate dehydrogenase deficient (G6PDd) children. Few studies have explored the effects of G6PD status on hemolysis in children treated with Intermittent Preventive Treatment in infants (IPTi) antimalarial regimens. We sought to examine the joint effects of G6PD status and IPTi antimalarial treatment on incidence of hemolysis in asymptomatic children treated with CD, sulfadoxine-pyrimethamine (SP), and mefloquine (MQ).<br><br>&emsp;A secondary analysis of data from a double-blind, placebo-controlled trial of IPTi was conducted. Hemoglobin (Hb) measurements were made at IPTi doses, regular follow-up and emergency visits. G6PD genotype was determined at 9 months looking for SNPs for the A- genotype at coding position 202. Multivariable linear and logistic regression models were used to examine hemolysis among children with valid G6PD genotyping results. Hemolysis was defined as the absolute change in Hb or as any post-dose Hb <8 g/dL. These outcomes were assessed using either a single follow-up Hb on day 7 after an IPTi dose or Hb obtained 1 to 14 or 28 days after each IPTi dose.<br><br>&emsp;Relative to placebo, CD reduced Hb by approximately 0.5 g/dL at day 7 and within 14 days of an IPTi dose, and by 0.2 g/dL within 28 days. Adjusted declines in the CD group were larger than in the MQ and SP groups. At day 7, homo-/hemizygous genotype was associated with higher odds of Hb <8 g/dL (adjusted odds ratio = 6.7, 95% CI 1.7 to 27.0) and greater absolute reductions in Hb (-0.6 g/dL, 95% CI -1.1 to 0.003). There was no evidence to suggest increased reductions in Hb among homo-/hemizygous children treated with CD compared to placebo, SP or MQ.<br><br>&emsp;While treatment with CD demonstrated greater reductions in Hb at 7 and 14 days after an IPTi dose compared to both SP and MQ, there was no evidence that G6PD deficiency exacerbated the adverse effects of CD, despite evidence for higher hemolysis risk among G6PDd infants.\n <br><br> <b>MeSH terms:<\/b> <b>MeSH terms:<\/b> Antimalarials; Cohort Studies; Dapsone; Double-Blind Method; Drug Combinations; Female; Genotype; Glucosephosphate Dehydrogenase; Glucosephosphate Dehydrogenase Deficiency; Hemoglobins; Hemolysis; Humans; Infant; Logistic Models; Malaria; Male; Mefloquine; Multivariate Analysis; Odds Ratio; Poisson Distribution; Polymorphism, Single Nucleotide; Proguanil; Pyrimethamine; Sulfadoxine; Tanzania <br><br> <b>OMOP Concepts (IDs):<\/b>  Proguanil (1792429); Pyrimethamine (1760039); Dapsone (1711759); Sulfadoxine (1836410); Malarial fever (4093997); Mefloquine (19000498); Genetic finding (4025367); Deficiency of glucose-6-phosphate dehydrogenase (4050620); "]},"columns":[{"id":"details","name":"","type":"character","html":true}],"dataKey":"bcfdb4498c8ca05db555acfd87cedb8c","static":false,"nested":true},"children":[]}]},{"name":"div","attribs":{"style":{"padding":"1rem"}},"children":[{"name":"Reactable","attribs":{"data":{"details":["<b>DOI:<\/b> 10.1371/journal.pone.0145105 <br><br> Human genetic factors influence the outcome of pegylated interferon and ribavirin hepatitis C therapy. We explored the role of IL28B, APOH and ITPA SNPs on the outcomes of triple therapy including telaprevir or boceprevir in patients with compensated cirrhosis chronically infected with HCV-1.<br><br>&emsp;A total of 256 HCV-1 Caucasian treatment-experienced patients with compensated cirrhosis from the ANRS CO20-CUPIC cohort were genotyped for a total of 10 candidate SNPs in IL28B (rs12979860 and rs368234815), APOH (rs8178822, rs12944940, rs10048158, rs52797880, rs1801689 and rs1801690) and ITPA (rs1127354 and rs7270101). We tested the association of IL28B and APOH SNPs with sustained virological response and of ITPA SNPs with anemia related phenotypes by means of logistic regression assuming an additive genetic model.<br><br>&emsp;None of the six APOH SNPs were associated with sustained virological response. The favorable alleles of the IL28B SNPs rs12979860 and rs368234815 were associated with sustained virological response (rs12979860: OR = 2.35[1.50-3.70], P = 2x10(-4)). Refined analysis showed that the effect of IL28B SNPs on sustained virological response was restricted to prior PegIFN/RBV relapse (OR = 3.80[1.82-8.92], P = 8x10(-4)). We also confirmed the association between ITPA low activity alleles and protection against early hemoglobin decline in triple therapy (P = 2x10(-5)).<br><br>&emsp;Our results suggest that the screening of rs12979860 may remain interesting for decision making in prior relapse HCV-1 Caucasian patients with compensated cirrhosis eligible for a telaprevir- or boceprevir-based therapy.\n <br><br> <b>MeSH terms:<\/b> <b>MeSH terms:<\/b> Anemia; Drug Therapy, Combination; Hemoglobins; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Interleukins; Liver Cirrhosis; Oligopeptides; Polymorphism, Single Nucleotide; Proline; Pyrophosphatases; Treatment Outcome; beta 2-Glycoprotein I <br><br> <b>OMOP Concepts (IDs):<\/b>  Proline (19052736); Cirrhosis of liver (4064161); Chronic hepatitis C (198964); Anemia (439777); "]},"columns":[{"id":"details","name":"","type":"character","html":true}],"dataKey":"73725af45c4524d27fb9856cdaeea3ce","static":false,"nested":true},"children":[]}]},{"name":"div","attribs":{"style":{"padding":"1rem"}},"children":[{"name":"Reactable","attribs":{"data":{"details":["<b>DOI:<\/b> 10.1371/journal.pone.0145230 <br><br> Hemoglobin Constant Spring (Hb CS) is an abnormal Hb caused by a mutation at the termination codon of α2-globin gene found commonly among Southeast Asian and Chinese people. Association of Hb CS with α°-thalassemia leads to a thalassemia intermedia syndrome commonly encountered in the region. We report chromosome background and addressed genetic origins of Hb CS observed in a large cohort of Hb CS among Southeast Asian populations.<br><br>&emsp;A study was done on 102 Vietnamese (aged 15-49 year-old) and 40 Laotian (aged 18-39 year-old) subjects with Hb CS and results compared with 120 Hb CS genes in Thailand. Hematological parameters were recorded and Hb analysis was performed using capillary electrophoresis. Hb CS mutation and thalassemia genotypes were defined by DNA analysis. Six DNA polymorphisms within α-globin gene cluster including 5'Xba I, Bgl I, Inter-zeta HVR, AccI, RsaI and αPstI 3', were determined using PCR-RFLP assay.<br><br>&emsp;Nine different genotypes of Hb CS were observed. In contrast to the Thai Hb CS alleles which are mostly linked to haplotype (+-S + + -), most of the Vietnamese and the Laotian Hb CS genes were associated with haplotype (+-M + + -), both of which are different from that of the European Hb CS.<br><br>&emsp;Hb CS is commonly found in combination with other thalassemias among Southeast Asian populations. Accurate genotyping of the cases requires both hematologic and DNA analyses. At least two independent origins are associated with the Hb CS gene which could indirectly explain the high prevalence of this Hb variant in the region.\n <br><br> <b>MeSH terms:<\/b> <b>MeSH terms:<\/b> Adolescent; Adult; Asian People; DNA Mutational Analysis; Female; Genetic Association Studies; Genetic Heterogeneity; Haplotypes; Hemoglobins, Abnormal; Humans; Laos; Middle Aged; Phylogeny; Prevalence; Vietnam; Young Adult; alpha-Thalassemia <br><br> <b>OMOP Concepts (IDs):<\/b>  Alpha thalassemia (4287844); "]},"columns":[{"id":"details","name":"","type":"character","html":true}],"dataKey":"b588d0dacfeca3795cbaa711517709b3","static":false,"nested":true},"children":[]}]},{"name":"div","attribs":{"style":{"padding":"1rem"}},"children":[{"name":"Reactable","attribs":{"data":{"details":["<b>DOI:<\/b> 10.1371/journal.pone.0147081 <br><br> Sickle cell disease (SCD) is a major health burden in India. The objective of the study was to establish a neonatal screening program and to understand the clinical course of children with SCD in central India.<br><br>&emsp;Pregnant mothers were screened for sickle hemoglobin using the solubility test. Babies were screened by high performance liquid chromatography if the mother was positive for sickle hemoglobin. The diagnosis was confirmed by molecular analysis. They received early prophylactic treatment and vaccination. Of 2134 newborns screened, 104 were sickle homozygous (SS), seven had sickle β-thalassemia (S-β thal) and 978 were sickle heterozygous (AS). The other hemoglobin abnormalities detected included HbS-δβ thalassemia-1, HbSD disease-2, HbE traits-5, β-thalassemia traits-4, alpha chain variants-3 and HbH disease-1.These babies were followed up regularly for hematological and clinical evaluation. Pain, severe anemia requiring blood transfusions and acute febrile illness were the major complications with 59.7, 45.1 and 42.6 cases per 100 person years. Fetal hemoglobin (HbF) levels were inversely associated with vaso-oclussive crisis (VOC) and severe anemia while presence of alpha thalassemia increased the rate of painful events and sepsis. Six early deaths occurred among the SS babies.<br><br>&emsp;A systematic follow up of this first newborn SCD cohort in central India showed that 47% of babies presented within 1 year of age. In spite of the presence of the Arab-Indian haplotype many babies had severe manifestations.\n <br><br> <b>MeSH terms:<\/b> <b>MeSH terms:<\/b> Anemia, Sickle Cell; Antisickling Agents; Child, Preschool; Female; Heterozygote; Homozygote; Humans; Hydroxyurea; India; Infant; Infant, Newborn; Male; Neonatal Screening; Phenotype; Pregnancy; Survival Rate; Treatment Outcome <br><br> <b>OMOP Concepts (IDs):<\/b>  Pregnant (4299535); Neonatal screening (4246502); Homozygote (4329704); Sickle cell-hemoglobin SS disease (22281); hydroxyurea (1377141); Phenotype (4215157); "]},"columns":[{"id":"details","name":"","type":"character","html":true}],"dataKey":"33c8a50f27002742c9ed26570d237d62","static":false,"nested":true},"children":[]}]},{"name":"div","attribs":{"style":{"padding":"1rem"}},"children":[{"name":"Reactable","attribs":{"data":{"details":["<b>DOI:<\/b> 10.1371/journal.pone.0144274 <br><br> To explore the association between postpartum haemorrhage (PPH) and postpartum depression (PPD), taking into account the role of postpartum anaemia, delivery experience and psychiatric history.<br><br>&emsp;A nested cohort study (n = 446), based on two population-based cohorts in Uppsala, Sweden. Exposed individuals were defined as having a bleeding of ≥1000 ml (n = 196) at delivery, and non-exposed individuals as having bleeding of <650 ml (n = 250). Logistic regression models with PPD symptoms (Edinburgh Postnatal Depression scale (EPDS) score ≥ 12) as the outcome variable and PPH, anaemia, experience of delivery, mood during pregnancy and other confounders as exposure variables were undertaken. Path analysis using Structural Equation Modeling was also conducted.<br><br>&emsp;There was no association between PPH and PPD symptoms. A positive association was shown between anaemia at discharge from the maternity ward and the development of PPD symptoms, even after controlling for plausible confounders (OR = 2.29, 95%CI = 1.15-4.58). Path analysis revealed significant roles for anaemia at discharge, negative self-reported delivery experience, depressed mood during pregnancy and postpartum stressors in increasing the risk for PPD.<br><br>&emsp;This study proposes important roles for postpartum anaemia, negative experience of delivery and mood during pregnancy in explaining the development of depressive symptoms after PPH.\n <br><br> <b>MeSH terms:<\/b> <b>MeSH terms:<\/b> Adult; Anemia; Cohort Studies; Confounding Factors, Epidemiologic; Delivery, Obstetric; Depression, Postpartum; Female; Humans; Mental Disorders; Postpartum Hemorrhage; Pregnancy; Pregnancy Complications; Pregnancy, Multiple; Socioeconomic Factors; Sweden; Young Adult <br><br> <b>OMOP Concepts (IDs):<\/b>  Pregnant (4299535); Delivery procedure (4128030); Postpartum depression (4239471); Complication occurring during pregnancy (43530950); Postpartum hemorrhage (443929); Mental disorder (432586); Anemia (439777); Multiple pregnancy (432969); "]},"columns":[{"id":"details","name":"","type":"character","html":true}],"dataKey":"c908981b77d92da7770531125dd954b1","static":false,"nested":true},"children":[]}]},{"name":"div","attribs":{"style":{"padding":"1rem"}},"children":[{"name":"Reactable","attribs":{"data":{"details":["<b>DOI:<\/b> 10.1371/journal.pone.0143729 <br><br> Severe bacterial infections are not considered as a leading cause of death in young children in sub-Saharan Africa. The worldwide emergence of extended-spectrum beta-lactamase producing Enterobacteriaceae (ESBL-E) could change the paradigm, especially in neonates who are at high risk of developing healthcare-associated infections.<br><br>&emsp;To evaluate the epidemiology and the burden of ESBL-E bloodstream infections (BSI).<br><br>&emsp;A case-case-control study was conducted in patients admitted in a pediatric hospital during two consecutive years. Cases were patients with Enterobacteriaceae BSI and included ESBL-positive (cases 1) and ESBL-negative BSI (cases 2). Controls were patients with no BSI. Multivariate analysis using a stepwise logistic regression was performed to identify risk factors for ESBL acquisition and for fatal outcomes. A multistate model was used to estimate the excess length of hospital stay (LOS) attributable to ESBL production while accounting for time of infection. Cox proportional hazards models were performed to assess the independent effect of ESBL-positive and negative BSI on LOS.<br><br>&emsp;The incidence rate of ESBL-E BSI was of 1.52 cases/1000 patient-days (95% CI: 1.2-5.6 cases per 1000 patient-days). Multivariate analysis showed that independent risk factors for ESBL-BSI acquisition were related to underlying comorbidities (sickle cell disease OR = 3.1 (95%CI: 2.3-4.9), malnutrition OR = 2.0 (95%CI: 1.7-2.6)) and invasive procedures (mechanical ventilation OR = 3.5 (95%CI: 2.7-5.3)). Neonates were also identified to be at risk for ESBL-E BSI. Inadequate initial antibiotic therapy was more frequent in ESBL-positive BSI than ESBL-negative BSI (94.2% versus 5.7%, p<0.0001). ESBL-positive BSI was associated with higher case-fatality rate than ESBL-negative BSI (54.8% versus 15.4%, p<0.001). Multistate modelling indicated an excess LOS attributable to ESBL production of 4.3 days. The adjusted end-of-LOS hazard ratio for ESBL-positive BSI was 0.07 (95%CI, 0.04-0.12).<br><br>&emsp;Control of ESBL-E spread is an emergency in pediatric populations and could be achieved with simple cost-effective measures such as hand hygiene, proper management of excreta and better stewardship of antibiotic use, especially for empirical therapy.\n <br><br> <b>MeSH terms:<\/b> <b>MeSH terms:<\/b> Adolescent; Anemia, Sickle Cell; Anti-Bacterial Agents; Bacterial Proteins; Case-Control Studies; Child; Child, Preschool; Comorbidity; Cross Infection; Disease Susceptibility; Drug Resistance, Multiple, Bacterial; Enterobacteriaceae; Enterobacteriaceae Infections; Female; Hospitals, Pediatric; Humans; Incidence; Infant; Infant, Newborn; Length of Stay; Male; Malnutrition; Postoperative Complications; Respiration, Artificial; Risk Factors; Senegal; Substrate Specificity; beta-Lactam Resistance; beta-Lactamases <br><br> <b>OMOP Concepts (IDs):<\/b>  Cross infection (4267804); Infection due to Enterobacteriaceae (4030292); Postoperative complication (4300243); Sickle cell-hemoglobin SS disease (22281); Undernutrition (4276360); Artificial respiration (4230167); "]},"columns":[{"id":"details","name":"","type":"character","html":true}],"dataKey":"962d544173ac29b15e68f12d03af5af5","static":false,"nested":true},"children":[]}]},{"name":"div","attribs":{"style":{"padding":"1rem"}},"children":[{"name":"Reactable","attribs":{"data":{"details":["<b>DOI:<\/b> 10.1371/journal.pone.0148938 <br><br> Anemia management, based on erythropoiesis stimulating agents (ESA) and iron supplementation, has become an increasingly challenging problem in hemodialysis patients. Maintaining hemodialysis patients within narrow hemoglobin targets, preventing cycling outside target, and reducing ESA dosing to prevent adverse outcomes requires considerable attention from caregivers. Anticipation of the long-term response (i.e. at 3 months) to the ESA/iron therapy would be of fundamental importance for planning a successful treatment strategy. To this end, we developed a predictive model designed to support decision-making regarding anemia management in hemodialysis (HD) patients treated in center. An Artificial Neural Network (ANN) algorithm for predicting hemoglobin concentrations three months into the future was developed and evaluated in a retrospective study on a sample population of 1558 HD patients treated with intravenous (IV) darbepoetin alfa, and IV iron (sucrose or gluconate). Model inputs were the last 90 days of patients' medical history and the subsequent 90 days of darbepoetin/iron prescription. Our model was able to predict individual variation of hemoglobin concentration 3 months in the future with a Mean Absolute Error (MAE) of 0.75 g/dL. Error analysis showed a narrow Gaussian distribution centered in 0 g/dL; a root cause analysis identified intercurrent and/or unpredictable events associated with hospitalization, blood transfusion, and laboratory error or misreported hemoglobin values as the main reasons for large discrepancy between predicted versus observed hemoglobin values. Our ANN predictive model offers a simple and reliable tool applicable in daily clinical practice for predicting the long-term response to ESA/iron therapy of HD patients.\n <br><br> <b>MeSH terms:<\/b> <b>MeSH terms:<\/b> Aged; Anemia; Darbepoetin alfa; Disease Management; Erythropoiesis; Female; Ferric Compounds; Ferric Oxide, Saccharated; Glucaric Acid; Hematinics; Hemoglobins; Humans; Injections, Intravenous; Kidney Failure, Chronic; Male; Middle Aged; Models, Statistical; Neural Networks, Computer; Renal Dialysis; Retrospective Studies <br><br> <b>OMOP Concepts (IDs):<\/b>  darbepoetin alfa (1304643); iron sucrose (1395773); End-stage renal disease (193782); Renal dialysis (4146536); Anemia (439777); Intravenous injection (4181778); "]},"columns":[{"id":"details","name":"","type":"character","html":true}],"dataKey":"0fac35aecae4bda4cc37089c74a48ade","static":false,"nested":true},"children":[]}]},{"name":"div","attribs":{"style":{"padding":"1rem"}},"children":[{"name":"Reactable","attribs":{"data":{"details":["<b>DOI:<\/b> 10.1371/journal.pone.0151703 <br><br> Despite the introduction of direct-acting antiviral agents for chronic hepatitis C virus (HCV) infection, peginterferon alfa/ribavirin remains relevant in many resource-constrained settings. The non-randomized GUARD-C cohort investigated baseline predictors of safety-related dose reductions or discontinuations (sr-RD) and their impact on sustained virologic response (SVR) in patients receiving peginterferon alfa/ribavirin in routine practice.<br><br>&emsp;A total of 3181 HCV-mono-infected treatment-naive patients were assigned to 24 or 48 weeks of peginterferon alfa/ribavirin by their physician. Patients were categorized by time-to-first sr-RD (Week 4/12). Detailed analyses of the impact of sr-RD on SVR24 (HCV RNA <50 IU/mL) were conducted in 951 Caucasian, noncirrhotic genotype (G)1 patients assigned to peginterferon alfa-2a/ribavirin for 48 weeks. The probability of SVR24 was identified by a baseline scoring system (range: 0-9 points) on which scores of 5 to 9 and <5 represent high and low probability of SVR24, respectively.<br><br>&emsp;SVR24 rates were 46.1% (754/1634), 77.1% (279/362), 68.0% (514/756), and 51.3% (203/396), respectively, in G1, 2, 3, and 4 patients. Overall, 16.9% and 21.8% patients experienced ≥1 sr-RD for peginterferon alfa and ribavirin, respectively. Among Caucasian noncirrhotic G1 patients: female sex, lower body mass index, pre-existing cardiovascular/pulmonary disease, and low hematological indices were prognostic factors of sr-RD; SVR24 was lower in patients with ≥1 vs. no sr-RD by Week 4 (37.9% vs. 54.4%; P = 0.0046) and Week 12 (41.7% vs. 55.3%; P = 0.0016); sr-RD by Week 4/12 significantly reduced SVR24 in patients with scores <5 but not ≥5.<br><br>&emsp;In conclusion, sr-RD to peginterferon alfa-2a/ribavirin significantly impacts on SVR24 rates in treatment-naive G1 noncirrhotic Caucasian patients. Baseline characteristics can help select patients with a high probability of SVR24 and a low probability of sr-RD with peginterferon alfa-2a/ribavirin.\n <br><br> <b>MeSH terms:<\/b> <b>MeSH terms:<\/b> Adult; Aged; Anemia; Antiviral Agents; Asthenia; Cohort Studies; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Host-Pathogen Interactions; Humans; Interferon-alpha; Male; Middle Aged; Neutropenia; Outcome Assessment, Health Care; Polyethylene Glycols; Proportional Hazards Models; RNA, Viral; Recombinant Proteins; Ribavirin; Withholding Treatment <br><br> <b>OMOP Concepts (IDs):<\/b>  Chronic hepatitis C (198964); Asthenia (437113); Polyethylene Glycols (948515); Ribavirin (1762711); Anemia (439777); Neutropenic disorder (4119158); "]},"columns":[{"id":"details","name":"","type":"character","html":true}],"dataKey":"a64b2a3fc868da9e2ef9c41dd0b97bec","static":false,"nested":true},"children":[]}]},{"name":"div","attribs":{"style":{"padding":"1rem"}},"children":[{"name":"Reactable","attribs":{"data":{"details":["<b>DOI:<\/b> 10.1093/aje/kwv332 <br><br> Anemia and low and high levels of hemoglobin have been associated with increased mortality and morbidity. However, most studies have measured hemoglobin at only 1 time point, and few studies have considered possible reverse causation. We used data from the Women's Health Initiative, in which baseline hemoglobin was measured in 160,081 postmenopausal women and year 3 hemoglobin was measured in 75,658 participants, to examine the associations of hemoglobin concentration with total mortality, coronary heart disease mortality, and cancer mortality. Women were enrolled from 1993 to 1998 and followed for a median of 16 years. Cox proportional hazards models were used to estimate the relative mortality hazards associated with deciles of baseline hemoglobin and the mean of baseline + year 3 hemoglobin. Both low and high deciles of baseline hemoglobin were positively associated with all 3 outcomes in the total cohort. In analyses restricted to women with 2 measurements, a low mean hemoglobin level was robustly and positively associated with all 3 outcomes, after exclusion of the early years of follow-up. High mean hemoglobin was also associated with increased risk of total mortality, whereas associations with heart disease mortality and cancer mortality were weaker and inconsistent. Our results provide evidence that low and high levels of hemoglobin are associated with increased risk of mortality in otherwise healthy women.\n <br><br> <b>MeSH terms:<\/b> <b>MeSH terms:<\/b> Age Factors; Aged; Anemia; Body Mass Index; Coronary Disease; Female; Health Behavior; Hemoglobins; Humans; Middle Aged; Mortality; Neoplasms; Postmenopause; Proportional Hazards Models; Prospective Studies; Risk Factors; Smoking; Socioeconomic Factors; Surveys and Questionnaires; Women's Health <br><br> <b>OMOP Concepts (IDs):<\/b>  Coronary arteriosclerosis (317576); Neoplastic disease (438112); Anemia (439777); "]},"columns":[{"id":"details","name":"","type":"character","html":true}],"dataKey":"a8edb7d2a11abe328adb6fed2ac59395","static":false,"nested":true},"children":[]}]},{"name":"div","attribs":{"style":{"padding":"1rem"}},"children":[{"name":"Reactable","attribs":{"data":{"details":["<b>DOI:<\/b> 10.1016/j.jacc.2016.02.064 <br><br> Dual-antiplatelet therapy with aspirin and clopidogrel after percutaneous coronary intervention reduces the risk for coronary thrombotic events (CTEs) at the expense of increasing risk for major bleeding (MB). Metrics to accurately predict the occurrence of each respective event and inform clinical decision making are lacking.<br><br>&emsp;The aim of this study was to develop and validate separate models to predict risks for out-of-hospital thrombotic and bleeding events after percutaneous coronary intervention with drug-eluting stents.<br><br>&emsp;Using data from 4,190 patients treated with drug-eluting stents and enrolled in the PARIS (Patterns of Non-Adherence to Anti-Platelet Regimen in Stented Patients) registry, separate risk scores were developed to predict CTE (defined as the composite of stent thrombosis or myocardial infarction) and MB (defined as the occurrence of a Bleeding Academic Research Consortium type 3 or 5 bleed). External validation was performed in the ADAPT-DES (Assessment of Dual Antiplatelet Therapy With Drug-Eluting Stents) registry.<br><br>&emsp;Over 2 years, CTEs occurred in 151 patients (3.8%) and MB in 133 (3.3%). Independent predictors of CTEs included acute coronary syndrome, prior revascularization, diabetes mellitus, renal dysfunction, and current smoking. Independent predictors of MB included older age, body mass index, triple therapy at discharge, anemia, current smoking, and renal dysfunction. Each model displayed moderate levels of discrimination and adequate calibration.<br><br>&emsp;Simple risk scores of baseline clinical variables may be useful to predict risks for ischemic and bleeding events after PCI with DES, thereby facilitating clinical decisions surrounding the optimal duration of DAPT. (Patterns of Non-Adherence to Anti-Platelet Regimen in Stented Patients [PARIS]; NCT00998127).\n <br><br> <b>MeSH terms:<\/b> <b>MeSH terms:<\/b> Acute Coronary Syndrome; Age Factors; Aged; Anemia; Aspirin; Body Mass Index; Clopidogrel; Cohort Studies; Coronary Thrombosis; Diabetes Mellitus; Drug Therapy, Combination; Drug-Eluting Stents; Female; Hemorrhage; Humans; Male; Medication Adherence; Middle Aged; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Registries; Renal Insufficiency; Risk Assessment; Smoking; Ticlopidine; United States <br><br> <b>OMOP Concepts (IDs):<\/b>  clopidogrel (1322184); Ticlopidine (1302398); Acute coronary syndrome (4215140); Bleeding (437312); Renal impairment (4030518); Diabetes mellitus (201820); Coronary artery thrombosis (4134723); Risk assessment (4024612); Aspirin (1112807); Percutaneous coronary intervention (4216130); Anemia (439777); Drug compliance good (4056965); "]},"columns":[{"id":"details","name":"","type":"character","html":true}],"dataKey":"e6a383f087239e029317321246bc1623","static":false,"nested":true},"children":[]}]},{"name":"div","attribs":{"style":{"padding":"1rem"}},"children":[{"name":"Reactable","attribs":{"data":{"details":["<b>DOI:<\/b> 10.1371/journal.pone.0153831 <br><br> The compound β°-thalassemia/Hb E hemoglobinopathy is characterized by an unusually large range of presentation from essentially asymptomatic to a severe transfusion dependent state. While a number of factors are known that moderate presentation, these factors do not account for the full spectrum of presentation. Mitochondria are subcellular organelles that are pivotal in a number of cellular processes including oxidative phosphorylation and apoptosis. A mitochondrial protein enriched proteome was determined and validated from erythroblasts from normal controls and β°-thalassemia/Hb E patients of different severities. Mitochondria were evaluated through the use of mitotracker staining, analysis of relative mitochondrial genome number and evaluation of mitochondrial gene expression in addition to assay of overall cellular redox status through the use of alamarBlue assays. Fifty differentially regulated mitochondrial proteins were identified. Mitotracker staining revealed significant differences in staining between normal control erythroblasts and those from β°-thalassemia/Hb E patients. Differences in relative mitochondria number and gene expression were seen primarily in day 10 cells. Significant differences were seen in redox status as evaluated by alamarBlue staining in newly isolated CD34+ cells. Mitochondria mediate oxidative phosphorylation and apoptosis, both of which are known to be dysregulated in differentiating erythrocytes from β°-thalassemia/Hb E patients. The evidence presented here suggest that there are inherent differences in these cells as early as the erythroid progenitor cell stage, and that maximum deficit is seen coincident with high levels of globin gene expression.\n <br><br> <b>MeSH terms:<\/b> <b>MeSH terms:<\/b> Antigens, CD34; Apoptosis; Case-Control Studies; Erythroblasts; Erythroid Precursor Cells; Gene Expression; Globins; Hemoglobin E; Hemoglobinopathies; Humans; Mitochondria; Proteome; beta-Thalassemia <br><br> <b>OMOP Concepts (IDs):<\/b>  Hemoglobinopathy (432868); Beta thalassemia (4278669); Gene expression (4232626); "]},"columns":[{"id":"details","name":"","type":"character","html":true}],"dataKey":"bccc5e843819d48f5bbfbda7d32411a7","static":false,"nested":true},"children":[]}]},{"name":"div","attribs":{"style":{"padding":"1rem"}},"children":[{"name":"Reactable","attribs":{"data":{"details":["<b>DOI:<\/b> 10.1371/journal.pone.0153244 <br><br> Sickle cell anemia (SCA) is an inherited hemolytic anemia with compensatory reticulocytosis. Recent studies have shown that increased levels of reticulocytosis during infancy are associated with increased hospitalizations for SCA sequelae as well as cerebrovascular pathologies. In this study, absolute reticulocyte counts (ARC) measured prior to transfusion were analysed among a cohort of 29 pediatric SCA patients receiving chronic transfusion therapy (CTT) for primary and secondary stroke prevention. A cross-sectional flow cytometric analysis of the reticulocyte phenotype was also performed. Mean duration of CTT was 3.1 ± 2.6 years. Fifteen subjects with magnetic resonance angiography (MRA) -vasculopathy had significantly higher mean ARC prior to initiating CTT compared to 14 subjects without MRA-vasculopathy (427.6 ± 109.0 K/μl vs. 324.8 ± 109.2 K/μl, p<0.05). No significant differences in hemoglobin or percentage sickle hemoglobin (HbS) were noted between the two groups at baseline. Reticulocyte phenotyping further demonstrated that the percentages of circulating immature [CD36(+), CD71(+)] reticulocytes positively correlated with ARC in both groups. During the first year of CTT, neither group had significant reductions in ARC. Among this group of children with SCA, cerebrovasculopathy on MRA at initiation of CTT was associated with increased reticulocytosis, which was not reduced after 12 months of transfusions.\n <br><br> <b>MeSH terms:<\/b> <b>MeSH terms:<\/b> Adolescent; Anemia, Sickle Cell; Blood Transfusion; Child; Child, Preschool; Cohort Studies; Cross-Sectional Studies; Female; Humans; Magnetic Resonance Angiography; Male; Reticulocyte Count; Reticulocytosis; Retrospective Studies; Stroke; Young Adult <br><br> <b>OMOP Concepts (IDs):<\/b>  Transfusion of blood product (4024656); Reticulocytosis (4261785); Cerebrovascular accident (381316); Reticulocyte count (4263581); Sickle cell-hemoglobin SS disease (22281); Magnetic resonance imaging (MRI) of vessels (4082989); "]},"columns":[{"id":"details","name":"","type":"character","html":true}],"dataKey":"3045a5f99438bd3ddd3860eee3afe16f","static":false,"nested":true},"children":[]}]},{"name":"div","attribs":{"style":{"padding":"1rem"}},"children":[{"name":"Reactable","attribs":{"data":{"details":["<b>DOI:<\/b> 10.1371/journal.pone.0155070 <br><br> β-thalasemia major (β-TM) patients often suffer from various vascular complications together with increased oxidative stress. Hyperhomocysteinemia (Hhcy) has been defined as a risk factor for these complications. Genetic polymorphism of methylenetetrahydrofolate reductase (MTHFR) C677T has been shown to cause Hhcy particularly in individuals with low B-vitamins. However, the status of homocysteine (hcy) in β-TM has not yet been adequately defined.<br><br>&emsp;To evaluate the genetic polymorphism of MTHFR C677T among β-TM patients and its prospective contribution to Hhcy and related oxidative changes.<br><br>&emsp;Genotyping for MTHFR C677T was done by PCR-RFLP technique. Plasma hcy, vitamin B12, folate, malondialdehyde (MDA), total antioxidant capacity (TAC), oxidized low density lipoprotein (oxLDL), total nitric oxide (NOx) and lipid profile were determined in 66 β-TM patients and 66 control subjects of matched age and sex.<br><br>&emsp;The prevalence of MTHFR 677TT genotype was significant among β-TM patients (12%) compared to (3%) controls (OR = 4.9, 95%CI:1.2-24.2,P = 0.03). A strong association between Hhcy and MTHFR TT genotype was observed (OR = 7.7, 95%CI:2.8-20.9) where all β-TM patients with TT genotype were hyperhomocystienemic (≥ 15 μmol/l) and having sub-optimal folate level than those with CT or CC genotypes. Hyperhomocystienemic patients have suffered from increased oxidative stress characterized by significant increase in plasma MDA and oxLDL, and a significant reduction of plasma TAC and total NOx. Lipid profile of those patients was severely affected indicated by reduction in HDL and HDL/LDL and elevation in atherogenic index as compared with CC genotype. Other measured parameters were not significantly different among β-TM patients with different MTHFR genotypes.<br><br>&emsp;This study suggests that Egyptian β-TM patients with MTHFR 677TT genotype could be at increasing risk of developing Hhcy particularly with folate deficiency. This state of Hhcy may account potentially for most oxidative changes and atherogenic vascular complications frequently reported in β-TM patients.\n <br><br> <b>MeSH terms:<\/b> <b>MeSH terms:<\/b> Adolescent; Adult; Alleles; Amino Acid Substitution; Biomarkers; Case-Control Studies; Child; Codon; Egypt; Female; Gene Frequency; Genotype; Humans; Hyperhomocysteinemia; Male; Methylenetetrahydrofolate Reductase (NADPH2); Oxidation-Reduction; Oxidative Stress; Polymorphism, Genetic; Prevalence; Young Adult; beta-Thalassemia <br><br> <b>OMOP Concepts (IDs):<\/b>  Genetic alleles (4235440); Hyperhomocysteinemia (4304907); Beta thalassemia (4278669); Genetic polymorphism (4177328); Gene frequency (4238822); Genetic finding (4025367); "]},"columns":[{"id":"details","name":"","type":"character","html":true}],"dataKey":"04550efa70c059259b087b923cc8e846","static":false,"nested":true},"children":[]}]},{"name":"div","attribs":{"style":{"padding":"1rem"}},"children":[{"name":"Reactable","attribs":{"data":{"details":["<b>DOI:<\/b> 10.1371/journal.pone.0157063 <br><br> Hepcidin is the key regulator of iron homeostasis but data are limited regarding its temporal response to iron therapy, and response to intravenous versus oral iron. In the 56-week, open-label, multicenter, prospective, randomized FIND-CKD study, 626 anemic patients with non-dialysis dependent chronic kidney disease (ND-CKD) and iron deficiency not receiving an erythropoiesis stimulating agent were randomized (1:1:2) to intravenous ferric carboxymaltose (FCM), targeting higher (400-600μg/L) or lower (100-200μg/L) ferritin, or to oral iron. Serum hepcidin levels were measured centrally in a subset of 61 patients. Mean (SD) baseline hepcidin level was 4.0(3.5), 7.3(6.4) and 6.5(5.6) ng/mL in the high ferritin FCM (n = 17), low ferritin FCM (n = 16) and oral iron group (n = 28). The mean (SD) endpoint value (i.e. the last post-baseline value) was 26.0(9.1),15.7(7.7) and 16.3(11.0) ng/mL, respectively. The increase in hepcidin from baseline was significantly smaller with low ferritin FCM or oral iron vs high ferritin FCM at all time points up to week 52. Significant correlations were found between absolute hepcidin and ferritin values (r = 0.65, p<0.001) and between final post-baseline increases in both parameters (r = 0.70, p<0.001). The increase in hepcidin levels over the 12-month study generally mirrored the cumulative iron dose in each group. Hepcidin and transferrin saturation (TSAT) absolute values showed no correlation, although there was an association between final post-baseline increases (r = 0.42, p<0.001). Absolute values (r = 0.36, p = 0.004) and final post-baseline increases of hepcidin and hemoglobin (p = 0.30, p = 0.030) correlated weakly. Baseline hepcidin levels were not predictive of a hematopoietic response to iron therapy. In conclusion, hepcidin levels rose in response to either intravenous or oral iron therapy, but the speed and extent of the rise was greatest with intravenous iron targeting a higher ferritin level. However neither the baseline level nor the change in hepcidin was able to predict response to therapy in this cohort.\n <br><br> <b>MeSH terms:<\/b> <b>MeSH terms:<\/b> Administration, Intravenous; Aged; Aged, 80 and over; Anemia, Iron-Deficiency; Female; Ferric Compounds; Ferritins; Hepcidins; Humans; Iron; Male; Maltose; Middle Aged; Prospective Studies; Renal Insufficiency, Chronic; Time Factors <br><br> <b>OMOP Concepts (IDs):<\/b>  Chronic renal insufficiency (36716947); Iron deficiency anemia (436659); Maltose (42899344); Iron (1360067); "]},"columns":[{"id":"details","name":"","type":"character","html":true}],"dataKey":"277246e021086639be280dc87baa8b95","static":false,"nested":true},"children":[]}]},{"name":"div","attribs":{"style":{"padding":"1rem"}},"children":[{"name":"Reactable","attribs":{"data":{"details":["<b>DOI:<\/b> 10.1371/journal.pone.0157090 <br><br> Cerebrovascular complications are frequent events in children with sickle cell disease, yet routinely used techniques such as Transcranial Doppler (TCD), Magnetic Resonance (MRI) and Angiography (MRA), insufficiently explain the cause of poor cognitive performances. Forty children with SS-Sβ° (mean age 8 years) underwent neurocognitive evaluation and comprehensive brain imaging assessment with TCD, MRI, MRA, Resting State (RS) Functional MRI with evaluation of the Default Mode Network (DMN). Sixteen healthy age-matched controls underwent MRI, MRA and RS functional MRI.Children with SCD display increased brain connectivity in the DMN even in the absence of alterations in standard imaging techniques. Patients with low neurocognitive scores presented higher brain connectivity compared to children without cognitive impairment or controls, suggesting an initial compensatory mechanism to maintain performances. In our cohort steady state haemoglobin level was not related to increased brain connectivity, but SatO2<97% was. Our findings provide novel evidence that SCD is characterized by a selective disruption of connectivity among relevant regions of the brain, potentially leading to reduced cognition and altered functional brain dynamics. RS functional MRI could be used as a useful tool to evaluate cognition and cerebral damage in SCD in longitudinal trials.\n <br><br> <b>MeSH terms:<\/b> <b>MeSH terms:<\/b> Adolescent; Anemia, Sickle Cell; Brain Mapping; Child; Child, Preschool; Cognition Disorders; Cross-Sectional Studies; Female; Humans; Magnetic Resonance Imaging; Male; Nerve Net; Neuropsychological Tests <br><br> <b>OMOP Concepts (IDs):<\/b>  Brain mapping (4098782); Sickle cell-hemoglobin SS disease (22281); Magnetic resonance imaging (4013636); Neuropsychological testing (4145254); Cognitive disorder (40480615); "]},"columns":[{"id":"details","name":"","type":"character","html":true}],"dataKey":"89d6bbf36f08b5a401e619673018a320","static":false,"nested":true},"children":[]}]},{"name":"div","attribs":{"style":{"padding":"1rem"}},"children":[{"name":"Reactable","attribs":{"data":{"details":["<b>DOI:<\/b> 10.1371/journal.pone.0157393 <br><br> Beta-thalassaemia is one of the most common autosomal recessive disorders worldwide. The disease's high incidence, which is observed in the broader Mediterranean area has led to the establishment of molecular diagnostics' assays to prevent affected births. Therefore, the development of a reliable, cost-effective and rapid scanning method for β globin gene point mutations, easily adapted to a routine laboratory, is absolutely essential. Here, we describe, for the first time, the development of a High-Resolution Melting Analysis (HRMA) approach, suitable for scanning the particularly heterogeneous beta globin gene mutations present in the Greek population, and thus adaptable to the Mediterranean and other areas where these mutations have been identified. Within this context, β globin gene regions containing mutations frequently identified in the Greek population were divided in ten overlapping amplicons. Our reactions' setup allowed for the simultaneous amplification of multiple primer sets and partial multiplexing, thereby resulting in significant reduction of the experimental time. DNA samples from β-thalassaemia patients/carriers with defined genotypes were tested. Distinct genotypes displayed distinguishable melting curves, enabling accurate detection of mutations. The described HRMA can be adapted to a high-throughput level. It represents a rapid, simple, cost-effective, reliable, highly feasible and sensitive method for β-thalassaemia gene scanning.\n <br><br> <b>MeSH terms:<\/b> <b>MeSH terms:<\/b> Case-Control Studies; Genetic Testing; Genotype; Greece; Heterozygote; Humans; Nucleic Acid Denaturation; Point Mutation; Sensitivity and Specificity; beta-Globins; beta-Thalassemia <br><br> <b>OMOP Concepts (IDs):<\/b>  Point mutation (43020565); Beta thalassemia (4278669); Genetic test (4237017); Genetic finding (4025367); "]},"columns":[{"id":"details","name":"","type":"character","html":true}],"dataKey":"07596430a44770de391a04acb8aaba9e","static":false,"nested":true},"children":[]}]},{"name":"div","attribs":{"style":{"padding":"1rem"}},"children":[{"name":"Reactable","attribs":{"data":{"details":["<b>DOI:<\/b> 10.1371/journal.pone.0158512 <br><br> Ribavirin blood levels vary considerably between patients with standard weight-based dosing. Their impact on sustained virological response (SVR) with pegylated interferon and ribavirin is controversial, but has mostly been studied before the IL28b gene polymorphism as a possible confounder was discovered.<br><br>&emsp;The impact of serum ribavirin trough levels at week 4, at the end of treatment and of mean levels across the entire antiviral treatment with pegylated interferon and ribavirin on relapse, SVR rates and anemia was retrospectively studied by univariate and multivariable logistic regression analyses in 214 patients with HCV genotype 1-4 infection, including 88 patients with available IL28b genotyping.<br><br>&emsp;Mean ribavirin levels varied between 0.68-5.65 mg/l and significantly differed between patients with or without SVR. By multivariable regression including age, sex, HCV viral load, HCV genotype, liver fibrosis stage, prior treatments, immunosuppression and IL28b genotype, ribavirin levels consistently displayed significant influence on SVR and relapse without indication for a specific importance of higher concentrations early or late in the treatment course. Although hemoglobin decline was on average more pronounced in patients with higher ribavirin levels, hemoglobin remained relatively stable in a significant proportion of these, indicating that ribavirin levels alone are insufficient to predict anemia.<br><br>&emsp;While data are scarce to draw conclusions applicable for modern DAA therapies, these results support ribavirin treatment based on serum levels instead of purely weight-based dosing in combination with pegylated interferon.\n <br><br> <b>MeSH terms:<\/b> <b>MeSH terms:<\/b> Adult; Aged; Anemia; Antiviral Agents; Cohort Studies; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Immunosuppression Therapy; Interferons; Interleukins; Male; Middle Aged; Multivariate Analysis; Polyethylene Glycols; Polymorphism, Genetic; RNA, Viral; ROC Curve; Retrospective Studies; Ribavirin; Treatment Outcome; Young Adult <br><br> <b>OMOP Concepts (IDs):<\/b>  Genetic polymorphism (4177328); Chronic hepatitis C (198964); Polyethylene Glycols (948515); Ribavirin (1762711); Genetic finding (4025367); Anemia (439777); "]},"columns":[{"id":"details","name":"","type":"character","html":true}],"dataKey":"5e93d389284d33d533b304c367b1c608","static":false,"nested":true},"children":[]}]},{"name":"div","attribs":{"style":{"padding":"1rem"}},"children":[{"name":"Reactable","attribs":{"data":{"details":["<b>DOI:<\/b> 10.1371/journal.pone.0157323 <br><br> Although major guidelines uniformly recommend iron supplementation and erythropoietin stimulating agents (ESAs) for managing chronic anemia in persons with chronic kidney disease (CKD), there are differences in the recommended hemoglobin (Hb) treatment target and no guidelines consider the costs or cost-effectiveness of treatment. In this study, we explored the most cost-effective Hb target for anemia treatment in persons with CKD stages 3-4.<br><br>&emsp;The CKD Health Policy Model was populated with a synthetic cohort of persons over age 30 with prevalent CKD stages 3-4 (i.e., not on dialysis) and anemia created from the 1999-2010 National Health and Nutrition Examination Survey. Incremental cost-effectiveness ratios (ICERs), computed as incremental cost divided by incremental quality adjusted life years (QALYs), were assessed for Hb targets of 10 g/dl to 13 g/dl at 0.5 g/dl increments. Targeting a Hb of 10 g/dl resulted in an ICER of $32,111 compared with no treatment and targeting a Hb of 10.5 g/dl resulted in an ICER of $32,475 compared with a Hb target of 10 g/dl. QALYs increased to 4.63 for a Hb target of 10 g/dl and to 4.75 for a target of 10.5 g/dl or 11 g/dl. Any treatment target above 11 g/dl increased medical costs and decreased QALYs.<br><br>&emsp;In persons over age 30 with CKD stages 3-4, anemia treatment is most cost-effective when targeting a Hb level of 10.5 g/dl. This study provides important information for framing guidelines related to treatment of anemia in persons with CKD.\n <br><br> <b>MeSH terms:<\/b> <b>MeSH terms:<\/b> Adult; Anemia; Cost-Benefit Analysis; Hemoglobins; Humans; Molecular Targeted Therapy; Quality-Adjusted Life Years; Renal Insufficiency, Chronic <br><br> <b>OMOP Concepts (IDs):<\/b>  Quality adjusted life years (4158643); Chronic renal insufficiency (36716947); Anemia (439777); "]},"columns":[{"id":"details","name":"","type":"character","html":true}],"dataKey":"c20fec0805621947c472ef64b7f93bd0","static":false,"nested":true},"children":[]}]},{"name":"div","attribs":{"style":{"padding":"1rem"}},"children":[{"name":"Reactable","attribs":{"data":{"details":["<b>DOI:<\/b> 10.1371/journal.pone.0159215 <br><br> To determine whether Sickle cell trait (SCT) is associated with an increased severity of diabetic retinopathy.<br><br>&emsp;This was a single center retrospective study case control study of 100 eyes of 100 patients with diabetes mellitus (DM) with SCT (SCT group) and 100 eyes of 100 age-matched patients with DM without SCT (control group). The main outcome measure was the difference in the prevalence of sight threatening DR [here defined as diabetic macular edema (DME) and/or proliferative diabetic retinopathy (PDR)], between the SCT and control groups. Secondary outcome measures included differences in visual acuity, ocular comorbidities, intraocular pressure, glycemic control as assessed by random blood glucose measurement, diabetes duration, nephropathy, hyperlipidemia and hypertension.<br><br>&emsp;The SCT group had statistically significantly shorter duration of DM (median [25% quartile] 15 [8.3] years versus 20 [14.7] years, respectively)(P<0.001) and presented with statistically better metabolic control (mean difference 1.6 mmol/l, (95% confidence interval [CI], 0.1-3.3;P = 0.03). The prevalence of PDR and/or DME was significantly lower in the SCT group (58%) compared to the control group, (95%)(P<0.001). The absence of SCT (adjusted odds ratio [AOR] = 24; 95% CI, 8-72; P<0.001) and longer duration of DM (AOR = 1.1 [95% CI, 1.02-1.13]; P = 0.003) were independent predictors of PDR and/or DME.<br><br>&emsp;SCT seems to protect against the development and progression of DR. This may have implications for monitoring and screening. Prospective studies are required to confirm this association. If true, this association may indicate an increased blood glucose buffering capacity of abnormal hemoglobin.\n <br><br> <b>MeSH terms:<\/b> <b>MeSH terms:<\/b> Aged; Blood Glucose; Case-Control Studies; Diabetic Retinopathy; Disease Progression; Female; Humans; Macular Edema; Male; Middle Aged; Prevalence; Retrospective Studies; Risk Factors; Saudi Arabia; Sickle Cell Trait <br><br> <b>OMOP Concepts (IDs):<\/b>  Retinopathy due to diabetes mellitus (4174977); Macular retinal edema (4290333); Sickle cell trait (25518); "]},"columns":[{"id":"details","name":"","type":"character","html":true}],"dataKey":"58c9ea9dc90bfc07ad60bd09d80c09a1","static":false,"nested":true},"children":[]}]},{"name":"div","attribs":{"style":{"padding":"1rem"}},"children":[{"name":"Reactable","attribs":{"data":{"details":["<b>DOI:<\/b> 10.1371/journal.pone.0160032 <br><br> Subjects with glucose-6-phosphate dehydrogenase (G6PD) deficiency may be more susceptible to infections due to impaired leukocyte bactericidal activity. The disorder is common in the Mediterranean area. The aim of this study was to investigate whether G6PD deficiency may be a risk factor for acquiring H. pylori infection.<br><br>&emsp;We performed a retrospective study. Data from clinical records of 6565 patients (2278 men and 4287 women, median age 51, range 7‒94) who underwent upper endoscopy between 2002 and 2014 were collected. H. pylori status, assessed by histology plus rapid urease test or 13C-urea breath test, and G6PD status were also reported. A multiple logistic regression model was used to investigate the association between G6PD deficiency and H. pylori infection.<br><br>&emsp;Enzyme deficiency was detected in 12% (789/6565) of the entire cohort, and more specifically in 8.3% of men and in 14.0% of women. Overall, the proportion of patients positive for H. pylori was 50.6% and 51.5% among G6PD deficient and non-deficient patients (χ² = 0.271; p = 0.315). Moreover, among G6PD-deficient and normal patients the frequency of previous H. pylori infection was similar. After adjustment for age and gender the risk for acquiring H. pylori infection was similar in G6PD-deficient and normal patients. Only age was a strong statistically significant risk predictor.<br><br>&emsp;These results demonstrate for the first time that G6PD deficiency does not enhance patients' susceptibility to acquire H. pylori infection in Sardinia.\n <br><br> <b>MeSH terms:<\/b> <b>MeSH terms:<\/b> Adult; Aged; Female; Glucosephosphate Dehydrogenase Deficiency; Helicobacter Infections; Helicobacter pylori; Humans; Italy; Male; Middle Aged <br><br> <b>OMOP Concepts (IDs):<\/b>  Helicobacter pylori (42903959); Deficiency of glucose-6-phosphate dehydrogenase (4050620); "]},"columns":[{"id":"details","name":"","type":"character","html":true}],"dataKey":"2e0329d2b36268818d9994b7173bfe45","static":false,"nested":true},"children":[]}]},{"name":"div","attribs":{"style":{"padding":"1rem"}},"children":[{"name":"Reactable","attribs":{"data":{"details":["<b>DOI:<\/b> 10.1200/JCO.2016.68.1106 <br><br> Purpose Interleukin-10 (IL-10) stimulates the expansion and cytotoxicity of tumor-infiltrating CD8+ T cells and inhibits inflammatory CD4+ T cells. Pegylation prolongs the serum concentration of IL-10 without changing the immunologic profile. This phase I study sought to determine the safety and antitumor activity of AM0010. Patients and Methods Patients with selected advanced solid tumors were treated with AM0010 in a dose-escalation study, which was followed by a renal cell cancer (RCC) dose-expansion cohort. AM0010 was self-administered subcutaneously at doses of 1 to 40 μg/kg once per day. Primary end points were safety and tolerability; clinical activity and immune activation were secondary end points. Results In the dose-escalation and -expansion cohorts, 33 and 18 patients, respectively, were treated with daily subcutaneous injection of AM0010. AM0010 was tolerated in a heavily pretreated patient population. Treatment-related adverse events (AEs) included anemia, fatigue, thrombocytopenia, fever, and injection site reactions. Grade 3 to 4 nonhematopoietic treatment-related AEs, including rash (n = 2) and transaminitis (n = 1), were observed in five of 33 patients. Grade 3 to 4 anemia or thrombocytopenia was observed in five patients. Most treatment-related AEs were transient or reversible. AM0010 led to systemic immune activation with elevated immune-stimulatory cytokines and reduced transforming growth factor beta in the serum. Partial responses were observed in one patient with uveal melanoma and four of 15 evaluable patients with RCC treated at 20 μg/kg (overall response rate, 27%). Prolonged stable disease of at least 4 months was observed in four patients, including one with colorectal cancer with disease stabilization for 20 months. Conclusion AM0010 has an acceptable toxicity profile with early evidence of antitumor activity, particularly in RCC. These data support the further evaluation of AM0010 both alone and in combination with other immune therapies and chemotherapies.\n <br><br> <b>MeSH terms:<\/b> <b>MeSH terms:<\/b> Adult; Aged; Aged, 80 and over; Anemia; Carcinoma, Renal Cell; Cytokines; Drug Eruptions; Exanthema; Fatigue; Female; Fever; Humans; Injections, Subcutaneous; Interferon-gamma; Interleukin-10; Interleukin-4; Interleukin-8; Kidney Neoplasms; Male; Melanoma; Middle Aged; Neoplasms; Polyethylene Glycols; Recombinant Proteins; Thrombocytopenia; Transforming Growth Factor beta; Uveal Neoplasms; Young Adult <br><br> <b>OMOP Concepts (IDs):<\/b>  Malignant melanoma (4162276); Drug-induced dermatosis (4295465); Eruption (140214); Interferon Type II (19122123); Fever (437663); Subcutaneous injection (4138262); Thrombocytopenic disorder (432870); Lack of energy (4087481); Polyethylene Glycols (948515); Renal cell carcinoma (45765451); Neoplasm of kidney (4131748); Neoplastic disease (438112); Anemia (439777); Interleukin-8 (43531933); Interleukin-10 (42900473); Interleukin-4 (44784851); "]},"columns":[{"id":"details","name":"","type":"character","html":true}],"dataKey":"e47998a3b884db2606c03e21741f31c2","static":false,"nested":true},"children":[]}]},{"name":"div","attribs":{"style":{"padding":"1rem"}},"children":[{"name":"Reactable","attribs":{"data":{"details":["<b>DOI:<\/b> 10.1161/CIRCINTERVENTIONS.115.003279 <br><br> Acute kidney injury (AKI) complicating percutaneous coronary intervention (PCI) is associated with adverse clinical outcomes. To date, no studies have evaluated the association of blood transfusion with AKI in patients undergoing PCI.<br><br>&emsp;We used a retrospective cohort study of all patients with acute coronary syndrome undergoing PCI from CathPCI Registry (n=1 756 864). The primary outcome was AKI defined as the rise in serum creatinine post procedure ≥0.5 mg/dL or ≥25% above baseline values. AKI developed in 9.0% of study sample. Patients with AKI were older, more often women, and had high prevalence of comorbidities, including diabetes mellitus, hypertension, and advanced stages of chronic kidney disease at baseline. Blood transfusion was utilized in 2.2% of patients. In the overall sample, AKI developed in 35.1% of patients who received transfusion versus 8.4% of patients without transfusion (adjusted odds ratio, 4.87 [4.71-5.04]). In the subgroup of patients who sustained bleeding event and received transfusion, the rate of AKI was significantly increased across all preprocedure hemoglobin levels versus no blood transfusion. Similar findings were seen in the subgroup of patients with no bleeding event.<br><br>&emsp;Blood transfusion is strongly associated with AKI in patients with acute coronary syndrome undergoing PCI. Further investigation is needed to determine whether a restrictive blood transfusion strategy might improve PCI outcomes by reducing the risk of AKI.\n <br><br> <b>MeSH terms:<\/b> <b>MeSH terms:<\/b> Acute Coronary Syndrome; Acute Kidney Injury; Aged; Anemia; Biomarkers; Blood Transfusion; Chi-Square Distribution; Creatinine; Female; Hemoglobins; Hemorrhage; Humans; Logistic Models; Male; Middle Aged; Odds Ratio; Percutaneous Coronary Intervention; Propensity Score; Registries; Retrospective Studies; Risk Assessment; Risk Factors; Time Factors; Transfusion Reaction; Treatment Outcome; United States; Up-Regulation <br><br> <b>OMOP Concepts (IDs):<\/b>  Acute coronary syndrome (4215140); Transfusion of blood product (4024656); Bleeding (437312); Blood transfusion reaction (440603); Risk assessment (4024612); Creatinine (19071968); Percutaneous coronary intervention (4216130); Acute injury of kidney (761083); Anemia (439777); Blood transfusion reaction (440603); "]},"columns":[{"id":"details","name":"","type":"character","html":true}],"dataKey":"6be897fdc8bf6d2a96d83257020ca772","static":false,"nested":true},"children":[]}]},{"name":"div","attribs":{"style":{"padding":"1rem"}},"children":[{"name":"Reactable","attribs":{"data":{"details":["<b>DOI:<\/b> 10.1371/journal.pone.0161821 <br><br> Approval of drugs in chronic hepatitis C is supported by registration trials. These trials might have limited generalizability through use of strict eligibility criteria. We compared effectiveness and safety of real world hepatitis C patients eligible and ineligible for registration trials.<br><br>&emsp;We performed a nationwide, multicenter, retrospective cohort study of chronic hepatitis C patients treated in the real world. We applied a combined set of inclusion and exclusion criteria of registration trials to our cohort to determine eligibility. We compared effectiveness and safety in eligible vs. ineligible patients, and performed sensitivity analyses with strict criteria. Further, we used log binomial regression to assess relative risks of criteria on outcomes.<br><br>&emsp;In this cohort (n = 467) 47% of patients would have been ineligible for registration trials. Main exclusion criteria were related to hepatic decompensation and co-morbidity (cardiac disease, anemia, malignancy and neutropenia), and were associated with an increased risk for serious adverse events (RR 1.45-2.31). Ineligible patients developed significantly more serious adverse events than eligible patients (27% vs. 11%, p< 0.001). Effectiveness was decreased if strict criteria were used.<br><br>&emsp;Nearly half of real world hepatitis C patients would have been excluded from registration trials, and these patients are at increased risk to develop serious adverse events. Hepatic decompensation and co-morbidity were important exclusion criteria, and were related to toxicity. Therefore, new drugs should also be studied in these patients, to genuinely assess benefits and risk of therapy in the real world population.\n <br><br> <b>MeSH terms:<\/b> <b>MeSH terms:<\/b> Adult; Aged; Anemia; Antiviral Agents; Cardiovascular Diseases; Eligibility Determination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Neoplasms; Netherlands; Neutropenia; Patient Selection; Polyethylene Glycols; Recombinant Proteins; Regression Analysis; Retrospective Studies; Ribavirin; Risk Factors <br><br> <b>OMOP Concepts (IDs):<\/b>  Disorder of cardiovascular system (134057); Chronic hepatitis C (198964); Polyethylene Glycols (948515); Ribavirin (1762711); Neoplastic disease (438112); Anemia (439777); Neutropenic disorder (4119158); "]},"columns":[{"id":"details","name":"","type":"character","html":true}],"dataKey":"9e4c7186b9a68cd663fea06f7085d4dd","static":false,"nested":true},"children":[]}]},{"name":"div","attribs":{"style":{"padding":"1rem"}},"children":[{"name":"Reactable","attribs":{"data":{"details":["<b>DOI:<\/b> 10.1371/journal.pone.0162382 <br><br> This study aimed to review and quantitatively analyze (1) the association of aplastic anemia (AA) with human leukocyte antigen (HLA)-DRB1*15 and HLA-DRB1*15:01 polymorphisms and (2) the association of HLA-DRB1*15 and HLA-DRB1*15:01 polymorphisms with response to immunosuppressive therapy (IST) in AA. Published studies have reported conflicting and heterogeneous results regarding the association of HLA-DRB1*15 and HLA-DRB1*15:01 polymorphisms with response to IST in AA. The PubMed, Embase, Cochrane Library, China National Knowledge Infrastructure, Chinese BioMedical Literature, Wangfang and Chinese Social Sciences Citation Index databases were searched. All relevant publications were searched through December 2015. Odds ratio (OR), risk ratio (RR), and 95% confidence intervals (CI) for the comparison between case-control or cohort studies were evaluated. Finally, 24 articles were identified. For HLA-DRB1*15 and HLA-DRB1*15:01, the OR (95% CI) was 2.24(1.33-3.77), P < 0.01 and 2.50(1.73-3.62), P < 0.01, respectively; and the overall pooled RR was 1.72 (1.30-2.29), P < 0.01 and 1.59 (1.29-1.96), P < 0.01, respectively. Statistical evidence showed no publication bias (P > 0.05). Sensitivity analyses revealed that the results were statistically robust. The meta-analysis suggested that HLA-DRB1*15 and HLA-DRB1*15:01 polymorphisms might be associated with increased AA risk in Asians. IST might be more effective in HLA-DRB1*15+ and HLA-DRB1*15:01+ Asian patients with AA than in HLA-DRB1*15- and HLA-DRB1*15:01- Asian patients with AA. Future studies with adequate methodological quality on gene-gene and gene-environment interactions and gene treatment may yield valid results.\n <br><br> <b>MeSH terms:<\/b> <b>MeSH terms:<\/b> Alleles; Anemia, Aplastic; Asian People; Gene Frequency; Genetic Predisposition to Disease; Genotype; HLA-DRB1 Chains; Humans; Immunosuppressive Agents; Odds Ratio; Pharmacogenomic Variants; Polymorphism, Genetic; Publication Bias; Treatment Outcome <br><br> <b>OMOP Concepts (IDs):<\/b>  Genetic alleles (4235440); Hematopoietic aplasia (4119473); Genetic polymorphism (4177328); Gene frequency (4238822); Genetic finding (4025367); Genetic predisposition (4166231); "]},"columns":[{"id":"details","name":"","type":"character","html":true}],"dataKey":"b128b07a89ed5c085f15b6342db1666a","static":false,"nested":true},"children":[]}]},{"name":"div","attribs":{"style":{"padding":"1rem"}},"children":[{"name":"Reactable","attribs":{"data":{"details":["<b>DOI:<\/b> 10.1371/journal.pone.0163013 <br><br> Diastolic dysfunction is common in sickle cell disease (SCD), and is associated with an increased risk of mortality. However, the molecular pathogenesis underlying this development is poorly understood. The aim of this study was to identify a gene expression profile that is associated with diastolic function in SCD, potentially elucidating molecular mechanisms behind diastolic dysfunction development.<br><br>&emsp;Diastolic function was measured via echocardiography in 65 patients with SCD from two independent study populations. Gene expression microarray data was compared with diastolic function in both study cohorts. Candidate genes that associated in both analyses were tested for validation in a murine SCD model. Lastly, genotyping array data from the replication cohort was used to derive cis-expression quantitative trait loci (cis-eQTLs) and genetic associations within the candidate gene regions.<br><br>&emsp;Transcriptome data from both patient cohorts implicated 7 genes associated with diastolic function, and mouse SCD myocardial expression validated 3 of these genes. Genetic associations and eQTLs were detected in 2 of the 3 genes, FUCA2 and IL18.<br><br>&emsp;FUCA2 and IL18 are associated with diastolic function in SCD patients, and may be involved in the pathogenesis of the disease. Genetic polymorphisms within the FUCA2 and IL18 gene regions are also associated with diastolic function in SCD, likely by affecting expression levels of the genes.\n <br><br> <b>MeSH terms:<\/b> <b>MeSH terms:<\/b> Adolescent; Anemia, Sickle Cell; Animals; Black People; Diastole; Genome-Wide Association Study; Humans; Interleukin-18; Mice; Middle Aged; Quantitative Trait Loci; alpha-L-Fucosidase <br><br> <b>OMOP Concepts (IDs):<\/b>  Sickle cell-hemoglobin SS disease (22281); "]},"columns":[{"id":"details","name":"","type":"character","html":true}],"dataKey":"7211d614f6df847698f5764ecd875dfe","static":false,"nested":true},"children":[]}]},{"name":"div","attribs":{"style":{"padding":"1rem"}},"children":[{"name":"Reactable","attribs":{"data":{"details":["<b>DOI:<\/b> 10.1371/journal.pone.0164364 <br><br> Discovery and validation of genetic variants that influence disease severity in children with sickle cell anemia (SCA) could lead to early identification of high-risk patients, better screening strategies, and intervention with targeted and preventive therapy. We hypothesized that newly identified genetic risk factors for the general African American population could also impact laboratory biomarkers known to contribute to the clinical disease expression of SCA, including variants influencing the white blood cell count and the development of albuminuria and abnormal glomerular filtration rate. We first investigated candidate genetic polymorphisms in well-characterized SCA pediatric cohorts from three prospective NHLBI-supported clinical trials: HUSTLE, SWiTCH, and TWiTCH. We also performed whole exome sequencing to identify novel genetic variants, using both a discovery and a validation cohort. Among candidate genes, DARC rs2814778 polymorphism regulating Duffy antigen expression had a clear influence with significantly increased WBC and neutrophil counts, but did not affect the maximum tolerated dose of hydroxyurea therapy. The APOL1 G1 polymorphism, an identified risk factor for non-diabetic renal disease, was associated with albuminuria. Whole exome sequencing discovered several novel variants that maintained significance in the validation cohorts, including ZFHX4 polymorphisms affecting both the leukocyte and neutrophil counts, as well as AGGF1, CYP4B1, CUBN, TOR2A, PKD1L2, and CD163 variants affecting the glomerular filtration rate. The identification of robust, reliable, and reproducible genetic markers for disease severity in SCA remains elusive, but new genetic variants provide avenues for further validation and investigation.\n <br><br> <b>MeSH terms:<\/b> <b>MeSH terms:<\/b> Adolescent; Albuminuria; Anemia, Sickle Cell; Apolipoprotein L1; Apolipoproteins; Child; Duffy Blood-Group System; Female; Genetic Variation; Genotype; Glomerular Filtration Rate; Homeodomain Proteins; Humans; Hydroxyurea; Leukocyte Count; Leukocytes; Lipoproteins, HDL; Male; Neutrophils; Phenotype; Polymorphism, Single Nucleotide; Prospective Studies; Receptors, Cell Surface; Risk Factors; Sequence Analysis, DNA; Transcription Factors <br><br> <b>OMOP Concepts (IDs):<\/b>  Sickle cell-hemoglobin SS disease (22281); Genetic variation (4271711); hydroxyurea (1377141); Phenotype (4215157); Albuminuria (4168705); White blood cell count (4298431); Genetic finding (4025367); "]},"columns":[{"id":"details","name":"","type":"character","html":true}],"dataKey":"d1d17f9b77c2569cb2f350cdfac8e443","static":false,"nested":true},"children":[]}]},{"name":"div","attribs":{"style":{"padding":"1rem"}},"children":[{"name":"Reactable","attribs":{"data":{"details":["<b>DOI:<\/b> 10.1371/journal.pone.0164526 <br><br> Sudden death is a leading cause of mortality in sickle cell disease, implicating ventricular tachyarrhythmias. Prolonged QTc on an electrocardiogram (ECG), commonly seen with myocardial ischemia, is a known risk for polymorphic ventricular tachycardia (VT). We hypothesized that prolonged QTc is associated with mortality in sickle cell disease. ECG were analyzed from a cohort of 224 sickle patients (University of Illinois at Chicago, UIC) along with available laboratory, and echocardiographic findings, and from another cohort of 38 patients (University of Chicago, UC) for which cardiac MRI and free heme values were also measured. In the UIC cohort, QTc was potentially related to mortality with a hazard ratio (HR) of 1.22 per 10ms, (P = 0.015), and a HR = 3.19 (P = 0.045) for a QTc>480ms. In multivariate analyses, QTc remained significantly associated with survival after adjusting for inpatient ECG status (HR 1.26 per 10ms interval, P = 0.010) and genotype status [HR 1.21 per 10ms interval, P = 0.037). QTc trended toward association with mortality after adjusting for both LDH and hydroxyurea use (HR 1.21 per 10ms interval, P = 0.062) but was not significant after adjusting for TRV. In univariate analyses, QTc was related to markers of hemolysis including AST (P = 0.031), hemoglobin (P = 0.014), TR velocity (P = 0.036), higher in inpatients (P<0.001) and those with an SS compared to SC genotype (P<0.001) in the UIC cohort as well as to free heme in the UC cohort (P = 0.002). These findings support a relationship of prolonged QTc with hemolysis and potentially mortality in sickle cell disease.\n <br><br> <b>MeSH terms:<\/b> <b>MeSH terms:<\/b> Adult; Anemia, Sickle Cell; Aspartate Aminotransferases; Cohort Studies; Death, Sudden, Cardiac; Echocardiography; Electrocardiography; Female; Genotype; Heart; Hemoglobins; Hemolysis; Humans; Hydroxyurea; Kaplan-Meier Estimate; L-Lactate Dehydrogenase; Long QT Syndrome; Magnetic Resonance Imaging; Male; Middle Aged; Proportional Hazards Models; Regression Analysis; Risk Factors <br><br> <b>OMOP Concepts (IDs):<\/b>  Echocardiography (4230911); Sudden cardiac death (4317150); Electrocardiographic procedure (4163951); Sickle cell-hemoglobin SS disease (22281); Magnetic resonance imaging (4013636); hydroxyurea (1377141); Long QT syndrome (314664); Genetic finding (4025367); "]},"columns":[{"id":"details","name":"","type":"character","html":true}],"dataKey":"0bda29f21bda18a60abd2a3cbc98219c","static":false,"nested":true},"children":[]}]},{"name":"div","attribs":{"style":{"padding":"1rem"}},"children":[{"name":"Reactable","attribs":{"data":{"details":["<b>DOI:<\/b> 10.1371/journal.pone.0164743 <br><br> White Blood Cell (WBC) count, %HbF, and serum creatinine (Cr), have been identified as markers for increased mortality in sickle cell anemia (SCA) but no studies have examined the significance of longitudinal rate of change in these or other biomarkers for SCA individuals.<br><br>&emsp;Clinical, demographic and laboratory data from SCA patients seen in 2002 by our hospital system were obtained. Those who were still followed in 2012 (survival cohort) were compared to those who had died in the interim (mortality cohort). Patients lost to follow-up were excluded. Age adjusted multivariable Cox proportional hazards models were constructed to assess hazard ratios of mortality risk associated with the direction and degree of change for each variable.<br><br>&emsp;359 SCA patients were identified. Baseline higher levels of WBC, serum creatinine and hospital admissions were associated with increased mortality, as were alkaline phosphatase and aspartate aminotransaminase levels. Lower baseline levels of %HbF were also associated with increased mortality. When longitudinal rates of change for individuals were assessed, increases in Hb or WBC over patient baseline values were associated with greater mortality risk (HR 1.54, p = 0.02 and HR 1.16, p = 0.01 with negative predictive values of 87.8 and 94.4 respectively), while increasing ED use was associated with decreased mortality (HR 0.84, p = 0.01). We did not detect any increased mortality risk for longitudinal changes in annual clinic visits or admissions, creatinine or %HbF.<br><br>&emsp;Although initial steady state observations can help predict survival in SCA, the longitudinal course of a patient may give additional prognostic information.\n <br><br> <b>MeSH terms:<\/b> <b>MeSH terms:<\/b> Adolescent; Adult; Anemia, Sickle Cell; Biomarkers; Child; Creatinine; Female; Fetal Hemoglobin; Humans; Leukocyte Count; Longitudinal Studies; Male; Middle Aged; Prognosis; Proportional Hazards Models; Survival Analysis; Young Adult <br><br> <b>OMOP Concepts (IDs):<\/b>  Determination of prognosis (4069425); Hemoglobin F (4339104); Creatinine (19071968); Sickle cell-hemoglobin SS disease (22281); White blood cell count (4298431); "]},"columns":[{"id":"details","name":"","type":"character","html":true}],"dataKey":"2021e23506609eaf1b54250f612f5d58","static":false,"nested":true},"children":[]}]},{"name":"div","attribs":{"style":{"padding":"1rem"}},"children":[{"name":"Reactable","attribs":{"data":{"details":["<b>DOI:<\/b> 10.1371/journal.pone.0164865 <br><br> Anemia is an important prognostic factor in hemodialysis patients. It has been reported that parathyroidectomy ameliorates anemia and reduces the requirement of postoperative erythropoiesis-stimulating agents. The objective of this study was to assess the effect of cinacalcet, which is considered as a pharmacological parathyroidectomy, on anemia in hemodialysis patients.<br><br>&emsp;We used data from a prospective cohort of Japanese hemodialysis patients with secondary hyperparathyroidism; the criteria were: intact parathyroid hormone concentrations ≥ 180 pg/mL or use of an intravenous or oral vitamin D receptor activator. All patients were cinacalcet-naïve at study enrollment. The main outcome measure was achievement of the target hemoglobin level (≥10.0 g/dL), which was measured repeatedly every 6 months. Cinacalcet exposure was defined as cumulative time since initiation. Both conventional longitudinal models and marginal structural models were adjusted for confounding factors.<br><br>&emsp;Among 3,201 cinacalcet-naïve individuals at baseline, cinacalcet was initiated in 1,337 individuals during the follow up. Cinacalcet users were slightly younger; included more patients with chronic glomerulonephritis and fewer with diabetes; were more likely to have a history of parathyroidectomy; and were more often on activated vitamin D agents, phosphate binders, and iron supplements. After adjusting for both time-invariant and time-varying potential confounders, including demographics, comorbidities, comedications, and laboratory values, each additional 6-month duration on cinacalcet was associated with a 1.1-fold increase in the odds of achieving the target hemoglobin level.<br><br>&emsp;Cinacalcet may improve anemia in chronic hemodialysis patients with secondary hyperparathyroidism, possibly through pathways both within and outside the parathyroid hormone pathways. Further investigations are warranted to delineate the roles of cinacalcet not only in the management of chronic kidney disease-mineral and bone disorder but also in anemia control.\n <br><br> <b>MeSH terms:<\/b> <b>MeSH terms:<\/b> Aged; Anemia; Calcimimetic Agents; Calcitriol; Case-Control Studies; Cinacalcet; Diabetes Complications; Female; Follow-Up Studies; Glomerulonephritis; Hemoglobins; Humans; Hyperparathyroidism, Secondary; Kidney Failure, Chronic; Male; Middle Aged; Odds Ratio; Parathyroid Hormone; Prospective Studies; Receptors, Calcitriol; Renal Dialysis; Treatment Outcome <br><br> <b>OMOP Concepts (IDs):<\/b>  cinacalcet (1548111); End-stage renal disease (193782); Calcitriol (19035631); Complication due to diabetes mellitus (442793); Glomerulonephritis (4263367); Renal dialysis (4146536); Secondary hyperparathyroidism (138388); Anemia (439777); Parathyroid Hormone (43532113); "]},"columns":[{"id":"details","name":"","type":"character","html":true}],"dataKey":"a44190683749c1c5ad4ab9ae18ad1cb3","static":false,"nested":true},"children":[]}]},{"name":"div","attribs":{"style":{"padding":"1rem"}},"children":[{"name":"Reactable","attribs":{"data":{"details":["<b>DOI:<\/b> 10.1371/journal.pone.0165238 <br><br> Pregnancy in women with Sickle Cell Disease (SCD) has been linked with an increased incidence of adverse foetal outcomes when compared to women without haemoglobinopathies (HbAA). There's a paucity of data into foetal outcomes for infants born to women with SCD. Customised growth charts have been demonstrated to be better than population-based growth charts at identifying unhealthy small babies. We analysed the mean birth weight and customised birth weight centiles of infants born to mothers with SCD versus mothers with HbAA genotype, to quantify the risk of having a smaller baby. Birth weight and birth weight centiles were analysed for 88 women with SCD (50 HbSS; 38 HbSC) and 176 controls (HbAA). Statistically significant differences were seen in the mean birth weight (P value = 0.004) and the mean birth weight centiles (P value = 0.016). We conclude that SCD is a risk factor for having a smaller baby.\n <br><br> <b>MeSH terms:<\/b> <b>MeSH terms:<\/b> Anemia, Sickle Cell; Birth Weight; Disease Progression; Female; Humans; Male; Pregnancy; Pregnancy Complications; Retrospective Studies <br><br> <b>OMOP Concepts (IDs):<\/b>  Birth weight finding (4187520); Pregnant (4299535); Complication occurring during pregnancy (43530950); Sickle cell-hemoglobin SS disease (22281); "]},"columns":[{"id":"details","name":"","type":"character","html":true}],"dataKey":"a0d68d65e718bf5e56caf8ba3d1f5986","static":false,"nested":true},"children":[]}]},{"name":"div","attribs":{"style":{"padding":"1rem"}},"children":[{"name":"Reactable","attribs":{"data":{"details":["<b>DOI:<\/b> 10.1371/journal.pone.0166192 <br><br> To examine the association of glucose-6-phosphate dehydrogenase (G6PD) deficiency with adolescent physical and mental health, as effects of G6PD deficiency on health are rarely reported.<br><br>&emsp;In a population-representative Chinese birth cohort: \"Children of 1997\" (n = 8,327), we estimated the adjusted associations of G6PD deficiency with growth using generalized estimating equations, with pubertal onset using interval censored regression, with hospitalization using Cox proportional hazards regression and with size, blood pressure, pubertal maturation and mental health using linear regression with multiple imputation and inverse probability weighting.<br><br>&emsp;Among 5,520 screened adolescents (66% follow-up), 4.8% boys and 0.5% girls had G6PD deficiency. G6PD-deficiency was not associated with birth weight-for-gestational age or length/height gain into adolescence, but was associated with lower childhood body mass index (BMI) gain (-0.38 z-score, 95% confidence interval (CI) -0.57, -0.20), adjusted for sex and parental education, and later onset of pubic hair development (time ratio = 1.029, 95% CI 1.007, 1.050). G6PD deficiency was not associated with blood pressure, height, BMI or mental health in adolescence, nor with serious infectious morbidity until adolescence.<br><br>&emsp;G6PD deficient adolescents had broadly similar physical and mental health indicators, but transiently lower BMI gain and later pubic hair development, whose long-term implications warrant investigation.\n <br><br> <b>MeSH terms:<\/b> <b>MeSH terms:<\/b> Birth Weight; Body Mass Index; Child; Child Development; Female; Glucosephosphate Dehydrogenase; Glucosephosphate Dehydrogenase Deficiency; Humans; Male; Mental Health; Puberty; Risk Factors; Sexual Maturation <br><br> <b>OMOP Concepts (IDs):<\/b>  Birth weight finding (4187520); Sexuality matured to pubertal state (43021217); Deficiency of glucose-6-phosphate dehydrogenase (4050620); "]},"columns":[{"id":"details","name":"","type":"character","html":true}],"dataKey":"864f1c2476a4e4e3702b811c877db819","static":false,"nested":true},"children":[]}]},{"name":"div","attribs":{"style":{"padding":"1rem"}},"children":[{"name":"Reactable","attribs":{"data":{"details":["<b>DOI:<\/b> 10.1371/journal.pone.0167146 <br><br> Ferric carboxymaltose (FCM) and iron isomaltoside 1000 (IIM) are increasingly used because they allow correction of severe iron deficiency in a single infusion. A transient decrease in serum phosphate concentrations is a frequent side effect of FCM.<br><br>&emsp;To characterize this adverse event and search for its predictors in a gastroenterology clinic patient cohort.<br><br>&emsp;Electronic medical records of patients attending the University Hospital of Innsbruck were searched for the keywords ferric carboxymaltose or iron isomaltoside. Eighty-one patients with documented administration of FCM or IIM with plasma phosphate concentrations before and after treatment were included.<br><br>&emsp;The prevalence of hypophosphatemia (<0.8 mmol/L) increased from 11% to 32.1% after treatment with i.v. iron. The hypophosphatemia risk was greater after FCM (45.5%) compared with IIM (4%). Severe hypophosphatemia (<0.6 mmol/L) occurred exclusively after FCM (32.7%). The odds for hypophosphatemia after i.v. iron treatment were independently determined by baseline phosphate and the choice of i.v. iron preparation (FCM vs. IIM-OR = 20.8; 95% CI, 2.6-166; p = 0.004). The median time with hypophosphatemia was 41 days, but prolonged hypophosphatemia of ≥ 2 months was documented in 13 of 17 patients in whom follow-up was available. A significant increase in the phosphaturic hormone intact FGF-23 in hypophosphatemic patients shows that this adverse event is caused by FCM-induced hormone dysregulation.<br><br>&emsp;Treatment with FCM is associated with a high risk of developing severe and prolonged hypophosphatemia and should therefore be monitored. Hypophosphatemia risk appears to be substantially lower with IIM.\n <br><br> <b>MeSH terms:<\/b> <b>MeSH terms:<\/b> Administration, Intravenous; Adult; Aged; Anemia, Iron-Deficiency; Biomarkers; Disaccharides; Female; Ferric Compounds; Fibroblast Growth Factor-23; Humans; Hypophosphatemia; Male; Maltose; Middle Aged; Phosphates; Prevalence; Retrospective Studies; Risk <br><br> <b>OMOP Concepts (IDs):<\/b>  Iron deficiency anemia (436659); Hypophosphatemia (4177973); Maltose (42899344); "]},"columns":[{"id":"details","name":"","type":"character","html":true}],"dataKey":"b3b2f4368e21bdd1af4266764eec46b6","static":false,"nested":true},"children":[]}]},{"name":"div","attribs":{"style":{"padding":"1rem"}},"children":[{"name":"Reactable","attribs":{"data":{"details":["<b>DOI:<\/b> 10.1371/journal.pone.0168121 <br><br> Nutrition in the school-aged child matters for brain development and public policy investments globally. Our group previously conducted a trial in urban schools of Haiti to examine the effects of a fortified peanut butter snack, Vita Mamba, with limited findings for anemia.<br><br>&emsp;We aimed to test the hypothesis that Vita Mamba, with systematic deworming in both study arms, would significantly reduce anemia among rural, school-aged children.<br><br>&emsp;A cluster, randomized longitudinal study was conducted in two rural communities of the North-East Department of Haiti, 2014-2015. Healthy children ages 3-16 years were enrolled (n = 321) and assigned by school to intervention (Vita Mamba and deworming) and control (deworming). Vita Mamba contains 260 kcal and meets >75% of the Recommended Dietary Allowance for critical micronutrients. Multivariate regression analyses including propensity score matching techniques to correct for potential group imbalance (Kernel-based Matching and Propensity Score Weighting) were applied to examine difference-in-difference intervention effects.<br><br>&emsp;At baseline, 51% of the children were anemic with no significant differences between study groups. Vita Mamba supplementation showed a consistent, positive effect across regression models on increasing Hb concentration and reducing the odds of anemia compared to the control group after adjusting for child age, vitamin A supplementation, milk consumption, and height-for-age z score. The average treatment effect for the treated in the Propensity Score Weighting models was 0.62±0.27 grams per 100 milliliters (g/dL) for Hb concentration (F = 4.64, P = 0.001), and the odds of anemia were reduced by 88% (Wald χ² = 9.77, P = 0.02). No differences in change in anthropometric markers were evident.<br><br>&emsp;School feeding programs that integrate fortified foods with deworming could reduce anemia burden with important implications for learning, health, and well-being. The rural-urban differences in anemia require further study.\n <br><br> <b>MeSH terms:<\/b> <b>MeSH terms:<\/b> Adolescent; Adult; Anemia; Anthropometry; Body Weight; Case-Control Studies; Child; Child, Preschool; Dietary Supplements; Female; Food, Fortified; Haiti; Humans; Longitudinal Studies; Male; Micronutrients; Rural Population; Schools; Snacks <br><br> <b>OMOP Concepts (IDs):<\/b>  Anemia (439777); "]},"columns":[{"id":"details","name":"","type":"character","html":true}],"dataKey":"47562d9689f9c308d5e0510a3dfb169e","static":false,"nested":true},"children":[]}]},{"name":"div","attribs":{"style":{"padding":"1rem"}},"children":[{"name":"Reactable","attribs":{"data":{"details":["<b>DOI:<\/b> 10.1371/journal.pone.0171067 <br><br> Invariant NKT (iNKT) cells can be activated to stimulate a broad inflammatory response. In murine models of sickle cell disease (SCD), interruption of iNKT cell activity prevents tissue injury from vaso-occlusion. NKTT120 is an anti-iNKT cell monoclonal antibody that has the potential to rapidly and specifically deplete iNKT cells and, potentially, prevent vaso-occlusion. We conducted an open-label, multi-center, single-ascending-dose study of NKTT120 to determine its pharmacokinetics, pharmacodynamics and safety in steady-state patients with SCD. Doses were escalated in a 3+3 study design over a range from 0.001 mg/kg to 1.0 mg/kg. Twenty-one adults with SCD were administered NKTT120 as part of 7 dose cohorts. Plasma levels of NKTT120 predictably increased with higher doses. Median half-life of NKTT120 was 263 hours. All subjects in the higher dose cohorts (0.1 mg/kg, 0.3 mg/kg, and 1 mg/kg) demonstrated decreased iNKT cells below the lower limit of quantification within 6 hours after infusion, the earliest time point at which they were measured. In those subjects who received the two highest doses of NKTT120 (0.3, 1 mg/kg), iNKT cells were not detectable in the peripheral blood for a range of 2 to 5 months. There were no serious adverse events in the study deemed to be related to NKTT120. In adults with SCD, NKTT120 produced rapid, specific and sustained iNKT cell depletion without any infusional toxicity or attributed serious adverse events. The next step is a trial to determine NKTT120's ability to decrease rate of vaso-occlusive pain episodes.<br><br>&emsp;clinicaltrials.gov NCT01783691.\n <br><br> <b>MeSH terms:<\/b> <b>MeSH terms:<\/b> Adolescent; Adult; Anemia, Sickle Cell; Animals; Antibodies, Monoclonal, Humanized; Child; Cohort Studies; Female; Half-Life; Humans; Lymphocyte Depletion; Male; Natural Killer T-Cells; Young Adult <br><br> <b>OMOP Concepts (IDs):<\/b>  Lymphocyte depletion (4157037); Sickle cell-hemoglobin SS disease (22281); "]},"columns":[{"id":"details","name":"","type":"character","html":true}],"dataKey":"847f1233ef8e3451fc9645ad761e5f85","static":false,"nested":true},"children":[]}]},{"name":"div","attribs":{"style":{"padding":"1rem"}},"children":[{"name":"Reactable","attribs":{"data":{"details":["<b>DOI:<\/b> 10.1371/journal.pone.0171066 <br><br> As the major toxicity induced by pemetrexed plus carboplatin is severe hematologic toxicities, the aim of this study was to determine the risk factors for severe hematologic toxicities in lung cancer patients.<br><br>&emsp;We retrospectively investigated data from lung cancer patients who had received pemetrexed plus carboplatin, with or without bevacizumab. This observational study was carried out at Ehime University Hospital using electronic medical records dating from July 2009 to March 2015. Severe hematologic toxicities were defined as grade 3 or 4, according to the Common Terminology Criteria for Adverse Events, version 4.0.<br><br>&emsp;Forty-two patients were included in the study. The incidence of grade 3 or 4 hematologic toxicities during the first cycle of chemotherapy and during all cycles was 19.0% and 16.1%, respectively. Multivariate time-depend generalized estimating equations logistic regression analysis revealed that regular use of non-steroidal anti-inflammatory drugs (NSAIDs) was significantly associated with an increased risk of severe hematologic toxicities during all cycles (adjusted odds ratio (OR): 8.32, 95% confidence interval (CI): 1.27-54.38; p = 0.03), whereas creatinine clearance of <45 mL/min was not significantly associated with an increased risk of severe hematologic toxicities during all cycles (adjusted OR: 0.91, 95% CI: 0.25-3.34; p = 0.88).<br><br>&emsp;The results suggest that severe hematologic toxicities in patients receiving carboplatin-based pemetrexed may be significantly induced by the inhibition of renal tubular pemetrexed secretion through drug-drug interactions between NSAIDs and pemetrexed rather than through glomerular filtration of pemetrexed, even with moderate to sufficient renal function.\n <br><br> <b>MeSH terms:<\/b> <b>MeSH terms:<\/b> Adult; Aged; Aged, 80 and over; Anemia; Anti-Inflammatory Agents, Non-Steroidal; Carboplatin; Female; Hematologic Diseases; Humans; Leukopenia; Lung Neoplasms; Male; Middle Aged; Multivariate Analysis; Neutropenia; Pemetrexed; Retrospective Studies; Thrombocytopenia; Treatment Outcome <br><br> <b>OMOP Concepts (IDs):<\/b>  pemetrexed (1304919); Carboplatin (1344905); Thrombocytopenic disorder (432870); Neoplasm of lung (4128888); Leukopenia (435224); Anemia (439777); Neutropenic disorder (4119158); "]},"columns":[{"id":"details","name":"","type":"character","html":true}],"dataKey":"7810c09ba422a25990a5905aa04ba7ed","static":false,"nested":true},"children":[]}]},{"name":"div","attribs":{"style":{"padding":"1rem"}},"children":[{"name":"Reactable","attribs":{"data":{"details":["<b>DOI:<\/b> 10.1371/journal.pone.0172980 <br><br> Glucose-6-phosphate dehydrogenase (G6PD) deficiency is an X-linked disorder that affects as many as 400 million people worldwide, making it the most common enzymatic defect. Subjects with G6PD deficiency are more likely to develop neonatal hyperbilirubinemia potentially leading to kernicterus and are at increased risk for acute hemolytic anemia when exposed to pro-oxidant compounds such as anti-malarial drugs. We collected umbilical cord blood from 300 males born in Uganda to assess for novel markers of systemic oxidative stress. We determined that 10.7% of the samples collected were G6PD A- deficient (G202A/A376G) and when these were compared with unaffected controls, there was significantly higher 8-hydroxy-2'-deoxyguanosine (8-OHdG) concentration, elevated ferritin, increased leukocyte count and higher small molecule antioxidant capacity. These data suggest increased baseline oxidative stress and an elevated antioxidant response in umbilical cord blood of patients with G6PD deficiency.\n <br><br> <b>MeSH terms:<\/b> <b>MeSH terms:<\/b> Biomarkers; Case-Control Studies; Fetal Blood; Glucosephosphate Dehydrogenase Deficiency; Humans; Infant, Newborn; Male; Oxidative Stress; Uganda <br><br> <b>OMOP Concepts (IDs):<\/b>  Deficiency of glucose-6-phosphate dehydrogenase (4050620); "]},"columns":[{"id":"details","name":"","type":"character","html":true}],"dataKey":"d35c846e0859c2434816b19f6735aa47","static":false,"nested":true},"children":[]}]},{"name":"div","attribs":{"style":{"padding":"1rem"}},"children":[{"name":"Reactable","attribs":{"data":{"details":["<b>DOI:<\/b> 10.1371/journal.pone.0173173 <br><br> Anemia affects around 38.2% and 22% of pregnant women at a global and national level respectively. In developing countries, women start pregnancy with already depleted body stores of iron and other vitamins with significant variation of anemia within and between regions.<br><br>&emsp;To identify the determinants of anemia among pregnant mothers attending antenatal care in Dessie town health facilities, northern central Ethiopia.<br><br>&emsp;A health facility based unmatched case control study was conducted among 112 cases and 336 controls from January to March 2016 G.C. The sample size was determined by using Epi Info version 7.1.5.2. Study subjects were selected using consecutive sampling technique. Data were collected using a structured questionnaire, entered using Epi Data version 3.1 and analyzed using SPSS version 20. Bivariable and multivariable logistic regression model was used to see the determinants of anemia. Adjusted odds ratio (AOR) with 95% confidence interval (CI) and p-value<0.05 were used to see the significant association.<br><br>&emsp;Failure to take dark green leafy vegetables per two weeks (AOR = 5.02, 95% CI: 2.16, 11.71), didn't take chicken per two weeks (AOR = 2.68, 95% CI: 1.22, 5.86), 1st trimester (AOR = 2.07, 95% CI: 1.12, 3.84), 3rd trimester (AOR = 2.96, 95% CI: 1.53, 5.72), HIV infection (AOR = 6.78, 95% CI: 2.28, 20.18) and medication (AOR = 3.57 95% CI: 1.60, 7.98) were positively associated with anemia.<br><br>&emsp;Inadequate intake of dark green leafy vegetables, inadequate consumption of chicken, trimester of the current pregnancy, HIV infection and medication were the determinants of anemia among pregnant women. Therefore, anemia prevention strategy should include promotion of adequate intake of dark green leafy vegetables and chicken, increase meal pattern during the entire pregnancy and strengthen the prevention of mother to child HIV transmission/antenatal care programs.\n <br><br> <b>MeSH terms:<\/b> <b>MeSH terms:<\/b> Adolescent; Adult; Anemia; Child Health Services; Ethiopia; Humans; Infant; Infant Mortality; Infant, Newborn; Mothers; Patient Acceptance of Health Care; Public Health Practice; Young Adult <br><br> <b>OMOP Concepts (IDs):<\/b>  Anemia (439777); "]},"columns":[{"id":"details","name":"","type":"character","html":true}],"dataKey":"a4bd1f1c22a2648cd896f389aab4f925","static":false,"nested":true},"children":[]}]},{"name":"div","attribs":{"style":{"padding":"1rem"}},"children":[{"name":"Reactable","attribs":{"data":{"details":["<b>DOI:<\/b> 10.1371/journal.pone.0170898 <br><br> As part of a field trial (PACTR201411000882128) to provide evidence on the combined use of long-lasting insecticidal nets and indoor residual spray for malaria prevention, we measured haemoglobin values among children aged 6 to 59 months. The aim of this study was to estimate the prevalence of anaemia, and to determine the risk factors of anaemia and change in haemoglobin value in Adami Tullu district in south-central Ethiopia.<br><br>&emsp;Repeated cross-sectional surveys among 2984 children in 2014 and 3128 children in 2015; and a cohort study (malaria as exposure and anaemia as outcome variable) were conducted. The study area faced severe drought and food shortages in 2015. Anaemia was diagnosed using HemoCue Hb 301, and children with haemoglobin <11 g/dl were classified as anaemic. Multilevel and Cox regression models were applied to assess predictors of anaemia.<br><br>&emsp;The prevalence of anaemia was 28.2% [95% Confidence Interval (CI), 26.6-29.8] in 2014 and increased to 36.8% (95% CI, 35.1-38.5) in 2015 (P<0.001). The incidence of anaemia was 30; (95% CI, 28-32) cases per 100 children years of observation. The risk of anaemia was high (adjusted Hazard Ratio = 10) among children with malaria. Children from poor families [Adjusted Odds Ratio (AOR); 1.3; 95% CI, 1.1-1.6)], stunted children (AOR 1.5; 95% CI; 1.2-1.8), and children aged less than 36 months (AOR; 2.0; 95% CI, 1.6-2.4) were at risk of anaemia compared to their counterparts. There was no significant difference in risk of anaemia among the trial arms.<br><br>&emsp;Young age, stunting, malaria and poverty were the main predictors of anaemia. An increase in the prevalence of anaemia was observed over a year, despite malaria prevention effort, which could be related to the drought and food shortage. Therefore, conducting trials in settings prone to drought and famine may bring unexpected challenges.\n <br><br> <b>MeSH terms:<\/b> <b>MeSH terms:<\/b> Anemia; Child; Child, Preschool; Cluster Analysis; Droughts; Ethiopia; Female; Humans; Infant; Male <br><br> <b>OMOP Concepts (IDs):<\/b>  Anemia (439777); "]},"columns":[{"id":"details","name":"","type":"character","html":true}],"dataKey":"abf3b09ce468c0d57b4f8ec16562454f","static":false,"nested":true},"children":[]}]},{"name":"div","attribs":{"style":{"padding":"1rem"}},"children":[{"name":"Reactable","attribs":{"data":{"details":["<b>DOI:<\/b> 10.1200/JCO.2016.71.3271 <br><br> Purpose Most anemic patients with non-deleted 5q lower-risk myelodysplastic syndromes (MDS) are treated with erythropoiesis-stimulating agents (ESAs), with a response rate of approximately 50%. Second-line treatments, including hypomethylating agents (HMAs), lenalidomide (LEN), and investigational drugs, may be used after ESA failure in some countries, but their effect on disease progression and overall survival (OS) is unknown. Here, we analyzed outcome after ESA failure and the effect of second-line treatments. Patients and Methods We examined an international retrospective cohort of 1,698 patients with non-del(5q) lower-risk MDS treated with ESAs. Results Erythroid response to ESAs was 61.5%, and median response duration was 17 months. Of 1,147 patients experiencing ESA failure, 653 experienced primary failure and 494 experienced relapse after a response. Primary failure of ESAs was associated with a higher risk of acute myeloid leukemia (AML) progression, which did not translate into an OS difference. Of 450 patients (39%) who received second-line treatment, 194 received HMAs, 148 received LEN, and 108 received other treatments (MISC), whereas 697 received RBC transfusions only. Five-year AML cumulative incidence was 20.3%, 20.3%, and 11.3% for those receiving HMAs, LEN, and MISC, respectively ( P = .05). Five-year OS for patients receiving HMA, LEN, and MISC was 36.5%, 41.7%, and 51%, respectively ( P = .21). In a multivariable analysis adjusted for age, sex, revised International Prognostic Scoring System score, and progression at ESA failure, there was no significant OS difference among the three groups. Conclusion In this large, multicenter, retrospective cohort of patients with non-del(5q) lower-risk MDS treated with ESAs, none of the most commonly used second-line treatments (HMA and LEN) significantly improved OS. Early failure of ESAs was associated with a higher risk of AML progression.\n <br><br> <b>MeSH terms:<\/b> <b>MeSH terms:<\/b> Aged; Aged, 80 and over; Anemia; Antilymphocyte Serum; Antineoplastic Agents; Arsenic; Azacitidine; Chromosome Deletion; Chromosomes, Human, Pair 5; Cyclosporine; Cytarabine; Decitabine; Disease Progression; Enzyme Inhibitors; Erythrocyte Transfusion; Female; Hematinics; Humans; Hydroxyurea; Immunologic Factors; Lenalidomide; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Recurrence; Retreatment; Retrospective Studies; Risk Factors; Survival Rate; Thalidomide; Treatment Failure; Tretinoin; Valproic Acid <br><br> <b>OMOP Concepts (IDs):<\/b>  lenalidomide (19026972); decitabine (19024728); Arsenic (19010961); Cytarabine (1311078); Myelodysplastic syndrome (138994); Acute myeloid leukemia, disease (140352); Tretinoin (903643); Cyclosporine (19010482); Transfusion of red blood cells (4022173); Congenital chromosomal disease (434153); Thalidomide (19137042); Azacitidine (1314865); hydroxyurea (1377141); Anemia (439777); "]},"columns":[{"id":"details","name":"","type":"character","html":true}],"dataKey":"d9d323a8222dd01696dc6df042b66a0d","static":false,"nested":true},"children":[]}]},{"name":"div","attribs":{"style":{"padding":"1rem"}},"children":[{"name":"Reactable","attribs":{"data":{"details":["<b>DOI:<\/b> 10.1371/journal.pone.0174673 <br><br> Micronutrient deficiencies can compromise the development potential of school-aged children, and their later health and productivity as adults. School feeding and school-based fortification approaches have been utilized globally to redress nutritional deficiencies in this age group.<br><br>&emsp;We explored the acceptability and micronutrient impact of a Bangladesh Government supported school-based micronutrient fortification program for children attending rural primary schools in 10 disadvantaged sub-districts.<br><br>&emsp;We applied a mixed methods approach. The quantitative component assessed the impact of micronutrient fortification on 351 children aged 6-11 years using a cohort pre-post research design with a control group. The qualitative component explored the acceptability of the intervention using focus group discussions, body mapping and semi-structured interviews with teachers, school-going children and school authorities.<br><br>&emsp;Daily consumption of fortified biscuits by primary school children had a significant positive impact on mean levels of iron, folic acid, vitamin B12, retinol and vitamin D controlling for sex, baseline deficiency status, CRP, and H. pylori. Levels of anemia and vitamin D deficiency were also significantly reduced. Qualitative findings indicated the widespread acceptability of the daily biscuit. Teachers perceived students to be more attentive in class, less tired, and some attributed better school performance to biscuit consumption. Children reported similar improvements in concentration and energy levels.<br><br>&emsp;This study is among the first in Bangladesh to comprehensively assess a school-based fortification program in terms of its acceptability and impact on micronutrient status of children aged 6-11 years of age. While results strongly support this modality of school feeding, research on the cognitive impacts of micronutrient fortified biscuits will help clarify the case for scaled-up investments in school- based feeding program in Bangladesh and other low and middle income countries.\n <br><br> <b>MeSH terms:<\/b> <b>MeSH terms:<\/b> Anemia; Bangladesh; Child; Child Nutrition Disorders; Female; Folic Acid; Food, Fortified; Humans; Iron; Male; Micronutrients; Vitamin A; Vitamin B 12; Vitamin D; Vitamin D Deficiency; Vitamins <br><br> <b>OMOP Concepts (IDs):<\/b>  Vitamin B 12 (1308738); Folic Acid (19111620); Vitamin D deficiency (436070); Vitamin A (19008339); Vitamin D (19009405); Anemia (439777); Iron (1360067); "]},"columns":[{"id":"details","name":"","type":"character","html":true}],"dataKey":"4ee919410d68280684dcdaca13ace400","static":false,"nested":true},"children":[]}]},{"name":"div","attribs":{"style":{"padding":"1rem"}},"children":[{"name":"Reactable","attribs":{"data":{"details":["<b>DOI:<\/b> 10.1093/jnci/djx056 <br><br> Female survivors of childhood cancer treated with abdominal radiotherapy who manage to conceive are at risk of delivering premature and low-birthweight offspring, but little is known about whether abdominal radiotherapy may also be associated with additional complications during pregnancy and labor. We investigated the risk of developing pregnancy and labor complications among female survivors of childhood cancer in the British Childhood Cancer Survivor Study (BCCSS).<br><br>&emsp;Pregnancy and labor complications were identified by linking the BCCSS cohort (n = 17 980) to the Hospital Episode Statistics (HES) for England. Relative risks (RRs) of pregnancy and labor complications were calculated by site of radiotherapy treatment (none/abdominal/cranial/other) and other cancer-related factors using log-binomial regression. All statistical tests were two-sided.<br><br>&emsp;A total of 2783 singleton pregnancies among 1712 female survivors of childhood cancer were identified in HES. Wilms tumor survivors treated with abdominal radiotherapy were at threefold risk of hypertension complicating pregnancy (relative risk = 3.29, 95% confidence interval [CI] = 2.29 to 4.71), while all survivors treated with abdominal radiotherapy were at risk of gestational diabetes mellitus (RR = 3.35, 95% CI = 1.41 to 7.93) and anemia complicating pregnancy (RR = 2.10, 95% CI = 1.27 to 3.46) compared with survivors treated without radiotherapy. Survivors treated without radiotherapy had similar risks of pregnancy and labor complications as the general population, except survivors were more likely to opt for an elective cesarean section (RR = 1.39, 95% CI = 1.16 to 1.70).<br><br>&emsp;Treatment with abdominal radiotherapy increases the risk of developing hypertension complicating pregnancy in Wilms tumor survivors, and diabetes mellitus and anemia complicating pregnancy in all survivors. These patients may require extra vigilance during pregnancy.\n <br><br> <b>MeSH terms:<\/b> <b>MeSH terms:<\/b> Anemia; Diabetes Mellitus; England; Female; Humans; Hypertension; Kidney Neoplasms; Obstetric Labor Complications; Pregnancy; Pregnancy Complications; Radiotherapy; Survivors; Wilms Tumor <br><br> <b>OMOP Concepts (IDs):<\/b>  Pregnant (4299535); Diabetes mellitus (201820); Hypertensive disorder (316866); Complication occurring during labor and delivery (440795); Complication occurring during pregnancy (43530950); Radiation therapy procedure or service (4205728); Neoplasm of kidney (4131748); Nephroblastoma (4120310); Anemia (439777); "]},"columns":[{"id":"details","name":"","type":"character","html":true}],"dataKey":"bbfa9b057b9f8d0cf509eeff4c265e30","static":false,"nested":true},"children":[]}]},{"name":"div","attribs":{"style":{"padding":"1rem"}},"children":[{"name":"Reactable","attribs":{"data":{"details":["<b>DOI:<\/b> 10.1371/journal.pone.0176847 <br><br> The benefit of alpha-Ketoanalogues (KA) supplementation for chronic kidney disease (CKD) patients that followed low-protein diet (LPD) remains undetermined.<br><br>&emsp;We extracted longitudinal data for all CKD patients in the Taiwan National Health Insurance from January 1, 2000 through December 31, 2010. A total of 1483 patients with anemic advanced CKD treated with LPD, who started KA supplementation, were enrolled in this study. We analyzed the risks of end stage renal disease and all-cause mortality using Cox proportional hazard models with influential drugs as time-dependent variables.<br><br>&emsp;A total of 1113 events of initiating long-term dialysis and 1228 events of the composite outcome of long-term dialysis or death occurred in patients with advanced CKD after a mean follow-up of 1.57 years. Data analysis suggests KA supplementation is associated with a lower risk for long-term dialysis and the composite outcome when daily dosage is more than 5.5 tablets. The beneficial effect was consistent in subgroup analysis, independent of age, sex, and comorbidities.<br><br>&emsp;Among advanced CKD patients that followed LPD, KA supplementation at an appropriate dosage may substantially reduce the risk of initiating long-term dialysis or of developing the composite outcome. KA supplementation represents an additional therapeutic strategy to slow the progression of CKD.\n <br><br> <b>MeSH terms:<\/b> <b>MeSH terms:<\/b> Aged; Anemia; Cohort Studies; Female; Humans; Kidney Failure, Chronic; Male; Middle Aged; Proportional Hazards Models; Renal Dialysis; Taiwan <br><br> <b>OMOP Concepts (IDs):<\/b>  End-stage renal disease (193782); Renal dialysis (4146536); Anemia (439777); "]},"columns":[{"id":"details","name":"","type":"character","html":true}],"dataKey":"6424a1ce42cbd954ce905a5f870063dc","static":false,"nested":true},"children":[]}]},{"name":"div","attribs":{"style":{"padding":"1rem"}},"children":[{"name":"Reactable","attribs":{"data":{"details":["<b>DOI:<\/b> 10.1371/journal.pone.0178353 <br><br> Painful vaso-occlusive crisis (VOC), a complication of sickle cell disease (SCD), occurs when sickled red blood cells obstruct flow in the microvasculature. We postulated that exaggerated sympathetically mediated vasoconstriction, endothelial dysfunction and the synergistic interaction between these two factors act together to reduce microvascular flow, promoting regional vaso-occlusions, setting the stage for VOC. We previously found that SCD subjects had stronger vasoconstriction response to pulses of heat-induced pain compared to controls but the relative degrees to which autonomic dysregulation, peripheral vascular dysfunction and their interaction are present in SCD remain unknown. In the present study, we employed a mathematical model to decompose the total vasoconstriction response to pain into: 1) the neurogenic component, 2) the vascular response to blood pressure, 3) respiratory coupling and 4) neurogenic-vascular interaction. The model allowed us to quantify the contribution of each component to the total vasoconstriction response. The most salient features of the components were extracted to represent biophysical markers of autonomic and vascular impairment in SCD and controls. These markers provide a means of phenotyping severity of disease in sickle-cell anemia that is based more on underlying physiology than on genotype. The marker of the vascular component (BMv) showed stronger contribution to vasoconstriction in SCD than controls (p = 0.0409), suggesting a dominant myogenic response in the SCD subjects as a consequence of endothelial dysfunction. The marker of neurogenic-vascular interaction (BMn-v) revealed that the interaction reinforced vasoconstriction in SCD but produced vasodilatory response in controls (p = 0.0167). This marked difference in BMn-v suggests that it is the most sensitive marker for quantifying combined alterations in autonomic and vascular function in SCD in response to heat-induced pain.\n <br><br> <b>MeSH terms:<\/b> <b>MeSH terms:<\/b> Adolescent; Adult; Anemia, Sickle Cell; Autonomic Nervous System; Biophysical Phenomena; Blood Pressure; Case-Control Studies; Female; Humans; Male; Microvessels; Middle Aged; Models, Biological; Pain; Sickle Cell Trait; Vasoconstriction; Young Adult; beta-Thalassemia <br><br> <b>OMOP Concepts (IDs):<\/b>  Blood pressure (4326744); Beta thalassemia (4278669); Sickle cell-hemoglobin SS disease (22281); Sickle cell trait (25518); Pain (4329041); "]},"columns":[{"id":"details","name":"","type":"character","html":true}],"dataKey":"d857cb67842f2b9a8151f3cc67f9eb60","static":false,"nested":true},"children":[]}]},{"name":"div","attribs":{"style":{"padding":"1rem"}},"children":[{"name":"Reactable","attribs":{"data":{"details":["<b>DOI:<\/b> 10.1371/journal.pone.0177894 <br><br> Chronic kidney disease (CKD) is a frequent and serious complication of atypical haemolytic uremic syndrome (aHUS). We aimed to develop a simple accurate model to predict the risk of renal dysfunction in aHUS based on clinical and biological features available at hospital admission. Renal function at 1-year follow-up, based on an estimated glomerular filtration rate < 60mL/min/1.73m2 as assessed by the Modification of Diet in Renal Disease equation, was used as an indicator of significant CKD. Prospectively collected data from a cohort of 156 aHUS patients who did not receive eculizumab were used to identify predictors of CKD. Covariates associated with renal impairment were identified by multivariate analysis. The model performance was assessed and a scoring system for clinical practice was constructed from the regression coefficient. Multivariate analyses identified three predictors of CKD: a high serum creatinine level, a high mean arterial pressure and a mildly decreased platelet count. The prognostic model had a good discriminative ability (area under the curve = .84). The scoring system ranged from 0 to 5, with corresponding risks of CKD ranging from 18% to 100%. This model accurately predicts development of 1-year CKD in patients with aHUS using clinical and biological features available on admission. After further validation, this model may assist in clinical decision making.\n <br><br> <b>MeSH terms:<\/b> <b>MeSH terms:<\/b> Adult; Atypical Hemolytic Uremic Syndrome; Female; Humans; Male; Middle Aged; Prognosis; Renal Insufficiency, Chronic; Risk Factors <br><br> <b>OMOP Concepts (IDs):<\/b>  Atypical hemolytic uremic syndrome (37312165); Determination of prognosis (4069425); Chronic renal insufficiency (36716947); "]},"columns":[{"id":"details","name":"","type":"character","html":true}],"dataKey":"a9894b0bde19db04655b109974e6a133","static":false,"nested":true},"children":[]}]},{"name":"div","attribs":{"style":{"padding":"1rem"}},"children":[{"name":"Reactable","attribs":{"data":{"details":["<b>DOI:<\/b> 10.1371/journal.pone.0178883 <br><br> Transfusion dependent subjects are at a great risk of viral hepatitis infection. We aimed to evaluate the prevalence and factors associated with hepatitis B virus (HBV) and hepatitis C virus (HCV) infection among transfusion-dependent patients in Taiwan.<br><br>&emsp;A total of 140 patients (67 thalassemic patients, 70 hemophilic patients, two patients with hereditary spherocytosis and one patient with von Willebrand disease) were prospectively enrolled to evaluate the prevalence and factors associated with viral hepatitis and spontaneous HCV clearance. All patients were tested for HBV and HCV serology and virology. Two consecutive serum samples, at least 1 year apart, were collected to clarify HCV seroclearance.<br><br>&emsp;The seropositivity rate of hepatitis B surface antigen (HBsAg), HCV antibody (anti-HCV), and both HBsAg/anti-HCV were 6.4%, 45.7% and 5%, respectively. Logistic regression analysis of factors associated with anti-HCV seropositivity included age (odds ratio/95% confidence interval [OR/CI]: 1.12/1.07-1.18, P<0.001), serum alanine aminotransferase (ALT) (OR/CI: 1.04/1.02-1.06, P<0.001) and platelet counts (OR/CI: 0.995/0.991-0.998, P = 0.002). Age was the only factor independently associated with HBsAg seropositivity (OR/CI: 1.08/1.02-1.14.4, P = 0.007). Compared to patients born before 1992, the seroprevalence of HCV among thalassemic patients decreased dramatically in those born after 1992 (46.0% vs. 11.8%, p = 0.012). The seroprevalence of HCV among hemophilic patients also decreased significantly when comparing patients born before 1987 to those born after 1987 (79.5% vs. 11.5%, p<0.001). Similarly, the seroprevalence of HBV decreased significantly in the post-vaccination cohort compared to its counterpart (13.1%, vs. 1.3%, p = 0.005). The spontaneous clearance of HCV was observed in 25.4% (15/59) of patients, and ALT was the only factor associated with it (OR/CI 0.98/0.96-1.00, P = 0.02).<br><br>&emsp;Both HBV and HCV infections are prevalent among transfusion-dependent thalassemic and hemophilic patients in Taiwan. Nevertheless, seroprevalence decreased significantly and dramatically for HCV after universal blood screening and for HBV after implementation of a universal mass vaccination program.\n <br><br> <b>MeSH terms:<\/b> <b>MeSH terms:<\/b> Adolescent; Adult; Biomarkers; Child; Female; Genotype; Hemophilia A; Hepatitis B Antibodies; Hepatitis B Surface Antigens; Hepatitis C Antibodies; Hepatitis, Viral, Human; Humans; Interferons; Interleukins; Male; Middle Aged; Polymorphism, Single Nucleotide; Seroepidemiologic Studies; Thalassemia; Transfusion Reaction; Young Adult <br><br> <b>OMOP Concepts (IDs):<\/b>  Blood transfusion reaction (440603); Thalassemia (30978); Hepatitis B Surface Antigen Vaccine (528323); Genetic finding (4025367); Hereditary factor VIII deficiency disease (434007); Blood transfusion reaction (440603); "]},"columns":[{"id":"details","name":"","type":"character","html":true}],"dataKey":"c2efd2638a69318fb24217aaeb9b7c94","static":false,"nested":true},"children":[]}]},{"name":"div","attribs":{"style":{"padding":"1rem"}},"children":[{"name":"Reactable","attribs":{"data":{"details":["<b>DOI:<\/b> 10.1371/journal.pone.0182543 <br><br> Preoperative anemia and high red cell distribution width (RDW) are associated with higher perioperative mortality. Conditions with high RDW levels can be categorized by mean corpuscular volume (MCV). The relationship between RDW, anemia and MCV may explain causality between high RDW levels and outcomes. We aim to establish the prevalence of preoperative anemia and distribution of RDW and MCV among pre-surgical patients in Singapore. In addition, we aim to investigate the association between preoperative anemia, RDW and MCV levels with one-year mortality after surgery.<br><br>&emsp;Retrospective review of 97,443 patients aged > = 18 years who underwent cardiac and non-cardiac surgeries under anesthesia between January 2012 and October 2016. Patient demographics, comorbidities, priority of surgery, surgical risk classification, perioperative transfusion, preoperative hemoglobin, RDW, MCV were collected. WHO anemia classification was used. High RDW was defined as >15.7%. Multivariate regression analyses were done to identify independent risk factors for mild or moderate/severe anemia and high RDW (>15.7). Multivariate cox regression analysis was done to determine the effect of preoperative anemia, abnormal RDW and MCV values on 1-year mortality.<br><br>&emsp;Our cohort comprised of 94.7% non-cardiac and 5.3% cardiac surgeries. 88.7% of patients achieved 1 year follow-up. Anemia prevalence was 27.8%-mild anemia 15.3%, moderate anemia 12.0% and severe anemia 0.5%. One-year mortality was 3.5%. Anemia increased with age in males, while in females, anemia was more prevalent between 18-49 years and > = 70 years. Most anemics were normocytic. Normocytosis and macrocytosis increased with age, while microcytosis decreased with age. Older age, male gender, higher ASA-PS score, anemia (mild- aHR 1.98; moderate/severe aHR 2.86), macrocytosis (aHR 1.47), high RDW (aHR 2.34), moderate-high risk surgery and emergency surgery were associated with higher hazard ratios of one-year mortality.<br><br>&emsp;Preoperative anemia is common. Anemia, macrocytosis and high RDW increases one year mortality.\n <br><br> <b>MeSH terms:<\/b> <b>MeSH terms:<\/b> Adolescent; Adult; Aged; Anemia; Erythrocyte Indices; Erythrocytes, Abnormal; Female; Hemoglobins; Humans; Male; Middle Aged; Preoperative Care; Prevalence; Prognosis; Retrospective Studies; Singapore; Survival Rate; Young Adult <br><br> <b>OMOP Concepts (IDs):<\/b>  Red blood cell indices determination (4299669); Preoperative care (4046549); Determination of prognosis (4069425); Anemia (439777); "]},"columns":[{"id":"details","name":"","type":"character","html":true}],"dataKey":"9d8adc36dec067416ee5690aef92a630","static":false,"nested":true},"children":[]}]},{"name":"div","attribs":{"style":{"padding":"1rem"}},"children":[{"name":"Reactable","attribs":{"data":{"details":["<b>DOI:<\/b> 10.1371/journal.pone.0184076 <br><br> Hematological changes can drive damage of endothelial cells, which potentially lead to an early endothelial dysfunction in patients with sickle cell anemia (SCA). An association may exist between endothelial dysfunction and several clinical manifestations of SCA. The present study aims to evaluate the links between changes in endothelial function and clinical and laboratory parameters in children and adolescents with SCA.<br><br>&emsp;This study included 40 children and adolescents with stable SCA as well as 25 healthy children; aged 6-18 years. All study subjects were evaluated for endothelial function using Doppler ultrasonography. In addition, a number of laboratory assays were performed, including reticulocyte and leukocyte counts as well as measurement of circulating levels of total bilirubin, C-reactive protein (CRP), glucose, lipoproteins and peripheral oxyhemoglobin saturation. These parameters were also compared between SCA patients who were undertaking hydroxyurea (HU) and those who were not.<br><br>&emsp;Flow-mediated vasodilation (FMD) values were found to be reduced in SCA patients compared with those detected in healthy controls. SCA individuals with lower FMD values exhibited higher number of hospital admissions due to vaso-occlusive events. Additional analyses revealed that patients who had decreased FMD values exhibited higher odds of acute chest syndrome (ACS) episodes. A preliminary analysis with limited number of individuals failed to demonstrate significant differences in FMD values between SCA individuals who were treated with HU and those who were not.<br><br>&emsp;Children and adolescents with SCA exhibit impaired endothelial function. Reductions in FMD values are associated with ACS. These findings underline the potential use of FMD as screening strategy of SCA patients with severe prognosis at early stages.\n <br><br> <b>MeSH terms:<\/b> <b>MeSH terms:<\/b> Adolescent; Anemia, Sickle Cell; Antisickling Agents; Bilirubin; C-Reactive Protein; Case-Control Studies; Child; Endothelial Cells; Endothelium, Vascular; Female; Glucose; Humans; Hydroxyurea; Leukocyte Count; Lipoproteins; Male; Oxyhemoglobins; Reticulocytes; Ultrasonography, Doppler; Vascular Diseases <br><br> <b>OMOP Concepts (IDs):<\/b>  Doppler ultrasound (35622931); Vascular disorder (443784); Bilirubin, total measurement (4230543); Sickle cell-hemoglobin SS disease (22281); hydroxyurea (1377141); White blood cell count (4298431); Glucose (1560524); "]},"columns":[{"id":"details","name":"","type":"character","html":true}],"dataKey":"835c2bd85f43f555ecaef2e6caf97937","static":false,"nested":true},"children":[]}]},{"name":"div","attribs":{"style":{"padding":"1rem"}},"children":[{"name":"Reactable","attribs":{"data":{"details":["<b>DOI:<\/b> 10.1371/journal.pone.0184079 <br><br> The ageing process is associated with gradual decline in respiratory system performance. Anemia is highly prevalent among older adults and usually associated with adverse outcomes. Myelodysplastic syndromes (MDS) are a heterogeneous group of hematologic malignancies with increasing incidence with age and characterized by anemia and other cytopenias. The main objectives of this study were to evaluate respiratory muscle strength and lung function in elderly patients with anemia, compare data between myelodysplastic syndromes and non-clonal anemias and evaluate the influence of serum IL-8 level and NF-kB activity on deteriorate pulmonary function in this specific population.<br><br>&emsp;Individuals aged 60 and older with anemia secondary to MDS, non-clonal anemia and healthy elderly individuals.<br><br>&emsp;Forced expiratory volume in 1 second (FEV1), forced vital capacity (FVC), and FEV1/ FVC ratio were measured by spirometry. Respiratory muscle strength was evaluated by maximal static respiratory pressures measurement. IL-8 analysis was performed by ELISA and activity of NF-kB by chemiluminescent assay.<br><br>&emsp;Mean Hb concentration was comparable between patients with anemia. Significant differences were detected between all patients with anemia and controls for maximum-effort inspiratory mouth pressure (PImax) and also for maximum-effort expiratory mouth pressure (PEmax). The MDS group recorded a significantly lower PImax and PEmax percent predicted when compared to non-clonal anemia group. For FVC and FEV1, a significant difference was found in anemic patients, with even significantly lower values for FVC and FEV1 in MDS group. No significant differences were detected for PImax and PEmax and spirometry parameters when anemic patients were stratified according to the degree of anemia. A significant negative impact in FVC (% pred), PImax (% pred) and PEmax (% pred) was observed in patients with MDS and higher levels of IL-8 or increased activity of NF-kB.<br><br>&emsp;A negative impact of anemia, independent of its degree, was demonstrated in respiratory muscle strength and lung function particularly in MDS. The well known elevated proinflammatory cytokines in MDS patients were proposed to play a role as was demonstrated by detrimental effect of higher IL-8 and NF-kB in pulmonary function tests in this population.\n <br><br> <b>MeSH terms:<\/b> <b>MeSH terms:<\/b> Anemia; Case-Control Studies; Forced Expiratory Volume; Humans; Inflammation; Interleukin-8; Lung; Muscle Strength; Myelodysplastic Syndromes; NF-kappa B; Respiratory Muscles; Vital Capacity <br><br> <b>OMOP Concepts (IDs):<\/b>  Forced expired volume (4065409); Myelodysplastic syndrome (138994); Vital capacity (4147814); Anemia (439777); Interleukin-8 (43531933); "]},"columns":[{"id":"details","name":"","type":"character","html":true}],"dataKey":"499418b151a6b41da81fa9f4ecdaa9c7","static":false,"nested":true},"children":[]}]},{"name":"div","attribs":{"style":{"padding":"1rem"}},"children":[{"name":"Reactable","attribs":{"data":{"details":["<b>DOI:<\/b> 10.1093/aje/kwx285 <br><br> There is concern that sickle cell trait (SCT) increases risk of exertional collapse, a primary cause of which is heat injury. However, to our knowledge, no population-based studies among active individuals have addressed this, representing a critical evidence gap. We conducted a retrospective cohort study of SCT-tested African-American soldiers who were on active duty in the US Army anytime between January 2011 and December 2014. Using Cox proportional hazards models and adjusting for demographic and medical factors, we observed no significant associations between SCT and either mild heat injury (hazard ratio (HR) = 1.15, 95% confidence interval (CI): 0.84, 1.56; n = 45,999) or heat stroke (HR = 1.11, 95% CI: 0.44, 2.79; n = 46,183). Risk of mild heat injury was substantially higher among soldiers with recent prescriptions for antipsychotic agents (HR = 3.25, 95% CI: 1.33, 7.90). Risk of heat stroke was elevated among those with a prior mild heat injury (HR = 17.7, 95% CI: 8.50, 36.7) and among overweight and obese individuals (HR = 2.91 (95% CI: 1.38, 6.17) and HR = 4.04 (95% CI: 1.72, 9.45), respectively). In a setting where universal precautions are utilized to mitigate risk of exertion-related illnesses, SCT is not associated with either mild heat injury or heat stroke.\n <br><br> <b>MeSH terms:<\/b> <b>MeSH terms:<\/b> Adult; Female; Heat Stress Disorders; Hot Temperature; Humans; Male; Military Personnel; Obesity; Occupational Diseases; Overweight; Proportional Hazards Models; Retrospective Studies; Risk Factors; Sickle Cell Trait; United States; Young Adult <br><br> <b>OMOP Concepts (IDs):<\/b>  Occupational disorder (4020924); Overweight (437525); Sickle cell trait (25518); Obesity (433736); "]},"columns":[{"id":"details","name":"","type":"character","html":true}],"dataKey":"9321d6701556daca95d961bfc37ba6f4","static":false,"nested":true},"children":[]}]},{"name":"div","attribs":{"style":{"padding":"1rem"}},"children":[{"name":"Reactable","attribs":{"data":{"details":["<b>DOI:<\/b> 10.1371/journal.pone.0185822 <br><br> Iron deficiency anemia in celiac disease is related to impaired duodenal mucosal uptake, due to villous atrophy. Iron enters the enterocytes through an apical divalent metal transporter, DMT1. Different DMT1 transcripts have been identified, depending on the presence of an iron-responsive element that allows DMT1 up-regulation during iron starvation. An intronic DMT1 polymorphism, IVS4+44C>A, has been associated with metal toxicity, and the CC-carriers show high iron levels.<br><br>&emsp;This study investigates the association between DMT1 IVS4+44C>A and anemia in a cohort of 387 Italian celiac children, and the functional role of the polymorphism.<br><br>&emsp;By association analysis, we found that DMT1 IVS4+44-AA genotype confers a four-fold risk of developing anemia, despite of atrophy degree. By analysis of mRNA from gastroesophageal biopsies, we found that total DMT1 is significantly upregulated in presence of mild, but not severe, atrophy, independently from IVS4+44C>A variant, and in normal but not in atrophic CC-biopsies. Moreover, we found that A-allele is associated to preferential expression of the DMT1 transcripts lacking the iron-responsive element, thus limiting the DMT1 overexpression that normally occurs to respond to iron starvation.<br><br>&emsp;Possibly, the IVS4+44-AA-related dysregulation of the iron-induced changes in DMT1 expression is not able to impair iron absorption in physiological condition. However, if exacerbated by the concomitant massive loss of functional absorbing tissue paralleling worsened stages of villus atrophy, it might be ineffective in counteracting iron deficiency, despite of DMT1 overexpression.<br><br>&emsp;We suggest, for the first time, that celiac disease may unmask the contribution of the DMT1 IVS4+44C>A polymorphism to the risk of anemia.\n <br><br> <b>MeSH terms:<\/b> <b>MeSH terms:<\/b> Adolescent; Alleles; Anemia, Iron-Deficiency; Biopsy; Cation Transport Proteins; Celiac Disease; Child; Child, Preschool; Cohort Studies; Female; Gene Expression Regulation; Humans; Infant; Male; Polymorphism, Genetic <br><br> <b>OMOP Concepts (IDs):<\/b>  Genetic alleles (4235440); Celiac disease (194992); Genetic polymorphism (4177328); Biopsy (4311405); Iron deficiency anemia (436659); "]},"columns":[{"id":"details","name":"","type":"character","html":true}],"dataKey":"07961ae385614bb3535324ebfab5e6be","static":false,"nested":true},"children":[]}]},{"name":"div","attribs":{"style":{"padding":"1rem"}},"children":[{"name":"Reactable","attribs":{"data":{"details":["<b>DOI:<\/b> 10.1371/journal.pone.0186724 <br><br> Anemia is a global public health problem that has affected a significant number of pregnant mothers worldwide. The World Health Organization has estimated the prevalence of anemia in pregnant women at 18% and 56% in developed and developing countries, respectively. This study aimed to identify factors associated with severe anemia among laboring women in Mekelle city public hospitals, Tigray, Ethiopia.<br><br>&emsp;This unmatched case-control study involved 264 (88 = cases and 176 = controls) pregnant women who were recruited when they came for delivery service in Mekelle city public hospitals. The data was collected from July to August, 2016. In this study, a systematic sampling technique was used inselecting controls, but the cases were enrolled until the required sample size was reached. Bivariate and multivariate analyses were conducted to find predictors of severe anemia. Statistically significant predictors of severe anemia were identified at P-value <0.05 and 95% confidence interval.<br><br>&emsp;A total of 264 pregnant women who came for delivery services were enrolled in this study. The major predicting variables for the occurrence of severe anemia among laboring women were residency (AOR = 3.28, 95% CI: 1.26-8.48), number of pregnancies (AOR = 2.46, 95% CI: 1.14-5.29), iron folate supplementation (AOR = 3.29, 95% CI: 1.27-8.49), dietary diversification score (AOR = 3.23, 95% CI: 1.19-8.71) and duration of menstrual cycle (AOR = 2.37, 95% CI: 1.10-5.10). The variable 'blood loss during pregnancy' (AOR = 6.63 95% CI: 2.96-14.86) was identified as a strong predictor of the outcome variable, severe anemia.<br><br>&emsp;This study identified determinants of severe anemia among laboring women in Mekelle city public hospitals, Northern Ethiopia. To reduce anemia, strengthening health education provision related to the importance of birth spacing and consuming diversified and iron-enriched food should be considered. Moreover, screening of pregnant women for state of anemia during their visits to health facilities, as well as de-worming for intestinal parasites infection are needed.\n <br><br> <b>MeSH terms:<\/b> <b>MeSH terms:<\/b> Adult; Anemia; Ethiopia; Female; Hospitals, Public; Humans; Labor, Obstetric; Middle Aged; Multivariate Analysis; Pregnancy; Pregnancy Complications, Hematologic; Young Adult <br><br> <b>OMOP Concepts (IDs):<\/b>  Pregnant (4299535); Anemia (439777); "]},"columns":[{"id":"details","name":"","type":"character","html":true}],"dataKey":"807f9a6c1fb9126cee152af8ad73f22a","static":false,"nested":true},"children":[]}]},{"name":"div","attribs":{"style":{"padding":"1rem"}},"children":[{"name":"Reactable","attribs":{"data":{"details":["<b>DOI:<\/b> 10.1371/journal.pone.0188155 <br><br> The treatment of choice for Atypical Hemolytic Uremic Syndrome (aHUS) is the monoclonal antibody eculizumab. The objective of this study was to assess the efficacy and safety of eculizumab in a cohort of kidney transplant patients suffering from aHUS.<br><br>&emsp;Description of the prospective cohort of all the patients primarily treated with eculizumab after transplantation and divided into the therapeutic (onset of aHUS after transplantation) and prophylactic use (patients with previous diagnosis of aHUS undergoing kidney transplantation).<br><br>&emsp;Seven cases were outlined: five of therapeutic use and two, prophylactic. From the five cases of therapeutic use, there was improvement of the thrombotic microangiopathy in the 48 hours following the start of the drug and no patient experienced relapse during an average follow-up of 21 months in the continuous use of eculizumab (minimum of 6 and maximum of 42 months). One patient died at 6 months, due to Aspergillus infection. From the two cases of prophylactic use, one patient experienced relapsed thrombotic microangiopathy after 4 months and another patient remained asymptomatic after 16 months of follow-up, both on chronic treatment.<br><br>&emsp;The therapeutic use of eculizumab showed to be effective, with improvement of the microangiopathy parameters and persisting up to the end of the follow-up, without relapses. The additional risk of immunosuppression, leading to opportunistic infections, was well tolerated. The prophylactic use showed to be effective and safe; however, the doses and intervals should be individualized in order to avoid relapsed microangiopathy, especially in patients with factor H mutation.\n <br><br> <b>MeSH terms:<\/b> <b>MeSH terms:<\/b> Antibodies, Monoclonal, Humanized; Atypical Hemolytic Uremic Syndrome; Brazil; Humans; Prospective Studies; Treatment Outcome <br><br> <b>OMOP Concepts (IDs):<\/b>  Atypical hemolytic uremic syndrome (37312165); "]},"columns":[{"id":"details","name":"","type":"character","html":true}],"dataKey":"b37e85a9fb53d5053d8339eda28a62ac","static":false,"nested":true},"children":[]}]},{"name":"div","attribs":{"style":{"padding":"1rem"}},"children":[{"name":"Reactable","attribs":{"data":{"details":["<b>DOI:<\/b> 10.1371/journal.pone.0189952 <br><br> Patients with gastrointestinal disease may have comorbid iron deficiency anaemia (IDA) and an increased risk of hospitalisation and re-attendance in hospital. The purpose of this study was to determine if oral and intravenous (IV) treatment of IDA in patients with gastrointestinal disease attending hospital were associated with differential rates of subsequent re-attendance.<br><br>&emsp;Data from the Clinical Practice Research Datalink (primary care) and Hospital Treatment Insights (secondary care) databases in England were used to conduct this retrospective cohort study. Patients with a coded gastrointestinal disease and IDA who attended hospital (inpatient or outpatient) and were dispensed oral or IV iron between 01/01/2010-31/10/2013 were included. Elective and emergency re-attendances in secondary care within 30 days of the initial attendance were determined. Demographics, medical diagnoses and treatments were extracted. Re-attendance rates following oral or IV iron were compared using chi-square tests and a step-wise logistic regression model to adjust for confounders. 2,844 patients contributed 6,294 initial attendances; 80% of patients received oral iron, 14% received intravenous iron, and 6% received both. Of initial attendances recording oral iron, 77% resulted in re-attendance in hospital, compared to 34% of those recording IV iron (unadjusted odds ratio [OR]: 0.16; adjusted OR: 0.52 [95% CI: 0.44-0.61]). Initial attendances using IV treatment were more likely to result in elective re-attendance (84%) than those recording oral treatment (43%) (p<0.001). Median length of stay in hospital tended to be shorter for patients using IV iron (1.4 days; interquartile range 0.5-3.6 days; oral iron: 5.1 days; interquartile range: 2.2-9.6 days).<br><br>&emsp;Patients with gastrointestinal disease and IDA who received IV iron were less likely to re-attend hospital, more likely to re-attend electively, and tended to have a shorter length of stay in hospital. The mode of IDA treatment could have a real-world impact on healthcare utilisation.\n <br><br> <b>MeSH terms:<\/b> <b>MeSH terms:<\/b> Adolescent; Adult; Aged; Aged, 80 and over; Anemia, Iron-Deficiency; Emergency Service, Hospital; England; Female; Gastrointestinal Diseases; Humans; Infusions, Intravenous; Iron; Iron Deficiencies; Logistic Models; Male; Middle Aged; Patient Acceptance of Health Care; Secondary Care <br><br> <b>OMOP Concepts (IDs):<\/b>  Intravenous infusion (4030886); Disorder of gastrointestinal tract (4000610); Iron deficiency anemia (436659); Iron (1360067); "]},"columns":[{"id":"details","name":"","type":"character","html":true}],"dataKey":"629e39544d37bfec22aeed0f15975f60","static":false,"nested":true},"children":[]}]},{"name":"div","attribs":{"style":{"padding":"1rem"}},"children":[{"name":"Reactable","attribs":{"data":{"details":["<b>DOI:<\/b> 10.1371/journal.pone.0191280 <br><br> Red cell distribution width (RDW) predicts disease outcome in several patient populations, but its prognostic value in addition to other disease parameters in unselected medical inpatients remains unclear. Our aim was to investigate the association of admission RDW levels and mortality adjusted for several disease pathways in unselected medical patients from a previous multicenter study.<br><br>&emsp;We included consecutive adult, medical patients at the time point of hospital admission through the emergency department into this observational, cohort study. The primary endpoint was mortality at 30-day. To study association of admission RDW and outcomes, we calculated regression analysis with step-wise inclusion of clinical and laboratory parameters from different biological pathways.<br><br>&emsp;The 30-day mortality of the 4273 included patients was 5.6% and increased from 1.4% to 14.3% from the lowest to the highest RDW quartile. There was a strong association of RDW and mortality in unadjusted analysis (OR 1.32; 95%CI 1.27-1.39, p<0.001). RDW was strongly correlated with different pathways including inflammation (coefficient of determination (R2) 0.30; p<0.001), nutrition (R2 0.20; p<0.001) and blood diseases (R2 0.30; p<0.001 The association was eliminated after including different biological pathways into the models with the fully adjusted regression model showing an OR of 1.02 (95%CI 0.93-1.12; p = 0.664) for the association of RDW and mortality. Similar effects were found for other outcomes including intensive care unit admission and hospital readmission.<br><br>&emsp;Our data suggests that RDW is a strong surrogate marker of mortality in unselected medical inpatients with most of the prognostic information being explained by other disease factors. The strong correlation of RDW and different biological pathways such as chronic inflammation, malnutrition and blood disease suggest that RDW may be viewed as an unspecific and general \"chronic disease prognostic marker\".\n <br><br> <b>MeSH terms:<\/b> <b>MeSH terms:<\/b> Adult; Aged; Anemia; Cohort Studies; Emergency Service, Hospital; Erythrocyte Indices; Female; Hospital Mortality; Humans; Inpatients; Male; Middle Aged; Patient Admission; Prognosis; Prospective Studies <br><br> <b>OMOP Concepts (IDs):<\/b>  Red blood cell indices determination (4299669); Determination of prognosis (4069425); Anemia (439777); "]},"columns":[{"id":"details","name":"","type":"character","html":true}],"dataKey":"cc431651f958420bb6968659cefba4cd","static":false,"nested":true},"children":[]}]},{"name":"div","attribs":{"style":{"padding":"1rem"}},"children":[{"name":"Reactable","attribs":{"data":{"details":["<b>DOI:<\/b> 10.1371/journal.pone.0192710 <br><br> Globally, the majority of persons born with sickle cell disease do not have access to hydroxyurea or more expensive interventions. The objectives were to estimate the survival in homozygous sickle cell disease, unbiased by symptomatic selection and to ascertain the causes of death in a pre-hydroxyurea population. The utility of early life biomarkers and genetically determined phenotypes to predict survival was assessed. A cohort study based on neonatal diagnosis was undertaken at the Sickle Cell Unit, a specialist clinic delivering care to persons with sickle cell disease in Jamaica. Screening of 100,000 deliveries detected 315 babies with homozygous sickle cell disease of whom 311 have been followed from birth for periods up to 43 years. Pneumococcal prophylaxis and teaching mothers splenic palpation were important, inexpensive interventions. Anticipatory guidance, routine care and out-patient acute care were provided. Each participant was classified as alive, dead, or defaulted (usually emigration). Causes of death were ascertained from clinical records and/or post-mortem reports. Survival was assessed using the Kaplan-Meier function. Sex-adjusted Cox semi-parametric proportional hazards and Weibull modelling were used to assess the effects on survival of biomarkers. Survival to 40 years was 55.5% (95% CI 48.7% to 61.7%). Acute Chest Syndrome (n = 31) and septicemia (n = 14) were significant causes of death at all ages. Acute splenic sequestration (n = 12) was the most common cause of early deaths. Survival was significantly shorter in those with lower hemoglobin at 1 year, high total nucleated count at 1 year, and a history of dactylitis ever. In these hydroxyurea naïve patients, survival into midlife was common. Causes of death were often age specific and some may be preventable. Early life biomarkers predictive of decreased survival in SS disease identify a patient group likely to benefit from close clinical supervision and potentially high risk therapies.\n <br><br> <b>MeSH terms:<\/b> <b>MeSH terms:<\/b> Acute Chest Syndrome; Adolescent; Adult; Anemia, Sickle Cell; Cause of Death; Child; Child, Preschool; Cohort Studies; Follow-Up Studies; Homozygote; Humans; Infant; Jamaica; Sepsis; Survival Analysis; Young Adult <br><br> <b>OMOP Concepts (IDs):<\/b>  Sepsis (132797); Acute chest syndrome (254062); Homozygote (4329704); Sickle cell-hemoglobin SS disease (22281); Cause of death (4083743); "]},"columns":[{"id":"details","name":"","type":"character","html":true}],"dataKey":"7998b40a5c6ab2b5e9f9e010179d8e00","static":false,"nested":true},"children":[]}]},{"name":"div","attribs":{"style":{"padding":"1rem"}},"children":[{"name":"Reactable","attribs":{"data":{"details":["<b>DOI:<\/b> 10.1371/journal.pone.0195985 <br><br> Tuberculosis (TB) induces a systemic inflammatory state affecting iron homeostasis. Patients with TB often have additional comorbidities such as anemia which can result in poorer treat outcomes. We studied the contribution of anemia and the role of the iron regulatory hormone hepcidin among TB patients and household contacts.<br><br>&emsp;We analyzed serum samples from 102 TB cases and 98 controls without TB, matched by age/sex, for hepcidin, iron, and inflammation parameters. Five controls developed TB within 12 months. We used linear regression to assess associations.<br><br>&emsp;Anemia of chronic disease (ACD) was more frequent among cases than controls (59.8% vs. 26.1%), but iron-deficiency anemia more frequent in controls (10% vs. 1%). The median hepcidin level was higher in cases than controls (63.7 vs. 14.2 ng/mL), but coinfections with HIV, helminths, and respiratory pathogens did not show cumulative effects. Hepcidin was associated with more severe TB symptom scoring (coefficient 0.8, 95% confidence interval [CI] 0.5-1.2) and higher mycobacterial load (0.7, 95% CI 0.4-1.0). Hepcidin was higher in TB cases and controls who developed TB compared to controls without TB (p<0.001), even when restricting to HIV-negative study participants.<br><br>&emsp;ACD was the predominate etiology in TB patients suggesting limited benefit from iron supplementation. Increased hepcidin levels long before active disease, indicating altered iron metabolism, may be a marker for developing disease among TB-exposed individuals. Clinical management of anemia and nutrition interventions in TB patients need to be considered to improve the clinical course and outcomes.\n <br><br> <b>MeSH terms:<\/b> <b>MeSH terms:<\/b> Adult; Anemia; Anemia, Iron-Deficiency; Case-Control Studies; Coinfection; Disease Progression; Family Characteristics; Female; Hepcidins; Humans; Linear Models; Male; Risk Factors; Tanzania; Tuberculosis <br><br> <b>OMOP Concepts (IDs):<\/b>  Infection due to Mycobacterium tuberculosis (4162434); Iron deficiency anemia (436659); Mixed infectious disease (4163969); Anemia (439777); "]},"columns":[{"id":"details","name":"","type":"character","html":true}],"dataKey":"771d3c39a81fa5d73ea8ed2bc5166e24","static":false,"nested":true},"children":[]}]},{"name":"div","attribs":{"style":{"padding":"1rem"}},"children":[{"name":"Reactable","attribs":{"data":{"details":["<b>DOI:<\/b> 10.1371/journal.pone.0197062 <br><br> To present a method for age-matched deviation mapping in the assessment of disease-related changes to the radial peripapillary capillaries (RPCs).<br><br>&emsp;We reviewed 4.5x4.5mm en face peripapillary OCT-A scans of 133 healthy control eyes (133 subjects, mean 41.5 yrs, range 11-82 yrs) and 4 eyes with distinct retinal pathologies, obtained using spectral-domain optical coherence tomography angiography. Statistical analysis was performed to evaluate the impact of age on RPC perfusion densities. RPC density group mean and standard deviation maps were generated for each decade of life. Deviation maps were created for the diseased eyes based on these maps. Large peripapillary vessel (LPV; noncapillary vessel) perfusion density was also studied for impact of age.<br><br>&emsp;Average healthy RPC density was 42.5±1.47%. ANOVA and pairwise Tukey-Kramer tests showed that RPC density in the ≥60yr group was significantly lower compared to RPC density in all younger decades of life (p<0.01). Average healthy LPV density was 21.5±3.07%. Linear regression models indicated that LPV density decreased with age, however ANOVA and pairwise Tukey-Kramer tests did not reach statistical significance. Deviation mapping enabled us to quantitatively and visually elucidate the significance of RPC density changes in disease.<br><br>&emsp;It is important to consider changes that occur with aging when analyzing RPC and LPV density changes in disease. RPC density, coupled with age-matched deviation mapping techniques, represents a potentially clinically useful method in detecting changes to peripapillary perfusion in disease.\n <br><br> <b>MeSH terms:<\/b> <b>MeSH terms:<\/b> Adolescent; Adult; Age Factors; Aged; Aged, 80 and over; Anemia, Sickle Cell; Case-Control Studies; Child; Diabetic Retinopathy; Female; Fluorescein Angiography; Glaucoma, Open-Angle; Humans; Image Interpretation, Computer-Assisted; Male; Middle Aged; Retina; Retinal Vein Occlusion; Retinal Vessels; Tomography, Optical Coherence <br><br> <b>OMOP Concepts (IDs):<\/b>  Optical coherence tomography (4213040); Pigmentary glaucoma (436975); Retinopathy due to diabetes mellitus (4174977); Sickle cell-hemoglobin SS disease (22281); Fluorescein angiography of eye (4068181); Thrombosis of retinal vein (4187790); "]},"columns":[{"id":"details","name":"","type":"character","html":true}],"dataKey":"f3496672ee36d9814ba8d549988af2ec","static":false,"nested":true},"children":[]}]},{"name":"div","attribs":{"style":{"padding":"1rem"}},"children":[{"name":"Reactable","attribs":{"data":{"details":["<b>DOI:<\/b> 10.1161/HYPERTENSIONAHA.118.11211 <br><br> Hemolysis predisposes to adverse pregnancy outcomes. Yet, there are limited data on hemolysis in hypertensive disorders of pregnancy other than hemolysis, elevated liver enzymes, and low platelet count syndrome. To evaluate the prevalence and impact of hemolysis in hypertensive disorders of pregnancy, we performed a retrospective cohort study at a single center (October 2013-May 2017), among women screened for hemolysis using lactate dehydrogenase (LDH) levels. We compared LDH levels by hypertensive disorder (chronic hypertension, gestational hypertension, preeclampsia, and preeclampsia with severe features) and evaluated impact on adverse pregnancy outcomes. Data were analyzed by χ2 or t test, ANOVA, test of medians, and logistic regression. Among 8645 deliveries, 1188 (13.7%) had a hypertensive disorder. Of these, 812 (68.4%) had LDH measurement before delivery: chronic hypertension (n=152); gestational hypertension (n=209); preeclampsia (n=216); and preeclampsia with severe features (n=235). LDH ≥400 U/L (≥1.6× normal) was more common in preeclampsia with severe features compared with other hypertensive disorders of pregnancy (9.8% versus 2.3%; P<0.001); adjusted odds ratio 4.52 (95% confidence interval, 2.2-9.2; P<0.001). LDH ≥400 U/L was associated with adverse maternal outcomes (41.7% versus 15.3%; P<0.001), adjusted odds ratio 3.05 (95% confidence interval, 1.4-6.7; P=0.006), and adverse neonatal outcomes (eg, preterm birth 59.4% versus 22.5%; P<0.001). We find that elevated LDH levels are associated with adverse maternal and neonatal outcomes in hypertension and preeclampsia, independent of hemolysis, elevated liver enzymes, and low platelet count syndrome. Therefore, elevated LDH levels (≥1.6× normal or ≥400 U/L) may be considered a severe feature of preeclampsia.\n <br><br> <b>MeSH terms:<\/b> <b>MeSH terms:<\/b> Adult; Anemia, Hemolytic; Female; Follow-Up Studies; Hemolysis; Humans; Infant, Newborn; Pre-Eclampsia; Pregnancy; Pregnancy Outcome; Prognosis; Retrospective Studies; Risk Factors; Severity of Illness Index <br><br> <b>OMOP Concepts (IDs):<\/b>  Pregnant (4299535); Determination of prognosis (4069425); Hemolytic anemia (435503); Pre-eclampsia (439393); "]},"columns":[{"id":"details","name":"","type":"character","html":true}],"dataKey":"44e388f8d251b89a21a49d4530b6ba1d","static":false,"nested":true},"children":[]}]},{"name":"div","attribs":{"style":{"padding":"1rem"}},"children":[{"name":"Reactable","attribs":{"data":{"details":["<b>DOI:<\/b> 10.1371/journal.pone.0201714 <br><br> Renal dysfunction and anaemia are common in patients with acute heart failure (HF). It is not known whether their combined presence has additive prognostic value. We investigated their prognostic value separately and in combination, on prognosis in acute HF patients. Furthermore, we examined whether the improvement in prognosis was comparable between patients with and without renal dysfunction.<br><br>&emsp;This prospective registry includes 1783 patients admitted to the (Intensive) Coronary Care Unit for acute HF in the period of 1985-2008. The outcome measure was the composite of all-cause mortality, heart transplantation and left ventricular assist device implantation. In patients without renal dysfunction, anemia was associated with worse 30-day outcome (HR 2.91; [95% CI 1.69-5.00]), but not with 10-year outcome (HR 1.13 [95% CI 0.93-1.37]). On the contrary, anemia was found to influence prognosis in patients with renal dysfunction, both at 30 days (HR 1.93 [95% CI 1.33-2.80]) and at 10 years (HR 1.27 [95% CI 1.10-1.47]). Over time, the 10-year survival rate improved in patients with preserved renal function (HR 0.73 [95% CI 0.55-0.97]), but not in patients with renal dysfunction.<br><br>&emsp;The long-term prognosis of acute HF patients with a preserved renal function was found to have improved significantly. However, the prognosis of patients with renal dysfunction did not change. Anemia was a strong prognosticator for short-term outcome in all patients. In patients with renal dysfunction, anemia was also associated with impaired long-term prognosis.\n <br><br> <b>MeSH terms:<\/b> <b>MeSH terms:<\/b> Acute Disease; Aged; Anemia; Cohort Studies; Female; Heart Failure; Humans; Kidney; Male; Middle Aged; Prognosis; Time Factors <br><br> <b>OMOP Concepts (IDs):<\/b>  Determination of prognosis (4069425); Heart failure (316139); Acute disease (443883); Anemia (439777); "]},"columns":[{"id":"details","name":"","type":"character","html":true}],"dataKey":"1904c9351e96bf725245c76d1f389cb2","static":false,"nested":true},"children":[]}]},{"name":"div","attribs":{"style":{"padding":"1rem"}},"children":[{"name":"Reactable","attribs":{"data":{"details":["<b>DOI:<\/b> 10.1371/journal.pone.0201860 <br><br> No large studies have examined the prevalence of enuresis, its various forms and risk factors in children with sickle cell anaemia (SCA) in Sub-Saharan Africa using standardised definitions. We determined age and gender-specific prevalence of enuresis and compared the nature of enuresis in children with and without SCA. We also identified predictors of enuresis in children with SCA.<br><br>&emsp;Caregivers of children with SCA attending a tertiary centre haematology clinic in Nigeria were interviewed using a questionnaire. In addition, a separate questionnaire was completed for every sibling aged 5-17 years whose haemoglobin genotype was known. Enuresis and its various forms were defined using the definitions of the International Children's Continence Society.<br><br>&emsp;The study involved 243 children with SCA and 243 controls matched for age and sex. The mean age of the study cohort was 9.9 (3.4). Females made up 45.7% of the cohorts. The prevalence of enuresis was 49.4% and 29.6% in children with and without SCA, respectively (p = 0.009). In both groups, the prevalence of enuresis declined with age but remained five times higher at 25% in children with SCA aged 14-17 years compared with controls. Also, children with SCA and enuresis were older, more likely to have non-monosymptomatic enuresis and wet at least three nights per week than controls. Independent predictors of enuresis in children with SCA were a family history of enuresis and young age.<br><br>&emsp;Children with SCA had more frequent and more severe enuresis which persisted to late adolescence than age and sex-matched controls. These features indicate a subset of enuresis that is difficult to treat in the general population. Young age and enuresis in a family member define a subset of children with SCA more likely to have enuresis. Healthcare workers need to discuss enuresis with parents of children with SCA and offer referral to continence services.\n <br><br> <b>MeSH terms:<\/b> <b>MeSH terms:<\/b> Adolescent; Anemia, Sickle Cell; Caregivers; Child; Child, Preschool; Cohort Studies; Enuresis; Female; Humans; Male; Nigeria; Parents; Prevalence; Risk Factors; Siblings; Surveys and Questionnaires <br><br> <b>OMOP Concepts (IDs):<\/b>  Sickle cell-hemoglobin SS disease (22281); Nocturnal enuresis (193874); "]},"columns":[{"id":"details","name":"","type":"character","html":true}],"dataKey":"8e15ddcce4afc05112fd8b913eb8faa9","static":false,"nested":true},"children":[]}]},{"name":"div","attribs":{"style":{"padding":"1rem"}},"children":[{"name":"Reactable","attribs":{"data":{"details":["<b>DOI:<\/b> 10.1371/journal.pone.0203493 <br><br> Pulmonary Arterial Hypertension (PAH) is a fatal disorder with limited treatment options and reduced life expectancy after diagnosis. Complex genetic backgrounds in PAH complicates identification of causative mutations that is essential for an understanding of the disease diagnostics and etiology especially for idiopathic PAH (iPAH). Hemolysis has been implicated as contributing to the pathobiology of PAH. Glucose-6-Phosphate Dehydrogenase (G6PD) expression and activity define erythrocyte's antioxidant capacity, and its decrease contributes to erythrocyte fragility. As G6PD deficiency was previously reported in a limited number of PAH cases, we tested whether iPAH patients exhibit underlying G6PD alterations in erythrocytes. A cohort of 22 PAH patients and 8 non-PAH patients were recruited for this study. DNA isolated from Peripheral Blood Mononuclear Cells (PBMC) was used for detection of mutations in the coding region of the G6PD gene. RNA isolated from PBMC was used for determination of G6PD mRNA expression level. G6PD activity was measured in Red Blood Cell (RBC) pellets. Three patients had missense mutations in G6PD (Val291Met, Asn126Asp, Asp194Glu), however, only one mutation (Val291Met) results in a severe G6PD deficiency. A single patient with mutation (Asn126Asp) showed a 21% decrease in G6PD activity, two subjects showed G6PD deficiency without mutations, and one patient had a decreased level of G6PD mRNA and reduced enzyme levels. This study demonstrates that a moderate decrease in G6PD activity is associated with PAH. Screening for G6PD activity and mutations in the G6PD gene may provide early detection of individuals predisposed to PAH.\n <br><br> <b>MeSH terms:<\/b> <b>MeSH terms:<\/b> Adult; Aged; Aged, 80 and over; Blotting, Western; Case-Control Studies; Erythrocytes; Familial Primary Pulmonary Hypertension; Glucosephosphate Dehydrogenase; Glucosephosphate Dehydrogenase Deficiency; Humans; Leukocytes, Mononuclear; Male; Middle Aged; Mutation, Missense; Reticulocytes; Sequence Analysis, DNA; Transcriptome; Young Adult <br><br> <b>OMOP Concepts (IDs):<\/b>  Familial primary pulmonary hypertension (4119611); Deficiency of glucose-6-phosphate dehydrogenase (4050620); "]},"columns":[{"id":"details","name":"","type":"character","html":true}],"dataKey":"a307ec00fe832942d8efe8093e50fcd7","static":false,"nested":true},"children":[]}]},{"name":"div","attribs":{"style":{"padding":"1rem"}},"children":[{"name":"Reactable","attribs":{"data":{"details":["<b>DOI:<\/b> 10.1371/journal.pone.0203396 <br><br> Imbalances of iron homeostasis are associated with an adverse clinical outcome of pulmonary hypertension (PH). Herein, we aimed to analyze the impact of iron deficiency (ID) in a real-life PH patient cohort according to different currently used ID definitions. In a retrospective study including 153 precapillary PH patients followed over a mean period of five years, iron deficiency was assessed according to five clinical definitions used in previous trials. The impact of ID on clinical, hematological and hemodynamic parameters was investigated. Depending on the different cutoff levels for serum ferritin and transferrin saturation, currently used ID definitions indicated a prevalence of either true or functional ID in 11 to 75 percent of PH patients. A good diagnostic accuracy was achieved by using the sTFRF/log ferritin (sTFRF) index, which identified 33 to 42 percent of PH patients as being iron deficient. The sTFRF index had the best prediction for the association between ID and clinical outcome. Iron deficient patients with precapillary PH had a significantly higher mortality as compared to non-iron deficiency subjects, which was true for both, PH patients with and without anemia. Although levels of the iron hormone hepcidin were rather affected by ID than by inflammation, they were not associated with the clinical course or mortality of PH subjects. To conclude, ID had a significant impact on the clinical course of precapillary PH patients. The appropriate use of robust biomarkers to define ID is a prerequisite to further evaluate the role of ID and the potential benefit of iron supplementation in precapillary PH patients.\n <br><br> <b>MeSH terms:<\/b> <b>MeSH terms:<\/b> Adult; Aged; Aged, 80 and over; Anemia, Iron-Deficiency; Female; Humans; Hypertension, Pulmonary; Iron Deficiencies; Male; Middle Aged; Retrospective Studies; Sensitivity and Specificity; Young Adult <br><br> <b>OMOP Concepts (IDs):<\/b>  Iron deficiency anemia (436659); Pulmonary hypertension (4322024); "]},"columns":[{"id":"details","name":"","type":"character","html":true}],"dataKey":"da352d86c79bc1fb756df9ef98cef929","static":false,"nested":true},"children":[]}]},{"name":"div","attribs":{"style":{"padding":"1rem"}},"children":[{"name":"Reactable","attribs":{"data":{"details":["<b>DOI:<\/b> 10.1371/journal.pone.0203229 <br><br> Evidence for association between sickle cell and alpha thalassemia trait and severe malaria is compelling. However, for these polymorphisms associations with uncomplicated malaria, and for G6PD deficiency associations with uncomplicated and severe malaria, findings have been inconsistent. We studied samples from a three-arm case-control study with the objective of determining associations between common host erythrocyte polymorphisms and both uncomplicated and severe malaria, including different severe malaria phenotypes.<br><br>&emsp;We assessed hemoglobin abnormalities, α-thalassemia, and G6PD deficiency by molecular methods in 325 children with severe malaria age-matched to 325 children with uncomplicated malaria and 325 healthy community controls. Conditional logistic regression was used to measure associations between specified genotypes and malaria outcomes.<br><br>&emsp;No tested polymorphisms offered significant protection against uncomplicated malaria. α-thalassemia homozygotes (_α/_α) had increased risk of uncomplicated malaria (OR 2.40; 95%CI 1.15, 5.03, p = 0.020). HbAS and α-thalassemia heterozygous (_α/αα) genotypes protected against severe malaria compared to uncomplicated malaria (HbAS OR 0.46; 0.23, 0.95, p = 0.036; _α/αα OR 0.51; 0.24, 0.77; p = 0.001) or community (HbAS OR 0.23; 0.11, 0.50; p<0.001; _α/αα; OR 0.49; 0.32, 0.76; p = 0.002) controls. The α-thalassemia homozygous (_α/_α) genotype protected against severe malaria when compared to uncomplicated malaria controls (OR 0.34; 95%CI 0.156, 0.73, p = 0.005), but not community controls (OR 1.03; 0.46, 2.27, p = 0.935). Stratifying by the severe malaria phenotype, compared to community controls, the protective effect of HbAS was limited to children with severe anemia (OR 0.17; 95%CI 0.04, 0.65; p = 0.009) and that of _α/αα to those with altered consciousness (OR 0.24; 0.09, 0.59; p = 0.002). A negative epistatic effect was seen between HbAS and _α/αα; protection compared to uncomplicated malaria controls was not seen in individuals with both polymorphisms (OR 0.45; 0.11, 1.84; p = 0.269). G6PD deficiency was not protective against severe malaria.<br><br>&emsp;Associations were complex, with HbAS principally protective against severe anemia, _α/αα against altered consciousness, and negative epistasis between the two polymorphisms.\n <br><br> <b>MeSH terms:<\/b> <b>MeSH terms:<\/b> Case-Control Studies; Child; Child, Preschool; Erythrocytes; Female; Genotype; Glucosephosphate Dehydrogenase Deficiency; Hemoglobins, Abnormal; Humans; Infant; Malaria; Male; Phenotype; Polymorphism, Genetic; Risk Factors; Sickle Cell Trait; Uganda; alpha-Thalassemia <br><br> <b>OMOP Concepts (IDs):<\/b>  Alpha thalassemia (4287844); Genetic polymorphism (4177328); Malarial fever (4093997); Phenotype (4215157); Sickle cell trait (25518); Genetic finding (4025367); Deficiency of glucose-6-phosphate dehydrogenase (4050620); "]},"columns":[{"id":"details","name":"","type":"character","html":true}],"dataKey":"b371d682f39c9432dc8ca54f57442bb7","static":false,"nested":true},"children":[]}]},{"name":"div","attribs":{"style":{"padding":"1rem"}},"children":[{"name":"Reactable","attribs":{"data":{"details":["<b>DOI:<\/b> 10.1371/journal.pone.0203767 <br><br> Whether and how anemia treatment with erythropoiesis stimulating agents (ESAs) before hemodialysis initiation may be associated with lower mortality after dialysis initiation is unknown. We compared all-cause and cardiovascular mortality in two groups of patients who experienced distinct anemia treatment patterns with ESAs before and after hemodialysis initiation. This retrospective cohort analysis included patients initiating hemodialysis April 1, 2012-June 30, 2013, identified from United States Renal Data System end-stage renal disease (ESRD) and pre-ESRD files. Patients treated with ESAs before and after hemodialysis initiation who maintained Hb ≥ 9.0 g/dL throughout (comparator group, n = 3662) were compared with patients with Hb < 9.0 g/dL before hemodialysis initiation (with or without ESAs) whose levels increased with ESAs after hemodialysis initiation (referent group, n = 4461). Cox proportional hazards models were used to calculate the hazard ratio of all-cause and cardiovascular mortality after hemodialysis initiation. Of 20,454 patients, 4855 (23.7%) had Hb < 9.0 g/dL upon hemodialysis initiation; of these 4855, 26.6% received ESAs before initiation. Comparator group Hb levels increased from 8.2 ± 0.8 mg/dL upon initiation to 10.9 ± 1.2 with ESAs afterward. Comparator patients were more likely than referent patients to be younger (76.3 ± 6.7 versus 77.2 ± 6.9 years), male (51.5% versus 49.8%), and black (24.6% versus 18.6%). Risk of all-cause mortality was lower for the comparator group versus the referent group at 3 (HR 0.83, 95% CI 0.68-1.00, P = 0.052), 6 (0.86, 0.74-1.00, P = 0.047), and 12 (0.88, 0.78-0.99, P = 0.036) months. The pattern was similar for cardiovascular mortality. Hb ≥ 9.0 with ESAs before and after hemodialysis initiation was generally associated with lower post-initiation all-cause and cardiovascular mortality compared with predialysis Hb < 9.0 g/dL in patients whose Hb levels subsequently improved with ESAs after hemodialysis initiation.\n <br><br> <b>MeSH terms:<\/b> <b>MeSH terms:<\/b> Aged; Anemia; Female; Hematinics; Hemoglobins; Humans; Male; Proportional Hazards Models; Renal Dialysis; Retrospective Studies; Treatment Outcome; United States <br><br> <b>OMOP Concepts (IDs):<\/b>  Renal dialysis (4146536); Anemia (439777); "]},"columns":[{"id":"details","name":"","type":"character","html":true}],"dataKey":"8e471f60a7170a571f1840f983165a77","static":false,"nested":true},"children":[]}]},{"name":"div","attribs":{"style":{"padding":"1rem"}},"children":[{"name":"Reactable","attribs":{"data":{"details":["<b>DOI:<\/b> 10.1371/journal.pone.0205463 <br><br> Treatment success rates of rifampicin resistant (RR)/multi-drug resistant (MDR) tuberculosis (TB) in South Africa range from 43-48%, falling short of the World Health Organization's target of ≥75%. We present rates and assess predictors of attrition by 12 months on treatment.<br><br>&emsp;Prospective observational cohort analysis of adults (≥18 years) initiating RR/MDR-TB treatment from 01 March 2013 to 30 September 2016. Attrition was defined as a combination of death and loss to follow-up (LTFU; treatment interruption ≥2 months) by 12 months on treatment. Predictors of attrition were identified using Cox Proportional Hazards models to estimate crude (HR) and adjusted hazard ratios (aHR) with corresponding 95% confidence intervals.<br><br>&emsp;By 12 months on treatment, 75/240 (31.3%) patients had either died (37/240; 15.4%) or been LTFU (38/240; 15.8%). Patients with moderate/severe anaemia (aHR: 2.10; 95% CI 1.00-4.39), and those who were smear positive at baseline (aHR: 2.04; 95% CI 1.01-4.12) were significantly more likely to die or be lost from care.<br><br>&emsp;At this outpatient DR-TB treatment site, there was a high rate of attrition halfway through the standard treatment course at 12 months of 31%. High rates of attrition by 12 months on treatment may continue during the second-half of therapy.\n <br><br> <b>MeSH terms:<\/b> <b>MeSH terms:<\/b> Adolescent; Adult; Anemia; Antitubercular Agents; Drug Administration Schedule; Drug Resistance, Bacterial; Female; Humans; Kaplan-Meier Estimate; Male; Medication Adherence; Middle Aged; Observational Studies as Topic; Proportional Hazards Models; Prospective Studies; Rifampin; Severity of Illness Index; Tuberculosis; Tuberculosis, Multidrug-Resistant; Young Adult <br><br> <b>OMOP Concepts (IDs):<\/b>  Infection due to Mycobacterium tuberculosis (4162434); Multidrug resistant tuberculosis (4307131); Rifampin (1763204); Anemia (439777); Drug compliance good (4056965); "]},"columns":[{"id":"details","name":"","type":"character","html":true}],"dataKey":"ef5a7d5b6835e5aa48418f6e0cf62ce0","static":false,"nested":true},"children":[]}]},{"name":"div","attribs":{"style":{"padding":"1rem"}},"children":[{"name":"Reactable","attribs":{"data":{"details":["<b>DOI:<\/b> 10.2337/dc18-1289 <br><br> The prevalence of type 2 diabetes (T2D) is rapidly increasing in sub-Saharan Africa, where sickle cell trait (SCT) is also frequent. Although SCT is generally considered a benign condition, evidence suggests that SCT could exaggerate vascular dysfunction in T2D. However, it remains unclear whether SCT could increase the risk of the development of T2D complications. Therefore, this study was conducted to determine whether T2D complications were more prevalent among Senegalese individuals with SCT and T2D than among those with T2D only.<br><br>&emsp;Rates of hypertension, retinopathy, peripheral neuropathy, peripheral artery disease, and impaired renal function as well as arterial stiffness, blood rheology, and concentrations of plasma advanced glycation end products (AGEs) and cytokines were compared between groups of Senegalese individuals with combined SCT and T2D (T2D-SCT) (n = 60), T2D (n = 52), SCT (n = 53), and neither T2D nor SCT (control) (n = 56). Human aortic endothelial cell (HAEC) expression of inflammatory and adhesion factors was measured after treatment with tumor necrosis factor-α and subjects' plasma. Effects of AGE inhibition or tiron on HAEC expression of E-selectin were measured.<br><br>&emsp;Retinopathy, hypertension, and reduced renal function were more prevalent, and arterial stiffness, blood viscosity at high shear rates, and thixotropic index were higher, in the SCT group compared with the other groups. Multivariable analysis showed that plasma AGE concentration was significantly associated with arterial stiffness. E-selectin expression was elevated in HAECs treated with T2D-SCT plasma compared with the other groups, but AGE inhibition reversed this.<br><br>&emsp;SCT could potentially augment the risk of the development of T2D-related complications, including retinopathy, nephropathy, and hypertension.\n <br><br> <b>MeSH terms:<\/b> <b>MeSH terms:<\/b> Adult; Case-Control Studies; Diabetes Complications; Diabetes Mellitus, Type 2; Female; Humans; Hypertension; Male; Middle Aged; Prevalence; Senegal; Sickle Cell Trait <br><br> <b>OMOP Concepts (IDs):<\/b>  Type 2 diabetes mellitus (201826); Complication due to diabetes mellitus (442793); Hypertensive disorder (316866); Sickle cell trait (25518); "]},"columns":[{"id":"details","name":"","type":"character","html":true}],"dataKey":"1f2134c81a5e2c3c331ee8c1f74fa53d","static":false,"nested":true},"children":[]}]},{"name":"div","attribs":{"style":{"padding":"1rem"}},"children":[{"name":"Reactable","attribs":{"data":{"details":["<b>DOI:<\/b> 10.1371/journal.pone.0205833 <br><br> Understanding the causes of inpatient mortality in hospitals is important for monitoring the population health and evidence-based planning for curative and public health care. Dearth of information on causes and trends of hospital mortality in most countries of Sub-Saharan Africa has resulted to wide use of model-based estimation methods which are characterized by estimation errors. This retrospective analysis used primary data to determine the cause-specific mortality patterns among inpatient hospital deaths in Tanzania from 2006-2015.<br><br>&emsp;The analysis was carried out from July to December 2016 and involved 39 hospitals in Tanzania. A review of hospital in-patient death registers and report forms was done to cover a period of 10 years. Information collected included demographic characteristics of the deceased and immediate underlying cause of death. Causes of death were coded using international classification of diseases (ICD)-10. Data were analysed to provide information on cause-specific, trends and distribution of death by demographic and geographical characteristics.<br><br>&emsp;A total of 247,976 deaths were captured over a 10-year period. The median age at death was 30 years, interquartile range (IQR) 1, 50. The five leading causes of death were malaria (12.75%), respiratory diseases (10.08%), HIV/AIDS (8.04%), anaemia (7.78%) and cardio-circulatory diseases (6.31%). From 2006 to 2015, there was a noted decline in the number of deaths due to malaria (by 47%), HIV/AIDS (28%) and tuberculosis (26%). However, there was an increase in number of deaths due to neonatal disorders by 128%. Malaria and anaemia killed more infants and children under 5 years while HIV/AIDS and Tuberculosis accounted for most of the deaths among adults.<br><br>&emsp;The leading causes of inpatient hospital death were malaria, respiratory diseases, HIV/AIDS, anaemia and cardio-circulatory diseases. Death among children under 5 years has shown an increasing trend. The observed trends in mortality indicates that the country is lagging behind towards attaining the global and national goals for sustainable development. The increasing pattern of respiratory diseases, cancers and septicaemia requires immediate attention of the health system.\n <br><br> <b>MeSH terms:<\/b> <b>MeSH terms:<\/b> Adolescent; Adult; Age Distribution; Aged; Aged, 80 and over; Anemia; Cardiovascular Diseases; Cause of Death; Child; Child, Preschool; Female; HIV Infections; Hospital Mortality; Humans; Infant; Infant, Newborn; Inpatients; International Classification of Diseases; Life Expectancy; Malaria; Male; Middle Aged; Respiratory Tract Diseases; Retrospective Studies; Tanzania; Tuberculosis, Pulmonary <br><br> <b>OMOP Concepts (IDs):<\/b>  Disorder of cardiovascular system (134057); Human immunodeficiency virus infection (439727); Cause of death (4083743); Malarial fever (4093997); Respiratory tuberculosis (45771090); Anemia (439777); "]},"columns":[{"id":"details","name":"","type":"character","html":true}],"dataKey":"ea68fa609bd97efd5ecf54059f9b3135","static":false,"nested":true},"children":[]}]},{"name":"div","attribs":{"style":{"padding":"1rem"}},"children":[{"name":"Reactable","attribs":{"data":{"details":["<b>DOI:<\/b> 10.1371/journal.pone.0208485 <br><br> Iron deficiency anemia (IDA) is a common micronutrient deficiency worldwide, and an important health problem especially in women of reproductive age. This study aimed to determine the relationship between IDA and sexual satisfaction and function among reproductive-aged Iranian women. In this study, 129 women (52 with IDA and 77 non-IDA) with age 18-45 in Mahshahr, Iran were recruited. Data was gathered by a demographic questionnaire, Female Sexual Function Index (FSFI) and Larson Sexual Satisfaction Questionnaire. Data were analyzed using an independent t-test, Mann-Whitney test, Chi-square, and correlation coefficient test. The results of this study showed that the means of hemoglobin (Hb), hematocrit (HCT), serum iron and ferritin were significantly lower in the IDA group than those in the non-IDA group (p<0.01). All dimensions of sexual function and satisfaction were significantly lower in women with IDA compared to the healthy women (p<0.001). Also, all blood indices for IDA had a significant relationship with all sexual function components and sexual satisfaction (p = 0.01) except for pain with Hb and ferritin. Health care providers should provide screening, education, and counseling about anemia and sexual function in reproductive age women.\n <br><br> <b>MeSH terms:<\/b> <b>MeSH terms:<\/b> Adult; Anemia, Iron-Deficiency; Case-Control Studies; Erythrocyte Indices; Female; Ferritins; Genital Diseases, Female; Hemoglobins; Humans; Iran; Iron; Orgasm; Personal Satisfaction; Sexual Dysfunction, Physiological; Surveys and Questionnaires; Women's Health; Young Adult <br><br> <b>OMOP Concepts (IDs):<\/b>  Red blood cell indices determination (4299669); Disorder of female genital system (443343); Iron deficiency anemia (436659); Iron (1360067); "]},"columns":[{"id":"details","name":"","type":"character","html":true}],"dataKey":"f857bbc993ec300b6a0508390f3f5c5f","static":false,"nested":true},"children":[]}]},{"name":"div","attribs":{"style":{"padding":"1rem"}},"children":[{"name":"Reactable","attribs":{"data":{"details":["<b>DOI:<\/b> 10.1371/journal.pone.0208417 <br><br> There has been an appreciable rise in postpartum hemorrhage requiring blood transfusions in the United States. Our objective is to better define patients at greatest risk for peripartum transfusion at the time of cesarean in order to identify cases for early intervention and monitoring.<br><br>&emsp;Our study is a secondary analysis of a retrospective cohort study. Cases of intraoperative and immediate postpartum blood transfusion among women undergoing cesarean delivery were identified. Multivariable logistic regression models were used to identify antepartum and intrapartum risk factors that were independently associated with blood transfusion. A risk calculator was then developed to predict the need for transfusion.<br><br>&emsp;Of 56,967 women, 1488 (2.6%) required any blood transfusion. The strongest risk factors for peripartum blood transfusion included anemia (odds ratio [OR] 3.7, 95% CI 3.3-4.3), abruption on presentation (OR 3.3, CI 2.6-4.1), general anesthesia (OR 5.2, CI 4.4-6.1) and abnormal placentation (OR 92.0, CI 57.4-147.6). An antepartum (model 1) and combined antepartum plus intrapartum risk model (model 2) were developed (model 1 AUC = 0.77, model 2 AUC = 0.83) and internally validated.<br><br>&emsp;Among women who required cesarean delivery, we were able to identify risk factors which predispose women to peripartum blood transfusion and developed a prediction model with good discrimination.\n <br><br> <b>MeSH terms:<\/b> <b>MeSH terms:<\/b> Adult; Anemia; Blood Transfusion; Cesarean Section; Early Medical Intervention; Female; Humans; Peripartum Period; Placenta Previa; Postpartum Hemorrhage; Pregnancy; Pregnancy Complications; Prognosis; Puerperal Disorders; Recurrence; Retrospective Studies; Risk Assessment; Risk Factors; United States; Vaginal Birth after Cesarean; Young Adult <br><br> <b>OMOP Concepts (IDs):<\/b>  Cesarean section (4015701); Disorder of puerperium (443404); Pregnant (4299535); Transfusion of blood product (4024656); Determination of prognosis (4069425); Complication occurring during pregnancy (43530950); Risk assessment (4024612); Postpartum hemorrhage (443929); Placenta previa (4284028); Anemia (439777); "]},"columns":[{"id":"details","name":"","type":"character","html":true}],"dataKey":"dc49429dd3b255c34b7b091baf4a3a61","static":false,"nested":true},"children":[]}]},{"name":"div","attribs":{"style":{"padding":"1rem"}},"children":[{"name":"Reactable","attribs":{"data":{"details":["<b>DOI:<\/b> 10.1161/CIRCINTERVENTIONS.118.007175 <br><br> Anemia may confer a poor prognosis among patients with the acute coronary syndrome. However, few data exist on the association of anemia with in-hospital outcomes, including bleeding, among ST-segment-elevation myocardial infarction patients receiving primary percutaneous coronary intervention.<br><br>&emsp;We identified 1919 ST-segment-elevation myocardial infarction patients who had undergone primary percutaneous coronary intervention within the Vancouver Coastal Health Authority (2007-2016) of whom 322 (16.8%) had anemia on admission. Between-group differences in (unadjusted) in-hospital outcomes, including heart failure, cardiogenic shock, major bleeding, and death were examined. Spearman correlation ( rs) and multivariate logistic regression were used to evaluate the relationship of anemia on admission with clinical outcomes. Compared with nonanemic patients, anemic patients were more likely to have preexisting hypertension, diabetes mellitus, and prior myocardial infarction. Anemic patients had higher unadjusted rates of in-hospital death (8.1% versus 3.7%; P<0.001), bleeding (18.2% versus 9.4%; P<0.001), and were more likely to develop heart failure (odds ratio [OR], 1.62; 95% CI, 1.19-2.22), shock (OR, 2.35; 95% CI, 1.62-3.40), or cardiac arrest (OR, 1.94; 95% CI, 1.10-3.40) during their hospital stay. Baseline anemia was independently associated with major bleeding (OR, 1.78; 95% CI, 1.25-2.56) but not all-cause mortality (OR, 0.99; 95% CI, 0.57-1.73). There was no significant correlation between anemia and overall reperfusion times (OR, 0.95; 95% CI, 0.74-1.22).<br><br>&emsp;In a contemporary ST-segment-elevation myocardial infarction cohort receiving primary percutaneous coronary intervention, nearly 1 in 5 patients were anemic. Anemia was associated with increased comorbidities and higher-risk features on presentation and was independently associated with subsequent major in-hospital bleeding but not all-cause mortality. These results suggest that anemic ST-segment-elevation myocardial infarction patients may safely receive timely primary percutaneous coronary intervention but with particular consideration for bleeding avoidance strategies.\n <br><br> <b>MeSH terms:<\/b> <b>MeSH terms:<\/b> Aged; Aged, 80 and over; Anemia; Biomarkers; British Columbia; Comorbidity; Female; Heart Arrest; Heart Failure; Hemoglobins; Hemorrhage; Hospital Mortality; Humans; Male; Middle Aged; Percutaneous Coronary Intervention; Registries; Retrospective Studies; Risk Assessment; Risk Factors; ST Elevation Myocardial Infarction; Shock, Cardiogenic; Time Factors; Treatment Outcome <br><br> <b>OMOP Concepts (IDs):<\/b>  Cardiac arrest (321042); Bleeding (437312); Heart failure (316139); Cardiogenic shock (198571); Risk assessment (4024612); Percutaneous coronary intervention (4216130); Anemia (439777); "]},"columns":[{"id":"details","name":"","type":"character","html":true}],"dataKey":"8460a7edf634da4bfa2f60d7d2ca3a5f","static":false,"nested":true},"children":[]}]},{"name":"div","attribs":{"style":{"padding":"1rem"}},"children":[{"name":"Reactable","attribs":{"data":{"details":["<b>DOI:<\/b> 10.1371/journal.pone.0209204 <br><br> Glucose-6-phosphate dehydrogenase (G6PD) deficiency may affect the clinical presentation of dengue due to the altered redox state in immune cells. We aimed to determine the association between G6PD deficiency and severity of dengue infection in paediatric patients in Myanmar. A cross-sectional study was conducted among paediatric patients aged 2-13 years with dengue in Yankin Children Hospital, Myanmar. One hundred and ninety-six patients positive for dengue infection, as determined via PCR or ELISA, were enrolled. Dengue severity was determined according to the 2009 WHO classification guidelines. Spectrophotometric assays determined G6PD levels. The adjusted median G6PD value of males in the study population was used to define various cut-off points according to the WHO classification guidelines. G6PD genotyping for Mahidol, Kaiping and Mediterranean mutations was performed for 128 out of 196 samples by real-time multiplex PCR. 51 of 196 (26.0%) patients had severe dengue. The prevalence of G6PD phenotype deficiency (< 60% activity) in paediatric patients was 14.8% (29/196), specifically, 13.6% (14/103) in males and 16.2% (15/93) in females. Severe deficiency (< 10% activity) accounted for 7.1% (14/196) of our cohort, occurring 11.7% (12/103) in males and 2.2% (2/93) in females. Among 128 samples genotyped, the G6PD gene mutations were detected in 19.5% (25/128) of patients, with 20.3% (13/ 64) in males and 18.8% (12/64) in females. The G6PD Mahidol mutation was 96.0% (24/25) while the G6PD Kaiping mutation was 4.0% (1/25). Severe dengue was not associated with G6PD enzyme deficiency or presence of the G6PD gene mutation. Thus, no association between G6PD deficiency and dengue severity could be detected. Trial registration: The study was registered following the WHO International Clinical Trials Registry Platform (WHO-ICTRP) on Thai Clinical Trials Registry (TCTR) website, registration number # TCTR20180720001.\n <br><br> <b>MeSH terms:<\/b> <b>MeSH terms:<\/b> Adolescent; Child; Child, Preschool; Cross-Sectional Studies; Dengue; Female; Genotype; Glucosephosphate Dehydrogenase; Glucosephosphate Dehydrogenase Deficiency; Humans; Male; Multiplex Polymerase Chain Reaction; Mutation; Myanmar; Prevalence; Prospective Studies <br><br> <b>OMOP Concepts (IDs):<\/b>  Dengue (440022); Genetic mutation (4205432); Genetic finding (4025367); Deficiency of glucose-6-phosphate dehydrogenase (4050620); "]},"columns":[{"id":"details","name":"","type":"character","html":true}],"dataKey":"3f5c652b89bd12a7871ef4652b60bc48","static":false,"nested":true},"children":[]}]},{"name":"div","attribs":{"style":{"padding":"1rem"}},"children":[{"name":"Reactable","attribs":{"data":{"details":["<b>DOI:<\/b> 10.1371/journal.pone.0212795 <br><br> Anemia is a major comorbidity of patients with end-stage renal disease and poses an enormous economic burden to health-care systems. High dose erythropoiesis-stimulating agents (ESAs) have been associated with unfavorable clinical outcomes. We explored whether mixed-dilution hemodiafiltration (Mixed-HDF), based on its innovative substitution modality, may improve anemia outcomes compared to the traditional post-dilution hemodiafiltration (Post-HDF).<br><br>&emsp;We included 174 adult prevalent dialysis patients (87 on Mixed-HDF, 87 on Post-HDF) treated in 24 NephroCare dialysis centers between January 2010 and August 2016 into this retrospective cohort study. All patients were dialyzed three times per week and had fistula/graft as vascular access. Patients were matched at baseline and followed over a one-year period. The courses of hemoglobin levels (Hb) and monthly ESA consumption were compared between the two groups with linear mixed models.<br><br>&emsp;Mean baseline Hb was 11.9±1.3 and 11.8±1.1g/dl in patients on Mixed- and Post-HDF, respectively. While Hb remained stable in patients on Mixed-HDF, it decreased slightly in patients on Post-HDF (at month 12: 11.8±1.2 vs 11.1±1.2g/dl). This tendency was confirmed by our linear mixed model (p = 0.0514 for treatment x time interaction). Baseline median ESA consumption was 6000 [Q1:0;Q3:16000] IU/4 weeks in both groups. Throughout the observation period ESA doses tended to be lower in the Mixed-HDF group (4000 [Q1:0;Q3:16000] vs 8000 [Q1:0;Q3:20000] IU/4 weeks at month 12; p = 0.0791 for treatment x time interaction). Sensitivity analyses, adjusting for differences not covered by matching at baseline, strengthened our results (Hb: p = 0.0124; ESA: p = 0.0687).<br><br>&emsp;Results of our explorative study suggest that patients on Mixed-HDF may have clinical benefits in terms of anemia management. This may also have a beneficial economic impact. Future studies are needed to confirm our hypothesis-generating results and to provide additional evidence on the potential beneficial effects of Mixed-HDF.\n <br><br> <b>MeSH terms:<\/b> <b>MeSH terms:<\/b> Adult; Aged; Anemia; Female; Follow-Up Studies; Hematinics; Hemodiafiltration; Hemoglobins; Humans; Kidney Failure, Chronic; Male; Middle Aged; Models, Biological; Retrospective Studies <br><br> <b>OMOP Concepts (IDs):<\/b>  End-stage renal disease (193782); Anemia (439777); Hemodiafiltration (4049845); "]},"columns":[{"id":"details","name":"","type":"character","html":true}],"dataKey":"cef4c8556e3080e90f2feed905adc810","static":false,"nested":true},"children":[]}]},{"name":"div","attribs":{"style":{"padding":"1rem"}},"children":[{"name":"Reactable","attribs":{"data":{"details":["<b>DOI:<\/b> 10.1371/journal.pone.0213024 <br><br> It has been proposed that ovarian sickling and/or iron overload in women with sickle cell disease (SCD) could contribute to gonadal dysfunction, but there are very few published studies. We hypothesised that the above phenomena might impair ovarian reserve.<br><br>&emsp;A total of 50 SCD patients were case-matched by age, ethnicity, and presence of regular cycles (28±5 days) with 73 patients without a known haemoglobinopathy who required anti-Müllerian hormone (AMH) assessment in a gynaecology clinic. SCD patients had AMH levels taken as part of routine care. The patients were case-controlled and matched with patients who had no haemoglobinopathy in a tertiary centre over a period of one year.<br><br>&emsp;The mean AMH in the SCD case group was 7.6 pmol/l compared with 13.4 pmol/l in the control group (p<0.001). The AMH distributions were subsequently categorised. This showed that SCD patients had a significantly higher chance of having lower AMH in comparison with the control group (OR 2.6 (CI 1.1-6.5, P = 0.02). The proportion of women with AMH > 20 pmol/l was significantly lower in the SCD group (6%) in comparison with the control group (19%) (P = 0.04).<br><br>&emsp;This is the first study showing that women of reproductive age with SCD are more likely to have a low ovarian reserve at a younger age in comparison with patients with no haemoglobinopathy.\n <br><br> <b>MeSH terms:<\/b> <b>MeSH terms:<\/b> Adult; Age Factors; Anemia, Sickle Cell; Anti-Mullerian Hormone; Case-Control Studies; Female; Humans; Middle Aged; Ovarian Reserve; Ovary <br><br> <b>OMOP Concepts (IDs):<\/b>  Sickle cell-hemoglobin SS disease (22281); "]},"columns":[{"id":"details","name":"","type":"character","html":true}],"dataKey":"a83e7733e5aa4edee7ac52bba13b5c87","static":false,"nested":true},"children":[]}]},{"name":"div","attribs":{"style":{"padding":"1rem"}},"children":[{"name":"Reactable","attribs":{"data":{"details":["<b>DOI:<\/b> 10.1371/journal.pone.0212817 <br><br> To investigate the association between maternal anemia and low/insufficient birth weight.<br><br>&emsp;A prospective cohort study of pregnant women who underwent prenatal care at the healthcare units in a municipality of northeast Brazil together with their newborn infants was carried out. The pregnant women were classified as having anemia when the hemoglobin level was below 11 g/dl. Infants who were born full term weighing less than 2500 grams were classified as low birth weight, and those weighing between 2500 and 2999 grams were classified as insufficient weight. The occurrence of maternal anemia and its association with birth weight was verified using crude and adjusted Relative Risk (RR) estimates with their corresponding 95% confidence intervals (95%CIs).<br><br>&emsp;The final sample was comprised of 622 women. Maternal anemia was considered a risk factor for low/insufficient birth weight, after adjusting the effect measurement for maternal age, family income, urinary infection, parity, alcoholic beverage consumption during pregnancy and gestational body mass index: RRadjusted = 1.38 [95% CI: 1.07 to 1.77].<br><br>&emsp;Maternal anemia was associated with low/insufficient birth weight, representing a risk factor for the gestational outcomes studied.\n <br><br> <b>MeSH terms:<\/b> <b>MeSH terms:<\/b> Adolescent; Adult; Anemia; Birth Weight; Brazil; Female; Hemoglobins; Humans; Infant, Low Birth Weight; Infant, Newborn; Middle Aged; Pregnancy; Pregnancy Complications; Pregnancy Outcome; Prospective Studies; Risk Factors; Socioeconomic Factors; Young Adult <br><br> <b>OMOP Concepts (IDs):<\/b>  Birth weight finding (4187520); Pregnant (4299535); Complication occurring during pregnancy (43530950); Low birth weight infant (4171115); Anemia (439777); "]},"columns":[{"id":"details","name":"","type":"character","html":true}],"dataKey":"51bd06ed3f3f6d68f02d99d07b1aa98d","static":false,"nested":true},"children":[]}]},{"name":"div","attribs":{"style":{"padding":"1rem"}},"children":[{"name":"Reactable","attribs":{"data":{"details":["<b>DOI:<\/b> 10.1371/journal.pone.0214358 <br><br> Poor nutritional status in pregnancy expressed as low mid-upper arm circumference (MUAC) is associated with low birth weight. The study aims were to assess the nutritional status of pregnant Ethiopian women using MUAC and examine association with nutrition-specific and nutrition-sensitive factors, using baseline data of a prospective longitudinal observational birth cohort study conducted in three rural districts in the Oromia region of Ethiopia. Recruitment into the cohort was rolling over a period of nine months, and the data used for this analysis were collected while the women were between 12-32 weeks of gestation. Detailed household socio-demographics, agricultural production, women's health, morbidity and diets, with weights, heights and MUAC, and anemia prevalence (HemoCue) were collected. The prevalence of low MUAC (< 23 cm) was 41%. Controlling for location and clustering, wealth quintile (OR = 0.88, CI = 0.82 to 0.96, p<0.01) was associated with decreased risk of low MUAC, while trimester (OR = 1.31, CI = 1.16 to 1.48, p<0.001) was associated with increased risk of low MUAC. The only significant factor amenable to nutrition-specific interventions was altitude-adjusted anemia, which was associated with increased risk of low MUAC (OR = 1.28, CI = 1.09 to 1.49, p<0.01). Significant factors amenable to nutrition-sensitive factors and associated with higher odds of low MUAC were household food insecurity (OR = 1.04, CI = 1.02 to 1.06, p<0.001), distance to the clinic in minutes (OR = 1.01, CI = 1.0 to 1.01, p<0.0001) and season of recruitment (lean versus non lean) (OR = 1.30, CI = 1.10 to 1.54, p<0.01). Literacy (OR = 0.85, CI = 0.74 to 0.98, p<0.05) and numeracy (OR = 0.75, CI = 0.62 to 0.91, p<0.01) were also significantly associated with lower odds of low MUAC. Poor nutritional status in pregnancy expressed as percent with low MUAC was high in Ethiopian women. It was associated with several nutrition-specific and -sensitive factors indicating the importance of multisectoral actions in improving outcomes within the first 1000 days.\n <br><br> <b>MeSH terms:<\/b> <b>MeSH terms:<\/b> Adolescent; Adult; Anemia; Arm; Ethiopia; Female; Food Supply; Gestational Age; Humans; Literacy; Longitudinal Studies; Middle Aged; Nutritional Status; Odds Ratio; Pregnancy; Seasons; Women's Health; Young Adult <br><br> <b>OMOP Concepts (IDs):<\/b>  Pregnant (4299535); Anemia (439777); "]},"columns":[{"id":"details","name":"","type":"character","html":true}],"dataKey":"886c0bf21493fb0260d0966663833137","static":false,"nested":true},"children":[]}]},{"name":"div","attribs":{"style":{"padding":"1rem"}},"children":[{"name":"Reactable","attribs":{"data":{"details":["<b>DOI:<\/b> 10.1200/JCO.18.02142 <br><br> To update the American Society of Clinical Oncology (ASCO)/American Society of Hematology (ASH) recommendations for use of erythropoiesis-stimulating agents (ESAs) in patients with cancer.<br><br>&emsp;PubMed and the Cochrane Library were searched for randomized controlled trials (RCTs) and meta-analyses of RCTs in patients with cancer published from January 31, 2010, through May 14, 2018. For biosimilar ESAs, the literature search was expanded to include meta-analyses and RCTs in patients with cancer or chronic kidney disease and cohort studies in patients with cancer due to limited RCT evidence in the cancer setting. ASCO and ASH convened an Expert Panel to review the evidence and revise previous recommendations as needed.<br><br>&emsp;The primary literature review included 15 meta-analyses of RCTs and two RCTs. A growing body of evidence suggests that adding iron to treatment with an ESA may improve hematopoietic response and reduce the likelihood of RBC transfusion. The biosimilar literature review suggested that biosimilars of epoetin alfa have similar efficacy and safety to reference products, although evidence in cancer remains limited.<br><br>&emsp;ESAs (including biosimilars) may be offered to patients with chemotherapy-associated anemia whose cancer treatment is not curative in intent and whose hemoglobin has declined to < 10 g/dL. RBC transfusion is also an option. With the exception of selected patients with myelodysplastic syndromes, ESAs should not be offered to most patients with nonchemotherapy-associated anemia. During ESA treatment, hemoglobin may be increased to the lowest concentration needed to avoid transfusions. Iron replacement may be used to improve hemoglobin response and reduce RBC transfusions for patients receiving ESA with or without iron deficiency. Additional information is available at www.asco.org/supportive-care-guidelines and www.hematology.org/guidelines .\n <br><br> <b>MeSH terms:<\/b> <b>MeSH terms:<\/b> Anemia; Biosimilar Pharmaceuticals; Hematinics; Humans; Meta-Analysis as Topic; Neoplasms; Randomized Controlled Trials as Topic <br><br> <b>OMOP Concepts (IDs):<\/b>  Neoplastic disease (438112); Anemia (439777); "]},"columns":[{"id":"details","name":"","type":"character","html":true}],"dataKey":"03337ec8739dfd71109edae81bfe6b0f","static":false,"nested":true},"children":[]}]},{"name":"div","attribs":{"style":{"padding":"1rem"}},"children":[{"name":"Reactable","attribs":{"data":{"details":["<b>DOI:<\/b> 10.1371/journal.pone.0215920 <br><br> The impact of low-normal hemoglobin (Hb) levels and anemia on the risk of end-stage renal disease (ESRD) in general populations has rarely been examined.<br><br>&emsp;510,620 Korean adults aged 40-80 years without known chronic kidney disease (CKD) underwent health examinations during 2002-2003 and were followed-up until 2013. Incidence of ESRD was identified by hospital discharge and clinical visit records.<br><br>&emsp;During a mean follow-up of 10.5, 575 women and 1047 men were diagnosed with ESRD. Lower Hb levels were associated with an increased risk of ESRD at given severity of albuminuria and at given estimated glomerular filtration rate (eGFR). Hb 13-13.9 g/dL in men, Hb 11-11.9 g/dL in women, and trace albuminuria assessed by dipstick urinalysis were associated with more than doubled risk. The risk associated with lower Hb was stronger in older (≥60 years) than younger women. Among 349,993 participants with information on eGFR, the multivariable-adjusted HRs associated with 1 g/dL lower Hb in participants with eGFR values ≥60, 30-59, and <30 mL/min/1.73 m2 were 1.34 (95% CI, 1.17-1.54), 1.55 (1.38-1.74), and 1.75 (1.47-2.09), respectively (Pinteraction between eGFR groups = .06).<br><br>&emsp;Low-normal Hb levels and anemia are risk factors for ESRD incidence in person without CKD and for CKD progression to ESRD. Lower Hb increases the risk of ESRD through synergistic biological interactions with lower eGFR and albuminuria. The impacts of lower Hb may be stronger in older than younger women. Proper management and screening at earlier stage of Hb decline and anemia might reduce the burden of CKD.\n <br><br> <b>MeSH terms:<\/b> <b>MeSH terms:<\/b> Adult; Aged; Albuminuria; Anemia; Female; Glomerular Filtration Rate; Hemoglobins; Humans; Incidence; Kidney Failure, Chronic; Male; Middle Aged; Prospective Studies; Risk Factors <br><br> <b>OMOP Concepts (IDs):<\/b>  End-stage renal disease (193782); Albuminuria (4168705); Anemia (439777); "]},"columns":[{"id":"details","name":"","type":"character","html":true}],"dataKey":"cd081f3194febe631f9126efddf34dae","static":false,"nested":true},"children":[]}]},{"name":"div","attribs":{"style":{"padding":"1rem"}},"children":[{"name":"Reactable","attribs":{"data":{"details":["<b>DOI:<\/b> 10.1371/journal.pone.0216062 <br><br> Anemia of chronic disease (ACD) refers to hypoproliferative anemia in the context of acute or chronic activation of the immune system. There is a paucity of prospective data addressing the risk factors for ACD development. An association between common chronic diseases and ACD was examined cross-sectionally and longitudinally.<br><br>&emsp;A cohort of 265,459 healthy participants without ACD at baseline were prospectively followed annually or biennially.<br><br>&emsp;During average follow-up period of 62 months, 4,906 participants developed ACD (incidence rate 3.58 per 1000 person-years). Multivariable-adjusted hazard ratio (HR) [95% confidence interval (CI)] for incident ACD comparing estimated glomerular filtration rate 30-60 and < 30 vs. ≥ 60 ml/min/1.73 m2 were 3.93 [3.18-4.85] and 39.11 [18.50-82.69]; HRs [95% CI] for ACD comparing prediabetes and diabetes vs. normal were 1.19 [1.12-1.27] and 2.46 [2.14-2.84], respectively. HRs [95% CI] for incident ACD comparing body-mass-index (BMI) of < 18.5, 23-24.9 and ≥ 25 vs. 18.5-22.9 kg/m2 were 0.89 [0.78-1.00], 0.89 [0.80-0.99] and 0.78 [0.66-0.91], respectively. HRs [95% CI] for incident ACD comparing prehypertension and hypertension vs. normal were 0.79 [0.73-0.86] and 1.10 [0.99-1.23], respectively. Metabolic syndrome, hypertension, chronic liver disease, and chronic obstructive pulmonary disease were not associated with incident ACD.<br><br>&emsp;The severity of chronic kidney disease and diabetic status were independently associated with an increased incidence of ACD, whereas prehypertension and an increasing BMI were significantly associated with decreased risk of ACD.\n <br><br> <b>MeSH terms:<\/b> <b>MeSH terms:<\/b> Adult; Anemia; Body Mass Index; Chronic Disease; Cross-Sectional Studies; Diabetes Complications; End Stage Liver Disease; Female; Humans; Hypertension; Incidence; Male; Metabolic Syndrome; Prediabetic State; Prehypertension; Prospective Studies; Pulmonary Disease, Chronic Obstructive; Republic of Korea; Risk Factors; Severity of Illness Index <br><br> <b>OMOP Concepts (IDs):<\/b>  Chronic obstructive lung disease (255573); Prediabetes (37018196); Complication due to diabetes mellitus (442793); Chronic disease (443783); Hypertensive disorder (316866); Metabolic syndrome X (436940); Anemia (439777); End stage liver disease (45769564); Prehypertension (45765798); "]},"columns":[{"id":"details","name":"","type":"character","html":true}],"dataKey":"d67cf343a415aab73f25a41064ca7f2a","static":false,"nested":true},"children":[]}]},{"name":"div","attribs":{"style":{"padding":"1rem"}},"children":[{"name":"Reactable","attribs":{"data":{"details":["<b>DOI:<\/b> 10.1371/journal.pone.0216994 <br><br> Chronic pain affects 50% of adults with sickle cell disease (SCD). Although central sensitization is thought to contribute to the pathogenesis of this chronic pain, no studies have examined differences in functional connectivity of the brain between patients with SCD with and without chronic pain. We performed an observational cohort study using resting-state functional MRI (rsfMRI) of the brain on adults with SCD with and without chronic pain. We tested the hypothesis that, compared to those without chronic pain, those with chronic pain would have differences in functional connectivity between the periaqueductal grey (PAG) and other regions of the brain. Twenty-two adults with SCD, 15 with chronic pain and 7 without chronic pain, as well as 10 African-American controls, underwent rsfMRI of the brain. When SCD patients with chronic pain were compared to those without chronic pain, significant differences in connectivity were noted between the PAG and 9 regions of the brain, including several in the default mode network, a network involved in introspection that has been implicated in other chronic pain syndromes. Changes in functional connectivity between patients with SCD with and without chronic pain suggest a mechanism for chronic pain that involves neuro-plastic changes to the brain.\n <br><br> <b>MeSH terms:<\/b> <b>MeSH terms:<\/b> Adolescent; Adult; Black or African American; Anemia, Sickle Cell; Brain; Brain Mapping; Chronic Pain; Female; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Nerve Net; Neural Pathways; Periaqueductal Gray; Rest; Young Adult <br><br> <b>OMOP Concepts (IDs):<\/b>  Brain mapping (4098782); Sickle cell-hemoglobin SS disease (22281); Magnetic resonance imaging (4013636); Chronic pain (436096); "]},"columns":[{"id":"details","name":"","type":"character","html":true}],"dataKey":"5640e375575c8d989ec7b34a8f061128","static":false,"nested":true},"children":[]}]},{"name":"div","attribs":{"style":{"padding":"1rem"}},"children":[{"name":"Reactable","attribs":{"data":{"details":["<b>DOI:<\/b> 10.1371/journal.pmed.1002818 <br><br> Emerging data in chronic kidney disease (CKD) patients suggest that iron deficiency and higher circulating levels of erythropoietin (EPO) stimulate the expression and concomitant cleavage of the osteocyte-derived, phosphate-regulating hormone fibroblast growth factor 23 (FGF23), a risk factor for premature mortality. To date, clinical implications of iron deficiency and high EPO levels in the general population, and the potential downstream role of FGF23, are unclear. Therefore, we aimed to determine the associations between iron deficiency and higher EPO levels with mortality, and the potential mediating role of FGF23, in a cohort of community-dwelling subjects.<br><br>&emsp;We analyzed 6,544 community-dwelling subjects (age 53 ± 12 years; 50% males) who participated in the Prevention of Renal and Vascular End-Stage Disease (PREVEND) study-a prospective population-based cohort study, of which we used the second survey (2001-2003)-and follow-up was performed for a median of 8 years. We measured circulating parameters of iron status, EPO levels, and plasma total FGF23 levels. Our primary outcome was all-cause mortality. In multivariable linear regression analyses, ferritin (ß = -0.43), transferrin saturation (TSAT) (ß = -0.17), hepcidin (ß = -0.36), soluble transferrin receptor (sTfR; ß = 0.33), and EPO (ß = 0.28) were associated with FGF23 level, independent of potential confounders. During median (interquartile range [IQR]) follow-up of 8.2 (7.7-8.8) years, 379 (6%) subjects died. In multivariable Cox regression analyses, lower levels of TSAT (hazard ratio [HR] per 1 standard deviation [SD], 0.84; 95% confidence interval [CI], 0.75-0.95; P = 0.004) and higher levels of sTfR (HR, 1.15; 95% CI 1.03-1.28; P = 0.01), EPO (HR, 1.17; 95% CI 1.05-1.29; P = 0.004), and FGF23 (HR, 1.20; 95% CI 1.10-1.32; P < 0.001) were each significantly associated with an increased risk of death, independent of potential confounders. Adjustment for FGF23 levels markedly attenuated the associations of TSAT (HR, 0.89; 95% CI 0.78-1.01; P = 0.06), sTfR (HR, 1.08; 95% CI 0.96-1.20; P = 0.19), and EPO (HR, 1.10; 95% CI 0.99-1.22; P = 0.08) with mortality. FGF23 remained associated with mortality (HR, 1.15; 95% CI 1.04-1.27; P = 0.008) after adjustment for TSAT, sTfR, and EPO levels. Mediation analysis indicated that FGF23 explained 31% of the association between TSAT and mortality; similarly, FGF23 explained 32% of the association between sTfR and mortality and 48% of the association between EPO and mortality (indirect effect P < 0.05 for all analyses). The main limitations of this study were the observational study design and the absence of data on intact FGF23 (iFGF23), precluding us from discerning whether the current results are attributable to an increase in iFGF23 or in C-terminal FGF23 fragments.<br><br>&emsp;In this study, we found that functional iron deficiency and higher EPO levels were each associated with an increased risk of death in the general population. Our findings suggest that FGF23 could be involved in the association between functional iron deficiency and increased EPO levels and death. Investigation of strategies aimed at correcting iron deficiency and reducing FGF23 levels is warranted.\n <br><br> <b>MeSH terms:<\/b> <b>MeSH terms:<\/b> Adult; Aged; Anemia, Iron-Deficiency; Biomarkers; Cohort Studies; Erythropoietin; Female; Fibroblast Growth Factor-23; Fibroblast Growth Factors; Humans; Male; Middle Aged; Mortality; Netherlands; Population Surveillance <br><br> <b>OMOP Concepts (IDs):<\/b>  Iron deficiency anemia (436659); "]},"columns":[{"id":"details","name":"","type":"character","html":true}],"dataKey":"f453c1a4a82e5cb9f1cd82e4ef9de537","static":false,"nested":true},"children":[]}]},{"name":"div","attribs":{"style":{"padding":"1rem"}},"children":[{"name":"Reactable","attribs":{"data":{"details":["<b>DOI:<\/b> 10.1371/journal.pone.0214563 <br><br> Africa has the highest rates of child mortality. Little is known about outcomes after hospitalization for children with very severe anemia.<br><br>&emsp;To determine one year mortality and predictors of mortality in Tanzanian children hospitalized with very severe anemia.<br><br>&emsp;We conducted a prospective cohort study enrolling children 2-12 years hospitalized from August 2014 to November 2014 at two public hospitals in northwestern Tanzania. Children were screened for anemia and followed until 12 months after discharge. The primary outcome measured was mortality. Predictors of mortality were determined using Cox regression analysis.<br><br>&emsp;Of the 505 children, 90 (17.8%) had very severe anemia and 415 (82.1%) did not. Mortality was higher for children with very severe anemia compared to children without over a one year period from admission, 27/90 (30.0%) vs. 59/415 (14.2%) respectively (Hazard Ratio (HR) 2.42, 95% Cl 1.53-3.83). In-hospital mortality was 11/90 (12.2%) and post-hospital mortality was 16/79 (20.2%) for children with very severe anemia. The strongest predictors of mortality were age (HR 1.01, 95% Cl 1.00-1.03) and decreased urine output (HR 4.30, 95% Cl 1.04-17.7).<br><br>&emsp;Children up to 12 years of age with very severe anemia have nearly a 30% chance of mortality following admission over a one year period, with over 50% of mortality occurring after discharge. Post-hospital interventions are urgently needed to reduce mortality in children with very severe anemia, and should include older children.\n <br><br> <b>MeSH terms:<\/b> <b>MeSH terms:<\/b> Anemia; Cause of Death; Child; Child, Preschool; Female; Hospitalization; Humans; Male; Mortality; Prevalence; Prospective Studies; Regression Analysis; Risk Factors; Tanzania <br><br> <b>OMOP Concepts (IDs):<\/b>  Cause of death (4083743); Inpatient care (4214577); Anemia (439777); "]},"columns":[{"id":"details","name":"","type":"character","html":true}],"dataKey":"0ebfb4ca351a236535d893c1fb8f65da","static":false,"nested":true},"children":[]}]},{"name":"div","attribs":{"style":{"padding":"1rem"}},"children":[{"name":"Reactable","attribs":{"data":{"details":["<b>DOI:<\/b> 10.1371/journal.pone.0219047 <br><br> The implication of lymphocytes in sickle cell disease pathogenesis is supported by a number of recent reports. These studies provided evidence for the activation of invariant natural killer T (iNKT) cells in adult patients, but did not investigate the involvement of other innate-like T cell subsets so far.<br><br>&emsp;Here we present a monocentric prospective observational study evaluating the number and functional properties of both circulating conventional and innate-like T cells, namely iNKT, Mucosal-Associated Invariant T (MAIT) and gammadelta (γδ) T cells in a cohort of 39 children with sickle cell disease.<br><br>&emsp;Relative to age-matched healthy controls, we found that patients had a higher frequency of IL-13- and IL-17-producing CD4+ T cells, as well as higher MAIT cell counts with an increased frequency of IL-17-producing MAIT cells. Patients also presented increased Vδ2 γδ T cell counts, especially during vaso-occlusive crisis, and a lower frequency of IFNγ-producing Vδ2 γδ T cells, except during crisis. iNKT cell counts and the frequency of IFNγ-producing iNKT cells were unchanged compared to controls. Our study revealed positive correlations between 1) the frequency of IFNγ-producing CD4+, CD8+ and Vδ2 γδ T cells and the number of hospitalizations for vaso-occlusive crisis in the previous year; 2) the frequency of IFNγ-producing iNKT cells and patients' age and 3) the frequency of IL-17-producing Vδ2 γδ T cells and hemoglobin S level.<br><br>&emsp;These results strongly suggest a role of innate-like T cells in sickle cell disease pathophysiology, especially that of IL-17-producing MAIT and γδ T cells.\n <br><br> <b>MeSH terms:<\/b> <b>MeSH terms:<\/b> Adolescent; Anemia, Sickle Cell; Child; Female; Humans; Immunity, Innate; Male; Mucosal-Associated Invariant T Cells; Natural Killer T-Cells; Prospective Studies; Receptors, Antigen, T-Cell, gamma-delta; T-Lymphocyte Subsets <br><br> <b>OMOP Concepts (IDs):<\/b>  Sickle cell-hemoglobin SS disease (22281); "]},"columns":[{"id":"details","name":"","type":"character","html":true}],"dataKey":"3960eb5b1ae3d47535bf6f6018102844","static":false,"nested":true},"children":[]}]},{"name":"div","attribs":{"style":{"padding":"1rem"}},"children":[{"name":"Reactable","attribs":{"data":{"details":["<b>DOI:<\/b> 10.1371/journal.pone.0219263 <br><br> Red blood cell (RBC) transfusions are associated with increased mortality and morbidity. The aim of this analysis was to examine the association between RBC transfusions and long-term survival for patients undergoing elective open infrarenal abdominal aortic aneurysm (AAA) repair with up to 15 years of follow-up.<br><br>&emsp;Prospective cohort study using data from The Danish Vascular Registry from 2000-2015. Primary endpoint was all-cause mortality. Secondary endpoints were in-hospital complications. Transfused patients were divided into subgroups based on received RBC transfusions (1, 2-3, 4-5 or > 5). Using Cox regression multi-adjusted analysis, non-transfused patients were compared to transfused patients (1, 2-3, 4-5, >5 transfusions) for both primary and secondary endpoints.<br><br>&emsp;There were 3 876 patients included with a mean survival of 9.1 years. There were 801 patients who did not receive transfusions. Overall 30-day mortality was 3.1% (121 patients) and 3.6% (112) for all transfused patients. For the five subgroups 30-day mortality was: No transfusions 1.1% (9 patients), 1 RBC 1.2% (4 patients), 2-3 RBC 2.2% (26 patients), 4-5 RBC 1.9% (14 patients) and > 5 RBC 7.9% (68 patients). After receiving RBCs, the hazard ratio for death was 1.54 (95% CI 1.27-1.85) compared to non-transfused patients. There was a significant increase in mortality when receiving 2-3 RBC: HR 1.32 (95% CI 1.07-1.62), 4-5 RBC: 1.64 (1.32-2.03) and >5 RBC: 1.96 (1.27-1.85) in a multi-adjusted model.<br><br>&emsp;There is a dose-dependent association between RBC transfusions received during elective AAA repair and an increase in short- and long-term mortality. Approximately 25% of included patients had preoperative anemia. These findings should raise awareness regarding potentially unnecessary and harmful RBC transfusions.\n <br><br> <b>MeSH terms:<\/b> <b>MeSH terms:<\/b> Aged; Anemia; Aorta; Aortic Aneurysm, Abdominal; Elective Surgical Procedures; Erythrocyte Transfusion; Erythrocytes; Female; Humans; Male; Middle Aged; Morbidity; Proportional Hazards Models; Risk Assessment; Risk Factors; Vascular Surgical Procedures <br><br> <b>OMOP Concepts (IDs):<\/b>  Abdominal aortic aneurysm (198177); Transfusion of red blood cells (4022173); Risk assessment (4024612); Vascular surgery procedure (4148948); Optional surgery (4166767); Anemia (439777); "]},"columns":[{"id":"details","name":"","type":"character","html":true}],"dataKey":"29095e8f15f1998e55f93076f197b68d","static":false,"nested":true},"children":[]}]},{"name":"div","attribs":{"style":{"padding":"1rem"}},"children":[{"name":"Reactable","attribs":{"data":{"details":["<b>DOI:<\/b> 10.1371/journal.pone.0219703 <br><br> Many women suffer from anemia during their pregnancy. Austria, a central European country, has an instituted mandatory prenatal care system and therein two anemia screening tests (before end of week 16 and in weeks 25-28) are scheduled. Epidemiological data on the prevalence of anemia in pregnant women in Austria are missing.<br><br>&emsp;We analysed data from Styria, an Austrian federal state, to determine the prevalence of anemia diagnosed in pregnant women aged 15-45 years with at least one examination in the first and second time period using the cut-off hemoglobin (Hb) concentration of 11 g/dl as recommended by the World Health Organisation (WHO). Sensitivity analyses for cut-off values with 10.5 and 7 g/dl (severe anemia) were performed. The STROBE checklist was applied for this retrospective cohort study.<br><br>&emsp;The study included anemia screening tests from 25,922 women during 31,429 pregnancies from 2006-2014. Anemia was diagnosed in either time period in 13.7% (95% confidence interval (CI) 13.4-14.1) of pregnancies, in the first time period in 2.2% (95% CI 2.0-2.2), and in the second time period in 13.0% (95% CI 12.6-13.4). The annual age-adjusted anemia prevalence showed no change over time. Reducing the cut-off value to 10.5 g/dl resulted in an anemia prevalence in either time period of 5.6% (95% CI 5.3-5.8). The pattern of a higher prevalence in the second time period remained unchanged. Severe anemia (Hb <7 g/dl) was diagnosed in four pregnancies (0.01%).<br><br>&emsp;The estimated anemia prevalence of around 14% in pregnant women in Styria (Austria) is stable over the observed time window (2006-2014) and almost all are diagnosed in the second test period (in weeks 25-28). It seems that in a developed country like Austria the first examination (before week 16) is not mandatory for pregnancy care. However, in other countries where a high prevalence of anemia is common due to risk factors such as malaria and HIV, early screening in pregnancy might be very important.\n <br><br> <b>MeSH terms:<\/b> <b>MeSH terms:<\/b> Adult; Anemia; Austria; Child; Female; Hemoglobins; Humans; Mothers; Pregnancy; Pregnancy Complications, Hematologic; Prevalence <br><br> <b>OMOP Concepts (IDs):<\/b>  Pregnant (4299535); Anemia (439777); "]},"columns":[{"id":"details","name":"","type":"character","html":true}],"dataKey":"e7a790c15b315e8c12a5985154019fe7","static":false,"nested":true},"children":[]}]},{"name":"div","attribs":{"style":{"padding":"1rem"}},"children":[{"name":"Reactable","attribs":{"data":{"details":["<b>DOI:<\/b> 10.1371/journal.pone.0220862 <br><br> The iron status of blood donors is a subject of concern for blood establishments. The Finnish Red Cross Blood Service addresses iron loss in blood donors by proposing systematic iron supplementation for demographic at-risk donor groups. We measured blood count, ferritin and soluble transferrin receptor (sTfR) and acquired lifestyle and health information from 2200 blood donors of the FinDonor 10000 cohort. We used modern data analysis methods to estimate iron status and factors affecting it with a special focus on the effects of the blood service's iron supplementation policy. Low ferritin (< 15 μg/L), an indicator of low iron stores, was present in 20.6% of pre-menopausal women, 10.6% of post-menopausal women and 6% of men. Anemia co-occurred with iron deficiency more frequently in pre-menopausal women (21 out of 25 cases) than in men (3/6) or post-menopausal women (1/2). In multivariable regression analyses, lifestyle, dietary, and blood donation factors explained up to 38% of the variance in ferritin levels but only ~10% of the variance in sTfR levels. Days since previous donation were positively associated with ferritin levels in all groups while the number of donations during the past 2 years was negatively associated with ferritin levels in pre-menopausal women and men. FRCBS-provided iron supplementation was negatively associated with ferritin levels in men only. Relative importance analyses showed that donation activity accounted for most of the explained variance in ferritin levels while iron supplementation explained less than 1%. Variation in ferritin levels was not significantly associated with variation in self-reported health. Donation activity was the most important factor affecting blood donor iron levels, far ahead of e.g. red-meat consumption or iron supplementation. Importantly, self-reported health of donors with lower iron stores was not lower than self-reported health of donors with higher iron stores.\n <br><br> <b>MeSH terms:<\/b> <b>MeSH terms:<\/b> Adolescent; Adult; Age Factors; Aged; Anemia, Iron-Deficiency; Blood Donors; Diet; Dietary Supplements; Female; Ferritins; Health Status; Humans; Iron Compounds; Life Style; Male; Middle Aged; Receptors, Transferrin; Sex Factors; Young Adult <br><br> <b>OMOP Concepts (IDs):<\/b>  Lifestyle (4046893); Dietary finding (4222559); Iron deficiency anemia (436659); "]},"columns":[{"id":"details","name":"","type":"character","html":true}],"dataKey":"2c30f7f771cedf3e000d3e83e0f21792","static":false,"nested":true},"children":[]}]},{"name":"div","attribs":{"style":{"padding":"1rem"}},"children":[{"name":"Reactable","attribs":{"data":{"details":["<b>DOI:<\/b> 10.1371/journal.pone.0223991 <br><br> Patients suffering from Sickle Cell Disease (SCD) are at increased risk for complications due to influenza virus. Annual influenza vaccination is strongly recommended but few clinical studies have assessed its immunogenicity in individuals with SCD. The aim of this study was to explore the biological efficacy of annual influenza vaccination in SCD patients by characterizing both their humoral and cell-mediated immunity against influenza antigen. We also aimed to investigate these immunological responses among SCD individuals according to their treatment (hydroxyurea (HU), chronic blood transfusions (CT), both HU and CT or none of them).<br><br>&emsp;Seventy-two SCD patients (49 receiving HU, 9 on CT, 7 with both and 7 without treatment) and 30 healthy controls were included in the study. All subjects received the tetravalent influenza α-RIX-Tetra® vaccine from the 2016-2017 or 2017-2018 season.<br><br>&emsp;Protective anti-influenza HAI titers were obtained for the majority of SCD patients one month after vaccination but seroconversion rates in patient groups were strongly decreased compared to controls. Immune cell counts, particularly cellular memory including memory T and memory B cells, were greatly reduced in SCD individuals. Functional activation assays confirmed a poorer CD8+ T cell memory. We also document an imbalance of cytokines after influenza vaccination in SCD individuals with an INFγ/IL-10 ratio (Th1-type/Treg-type response) significantly lower in the SCD cohort.<br><br>&emsp;SCD patients undergoing CT showed altered immune regulation as compared to other treatment subgroups. Altogether, the cytokine imbalance, the high regulatory T cell levels and the low memory lymphocyte subset levels observed in the SCD cohort, namely for those on CT, suggest a poor ability of SCD patients to fight against influenza infection. Nevertheless, our serological data support current clinical practice for annual influenza vaccination, though immunogenicity to other vaccines involving immunological memory might be hampered in SCD patients and should be further investigated.\n <br><br> <b>MeSH terms:<\/b> <b>MeSH terms:<\/b> Adult; Aged; Anemia, Sickle Cell; CD8-Positive T-Lymphocytes; Female; Humans; Immunologic Memory; Influenza Vaccines; Influenza, Human; Interferon-gamma; Interleukin-10; Male; Middle Aged; Vaccination <br><br> <b>OMOP Concepts (IDs):<\/b>  Interferon Type II (19122123); Unlisted vaccine/toxoid (2213495); Sickle cell-hemoglobin SS disease (22281); Influenza (4266367); Interleukin-10 (42900473); "]},"columns":[{"id":"details","name":"","type":"character","html":true}],"dataKey":"4c5d8cde3d16efd767d7c6c3113be657","static":false,"nested":true},"children":[]}]},{"name":"div","attribs":{"style":{"padding":"1rem"}},"children":[{"name":"Reactable","attribs":{"data":{"details":["<b>DOI:<\/b> 10.1371/journal.pone.0223996 <br><br> α0-Thalassemia is an inherited hematological disorder caused by the deletion of α-globin genes. The Southeast Asian deletion (--SEA) is the most common type of α0-thalassemia observed in Southeast Asian countries. Regarding WHO health policy, an effective α0-thalassemia screening strategy is needed to control new severe α-thalassemia cases. In this study, a monoclonal antibody panel was used to develop immunochromatographic (IC) strip tests for detecting the Hb Bart's and ζ-globin chain. Among 195 samples, all α0-thalassemia traits (78 α0-thalassemia (--SEA) and 4 α0-thalassemia (--THAI)) had low MCV or MCH values. The sensitivity, specificity, PPV and NPV of the IC strip tests for ζ-globin and Hb Bart's for screening α0-thalassemia (--SEA) within the low MCV or MCH samples were 100%, 65.2%, 90.7%, 100% and 96.2%, 47.8%, 86.6%, 78.6%, respectively. All 4 α0-thalassemia (--THAI) traits were negative for ζ-globin chains but positive for Hb Bart's using the IC strip tests. These results led to a α0-thalassemia screening being proposed in which blood samples are first evaluated by MCV, MCH and Hb typing. Samples with high MCV and MCH values are excluded for the presence of the α0-thalassemia gene. Samples with low MCV or MCH values are assayed using the developed IC strip tests, where only samples testing positive are further assayed for α0-thalassemia by PCR. Patients with Hb H, EA Bart's or EF Bart's diseases do not need to use this IC strip assay. Thus, in this study, a simple and cost effective α0-thalassemia point of care test was developed.\n <br><br> <b>MeSH terms:<\/b> <b>MeSH terms:<\/b> Case-Control Studies; Chromatography, Affinity; Diagnosis, Differential; Hemoglobins, Abnormal; Humans; alpha-Thalassemia; zeta-Globins <br><br> <b>OMOP Concepts (IDs):<\/b>  Alpha thalassemia (4287844); Affinity chromatography measurement (4339408); "]},"columns":[{"id":"details","name":"","type":"character","html":true}],"dataKey":"c6c0d8dda945c32e93856f06202b2459","static":false,"nested":true},"children":[]}]},{"name":"div","attribs":{"style":{"padding":"1rem"}},"children":[{"name":"Reactable","attribs":{"data":{"details":["<b>DOI:<\/b> 10.1371/journal.pone.0224514 <br><br> Anemia is a common clinical problem contributing to increased maternal and fetal morbidity and mortality during pregnancy. Anemia can be caused by different factors apart from known diseases. The main aim of this study was to identify determinants of anemia among pregnant women attending antenatal care at the public health facilities of Horo Guduru Wollega Zone, West Ethiopia, 2017.<br><br>&emsp;Health facility-based unmatched case-control study was conducted among 191 anemic and 382 non-anemic pregnant women from September 7, 2017, to October 25, 2017, in Horo Guduru Wollega Zone, West Ethiopia. Data were collected using pre-tested questionnaires from nine health facilities. Hemoglobin level determination, hemo-parasite diagnosis, venereal disease research laboratory (VDRL) test, and stool examination were done in the laboratories of the respective health centers. Cleaned and coded data were entered and analyzed using SPSS version 20. Frequency, proportion, mean and standard deviation were computed to summarize the data and presented by tables and bar graphs. Multivariate binary logistic regression analysis was used to determine the association of predictors and response variables at P ≤ 0.05. Adjusted odds ratio with 95% CI was used to show the strength of association between predictors and outcome variables.<br><br>&emsp;A total of 573 pregnant women were enrolled in this study. Monthly income < 500 Ethiopian birr (AOR = 9.16, 95% CI: 4.23, 19.82), heavy menstrual bleeding (AOR = 2.38, 95%CI: 1.38, 4.09), taking iron supplement irregularly (AOR = 2.87, 95%CI:1.41, 5.84), Mid-upper Arm Circumference (MUAC) < 23 cm (AOR = 3.42, 95%CI: 2.07, 5.63), low dietary diversity score (AOR = 12.30, 95%CI: 4.64, 32.72), medium dietary diversity score (AOR = 3.40, 95%CI:1.48, 7.84) and intestinal helminthic infections (AOR = 6.31, 95%CI: 3.44, 11.58) were significantly associated with anemia during pregnancy.<br><br>&emsp;Average monthly income < 500 Ethiopian birr, heavy menstrual bleeding, low and medium dietary diversity score, taking of iron supplements irregularly, MUAC < 23 cm and intestinal helminthic infections were identified as independent determinants of anemia during pregnancy. Therefore, improving dietary diversity intake, routine deworming and empowering women on taking iron regularly are vital to prevent anemia during pregnancy.\n <br><br> <b>MeSH terms:<\/b> <b>MeSH terms:<\/b> Adolescent; Adult; Anemia; Case-Control Studies; Cross-Sectional Studies; Diet; Dietary Supplements; Ethiopia; Female; Helminthiasis; Humans; Intestinal Diseases, Parasitic; Logistic Models; Odds Ratio; Pregnancy; Pregnancy Complications, Hematologic; Prenatal Care; Risk Factors; Young Adult <br><br> <b>OMOP Concepts (IDs):<\/b>  Helminth infection (441793); Pregnant (4299535); Intestinal parasitism (196347); Dietary finding (4222559); Antepartum care only (2110313); 7 or more visits (4173786); Antenatal care (439777); Anemia (441793); "]},"columns":[{"id":"details","name":"","type":"character","html":true}],"dataKey":"3c8c5c6478c4bd3273c25434eb37534b","static":false,"nested":true},"children":[]}]},{"name":"div","attribs":{"style":{"padding":"1rem"}},"children":[{"name":"Reactable","attribs":{"data":{"details":["<b>DOI:<\/b> 10.1371/journal.pone.0215195 <br><br> Although maternal survival has improved in the last decades, evidence on illnesses and the use of health services during pregnancy remains scarce. Therefore, we aimed to assess the incidence and risk factors for illnesses among pregnant women and measure the use of health services. A prospective cohort study was conducted in three kebeles in rural southern Ethiopia among 794 pregnant women from May 2017 to July 2018. Each woman was followed every two weeks at home. Poisson and survival regression models were used for analysis. The incidence rate of episodes of illnesses was 93 per 100 pregnant-woman-weeks (95%CI: 90.6, 94.2), with an average of eight episodes of illnesses per woman. Anaemia accounted for 22% (177 of 794 women), and hypertension 3% (21 women of 794 women). However, utilization of health services for any illness episodes was only 8% (95%CI: 7.6%, 8.9%). The main reasons for not using health services were that the women thought the illness would heal by itself, women thought the illness was not serious, women could not afford to visit the health institutions, or women lacked confidence in the health institutions. The risk factors for illnesses are having many previous pregnancies in life time (ARR = 1.42; 95%CI = 1.02, 1.96), having history of stillbirth (ARR = 1.30; 95%CI = 1.03, 1.64), having history of abortion (AHR = 1.06; 95%CI = 1.02, 1.11), and walking more than 60 minutes to access the nearest hospital (AHR = 1.08; 95%CI = 1.03, 1.14). The risk factors for low use of health services are also having history of abortion (AHR = 2.50; 95%CI = 1.00, 6.01) and walking more than 60 minutes to access the nearest hospital (AHR = 1.91; 95%CI = 1.00, 3.63). Rural Ethiopian pregnant women experience a high burden of illness during pregnancy. Unfortunately, very few of these women utilize health services.\n <br><br> <b>MeSH terms:<\/b> <b>MeSH terms:<\/b> Abortion, Spontaneous; Adolescent; Adult; Anemia; Ethiopia; Female; Health Services; Health Services Needs and Demand; Humans; Middle Aged; Pregnancy; Pregnancy Complications; Prospective Studies; Rural Population; Young Adult <br><br> <b>OMOP Concepts (IDs):<\/b>  Pregnant (4299535); Miscarriage (4067106); Complication occurring during pregnancy (43530950); Anemia (439777); "]},"columns":[{"id":"details","name":"","type":"character","html":true}],"dataKey":"fe477a792d28adbe0293b29e812f6f7e","static":false,"nested":true},"children":[]}]},{"name":"div","attribs":{"style":{"padding":"1rem"}},"children":[{"name":"Reactable","attribs":{"data":{"details":["<b>DOI:<\/b> 10.1371/journal.pone.0216020 <br><br> The diagnosis of sickle cell disease (SCD) is made by hemoglobin assays such as high-performance liquid chromatography (HPLC), isoelectric focusing and cellulose acetate or citrate agar electrophoresis. These assays are easy to perform and used in large-scale newborn screening in many countries. These tests however may not easily differentiate Sβ0 thalassemia from SS or identify other hemoglobin variants, and in this case, hemoglobin (HBB) gene sequencing may be necessary.<br><br>&emsp;To develop a high throughput DNA based confirmatory assay for SCD and to detect mutations in the HBB gene.<br><br>&emsp;We developed an automated pyrosequencing technique (PyS) based on QIAGEN technology (Hilden, Germany) to detect homozygous or heterozygous hemoglobin S mutations as well as hemoglobin C mutations. The technique was tested on 2,748 samples from patients enrolled in a multi-center SCD cohort in Brazil. Patients were previously tested using HPLC to diagnose SCD as part of routine clinical care. Any subjects with discrepant results between HPLC and PyS or with heterozygous hemoglobin S detected had Sanger sequencing of the HBB gene.<br><br>&emsp;We identified 168 samples with discrepant results between HPLC and PyS and 100 with concordant PyS = heterozygous S and HPLC, which would suggest SB-thalassemia or other heterozygous S variants. The PyS assay correctly identified 1906 (98.7%) of the 1930 HbSS and 628 (98.7%) of the 636 HbSC samples. Of the 179 remaining samples, PyS correctly indicated S heterozygosis in 165 (92.2%). Of the 165 heterozygous S samples confirmed by Sanger as consistent with Sβ thalassemia genotype, 84 samples were classified as Sβ0 thalassemia and 81 as Sβ+ thalassemia. The most frequent beta thalassemia mutations of Sβ0 and Sβ+ were HBB: c.118C>T (Gln40Stop) and HBB c.92 + 6T> C, respectively.<br><br>&emsp;The PyS proved to be satisfactory for large-scale confirmatory testing of hemoglobin mutation. Moreover, with this study we were able to describe the most common β+ and β0 mutations in SCD patients with Sβ-thalassemia in a large multi-institutional SCD cohort in Brazil.\n <br><br> <b>MeSH terms:<\/b> <b>MeSH terms:<\/b> Anemia, Sickle Cell; Brazil; Cohort Studies; Genotype; Hemoglobin, Sickle; High-Throughput Nucleotide Sequencing; Humans; Mutation; beta-Thalassemia <br><br> <b>OMOP Concepts (IDs):<\/b>  Genetic mutation (4205432); Beta thalassemia (4278669); Sickle cell-hemoglobin SS disease (22281); Genetic finding (4025367); "]},"columns":[{"id":"details","name":"","type":"character","html":true}],"dataKey":"4821cdf678e22e23d8c276ddd290ddf7","static":false,"nested":true},"children":[]}]},{"name":"div","attribs":{"style":{"padding":"1rem"}},"children":[{"name":"Reactable","attribs":{"data":{"details":["<b>DOI:<\/b> 10.1371/journal.pone.0226226 <br><br> Diabetes is a life-long and debilitating disease that is fraught with both acute and chronic complications. Of particular concern to sufferers of the disease is the development of foot problems. These problems range from foot deformities to slowly healing or non-healing ulcers (that may necessitate amputation) and in the worst-case scenario, to death. Identification and prompt treatment of comorbid conditions, such as anemia may improve outcome in patients with diabetic foot ulcers (DFU). We determined the prevalence of anemia in Nigerians with DFU and its impact on disease outcome.<br><br>&emsp;We prospectively followed 336 patients with diabetes hospitalized for DFU and managed by a multidisciplinary team until discharge or death. Demographic and diabetes-related information and ulcer characteristics were documented. We evaluated each patient for neuropathy, vasculopathy and medical co-morbidities. Relevant laboratory and imaging studies were performed. We present the results of the sub-group analysis of patients with anemia to determine its prevalence and impact on disease outcome in patients with DFU in the MEDFUN study.<br><br>&emsp;Anemia was detected in 180(53.6%) subjects with 88(48.9%) of them requiring blood transfusion. Significant demographic and clinical determinants of anemia were ulcer duration more than one month prior to hospitalization (p<0.009), PAD (p<0.001) and presence of gangrene (p<0.001). The comorbid conditions that were significantly associated with anemia included proteinuria (p<0.003), osteomyelitis (p<0.006), moderate (p<0.002) as well as severe (p<0.001) vascular stenosis, history of stroke (p<0.014) and renal impairment (p<0.002). Anemia was significantly associated with poor wound healing (p<0.009), amputation (p<0.036) and risk of death (p<0.034).<br><br>&emsp;We detected anemia in more than half of our cohort with DFU. We found significant association between anemia and poor wound healing, amputation and mortality among our studied subjects. Future studies should explore whether prompt correction of anemia in subjects hospitalized for DFU would improve outcome.\n <br><br> <b>MeSH terms:<\/b> <b>MeSH terms:<\/b> Adult; Aged; Anemia; Diabetic Foot; Female; Humans; Male; Middle Aged; Nigeria; Prevalence; Prognosis <br><br> <b>OMOP Concepts (IDs):<\/b>  Determination of prognosis (4069425); Diabetic foot (4087682); Anemia (439777); "]},"columns":[{"id":"details","name":"","type":"character","html":true}],"dataKey":"569288f67ec88f91f03786d7a7b903e0","static":false,"nested":true},"children":[]}]},{"name":"div","attribs":{"style":{"padding":"1rem"}},"children":[{"name":"Reactable","attribs":{"data":{"details":["<b>DOI:<\/b> 10.1371/journal.pone.0226583 <br><br> Neutrophilia is a feature of sickle cell disease (SCD) that has been consistently correlated with clinical severity and has been shown to remain highly activated even at steady state. In addition to induction of fetal hemoglobin (HbF), hydroxyurea (HU) leads to reduction in neutrophil count and their adhesion properties, which contributes to the clinical efficacy of HU in SCD. Although HU reduces the frequency and severity of acute vaso-occlusive crises (VOCs) and chest syndrome, HU therapy does not abolish these acute clinical events. In this study we investigated whether neutrophils in SCD patients whilst on HU therapy retained features of detrimental pro-inflammatory activity. Freshly isolated neutrophils from SCD patients on HU therapy at steady state and from ethnic-matched healthy controls were evaluated ex vivo for their degranulation response and production of neutrophil extracellular traps (NETs). Unstimulated SCD patient neutrophils already produced NETs within 30 minutes, compared to none for healthy neutrophils, and by 4 hours, these neutrophils produced significantly more NETs than the control neutrophils (P = 0.0079**). Higher numbers of neutrophils from SCD patients also showed higher degree of degranulation-related intracellular features compared to healthy neutrophils, including rough-textured cellular membranes (P = 0.03*), double-positivity for F-Actin and CD63 (P = 0.02*) and re-located CD63 within cytoplasm more efficiently than their healthy counterparts (P = 0.02*). The neutrophils from SCD donors released more myeloperoxidase (P = 0.02*) in the absence of any trigger. Our data showed that neutrophils from patients with SCD at steady state remained active during hydroxyurea treatment and are likely to be able to contribute to the SCD pro-inflammatory environment.\n <br><br> <b>MeSH terms:<\/b> <b>MeSH terms:<\/b> Adolescent; Adult; Aged; Aged, 80 and over; Anemia, Sickle Cell; Antisickling Agents; Case-Control Studies; Cell Degranulation; Cells, Cultured; Extracellular Traps; Female; Humans; Hydroxyurea; Male; Middle Aged; Neutrophils; Peroxidase; Primary Cell Culture; Young Adult <br><br> <b>OMOP Concepts (IDs):<\/b>  Sickle cell-hemoglobin SS disease (22281); hydroxyurea (1377141); Peroxidase (45892043); "]},"columns":[{"id":"details","name":"","type":"character","html":true}],"dataKey":"bc25a799a9387792f79ce005fc4e7159","static":false,"nested":true},"children":[]}]},{"name":"div","attribs":{"style":{"padding":"1rem"}},"children":[{"name":"Reactable","attribs":{"data":{"details":["<b>DOI:<\/b> 10.1371/journal.pone.0227351 <br><br> Iron and Folic Acid Supplementation (IFAS) is an essential and affordable intervention strategy for prevention of anaemia during pregnancy. The supplements are currently provided for free to pregnant women in Kenya during antenatal care (ANC), but compliance remains low over the years. There is need for diversification of IFAS programme implementation by exploring other distribution channels to complement existing antenatal distribution and ensure consistent access to IFAS supplements.<br><br>&emsp;To determine the effect of a community-based approach of IFAS distribution on compliance and assess side-effects experienced and their mitigation by pregnant women in Kiambu County.<br><br>&emsp;A pretest-posttest quasi-experimental study design was used, consisting of an intervention and a control group, among 340 pregnant women 15-49 years, in five health facilities in Lari Sub-County in Kiambu County, between June 2016 and March 2017. Community health volunteers provided IFAS supplements, counselling and weekly follow-up to pregnant women in the intervention group while the control group followed standard practice from health facilities. Baseline and endline data were collected during antenatal care and compared. Quantitative data was analyzed using STATA version 14. Analysis of effect of intervention was done using Difference-In-Difference regression approach.<br><br>&emsp;Levels of compliance increased by 8% in intervention group and 6% in control group. There was increased awareness of IFAS side-effects across groups. The intervention group reported experiencing less side-effects and were better able to manage them compared to the control group.<br><br>&emsp;Implementation a community-based approach improved maternal compliance with IFAS, awareness of IFAS side effects and their management, with better improvement being recorded in the intervention group. Hence, there is need to integrate community-based approach with antenatal distribution of IFAS to improve supplementation.\n <br><br> <b>MeSH terms:<\/b> <b>MeSH terms:<\/b> Adolescent; Adult; Anemia; Case-Control Studies; Community Health Services; Dietary Supplements; Female; Folic Acid; Health Knowledge, Attitudes, Practice; Humans; Iron; Kenya; Middle Aged; Patient Compliance; Pregnancy; Pregnant Women; Prenatal Care; Young Adult <br><br> <b>OMOP Concepts (IDs):<\/b>  Pregnant (4299535); Folic Acid (19111620); Antepartum care only (2110313); 7 or more visits (4173786); Antenatal care (439777); Anemia (1360067); Iron (4299535); "]},"columns":[{"id":"details","name":"","type":"character","html":true}],"dataKey":"16d2dbe3ef6150d92f14c434574bc128","static":false,"nested":true},"children":[]}]},{"name":"div","attribs":{"style":{"padding":"1rem"}},"children":[{"name":"Reactable","attribs":{"data":{"details":["<b>DOI:<\/b> 10.1371/journal.pone.0227603 <br><br> In-vitro studies with different Fanconi anemia (FA) cell lines and FANC gene silenced cell lines indicating involvement of mitochondria function in pathogenesis of FA have been reported. However, in-vivo studies have not been studied so far to understand the role of mitochondrial markers in pathogenesis of FA. We have carried out a systematic set of biomarker studies for elucidating involvement of mitochondrial dysfunction in disease pathogenesis for Indian FA patients. We report changes in the mtDNA number in 59% of FA patients studied, a high frequency of mtDNA variations (37.5% of non-synonymous variations and 62.5% synonymous variations) and downregulation of mtDNA complex-I and complex-III encoding genes of OXPHOS (p<0.05) as strong biomarkers for impairment of mitochondrial functions in FA. Deregulation of expression of mitophagy genes (ATG; p>0.05, Beclin-1; p>0.05, and MAP1-LC3, p<0.05) has also been observed, suggesting inability of FA cells to clear off impaired mitochondria. We hypothesize that accumulation of such impaired mitochondria in FA cells therefore may be the principal cause for bone marrow failure (BMF) and a plausible effect of inefficient clearance of impaired mitochondria in FA.\n <br><br> <b>MeSH terms:<\/b> <b>MeSH terms:<\/b> Adolescent; Adult; Autophagy-Related Protein 12; Autophagy-Related Protein 8 Family; Beclin-1; Case-Control Studies; Cell Line; Child; DNA, Mitochondrial; Fanconi Anemia; Female; Genetic Variation; Humans; India; Male; Mitochondria; Mitophagy; Reactive Oxygen Species <br><br> <b>OMOP Concepts (IDs):<\/b>  Fanconi's anemia (4148471); Genetic variation (4271711); "]},"columns":[{"id":"details","name":"","type":"character","html":true}],"dataKey":"a18837e38a33c073b8370042f5869df2","static":false,"nested":true},"children":[]}]},{"name":"div","attribs":{"style":{"padding":"1rem"}},"children":[{"name":"Reactable","attribs":{"data":{"details":["<b>DOI:<\/b> 10.1371/journal.pone.0228330 <br><br> Inter-pregnancy interval is an important determinant of both maternal and child health. Suboptimal inter-pregnancy interval has been associated with adverse maternal outcomes -including postpartum hemorrhage and hypertensive disorders, direct causes of maternal mortality. Both overall maternal mortality and the contribution of postpartum hemorrhage on maternal mortality have increased in Tanzania. If we are to achieve sustainable development goal (SDG) number 3.1 to reduce the global maternal mortality ration to less than 70 per 100,000 live births by 2030, it is highly important that such contributors are dealt with. This study aimed to determine the distribution and trends of inter-pregnancy interval and to deduce its association with adverse maternal outcomes among women who delivered at Kilimanjaro Christian Medical Centre (2000-2015).A retrospective cohort study was designed using Kilimanjaro Christian Medical Centre medical birth registry data for women who delivered from 2000 to 2015. Women with at least two births recorded in the registry were included. A total of 7,995 births from 6,612 mothers were analyzed. Anemia during pregnancy, post-partum hemorrhage and pre-eclampsia were adverse maternal outcomes of interest. Data analysis was performed using multivariable logistic regression models allowing for robust standard errors. Crude and adjusted odds ratio with their respective 95% confidence intervals were estimated. More than half (51.7%) of non-first births were born within sub-optimal IPI. The median IPI was 34 months (IQR: 33.5 months). The median IPI increased from 11 months in 2002 to 35 months in 2006 and plateaued until 2014, but it rose to 41.6 months in 2015. Median IPI was shorter in young women <20 years and in birth order seven and above (16 vs. 27 months, respectively). Short IPI was associated with lower risk of pre-eclampsia [aOR: 0.71, 95%CI: 0.52, 0.97] while long IPI was associated with lower risk of post-partum hemorrhage [aOR: 0.70, 95%CI: 0.52, 0.94]. This study found an association between long and short IPI with adverse maternal outcomes. Even though these results should be interpreted with caution based on the fact that the data was sampled from a referral hospital and hence there could be overrepresentation of women with maternal complications, our findings still warrant the importance of supporting modern family planning methods as a measure to improve IPI and thereby improve maternal outcomes as well.\n <br><br> <b>MeSH terms:<\/b> <b>MeSH terms:<\/b> Adult; Age Factors; Anemia; Birth Intervals; Female; Humans; Logistic Models; Maternal Mortality; Odds Ratio; Postpartum Hemorrhage; Pre-Eclampsia; Pregnancy; Registries; Retrospective Studies; Tanzania; Young Adult <br><br> <b>OMOP Concepts (IDs):<\/b>  Pregnant (4299535); Postpartum hemorrhage (443929); Pre-eclampsia (439393); Anemia (439777); Maternal death (4244279); "]},"columns":[{"id":"details","name":"","type":"character","html":true}],"dataKey":"28dcd75c6a31d08a174f75b4e7ba38dd","static":false,"nested":true},"children":[]}]},{"name":"div","attribs":{"style":{"padding":"1rem"}},"children":[{"name":"Reactable","attribs":{"data":{"details":["<b>DOI:<\/b> 10.1371/journal.pone.0228486 <br><br> To report our clinical experience with bevacizumab in a cohort of Hereditary Hemorrhagic Telangiectasia (HHT) patients with severe hepatic involvement and/or refractory anemia.<br><br>&emsp;Observational, ambispective study of the Institutional Registry of HHT at Hospital Italiano de Buenos Aires. Patients were treated with bevacizumab due to iron deficiency refractory anemia secondary to nasal/gastrointestinal bleeding and/or high output cardiac failure. We describe basal clinical data, bevacizumab schedules, efficacy outcomes and adverse events. Wilcoxon signed ranks test and longitudinal analysis were conducted.<br><br>&emsp;Twenty adult patients were included from July 2013 to June 2019. Clinical indications were: 13 for anemia, 4 for heart failure and 3 for both. In the anemia group, median pretreatment hemoglobin was 8.1 g/dl [IQR: 7.2-8.4] and median transfusion requirement was 4 units [2-6]. In heart failure group, pretreatment median cardiac index was 4.5 L/min/m2 [4.1-5.6] and cardiac output was 8.3 L/min [7.5-9.2]. Bevacizumab 5 mg/kg/dose every 2 weeks for 6 applications was scheduled. By the end of induction, median hemoglobin at 3 months was 10.9 g/dl [9.5-12.8] (p = 0.01) and median transfusion requirement 0 units [0-1] (p<0.01), and this effect was more or less sustained during a year. Regarding heart failure group, two patients had complete hemodynamic response and achieved liver transplantation and two had partial response. No serious adverse events were registered.<br><br>&emsp;Bevacizumab is a promising line of treatment for HHT patients with refractory anemia. For patients with high output cardiac failure, bevacizumab may be useful as bridge therapy awaiting for liver transplantation.\n <br><br> <b>MeSH terms:<\/b> <b>MeSH terms:<\/b> Adult; Aged; Anemia, Refractory; Argentina; Bevacizumab; Female; Humans; Liver Diseases; Male; Middle Aged; Retrospective Studies; Severity of Illness Index; Telangiectasia, Hereditary Hemorrhagic; Treatment Outcome <br><br> <b>OMOP Concepts (IDs):<\/b>  bevacizumab (1397141); Refractory anemia (4003185); Disease of liver (194984); Osler hemorrhagic telangiectasia syndrome (313504); "]},"columns":[{"id":"details","name":"","type":"character","html":true}],"dataKey":"7d208777e053336c214d318738ce323e","static":false,"nested":true},"children":[]}]},{"name":"div","attribs":{"style":{"padding":"1rem"}},"children":[{"name":"Reactable","attribs":{"data":{"details":["<b>DOI:<\/b> 10.1371/journal.pone.0228733 <br><br> Thalassaemia is a chronic disease which requires lifelong treatment in a majority. Despite recent advances in the medical care, minimal attempts are made to improve psychological health in these patients. In this study, we aim to describe the psychological morbidity in patients with transfusion dependent β-thalassaemia and their mothers in Sri Lanka.<br><br>&emsp;This case control study was conducted in the three largest thalassaemia centres of Sri Lanka. All patients with transfusion dependent β-thalassaemia aged 4-18 years were recruited as cases whilst a randomly selected group of children without chronic diseases were recruited as controls. Psychological morbidity of children was assessed using the Strengths and Difficulties Questionnaire and depressive symptoms of mothers was assessed by the Centre for Epidemiological Studies Depression Scale.<br><br>&emsp;288 transfusion dependent β-thalassaemia patients and equal number of controls were recruited. Abnormal emotional, conduct, hyperactivity and peer relationship symptom scores were reported by 18%, 17%, 9% and 14% of patients with thalassaemia respectively. Prevalences of abnormal psychological symptom scores in all domains were significantly higher among patients compared to controls. Abnormal conduct symptoms were significantly more prevalent among patients with HbE β-thalassaemia and those with suboptimal pretransfusion haemoglobin levels, lower transfusion volumes, hypothyroidism and undernutrition. Short stature was associated with abnormal emotional and hyperactivity scores. Depressive symptoms were significantly higher among mothers of patients with thalassaemia. Higher depressive symptom scores in mothers were significantly associated with abnormal emotional, conduct and peer relationship symptom scores in children.<br><br>&emsp;A higher proportion of patients with transfusion dependent β-thalassaemia had abnormal psychological symptom scores. Abnormal conduct symptoms were more prevalent among patients with HbE β-thalassaemia, those who were inadequately transfused and having hypothyroidism and undernutrition. Mothers of the children with transfusion dependent β-thalassaemia had significantly higher depressive symptoms which were significantly associated with psychological symptoms among children.\n <br><br> <b>MeSH terms:<\/b> <b>MeSH terms:<\/b> Adolescent; Blood Transfusion; Case-Control Studies; Child; Child, Preschool; Depression; Emotions; Female; Hemoglobin E; Humans; Male; Mothers; Parents; Sri Lanka; beta-Thalassemia <br><br> <b>OMOP Concepts (IDs):<\/b>  Transfusion of blood product (4024656); Emotional state finding (4025215); Beta thalassemia (4278669); Depressive disorder (440383); "]},"columns":[{"id":"details","name":"","type":"character","html":true}],"dataKey":"230ac985c694dbf1e6fd1dc68a643736","static":false,"nested":true},"children":[]}]},{"name":"div","attribs":{"style":{"padding":"1rem"}},"children":[{"name":"Reactable","attribs":{"data":{"details":["<b>DOI:<\/b> 10.1371/journal.pone.0229325 <br><br> Postoperative anaemia is a frequent surgical complication and in contrast to preoperative anaemia has not been validated in relation to mortality, morbidity and its associated health economic effect. Postoperative anaemia can predispose postoperative delirium through impairment of cerebral oxygenation. The aim of this secondary analysis is to investigate the association of postoperative anaemia in accordance with the sex specific World Health Organization definition of anaemia to postoperative delirium and its impact on the duration of hospital stay.<br><br>&emsp;A secondary analysis of the prospective multicentric observational CESARO-study was conducted. 800 adult patients undergoing elective surgery were enrolled from various operative disciplines across seven hospitals ranging from university hospitals, district general hospitals to specialist clinics of minimally invasive surgery in Germany. Patients were classified as anaemic according to the World Health Organization parameters, setting the haemoglobin level cut off below 12g/dl for females and below 13g/dl for males. Focus of the investigation were patients with acute anaemia. Patients with present preoperative anaemia or missing haemoglobin measurement were excluded from the sample set. Delirium screening was established postoperatively for at least 24 hours and up to three days, applying the validated Nursing Delirium Screening Scale.<br><br>&emsp;The initial sample set contained 800 patients of which 183 were suitable for analysis in the study. Ninety out of 183 (49.2%) suffered from postoperative anaemia. Ten out of 93 (10.9%) patients without postoperative anaemia developed a postoperative delirium. In the group with postoperative anaemia, 28 (38.4%) out of 90 patients suffered from postoperative delirium (odds ratio 3.949, 95% confidence interval, (1.358-11.480)) after adjustment for NYHA-stadium, severity of surgery, cutting/suture time, duration of anaesthesia, transfusion of packed red cells and sedation status with Richmond Agitation Scale after surgery. Additionally, patients who suffered from postoperative anaemia showed a significantly longer duration of hospitalisation (7.75 vs. 12.42 days, odds ratio = 1.186, 95% confidence interval, 1.083-1.299, after adjustments).<br><br>&emsp;The study results reveal that postoperative anaemia is not only a frequent postsurgical complication with an incidence probability of almost 50%, but could also be associated with a postoperative delirium and a prolonged hospitalisation.\n <br><br> <b>MeSH terms:<\/b> <b>MeSH terms:<\/b> Aged; Anemia; Delirium; Elective Surgical Procedures; Female; Humans; Incidence; Length of Stay; Male; Postoperative Complications; Prospective Studies; Risk Factors <br><br> <b>OMOP Concepts (IDs):<\/b>  Postoperative complication (4300243); Delirious (4303087); Optional surgery (4166767); Anemia (439777); "]},"columns":[{"id":"details","name":"","type":"character","html":true}],"dataKey":"765457b1b7cef63d6b797273ebce8ac3","static":false,"nested":true},"children":[]}]},{"name":"div","attribs":{"style":{"padding":"1rem"}},"children":[{"name":"Reactable","attribs":{"data":{"details":["<b>DOI:<\/b> 10.1371/journal.pone.0230980 <br><br> Anemia is highly prevalent in chronic kidney disease patients; however, its identification and management have been reported to be suboptimal. In this study we aimed to describe the prevalence, severity, risk factors, and treatment of anemia in different nephrology centers, among chronic kidney disease patients who were not given renal replacement therapy.<br><br>&emsp;We performed a multicenter cross-sectional study in three different nephrology clinics. Adult (>18 years of age) chronic kidney disease patients with an estimated glomerular filtration rate (eGFR) below 60 ml/min, and who were not started dialysis were recruited. Demographic, clinical and laboratory data regarding anemia and its management were collected using a standard data form. Anemia was defined as a hemoglobin level below 12g/dL and severe anemia as a hemoglobin level below 10g/dl.<br><br>&emsp;A total of 1066 patients were enrolled in the study. Anemia and severe anemia were present in 55.9% and 14.9% of the patients, respectively. The mean hemoglobin level for the whole cohort was 11.8±1.8 g/dL. Univariate analyses revealed that the mean hemoglobin level was significantly different among the centers. Moreover, the frequency of the presence of anemia stratified by severity was also significantly different among the centers. According to binary logistic regression analysis, gender, levels of eGFR and iron, ferritin ≥ 100 ng/mL, and the nephrology center were independent determinants of severe anemia.<br><br>&emsp;We found a high prevalence of anemia among chronic kidney disease patients who were not on renal replacement therapy. Each center should determine the treatment strategy according to the patient's characteristics. According to our results, the center-specific management of anemia seems to be important.\n <br><br> <b>MeSH terms:<\/b> <b>MeSH terms:<\/b> Aged; Anemia; Cohort Studies; Cross-Sectional Studies; Female; Ferritins; Glomerular Filtration Rate; Hemoglobins; Humans; Iron; Kidney Failure, Chronic; Male; Middle Aged; Nephrology; Prevalence; Renal Dialysis; Renal Insufficiency, Chronic; Risk Factors <br><br> <b>OMOP Concepts (IDs):<\/b>  End-stage renal disease (193782); Chronic renal insufficiency (36716947); Renal dialysis (4146536); Anemia (439777); Iron (1360067); "]},"columns":[{"id":"details","name":"","type":"character","html":true}],"dataKey":"ff4072cb14e6cbd096014729ab30a854","static":false,"nested":true},"children":[]}]},{"name":"div","attribs":{"style":{"padding":"1rem"}},"children":[{"name":"Reactable","attribs":{"data":{"details":["<b>DOI:<\/b> 10.1371/journal.pone.0231284 <br><br> Evans syndrome is defined by autoimmune haemolytic anaemia and immune thrombocytopenia occurring in the same patient. Although known to be rare the frequency and prognosis of Evans syndrome in children is unknown, and only few registry-based studies are available. The epidemiology and prognosis of Evans syndrome in patients above 13 years of age has recently been investigated. In this age group both incidence and prevalence of Evans syndrome increased during the study period and median survival was just 7.2 years. Using Danish health registries and the same approach, we identified 21 children below 13 years of age with Evans syndrome during 1981-2015. Patients with Evans syndrome were age-and sex matched with children both from the general population, and with patients with either autoimmune haemolytic anaemia or immune thrombocytopenia. The incidence of Evans syndrome ranged between 0.5 and 1.2/1,000,000 person-years. Prevalence was 6.7 and 19.3/1,000,000 in 1990 and 2015 respectively. Hazard ratio for death was 22 fold higher for children with ES compared to matched children from general population, and was also elevated compared to children with autoimmune haemolytic anaemia or immune thrombocytopenia. We conclude that pediatric ES is very rare and associated with elevated mortality. However, despite the nationwide study and a long and complete follow-up, results are imprecise due to the rarity of this disorder.\n <br><br> <b>MeSH terms:<\/b> <b>MeSH terms:<\/b> Adolescent; Anemia, Hemolytic, Autoimmune; Child; Child, Preschool; Cohort Studies; Female; Humans; Kaplan-Meier Estimate; Male; Thrombocytopenia <br><br> <b>OMOP Concepts (IDs):<\/b>  Thrombocytopenic disorder (432870); Autoimmune hemolytic anemia (441269); "]},"columns":[{"id":"details","name":"","type":"character","html":true}],"dataKey":"ea81719073ca70a5b5f02ba95dd5951e","static":false,"nested":true},"children":[]}]},{"name":"div","attribs":{"style":{"padding":"1rem"}},"children":[{"name":"Reactable","attribs":{"data":{"details":["<b>DOI:<\/b> 10.1371/journal.pone.0232721 <br><br> Pain in sickle cell disease (SCD) is severe and multifaceted resulting in significant differences in its frequency and intensity among individuals. In this study, we examined the influence of S100B gene single nucleotide polymorphisms (SNP) on acute and chronic pain variability in SCD.<br><br>&emsp;Composite pain index (CPI) scores captured chronic pain. Painful crisis related emergency care utilization recorded acute pain incidence. Genotyping was performed using MassARRAY iPLEX platform.<br><br>&emsp;Regression analysis revealed associations of increased CPI with rs9722 A allele in additive (p = 0.005) and dominant (p = 0.005) models. Rs1051169 G allele on the other hand was associated with decreased CPI in additive (p = 0.001), and dominant (p = 0.005) models. Sex-specific analysis found that these associations were significant in females but not males in this cohort. Linkage analysis identified two haploblocks. Block 1 (rs9983698-rs9722) haplotype T-A was associated with increased CPI (p = 0.002) while block 2 (rs1051169-rs11911834) haplotype G-G was associated with decreased CPI (p = 0.001). Both haplotypic associations were only significant in females. No association of S100B SNPs with utilization reached statistical significance.<br><br>&emsp;S100B SNPs and haplotypes are associated with chronic pain in female, but not male, patients with SCD, implicating a potential role of S100B polymorphism in SCD pain heterogeneity in a sex-dependent manner.\n <br><br> <b>MeSH terms:<\/b> <b>MeSH terms:<\/b> Adult; Black or African American; Anemia, Sickle Cell; Chronic Pain; Cohort Studies; Female; Genetic Predisposition to Disease; Humans; Male; Middle Aged; Polymorphism, Single Nucleotide; S100 Calcium Binding Protein beta Subunit; Sex Factors <br><br> <b>OMOP Concepts (IDs):<\/b>  Sickle cell-hemoglobin SS disease (22281); Genetic predisposition (4166231); Chronic pain (436096); "]},"columns":[{"id":"details","name":"","type":"character","html":true}],"dataKey":"20e3be651b130d90b6ffe5f7b1a2994b","static":false,"nested":true},"children":[]}]},{"name":"div","attribs":{"style":{"padding":"1rem"}},"children":[{"name":"Reactable","attribs":{"data":{"details":["<b>DOI:<\/b> 10.1371/journal.pone.0234151 <br><br> To examine interocular asymmetry of foveal avascular zone (FAZ) and parafoveal capillary density metrics in sickle cell retinopathy (SCR) using optical coherence tomography angiography (OCT-A).<br><br>&emsp;This cross-sectional, retrospective study evaluated SCR patients and unaffected controls who underwent 3x3mm macular OCT-A imaging using a spectral domain-OCT system. FAZ (area, perimeter, and acircularity index) and parafoveal capillary density metrics were computed for both eyes of each participant. In unaffected controls, interocular difference in FAZ and parafoveal capillary density metrics were evaluated using Bland-Altman plots. SCR patients with interocular difference outside the upper 97.5% and lower 2.5% limits of agreement from controls were defined as having interocular asymmetry. Area under receiver operating characteristic curve (AROC) was also performed to determine the ability of the absolute interocular difference to differentiate between subjects with SCR-including non-proliferative SCR (NP-SCR) and proliferative SCR (P-SCR)-and unaffected controls.<br><br>&emsp;Thirty-one patients with SCR (21 NP-SCR and 10 P-SCR) and 14 race-matched and age-matched controls were included for analysis. Interocular asymmetry was seen for all FAZ and parafoveal capillary density metrics in NP-SCR and P-SCR subjects. SCR subjects showed greater disease severity in the left-eye for FAZ and parafoveal capillary density metrics.<br><br>&emsp;NP-SCR and P-SCR patients demonstrated quantifiable interocular asymmetry in FAZ and parafoveal capillary density metrics compared to unaffected subjects, with left-eye predominance in disease severity.\n <br><br> <b>MeSH terms:<\/b> <b>MeSH terms:<\/b> Adult; Anemia, Sickle Cell; Area Under Curve; Capillaries; Case-Control Studies; Cross-Sectional Studies; Eye; Female; Fovea Centralis; Humans; Male; Middle Aged; ROC Curve; Retinal Diseases; Retrospective Studies; Severity of Illness Index; Tomography, Optical Coherence; Young Adult <br><br> <b>OMOP Concepts (IDs):<\/b>  Retinal disorder (378416); Optical coherence tomography (4213040); Sickle cell-hemoglobin SS disease (22281); "]},"columns":[{"id":"details","name":"","type":"character","html":true}],"dataKey":"02f05dac16e512fd15278ea73d45dd24","static":false,"nested":true},"children":[]}]},{"name":"div","attribs":{"style":{"padding":"1rem"}},"children":[{"name":"Reactable","attribs":{"data":{"details":["<b>DOI:<\/b> 10.1371/journal.pone.0235192 <br><br> As marijuana use becomes more common, it is essential clinicians understand the relationship between marijuana use and health behaviors.<br><br>&emsp;Using a retrospective cohort of adolescents and adults with sickle cell disease (SCD) stratified into a young (<25 years) and older cohort (> = 25 years), we conducted multiple linear regression examining relationship of marijuana use (independent variable) on each dependent variable (SCD self-management score and pain management).<br><br>&emsp;Among young cohort, 16.9% used marijuana compared to 21.8% of older cohort. The younger cohort reporting marijuana use had lower mean self-care scores (β = -2.74;p = 0.009) and were more likely to have admissions to the hospital for pain (β = 0.87;p = 0.047) compared to non-users. In contrast, the older cohort reporting marijuana use had more days treating pain at home (β = 0.44;p = 0.035).<br><br>&emsp;Only a minority of patients with SCD reported lifetime marijuana use. Among those reporting marijuana use, there were different associations with self-care and health-related behaviors by age. The older cohort who endorsed marijuana use reported more days of treating pain at home, although this did not translate into increased acute care visits for pain crisis. Among youth, endorsing marijuana use was associated with worse SCD self-care.\n <br><br> <b>MeSH terms:<\/b> <b>MeSH terms:<\/b> Adult; Age Factors; Anemia, Sickle Cell; Female; Health Behavior; Humans; Male; Marijuana Use; Pain; Pain Management; Retrospective Studies; Self Care; United States; Young Adult <br><br> <b>OMOP Concepts (IDs):<\/b>  Pain management (4083171); Sickle cell-hemoglobin SS disease (22281); Self-care interventions (4293157); Pain (4329041); "]},"columns":[{"id":"details","name":"","type":"character","html":true}],"dataKey":"fefd6f720923f33eb70899345877dc01","static":false,"nested":true},"children":[]}]},{"name":"div","attribs":{"style":{"padding":"1rem"}},"children":[{"name":"Reactable","attribs":{"data":{"details":["<b>DOI:<\/b> 10.1371/journal.pone.0236132 <br><br> The Japan Chronic Kidney Disease Database (J-CKD-DB) is a nationwide clinical database of patients with chronic kidney disease (CKD) based on electronic health records. The objective of this study was to assess the prevalence of anemia and the utilization rate of erythropoiesis-stimulating agents (ESAs) in Japanese patients with CKD.<br><br>&emsp;In total, 31,082 adult outpatients with estimated glomerular filtration rates of 5-60 ml/min/1.73 m2 in seven university hospitals were included this analysis. The proportions of patients with CKD stages G3b, G4, and G5 were 23.5%, 7.6%, and 3.1%, respectively.<br><br>&emsp;The mean (standard deviation) hemoglobin level of male patients was 13.6 (1.9) g/dl, which was significantly higher than the mean hemoglobin level of female patients (12.4 (1.6) g/dl). The mean (standard deviation) hemoglobin levels were 11.4 (2.1) g/dl in patients with CKD stage G4 and 11.2 (1.8) g/dl in patients with CKD stage G5. The prevalences of anemia were 40.1% in patients with CKD stage G4 and 60.3% in patients with CKD stage G5. Logistic regression analysis showed that diagnoses of CKD stage G3b (adjusted odds ratio [95% confidence interval]: 2.32 [2.09-2.58]), G4 (5.50 [4.80-6.31]), and G5 (9.75 [8.13-11.7]) were associated with increased prevalence of anemia. The utilization rates of ESAs were 7.9% in patients with CKD stage G4 and 22.4% in patients with CKD stage G5.<br><br>&emsp;We determined the prevalence of anemia and utilization rate of ESAs in Japanese patients with CKD using data from a nationwide cohort study.\n <br><br> <b>MeSH terms:<\/b> <b>MeSH terms:<\/b> Anemia; Cohort Studies; Cross-Sectional Studies; Databases, Factual; Female; Glomerular Filtration Rate; Hemoglobins; Humans; Japan; Male; Middle Aged; Prevalence; Renal Insufficiency, Chronic <br><br> <b>OMOP Concepts (IDs):<\/b>  Chronic renal insufficiency (36716947); Anemia (439777); "]},"columns":[{"id":"details","name":"","type":"character","html":true}],"dataKey":"2e3b6e86c4e0f3015d6c03fbf027f0f6","static":false,"nested":true},"children":[]}]},{"name":"div","attribs":{"style":{"padding":"1rem"}},"children":[{"name":"Reactable","attribs":{"data":{"details":["<b>DOI:<\/b> 10.1371/journal.pone.0236264 <br><br> Extensively drug-resistant tuberculosis (XDR TB) is a very serious form of tuberculosis that is burdened with a heavy mortality toll, especially before the advent of new TB drugs. The Democratic Republic of the Congo (DRC) is among the countries most affected by this new epidemic.<br><br>&emsp;A retrospective analysis was performed of the records of all patients with pre- and extensively drug-resistant tuberculosis hospitalized from January 1, 2015 to December 31, 2017 and monitored for at least 6 months to one year after the end of their treatment in Kinshasa; an individualized therapeutic regimen with bedaquiline for 20 months was built for each patient. The adverse effects were systematically monitored.<br><br>&emsp;Of the 40 laboratory-confirmed patients, 32 (80%) patients started treatment, including 29 preXRB and 3 XDR TB patients. In the eligible group, 3 patients (9.4%) had HIV-TB coinfections. The therapeutic success rate was 53.2%, and the mortality rate was 46.8% (15/32); there were no relapses, failures or losses to follow-up. All coinfected HIV-TB patients died during treatment. The cumulative patient survival rate was 62.5% at 3 months, 53.1% at 6 months and 53.1% at 20 months. The most common adverse events were vomiting, Skin rash, anemia and peripheral neuropathy.<br><br>&emsp;The new anti-tuberculosis drugs are a real hope for the management of Drug Resistant tuberculosis patient and other new therapeutic combinations may improve favorable outcomes.\n <br><br> <b>MeSH terms:<\/b> <b>MeSH terms:<\/b> Adolescent; Adult; Aged; Anemia; Antitubercular Agents; Cost of Illness; Democratic Republic of the Congo; Diarylquinolines; Drug Administration Schedule; Drug Therapy, Combination; Exanthema; Extensively Drug-Resistant Tuberculosis; Female; Humans; Male; Middle Aged; Peripheral Nervous System Diseases; Retrospective Studies; Survival Rate; Treatment Outcome; Vomiting; Young Adult <br><br> <b>OMOP Concepts (IDs):<\/b>  Peripheral nerve disease (4117779); Eruption (140214); Finding of vomiting (4101344); Anemia (439777); Extensively drug resistant tuberculosis (46273571); "]},"columns":[{"id":"details","name":"","type":"character","html":true}],"dataKey":"21e400d3996ccb4996532496052914bf","static":false,"nested":true},"children":[]}]},{"name":"div","attribs":{"style":{"padding":"1rem"}},"children":[{"name":"Reactable","attribs":{"data":{"details":["<b>DOI:<\/b> 10.1371/journal.pone.0237543 <br><br> Sickle cell disease (SCD) impacts liver and kidney function as well as skin integrity. These complications, as well as the hyperinflammatory state of SCD, could affect serum albumin. Serum albumin has key roles in antioxidant, anti-inflammatory and antithrombotic pathways and maintains vascular integrity. In SCD, these pathways modulate disease severity and clinical outcomes. We used three independent SCD adult cohorts to assess clinical predictors of serum albumin as well its association with mortality. In 2553 SCD adult participants, the frequency of low (<35 g/L) serum albumin was 5%. Older age and lower hemoglobin (P <0.001) were associated with lower serum albumin in all three cohorts. In age and hemoglobin adjusted analysis, higher liver enzymes (P <0.05) were associated with lower serum albumin. In two of the three cohorts, lower kidney function as measured by Glomerular Filtration Rate (P<0.001) was associated with lower serum albumin. Lower serum albumin predicted higher risk of tricuspid regurgitation velocity ≥ 2.5 m/s (OR = 1.1 per g/L, P ≤0.01). In all three cohorts, patients with low serum albumin had higher mortality (adjusted HR ≥2.9, P ≤0.003). This study confirms the role of serum albumin as a biomarker of disease severity and prognosis in patients with SCD. Albumin as a biomarker and possible mediator of SCD severity should be studied further.\n <br><br> <b>MeSH terms:<\/b> <b>MeSH terms:<\/b> Adult; Anemia, Sickle Cell; Biomarkers; Cohort Studies; Female; Hemoglobins; Humans; Male; Prognosis; Serum Albumin; Survival Rate <br><br> <b>OMOP Concepts (IDs):<\/b>  Determination of prognosis (4069425); Sickle cell-hemoglobin SS disease (22281); "]},"columns":[{"id":"details","name":"","type":"character","html":true}],"dataKey":"26069404aa41deada975fc91a1bbeb84","static":false,"nested":true},"children":[]}]},{"name":"div","attribs":{"style":{"padding":"1rem"}},"children":[{"name":"Reactable","attribs":{"data":{"details":["<b>DOI:<\/b> 10.2337/dc20-0908 <br><br> We systematically explored the link of pancreatic iron with glucose metabolism and with cardiac complications in a cohort of 1,079 patients with thalassemia major (TM) enrolled in the Extension-Myocardial Iron Overload in Thalassemia (E-MIOT) project.<br><br>&emsp;MRI was used to quantify iron overload (T2* technique) and cardiac function (cine images) and to detect macroscopic myocardial fibrosis (late gadolinium enhancement technique). Glucose metabolism was assessed by the oral glucose tolerance test (OGTT).<br><br>&emsp;Patients with normal glucose metabolism showed significantly higher global pancreas T2* values than patients with impaired fasting glucose, impaired glucose tolerance, and diabetes. A pancreas T2* <13.07 ms predicted an abnormal OGTT. A normal pancreas T2* value showed a 100% negative predictive value for disturbances of glucose metabolism and for cardiac iron. Patients with myocardial fibrosis showed significantly lower pancreas T2* values. Patients with cardiac complications had significantly lower pancreas T2* values. No patient with arrhythmias/heart failure had a normal global pancreas T2*.<br><br>&emsp;Pancreatic iron is a powerful predictor not only for glucose metabolism but also for cardiac iron and complications, supporting the close link between pancreatic iron and heart disease and the need to intensify iron chelation therapy to prevent both alterations of glucose metabolism and cardiac iron accumulation.\n <br><br> <b>MeSH terms:<\/b> <b>MeSH terms:<\/b> Adolescent; Adult; Aged; Child; Contrast Media; Diabetes Mellitus; Female; Fibrosis; Gadolinium; Glucose; Glucose Intolerance; Glucose Tolerance Test; Heart Diseases; Humans; Iron; Iron Overload; Magnetic Resonance Imaging; Male; Middle Aged; Myocardium; Pancreas; Prospective Studies; Young Adult; beta-Thalassemia <br><br> <b>OMOP Concepts (IDs):<\/b>  Glucose tolerance test (4012477); Beta thalassemia (4278669); Diabetes mellitus (201820); Magnetic resonance imaging (4013636); Heart disease (321588); Glucose (1560524); Malabsorption of glucose (4150016); Iron overload (4246084); Gadolinium (42899255); Iron (1360067); "]},"columns":[{"id":"details","name":"","type":"character","html":true}],"dataKey":"dd1f0eaed44070096513507fdf4ccc1e","static":false,"nested":true},"children":[]}]},{"name":"div","attribs":{"style":{"padding":"1rem"}},"children":[{"name":"Reactable","attribs":{"data":{"details":["<b>DOI:<\/b> 10.1371/journal.pone.0238244 <br><br> Anemia is a common manifestation of inflammatory bowel disease (IBD), but it remains unclear whether anemia is associated with the development of IBD. We assessed the risk of developing IBD in anemic patients, and stratified the results with respect to their hemoglobin concentrations. A population-based study was conducted using the National Healthcare Insurance Service database in South Korea. We included individuals over 20 years' old who participated in the national health screening program in 2009 (n = 9,962,064). Anemia was defined as a hemoglobin level less than 13 g/dL in men and less than 12 g/dL in women. We compared the rate of newly diagnosed IBD in anemic patients and non-anemic individuals. Newly diagnosed IBD was identified using both the ICD-10 medical code and specialized V codes for rare intractable diseases in South Korea. During the mean follow-up period of 7.3 years, the incidences of CD and UC in anemic patients were 2.89 and 6.88 per 100,000 person-years, respectively. The risk of CD was significantly higher in anemic patients than in non-anemic individuals [adjusted hazard ratio (aHR), 2.084; 95% confidence interval (CI), 1.769-2.455]. The risk of CD development was inversely proportional to the hemoglobin concentration. A J-curve relationship was observed between age and the risk of CD in anemic patients. The risk of CD in male anemic patients was significantly higher than that in female anemic patients (aHR, 1.432 vs. 1.240, respectively). By contrast, there was no statistically significant difference in the risk of developing UC in anemic and non-anemic individuals (aHR, 0.972; 95% CI, 0.880-1.073). This work indicates that anemia is related to the development of CD, and this risk was inversely proportional to the hemoglobin concentration.\n <br><br> <b>MeSH terms:<\/b> <b>MeSH terms:<\/b> Anemia; Cohort Studies; Colitis, Ulcerative; Crohn Disease; Female; Humans; Incidence; Male; Middle Aged; Republic of Korea; Risk Factors <br><br> <b>OMOP Concepts (IDs):<\/b>  Ulcerative colitis (81893); Crohn's disease (201606); Anemia (439777); "]},"columns":[{"id":"details","name":"","type":"character","html":true}],"dataKey":"35e5b1c12d95dbad97890037bc2d7f90","static":false,"nested":true},"children":[]}]},{"name":"div","attribs":{"style":{"padding":"1rem"}},"children":[{"name":"Reactable","attribs":{"data":{"details":["<b>DOI:<\/b> 10.1161/CIRCGEN.120.003025 <br><br> Ischemic stroke is a devastating complication affecting children with sickle cell anemia. Genetic factors are likely to be important in determining the risk of stroke but are poorly defined.<br><br>&emsp;We have studied a cohort of 19 children who had an overt ischemic stroke before 4 years of age. We predicted genetic determinants of stroke would be more prominent in this group. We performed whole exome sequencing on this cohort and applied 2 hypotheses to our variant filtering. First, we looked for strong, potentially mono- or oligogenic variants for ischemic stroke, and second, we considered that more common polygenic variants will be enriched in our cohort. Candidate variants emerging from both strategies were validated in a cohort of 283 patients with sickle cell anemia and known pediatric cerebrovascular outcomes. We used principal component analysis in this cohort to control for relatedness and population substructure.<br><br>&emsp;Our primary finding was that the Apoliprotein E genotypes ε2/ε4 and ε4/ ε4, defined by the interplay of rs7412 and rs429358, were associated with increased stroke risk, with an odds ratio of 4.35 ([95% CI, 1.85-10.0] P=0.0011) for ischemic stroke in the validation cohort. We also found that rs2297518 in NOS (NO synthase) 2 (odds ratio, 2.25 [95% CI, 1.21-4.19]; P=0.014) and rs2230123 in signal transducer and activator of transcription (odds ratio, 2.60 [95% CI, 1.30-5.20]; P=0.009) both had increased odds ratios for ischemic stroke, although these two variants were below the threshold for statistical significance after correction for multiple testing.<br><br>&emsp;These data identify new loci for future functional investigations into cerebrovascular disease in sickle cell anemia. Based on African population reference allele frequencies, the Apoliprotein E genotypes would be present in about 10% of children with sickle cell anemia and represent a genetic risk factor that is potentially modifiable by both dietary and pharmaceutical manipulation of its dyslipidemic effects.\n <br><br> <b>MeSH terms:<\/b> <b>MeSH terms:<\/b> Anemia, Sickle Cell; Apolipoproteins E; CX3C Chemokine Receptor 1; Child, Preschool; Collagen Type VII; Gene Frequency; Genotype; Humans; Membrane Proteins; Multifactorial Inheritance; Nerve Tissue Proteins; Odds Ratio; Polymorphism, Single Nucleotide; Protein Subunits; Risk Factors; Stroke <br><br> <b>OMOP Concepts (IDs):<\/b>  Cerebrovascular accident (381316); Sickle cell-hemoglobin SS disease (22281); Gene frequency (4238822); Genetic finding (4025367); "]},"columns":[{"id":"details","name":"","type":"character","html":true}],"dataKey":"10c387e833c675b781afd0ade085f21c","static":false,"nested":true},"children":[]}]},{"name":"div","attribs":{"style":{"padding":"1rem"}},"children":[{"name":"Reactable","attribs":{"data":{"details":["<b>DOI:<\/b> 10.1371/journal.pone.0240694 <br><br> Severe anaemia is a common clinical problem among young children in sub-Saharan Africa. However, the effect of severe anaemia on neurodevelopment of these children is not well described. Therefore, we assessed the neurodevelopmental performance of preschool children diagnosed with severe anaemia in Northern Uganda.<br><br>&emsp;We conducted a prospective cohort study among children < 5 years of age 14 days post discharge after an episode of severe anaemia (Hb < 5.0 g/dl; n = 171; mean Hb = 3.9g/dl) at Lira Regional Referral Hospital, Uganda. Neurodevelopmental outcomes (cognitive, language and motor) were assessed using Bayley Scales of Infant and Toddler Development, 3rd edition (Bayley-III). Age-adjusted z-scores for each domain were calculated using scores from healthy community control children (n = 88) recruited from the same environment for each age category. Multiple linear regression was used to compare z-scores in the cognitive, language and motor scales between the two groups after adjusting for weight-for-age z-score, socioeconomic status, mother's education, and father's employment on all the scales.<br><br>&emsp;The prevalence of neurodevelopmental impairment was 2.3% (95% CI: 0.8-6.1) for cognition, 1.7% (95%: 0.6-5.3) for language and 3.5% (95% CI: 1.6-7.6) for motor scales and 4.6% (95% CI: 2.3-9.1) for deficits in ≥1 area of neurodevelopment. Significant differences were observed between the two groups with the SA group performing worse on cognition [adjusted mean score, (Standard error, SE), P-value] [-0.20, (0.01) vs. 0.00, (0.01), P = 0.02]; language [-0.25, (0.01) vs. 0.00, (0.01), P< 0.001]; and motor [-0.17, (0.01) vs. 0.00, (0.01), P = 0.05] scales.<br><br>&emsp;In children < 5 years of age, severe anaemia was associated with neurocognitive (cognition, language and motor) deficits in the immediate period post treatment. Further research is needed to identify risk factors and determine the long-term effects of poor neurodevelopment in young children with severe anaemia.\n <br><br> <b>MeSH terms:<\/b> <b>MeSH terms:<\/b> Anemia; Child, Preschool; Cognition; Comorbidity; Female; Hospitals; Humans; Infant; Infant, Newborn; Language Development; Male; Motor Skills; Neurodevelopmental Disorders; Patient Discharge; Prevalence; Prospective Studies; Referral and Consultation; Severity of Illness Index; Uganda <br><br> <b>OMOP Concepts (IDs):<\/b>  Neurodevelopmental disorder (45771096); Patient discharge (4240723); Anemia (439777); Cognitive function finding (4162723); "]},"columns":[{"id":"details","name":"","type":"character","html":true}],"dataKey":"c91d28f691e04b71b064dd6a14f12612","static":false,"nested":true},"children":[]}]},{"name":"div","attribs":{"style":{"padding":"1rem"}},"children":[{"name":"Reactable","attribs":{"data":{"details":["<b>DOI:<\/b> 10.1371/journal.pone.0242068 <br><br> Infection with Human Immunodeficiency Virus (HIV) is highly prevalent worldwide, especially in Sub-Saharan Africa, where anaemia is also widespread. HIV infection is known to be associated with anaemia and various other haematologic alterations, but little data on correlation with immunological and virologic conditions in treatment-naïve patients and impact on mortality are available. Our study aims to investigate hematologic features in HIV-infected individuals in Malawi and Mozambique and assesses possible correlations with early morality.<br><br>&emsp;We conducted a retrospective analysis of baseline data (general details, nutritional status, full blood count and HIV infection progress data) and 12 months follow-up status for HIV+ adult patients in 22 health facilities in Malawi (11 sites) and Mozambique (11 sites) run by DREAM program. Anagraphic details, anthropometric characteristics, full blood count, CD4+ count and Viral Load data were collected from electronical medical records (EMR) for all the HIV-positive, treatment-naïve patients starting care in the sites in the period January 2007 -December 2016. Follow-up status after one year since enrolment in care was also considered. All the data extracted from the EMR were included in a dataset and then analysed. Univariate and multivariate analysis were conducted through logistical regression to investigate associations, and survival analysis analysed in a Cox regression model.<br><br>&emsp;On the whole, 22.657 patients were included; severe and moderate anaemia were observed in 1.174 (8,2%) and 4.703 (21,9%) patients respectively. Gender, nutritional status, CD4+ count, and viral load (VL) were associated with anaemia, leukopenia, and thrombocytopenia. Among 21.166 fully evaluable patients, 8.494 (40,1%) had at least one cytopenia. Any cytopenia was present in 1/3 of patients with normal nutritional status and less advanced HIV infection, and it wouldn't be diagnosed in a basic HIV care setting. During the first year of treatment, 1.725 subjects (7,6% of the entire sample) died. Anaemia, lower Red blood cells and platelets counts correlated with mortality in the first year of care, independently by body mass index, haemoglobin, CD4+ count and VL.<br><br>&emsp;Notwithstanding anaemia is known to be associated with HIV infection at diagnosis, full blood count is not routinely performed in many African countries. Our results emphasize that including the study of a broader set of parameters in the routine HIV care services in Sub-Saharan Africa would provide significant clinical information able to predict other alterations and poor outcomes.\n <br><br> <b>MeSH terms:<\/b> <b>MeSH terms:<\/b> Adult; Africa South of the Sahara; Anemia; Antiretroviral Therapy, Highly Active; Body Mass Index; CD4 Lymphocyte Count; Cohort Studies; Comorbidity; Female; HIV Infections; HIV Seropositivity; HIV-1; Humans; Malawi; Male; Mozambique; Nutritional Status; Proportional Hazards Models; Retrospective Studies; Viral Load <br><br> <b>OMOP Concepts (IDs):<\/b>  Human immunodeficiency virus infection (439727); HIV positive (4013106); Highly active anti-retroviral therapy (4166414); Anemia (439777); "]},"columns":[{"id":"details","name":"","type":"character","html":true}],"dataKey":"8bedbde8eeb37d6eab95fa7a26c4a4b6","static":false,"nested":true},"children":[]}]},{"name":"div","attribs":{"style":{"padding":"1rem"}},"children":[{"name":"Reactable","attribs":{"data":{"details":["<b>DOI:<\/b> 10.1371/journal.pone.0242861 <br><br> In Nigeria, about 150000 babies are born annually with sickle cell disease (SCD), and this figure has been estimated to increase by 100% by the year 2050 without effective and sustainable control strategies. Despite the high prevalence, newborn screening for SCD which allows for early prophylactic treatment, education of parents/guardians and comprehensive management is not yet available. This study explored a strategy for screening in early infancy during the first and second immunization visits, determined the prevalence, feasibility and acceptability of early infant screening for SCD and the evaluation of the HemoTypeSC diagnostic test as compared to the high-performance liquid chromatography (HPLC) gold standard. A cross-sectional study was conducted in two selected primary health care centres in Somolu local government area (LGA) in Lagos, Nigeria. Two hundred and ninety-one mother-infant pairs who presented for the first or second immunization visit were consecutively enrolled in the study following written informed consent. The haemoglobin genotype of mother-infant pairs was determined using the HemoTypeSC rapid test kit. Confirmation of the infants' Hb genotype was done with HPLC. Data were analysed with SPSS version 22. Validity and Predictive value of HemotypeSC rapid screening test were also calculated. Infant screening for SCD was acceptable to 86% of mothers presenting to the immunization clinics. The prevalence of SCD among the infant cohort was 0.8%. The infants diagnosed with SCD were immediately enrolled in the paediatric SCD clinic for disease-specific care. The HemoTypeSC test had 100% sensitivity and specificity for sickle cell disease in early infancy compared to HPLC. This study affirms that it is feasible and acceptable for mothers to implement a SCD screening intervention program in early infancy in Lagos State. The study also demonstrates the utility of the HemotypeSC rapid testing for ease and reduced cost of screening infants for SCD.\n <br><br> <b>MeSH terms:<\/b> <b>MeSH terms:<\/b> Adolescent; Adult; Anemia, Sickle Cell; Feasibility Studies; Female; Humans; Infant, Newborn; Male; Middle Aged; Neonatal Screening; Nigeria; Patient Acceptance of Health Care; Pilot Projects; Prevalence; Young Adult <br><br> <b>OMOP Concepts (IDs):<\/b>  Neonatal screening (4246502); Sickle cell-hemoglobin SS disease (22281); "]},"columns":[{"id":"details","name":"","type":"character","html":true}],"dataKey":"409528c945edad7078169e8cc56b7923","static":false,"nested":true},"children":[]}]},{"name":"div","attribs":{"style":{"padding":"1rem"}},"children":[{"name":"Reactable","attribs":{"data":{"details":["<b>DOI:<\/b> 10.1371/journal.pone.0244362 <br><br> Anaemia and underweight or overweight/obesity are major public health problems driving maternal and child mortality in low- and middle-income countries. While the burden of these conditions is recognised, the evidence for the co-occurrence of these conditions is fragmented and mixed, especially at the individual level. Further, many studies have focused on families and communities. The different pathways for the occurrence of anaemia and BMI challenges indicate that an individual can potentially live with both conditions and suffer the complications. This study examined the prevalence and factors associated with the co-occurrence of anaemia and BMI challenges among a cohort of women in Ghana. Data from the 2014 Ghana Demographic and Health Survey were used. The sample size was 4 337 women aged 15-49 years who were not pregnant during the survey. Women who suffered simultaneously from underweight or overweight/obesity and anaemia were considered as having the double burden of malnutrition. The data were analysed using descriptive statistics, Chi-square test and logistic regression in STATA. One-fifth of the participants were overweight (21%), 4% were underweight and about one-tenth were obese (12%). The prevalence of anaemia was 41%. Only one in three women had normal weight and was not anaemic (34%). About 14% of the women experienced the double burden of malnutrition. Being overweight and anaemic (57%) was the most common form of this double burden. Age, marital status, parity, and wealth were t key risk factors associated with the double burden of malnutrition. The findings from this study show that women experience multiple nutritional challenges concurrently and that only a few women had healthy nutritional status. This information is particularly important and can be introduced into health education programmes to help address misconceptions about body weight and health.\n <br><br> <b>MeSH terms:<\/b> <b>MeSH terms:<\/b> Adolescent; Adolescent Health; Adult; Anemia; Body Mass Index; Cross-Sectional Studies; Female; Ghana; Health Surveys; Humans; Malnutrition; Middle Aged; Nutrition Surveys; Obesity; Overweight; Prevalence; Risk Assessment; Sample Size; Socioeconomic Factors; Thinness; Women's Health; Young Adult <br><br> <b>OMOP Concepts (IDs):<\/b>  Overweight (437525); Risk assessment (4024612); Thin build (4265473); Undernutrition (4276360); Anemia (439777); Obesity (433736); "]},"columns":[{"id":"details","name":"","type":"character","html":true}],"dataKey":"35501006b0ab6905425f37e13a8a7feb","static":false,"nested":true},"children":[]}]},{"name":"div","attribs":{"style":{"padding":"1rem"}},"children":[{"name":"Reactable","attribs":{"data":{"details":["<b>DOI:<\/b> 10.1371/journal.pone.0244782 <br><br> Hemoglobin A1c (HbA1c) is recommended for diagnosing and monitoring diabetes. However, in people with sickle cell disease (SCD), sickle cell trait (SCT), α-thalassemia or glucose-6-phosphate dehydrogenase (G6PD) deficiency, HbA1c may underestimate the prevalence of diabetes. There are no data on the extent of this problem in sub-Saharan Africa despite having high prevalence of these red blood cell disorders.<br><br>&emsp;Blood samples from 431 adults in northwestern Tanzania, randomly selected from the prospective cohort study, Chronic Infections, Comorbidities and Diabetes in Africa (CICADA), were analysed for SCT/SCD, α-thalassemia and G6PD deficiency and tested for associations with the combined prevalence of prediabetes and diabetes (PD/DM) by HbA1c, using the HemoCue 501 HbA1c instrument, and by 2-hour oral glucose tolerance test (OGTT).<br><br>&emsp;The mean age of the participants was 40.5 (SD11.6) years; 61% were females and 71% were HIV-infected. Among 431 participants, 110 (25.5%) had SCT and none had SCD. Heterozygous α-thalassemia (heterozygous α+ AT) was present in 186 (43%) of the participants, while 52 participants (12%) had homozygous α-thalassemia (homozygous α+ AT). Furthermore, 40 (9.3%) participants, all females, had heterozygous G6PD deficiency while 24 (5.6%) males and 4 (0.9%) females had hemizygous and homozygous G6PD deficiency, respectively. In adjusted analysis, participants with SCT were 85% less likely to be diagnosed with PD/DM by HbA1c compared to those without SCT (OR = 0.15, 95% CI: 0.08, 0.26, P < 0.001). When using OGTT, in adjusted analysis, SCT was not associated with diagnosis of PD/DM while participants with homozygous α+ AT and hemizygous G6PD deficiency were more likely to be diagnosed with PD/DM.<br><br>&emsp;HbA1c underestimates the prevalence of PD/DM among Tanzanian adults with SCT. Further research using other HbA1c instruments is needed to optimize HbA1c use among populations with high prevalence of hemoglobinopathies or G6PD deficiency.\n <br><br> <b>MeSH terms:<\/b> <b>MeSH terms:<\/b> Adult; Comorbidity; Cross-Sectional Studies; Diabetes Mellitus, Type 2; Female; Glucosephosphate Dehydrogenase Deficiency; Glycated Hemoglobin; HIV Infections; Hemoglobinopathies; Humans; Male; Middle Aged; Prediabetic State; Prevalence; Prospective Studies; Tanzania <br><br> <b>OMOP Concepts (IDs):<\/b>  Type 2 diabetes mellitus (201826); Prediabetes (37018196); Human immunodeficiency virus infection (439727); Hemoglobinopathy (432868); Deficiency of glucose-6-phosphate dehydrogenase (4050620); "]},"columns":[{"id":"details","name":"","type":"character","html":true}],"dataKey":"99b69fdb2be86b57682397f824623ef7","static":false,"nested":true},"children":[]}]},{"name":"div","attribs":{"style":{"padding":"1rem"}},"children":[{"name":"Reactable","attribs":{"data":{"details":["<b>DOI:<\/b> 10.1371/journal.pone.0243782 <br><br> Intensive care unit (ICU) patients are at high risk of anemia, and phlebotomy is a potentially modifiable source of blood loss. Our objective was to quantify daily phlebotomy volume for ICU patients, including blood discarded as waste during vascular access, and evaluate the impact of phlebotomy volume on patient outcomes.<br><br>&emsp;This was a retrospective observational cohort study between September 2014 and August 2015 at a tertiary care academic medical-surgical ICU. A prospective audit of phlebotomy practices in March 2018 was used to estimate blood waste during vascular access. Multivariable logistic regression was used to evaluate phlebotomy volume as a predictor of ICU nadir hemoglobin < 80 g/L, and red blood cell transfusion.<br><br>&emsp;There were 428 index ICU admissions, median age 64.4 yr, 41% female. Forty-four patients (10%) with major bleeding events were excluded. Mean bedside waste per blood draw (144 draws) was: 3.9 mL from arterial lines, 5.5 mL central venous lines, and 6.3 mL from peripherally inserted central catheters. Mean phlebotomy volume per patient day was 48.1 ± 22.2 mL; 33.1 ± 15.0 mL received by the lab and 15.0 ± 8.1 mL discarded as bedside waste. Multivariable regression, including age, sex, admission hemoglobin, sequential organ failure assessment score, and ICU length of stay, showed total daily phlebotomy volume was predictive of hemoglobin <80 g/L (p = 0.002), red blood cell transfusion (p<0.001), and inpatient mortality (p = 0.002). For every 5 mL increase in average daily phlebotomy the odds ratio for nadir hemoglobin <80 g/L was 1.18 (95% CI 1.07-1.31) and for red blood cell transfusion was 1.17 (95% CI 1.07-1.28).<br><br>&emsp;A substantial portion of daily ICU phlebotomy is waste discarded during vascular access. Average ICU phlebotomy volume is independently associated with ICU acquired anemia and red blood cell transfusion which supports the need for phlebotomy stewardship programs.\n <br><br> <b>MeSH terms:<\/b> <b>MeSH terms:<\/b> Academic Medical Centers; Adolescent; Adult; Aged; Aged, 80 and over; Anemia; Critical Care; Erythrocyte Transfusion; Female; Hemorrhage; Humans; Intensive Care Units; Male; Middle Aged; Ontario; Patient Harm; Phlebotomy; Retrospective Studies; Tertiary Care Centers; Young Adult <br><br> <b>OMOP Concepts (IDs):<\/b>  Bleeding (437312); Care of intensive care unit patient (4046295); Venipuncture for blood test (4102442); Transfusion of red blood cells (4022173); Anemia (439777); "]},"columns":[{"id":"details","name":"","type":"character","html":true}],"dataKey":"81932e3be1a076c8178df7aa7494de96","static":false,"nested":true},"children":[]}]},{"name":"div","attribs":{"style":{"padding":"1rem"}},"children":[{"name":"Reactable","attribs":{"data":{"details":["<b>DOI:<\/b> 10.1371/journal.pone.0245743 <br><br> Both malaria and intestinal parasites are endemic in Cameroon, and their co-infection can be of great impact on anaemia among people living with HIV (PLWH). This community-based retrospective cohort study determined the prevalence and association of infections with anaemia in PLWH and HIV-negative individuals in Buea, Cameroon from March to August 2019.<br><br>&emsp;The study population comprised of 190 PLWH and 216 consenting HIV-negative individuals from the Buea community. Participants were examined clinically, the collected blood sample was used for malaria parasite (MP) detection, HIV diagnosis and haemoglobin (Hb) measurement while stool samples were examined for the detection of intestinal parasites (IPs). Proportions were compared using Pearson's Chi-square test and association of anaemia with independent variables was evaluated using logistic regression analysis.<br><br>&emsp;Out of the 406 participants, MP, IPs and MP/IP co-infection prevalences were 15.5%, 13.0% and 3.0% respectively. PLWH had a higher prevalence of MP (16.3%, P = 0.17), IPs (23.7%, P ˂ 0.001) and MP/IPs co-infection (3.7%, P = 0.04) when compared with HIV-negative participants. Similarly, PLWH had significantly lower mean haemoglobin value (11.10 ± 1.54 g/dL) than their HIV-negative counterparts (12.45 ± 2.06 g/dL). Also, PLWH co-infected with MP and IPs were observed to have a significantly lower mean haemoglobin value (10.6 ± 1.21 g/dL). PLWH had a significantly (P ˂ 0.001) higher prevalence of mild (56.8%), moderate (18.4%) and severe (1.6%) anaemia when compared with HIV-negative counterparts. The significant risk factors associated with anaemia included being febrile (P = 0.03), MP-infected only (P = 0.001), HIV-infected only (P < 0.001), having dual (P < 0.001) or triple-infections (P = 0.03).<br><br>&emsp;Malaria and intestinal parasites remain public health concerns among PLWH and anaemia as a serious haematological abnormality gets exacerbated even with the viral load suppression. Hence, routine medical check-ups among PLWH are recommended.\n <br><br> <b>MeSH terms:<\/b> <b>MeSH terms:<\/b> Adolescent; Aged; Anemia; Cameroon; Child; Child, Preschool; Cohort Studies; Coinfection; Female; HIV Infections; Hemoglobins; Humans; Infant; Intestinal Diseases, Parasitic; Malaria; Male; Middle Aged; Retrospective Studies; Risk Factors; Young Adult <br><br> <b>OMOP Concepts (IDs):<\/b>  Human immunodeficiency virus infection (439727); Intestinal parasitism (196347); Malarial fever (4093997); Mixed infectious disease (4163969); Anemia (439777); "]},"columns":[{"id":"details","name":"","type":"character","html":true}],"dataKey":"c2780c245b5d533163b6b8c14be3c369","static":false,"nested":true},"children":[]}]},{"name":"div","attribs":{"style":{"padding":"1rem"}},"children":[{"name":"Reactable","attribs":{"data":{"details":["<b>DOI:<\/b> 10.1371/journal.pone.0246267 <br><br> Moderate to severe acute malnutrition (SAM/MAM) and severe anaemia are important and associated co-morbidities in children aged less than five years. Independently, these two morbidities are responsible for high risk of in-hospital and post-discharge deaths and hospital readmissions. The primary objective of this study is to investigate the risk of death among severely anaemic children with moderate to severe acute malnutrition compared to children with severe anaemia alone.<br><br>&emsp;This was a retrospective analysis of data collected from a large prospective study that was investigating severe anaemia in children aged less than 5 years old. The study was conducted at Queen Elizabeth Central Hospital in Blantyre and Chikhwawa district hospital in southern Malawi. Children aged less than five years old; with severe anaemia were screened and enrolled. Each child was followed up for eighteen months at one, three, six, twelve and eighteen months after enrolment. Data were analysed using STATA 15.<br><br>&emsp;Between July 2002 and July 2004, 382 severely anaemic children were enrolled in the main study. A total of 52 children were excluded due to missing anthropometric data. Out of the 330 included, 53 children were moderately to severely malnourished and 277 were not. At the end of the 18-month follow period, 28.3% of children with MAM/SAM died compared to 13% of children without MAM/SAM (RR 2.1, CI 0.9-4.2, p = 0.03). Similarly, children with moderate to severe malnutrition reported a significantly higher number of malaria infection cases (33.9%) compared to children with severe anaemia alone (27.9%, p = 0.02). However, the number of hospitalizations and recurrence of severe anaemia was similar and not statistically significant between the two groups (RR 0.8 (0.4-1.4), p = 0.6 and RR 1.1 (0.3-2.8), p = 0.8).<br><br>&emsp;Among children with severe anaemia, those who also had moderate to severe malnutrition had a twofold higher risk of dying compared to those who did not. It is therefore crucial to investigate acute malnutrition among severely anaemic children, as this might be treatable factor associated with high mortality.\n <br><br> <b>MeSH terms:<\/b> <b>MeSH terms:<\/b> Aftercare; Anemia; Child Nutrition Disorders; Child, Preschool; Cohort Studies; Comorbidity; Female; Hospitalization; Humans; Infant; Infant, Newborn; Malawi; Male; Malnutrition; Patient Discharge; Recurrence; Retrospective Studies; Severe Acute Malnutrition <br><br> <b>OMOP Concepts (IDs):<\/b>  Aftercare (4186037); Patient discharge (4240723); Undernutrition (4276360); Inpatient care (4214577); Anemia (439777); "]},"columns":[{"id":"details","name":"","type":"character","html":true}],"dataKey":"c858170254299940d860bcfa30c1cbaa","static":false,"nested":true},"children":[]}]},{"name":"div","attribs":{"style":{"padding":"1rem"}},"children":[{"name":"Reactable","attribs":{"data":{"details":["<b>DOI:<\/b> 10.1371/journal.pone.0245458 <br><br> Anemia is a common condition at tuberculosis diagnosis, and there is evidence that its prevalence is higher in patients with tuberculosis than in those infected with Mycobacterium tuberculosis and healthy controls. Information about anemia during tuberculosis diagnosis is still scarce in the Brazilian population. The aim of this study was to describe the prevalence of anemia in patients with tuberculosis cared for at a referral center and its association with clinical forms of tuberculosis and other characteristics of these patients.<br><br>&emsp;This was a retrospective cross-sectional study of tuberculosis patients diagnosed from January 2015 to December 2018 at the Clinical Research Laboratory on Mycobacteria (LAPCLIN-TB) of Evandro Chagas National Institute of Infectious Diseases (INI)/Oswaldo Cruz Foundation (Fiocruz). A database of an ongoing cohort study underway at this service since 2000 provided the baseline information on tuberculosis cases extracted from a visit template. Exploratory and logistic regression analyses were performed to verify associations between anemia and demographic characteristics, socioeconomic status, clinical conditions, and laboratory results.<br><br>&emsp;Of the 328 cases reviewed, 70 were excluded, with258 retained. The prevalence of anemia was 61.2% (27.5% mild, 27.5% moderate and 6.2% severe). Among patients with anemia, 60.8% had normochromic normocytic anemia, and 27.8% showed hypochromic microcytic anemia. In logistic regression analysis, anemia was associated with a history of weight loss >10%, hospitalizations, coinfection with HIV, increased platelet count and microcytosis. Anemia was more frequent in the most severe clinical forms, such as meningeal and disseminated tuberculosis.<br><br>&emsp;Anemia was highly prevalent in tuberculosis patients at diagnosis, predominantly as normochromic normocytic anemia and in mild and moderate forms. It was associated with baseline characteristics and conditions indicative of severe disease, suggesting that anemia could be a biomarker of tuberculosis severity.\n <br><br> <b>MeSH terms:<\/b> <b>MeSH terms:<\/b> Adult; Anemia; Brazil; Cross-Sectional Studies; Female; Humans; Male; Middle Aged; Prevalence; Retrospective Studies; Risk Factors; Severity of Illness Index; Tuberculosis, Pulmonary <br><br> <b>OMOP Concepts (IDs):<\/b>  Respiratory tuberculosis (45771090); Anemia (439777); "]},"columns":[{"id":"details","name":"","type":"character","html":true}],"dataKey":"a1fa41e1860c9b67c8d6d03515a58b56","static":false,"nested":true},"children":[]}]},{"name":"div","attribs":{"style":{"padding":"1rem"}},"children":[{"name":"Reactable","attribs":{"data":{"details":["<b>DOI:<\/b> 10.1371/journal.pone.0246067 <br><br> Priapism is a urologic emergency characterized by an uncontrolled, persistent and painful erection in the absence of sexual stimulation, which can lead to penile fibrosis and impotence. It is highly frequent in sickle cell disease (SCD) associated with hemolytic episodes. Our aim was to investigate molecules that may participate in the regulation of vascular tone. Eighty eight individuals with SCD were included, of whom thirty-seven reported a history of priapism. Priapism was found to be associated with alterations in laboratory biomarkers, as well as lower levels of HbF. Patients with sickle cell anemia using hydroxyurea and those who received blood products seemed to be less affected by priapism. Multivariate analysis suggested that low HbF and NOm were independently associated with priapism. The frequency of polymorphisms in genes NOS3 and EDN1 was not statistically significant between the studied groups, and the presence of the variant allele was not associated with alterations in NOm and ET-1 levels in patients with SCD. The presence of the variant allele in the polymorphisms investigated did not reveal any influence on the occurrence priapism. Future studies involving larger samples, as well as investigations including patients in priapism crisis, could contribute to an enhanced understanding of the development of priapism in SCD.\n <br><br> <b>MeSH terms:<\/b> <b>MeSH terms:<\/b> Adolescent; Anemia, Sickle Cell; Case-Control Studies; Child; Endothelin-1; Fetal Hemoglobin; Genetic Association Studies; Humans; Male; Multivariate Analysis; Nitric Oxide; Nitric Oxide Synthase Type III; Polymorphism, Single Nucleotide; Priapism <br><br> <b>OMOP Concepts (IDs):<\/b>  Hemoglobin F (4339104); Priapism (315586); Sickle cell-hemoglobin SS disease (22281); Nitric Oxide (19020068); "]},"columns":[{"id":"details","name":"","type":"character","html":true}],"dataKey":"da8af121e9b90f411a6be72d59a2926a","static":false,"nested":true},"children":[]}]},{"name":"div","attribs":{"style":{"padding":"1rem"}},"children":[{"name":"Reactable","attribs":{"data":{"details":["<b>DOI:<\/b> 10.1371/journal.pmed.1003576 <br><br> Glucose-6-phosphate dehydrogenase (G6PD) activity is dependent upon G6PD genotype and age of the red blood cell (RBC) population, with younger RBCs having higher activity. Peripheral parasitemia with Plasmodium spp. induces hemolysis, replacing older RBCs with younger cells with higher G6PD activity. This study aimed to assess whether G6PD activity varies between individuals with and without malaria or a history of malaria.<br><br>&emsp;Individuals living in the Chittagong Hill Tracts of Bangladesh were enrolled into 3 complementary studies: (i) a prospective, single-arm clinical efficacy trial of patients (n = 175) with uncomplicated malaria done between 2014 and 2015, (ii) a cross-sectional survey done between 2015 and 2016 (n = 999), and (iii) a matched case-control study of aparasitemic individuals with and without a history of malaria done in 2020 (n = 506). G6PD activity was compared between individuals with and without malaria diagnosed by microscopy, rapid diagnostic test (RDT), or polymerase chain reaction (PCR), and in aparasitemic participants with and without a history of malaria. In the cross-sectional survey and clinical trial, 15.5% (182/1,174) of participants had peripheral parasitemia detected by microscopy or RDT, 3.1% (36/1,174) were positive by PCR only, and 81.4% (956/1,174) were aparasitemic. Aparasitemic individuals had significantly lower G6PD activity (median 6.9 U/g Hb, IQR 5.2-8.6) than those with peripheral parasitemia detected by microscopy or RDT (7.9 U/g Hb, IQR 6.6-9.8, p < 0.001), but G6PD activity similar to those with parasitemia detected by PCR alone (submicroscopic parasitemia) (6.1 U/g Hb, IQR 4.8-8.6, p = 0.312). In total, 7.7% (14/182) of patients with malaria had G6PD activity < 70% compared to 25.0% (248/992) of participants with submicroscopic or no parasitemia (odds ratio [OR] 0.25, 95% CI 0.14-0.44, p < 0.001). In the case-control study, the median G6PD activity was 10.3 U/g Hb (IQR 8.8-12.2) in 253 patients with a history of malaria and 10.2 U/g Hb (IQR 8.7-11.8) in 253 individuals without a history of malaria (p = 0.323). The proportion of individuals with G6PD activity < 70% was 11.5% (29/253) in the cases and 15.4% (39/253) in the controls (OR 0.7, 95% CI 0.41-1.23, p = 0.192). Limitations of the study included the non-contemporaneous nature of the clinical trial and cross-sectional survey.<br><br>&emsp;Patients with acute malaria had significantly higher G6PD activity than individuals without malaria, and this could not be accounted for by a protective effect of G6PD deficiency. G6PD-deficient patients with malaria may have higher than expected G6PD enzyme activity and an attenuated risk of primaquine-induced hemolysis compared to the risk when not infected.\n <br><br> <b>MeSH terms:<\/b> <b>MeSH terms:<\/b> Adolescent; Adult; Aged; Aged, 80 and over; Bangladesh; Case-Control Studies; Child; Child, Preschool; Clinical Trials as Topic; Cross-Sectional Studies; Female; Glucosephosphate Dehydrogenase; Glucosephosphate Dehydrogenase Deficiency; Humans; Infant; Infant, Newborn; Malaria; Male; Middle Aged; Parasitemia; Young Adult <br><br> <b>OMOP Concepts (IDs):<\/b>  Clinical trial (4002165); Malarial fever (4093997); Deficiency of glucose-6-phosphate dehydrogenase (4050620); "]},"columns":[{"id":"details","name":"","type":"character","html":true}],"dataKey":"0432afc031bac0d40187aa153a67686f","static":false,"nested":true},"children":[]}]},{"name":"div","attribs":{"style":{"padding":"1rem"}},"children":[{"name":"Reactable","attribs":{"data":{"details":["<b>DOI:<\/b> 10.1371/journal.pone.0250246 <br><br> Iron Deficiency Anaemia (IDA) is reportedly high in pregnant adults and the causes well studied. However, among pregnant teenagers, the levels and associated factors of IDA are not fully understood.<br><br>&emsp;In a prospective cohort study among Ghanaian pregnant teenagers, aged 13-19 years, IDA prevalence and associated factors were investigated. Sociodemographic data, household hunger scale (HHS), lived poverty index (LPI), FAO's women's dietary diversity score (WDDS) and interventions received during antenatal care (ANC) were obtained from 416 pregnant teenagers in Ashanti Region, Ghana. Micronutrient intakes using a repeated 24-hour dietary recall, and mid-upper arm circumference (MUAC) were determined and blood samples analysed for haemoglobin (Hb), serum levels of ferritin, prealbumin, vitamin A, total antioxidant capacity (TAC), C-reactive protein (CRP), and zinc protoporphyrin (ZPP).<br><br>&emsp;Anaemia (Hb cutoff <11.0 g/dL) was 57.1%; deficient systemic supply of iron stores (31.4%), depleted body stores of iron (4.4%), inadequate dietary iron intake (94.5%), and inadequate multiple micronutrient intakes (49.5%), were all notable among study participants. Between-subject effects using Generalized Linear Modelling indicated malaria tablet given at ANC (p = 0.035), MUAC (p = 0.043), ZPP (p<0.001), ZPP/Hb ratio (p<0.001) and depleted body iron stores (DBIS) (p<0.001) to significantly affect Hb levels. Pregnant teenagers with a high ZPP/Hb ratio (OR = 9.7, p<0.001, 95%CI = 6.0-15.8) had increased odds of being anaemic compared to those with normal ZPP/Hb ratio. Participants who were wasted (OR = 1.2, p = 0.543, 95%CI = 0.6-2.3), and those with depleted iron stores (OR = 3.0, p = 0.167, 95%CI = 0.6-14.6) had increased odds of being anaemic. Participants who experienced hunger were close to 3 times more likely (OR = 2.9, p = 0.040, 95%CI = 1.1-7.8) for depleted iron stores, compared to those who did not experience hunger. Also, participants with inadequate multiple micronutrients intakes (OR = 2.6, p = 0.102, 95%CI = 0.8-8.4), and those with low serum levels of ferritin (OR = 3.3, p = 0.291, 95%CI = 0.4-29.2) had increased odds of depleted body iron stores.<br><br>&emsp;IDA is common among pregnant teenagers and the related factors include malaria tablets given at ANC, maternal hunger, maternal MUAC, a deficient systemic supply of iron, depleted body iron stores, ZPP, and ZPP/Hb ratio. Appropriate interventions are urgently needed to address the causes of IDA among pregnant teenagers.\n <br><br> <b>MeSH terms:<\/b> <b>MeSH terms:<\/b> Adolescent; Anemia; Anemia, Iron-Deficiency; Cohort Studies; Diet; Eating; Female; Ferritins; Ghana; Hemoglobins; Hospitals; Humans; Iron; Nutritional Status; Pregnancy; Pregnancy Complications, Hematologic; Prevalence; Prospective Studies <br><br> <b>OMOP Concepts (IDs):<\/b>  Pregnant (4299535); Dietary finding (4222559); Iron deficiency anemia (436659); Anemia (439777); Iron (1360067); "]},"columns":[{"id":"details","name":"","type":"character","html":true}],"dataKey":"dddfe53b9b40c9aba211501b97641fb8","static":false,"nested":true},"children":[]}]},{"name":"div","attribs":{"style":{"padding":"1rem"}},"children":[{"name":"Reactable","attribs":{"data":{"details":["<b>DOI:<\/b> 10.1371/journal.pone.0250990 <br><br> Intestinal parasitosis is a common disease that causes misery and disability in poor populations. The number of individuals affected is staggering. From two billion peoples who harbor parasites worldwide, 300 million suffer severe morbidity and more than 25% of pregnant women are infected with hookworm, which causes intestinal bleeding and blood loss, and has been most commonly associated with anemia. Intestinal parasite infection during pregnancy has been associated with iron deficiency, maternal anemia, and impaired nutritional status, as well as decreased infant birth weight.<br><br>&emsp;This study aimed to assess the effects of intestinal parasite infection on hematological profiles of pregnant women attending antenatal care in Debre Markos Referral Hospital from December 2017 to February 2019.<br><br>&emsp;A prospective cohort study design was conducted among 94 intestinal parasite-infected pregnant women as an exposed group and 187 pregnant women free from intestinal parasite were used as a control group. The effect of intestinal parasites on hematological profiles of pregnant women was assessed at Debre Markos Referral Hospital antenatal care ward. Socio-demographic data and nutrition status were assessed by using structured questionnaires and mid-upper arm circumference (MUAC), respectively. Two ml of venous blood and 2 gm of stool samples were collected to analyze the hematological profiles and detect intestinal parasites, respectively. Wet mount and formol-ether concentration (FEC) techniques were used to detect intestinal parasites. Hematological profile was analyzed using Mind ray BC-3000 plus instrument. Data were double entered into EpiData version 3.1 software and exported to SPSS version 24 software for analysis. Results were presented using tables and graphs. Associations of hemoglobin levels with intestinal parasitic infections were determined using binary logistic regression models. P≤0.05 was considered statistically significant. The mean hematological profile difference between parasite-infected and parasite-free pregnant women was computed using independent t-test.<br><br>&emsp;In the present study, the predominant parasites identified were Entamoeba histolytica, hookworm, Giardia lamblia, Schistosoma mansoni, and Ascaris lumbricoides. About 8.2% of intestinal parasite-infected pregnant women had mild anemia while 4% had moderate anemia. Only 1.2% of intestinal parasite-free pregnant women developed moderate anemia. The mean HGB, HCT, MCV, MCH, and MCHC values of intestinal parasite-infected pregnant women were 12.8g/dl, 38.2%, 94.7fl, 33.1pg and 34.7g/dl, respectively. But the mean HGB, HCT, MCV, MCH and MCHC values of pregnant women who were free from intestinal parasites were 14.4 g/dl, 39.8%, 94.9fl, 33.9pg and 35.5g/dl, respectively. Anemia was strongly associated with hookworm (AOR = 21.29, 95%CI: 8.28-54.75, P<0.001), S.mansoni (AOR = 63.73, 95% CI: 19.15-212, P<0.001) and A.lumbricoide (AOR = 14.12, 95% CI 3.28-60.65, P<0.001).<br><br>&emsp;Intestinal parasitic infection in pregnant women caused adverse impact on hematological profiles and was an independent predictor of anemia. Intestinal parasitic infection significantly decreased pregnant the level of HGB, HCT, MCV, MCH, and MCHC values. To minimize maternal anemia deworming could be good before pregnancy.\n <br><br> <b>MeSH terms:<\/b> <b>MeSH terms:<\/b> Adolescent; Adult; Anemia; Animals; Cross-Sectional Studies; Ethiopia; Female; Humans; Intestinal Diseases, Parasitic; Pregnancy; Pregnancy Complications, Parasitic; Prenatal Care; Prevalence; Prospective Studies; Referral and Consultation; Risk Factors; Young Adult <br><br> <b>OMOP Concepts (IDs):<\/b>  Pregnant (4299535); Intestinal parasitism (196347); Antepartum care only (2110313); 7 or more visits (4173786); Antenatal care (439777); Anemia (4299535); "]},"columns":[{"id":"details","name":"","type":"character","html":true}],"dataKey":"a0bdba598f3964bdab97e71ccf346a10","static":false,"nested":true},"children":[]}]},{"name":"div","attribs":{"style":{"padding":"1rem"}},"children":[{"name":"Reactable","attribs":{"data":{"details":["<b>DOI:<\/b> 10.1371/journal.pone.0254810 <br><br> The relationship between severe anemia, red blood cell transfusion and Neonatal necrotizing enterocolitis (NEC) remains controversial. The purpose of this study was to determine the association of severe anemia and RBC transfusion with NEC in neonates.<br><br>&emsp;The clinical characteristics of NEC were observed in 467 infants with different birth weights from January 2012 to July 2020. A 1:1 ratio case-control study was performed in very low birth weight (VLBW) infants. Severe anemia, RBC transfusion, and confounding factors, including maternal and perinatal complications, feeding, and antibiotics administration were collected in both groups. Univariate and multivariate analyses were used to investigate effects on the risk of NEC.<br><br>&emsp;The day of NEC onset and mortality were inversely associated with birth weight. In VLBW infants, adjusting for other factors, severe anemia within 72 h [OR = 2.404, P = 0.016], RBC transfusion within 24 h [OR = 4.905, P = 0.016], within 48 h [OR = 5.587, P = 0.008], and within 72 h [OR = 2.858, P = 0.011] increased the risk of NEC.<br><br>&emsp;Both severe anemia and RBC transfusion appears to increase the risk of NEC in VLBW infants. The early prevention and treatment of anemia, strict evaluation of the indications for transfusion and enhanced monitoring after transfusion is encouraged in the NICU.\n <br><br> <b>MeSH terms:<\/b> <b>MeSH terms:<\/b> Anemia; Birth Weight; Case-Control Studies; Enterocolitis, Necrotizing; Erythrocyte Transfusion; Female; Gestational Age; Humans; Infant, Newborn; Infant, Premature; Infant, Premature, Diseases; Infant, Very Low Birth Weight; Male; Retrospective Studies; Risk Factors <br><br> <b>OMOP Concepts (IDs):<\/b>  Birth weight finding (4187520); Necrotizing enterocolitis in fetus OR newborn (201957); Premature infant (4217564); Transfusion of red blood cells (4022173); Anemia (439777); Very low birth weight infant (4079858); "]},"columns":[{"id":"details","name":"","type":"character","html":true}],"dataKey":"e71268aca67868f8a4cff552563191f4","static":false,"nested":true},"children":[]}]},{"name":"div","attribs":{"style":{"padding":"1rem"}},"children":[{"name":"Reactable","attribs":{"data":{"details":["<b>DOI:<\/b> 10.1371/journal.pone.0255956 <br><br> Sickle Cell Disease (SCD) is an inherited blood disorder that leads to hemolytic anemia, pain, organ damage and early mortality. It is characterized by polymerized deoxygenated hemoglobin, rigid sickle red blood cells and vaso-occlusive crises (VOC). Recurrent hypoxia-reperfusion injury in the gut of SCD patients could increase tissue injury, permeability, and bacterial translocation. In this context, the gut microbiome, a major player in health and disease, might have significant impact. This study sought to characterize the gut microbiome in SCD.<br><br>&emsp;Stool and saliva samples were collected from healthy controls (n = 14) and SCD subjects (n = 14). Stool samples were also collected from humanized SCD murine models including Berk, Townes and corresponding control mice. Amplified 16S rDNA was used for bacterial composition analysis using Next Generation Sequencing (NGS). Pairwise group analyses established differential bacterial groups at many taxonomy levels. Bacterial group abundance and differentials were established using DeSeq software.<br><br>&emsp;A major dysbiosis was observed in SCD patients. The Firmicutes/Bacteroidetes ratio was lower in these patients. The following bacterial families were more abundant in SCD patients: Acetobacteraceae, Acidaminococcaceae, Candidatus Saccharibacteria, Peptostreptococcaceae, Bifidobacteriaceae, Veillonellaceae, Actinomycetaceae, Clostridiales, Bacteroidacbactereae and Fusobacteriaceae. This dysbiosis translated into 420 different operational taxonomic units (OTUs). Townes SCD mice also displayed gut microbiome dysbiosis as seen in human SCD.<br><br>&emsp;A major dysbiosis was observed in SCD patients for bacteria that are known strong pro-inflammatory triggers. The Townes mouse showed dysbiosis as well and might serve as a good model to study gut microbiome modulation and its impact on SCD pathophysiology.\n <br><br> <b>MeSH terms:<\/b> <b>MeSH terms:<\/b> Adult; Anemia, Sickle Cell; Animals; Bacteria; Case-Control Studies; Dysbiosis; Female; Gastrointestinal Microbiome; Humans; Male; Mice; Middle Aged; Young Adult <br><br> <b>OMOP Concepts (IDs):<\/b>  Sickle cell-hemoglobin SS disease (22281); "]},"columns":[{"id":"details","name":"","type":"character","html":true}],"dataKey":"3066528672c0b77a31fbe00d62785e8d","static":false,"nested":true},"children":[]}]},{"name":"div","attribs":{"style":{"padding":"1rem"}},"children":[{"name":"Reactable","attribs":{"data":{"details":["<b>DOI:<\/b> 10.1371/journal.pone.0257305 <br><br> Anemia is a common complication of chronic kidney disease (CKD). Blood urea nitrogen (BUN) in CKD represents nitrogenous uremic toxin accumulation which could be involved in anemia of CKD. We investigated the effects of BUN independent of estimated glomerular filtration rate (eGFR) on anemia in non-dialysis CKD (NDCKD).<br><br>&emsp;This prospective study included 2,196 subjects enrolled in the KoreaN Cohort Study for Outcome in Patients With Chronic Kidney Disease (KNOW-CKD) cohort with BUN and hemoglobin level data. Initially, we investigated the association between BUN and hemoglobin level. To examine the impact of baseline BUN on the incident anemia, a longitudinal study was performed on 1,169 patients without anemia at study enrollment. BUN residuals were obtained from the fitted curve between BUN and eGFR. Anemia was defined as a hemoglobin level of <13.0 g/dL for men and <12.0 g/dL for women.<br><br>&emsp;BUN residuals were not related to eGFR but to daily protein intake (DPI), while BUN was related to both eGFR and DPI. BUN was inversely associated with hemoglobin level (β -0.03; 95% confidence interval [CI] -0.04, -0.03; P <0.001) in the multivariable linear regression analysis adjusted for multiple confounders including eGFR, and BUN residual used instead of BUN was also inversely associated with hemoglobin level (β -0.03; 95% CI -0.04, -0.02; P <0.001). Among the 1,169 subjects without anemia at baseline, 414 (35.4%) subjects newly developed anemia during the follow-up period of 37.5 ± 22.1 months. In the multivariable Cox regression analysis with adjustment, both high BUN level (Hazard ratio [HR] 1.02; 95% CI 1.01, 1.04; P = 0.002) and BUN residual used instead of BUN (HR 1.02; 95% CI 1.00, 1.04; P = 0.031) increased the risk of anemia development. Moreover, BUN, rather than eGFR, increased the risk of anemia development in patients with CKD stage 3 in the multivariable Cox regression.<br><br>&emsp;Higher BUN levels derived from inappropriately high protein intake relative to renal function were associated with low hemoglobin levels and the increased risk of anemia independent of eGFR in NDCKD patients.\n <br><br> <b>MeSH terms:<\/b> <b>MeSH terms:<\/b> Adult; Aged; Anemia; Blood Urea Nitrogen; Cohort Studies; Female; Glomerular Filtration Rate; Hemoglobins; Humans; Kaplan-Meier Estimate; Longitudinal Studies; Male; Middle Aged; Proportional Hazards Models; Prospective Studies; Renal Insufficiency, Chronic; Republic of Korea; Young Adult <br><br> <b>OMOP Concepts (IDs):<\/b>  Chronic renal insufficiency (36716947); Blood urea nitrogen measurement (4017361); Anemia (439777); "]},"columns":[{"id":"details","name":"","type":"character","html":true}],"dataKey":"548a6df66d2f43bc65fc5e3590562b91","static":false,"nested":true},"children":[]}]},{"name":"div","attribs":{"style":{"padding":"1rem"}},"children":[{"name":"Reactable","attribs":{"data":{"details":["<b>DOI:<\/b> 10.1200/JCO.21.01495 <br><br> Fanconi anemia (FA) and ataxia-telangiectasia (AT) are rare inherited syndromes characterized by abnormal DNA damage response and caused by pathogenic variants in key DNA repair proteins that are also relevant in the pathogenesis of breast cancer and other cancer types. The risk of cancer in children with these diseases is poorly understood and has never been assessed in a population-based cohort before.<br><br>&emsp;We identified 421 patients with FA and 160 patients with AT diagnosed between 1973 and 2020 through German DNA repair disorder reference laboratories. We linked patients' laboratory data with childhood cancer data from the German Childhood Cancer Registry.<br><br>&emsp;Among 421 patients with FA, we observed 33 cases of childhood cancer (15 cases of myelodysplastic syndrome; seven cases of acute myeloid leukemia; two cases of lymphoma, carcinoma, medulloblastoma, and nephroblastoma, respectively; and one case of rhabdomyosarcoma, acute lymphoblastic leukemia, and glioma, respectively) versus 0.74 expected (on the basis of population-based incidence rates in Germany). This corresponds to a 39-fold increased risk (standardized incidence ratio [SIR] = 39; 95% CI, 26 to 56). For all FA subgroups combined, the cancer-specific SIR for myeloid neoplasms was 445 (95% CI, 272 to 687). Among the 160 patients with AT, we observed 19 cases of childhood cancer (15 cases of lymphoma, three cases of leukemia, and one case of medulloblastoma) versus 0.32 expected. This corresponds to a 56-fold increased risk (SIR = 56; 95% CI, 33 to 88). The cancer-specific SIR for Hodgkin lymphoma was 215 (95% CI, 58 to 549) and for non-Hodgkin lymphoma 470 (95% CI, 225 to 865).<br><br>&emsp;Approximately 11% of patients with FA and 14% of patients with AT develop cancer by age 18 years.\n <br><br> <b>MeSH terms:<\/b> <b>MeSH terms:<\/b> Adolescent; Age Factors; Ataxia Telangiectasia; Child; Child, Preschool; Fanconi Anemia; Female; Germany; Humans; Incidence; Infant; Male; Neoplasms; Prognosis; Registries; Risk Assessment; Risk Factors; Time Factors <br><br> <b>OMOP Concepts (IDs):<\/b>  Determination of prognosis (4069425); Risk assessment (4024612); Fanconi's anemia (4148471); Ataxia-telangiectasia syndrome (4285430); Neoplastic disease (438112); "]},"columns":[{"id":"details","name":"","type":"character","html":true}],"dataKey":"c6117986cbec6089fb13efc77f5139aa","static":false,"nested":true},"children":[]}]},{"name":"div","attribs":{"style":{"padding":"1rem"}},"children":[{"name":"Reactable","attribs":{"data":{"details":["<b>DOI:<\/b> 10.1371/journal.pone.0258127 <br><br> Population risks for neonatal hyperbilirubinaemia (NH) vary. Knowledge of local risks permits interventions that may reduce the proportion becoming severe. Between January 2015 and May 2016, in a resource-limited setting on the Thailand-Myanmar border, neonates from 28 weeks' gestation were enrolled into a prospective birth cohort. Each neonate had total serum bilirubin measurements: scheduled (24, 48, 72 and 144 hours of life) and clinically indicated; and weekly follow up until 1 month of age. Risk factors for developing NH were evaluated using Cox proportional hazard mixed model. Of 1710 neonates, 22% (376) developed NH (83% preterm, 19% term). All neonates born <35 weeks, four in five born 35-37 weeks, and three in twenty born ≥38 weeks had NH, giving an overall incidence of 249 per 1000 livebirths [95%CI 225, 403]. Mortality from acute bilirubin encephalopathy was 10% (2/20) amongst the 5.3% (20/376) who reached the severe NH threshold. One-quarter (26.3%) of NH occurred within 24 hours. NH onset varied with gestational age: at a median [IQR] 24 hours [24, 30] for neonates born 37 weeks or prematurely vs 59 hours [48, 84] for neonates born ≥38 weeks. Risk factors for NH in the first week of life independent of gestational age were: neonatal G6PD deficiency, birth bruising, Sgaw Karen ethnicity, primigravidae, pre-eclampsia, and prolonged rupture of membranes. The genetic impact of G6PD deficiency on NH was partially interpreted by using the florescent spot test and further genotyping work is in progress. The risk of NH in Sgaw Karen refugees may be overlooked internationally as they are most likely regarded as Burmese in countries of resettlement. Given high levels of pathological jaundice in the first 24 hours and overall high NH burden, guidelines changes were implemented including preventive PT for all neonates <35 weeks and for those 35-37 weeks with risk factors.\n <br><br> <b>MeSH terms:<\/b> <b>MeSH terms:<\/b> Bilirubin; Cohort Studies; Epidemiologic Studies; Ethnicity; Female; Genotype; Glucosephosphate Dehydrogenase Deficiency; Humans; Hyperbilirubinemia, Neonatal; Infant, Newborn; Kernicterus; Male; Myanmar; Pre-Eclampsia; Pregnancy; Proportional Hazards Models; Prospective Studies; Risk Factors; Thailand <br><br> <b>OMOP Concepts (IDs):<\/b>  Pregnant (4299535); Bilirubin, total measurement (4230543); Kernicterus of newborn (4173577); Neonatal hyperbilirubinemia (4105871); Pre-eclampsia (439393); Genetic finding (4025367); Deficiency of glucose-6-phosphate dehydrogenase (4050620); "]},"columns":[{"id":"details","name":"","type":"character","html":true}],"dataKey":"fe47df831f1acc8710f05003407d63a9","static":false,"nested":true},"children":[]}]},{"name":"div","attribs":{"style":{"padding":"1rem"}},"children":[{"name":"Reactable","attribs":{"data":{"details":["<b>DOI:<\/b> 10.1371/journal.pone.0258560 <br><br> Priapism impairs quality of life and has a predilection for males with sickle cell disease (SCD). The Priapism Impact Profile (PIP) is a novel 12-item instrument designed to measure general health-related impact of priapism. The aim of the study was to evaluate the validity and reliability of the PIP in a Jamaican cohort of SCD patients experiencing priapism.<br><br>&emsp;One hundred SCD patients with a history of priapism were recruited from a sickle cell clinic in Kingston, Jamaica and administered the PIP questionnaire. Patients rated each item of the PIP for clarity and importance. Statistical testing was employed to evaluate the psychometric performance of the PIP. Content validation was assessed based on patient descriptive rating of the items based on clarity, and importance and criterion-oriented validity were assessed by evaluating the PIP's ability to distinguish between patient subgroups. Test-retest repeatability was assessed in 20 of the 100 patients.<br><br>&emsp;Patients were stratified into active (54) and remission (46) priapism groups based on their experience of priapism within the past year. Patients in the active priapism group were younger (p = 0.011), had a shorter duration of disease (p = 0.023), and had more frequent priapism episodes (p = 0.036) than the remission group. PIP questionnaire scores differed significantly with respect to priapism activity (p < 0.001) and prevalence of erectile dysfunction (p < 0.05) but not by priapism severity (p = 0.62). The PIP questionnaire had good content validity, with questions rated as having medium or high clarity and importance by an average of 82.8% and 69.2% of patients, respectively.<br><br>&emsp;The PIP questionnaire was successfully validated in a Jamaican cohort of SCD patients and adequately discriminated patients with active priapism from those in remission. The instrument may be utilized in routine clinical management of patients with SCD-associated priapism. Further clinical investigations are warranted in other populations.\n <br><br> <b>MeSH terms:<\/b> <b>MeSH terms:<\/b> Adult; Anemia, Sickle Cell; Cohort Studies; Humans; Jamaica; Male; Outcome Assessment, Health Care; Physical Fitness; Priapism; Quality of Life; Severity of Illness Index; Sexual Dysfunction, Physiological; Surveys and Questionnaires; Young Adult <br><br> <b>OMOP Concepts (IDs):<\/b>  Priapism (315586); Sickle cell-hemoglobin SS disease (22281); "]},"columns":[{"id":"details","name":"","type":"character","html":true}],"dataKey":"e4738abef2580dcea4c572b0d4ee27ff","static":false,"nested":true},"children":[]}]},{"name":"div","attribs":{"style":{"padding":"1rem"}},"children":[{"name":"Reactable","attribs":{"data":{"details":["<b>DOI:<\/b> 10.1371/journal.pone.0258727 <br><br> Patients with hemoglobinopathies have been reported to have higher rates of pulmonary complications. Few studies have investigated the association between thalassemia and asthma in children.<br><br>&emsp;We used the data of one million individuals randomly selected from the Registry for Beneficiaries of the National Health Insurance Research Database. One thalassemic child was matched with four control children without thalassemia according to sex, birth year, birth season, prematurity, and previous enteroviral infection.<br><br>&emsp;A total of 800 hundred thalassemic children and 3200 controls were included. Children with thalassemia had higher rates of developing asthma (41.81 vs 25.70 per 1000 person-years, P < 0.001) than the non-thalassemia controls with an adjusted hazard ratio of 1.37 (95% confidence interval [CI] = 1.19-1.58). Boys in the thalassemia cohort had a significantly higher adjusted incidence hazard ratio (IRR) of asthma than those in the non-thalassemia cohort (adjusted IRR = 1.45, 95% CI = 1.02-1.73). The risk of atopic and nonatopic asthma was higher in the thalassemia cohort than in the non-thalassemia cohort (IRR = 1.3, 1.61, respectively).<br><br>&emsp;Children with thalassemia were more likely to develop asthma. More attention should be paid to the early diagnosis of asthma and prevention of asthma attacks.\n <br><br> <b>MeSH terms:<\/b> <b>MeSH terms:<\/b> Adolescent; Adult; Asthma; Child; Child, Preschool; Cohort Studies; Databases, Factual; Enterovirus Infections; Female; Humans; Infant; Male; Men; Premature Birth; Proportional Hazards Models; Respiratory Tract Infections; Risk Factors; Thalassemia; Young Adult <br><br> <b>OMOP Concepts (IDs):<\/b>  Disease due to Enterovirus (438068); Asthma (317009); Thalassemia (30978); Respiratory tract infection (4170143); Premature pregnancy delivered (4175637); "]},"columns":[{"id":"details","name":"","type":"character","html":true}],"dataKey":"911ee1dd43c73312290dfd214efa4411","static":false,"nested":true},"children":[]}]},{"name":"div","attribs":{"style":{"padding":"1rem"}},"children":[{"name":"Reactable","attribs":{"data":{"details":["<b>DOI:<\/b> 10.1371/journal.pone.0258319 <br><br> Atypical Hemolytic Uremic Syndrome (aHUS) is an ultra-rare disease that potentially leads to kidney graft failure due to ongoing Thrombotic Microangiopathy (TMA). The aim was evaluating the frequency of TMA after kidney transplantation in patients with aHUS in a Brazilian cohort stratified by the use of the specific complement-inhibitor eculizumab.<br><br>&emsp;This was a multicenter retrospective cohort study including kidney transplant patients diagnosed with aHUS. We collected data from 118 transplant centers in Brazil concerning aHUS transplanted patients between 01/01/2007 and 12/31/2019. Patients were stratified into three groups: no use of eculizumab (No Eculizumab Group), use of eculizumab for treatment of after transplantation TMA (Therapeutic Group), and use of eculizumab for prophylaxis of aHUS recurrence (Prophylactic Group).<br><br>&emsp;Thirty-eight patients with aHUS who received kidney transplantation were enrolled in the study. Patients' mean age was 30 years (24-40), and the majority of participants was women (63% of cases). In the No Eculizumab Group (n = 11), there was a 91% graft loss due to the TMA. The hazard ratio of TMA graft loss was 0.07 [0.01-0.55], p = 0.012 in the eculizumab Prophylactic Group and 0.04 [0.00-0.28], p = 0.002 in the eculizumab Therapeutic Group.<br><br>&emsp;The TMA graft loss in the absence of a specific complement-inhibitor was higher among the Brazilian cohort of kidney transplant patients. This finding reinforces the need of eculizumab use for treatment of aHUS kidney transplant patients. Cost optimization analysis and the early access to C5 inhibitors are suggested, especially in low-medium income countries.\n <br><br> <b>MeSH terms:<\/b> <b>MeSH terms:<\/b> Adult; Antibodies, Monoclonal, Humanized; Atypical Hemolytic Uremic Syndrome; Brazil; Complement Inactivating Agents; Female; Graft Rejection; Humans; Kidney Transplantation; Male; Retrospective Studies; Thrombotic Microangiopathies; Young Adult <br><br> <b>OMOP Concepts (IDs):<\/b>  Atypical hemolytic uremic syndrome (37312165); Graft rejection (4248020); Thrombotic microangiopathy (313800); Transplant of kidney (4322471); "]},"columns":[{"id":"details","name":"","type":"character","html":true}],"dataKey":"d81d7751fd5fafbcf9d6323987caa582","static":false,"nested":true},"children":[]}]},{"name":"div","attribs":{"style":{"padding":"1rem"}},"children":[{"name":"Reactable","attribs":{"data":{"details":["<b>DOI:<\/b> 10.1371/journal.pone.0257895 <br><br> Globally, iron-deficiency anemia (IDA) remains a major health obstacle. This health condition has been identified in 47% of pre-school students (aged 0 to 5 years), 42% of pregnant females, and 30% of non-pregnant females (aged 15 to 50 years) worldwide according to the WHO. Environmental and genetic factors play a crucial role in the development of IDA; genetic testing has revealed the association of a number of polymorphisms with iron status and serum ferritin.<br><br>&emsp;The current study aims to reveal the association of TMPRSS6 rs141312 and BMP2 rs235756 with the iron status of females in Saudi Arabia.<br><br>&emsp;A cohort of 108 female university students aged 18-25 years was randomly selected to participate: 50 healthy and 58 classified as iron deficient. A 3-5 mL sample of blood was collected from each one and analyzed based on hematological and biochemical iron status followed by genotyping by PCR.<br><br>&emsp;The genotype distribution of TMPRSS6 rs141312 was 8% (TT), 88% (TC) and 4% (CC) in the healthy group compared with 3.45% (TT), 89.66% (TC) and 6.89% (CC) in the iron-deficient group (P = 0.492), an insignificant difference in the allelic distribution. The genotype distribution of BMP2 rs235756 was 8% (TT), 90% (TC) and 2% (CC) in the healthy group compared with 3.45% (TT), 82.76% (TC) and 13.79% (CC) in iron-deficient group (P = 0.050) and was significantly associated with decreased ferritin status (P = 0.050). In addition, TMPRSS6 rs141312 is significantly (P<0.001) associated with dominant genotypes (TC+CC) and increased risk of IDA while BMP2 rs235756 is significantly (P<0.026) associated with recessive homozygote CC genotypes and increased risk of IDA.<br><br>&emsp;Our finding potentially helps in the early prediction of iron deficiency in females through the genetic testing.\n <br><br> <b>MeSH terms:<\/b> <b>MeSH terms:<\/b> Adolescent; Adult; Alleles; Anemia, Iron-Deficiency; Bone Morphogenetic Protein 2; Case-Control Studies; Cohort Studies; Female; Genetic Testing; Genotype; Humans; Membrane Proteins; Polymorphism, Single Nucleotide; Risk Factors; Saudi Arabia; Serine Endopeptidases; Students; Universities; Young Adult <br><br> <b>OMOP Concepts (IDs):<\/b>  Genetic alleles (4235440); Iron deficiency anemia (436659); Genetic test (4237017); Genetic finding (4025367); "]},"columns":[{"id":"details","name":"","type":"character","html":true}],"dataKey":"f5102e92a82caf4ff82fb245ef8a9108","static":false,"nested":true},"children":[]}]},{"name":"div","attribs":{"style":{"padding":"1rem"}},"children":[{"name":"Reactable","attribs":{"data":{"details":["<b>DOI:<\/b> 10.1371/journal.pone.0261899 <br><br> Mild anemia is a frequent although often overlooked finding in old age. Nevertheless, in recent years anemia has been linked to several adverse outcomes in the elderly population. Objective of the study was to investigate the association of mild anemia (hemoglobin concentrations: 10.0-11.9/12.9 g/dL in women/men) with all-cause mortality over 11-15 years and the effect of change in anemia status on mortality in young-old (65-84 years) and old-old (80+ years).<br><br>&emsp;The Health and Anemia and Monzino 80-plus are two door-to-door, prospective population-based studies that included residents aged 65-plus years in Biella municipality and 80-plus years in Varese province, Italy. No exclusion criteria were used.<br><br>&emsp;Among 4,494 young-old and 1,842 old-old, mortality risk over 15/11 years was significantly higher in individuals with mild anemia compared with those without (young-old: fully-adjusted HR: 1.35, 95%CI, 1.15-1.58; old-old: fully-adjusted HR: 1.28, 95%CI, 1.14-1.44). Results were similar in the disease-free subpopulation (age, sex, education, smoking history, and alcohol consumption adjusted HR: 1.54, 95%CI, 1.02-2.34). Both age groups showed a dose-response relationship between anemia severity and mortality (P for trend <0.0001). Mortality risk was significantly associated with chronic disease and chronic kidney disease mild anemia in both age groups, and with vitamin B12/folate deficiency and unexplained mild anemia in young-old. In participants with two hemoglobin determinations, seven-year mortality risk was significantly higher in incident and persistent anemic cases compared to constant non-anemic individuals in both age groups. In participants without anemia at baseline also hemoglobin decline was significantly associated with an increased mortality risk over seven years in both young-old and old-old. Limited to the Monzino 80-plus study, the association remained significant also when the risk was further adjusted also for time-varying covariates and time-varying anemia status over time.<br><br>&emsp;Findings from these two large prospective population-based studies consistently suggest an independent, long-term impact of mild anemia on survival at older ages.\n <br><br> <b>MeSH terms:<\/b> <b>MeSH terms:<\/b> Aged; Aged, 80 and over; Anemia; Hemoglobins; Humans; Middle Aged; Prospective Studies <br><br> <b>OMOP Concepts (IDs):<\/b>  Anemia (439777); "]},"columns":[{"id":"details","name":"","type":"character","html":true}],"dataKey":"f0d6933897f6d56d8e77980c3ace63b0","static":false,"nested":true},"children":[]}]},{"name":"div","attribs":{"style":{"padding":"1rem"}},"children":[{"name":"Reactable","attribs":{"data":{"details":["<b>DOI:<\/b> 10.1371/journal.pone.0259944 <br><br> Anemia is a major public health problem worldwide which accounts 24.8% of the population. Subsequently, anemia is a leading killer of people living with human immunodeficiency virus and many of these deaths occur in developing countries including Ethiopia. Cross sectional studies have done on anemia and human immunodeficiency virus. However, there is limited study on incidence of anemia and its predictors among adults on HIV care, especially no survival study has been conducted in the study area.<br><br>&emsp;To assess incidence and predictors of anemia among adults on Human immunodeficiency virus care.<br><br>&emsp;An institution-based retrospective cohort study was conducted among 434 adults on HIV care from January 1st 2015 to December 30th 2019 at Debre Tabor Referral Hospital. A computer-generated simple random sampling technique was employed to select the study participants. Ethical clearance was obtained from the Institutional Review Board of Bahir Dar University, and also, we got implied consent to review charts from the concerned bodies in the hospital. Data were entered using Epi-data version 3.1 and analyzed by using STATA version 14.0. A Kaplan Meier survival curve was utilized to estimate anemia free survival time. Bivariable and Multivariable Cox proportional hazards model were fitted to identify predictors of anemia.<br><br>&emsp;The overall incidence density rate of anemia was 6.27 (95% CI: 0.051, 0.077) per 100 person years. Clinical stage III/IV (AHR = 1.04; 95% CI = 1.02, 1.06), Body Mass Index less than 18.5 kg/m2 (AHR = 3.11; 95% CI = 1.56, 6.22), serum creatinine greater than 1.1 IU/L(AHR = 2.07; 95% CI = 1.12, 3.81) and fair/poor level of adherence(AHR = 1.05; 95% CI = 1.03, 1.07) were statistically significant predictors of anemia while increased anti-retroviral treatment duration (AHR = 0.98; 95% CI = 0.97, 0.99) decrease the risk of anemia at 95% confidence level.<br><br>&emsp;The overall incidence density rate of anemia was high. Patients with clinical stage III/IV, body mass index < 18.5 kg/m2, serum creatinine greater than 1.1 IU/L and fair/poor level of adherence were significant predictors of anemia while increased antiretroviral treatment duration had decreased the risk of anemia.<br><br>&emsp;Even if the overall incidence rate of anemia was lower as compared to previous studies in Ethiopia, still the incidence of anemia was high. So, prevention measures should be taken beside with HIV care especially within 6-months ART initiation.\n <br><br> <b>MeSH terms:<\/b> <b>MeSH terms:<\/b> Adolescent; Adult; Anemia; Anti-Retroviral Agents; Body Mass Index; CD4 Lymphocyte Count; Creatinine; Ethiopia; Female; HIV Infections; Hospitals, General; Humans; Incidence; Kaplan-Meier Estimate; Male; Middle Aged; Proportional Hazards Models; Retrospective Studies; Severity of Illness Index; Young Adult <br><br> <b>OMOP Concepts (IDs):<\/b>  Human immunodeficiency virus infection (439727); Creatinine (19071968); Anemia (439777); "]},"columns":[{"id":"details","name":"","type":"character","html":true}],"dataKey":"bd1b7ada1c2b77605f6079a4eebf93a8","static":false,"nested":true},"children":[]}]},{"name":"div","attribs":{"style":{"padding":"1rem"}},"children":[{"name":"Reactable","attribs":{"data":{"details":["<b>DOI:<\/b> 10.1371/journal.pone.0262436 <br><br> The definition for anemia in pregnancy is outdated, derived from Scandinavian studies in the 1970's to 1980's. To identity women at risk of blood transfusion, a common cause of Severe Maternal Morbidity, a standard definition of anemia in pregnancy in a modern, healthy United States cohort is needed.<br><br>&emsp;To define anemia in pregnancy in a United States population including a large county vs. private hospital population using uncomplicated patients.<br><br>&emsp;Inclusion criteria were healthy women with the first prenatal visit before 20 weeks. Exclusion criteria included preterm birth, preeclampsia, hypertension, diabetes, short interval pregnancy (<18 months), multiple gestation, abruption, and fetal demise. All women had iron fortification (Ferrous sulfate 325 mg daily) recommended. The presentation to care and pre-delivery hematocrits were obtained, and the percentiles determined. A total of 2000 patients were included, 1000 from the public county hospital and 1000 from the private hospital. Each cohort had 250 patients in each 2011, 2013, 2015, and 2018. The cohorts were compared for differences in the fifth percentile for each antepartum epoch. Student's t-test and chi-squared statistical tests were used for analysis, p-value of ≤0.05 was considered significant.<br><br>&emsp;In the public and private populations, 777 and 785 women presented in the first trimester while 223 and 215 presented in the second. The women at the private hospital were more likely to be older, Caucasian race, nulliparous, and present earlier to care. The fifth percentile was compared between the women in the private and public hospitals and were clinically indistinguishable. When combining the cohorts, the fifth percentile for hemoglobin/hematocrit was 11 g/dL/32.8% in the first trimester, 10.3 g/dL/30.6% in the second trimester, and 10.0 g/dL/30.2% pre-delivery.<br><br>&emsp;Fifth percentile determinations were made from a combined cohort of normal, uncomplicated pregnancies to define anemia in pregnancy. Comparison of two different cohorts confirms that the same definition for anemia is appropriate regardless of demographics or patient mix.\n <br><br> <b>MeSH terms:<\/b> <b>MeSH terms:<\/b> Adult; Anemia; Cohort Studies; Evidence-Based Medicine; Female; Hematocrit; Hemoglobins; Humans; Pregnancy; United States <br><br> <b>OMOP Concepts (IDs):<\/b>  Pregnant (4299535); Hematocrit determination (4151358); Anemia (439777); "]},"columns":[{"id":"details","name":"","type":"character","html":true}],"dataKey":"93b8d559f20585b140a13630967529d4","static":false,"nested":true},"children":[]}]},{"name":"div","attribs":{"style":{"padding":"1rem"}},"children":[{"name":"Reactable","attribs":{"data":{"details":["<b>DOI:<\/b> 10.1371/journal.pone.0262760 <br><br> Fetal growth restriction is a major complication of pregnancy and is associated with stillbirth, infant death and child morbidity. Ultrasound monitoring of pregnancy is becoming more common in Africa for fetal growth monitoring in clinical care and research, but many countries have no national growth charts. We evaluated the new international fetal growth standards from INTERGROWTH-21st and WHO in a cohort from southern Benin.<br><br>&emsp;Repeated ultrasound and clinical data were collected in women from the preconceptional RECIPAL cohort (241 women with singleton pregnancies, 964 ultrasounds). We modelled fetal biometric parameters including abdominal circumference (AC) and estimated fetal weight (EFW) and compared centiles to INTERGROWTH-21st and WHO standards, using the Bland and Altman method to assess agreement. For EFW, we used INTERGROWTH-21st standards based on their EFW formula (IG21st) as well as a recent update using Hadlock's EFW formula (IG21hl). Proportions of fetuses with measurements under the 10th percentile were compared.<br><br>&emsp;Maternal malaria and anaemia prevalence was 43% and 69% respectively and 11% of women were primigravid. Overall, the centiles in the RECIPAL cohort were higher than that of INTERGROWTH-21st and closer to that of WHO. Consequently, the proportion of fetuses under 10th percentile thresholds was systematically lower when applying IG21st compared to WHO standards. At 27-31 weeks and 33-38 weeks, respectively, 7.4% and 5.6% of fetuses had EFW <10th percentile using IG21hl standards versus 10.7% and 11.6% using WHO standards.<br><br>&emsp;Despite high anemia and malaria prevalence in the cohort, IG21st and WHO standards did not identify higher than expected proportions of fetuses under the 10th percentiles of ultrasound parameters or EFW. The proportions of fetuses under the 10th percentile threshold for IG21st charts were particularly low, raising questions about its use to identify growth-restricted fetuses in Africa.\n <br><br> <b>MeSH terms:<\/b> <b>MeSH terms:<\/b> Adult; Anemia; Benin; Female; Fetal Development; Growth Charts; Humans; Malaria; Pregnancy; Pregnancy Complications; Tanzania; World Health Organization; Young Adult <br><br> <b>OMOP Concepts (IDs):<\/b>  Pregnant (4299535); Complication occurring during pregnancy (43530950); Malarial fever (4093997); Anemia (439777); "]},"columns":[{"id":"details","name":"","type":"character","html":true}],"dataKey":"3dabcc9811ce4d7a180eb5be6e3a4ccf","static":false,"nested":true},"children":[]}]},{"name":"div","attribs":{"style":{"padding":"1rem"}},"children":[{"name":"Reactable","attribs":{"data":{"details":["<b>DOI:<\/b> 10.1371/journal.pone.0263349 <br><br> The role of antibiotics in the treatment of Shiga toxin-producing Escherichia coli (STEC) infection is controversial.<br><br>&emsp;To evaluate the association between treatment (antibiotics, antidiarrheal agents, and probiotics) for STEC infection and hemolytic uremic syndrome (HUS) development.<br><br>&emsp;We performed a population-based matched case-control study using the data from the National Epidemiological Surveillance of Infectious Diseases (NESID) between January 1, 2017 and December 31, 2018. We identified all patients with STEC infection and HUS as cases and matched patients with STEC infection without HUS as controls, with a case-control a ratio of 1:5. Further medical information was obtained by a standardized questionnaire. Multivariable conditional logistic regression model was used.<br><br>&emsp;7760 patients with STEC infection were registered in the NESID. 182 patients with HUS and 910 matched controls without HUS were selected. 90 patients with HUS (68 children and 22 adults) and 371 patients without HUS (266 children and 105 adults) were included in the main analysis. The matched ORs of any antibiotics and fosfomycin for HUS in children were 0.56 (95% CI 0.32-0.98), 0.58 (0.34-1.01). The matched ORs for HUS were 2.07 (1.07-4.03), 0.86 (0.46-1.61) in all ages treated with antidiarrheal agent and probiotics.<br><br>&emsp;Antibiotics, especially fosfomycin, may prevent the development of HUS in children, while use of antidiarrheal agents should be avoided.\n <br><br> <b>MeSH terms:<\/b> <b>MeSH terms:<\/b> Adolescent; Adult; Aged; Anti-Bacterial Agents; Antidiarrheals; Case-Control Studies; Child; Child, Preschool; Databases, Factual; Diarrhea; Escherichia coli Infections; Female; Gastroenteritis; Hemolytic-Uremic Syndrome; Humans; Infant; Infant, Newborn; Japan; Male; Middle Aged; Probiotics; Shiga Toxin; Shiga-Toxigenic Escherichia coli; Surveys and Questionnaires; Treatment Outcome; Young Adult <br><br> <b>OMOP Concepts (IDs):<\/b>  Infection due to Escherichia coli (440320); Gastroenteritis (4101468); Hemolytic uremic syndrome (197253); Diarrhea (196523); "]},"columns":[{"id":"details","name":"","type":"character","html":true}],"dataKey":"f4b603c5dfa02999aa4b01935ff3283a","static":false,"nested":true},"children":[]}]},{"name":"div","attribs":{"style":{"padding":"1rem"}},"children":[{"name":"Reactable","attribs":{"data":{"details":["<b>DOI:<\/b> 10.1371/journal.pone.0263795 <br><br> So far, no comprehensive studies have been performed to assess burden and determinants of anemia in Iran. In the present study, we aimed to answer this query using the data obtained from the Prospective Epidemiological Research Studies in IrAN (PERSIAN).<br><br>&emsp;In this cross-sectional study, we included 161,686 adult participants (aged 35 years and older) from 16 provinces of Iran. Anemia was defined as a hemoglobin concentration of <13 g/dL in males and <12 g/dL in females. To evaluate the association between anemia and different factors, we used the multivariable Poisson regression analysis with robust variance by applying adjusted prevalence ratio (PR) with 95% confidence interval (CI).<br><br>&emsp;Of the total number of subjects, 72,387 (44.77%) were male and others were female. Mean age was 49.39±9.15 years old. The overall age- and sex-standardized prevalence of anemia was 8.83% (95% CI: 8.70-8.96%) in the included population. The highest and the lowest age- and sex-standardized prevalence of anemia pertained to Hormozgan (37.41%, 95% CI: 35.97-38.85%) and Kurdistan (4.57%, 95% CI: 3.87-5.27%) provinces, respectively. Being female (PR = 2.97), rural residence (PR = 1.24), being retired (PR = 1.53) and housewife (PR = 1.11), third and fourth wealth status quartiles (PR = 1.09 and PR = 1.11, respectively), being underweight (PR = 1.49), drug user (PR = 1.35), inadequate sleep (PR = 1.16), poor physical activity (PR = 1.15), diabetes (PR = 1.09), renal failure (PR = 2.24), and cancer (PR = 1.35) were associated with increased risk of anemia. On the other hand, illiteracy (PR = 0.79) and abdominal obesity (PR = 0.77) decreased the risk of anemia.<br><br>&emsp;According to the results, a variable prevalence of anemia was observed across the included provinces. We tried to provide an informative report on anemia prevalence for health professionals and authorities to take measures for identification and management of the cases of anemia in high-prevalence areas.\n <br><br> <b>MeSH terms:<\/b> <b>MeSH terms:<\/b> Adult; Age Factors; Aged; Aged, 80 and over; Anemia; Cohort Studies; Cross-Sectional Studies; Female; Humans; Iran; Male; Middle Aged; Prevalence; Risk Factors; Social Determinants of Health; Socioeconomic Factors <br><br> <b>OMOP Concepts (IDs):<\/b>  Anemia (439777); "]},"columns":[{"id":"details","name":"","type":"character","html":true}],"dataKey":"c1e2663683f254fb2bac70333f520759","static":false,"nested":true},"children":[]}]},{"name":"div","attribs":{"style":{"padding":"1rem"}},"children":[{"name":"Reactable","attribs":{"data":{"details":["<b>DOI:<\/b> 10.1093/ije/dyac017 <br><br> Anaemia is common among HIV-infected children and iron supplementation is prescribed routinely for the prevention and management of anaemia among children. Limited evidence suggests iron supplementation may have adverse effects among HIV-infected populations. We aimed to estimate the effect of iron supplement use on mortality, disease progression and haematological outcomes among HIV-infected children in Dar es Salaam, Tanzania.<br><br>&emsp;A prospective cohort study was conducted among HIV-infected children (aged 0-14 years) receiving antiretroviral treatment or supportive care between October 2004 and September 2014. Clinical data were recorded on morbidity and vital status, haematological status and prescriptions at each clinical visit. Cox proportional hazards models adjusted for time-varying covariates were used to estimate the association of time-varying iron supplementation on the hazard rate of mortality, HIV disease stage progression, tuberculosis incidence and anaemia and microcytosis persistence.<br><br>&emsp;In all, 4229 children were observed during 149 260 clinic visits for a mean follow-up of 2.9 years. After adjustment for time-varying clinical covariates, time-varying iron supplementation was associated with a 2.87 times higher hazard rate of mortality (95% CI: 1.70, 4.87) and a 1.48 times higher hazard rate of HIV disease stage progression (95% CI: 1.10, 1.98). Iron supplementation was also associated with a lower rate of anaemia persistence (HR = 0.47; 95% CI: 0.37, 0.61). No differences in the association between iron supplementation and clinical outcomes were observed by antiretroviral therapy or anaemia status.<br><br>&emsp;Iron supplementation may increase the risk of HIV disease stage progression and mortality among HIV-infected children, while reducing the risk of anaemia.\n <br><br> <b>MeSH terms:<\/b> <b>MeSH terms:<\/b> Anemia; Child; Cohort Studies; Dietary Supplements; Disease Progression; HIV Infections; Humans; Iron; Prospective Studies; Tanzania <br><br> <b>OMOP Concepts (IDs):<\/b>  Human immunodeficiency virus infection (439727); Anemia (439777); Iron (1360067); "]},"columns":[{"id":"details","name":"","type":"character","html":true}],"dataKey":"fb79f1ee900dc22eeb55cdf98480f41a","static":false,"nested":true},"children":[]}]},{"name":"div","attribs":{"style":{"padding":"1rem"}},"children":[{"name":"Reactable","attribs":{"data":{"details":["<b>DOI:<\/b> 10.1371/journal.pone.0263236 <br><br> Severe acute malnutrition (SAM) is defined as a weight-for-height < -3z scores of the median WHO growth standards, or visible severe wasting or the presence of nutritional edema. SAM related mortality rates in under-five children are well documented in Ethiopia but data on their predictors are limited. We aimed to document factors associated with SAM related mortality to inform better inpatient management.<br><br>&emsp;A facility-based retrospective cohort study was conducted among children admitted due to SAM at Pawe General Hospital, Northwest Ethiopia, from the 1st of January 2015 to the 31st of December 2019. Data from the records of SAM children were extracted using a standardized checklist. Epi-Data version 3.2 was used for data entry, and Stata version 14 was used for analysis. Bi-variable and multivariable Cox regression analyses were conducted to identify predictors of mortality. Variables with P<0.05 were considered significant predictors of mortality.<br><br>&emsp;Five-hundred sixty-eight SAM cases were identified of mean age was 27.4 (SD± 16.5) months. The crude death rate was 91/568 (16.02%) and the mean time to death was determined as 13 (±8) days. Independent risk factors for death were: (i) vomiting AHR = 5.1 (1.35-21.1, p = 0.026), (ii) diarrhea AHR = 2.79 (1.46-5.4, p = 0.002), (iii) needing nasogastric therapy AHR = 3.22 (1.65-6.26, p = 0.001), (iv) anemia AHR = 1.89 (1.15-3.2, p = 0.012), and (v) being readmitted with SAM AHR = 1.7 (1.12-2.8, p = 0.037).<br><br>&emsp;SAM mortality was high in under-five children in our setting. The identified risk factors should inform treatment and prevention strategies. Improved community health education should focus on healthy nutrition and seeking early treatment. Inpatient mortality may be reduced by stricter adherence to treatment guidelines and recognizing early the key risk factors for death.\n <br><br> <b>MeSH terms:<\/b> <b>MeSH terms:<\/b> Anemia; Child Nutrition Disorders; Child, Preschool; Diarrhea; Ethiopia; Female; Humans; Infant; Inpatients; Male; Mortality; Risk Factors; Severe Acute Malnutrition; Vomiting <br><br> <b>OMOP Concepts (IDs):<\/b>  Finding of vomiting (4101344); Anemia (439777); Diarrhea (196523); "]},"columns":[{"id":"details","name":"","type":"character","html":true}],"dataKey":"ad0fd4c53ee8f47a26d682bad610e673","static":false,"nested":true},"children":[]}]},{"name":"div","attribs":{"style":{"padding":"1rem"}},"children":[{"name":"Reactable","attribs":{"data":{"details":["<b>DOI:<\/b> 10.1371/journal.pone.0265337 <br><br> Although antiretroviral therapy has significantly altered the natural history of human immunodeficiency virus infection and improved the quality of life of patients, there are conflicting reports regarding its impact on hematological outcomes. Thus, this study aimed at investigating the prevalence and predictors of anemia among adults on antiretroviral therapy in Northeast Ethiopia.<br><br>&emsp;A retrospective cohort study was carried out among adults who began antiretroviral treatment between September 2005 and January 2019 at two governmental hospitals in Dessie town. Data were collected from patients' medical records using a pretested data extraction instrument. Anemia was the primary outcome variable of the study. It was defined based on WHO criteria after adjustment for altitude and smoking status of measured values. Data were entered and validated using EpiData Version 3.1 and then exported to SPSS Version 20.0 for analysis. Descriptive analysis was done for prevalence and binary logistic regression was carried out to assess whether covariates were associated with experiencing anemia. Statistical significance has been considered at p-value <0.05.<br><br>&emsp;Medical records of 392 patients (mean age: 35.58 ± 9.46 years) were reviewed. Of the total 392 patients, 218 (55.6%) were females, 261 (66.6%) were categorized under WHO clinical stage III/IV and 134 (34.2%) had a baseline CD4 cell count of <100 cells/mm3. The mean baseline CD4 cell count was 179 cells/mm3 (range: 2 to 853 cells) and 230 (58.7%) of the participants were on zidovudine-based regimen. Anemia was diagnosed among 162 (41.3%) patients. After adjustment for other confounding factors, risk of anemia was significantly associated with low baseline CD4 cell count (AOR 1.80, 95% CI 1.05-3.06) and tenofovir based regimen (AOR 2.05, 95% CI 1.31-3.21). On the other hand, being educated was found to be protective (AOR 0.40, 95% CI 0.21-0.78).<br><br>&emsp;In this research, the prevalence of anemia was relatively high. Low baseline CD4 cell count and tenofovir based regimen were independent predictors of anemia; while being educated was protective. Treatment programs should focus on early diagnosis and treatment of HIV as well as routine screening and proper treatment of anemia.\n <br><br> <b>MeSH terms:<\/b> <b>MeSH terms:<\/b> Adult; Anemia; Antiretroviral Therapy, Highly Active; Ethiopia; Female; HIV Infections; Humans; Male; Middle Aged; Prevalence; Quality of Life; Retrospective Studies; Tenofovir <br><br> <b>OMOP Concepts (IDs):<\/b>  Tenofovir (19011093); Human immunodeficiency virus infection (439727); Highly active anti-retroviral therapy (4166414); Anemia (439777); "]},"columns":[{"id":"details","name":"","type":"character","html":true}],"dataKey":"b16d568cd8a11375af57f0deeaa61684","static":false,"nested":true},"children":[]}]},{"name":"div","attribs":{"style":{"padding":"1rem"}},"children":[{"name":"Reactable","attribs":{"data":{"details":["<b>DOI:<\/b> 10.1371/journal.pone.0268842 <br><br> We investigated the diagnostic utility of combined nerve and vascular ultrasound in thoracic outlet syndrome (TOS) in a retrospective cohort study on two sites, involving 167 consecutive patients with the clinical symptoms suggestive of neurogenic and/or vascular TOS, and an age- and sex-matched control group. All patients and control subjects underwent nerve ultrasound of the supraclavicular brachial plexus to look for fibromuscular anomalies / compression of the brachial plexus in the scalenic region, and vascular ultrasound of the infraclavicular subclavian artery with the arm in neutral and abducted position, serving as an indicator for costoclavicular compression of the neurovascular bundle. Based on clinical symptoms, neurogenic TOS (81%) was the most frequent type of TOS, followed by combined neurogenic and arterial TOS (8%). The frequency of abnormal nerve and/or vascular ultrasound findings differed significantly from the control group (P<0.00001). The pooled sensitivity was 48% for nerve ultrasound, 85% for vascular ultrasound, and 94% when combined. Among the findings, the fibromuscular 'wedge-sickle sign', indicating compression of the lower trunk in the scalenic region by a congenital fibromuscular anomaly (e.g. Roos ligaments), showed the highest specificity (100%). A bony 'wedge-sickle sign' was also delineated, where lower trunk compression is caused by the neck of the 1st rib. As implied by the higher sensitivity of vascular ultrasound, the most common site of compression was the costoclavicular space, but multilevel compression was also frequently observed. In summary, combined nerve and vascular ultrasound is a sensitive and reliable method to support the diagnosis of TOS. It can also identify the site(s) of compression, with obvious therapeutic consequences.\n <br><br> <b>MeSH terms:<\/b> <b>MeSH terms:<\/b> Anemia, Sickle Cell; Brachial Plexus; Humans; Retrospective Studies; Thoracic Outlet Syndrome; Ultrasonography <br><br> <b>OMOP Concepts (IDs):<\/b>  Ultrasonography (4037672); Sickle cell-hemoglobin SS disease (22281); Thoracic outlet syndrome (4027534); "]},"columns":[{"id":"details","name":"","type":"character","html":true}],"dataKey":"8c5bf0945fe32ac9bcbf9524b2ace67b","static":false,"nested":true},"children":[]}]},{"name":"div","attribs":{"style":{"padding":"1rem"}},"children":[{"name":"Reactable","attribs":{"data":{"details":["<b>DOI:<\/b> 10.1371/journal.pone.0271563 <br><br> It is well established that counter-regulation to hypoxia follows a hierarchical pattern, with brain-sparing in preference to peripheral tissues. In contrast, it is unknown if the same hierarchical sequence applies to recovery from hypoxia after correction of anemia with packed red blood cell transfusion (PRBCT).<br><br>&emsp;To understand the chronology of cerebral and splanchnic tissue oxygenation resulting after correction of anemia by PRBCT in preterm infants using near-infrared spectroscopy (NIRS).<br><br>&emsp;Prospective cohort study.<br><br>&emsp;Neonatal intensive care.<br><br>&emsp;Haemodynamically stable infants: <32 weeks gestation, <37weeks postmenstrual age, <1500 grams birth weight; and ≥120 mL/kg/day feeds tolerated.<br><br>&emsp;PRBCT at 15 mL/Kg over 4 hours.<br><br>&emsp;Transfusion-associated changes were determined by comparing the 4-hour mean pre-transfusion cerebral and splanchnic fractional tissue oxygen extraction (FTOEc0; FTOEs0) with hourly means during (FTOEc1-4; FTOEs1-4) and for 24 hours after PRBCT completion (FTOEc5-28; FTOEs5-28).<br><br>&emsp;Of 30 enrolled infants, 14[46.7%] male; median[IQR] birth weight, 923[655-1064]g; gestation, 26.4[25.5-28.1]weeks; enrolment weight, 1549[1113-1882]g; and postmenstrual age, 33.6[32.4-35]weeks, 1 infant was excluded because of corrupted NIRS data. FTOEc significantly decreased during and for 24 hours after PRBCT (p < 0.001), indicating prompt improvement in cerebral oxygenation. In contrast, FTOEs showed no significant changes during and after PRBCT (p>0.05), indicating failure of improvement in splanchnic oxygenation.<br><br>&emsp;Improvement in regional oxygenation after PRBCT follows the same hierarchical pattern with a prompt improvement of cerebral but not splanchnic tissue oxygenation. We hypothesise that this hierarchical recovery may indicate continued splanchnic hypoxia in the immediate post-transfusion period and vulnerability to transfusion-associated necrotizing enterocolitis (TANEC). Our study provides a possible mechanistic underpinning for TANEC and warrants future randomised controlled studies to stratify its prevention.\n <br><br> <b>MeSH terms:<\/b> <b>MeSH terms:<\/b> Adult; Anemia; Birth Weight; Enterocolitis, Necrotizing; Erythrocyte Transfusion; Female; Humans; Hypoxia; Infant, Newborn; Infant, Premature; Male; Oxygen; Prospective Studies <br><br> <b>OMOP Concepts (IDs):<\/b>  Birth weight finding (4187520); Necrotizing enterocolitis in fetus OR newborn (201957); Oxygen (19025274); Hypoxia (4306572); Premature infant (4217564); Transfusion of red blood cells (4022173); Anemia (439777); "]},"columns":[{"id":"details","name":"","type":"character","html":true}],"dataKey":"be70f7d53eda09add33d2fc905a27afa","static":false,"nested":true},"children":[]}]},{"name":"div","attribs":{"style":{"padding":"1rem"}},"children":[{"name":"Reactable","attribs":{"data":{"details":["<b>DOI:<\/b> 10.1371/journal.pone.0269309 <br><br> Anemia is present in up to two-thirds of patients undergoing colorectal surgery mainly caused by iron deficiency and inflammation. As anemia is associated with increased risk of perioperative death, diagnosis and treatment of preoperative anemia according to etiology have been recommended.<br><br>&emsp;The aim of the present study was to assess if the association between anemia and survival in patients undergoing colorectal surgery was determined by the severity of anemia alone or also by anemia etiology.<br><br>&emsp;To determine the prevalence of anemia and etiology, preoperative hematological parameters, C-reactive protein, ferritin and transferrin saturation were retrospectively assessed and correlated with outcome in a cohort of patients undergoing colorectal surgery between 2005 and 2019 at the University Hospital of Innsbruck. Anemia was defined as hemoglobin <120 g/L in females and <130 g/L in males. The etiology of anemia was classified on the basis of serum iron parameters, as iron deficiency anemia, anemia of inflammation or other anemia etiologies.<br><br>&emsp;Preoperative anemia was present in 54% (1316/2458) of all patients. Anemia was associated with iron deficiency in 45% (134/299) and classified as anemia of inflammation in 32% (97/299) of patients with available serum iron parameters. The etiology of anemia was a strong and independent predictor of survival, where iron deficiency and anemia of inflammation were associated with better postoperative survival than other anemia etiologies. One year survival rates were 84.3%, 77.3% and 69.1% for patients with iron deficiency anemia, anemia of inflammation and other anemia types. Inflammation indicated by high C-reactive protein is a strong negative predictor of overall survival.<br><br>&emsp;Anemia has a high prevalence among patients undergoing colorectal surgery and rational treatment requires early assessment of serum iron parameters and C-reactive protein.\n <br><br> <b>MeSH terms:<\/b> <b>MeSH terms:<\/b> Anemia; Anemia, Iron-Deficiency; C-Reactive Protein; Cohort Studies; Colorectal Surgery; Female; Hemoglobins; Humans; Inflammation; Iron; Iron Deficiencies; Male; Retrospective Studies <br><br> <b>OMOP Concepts (IDs):<\/b>  Iron deficiency anemia (436659); Anemia (439777); Iron (1360067); "]},"columns":[{"id":"details","name":"","type":"character","html":true}],"dataKey":"bc8f5fb71d1befc18edfd6e2059c2bdb","static":false,"nested":true},"children":[]}]},{"name":"div","attribs":{"style":{"padding":"1rem"}},"children":[{"name":"Reactable","attribs":{"data":{"details":["<b>DOI:<\/b> 10.1371/journal.pone.0272641 <br><br> Sri Lanka is a developing country where the majority of households still rely on firewood for cooking. Furthermore, the prevalence of anemia among reproductive-aged women is of moderate public health importance, according the classification of World Health Organization. Despite the researchers' ongoing efforts to investigate a link between solid fuel smoke exposure and anemia, the veracity of their findings remains uncertain. As a result, the purpose of this study was to examine the relationship between biomass fuel smoke exposure and anemia in non-pregnant reproductive-aged women in Sri Lanka.<br><br>&emsp;A descriptive cross-sectional study was conducted among 382 non-pregnant reproductive-aged (15 to 49 years) women in Central Province, Sri Lanka. Data was collected using a standardized interviewer-administered questionnaire, and exposure was assessed using a breath carbon monoxide monitor. Drabkin's cynomethhemoglobin technique was used to determine blood hemoglobin concentration.<br><br>&emsp;The overall prevalence of anemia was 36.1%. The logistic regression model revealed no effect of cooking fuel type on anemic or non-anemic status after adjusting for potential confounding factors (p > 0.05). The multivariate regression analysis also discovered that cooking fuel type had no effect on women's blood hemoglobin concentration.<br><br>&emsp;The study results suggest no impact of solid fuel smoke exposure on anemia among non-pregnant, reproductive-aged women. Larger scale prospective cohort studies are recommended. The reasons behind the high prevalence of anemia among reproductive-aged women should be further investigated, and corrective measures should be implemented urgently.\n <br><br> <b>MeSH terms:<\/b> <b>MeSH terms:<\/b> Adult; Air Pollution, Indoor; Anemia; Biomass; Cooking; Cross-Sectional Studies; Female; Hemoglobins; Humans; Prospective Studies; Smoke <br><br> <b>OMOP Concepts (IDs):<\/b>  Anemia (439777); "]},"columns":[{"id":"details","name":"","type":"character","html":true}],"dataKey":"65e3c48b7a601ec48165cb861b7cac1a","static":false,"nested":true},"children":[]}]},{"name":"div","attribs":{"style":{"padding":"1rem"}},"children":[{"name":"Reactable","attribs":{"data":{"details":["<b>DOI:<\/b> 10.1200/JCO.22.00710 <br><br> Secondary myeloid neoplasms (sMNs) remain the most serious long-term complications in patients with aplastic anemia (AA) and paroxysmal nocturnal hemoglobinuria (PNH). However, sMNs lack specific predictors, dedicated surveillance measures, and early therapeutic interventions.<br><br>&emsp;We studied a multicenter, retrospective cohort of 1,008 patients (median follow-up 8.6 years) with AA and PNH to assess clinical and molecular determinants of clonal evolution.<br><br>&emsp;Although none of the patients transplanted upfront (n = 117) developed clonal complications (either sMN or secondary PNH), the 10-year cumulative incidence of sMN in nontransplanted cases was 11.6%. In severe AA, older age at presentation and lack of response to immunosuppressive therapy were independently associated with increased risk of sMN, whereas untreated patients had the highest risk among nonsevere cases. The elapsed time from AA to sMN was 4.5 years. sMN developed in 94 patients. The 5-year overall survival reached 40% and was independently associated with bone marrow blasts at sMN onset. Myelodysplastic syndrome with high-risk phenotypes, del7/7q, and ASXL1, SETBP1, RUNX1, and RAS pathway gene mutations were the most frequent characteristics. Cross-sectional studies of clonal dynamics from baseline to evolution revealed that PIGA/human leukocyte antigen lesions decreased over time, being replaced by clones with myeloid hits. PIGA and BCOR/L1 mutation carriers had a lower risk of sMN progression, whereas myeloid driver lesions marked the group with a higher risk.<br><br>&emsp;The risk of sMN in AA is associated with disease severity, lack of response to treatment, and patients' age. sMNs display high-risk morphological, karyotypic, and molecular features. The landscape of acquired somatic mutations is complex and incompletely understood and should be considered with caution in medical management.\n <br><br> <b>MeSH terms:<\/b> <b>MeSH terms:<\/b> Humans; Anemia, Aplastic; Hemoglobinuria, Paroxysmal; Retrospective Studies; Cross-Sectional Studies; Clonal Evolution <br><br> <b>OMOP Concepts (IDs):<\/b>  Hemoglobinuria due to hemolysis from external causes (434616); Hematopoietic aplasia (4119473); "]},"columns":[{"id":"details","name":"","type":"character","html":true}],"dataKey":"56e63ac0ba45262bb1fcf28902eb56fd","static":false,"nested":true},"children":[]}]},{"name":"div","attribs":{"style":{"padding":"1rem"}},"children":[{"name":"Reactable","attribs":{"data":{"details":["<b>DOI:<\/b> 10.1371/journal.pone.0275311 <br><br> Anemia is common in heart failure (HF) patients with chronic kidney disease (CKD) and is associated with worse outcomes. Iron supplementation improves symptoms and is associated with reduced risk of hospitalization for HF in iron-deficiency HF patients. However, iron deficiency is present in <30% of anemic HF patients. Erythropoiesis stimulating agents (ESAs) improve symptoms but are associated with increased risk of thromboembolic events in anemic HF patients with CKD. Hypoxia-inducible factor prolyl hydroxylase (HIF-PH) inhibitors are a new class of agents for the treatment of anemia. These agents work by stabilizing the HIF complex, thereby stimulating endogenous erythropoietin production. We hypothesized that HIF-PH inhibitors may be associated with reduced risk of cardiovascular outcomes compared with ESAs in anemic HF patients with CKD. Accordingly, we aim to perform the meta-analysis of studies on the efficacy and safety of HIF-PH inhibitors compared with ESAs in anemic HF patients with CKD.<br><br>&emsp;This meta-analysis will include prospective cohort studies and randomized controlled trials on the effect of HIF-PH inhibitors compared with ESAs in anemic HF patients with CKD. Information of studies will be collected from PubMed, Web of Science, Cochrane Library, and ClinicalTrials.gov. The primary outcome will be cardiovascular death. The secondary outcomes will be all-cause death, hospitalization for HF, HF symptoms, exercise capacity, health-related quality of life, and hemoglobin levels.<br><br>&emsp;This meta-analysis will evaluate the effect of HIF-PH inhibitors in anemic HF patients with CKD, providing evidence regarding the use of HIF-PH inhibitors in these patients.<br><br>&emsp;INPLASY202230103.\n <br><br> <b>MeSH terms:<\/b> <b>MeSH terms:<\/b> Anemia; Erythropoietin; Heart Failure; Hematinics; Hemoglobins; Humans; Hypoxia; Hypoxia-Inducible Factor-Proline Dioxygenases; Iron; Meta-Analysis as Topic; Prolyl-Hydroxylase Inhibitors; Prospective Studies; Quality of Life; Renal Insufficiency, Chronic; Systematic Reviews as Topic <br><br> <b>OMOP Concepts (IDs):<\/b>  Chronic renal insufficiency (36716947); Hypoxia (4306572); Heart failure (316139); Anemia (439777); Iron (1360067); "]},"columns":[{"id":"details","name":"","type":"character","html":true}],"dataKey":"c55b7426a6ed03e01e83a86f7824525d","static":false,"nested":true},"children":[]}]},{"name":"div","attribs":{"style":{"padding":"1rem"}},"children":[{"name":"Reactable","attribs":{"data":{"details":["<b>DOI:<\/b> 10.1371/journal.pone.0274642 <br><br> Globally, more than a third of pregnant women are anemic, and progress in its prevention and control is slow. Sri Lanka is a lower-middle-income country with a unique public health infrastructure that provides multiple interventions across the lifecycle for anemia prevention, despite which anemia in pregnancy remains a challenge. Studying the factors associated with maternal anemia in this context would provide unique information on challenges and opportunities encountered as low-and-middle-income countries attempt to control anemia by improving health care coverage. All first-trimester pregnant women registered for antenatal care in the Anuradhapura district between July 2019 to September 2019 were invited to participate in the baseline of a cohort study. Interviewer-administered and self-completed questionnaires were used. Anemia was defined using a full blood count. A hierarchical logistic regression model was built to identify factors associated with anemia. Out of 3127 participants, 451 (14.4%) were anemic. According to the regression model (Chi-square = 139.3, p<0.001, n = 2692), the odds of being anemic increased with the Period of gestation (PoG) (OR = 1.07, 95% CI = 1.01-1.13). While controlling for PoG, age and parity, history of anemia (OR = 3.22, 95%CI = 2.51-4.13), being underweight (OR = 1.64, 95%CI = 1.24-2.18), having the last pregnancy five or more years back (OR = 1.57,95%CI = 1.15-2.15) and having used intrauterine devices for one year or more (OR = 1.63, 95%CI = 1.16-2.30) increased the odds of anemia. Breast feeding during the last year (OR = 0.66, 95%CI = 0.49-0.90) and having used contraceptive injections for one year or more (OR = 0.61,95%CI = 0.45-0.83) reduced the risk of anemia. Proxy indicators of being in frequent contact with the national family health program have a protective effect over the socioeconomic disparities in preventing early pregnancy anemia. Maintaining the continuum of care through the lifecycle, especially through optimizing pre and inter-pregnancy care provision should be the way forward for anemia control.\n <br><br> <b>MeSH terms:<\/b> <b>MeSH terms:<\/b> Anemia; Cohort Studies; Contraceptive Agents; Female; Humans; Iron Deficiencies; Parity; Pregnancy; Puerperal Disorders; Risk Factors; Socioeconomic Factors; Sri Lanka <br><br> <b>OMOP Concepts (IDs):<\/b>  Disorder of puerperium (443404); Pregnant (4299535); Parity finding (4041279); Anemia (439777); "]},"columns":[{"id":"details","name":"","type":"character","html":true}],"dataKey":"3d30fc50d93cb17d224d7a822c3d71c5","static":false,"nested":true},"children":[]}]},{"name":"div","attribs":{"style":{"padding":"1rem"}},"children":[{"name":"Reactable","attribs":{"data":{"details":["<b>DOI:<\/b> 10.1371/journal.pone.0275115 <br><br> Malaria is associated with high morbidity during pregnancy. Homozygous sickle cell pregnant women are even more exposed during complicated malaria. The objective of the study was to evaluate the maternal and fetal morbidity of homozygous sickle cell pregnant pregnant women with complicated malaria.<br><br>&emsp;We conducted a retrospective case-control study of 982 pregnancies in sickle cell pregnant women, during which a group of sickle cell pregnant women who received antimalarial chemoprophylaxis was compared to another group without chemoprophylaxis. We analyzed the clinical evolution of pregnant women (VOCs and transfusions, pregnancy weight gain) and parasite (parasite density at the time of diagnosis of complicated malaria and during treatment for three days). We analyzed the parameters of newborns at birth (age of pregnancy at the time of delivery, birth weight, weight of the placenta and histopathological examination of the placenta.<br><br>&emsp;Out of 982 pregnancies, 15% of pregnant women suffered from complicated malaria, 57% suffered from uncomplicated malaria and 28% did not suffer from malaria. Pregnancy weight gain, birth weight, was better in the group of pregnant women who received chemoprophylaxis and the placenta had less histological lesions. Parasite density was low. There was a significant positive correlation between parasite density and the number of CVOs and transfusions and between parasite density and histological lesions of the placenta and low birth weight.<br><br>&emsp;Complicated malaria is associated with high maternal and fetal morbidity in sickle cell patients. Malaria chemoprophylaxis can reduce maternal and fetal complications and parasite density during malaria infection.\n <br><br> <b>MeSH terms:<\/b> <b>MeSH terms:<\/b> Anemia, Sickle Cell; Antimalarials; Birth Weight; Case-Control Studies; Democratic Republic of the Congo; Female; Gestational Weight Gain; Humans; Infant, Newborn; Malaria; Pregnancy; Pregnancy Complications, Parasitic; Retrospective Studies <br><br> <b>OMOP Concepts (IDs):<\/b>  Birth weight finding (4187520); Pregnant (4299535); Sickle cell-hemoglobin SS disease (22281); Malarial fever (4093997); "]},"columns":[{"id":"details","name":"","type":"character","html":true}],"dataKey":"99e4156583476dfca130dec0b3a235af","static":false,"nested":true},"children":[]}]},{"name":"div","attribs":{"style":{"padding":"1rem"}},"children":[{"name":"Reactable","attribs":{"data":{"details":["<b>DOI:<\/b> 10.2337/dc22-1399 <br><br> Glycated hemoglobin (HbA1c) can predict risk for microvascular complications in patients with diabetes. However, HbA1c's reliability in chronic kidney disease (CKD) has been questioned, with concerns including competition from another posttranslational protein modification, carbamylation, acting on the same amino groups as glycation, and anemia with reduced erythrocyte lifespans leading to altered glycation accumulation. We investigated whether carbamylation and anemia modify the impact of HbA1c on renal outcomes in patients with diabetes and CKD.<br><br>&emsp;In 1,516 participants from the Chronic Renal Insufficiency Cohort study with diabetes and CKD, Cox regression models were applied to evaluate the association between HbA1c and CKD progression (composite of end-stage kidney disease or 50% decline in estimated glomerular filtration rate [eGFR]), stratified by carbamylated albumin (C-Alb) quartiles and anemia.<br><br>&emsp;The mean eGFR was 38.1 mL/min/1.73 m2, mean HbA1c was 7.5% (58 mmol/mol), and median C-Alb was 8.4 mmol/mol. HbA1c was lower in the higher C-Alb quartiles. During a median follow-up of 6.9 years, 763 participants experienced CKD progression. Overall, higher HbA1c was associated with an increased risk of CKD progression (adjusted hazard ratio 1.07 [95% CI 1.02-1.13]). However, using stratified analyses, HbA1c was no longer associated with CKD progression in the highest C-Alb quartile, but did show a monotonic increase in CKD progression risk across each lower C-Alb quartile (P-interaction = 0.022). Anemia also modified the association between HbA1c and CKD progression (P-interaction = 0.025).<br><br>&emsp;In patients with coexisting diabetes and CKD, the association between HbA1c and CKD progression is modified by carbamylation and anemia.\n <br><br> <b>MeSH terms:<\/b> <b>MeSH terms:<\/b> Humans; Glycated Hemoglobin; Cohort Studies; Protein Carbamylation; Reproducibility of Results; Disease Progression; Renal Insufficiency, Chronic; Diabetes Mellitus; Glomerular Filtration Rate; Anemia <br><br> <b>OMOP Concepts (IDs):<\/b>  Chronic renal insufficiency (36716947); Diabetes mellitus (201820); Anemia (439777); "]},"columns":[{"id":"details","name":"","type":"character","html":true}],"dataKey":"f2c8b229ce68397d9158f04e7d2418c1","static":false,"nested":true},"children":[]}]},{"name":"div","attribs":{"style":{"padding":"1rem"}},"children":[{"name":"Reactable","attribs":{"data":{"details":["<b>DOI:<\/b> 10.1371/journal.pone.0273745 <br><br> Sickle cell anemia (SCA) is caused by a single point variation in the β-globin gene (HBB): c.20A> T (p.Glu7Val), in homozygous state. SCA is characterized by sickling of red blood cells in small blood vessels which leads to a range of multiorgan complications, including kidney dysfunction. This case-control study aims at identifying sickle cell nephropathy biomarkers in a group of patients living with SCA from Senegal. A total of 163 patients living with SCA and 177 ethnic matched controls were investigated. Biological phenotyping included evaluation of glycemia, glucosuria, albuminuria, proteinuria, tubular proteinuria, serum creatinine, urine creatinine, urine specific gravity and glomerular filtration rate. Descriptive statistics of biomarkers were performed using the χ2 -test, with the significance level set at p<0.05. Patients living with SCA had a median age of 20 years (range 4 to 57) with a female sex frequency of 53.21%. The median age of the control participants was 29 years (range: 4-77) with a female sex frequency of 66.09%. The following proportions of abnormal biological indices were observed in SCA patients versus (vs.) controls, as follows: hyposthenuria: 35.3%vs.5.2% (p<0.001); glomerular hyperfiltration: 47.66%vs.19.75% (p<0.001), renal insufficiency: 5.47%vs.3.82% (p = 0.182); microalbuminuria: 42.38%vs.5.78% (p<0.001); proteinuria: 39.33%vs.4.62% (p<0.001); tubular proteinuria: 40.97%vs.4.73% (p<0.001) and microglucosuria: 22.5%vs.5.1% (p<0.001). This study shows a relatively high proportion of SCA nephropathy among patients living with SCA in Senegal. Microglucosuria, proteinuria, tubular proteinuria, microalbuminuria, hyposthenuria and glomerular hyperfiltration are the most prevalent biomarkers of nephropathy in this group of Senegalese patients with SCA.\n <br><br> <b>MeSH terms:<\/b> <b>MeSH terms:<\/b> Humans; Female; Child, Preschool; Child; Adolescent; Young Adult; Adult; Middle Aged; Aged; Case-Control Studies; Senegal; Kidney Diseases; Albuminuria; Anemia, Sickle Cell; Proteinuria; Biomarkers; Vascular Diseases; Renal Insufficiency <br><br> <b>OMOP Concepts (IDs):<\/b>  Vascular disorder (443784); Proteinuria (75650); Renal impairment (4030518); Sickle cell-hemoglobin SS disease (22281); Albuminuria (4168705); Kidney disease (198124); "]},"columns":[{"id":"details","name":"","type":"character","html":true}],"dataKey":"fadbdcca393c323fdff3ce1f12951327","static":false,"nested":true},"children":[]}]},{"name":"div","attribs":{"style":{"padding":"1rem"}},"children":[{"name":"Reactable","attribs":{"data":{"details":["<b>DOI:<\/b> 10.1371/journal.pone.0278137 <br><br> Sickle cell disease (SCD) is a severe monogenic disease associated with high morbidity and mortality and a disproportionate burden on Black communities. Few population-based studies have examined the prevalence of comorbidities among persons with SCD. We estimated the prevalence of comorbidities experienced by individuals with SCD enrolled in employer-based health insurance plans in the US over their non-elderly lifetimes (0-64 years of age) with a retrospective cohort design using Truven Health MarketScan commercial claims data from 2007-2018. ICD-9/10 codes were used to identify individuals with SCD using a previously published algorithm. For this cohort, comorbidities associated with SCD were identified across 3 age categories (<18, 18-45, 46-64 years-old), based on the CMS Chronic Comorbidities Warehouse or SCD-specific diagnosis codes, when applicable. The total number of SCD patients available for analysis in each age category was 7,502 (<18 years), 10,183 (18-45 years) and 4,459 (46-64 years). Across all ages, vaso-occlusive pain, infections (non-specific), and fever were the most common comorbidities. Vaso-occlusive pain and infection were the most prevalent conditions for persons age <18- and 18-45-year-olds, while in the 46-54-year-old age group, infection and cardiovascular including pulmonary hypertension were most prevalent. Compared to persons <18 years old, the prevalence of vaso-occlusive pain, fever, and acute chest syndrome claims declined in older populations. The comorbidity burden of SCD is significant across all age groups. SCD patients experience comorbidities of age such as chronic pain, cardio-vascular conditions including pulmonary hypertension and renal disease at far higher rates than the general population. Novel disease modifying therapies in development have the potential to significantly reduce the comorbidity burden of SCD.\n <br><br> <b>MeSH terms:<\/b> <b>MeSH terms:<\/b> Humans; Middle Aged; Aged; Adolescent; Prevalence; Retrospective Studies; Hypertension, Pulmonary; Anemia, Sickle Cell; Comorbidity; Insurance, Health; Chronic Pain; Fever <br><br> <b>OMOP Concepts (IDs):<\/b>  Fever (437663); Sickle cell-hemoglobin SS disease (22281); Chronic pain (436096); Pulmonary hypertension (4322024); "]},"columns":[{"id":"details","name":"","type":"character","html":true}],"dataKey":"272ccfe8605f515e1be2ddf0bfc97aca","static":false,"nested":true},"children":[]}]},{"name":"div","attribs":{"style":{"padding":"1rem"}},"children":[{"name":"Reactable","attribs":{"data":{"details":["<b>DOI:<\/b> 10.1371/journal.pone.0276617 <br><br> Cold agglutinin disease (CAD) is a rare, chronic form of autoimmune hemolytic anemia. Clinical manifestations can include classical complement pathway-mediated chronic hemolysis, anemia, and profound fatigue. Research has shown that patients with other anemias may develop anxiety and depression, but this has not been studied previously in patients with CAD.<br><br>&emsp;CAD patients were identified in the Optum Claims-Clinical dataset (between January 1, 2006-June 30, 2016) and matched to comparison patients without CAD by patient factors. Adjusted Cox regression models estimated time to anxiety and depression, defined by three different outcomes: medication use, hospitalization, and therapy related to anxiety and depression. Subset analyses were performed for primary CAD. Patients were followed until they had anxiety and depression, they left the Optum system, death, or the study period ended (June 30, 2016).<br><br>&emsp;Patients with CAD (n = 384) were more likely to have medically attended anxiety and depression (adjusted hazard ratio [aHR]: 1.6; 95% confidence interval [CI]: 1.3-2.1), to be prescribed antidepressants or psychotherapy after their CAD diagnosis (aHR: 1.8; 95% CI: 1.2-2.9), or to be hospitalized for an anxiety and depression-related event along with medication or psychotherapy (aHR: 2.0; 95% CI: 1.4-2.9) relative to matched comparisons (n = 2789), during the follow-up period. Patients with primary CAD were at increased risk for medically attended anxiety and depression (aHR: 1.8; 95% CI: 1.4-2.4), with the highest risk for prescription medication or therapy (aHR: 2.7; 95% CI: 1.6-4.6).<br><br>&emsp;Our study indicates that medically attended anxiety and depression manifest at a higher rate in CAD patients than in a matched non-CAD cohort. Study findings suggest that CAD patients may experience a greater burden on mental health that may negatively contribute to their overall quality of life. Further investigation on this topic is warranted.\n <br><br> <b>MeSH terms:<\/b> <b>MeSH terms:<\/b> Humans; United States; Anemia, Hemolytic, Autoimmune; Depression; Quality of Life; Anxiety; Antidepressive Agents <br><br> <b>OMOP Concepts (IDs):<\/b>  Anxiety (441542); Depressive disorder (440383); Autoimmune hemolytic anemia (441269); "]},"columns":[{"id":"details","name":"","type":"character","html":true}],"dataKey":"b0f94674d0162b479611ebac314e1860","static":false,"nested":true},"children":[]}]},{"name":"div","attribs":{"style":{"padding":"1rem"}},"children":[{"name":"Reactable","attribs":{"data":{"details":["<b>DOI:<\/b> 10.1371/journal.pone.0278838 <br><br> Malnutrition and poor health are common among recently resettled refugees and may be differentially associated with pre-migration exposure to refugee camp versus non-camp dwelling. We aimed to investigate the associations of iron deficiency (ID), anemia, and ID anemia (IDA) with pre-migration refugee camp exposure among recently arrived refugees to Canada. To this end, we conducted a retrospective cohort study of 1032 adult refugees who received care between January 1, 2011, and December 31, 2015, within a specialized refugee health clinic in Calgary, Canada. We evaluated the prevalence, severity, and predictors of ID, anemia, and IDA, stratified by sex. Using multivariable logistic regression, we estimated the association of refugee camp exposure with these outcomes, adjusting for age, months in Canada prior to investigations, global region of origin, and parity. Among female refugees, the prevalence of ID, anemia, and IDA was 25% (134/534), 21% (110/534), and 14% (76/534), respectively; among males, 0.8% (4/494), 1.8% (9/494), and 0% (0/494), respectively. Anemia was mild, moderate, and severe in 55% (60/110), 44% (48/110) and 1.8% (2/110) of anemic females. Refugee camp exposure was not associated with ID, anemia, or IDA while age by year (ID OR = 0.96, 95% CI 0.93-0.98; anemia OR = 0.98, 95% CI 0.96-1.00; IDA OR = 0.96, 95% CI 0.94-0.99) and months in Canada prior to investigations (ID OR = 0.85, 95% CI 0.72-1.01; anemia OR = 0.81, 95% CI 0.67-0.97; IDA OR = 0.80, 95% CI 0.64-1.00) were inversely correlated with these outcomes. ID, anemia, and IDA are common among recently arrived refugee women irrespective of refugee camp exposure. Our findings suggest these outcomes likely improve after resettlement; however, given proportionally few refugees are resettled globally, likely millions of refugee women and girls are affected.\n <br><br> <b>MeSH terms:<\/b> <b>MeSH terms:<\/b> Male; Adult; Humans; Female; Refugees; Refugee Camps; Retrospective Studies; Canada; Iron Deficiencies; Anemia, Iron-Deficiency <br><br> <b>OMOP Concepts (IDs):<\/b>  Refugee (40488824); Iron deficiency anemia (436659); "]},"columns":[{"id":"details","name":"","type":"character","html":true}],"dataKey":"6c01671185227a5cc3a8787a34c53c6d","static":false,"nested":true},"children":[]}]},{"name":"div","attribs":{"style":{"padding":"1rem"}},"children":[{"name":"Reactable","attribs":{"data":{"details":["<b>DOI:<\/b> 10.1371/journal.pone.0278478 <br><br> Sickle cell anemia (SCA) is a monogenic hemoglobinopathy associated with severe acute and chronic complications, with the highest incidence worldwide in Sub-Saharan Africa. The wide variability in clinical manifestations suggest that a uniform response to hydroxurea may not be attained. In view of a potential treatment with hydroxyurea (HU), we assessed the variability of clinical and hematological manifestations in a cohort of adults with SCA in Kinshasa, capital of the DR Congo in Central Africa.<br><br>&emsp;A cross-sectional study was conducted in a hospital dedicated to SCA management in Kinshasa. Clinical history of patients was recorded, a complete physical examination performed. The diagnosis was confirmed by means of DNA analysis. A full blood count and hemolysis markers were measured. The severity of the disease was evaluated by means of a previously reported score.<br><br>&emsp;The study group consisted of 166 genetically confirmed SCA patients. The SCA severity was mild in 28.9%, moderate in 64.5% and severe in 6.6%. The disease severity score increased with patient's age (p ≤ 0.001). The severity was higher in males compared to females (p = 0.012). In males, the severity score was correlated with the presence of priapism (p = 0.045), a manifestation not previously incorporated in the severity score. The severity score was inversely correlated with the fetal hemoglobin (HbF) rate (p = 0.005). Malnutrition (BMI <18.5 kg/m2) was present in 47% of patients and was related to the male sex, hip disease (aOR 3.11; p = 0.019) and severe phenotype (aOR 3.53; p = 0.012). Leg ulcers were more frequent in males than in females (p = 0.001; OR 24.3) and were correlated with the number of days of hospitalization (p = 0.029). Hip disease was related to the increasing age (p = 0.008).<br><br>&emsp;In this selected, hospital-based populations of adults with SCA, severe disease was rare, which may be due to survival bias. However, two thirds had moderate severity of the disease, mostly with a low HbF, and they may benefit from HU treatment. In the Central-African setting the separation between vaso-occlusive and hyperhemolytic sub-phenotypes was not applicable.\n <br><br> <b>MeSH terms:<\/b> <b>MeSH terms:<\/b> Female; Male; Humans; Cross-Sectional Studies; Democratic Republic of the Congo; Anemia, Sickle Cell; Hydroxyurea; Fetal Hemoglobin <br><br> <b>OMOP Concepts (IDs):<\/b>  Hemoglobin F (4339104); Sickle cell-hemoglobin SS disease (22281); hydroxyurea (1377141); "]},"columns":[{"id":"details","name":"","type":"character","html":true}],"dataKey":"a51aab4013025f5dc8164c0404d76bae","static":false,"nested":true},"children":[]}]},{"name":"div","attribs":{"style":{"padding":"1rem"}},"children":[{"name":"Reactable","attribs":{"data":{"details":["<b>DOI:<\/b> 10.1371/journal.pone.0283427 <br><br> Anaemia in pregnancy is common in underdeveloped countries, and malaria remains the predominant cause of the condition in Ghana. Anti-erythropoietin (anti-EPO) antibody production may be implicated in the pathogenesis of Plasmodium falciparum malaria-related anaemia in pregnancy. This study ascertained the prevalence of anti-EPO antibody production and evaluated the antibodies' relationship with Plasmodium falciparum malaria and malaria-related anaemia in pregnancy.<br><br>&emsp;This hospital-based case-control study recruited a total of 85 pregnant women (55 with Plasmodium falciparum malaria and 30 controls without malaria). Venous blood was taken from participants for thick and thin blood films for malaria parasite microscopy. Complete blood count (CBC) analyses were done using an automated haematology analyzer. Sandwich enzyme-linked immunosorbent assay (ELISA) was used to assess serum erythropoietin (EPO) levels and anti-EPO antibodies. Data were analyzed using IBM SPSS version 22.0.<br><br>&emsp;Haemoglobin (p<0.001), RBC (p<0.001), HCT (p = 0.006) and platelet (p<0.001) were significantly lower among pregnant women infected with Plasmodium falciparum. Of the 85 participants, five (5.9%) had anti-EPO antibodies in their sera, and the prevalence of anti-EPO antibody production among the Plasmodium falciparum-infected pregnant women was 9.1%. Plasmodium falciparum-infected pregnant women with anti-EPO antibodies had lower Hb (p<0.001), RBC (p<0.001), and HCT (p<0.001), but higher EPO levels (p<0.001). Younger age (p = 0.013) and high parasite density (p = 0.004) were significantly associated with Plasmodium falciparum-related anti-EPO antibodies production in pregnancy. Also, younger age (p = 0.039) and anti-EPO antibody production (p = 0.012) related to the development of Plasmodium falciparum malaria anaemia in pregnancy.<br><br>&emsp;The prevalence of anti-EPO antibodies among pregnant women with Plasmodium falciparum malaria was high. Plasmodium falciparum parasite density and younger age could stimulate the production of anti-EPO antibodies, and the antibodies may contribute to the development of malarial anaemia in pregnancy. Screening for anti-EPO antibodies should be considered in pregnant women with P. falciparum malaria.\n <br><br> <b>MeSH terms:<\/b> <b>MeSH terms:<\/b> Female; Humans; Pregnancy; Anemia; Case-Control Studies; Ghana; Malaria; Malaria, Falciparum; Plasmodium falciparum; Pregnant Women; Erythropoietin <br><br> <b>OMOP Concepts (IDs):<\/b>  Pregnant (4299535); Falciparum malaria (438343); Malarial fever (4093997); Anemia (439777); "]},"columns":[{"id":"details","name":"","type":"character","html":true}],"dataKey":"f5004a3e6545dc5e69ab230e0aa028c8","static":false,"nested":true},"children":[]}]},{"name":"div","attribs":{"style":{"padding":"1rem"}},"children":[{"name":"Reactable","attribs":{"data":{"details":["<b>DOI:<\/b> 10.1371/journal.pone.0283051 <br><br> To determine the frequency and etiology of unnecessary prenatal diagnosis for hemoglobinopathies during 12 years of services at a single university center in Thailand.<br><br>&emsp;We conducted a retrospective cohort analysis of prenatal diagnosis during 2009-2021. A total of 4,932 couples at risk and 4,946 fetal specimens, including fetal blood (5.6%), amniotic fluid (92.3%), and chorionic villus samples (2.2%) were analyzed. Identification of mutations causing hemoglobinopathies was carried out by PCR-based methods. Maternal contamination was monitored by analysis of the D1S80 VNTR locus.<br><br>&emsp;Among 4,946 fetal specimens, 12 were excluded because of poor PCR amplification, maternal contamination, non-paternity, and inconsistency of the results of the fetuses and parents. Breakdown of 4,934 fetuses revealed 3,880 (78.6%) at risk for the three severe thalassemia diseases, including β-thalassemia major, Hb E-β-thalassemia, and homozygous α0-thalassemia, 58 (1.2%) at risk for other α-thalassemia diseases, 168 (3.4%) at risk for β+-thalassemia, 109 (2.2%) at risk for high Hb F determinants, 16 (0.3%) at risk for abnormal Hbs, and 294 (6.0%) with no risk of having severe hemoglobinopathies. The parents of 409 (8.3%) fetuses had inadequate data for fetal risk assessment. Overall, we encountered unnecessary prenatal diagnostic requests for 645 (13.1%) fetuses.<br><br>&emsp;The frequency of unnecessary prenatal diagnosis was high. This could lead to unnecessary risk of complications associated with fetal specimen collection, psychological impacts to the pregnant women and their families, as well as laboratory expenses and workload.\n <br><br> <b>MeSH terms:<\/b> <b>MeSH terms:<\/b> Pregnancy; Female; Humans; Retrospective Studies; Prenatal Diagnosis; Hemoglobinopathies; beta-Thalassemia; alpha-Thalassemia; Amniotic Fluid <br><br> <b>OMOP Concepts (IDs):<\/b>  Pregnant (4299535); Alpha thalassemia (4287844); Hemoglobinopathy (432868); Beta thalassemia (4278669); "]},"columns":[{"id":"details","name":"","type":"character","html":true}],"dataKey":"032daaa1ade6a716b00588683a79899d","static":false,"nested":true},"children":[]}]}]},{"id":"pmid","name":"","type":"character","width":150,"vAlign":"center"},{"id":"title","name":"","type":"character","width":700,"vAlign":"center"},{"id":"journal","name":"","type":"character","width":450,"vAlign":"center"}],"pagination":false,"highlight":true,"striped":true,"theme":{"borderColor":"#dfe2e5","stripedColor":"#f6f8fa","highlightColor":"#f0f5f9","cellPadding":"4px 0px","style":{"fontFamily":"-apple-system, BlinkMacSystemFont, Segoe UI, Helvetica, Arial, sans-serif"},"searchInputStyle":{"width":"100%"}},"dataKey":"2dab9dc084f2d6d157d7865544001378"},"children":[]},"class":"reactR_markup"},"evals":[],"jsHooks":[]}</script>
<p>And further, we may plot a few summary graphs of these returned
results. We must first pick a domain that we are interested in viewing.
To start with, we may choose to look at the conditions contained within
our results. We choose N such that we limit our plot to the top 15 most
frequent results.</p>
<p>More information on which domains are available and what information
they contain can be found here:</p>
<p><a href="https://www.ohdsi.org/web/wiki/doku.php?id=documentation:vocabulary:domains" class="uri">https://www.ohdsi.org/web/wiki/doku.php?id=documentation:vocabulary:domains</a></p>
<div class="sourceCode" id="cb12"><pre class="sourceCode r"><code class="sourceCode r"><span id="cb12-1"><a href="#cb12-1" aria-hidden="true" tabindex="-1"></a><span class="fu">plotResultsBar</span>(res, <span class="at">domain =</span> <span class="st">&quot;Condition&quot;</span>, <span class="at">N =</span> <span class="dv">15</span>, <span class="at">conceptDict =</span> resDict)</span></code></pre></div>
<p><img src="data:image/png;base64,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" style="display: block; margin: auto;" /></p>
<p>We may also wish to view a cumulative track of terms as they change
over time. For convenience, we store a cumulative date object in the
environment rather than recreate it for each plot:</p>
<div class="sourceCode" id="cb13"><pre class="sourceCode r"><code class="sourceCode r"><span id="cb13-1"><a href="#cb13-1" aria-hidden="true" tabindex="-1"></a></span>
<span id="cb13-2"><a href="#cb13-2" aria-hidden="true" tabindex="-1"></a>cumuDate <span class="ot">&lt;-</span> <span class="fu">cumuDate</span>(res)</span>
<span id="cb13-3"><a href="#cb13-3" aria-hidden="true" tabindex="-1"></a></span>
<span id="cb13-4"><a href="#cb13-4" aria-hidden="true" tabindex="-1"></a><span class="fu">plotCumulative</span>(res, <span class="at">domain =</span> <span class="st">&quot;Condition&quot;</span>, <span class="at">N =</span> <span class="dv">15</span>, <span class="at">conceptDict =</span> resDict, cumuDate)</span></code></pre></div>
<p><img src="data:image/png;base64,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" style="display: block; margin: auto;" /></p>
<p>Finally, we may wish to view how these individual terms “roll up” in
the OMOP hierarchy to ATC1 or ATC2 categories:</p>
<div class="sourceCode" id="cb14"><pre class="sourceCode r"><code class="sourceCode r"><span id="cb14-1"><a href="#cb14-1" aria-hidden="true" tabindex="-1"></a><span class="fu">plotRollUp</span>(resDict, <span class="dv">15</span>)</span></code></pre></div>
<p><img src="data:image/png;base64,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" style="display: block; margin: auto;" /></p>
</div>
</div>



<!-- code folding -->


<!-- dynamically load mathjax for compatibility with self-contained -->
<script>
  (function () {
    var script = document.createElement("script");
    script.type = "text/javascript";
    script.src  = "https://mathjax.rstudio.com/latest/MathJax.js?config=TeX-AMS-MML_HTMLorMML";
    document.getElementsByTagName("head")[0].appendChild(script);
  })();
</script>

</body>
</html>
